{"matching_results": 21079, "aggregations": [{"type": "term", "field": "host", "results": [{"key": "americanbankingnews.com", "matching_results": 1040, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 852}, {"key": "negative", "matching_results": 168}, {"key": "neutral", "matching_results": 20}]}]}, {"key": "freelancer.com.co", "matching_results": 823, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 750}, {"key": "negative", "matching_results": 67}, {"key": "neutral", "matching_results": 6}]}]}, {"key": "thelincolnianonline.com", "matching_results": 812, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 693}, {"key": "negative", "matching_results": 119}]}]}, {"key": "dailypolitical.com", "matching_results": 706, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 631}, {"key": "negative", "matching_results": 75}]}]}, {"key": "watchlistnews.com", "matching_results": 701, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 612}, {"key": "negative", "matching_results": 89}]}]}, {"key": "tickerreport.com", "matching_results": 695, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 622}, {"key": "negative", "matching_results": 73}]}]}, {"key": "wkrb13.com", "matching_results": 571, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 502}, {"key": "negative", "matching_results": 69}]}]}, {"key": "zolmax.com", "matching_results": 547, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 489}, {"key": "negative", "matching_results": 58}]}]}, {"key": "findmarketresearch.org", "matching_results": 432, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 378}, {"key": "negative", "matching_results": 54}]}]}, {"key": "marketscreener.com", "matching_results": 429, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 284}, {"key": "negative", "matching_results": 142}, {"key": "neutral", "matching_results": 3}]}]}]}], "results": [{"id": "A6NfE0fMYByNGwcaf3Qp-QMWFB8YhjEBhz6VcsR47dP223Jy4iU8Wl5NH61GQcKg", "result_metadata": {"score": 37.090374}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0.419369, "label": "positive"}, "text": "Takeda", "relevance": 0.33, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$62 billion", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": "Takeda sets vote date, aims to close $62 billion Shire deal January 8", "object": {"text": "vote date", "keywords": [{"text": "vote date"}]}, "action": {"verb": {"text": "set", "tense": "present"}, "text": "sets", "normalized": "set"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": "Takeda sets vote date, aims to close $62 billion Shire deal January 8", "object": {"text": "to close $62 billion Shire deal January 8", "keywords": [{"text": "Shire deal"}], "entities": [{"type": "Quantity", "text": "$62 billion"}]}, "action": {"verb": {"text": "aim", "tense": "present"}, "text": "aims", "normalized": "aim"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": "Takeda sets vote date, aims to close $62 billion Shire deal January 8", "object": {"text": "$62 billion Shire deal", "keywords": [{"text": "Shire deal"}], "entities": [{"type": "Quantity", "text": "$62 billion"}]}, "action": {"verb": {"text": "close", "tense": "future"}, "text": "aims to close", "normalized": "aim to close"}}], "concepts": [], "categories": [{"score": 0.517617, "label": "/law, govt and politics/government/state and local government"}, {"score": 0.491189, "label": "/finance/investing"}, {"score": 0.491189, "label": "/finance/investing/beginning investing"}], "relations": [], "keywords": [{"text": "Shire deal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.942864}, {"text": "vote date", "sentiment": {"score": 0.419369, "label": "positive"}, "relevance": 0.854514}, {"text": "Takeda", "sentiment": {"score": 0.419369, "label": "positive"}, "relevance": 0.703673}]}, "crawl_date": "2018-11-12T12:27:11Z", "url": "http://www.4-traders.com/TAKEDA-PHARMACEUTICAL-CO-6491073/news/Takeda-sets-vote-date-aims-to-close-62-billion-Shire-deal-January-8-27589491/", "host": "4-traders.com", "text": "(Reporting by Ben Hirschler; editing by Jason Neely and Louise Heavens) By Ben Hirschler Stocks treated in this article : Takeda Pharmaceutical Co Ltd , Roche Holding Ltd. , Shire", "main_image_url": "https://img.zonebourse.com/reuters/2018-11-12T083009Z_1_LYNXNPEEAB0GM_RTROPTP_3_SHIRE-M-A-TAKEDA-PHARMA-EU.JPG", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-12T00:00:00+01:00", "enriched_text": {"entities": [{"count": 8, "sentiment": {"score": -0.194682, "label": "negative"}, "text": "Takeda", "relevance": 0.898429, "type": "Person"}, {"count": 8, "sentiment": {"score": -0.307208, "label": "negative"}, "text": "Shire", "relevance": 0.501904, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical", "relevance": 0.41736, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.34541, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.41776, "label": "positive"}, "text": "London-listed Shire", "relevance": 0.303719, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 4, "sentiment": {"score": 0.371996, "label": "positive"}, "text": "Chief Executive Christophe Weber", "relevance": 0.289084, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Reuters", "relevance": 0.21042, "type": "Company", "disambiguation": {"subtype": [], "name": "Reuters", "dbpedia_resource": "http://dbpedia.org/resource/Reuters"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ben Hirschler", "relevance": 0.196477, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.177516, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": -0.454906, "label": "negative"}, "text": "Roche", "relevance": 0.152336, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Hoffmann-La Roche", "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann-La_Roche"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.146146, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "EU", "relevance": 0.137313, "type": "Organization", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}, {"count": 1, "sentiment": {"score": 0.223648, "label": "positive"}, "text": "CEO", "relevance": 0.133076, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "United States", "relevance": 0.128432, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roche Holding Ltd.", "relevance": 0.127853, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.48302, "label": "positive"}, "text": "Louise Heavens", "relevance": 0.126804, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.48302, "label": "positive"}, "text": "Jason Neely", "relevance": 0.120534, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "China", "relevance": 0.110998, "type": "Location", "disambiguation": {"subtype": ["GeographicFeature", "Island", "Country"], "name": "Taiwan", "dbpedia_resource": "http://dbpedia.org/resource/Taiwan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Brazil", "relevance": 0.107729, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$30.9 billion", "relevance": 0.107729, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$32 billion", "relevance": 0.107729, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$62 billion", "relevance": 0.107729, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "3 percent", "relevance": 0.107729, "type": "Quantity"}], "sentiment": {"document": {"score": 0.270794, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Japan's Takeda Pharmaceutical", "keywords": [{"text": "Takeda Pharmaceutical"}, {"text": "Japan"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Company", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": "LONDON (Reuters) - Japan's Takeda Pharmaceutical will hold an investor vote on its $62 billion acquisition of Shire next month and aims to close the deal on Jan. 8, signalling its confidence in securing the required support.", "object": {"text": "an investor vote", "keywords": [{"text": "investor vote"}]}, "action": {"verb": {"text": "hold", "tense": "future"}, "text": "will hold", "normalized": "will hold"}}, {"subject": {"text": "Shares in London-listed Shire", "keywords": [{"text": "London-listed Shire"}, {"text": "Shares"}], "entities": [{"type": "Location", "text": "London-listed Shire", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Shares in London-listed Shire rose 3 percent on the news, hitting their highest level since Takeda first disclosed its interest in buying the rare diseases specialist in March.", "object": {"text": "3 percent", "keywords": [{"text": "percent"}], "entities": [{"type": "Quantity", "text": "3 percent"}]}, "action": {"verb": {"text": "rise", "tense": "past"}, "text": "rose", "normalized": "rise"}}, {"subject": {"text": "Shares in London-listed Shire", "keywords": [{"text": "London-listed Shire"}, {"text": "Shares"}], "entities": [{"type": "Location", "text": "London-listed Shire", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Shares in London-listed Shire rose 3 percent on the news, hitting their highest level since Takeda first disclosed its interest in buying the rare diseases specialist in March.", "object": {"text": "their highest level", "keywords": [{"text": "highest level"}]}, "action": {"verb": {"text": "hit", "tense": "present"}, "text": "hitting", "normalized": "hit"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Shares in London-listed Shire rose 3 percent on the news, hitting their highest level since Takeda first disclosed its interest in buying the rare diseases specialist in March.", "object": {"text": "its interest"}, "action": {"verb": {"text": "disclose", "tense": "past"}, "text": "disclosed", "normalized": "disclose"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Shares in London-listed Shire rose 3 percent on the news, hitting their highest level since Takeda first disclosed its interest in buying the rare diseases specialist in March.", "object": {"text": "the rare diseases specialist", "keywords": [{"text": "rare diseases specialist"}]}, "action": {"verb": {"text": "buy", "tense": "present"}, "text": "buying", "normalized": "buy"}}, {"subject": {"text": "The deal", "keywords": [{"text": "deal"}], "entities": []}, "sentence": " The deal would be the biggest-ever overseas acquisition by a Japanese company - but it needs two-thirds support from shareholders, some of whom are worried about the enlarged company's resulting debt burden.", "object": {"text": "the biggest-ever overseas acquisition", "keywords": [{"text": "biggest-ever overseas acquisition"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "would be", "normalized": "would be"}}, {"subject": {"text": "it"}, "sentence": " The deal would be the biggest-ever overseas acquisition by a Japanese company - but it needs two-thirds support from shareholders, some of whom are worried about the enlarged company's resulting debt burden.", "object": {"text": "two-thirds support from shareholders, some of whom are worried about the enlarged company's resulting debt burden", "keywords": [{"text": "debt burden"}, {"text": "enlarged company"}, {"text": "two-thirds"}, {"text": "shareholders"}]}, "action": {"verb": {"text": "need", "tense": "present"}, "text": "needs", "normalized": "need"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda said on Monday it would hold an extraordinary general meeting (EGM) of shareholders to vote on the transaction on Dec. 5.", "object": {"text": "it would hold an extraordinary general meeting (EGM) of shareholders to vote on the transaction on Dec. 5", "keywords": [{"text": "extraordinary general meeting"}, {"text": "EGM"}, {"text": "shareholders"}, {"text": "transaction"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Previously, Takeda had said it hoped to hold the EGM early in 2019, leaving uncertain the level of backing for the deal, which has been opposed by some members of the founding Takeda family.", "object": {"text": "it hoped to hold the EGM early in 2019, leaving uncertain the level of backing for the deal, which has been opposed by some members of the founding Takeda family", "keywords": [{"text": "founding Takeda family"}, {"text": "EGM"}, {"text": "deal"}, {"text": "level"}], "entities": []}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "had said", "normalized": "have say"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Previously, Takeda had said it hoped to hold the EGM early in 2019, leaving uncertain the level of backing for the deal, which has been opposed by some members of the founding Takeda family.", "object": {"text": "the level of backing for the deal, which has been opposed by some members of the founding Takeda family", "keywords": [{"text": "founding Takeda family"}, {"text": "deal"}, {"text": "level"}, {"text": "members"}], "entities": []}, "action": {"verb": {"text": "leave", "tense": "present"}, "text": "leaving", "normalized": "leave"}}, {"subject": {"text": "by some members of the founding Takeda family", "keywords": [{"text": "founding Takeda family"}]}, "sentence": " Previously, Takeda had said it hoped to hold the EGM early in 2019, leaving uncertain the level of backing for the deal, which has been opposed by some members of the founding Takeda family.", "object": {"text": "the deal", "keywords": [{"text": "deal"}], "entities": []}, "action": {"verb": {"text": "oppose", "tense": "past"}, "text": "has been opposed", "normalized": "have be oppose"}}, {"subject": {"text": "the date of our extraordinary general meeting of shareholders", "keywords": [{"text": "extraordinary general meeting"}, {"text": "shareholders"}, {"text": "date"}]}, "sentence": " \"With the date of our extraordinary general meeting of shareholders now set, we are looking forward to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction,\" Chief Executive Christophe Weber said.", "action": {"verb": {"text": "set", "tense": "past"}, "text": "set", "normalized": "set"}}, {"subject": {"text": "we"}, "sentence": " \"With the date of our extraordinary general meeting of shareholders now set, we are looking forward to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction,\" Chief Executive Christophe Weber said.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "we"}, "sentence": " \"With the date of our extraordinary general meeting of shareholders now set, we are looking forward to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction,\" Chief Executive Christophe Weber said.", "object": {"text": "to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction", "keywords": [{"text": "financial benefits"}, {"text": "shareholders"}, {"text": "dialogue"}, {"text": "transaction"}]}, "action": {"verb": {"text": "look", "tense": "present"}, "text": "are looking", "normalized": "be look"}}, {"subject": {"text": "we"}, "sentence": " \"With the date of our extraordinary general meeting of shareholders now set, we are looking forward to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction,\" Chief Executive Christophe Weber said.", "object": {"text": "our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction", "keywords": [{"text": "financial benefits"}, {"text": "shareholders"}, {"text": "dialogue"}, {"text": "transaction"}]}, "action": {"verb": {"text": "continue", "tense": "future"}, "text": "to continue", "normalized": "to continue"}}, {"subject": {"text": "Chief Executive Christophe Weber", "keywords": [{"text": "Executive Christophe Weber"}], "entities": [{"type": "Person", "text": "Chief Executive Christophe Weber"}]}, "sentence": " \"With the date of our extraordinary general meeting of shareholders now set, we are looking forward to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction,\" Chief Executive Christophe Weber said.", "object": {"text": "With the date of our extraordinary general meeting of shareholders now set, we are looking forward to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction", "keywords": [{"text": "extraordinary general meeting"}, {"text": "financial benefits"}, {"text": "shareholders"}, {"text": "dialogue"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Weber -- a Frenchman and the first non-Japanese CEO of the company --", "keywords": [{"text": "non-Japanese CEO"}, {"text": "Frenchman"}, {"text": "Weber"}, {"text": "company"}], "entities": [{"type": "Person", "text": "Chief Executive Christophe Weber"}, {"type": "JobTitle", "text": "CEO"}]}, "sentence": " Weber -- a Frenchman and the first non-Japanese CEO of the company -- believes that buying Shire will accelerate Takeda's growth and increase its international reach, boosting earnings.", "object": {"text": "that buying Shire will accelerate Takeda's growth and increase its international reach, boosting earnings", "keywords": [{"text": "international reach"}, {"text": "Takeda"}, {"text": "earnings"}, {"text": "Shire"}], "entities": [{"type": "Company", "text": "Shire"}, {"type": "Location", "text": "Takeda", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "believe", "tense": "present"}, "text": "believes", "normalized": "believe"}}, {"subject": {"text": "that buying Shire", "keywords": [{"text": "Shire"}], "entities": [{"type": "Company", "text": "Shire"}]}, "sentence": " Weber -- a Frenchman and the first non-Japanese CEO of the company -- believes that buying Shire will accelerate Takeda's growth and increase its international reach, boosting earnings.", "object": {"text": "its international reach", "keywords": [{"text": "international reach"}]}, "action": {"verb": {"text": "increase", "tense": "present"}, "text": "increase", "normalized": "increase"}}, {"subject": {"text": "The transaction", "keywords": [{"text": "transaction"}]}, "sentence": " The transaction is still awaiting approval from European regulators, although two people familiar with the matter told Reuters last week that Takeda was set to win conditional EU antitrust approval.", "object": {"text": "still awaiting approval from European regulators", "keywords": [{"text": "European regulators"}, {"text": "approval"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The transaction", "keywords": [{"text": "transaction"}]}, "sentence": " The transaction is still awaiting approval from European regulators, although two people familiar with the matter told Reuters last week that Takeda was set to win conditional EU antitrust approval.", "object": {"text": "approval from European regulators", "keywords": [{"text": "European regulators"}, {"text": "approval"}]}, "action": {"verb": {"text": "await", "tense": "present"}, "text": "awaiting", "normalized": "await"}}, {"subject": {"text": "two people familiar with the matter", "keywords": [{"text": "matter"}, {"text": "people"}]}, "sentence": " The transaction is still awaiting approval from European regulators, although two people familiar with the matter told Reuters last week that Takeda was set to win conditional EU antitrust approval.", "object": {"text": "that Takeda was set to win conditional EU antitrust approval", "keywords": [{"text": "EU antitrust approval"}, {"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "action": {"verb": {"text": "tell", "tense": "past"}, "text": "told", "normalized": "tell"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " The transaction is still awaiting approval from European regulators, although two people familiar with the matter told Reuters last week that Takeda was set to win conditional EU antitrust approval.", "object": {"text": "to win conditional EU antitrust approval", "keywords": [{"text": "EU antitrust approval"}], "entities": [{"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "action": {"verb": {"text": "set", "tense": "past"}, "text": "set", "normalized": "set"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda has offered to divest Shire's experimental drug SHP647 to address concerns about overlap in inflammatory bowel disease treatments.", "object": {"text": "offered to divest Shire's experimental drug SHP647 to address concerns about overlap in inflammatory bowel disease treatments", "keywords": [{"text": "inflammatory bowel disease"}, {"text": "experimental drug SHP647"}, {"text": "overlap"}, {"text": "Shire"}], "entities": [{"type": "Organization", "text": "Shire"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda has offered to divest Shire's experimental drug SHP647 to address concerns about overlap in inflammatory bowel disease treatments.", "object": {"text": "Shire's experimental drug SHP647", "keywords": [{"text": "experimental drug"}, {"text": "Shire"}], "entities": [{"type": "Organization", "text": "Shire"}]}, "action": {"verb": {"text": "divest", "tense": "future"}, "text": "has offered to divest", "normalized": "have offer to divest"}}, {"subject": {"text": "The takeover", "keywords": [{"text": "takeover"}]}, "sentence": " The takeover has already secured clearance from regulators in the United States, Japan, China and Brazil.", "object": {"text": "already secured clearance from regulators in the United States, Japan, China and Brazil", "keywords": [{"text": "United States"}, {"text": "clearance"}, {"text": "regulators"}, {"text": "Brazil"}], "entities": [{"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["GeographicFeature", "Country", "Island", "Country"], "name": "Taiwan", "dbpedia_resource": "http://dbpedia.org/resource/Taiwan"}}, {"type": "Location", "text": "Brazil", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The takeover", "keywords": [{"text": "takeover"}]}, "sentence": " The takeover has already secured clearance from regulators in the United States, Japan, China and Brazil.", "object": {"text": "clearance", "keywords": [{"text": "clearance"}]}, "action": {"verb": {"text": "secure", "tense": "past"}, "text": "secured", "normalized": "secure"}}, {"subject": {"text": "Weber", "keywords": [{"text": "Weber"}], "entities": [{"type": "Person", "text": "Chief Executive Christophe Weber"}]}, "sentence": " Weber said last week he was confident of securing investor backing for the purchase of Shire, but until now it has not been clear when exactly Takeda would call its EGM.", "object": {"text": "he was confident of securing investor backing for the purchase of Shire, but until now it has not been clear when exactly Takeda would call its EGM", "keywords": [{"text": "exactly Takeda"}, {"text": "investor backing"}, {"text": "EGM"}, {"text": "Shire"}], "entities": [{"type": "Person", "text": "Chief Executive Christophe Weber"}, {"type": "Company", "text": "Shire"}, {"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Chief Executive Christophe Weber"}]}, "sentence": " Weber said last week he was confident of securing investor backing for the purchase of Shire, but until now it has not been clear when exactly Takeda would call its EGM.", "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Chief Executive Christophe Weber"}]}, "sentence": " Weber said last week he was confident of securing investor backing for the purchase of Shire, but until now it has not been clear when exactly Takeda would call its EGM.", "object": {"text": "investor backing", "keywords": [{"text": "investor backing"}]}, "action": {"verb": {"text": "secure", "tense": "future"}, "text": "securing", "normalized": "secure"}}, {"subject": {"text": "it"}, "sentence": " Weber said last week he was confident of securing investor backing for the purchase of Shire, but until now it has not been clear when exactly Takeda would call its EGM.", "object": {"text": "clear"}, "action": {"verb": {"text": "be", "tense": "past", "negated": true}, "text": "been", "normalized": "be"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda, which has a market value of around $32 billion, has secured a $30.9 billion bridge loan to help finance the Shire acquisition and some investors are concerned as to how well it will cope with debt repayments.", "object": {"text": "a market value of around $32 billion", "keywords": [{"text": "market value"}], "entities": [{"type": "Quantity", "text": "$32 billion"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Takeda, which has a market value of around $32 billion,", "keywords": [{"text": "Takeda"}, {"text": "market value"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Quantity", "text": "$32 billion"}]}, "sentence": " Takeda, which has a market value of around $32 billion, has secured a $30.9 billion bridge loan to help finance the Shire acquisition and some investors are concerned as to how well it will cope with debt repayments.", "object": {"text": "secured a $30.9 billion bridge loan", "keywords": [{"text": "bridge loan"}], "entities": [{"type": "Quantity", "text": "$30.9 billion"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Takeda, which has a market value of around $32 billion,", "keywords": [{"text": "Takeda"}, {"text": "market value"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Quantity", "text": "$32 billion"}]}, "sentence": " Takeda, which has a market value of around $32 billion, has secured a $30.9 billion bridge loan to help finance the Shire acquisition and some investors are concerned as to how well it will cope with debt repayments.", "object": {"text": "a $30.9 billion bridge loan", "keywords": [{"text": "bridge loan"}], "entities": [{"type": "Quantity", "text": "$30.9 billion"}]}, "action": {"verb": {"text": "secure", "tense": "past"}, "text": "has secured", "normalized": "have secure"}}, {"subject": {"text": "some investors", "keywords": [{"text": "investors"}]}, "sentence": " Takeda, which has a market value of around $32 billion, has secured a $30.9 billion bridge loan to help finance the Shire acquisition and some investors are concerned as to how well it will cope with debt repayments.", "object": {"text": "concerned as to how well it will cope with debt repayments", "keywords": [{"text": "debt repayments"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "some investors", "keywords": [{"text": "investors"}]}, "sentence": " Takeda, which has a market value of around $32 billion, has secured a $30.9 billion bridge loan to help finance the Shire acquisition and some investors are concerned as to how well it will cope with debt repayments.", "object": {"text": "as to how well it will cope with debt repayments", "keywords": [{"text": "debt repayments"}]}, "action": {"verb": {"text": "concern", "tense": "past"}, "text": "concerned", "normalized": "concern"}}, {"subject": {"text": "The Japanese company", "keywords": [{"text": "Japanese company"}]}, "sentence": " The Japanese company struck its agreement to take over Shire in May, in a deal that will propel it into the top 10 rankings of global drugmakers by sales.", "object": {"text": "its agreement to take over Shire in May", "keywords": [{"text": "agreement"}, {"text": "Shire"}], "entities": [{"type": "Organization", "text": "Shire"}]}, "action": {"verb": {"text": "strike", "tense": "past"}, "text": "struck", "normalized": "strike"}}, {"subject": {"text": "The Japanese company", "keywords": [{"text": "Japanese company"}]}, "sentence": " The Japanese company struck its agreement to take over Shire in May, in a deal that will propel it into the top 10 rankings of global drugmakers by sales.", "object": {"text": "its agreement", "keywords": [{"text": "agreement"}]}, "action": {"verb": {"text": "take", "tense": "future"}, "text": "to take", "normalized": "to take"}}, {"subject": {"text": "a deal", "keywords": [{"text": "deal"}], "entities": []}, "sentence": " The Japanese company struck its agreement to take over Shire in May, in a deal that will propel it into the top 10 rankings of global drugmakers by sales.", "object": {"text": "it"}, "action": {"verb": {"text": "propel", "tense": "future"}, "text": "will propel", "normalized": "will propel"}}, {"subject": {"text": "the enlarged group", "keywords": [{"text": "enlarged group"}]}, "sentence": " However, the enlarged group faces significant challenges, particularly in haemophilia, where a new drug from Roche and the prospect of new gene therapies now in development threaten a key part of Shire's existing business.", "object": {"text": "significant challenges", "keywords": [{"text": "significant challenges"}]}, "action": {"verb": {"text": "face", "tense": "present"}, "text": "faces", "normalized": "face"}}, {"subject": {"text": "Stocks", "keywords": [{"text": "Stocks"}]}, "sentence": " Stocks treated in this article : Takeda Pharmaceutical Co Ltd , Roche Holding Ltd. , Shire", "object": {"text": "in this article", "keywords": [{"text": "article"}]}, "action": {"verb": {"text": "treat", "tense": "past"}, "text": "treated", "normalized": "treat"}}], "concepts": [{"text": "Inflammatory bowel disease", "relevance": 0.944132, "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}, {"text": "Stock", "relevance": 0.756847, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Inflammation", "relevance": 0.692372, "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}, {"text": "Ulcerative colitis", "relevance": 0.672218, "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.644805, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Hoffmann\u2013La Roche", "relevance": 0.642698, "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann\u2013La_Roche"}, {"text": "Takeda clan", "relevance": 0.627417, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_clan"}], "categories": [{"score": 0.572623, "label": "/finance/financial news"}, {"score": 0.499838, "label": "/business and industrial/company/merger and acquisition"}, {"score": 0.427536, "label": "/finance/investing"}], "relations": [{"type": "partOf", "sentence": "LONDON (Reuters) - Japan's Takeda Pharmaceutical will hold an investor vote on its $62 billion acquisition of Shire next month and aims to close the deal on Jan. 8, signalling its confidence in securing the required support.", "score": 0.545834, "arguments": [{"text": "Takeda Pharmaceutical", "location": [27, 48], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Japan", "location": [19, 24], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "Takeda said on Monday it would hold an extraordinary general meeting (EGM) of shareholders to vote on the transaction on Dec. 5.", "score": 0.998022, "arguments": [{"text": "Takeda", "location": [610, 616], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co Ltd"}]}, {"text": "said", "location": [617, 621], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "Previously, Takeda had said it hoped to hold the EGM early in 2019, leaving uncertain the level of backing for the deal, which has been opposed by some members of the founding Takeda family.", "score": 0.976386, "arguments": [{"text": "Takeda", "location": [751, 757], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co Ltd"}]}, {"text": "said", "location": [762, 766], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "timeOf", "sentence": "Takeda said on Monday it would hold an extraordinary general meeting (EGM) of shareholders to vote on the transaction on Dec. 5.", "score": 0.957937, "arguments": [{"text": "Monday", "location": [625, 631], "entities": [{"type": "Date", "text": "Monday"}]}, {"text": "said", "location": [617, 621], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "participantIn", "sentence": "Takeda said on Monday it would hold an extraordinary general meeting (EGM) of shareholders to vote on the transaction on Dec. 5.", "score": 0.856573, "arguments": [{"text": "shareholders", "location": [688, 700], "entities": [{"type": "Person", "text": "shareholders"}]}, {"text": "meeting", "location": [671, 678], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "agentOf", "sentence": "Previously, Takeda had said it hoped to hold the EGM early in 2019, leaving uncertain the level of backing for the deal, which has been opposed by some members of the founding Takeda family.", "score": 0.479637, "arguments": [{"text": "members", "location": [891, 898], "entities": [{"type": "Person", "text": "members"}]}, {"text": "opposed", "location": [875, 882], "entities": [{"type": "EventCommunication", "text": "opposed"}]}]}, {"type": "partOfMany", "sentence": "Previously, Takeda had said it hoped to hold the EGM early in 2019, leaving uncertain the level of backing for the deal, which has been opposed by some members of the founding Takeda family.", "score": 0.498158, "arguments": [{"text": "members", "location": [891, 898], "entities": [{"type": "Person", "text": "members"}]}, {"text": "Takeda family", "location": [915, 928], "entities": [{"type": "Person", "text": "Takeda family"}]}]}, {"type": "participantIn", "sentence": "\"With the date of our extraordinary general meeting of shareholders now set, we are looking forward to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction,\" Chief Executive Christophe Weber said.", "score": 0.548738, "arguments": [{"text": "our", "location": [948, 951], "entities": [{"type": "Organization", "text": "its"}]}, {"text": "meeting", "location": [974, 981], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "participantIn", "sentence": "\"With the date of our extraordinary general meeting of shareholders now set, we are looking forward to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction,\" Chief Executive Christophe Weber said.", "score": 0.917476, "arguments": [{"text": "shareholders", "location": [985, 997], "entities": [{"type": "Person", "text": "shareholders"}]}, {"text": "meeting", "location": [974, 981], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "agentOf", "sentence": "\"With the date of our extraordinary general meeting of shareholders now set, we are looking forward to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction,\" Chief Executive Christophe Weber said.", "score": 0.989981, "arguments": [{"text": "Christophe Weber", "location": [1169, 1185], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "said", "location": [1186, 1190], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "Weber said last week he was confident of securing investor backing for the purchase of Shire, but until now it has not been clear when exactly Takeda would call its EGM.", "score": 0.997542, "arguments": [{"text": "Weber", "location": [1821, 1826], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "said", "location": [1827, 1831], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "managerOf", "sentence": "Weber -- a Frenchman and the first non-Japanese CEO of the company -- believes that buying Shire will accelerate Takeda's growth and increase its international reach, boosting earnings.", "score": 0.472678, "arguments": [{"text": "CEO", "location": [1240, 1243], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "company", "location": [1251, 1258], "entities": [{"type": "Organization", "text": "Shire"}]}]}, {"type": "employedBy", "sentence": "The transaction is still awaiting approval from European regulators, although two people familiar with the matter told Reuters last week that Takeda was set to win conditional EU antitrust approval.", "score": 0.631878, "arguments": [{"text": "regulators", "location": [1435, 1445], "entities": [{"type": "Person", "text": "regulators"}]}, {"text": "European", "location": [1426, 1434], "entities": [{"type": "GeopoliticalEntity", "text": "European", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "hasAttribute", "sentence": "LONDON (Reuters) - Japan's Takeda Pharmaceutical will hold an investor vote on its $62 billion acquisition of Shire next month and aims to close the deal on Jan. 8, signalling its confidence in securing the required support.", "score": 0.54532, "arguments": [{"text": "its", "location": [79, 82], "entities": [{"type": "Organization", "text": "its"}]}, {"text": "$62 billion", "location": [83, 94], "entities": [{"type": "Money", "text": "$62 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "agentOf", "sentence": "The transaction is still awaiting approval from European regulators, although two people familiar with the matter told Reuters last week that Takeda was set to win conditional EU antitrust approval.", "score": 0.846481, "arguments": [{"text": "people", "location": [1460, 1466], "entities": [{"type": "Person", "text": "people"}]}, {"text": "told", "location": [1492, 1496], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "affectedBy", "sentence": "The transaction is still awaiting approval from European regulators, although two people familiar with the matter told Reuters last week that Takeda was set to win conditional EU antitrust approval.", "score": 0.921743, "arguments": [{"text": "Reuters", "location": [1497, 1504], "entities": [{"type": "Organization", "text": "Reuters", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "told", "location": [1492, 1496], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "timeOf", "sentence": "The transaction is still awaiting approval from European regulators, although two people familiar with the matter told Reuters last week that Takeda was set to win conditional EU antitrust approval.", "score": 0.903787, "arguments": [{"text": "last week", "location": [1505, 1514], "entities": [{"type": "Date", "text": "last week"}]}, {"text": "told", "location": [1492, 1496], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "Takeda has offered to divest Shire's experimental drug SHP647 to address concerns about overlap in inflammatory bowel disease treatments.", "score": 0.974941, "arguments": [{"text": "Takeda", "location": [1577, 1583], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co Ltd"}]}, {"text": "offered", "location": [1588, 1595], "entities": [{"type": "EventCommunication", "text": "offered"}]}]}, {"type": "agentOf", "sentence": "Takeda has offered to divest Shire's experimental drug SHP647 to address concerns about overlap in inflammatory bowel disease treatments.", "score": 0.736775, "arguments": [{"text": "SHP647", "location": [1632, 1638], "entities": [{"type": "Person", "text": "SHP647"}]}, {"text": "address", "location": [1642, 1649], "entities": [{"type": "EventCommunication", "text": "address"}]}]}, {"type": "timeOf", "sentence": "Weber said last week he was confident of securing investor backing for the purchase of Shire, but until now it has not been clear when exactly Takeda would call its EGM.", "score": 0.943401, "arguments": [{"text": "last week", "location": [1832, 1841], "entities": [{"type": "Date", "text": "last week"}]}, {"text": "said", "location": [1827, 1831], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "employedBy", "sentence": "Weber said last week he was confident of securing investor backing for the purchase of Shire, but until now it has not been clear when exactly Takeda would call its EGM.", "score": 0.469384, "arguments": [{"text": "Takeda", "location": [1964, 1970], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co Ltd"}]}, {"text": "Shire", "location": [1908, 1913], "entities": [{"type": "Organization", "text": "Shire"}]}]}, {"type": "agentOf", "sentence": "Weber said last week he was confident of securing investor backing for the purchase of Shire, but until now it has not been clear when exactly Takeda would call its EGM.", "score": 0.877972, "arguments": [{"text": "Takeda", "location": [1964, 1970], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co Ltd"}]}, {"text": "call", "location": [1977, 1981], "entities": [{"type": "EventCommunication", "text": "call"}]}]}, {"type": "affectedBy", "sentence": "Weber said last week he was confident of securing investor backing for the purchase of Shire, but until now it has not been clear when exactly Takeda would call its EGM.", "score": 0.584159, "arguments": [{"text": "EGM", "location": [1986, 1989], "entities": [{"type": "Organization", "text": "EGM"}]}, {"text": "call", "location": [1977, 1981], "entities": [{"type": "EventCommunication", "text": "call"}]}]}, {"type": "partOf", "sentence": "Weber said last week he was confident of securing investor backing for the purchase of Shire, but until now it has not been clear when exactly Takeda would call its EGM.", "score": 0.902789, "arguments": [{"text": "EGM", "location": [1986, 1989], "entities": [{"type": "Organization", "text": "EGM"}]}, {"text": "its", "location": [1982, 1985], "entities": [{"type": "GeopoliticalEntity", "text": "Shire"}]}]}, {"type": "agentOf", "sentence": "LONDON (Reuters) - Japan's Takeda Pharmaceutical will hold an investor vote on its $62 billion acquisition of Shire next month and aims to close the deal on Jan. 8, signalling its confidence in securing the required support.", "score": 0.579066, "arguments": [{"text": "its", "location": [79, 82], "entities": [{"type": "Organization", "text": "its"}]}, {"text": "acquisition", "location": [95, 106], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "hasAttribute", "sentence": "Takeda, which has a market value of around $32 billion, has secured a $30.9 billion bridge loan to help finance the Shire acquisition and some investors are concerned as to how well it will cope with debt repayments.", "score": 0.772155, "arguments": [{"text": "which", "location": [1999, 2004], "entities": [{"type": "Organization", "text": "EGM"}]}, {"text": "$32 billion", "location": [2034, 2045], "entities": [{"type": "Money", "text": "$32 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "Takeda, which has a market value of around $32 billion, has secured a $30.9 billion bridge loan to help finance the Shire acquisition and some investors are concerned as to how well it will cope with debt repayments.", "score": 0.417126, "arguments": [{"text": "which", "location": [1999, 2004], "entities": [{"type": "Organization", "text": "EGM"}]}, {"text": "$30.9 billion", "location": [2061, 2074], "entities": [{"type": "Money", "text": "$30.9 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "agentOf", "sentence": "Takeda, which has a market value of around $32 billion, has secured a $30.9 billion bridge loan to help finance the Shire acquisition and some investors are concerned as to how well it will cope with debt repayments.", "score": 0.708486, "arguments": [{"text": "Shire", "location": [2107, 2112], "entities": [{"type": "Organization", "text": "Shire"}]}, {"text": "acquisition", "location": [2113, 2124], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "basedIn", "sentence": "The Japanese company struck its agreement to take over Shire in May, in a deal that will propel it into the top 10 rankings of global drugmakers by sales.", "score": 0.981252, "arguments": [{"text": "company", "location": [2221, 2228], "entities": [{"type": "Organization", "text": "Shire"}]}, {"text": "Japanese", "location": [2212, 2220], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "(Reporting by Ben Hirschler; editing by Jason Neely and Louise Heavens) By Ben Hirschler Stocks treated in this article : Takeda Pharmaceutical Co Ltd , Roche Holding Ltd. , Shire", "score": 0.561924, "arguments": [{"text": "Ben Hirschler", "location": [2600, 2613], "entities": [{"type": "Person", "text": "Ben Hirschler\nStocks"}]}, {"text": "Reporting", "location": [2587, 2596], "entities": [{"type": "EventCommunication", "text": "Reporting"}]}]}, {"type": "hasAttribute", "sentence": "LONDON (Reuters) - Japan's Takeda Pharmaceutical will hold an investor vote on its $62 billion acquisition of Shire next month and aims to close the deal on Jan. 8, signalling its confidence in securing the required support.", "score": 0.68451, "arguments": [{"text": "Shire", "location": [110, 115], "entities": [{"type": "Organization", "text": "Shire"}]}, {"text": "$62 billion", "location": [83, 94], "entities": [{"type": "Money", "text": "$62 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "timeOf", "sentence": "LONDON (Reuters) - Japan's Takeda Pharmaceutical will hold an investor vote on its $62 billion acquisition of Shire next month and aims to close the deal on Jan. 8, signalling its confidence in securing the required support.", "score": 0.902771, "arguments": [{"text": "next month", "location": [116, 126], "entities": [{"type": "Date", "text": "next month"}]}, {"text": "acquisition", "location": [95, 106], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "Shares in London-listed Shire rose 3 percent on the news, hitting their highest level since Takeda first disclosed its interest in buying the rare diseases specialist in March.", "score": 0.626596, "arguments": [{"text": "Takeda", "location": [317, 323], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "disclosed", "location": [330, 339], "entities": [{"type": "EventCommunication", "text": "disclosed"}]}]}, {"type": "hasAttribute", "sentence": "Shares in London-listed Shire rose 3 percent on the news, hitting their highest level since Takeda first disclosed its interest in buying the rare diseases specialist in March.", "score": 0.952783, "arguments": [{"text": "specialist", "location": [381, 391], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co Ltd"}]}, {"text": "diseases", "location": [372, 380], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "affectedBy", "sentence": "The deal would be the biggest-ever overseas acquisition by a Japanese company - but it needs two-thirds support from shareholders, some of whom are worried about the enlarged company's resulting debt burden.", "score": 0.510604, "arguments": [{"text": "company", "location": [472, 479], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [446, 457], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "basedIn", "sentence": "The deal would be the biggest-ever overseas acquisition by a Japanese company - but it needs two-thirds support from shareholders, some of whom are worried about the enlarged company's resulting debt burden.", "score": 0.986137, "arguments": [{"text": "company", "location": [472, 479], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Japanese", "location": [463, 471], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}], "keywords": [{"text": "Takeda", "sentiment": {"score": -0.0448537, "label": "negative"}, "relevance": 0.982002}, {"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.829742}, {"text": "founding Takeda family", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.800722}, {"text": "extraordinary general meeting", "sentiment": {"score": 0.738908, "label": "positive"}, "relevance": 0.772268}, {"text": "exactly Takeda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.610356}, {"text": "Shire", "sentiment": {"score": -0.11834, "label": "negative"}, "relevance": 0.557918}, {"text": "London-listed Shire", "sentiment": {"score": 0.41776, "label": "positive"}, "relevance": 0.496661}, {"text": "rare diseases specialist", "sentiment": {"score": -0.294672, "label": "negative"}, "relevance": 0.469876}, {"text": "Executive Christophe Weber", "sentiment": {"score": 0.207328, "label": "positive"}, "relevance": 0.461481}, {"text": "biggest-ever overseas acquisition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.448332}, {"text": "Ben Hirschler", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.441493}, {"text": "Japanese company", "sentiment": {"score": -0.484551, "label": "negative"}, "relevance": 0.435844}, {"text": "EU antitrust approval", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.429733}, {"text": "inflammatory bowel disease", "sentiment": {"score": -0.783712, "label": "negative"}, "relevance": 0.423997}, {"text": "experimental drug SHP647", "sentiment": {"score": -0.783712, "label": "negative"}, "relevance": 0.418292}, {"text": "Shire acquisition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.41817}, {"text": "Roche Holding Ltd.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.41341}, {"text": "new gene therapies", "sentiment": {"score": -0.454906, "label": "negative"}, "relevance": 0.385619}, {"text": "enlarged company", "sentiment": {"score": -0.535826, "label": "negative"}, "relevance": 0.313453}, {"text": "investor vote", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.306233}, {"text": "shareholders", "sentiment": {"score": 0.732279, "label": "positive"}, "relevance": 0.30296}, {"text": "two-thirds support", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.301493}, {"text": "required support", "sentiment": {"score": 0.506845, "label": "positive"}, "relevance": 0.301153}, {"text": "EGM", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.296499}, {"text": "highest level", "sentiment": {"score": -0.294672, "label": "negative"}, "relevance": 0.295249}, {"text": "non-Japanese CEO", "sentiment": {"score": 0.223648, "label": "positive"}, "relevance": 0.291806}, {"text": "debt burden", "sentiment": {"score": -0.535826, "label": "negative"}, "relevance": 0.288917}, {"text": "European regulators", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.283231}, {"text": "enlarged group", "sentiment": {"score": -0.27119, "label": "negative"}, "relevance": 0.281835}, {"text": "financial benefits", "sentiment": {"score": 0.725649, "label": "positive"}, "relevance": 0.281548}, {"text": "international reach", "sentiment": {"score": 0.494338, "label": "positive"}, "relevance": 0.274887}, {"text": "debt repayments", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.274152}, {"text": "investor backing", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.274024}, {"text": "United States", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.272839}, {"text": "market value", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.268823}, {"text": "global drugmakers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.265233}, {"text": "deal", "sentiment": {"score": -0.436664, "label": "negative"}, "relevance": 0.264485}, {"text": "Jason Neely", "sentiment": {"score": 0.48302, "label": "positive"}, "relevance": 0.263553}, {"text": "Louise Heavens", "sentiment": {"score": 0.48302, "label": "positive"}, "relevance": 0.26299}, {"text": "bridge loan", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.261732}, {"text": "new drug", "sentiment": {"score": -0.454906, "label": "negative"}, "relevance": 0.258755}, {"text": "significant challenges", "sentiment": {"score": -0.27119, "label": "negative"}, "relevance": 0.25373}, {"text": "transaction", "sentiment": {"score": 0.725649, "label": "positive"}, "relevance": 0.216548}]}, "extracted_metadata": {"sha1": "5210ec6acc18f324858fd555d6b0466bf33bc977", "filename": "1542025631875.zip-2aeae6377536de4c45122d4508720f27.xml", "file_type": "json"}, "title": "Takeda sets vote date, aims to close $62 billion Shire deal January 8", "forum_title": "Stock Market Quotes and News : Equities, Indexes, Commodities, Forex on MarketScreener.com"}, {"id": "3tOXT-srDPP8atBRbbUO0l-TutwIDLoG_XDsd9hSG3CUs-CRTXUW-TQwQZf5p68o", "result_metadata": {"score": 35.903908}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Publication of Circular", "relevance": 0.33, "type": "PrintMedia"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Publication of Circular and Notice of Extraordinary General Meeting of Shareholders", "keywords": [{"text": "Extraordinary General Meeting"}, {"text": "Shareholders"}, {"text": "Notice"}, {"text": "Circular"}], "entities": [{"type": "PrintMedia", "text": "Publication of Circular"}]}, "sentence": "Takeda Pharmaceutical : Announces Publication of Circular and Notice of Extraordinary General Meeting of Shareholders in relation to the Proposed Acquisition of Shire | MarketScreener", "object": {"text": "in relation to the Proposed Acquisition of Shire | MarketScreener", "keywords": [{"text": "Proposed Acquisition"}, {"text": "relation"}, {"text": "Shire"}, {"text": "MarketScreener"}], "entities": [{"type": "Company", "text": "Shire"}]}, "action": {"verb": {"text": "Announces", "tense": "present"}, "text": "Announces", "normalized": "Announces"}}], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.794194, "label": "/business and industrial/company/merger and acquisition"}, {"score": 0.406035, "label": "/business and industrial/pharmaceutical industry"}], "relations": [{"type": "partOf", "sentence": "Takeda Pharmaceutical : Announces Publication of Circular and Notice of Extraordinary General Meeting of Shareholders in relation to the Proposed Acquisition of Shire | MarketScreener", "score": 0.380423, "arguments": [{"text": "Acquisition of Shire", "location": [146, 166], "entities": [{"type": "Organization", "text": "Acquisition of Shire"}]}, {"text": "Notice of Extraordinary General Meeting of Shareholders", "location": [62, 117], "entities": [{"type": "Organization", "text": "Notice of Extraordinary General Meeting of Shareholders"}]}]}], "keywords": [{"text": "Extraordinary General Meeting", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.952837}, {"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.839887}, {"text": "Proposed Acquisition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.789179}, {"text": "Shareholders", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.448201}, {"text": "Notice", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.392367}, {"text": "Shire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.37935}, {"text": "relation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.376241}, {"text": "Circular", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.372256}, {"text": "Publication", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.246081}]}, "crawl_date": "2018-11-12T07:38:38Z", "url": "https://www.marketscreener.com/TAKEDA-PHARMACEUTICAL-CO-6491073/news/Takeda-Pharmaceutical-Announces-Publication-of-Circular-and-Notice-of-Extraordinary-General-Meetin-27589065/", "host": "marketscreener.com", "text": "Attachments Original document Permalink Disclaimer Takeda Pharmaceutical Co.", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-12T00:00:00Z", "enriched_text": {"entities": [{"count": 24, "sentiment": {"score": 0.213882, "label": "positive"}, "text": "Takeda", "relevance": 0.892661, "type": "Person"}, {"count": 18, "sentiment": {"score": 0.13908, "label": "positive"}, "text": "Takeda", "relevance": 0.842427, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company", "relevance": 0.495402, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "President and Chief Executive Officer of Takeda", "relevance": 0.340918, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co. Ltd.", "relevance": 0.311958, "type": "Company"}, {"count": 6, "sentiment": {"score": 0.410785, "label": "positive"}, "text": "Shire", "relevance": 0.253647, "type": "Company"}, {"count": 6, "sentiment": {"score": 0.308459, "label": "positive"}, "text": "Japan", "relevance": 0.249354, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 3, "sentiment": {"score": -0.325145, "label": "negative"}, "text": "Shire", "relevance": 0.201384, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire plc", "relevance": 0.201183, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 3, "sentiment": {"score": 0.415573, "label": "positive"}, "text": "United States", "relevance": 0.195752, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Securities and Exchange Commission", "relevance": 0.181546, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "U.S. Securities and Exchange Commission", "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}}, {"count": 6, "sentiment": {"score": 0.0777938, "label": "positive"}, "text": "Dealing Disclosures", "relevance": 0.180976, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "solicitation", "relevance": 0.173394, "type": "Crime"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.169231, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Osaka", "relevance": 0.167671, "type": "Location", "disambiguation": {"subtype": ["JapaneseDesignatedCity", "OlympicBiddingCity", "City"], "name": "Osaka", "dbpedia_resource": "http://dbpedia.org/resource/Osaka"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "INTEX Osaka", "relevance": 0.165666, "type": "Company"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "London", "relevance": 0.161443, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tokyo Stock Exchange", "relevance": 0.156318, "type": "Company", "disambiguation": {"subtype": [], "name": "Tokyo Stock Exchange", "dbpedia_resource": "http://dbpedia.org/resource/Tokyo_Stock_Exchange"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Christophe Weber", "relevance": 0.150419, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ARIAD Pharmaceuticals", "relevance": 0.150414, "type": "Company", "disambiguation": {"subtype": [], "name": "ARIAD Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/ARIAD_Pharmaceuticals"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.146484, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.273174, "label": "negative"}, "text": "Entyvio", "relevance": 0.145052, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "European Commission", "relevance": 0.144739, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0.74301, "label": "positive"}, "text": "Takashi Okubo", "relevance": 0.141892, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Kazumi Kobayashi", "relevance": 0.141591, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tsuyoshi Tada", "relevance": 0.141227, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.639078, "label": "positive"}, "text": "Elissa Johnsen", "relevance": 0.140909, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.K.", "relevance": 0.140804, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UK", "relevance": 0.139439, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "New York", "relevance": 0.137569, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "New York, Lincolnshire", "dbpedia_resource": "http://dbpedia.org/resource/New_York,_Lincolnshire"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Investor Relations", "relevance": 0.130449, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chris Ryall", "relevance": 0.127292, "type": "Person", "disambiguation": {"subtype": [], "name": "Chris Ryall", "dbpedia_resource": "http://dbpedia.org/resource/Chris_Ryall"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Kal Goldberg", "relevance": 0.121129, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Rollo Head", "relevance": 0.117988, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Anjali Unnikrishnan", "relevance": 0.113503, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "James Murgatroyd", "relevance": 0.105058, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.105058, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "takeda.ir.contact@takeda.com", "relevance": 0.105058, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Kazumi.Kobayashi@takeda.com", "relevance": 0.105058, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Elissa.Johnsen@takeda.com", "relevance": 0.105058, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tsuyoshi.Tada@takeda.com", "relevance": 0.105058, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1.4 billion", "relevance": 0.105058, "type": "Quantity"}], "sentiment": {"document": {"score": 0.512678, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "by Takeda Pharmaceutical Company Limited ('Takeda' or the 'Company')", "keywords": [{"text": "Takeda Pharmaceutical Company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " Osaka, Japan, November 12 , 2018 --- Further to the announcement on May 8, 2018, by Takeda Pharmaceutical Company Limited ('Takeda' or the 'Company') regarding the proposed acquisition (the 'Acquisition') of Shire plc ('Shire'), Takeda announces the publication of a circular (the 'Circular') containing a notice of its decision to hold an Extraordinary General Meeting of Shareholders (the 'EGM') to vote on the necessary matters relating to the Acquisition.", "object": {"text": "the proposed acquisition (the 'Acquisition') of Shire plc ('Shire')", "keywords": [{"text": "Shire plc"}, {"text": "acquisition"}], "entities": [{"type": "Company", "text": "Shire plc", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}]}, "action": {"verb": {"text": "regard", "tense": "present"}, "text": "regarding", "normalized": "regard"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Osaka, Japan, November 12 , 2018 --- Further to the announcement on May 8, 2018, by Takeda Pharmaceutical Company Limited ('Takeda' or the 'Company') regarding the proposed acquisition (the 'Acquisition') of Shire plc ('Shire'), Takeda announces the publication of a circular (the 'Circular') containing a notice of its decision to hold an Extraordinary General Meeting of Shareholders (the 'EGM') to vote on the necessary matters relating to the Acquisition.", "object": {"text": "the publication of a circular (the 'Circular') containing a notice of its decision to hold an Extraordinary General Meeting of Shareholders (the 'EGM') to vote on the necessary matters relating to the Acquisition", "keywords": [{"text": "Extraordinary General Meeting"}, {"text": "necessary matters"}, {"text": "EGM"}, {"text": "Circular"}]}, "action": {"verb": {"text": "announce", "tense": "present"}, "text": "announces", "normalized": "announce"}}, {"subject": {"text": "shareholders", "keywords": [{"text": "shareholders"}]}, "sentence": " The procedures and timings for shareholders to vote on the resolutions are set out in the notice of the EGM in the Circular.", "object": {"text": "on the resolutions", "keywords": [{"text": "resolutions"}]}, "action": {"verb": {"text": "vote", "tense": "future"}, "text": "to vote", "normalized": "to vote"}}, {"subject": {"text": "timings for shareholders to vote on the resolutions", "keywords": [{"text": "shareholders"}, {"text": "timings"}, {"text": "resolutions"}]}, "sentence": " The procedures and timings for shareholders to vote on the resolutions are set out in the notice of the EGM in the Circular.", "object": {"text": "in the notice of the EGM in the Circular", "keywords": [{"text": "EGM"}, {"text": "notice"}, {"text": "Circular"}]}, "action": {"verb": {"text": "set", "tense": "past"}, "text": "are set", "normalized": "be set"}}, {"subject": {"text": "The Circular"}, "sentence": " The Circular will shortly be available to view on the Company's website at www.takeda.com/investors/offer-for-shire .", "object": {"text": "available to view on the Company's website at www.takeda.com/investors/offer-for-shire", "keywords": [{"text": "Company"}, {"text": "website"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "'The acquisition of Shire", "keywords": [{"text": "Shire"}, {"text": "acquisition"}], "entities": [{"type": "Company", "text": "Shire"}]}, "sentence": " 'The acquisition of Shire will accelerate our strategic transformation to create a stronger, more global and more competitive company with the financial strength to continue investing in delivering highly innovative medicines and transformative care to patients around the world,' said Christophe Weber, President and Chief Executive Officer of Takeda.", "object": {"text": "our strategic transformation", "keywords": [{"text": "strategic transformation"}]}, "action": {"verb": {"text": "accelerate", "tense": "future"}, "text": "will accelerate", "normalized": "will accelerate"}}, {"subject": {"text": "'The acquisition of Shire", "keywords": [{"text": "Shire"}, {"text": "acquisition"}], "entities": [{"type": "Company", "text": "Shire"}]}, "sentence": " 'The acquisition of Shire will accelerate our strategic transformation to create a stronger, more global and more competitive company with the financial strength to continue investing in delivering highly innovative medicines and transformative care to patients around the world,' said Christophe Weber, President and Chief Executive Officer of Takeda.", "object": {"text": "a stronger, more global and more competitive company", "keywords": [{"text": "competitive company"}]}, "action": {"verb": {"text": "create", "tense": "future"}, "text": "to create", "normalized": "to create"}}, {"subject": {"text": "highly innovative medicines and transformative care", "keywords": [{"text": "transformative care"}, {"text": "medicines"}]}, "sentence": " 'The acquisition of Shire will accelerate our strategic transformation to create a stronger, more global and more competitive company with the financial strength to continue investing in delivering highly innovative medicines and transformative care to patients around the world,' said Christophe Weber, President and Chief Executive Officer of Takeda.", "object": {"text": "to patients around the world", "keywords": [{"text": "patients"}, {"text": "world"}]}, "action": {"verb": {"text": "deliver", "tense": "present"}, "text": "delivering", "normalized": "deliver"}}, {"subject": {"text": "Christophe Weber, President and Chief Executive Officer of Takeda", "keywords": [{"text": "Chief Executive Officer"}, {"text": "Christophe Weber"}, {"text": "Takeda"}, {"text": "President"}], "entities": [{"type": "Person", "text": "Christophe Weber"}, {"type": "JobTitle", "text": "President and Chief Executive Officer of Takeda"}]}, "sentence": " 'The acquisition of Shire will accelerate our strategic transformation to create a stronger, more global and more competitive company with the financial strength to continue investing in delivering highly innovative medicines and transformative care to patients around the world,' said Christophe Weber, President and Chief Executive Officer of Takeda.", "object": {"text": "'The acquisition of Shire will accelerate our strategic transformation to create a stronger, more global and more competitive company with the financial strength to continue investing in delivering highly innovative medicines and transformative care to patients around the world", "keywords": [{"text": "highly innovative medicines"}, {"text": "transformative care"}, {"text": "strategic transformation"}, {"text": "financial strength"}], "entities": [{"type": "Company", "text": "Shire"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Shareholders", "keywords": [{"text": "Shareholders"}]}, "sentence": " 'With the date of our Extraordinary General Meeting of Shareholders now set, we are looking forward to continuing our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction.'", "action": {"verb": {"text": "set", "tense": "past"}, "text": "set", "normalized": "set"}}, {"subject": {"text": "we"}, "sentence": " 'With the date of our Extraordinary General Meeting of Shareholders now set, we are looking forward to continuing our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction.'", "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "we"}, "sentence": " 'With the date of our Extraordinary General Meeting of Shareholders now set, we are looking forward to continuing our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction.'", "object": {"text": "to continuing our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction", "keywords": [{"text": "financial benefits"}, {"text": "shareholders"}, {"text": "dialogue"}, {"text": "transaction"}]}, "action": {"verb": {"text": "look", "tense": "present"}, "text": "are looking", "normalized": "be look"}}, {"subject": {"text": "we"}, "sentence": " 'With the date of our Extraordinary General Meeting of Shareholders now set, we are looking forward to continuing our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction.'", "object": {"text": "our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction", "keywords": [{"text": "financial benefits"}, {"text": "shareholders"}, {"text": "dialogue"}, {"text": "transaction"}]}, "action": {"verb": {"text": "continue", "tense": "future"}, "text": "continuing", "normalized": "continue"}}, {"subject": {"text": "Takeda and Shire", "keywords": [{"text": "Takeda"}, {"text": "Shire"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Company", "text": "Shire"}]}, "sentence": " Further to the announcement on October 26, 2018, Takeda and Shire have held discussions with the European Commission ('EC') in relation to the future potential overlap in the area of inflammatory bowel disease between Takeda's marketed product Entyvio (vedolizumab) and Shire's pipeline compound SHP647, which is currently in Phase III clinical trials.", "object": {"text": "held discussions with the European Commission ('EC')", "keywords": [{"text": "discussions"}], "entities": [{"type": "Organization", "text": "European Commission"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Takeda and Shire", "keywords": [{"text": "Takeda"}, {"text": "Shire"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Company", "text": "Shire"}]}, "sentence": " Further to the announcement on October 26, 2018, Takeda and Shire have held discussions with the European Commission ('EC') in relation to the future potential overlap in the area of inflammatory bowel disease between Takeda's marketed product Entyvio (vedolizumab) and Shire's pipeline compound SHP647, which is currently in Phase III clinical trials.", "object": {"text": "discussions", "keywords": [{"text": "discussions"}]}, "action": {"verb": {"text": "hold", "tense": "past"}, "text": "have held", "normalized": "have hold"}}, {"subject": {"text": "product Entyvio (vedolizumab) and Shire's pipeline compound SHP647", "keywords": [{"text": "pipeline compound"}, {"text": "product Entyvio"}, {"text": "Shire"}, {"text": "vedolizumab"}], "entities": [{"type": "Company", "text": "Entyvio"}, {"type": "Organization", "text": "Shire"}]}, "sentence": " Further to the announcement on October 26, 2018, Takeda and Shire have held discussions with the European Commission ('EC') in relation to the future potential overlap in the area of inflammatory bowel disease between Takeda's marketed product Entyvio (vedolizumab) and Shire's pipeline compound SHP647, which is currently in Phase III clinical trials.", "object": {"text": "in Phase III clinical trials", "keywords": [{"text": "Phase"}, {"text": "clinical trials"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " As a result of those discussions, Takeda has offered commitments to divest SHP647 and certain associated rights, with a view to the EC granting a Phase I conditional clearance for the Acquisition and not initiating proceedings under Article 6(1)(c) of Council Regulation (EC) 139/2004.", "object": {"text": "offered commitments to divest SHP647 and certain associated rights", "keywords": [{"text": "certain associated rights"}, {"text": "commitments"}, {"text": "SHP647"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " As a result of those discussions, Takeda has offered commitments to divest SHP647 and certain associated rights, with a view to the EC granting a Phase I conditional clearance for the Acquisition and not initiating proceedings under Article 6(1)(c) of Council Regulation (EC) 139/2004.", "object": {"text": "commitments to divest SHP647 and certain associated rights, with a view to the EC granting a Phase I conditional clearance for the Acquisition and not initiating proceedings under Article 6(1)(c) of Council Regulation (EC) 139/2004", "keywords": [{"text": "certain associated rights"}, {"text": "conditional clearance"}, {"text": "Council Regulation"}, {"text": "EC"}]}, "action": {"verb": {"text": "offer", "tense": "past"}, "text": "has offered", "normalized": "have offer"}}, {"subject": {"text": "proceedings", "keywords": [{"text": "proceedings"}]}, "sentence": " As a result of those discussions, Takeda has offered commitments to divest SHP647 and certain associated rights, with a view to the EC granting a Phase I conditional clearance for the Acquisition and not initiating proceedings under Article 6(1)(c) of Council Regulation (EC) 139/2004.", "action": {"verb": {"text": "initiate", "tense": "present", "negated": true}, "text": "initiating", "normalized": "initiate"}}, {"subject": {"text": "The EC", "keywords": [{"text": "EC"}]}, "sentence": " The EC will issue its decision in relation to the Acquisition on or before November 20, 2018 and an announcement containing the substance of that decision will be made in due course.", "object": {"text": "its decision in relation to the Acquisition", "keywords": [{"text": "relation"}, {"text": "decision"}, {"text": "Acquisition"}]}, "action": {"verb": {"text": "issue", "tense": "future"}, "text": "will issue", "normalized": "will issue"}}, {"subject": {"text": "an announcement", "keywords": [{"text": "announcement"}]}, "sentence": " The EC will issue its decision in relation to the Acquisition on or before November 20, 2018 and an announcement containing the substance of that decision will be made in due course.", "object": {"text": "the substance of that decision will be made in due course", "keywords": [{"text": "substance"}, {"text": "decision"}, {"text": "course"}]}, "action": {"verb": {"text": "contain", "tense": "present"}, "text": "containing", "normalized": "contain"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Subject to receiving the necessary regulatory and shareholder approvals, Takeda intends that completion of the Acquisition will take place on January 8, 2019 or as soon as practicable thereafter following approval from the EC to proceed to completion.", "object": {"text": "the necessary regulatory and shareholder approvals", "keywords": [{"text": "shareholder approvals"}]}, "action": {"verb": {"text": "receive", "tense": "future"}, "text": "receiving", "normalized": "receive"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Subject to receiving the necessary regulatory and shareholder approvals, Takeda intends that completion of the Acquisition will take place on January 8, 2019 or as soon as practicable thereafter following approval from the EC to proceed to completion.", "object": {"text": "that completion of the Acquisition will take place on January 8, 2019 or as soon as practicable thereafter following approval from the EC to proceed to completion", "keywords": [{"text": "completion"}, {"text": "EC"}, {"text": "approval"}, {"text": "Acquisition"}]}, "action": {"verb": {"text": "intend", "tense": "present"}, "text": "intends", "normalized": "intend"}}, {"subject": {"text": "approval", "keywords": [{"text": "approval"}]}, "sentence": " Subject to receiving the necessary regulatory and shareholder approvals, Takeda intends that completion of the Acquisition will take place on January 8, 2019 or as soon as practicable thereafter following approval from the EC to proceed to completion.", "object": {"text": "from the EC to proceed to completion", "keywords": [{"text": "EC"}, {"text": "completion"}]}, "action": {"verb": {"text": "follow", "tense": "present"}, "text": "following", "normalized": "follow"}}, {"subject": {"text": "Further announcements", "keywords": [{"text": "announcements"}]}, "sentence": " Further announcements will be made as appropriate.", "object": {"text": "made as appropriate"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Further announcements", "keywords": [{"text": "announcements"}]}, "sentence": " Further announcements will be made as appropriate.", "object": {"text": "as appropriate"}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "will be made", "normalized": "will be make"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda also reaffirms the compelling strategic and financial rationale for the Acquisition:", "object": {"text": "the compelling strategic and financial rationale for the Acquisition", "keywords": [{"text": "financial rationale"}, {"text": "Acquisition"}]}, "action": {"verb": {"text": "reaffirm", "tense": "present"}, "text": "reaffirms", "normalized": "reaffirm"}}, {"subject": {"text": "The Acquisition", "keywords": [{"text": "Acquisition"}]}, "sentence": " The Acquisition will create a global, values-based, R&D-driven biopharmaceutical company incorporated and headquartered in Japan, with an attractive geographic footprint and leading positions in Japan and the United States, respectively the third and first largest pharmaceutical markets globally.", "object": {"text": "a global, values-based, R&D-driven biopharmaceutical company incorporated and headquartered in Japan,", "keywords": [{"text": "R&D-driven biopharmaceutical company"}, {"text": "Japan"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}]}, "action": {"verb": {"text": "create", "tense": "future"}, "text": "will create", "normalized": "will create"}}, {"subject": {"text": "The Acquisition", "keywords": [{"text": "Acquisition"}]}, "sentence": " The Acquisition will strengthen Takeda's presence across two of its three core therapeutic areas - gastroenterology (GI) and neuroscience - and provide leading positions in rare diseases and plasma-derived therapies.", "object": {"text": "Takeda's presence across two of its three core therapeutic areas - gastroenterology (GI) and neuroscience - and provide leading positions in rare diseases and plasma-derived therapies", "keywords": [{"text": "core therapeutic areas"}, {"text": "plasma-derived therapies"}, {"text": "rare diseases"}, {"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "strengthen", "tense": "future"}, "text": "will strengthen", "normalized": "will strengthen"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Following completion of the Acquisition, Takeda will continue to focus on the acceleration of its oncology business, following its recent acquisition of ARIAD Pharmaceuticals.", "action": {"verb": {"text": "continue", "tense": "future"}, "text": "will continue to focus", "normalized": "will continue to focus"}}, {"subject": {"text": "Takeda's vaccine business", "keywords": [{"text": "vaccine business"}, {"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " In addition, Takeda's vaccine business will continue to address the world's most pressing public health needs.", "object": {"text": "the world", "keywords": [{"text": "world"}]}, "action": {"verb": {"text": "address", "tense": "future"}, "text": "will continue to address", "normalized": "will continue to address"}}, {"subject": {"text": "the world", "keywords": [{"text": "world"}]}, "sentence": " In addition, Takeda's vaccine business will continue to address the world's most pressing public health needs.", "object": {"text": "most pressing public health needs", "keywords": [{"text": "public health needs"}], "entities": []}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "has", "normalized": "has"}}, {"subject": {"text": "The Acquisition", "keywords": [{"text": "Acquisition"}]}, "sentence": " The Acquisition will also create a highly complementary, modality-diverse pipeline and a strengthened R&D engine focused on breakthrough innovation.", "object": {"text": "a highly complementary, modality-diverse pipeline", "keywords": [{"text": "modality-diverse pipeline"}]}, "action": {"verb": {"text": "create", "tense": "future"}, "text": "will also create", "normalized": "will also create"}}, {"subject": {"text": "R&D engine", "keywords": [{"text": "R&D engine"}]}, "sentence": " The Acquisition will also create a highly complementary, modality-diverse pipeline and a strengthened R&D engine focused on breakthrough innovation.", "object": {"text": "on breakthrough innovation", "keywords": [{"text": "breakthrough innovation"}]}, "action": {"verb": {"text": "focus", "tense": "past"}, "text": "focused", "normalized": "focus"}}, {"subject": {"text": "the Acquisition", "keywords": [{"text": "Acquisition"}]}, "sentence": " As a result of greater scale and efficiencies in commercial activities, the Acquisition will enable the combined group to further fuel its R&D investment, better positioning Takeda to deliver highly-innovative medicines and transformative care to patients around the world.", "object": {"text": "the combined group to further fuel its R&D investment, better positioning Takeda to deliver highly-innovative medicines and transformative care to patients around the world", "keywords": [{"text": "better positioning Takeda"}, {"text": "transformative care"}, {"text": "highly-innovative medicines"}, {"text": "R&D investment"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "enable", "tense": "future"}, "text": "will enable", "normalized": "will enable"}}, {"subject": {"text": "its R&D investment, better positioning Takeda to deliver highly-innovative medicines and transformative care to patients around the world", "keywords": [{"text": "better positioning Takeda"}, {"text": "transformative care"}, {"text": "highly-innovative medicines"}, {"text": "R&D investment"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " As a result of greater scale and efficiencies in commercial activities, the Acquisition will enable the combined group to further fuel its R&D investment, better positioning Takeda to deliver highly-innovative medicines and transformative care to patients around the world.", "object": {"text": "the combined group", "keywords": [{"text": "group"}]}, "action": {"verb": {"text": "fuel", "tense": "present"}, "text": "to further fuel", "normalized": "to far fuel"}}, {"subject": {"text": "the Acquisition", "keywords": [{"text": "Acquisition"}]}, "sentence": " In addition to the significant strategic benefits of the transaction, the Acquisition will also deliver compelling financial benefits for the combined group.", "object": {"text": "compelling financial benefits", "keywords": [{"text": "compelling financial benefits"}]}, "action": {"verb": {"text": "deliver", "tense": "future"}, "text": "will also deliver", "normalized": "will also deliver"}}, {"subject": {"text": "The Acquisition", "keywords": [{"text": "Acquisition"}]}, "sentence": " The Acquisition is expected to deliver substantial pre-tax cost synergies of at least $1.4 billion each year by the end of the third fiscal year following completion [1] , with the potential for additional revenue synergies from the complementary geographic and therapeutic focus.", "object": {"text": "substantial pre-tax cost synergies of at least $1.4 billion", "keywords": [{"text": "pre-tax cost synergies"}], "entities": [{"type": "Quantity", "text": "$1.4 billion"}]}, "action": {"verb": {"text": "deliver", "tense": "future"}, "text": "is expected to deliver", "normalized": "be expect to deliver"}}, {"subject": {"text": "The Acquisition", "keywords": [{"text": "Acquisition"}]}, "sentence": " The Acquisition is expected to be significantly accretive to underlying earnings per Takeda share from the first full fiscal year following completion and to produce strong combined cashflows.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "is expected to be", "normalized": "be expect to be"}}, {"subject": {"text": "The Acquisition", "keywords": [{"text": "Acquisition"}]}, "sentence": " The Acquisition is also expected to be earnings accretive per Takeda share on a reported basis within three years post completion.", "object": {"text": "earnings accretive per Takeda share", "keywords": [{"text": "Takeda"}, {"text": "earnings"}, {"text": "share"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "is also expected to be", "normalized": "be also expect to be"}}, {"subject": {"text": "The Acquisition", "keywords": [{"text": "Acquisition"}]}, "sentence": " The Acquisition is expected to result in attractive returns for Takeda shareholders, with the return on invested capital (ROIC) expected to exceed Takeda's cost of capital within the first full fiscal year following completion.", "object": {"text": "in attractive returns for Takeda shareholders", "keywords": [{"text": "Takeda shareholders"}, {"text": "attractive returns"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "result", "tense": "future"}, "text": "is expected to result", "normalized": "be expect to result"}}, {"subject": {"text": "Takeda's cost of capital", "keywords": [{"text": "Takeda"}, {"text": "cost"}, {"text": "capital"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " The Acquisition is expected to result in attractive returns for Takeda shareholders, with the return on invested capital (ROIC) expected to exceed Takeda's cost of capital within the first full fiscal year following completion.", "action": {"verb": {"text": "exceed", "tense": "future"}, "text": "expected to exceed", "normalized": "expect to exceed"}}, {"subject": {"text": "the Acquisition", "keywords": [{"text": "Acquisition"}]}, "sentence": " The substantial cash flow generation expected to result from the Acquisition will enable the combined group to de-lever quickly following completion.", "object": {"text": "the combined group to de-lever quickly following completion", "keywords": [{"text": "quickly following completion"}, {"text": "group"}]}, "action": {"verb": {"text": "enable", "tense": "future"}, "text": "will enable", "normalized": "will enable"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda intends to maintain its investment grade credit rating with a target net debt to Adjusted EBITDA ratio of 2.0x or less within three to five years following completion of the Acquisition, without the need to issue new shares.", "object": {"text": "to maintain its investment grade credit rating with a target net debt to Adjusted EBITDA ratio of 2.0x or less within three to five years following completion of the Acquisition, without the need to issue new shares", "keywords": [{"text": "target net debt"}, {"text": "investment grade credit"}, {"text": "EBITDA ratio"}, {"text": "new shares"}], "entities": [{"type": "Quantity", "text": "five years"}]}, "action": {"verb": {"text": "intend", "tense": "present"}, "text": "intends", "normalized": "intend"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda intends to maintain its investment grade credit rating with a target net debt to Adjusted EBITDA ratio of 2.0x or less within three to five years following completion of the Acquisition, without the need to issue new shares.", "object": {"text": "its investment grade credit rating", "keywords": [{"text": "investment grade credit"}, {"text": "rating"}], "entities": []}, "action": {"verb": {"text": "maintain", "tense": "future"}, "text": "intends to maintain", "normalized": "intend to maintain"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda intends to maintain its investment grade credit rating with a target net debt to Adjusted EBITDA ratio of 2.0x or less within three to five years following completion of the Acquisition, without the need to issue new shares.", "object": {"text": "new shares", "keywords": [{"text": "new shares"}]}, "action": {"verb": {"text": "issue", "tense": "future"}, "text": "to issue", "normalized": "to issue"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " To help accelerate the de-leveraging process and ensure an optimal business mix, Takeda will consider selected disposals of non-core assets.", "object": {"text": "accelerate the de-leveraging process", "keywords": [{"text": "de-leveraging process"}]}, "action": {"verb": {"text": "help", "tense": "future"}, "text": "help", "normalized": "help"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " To help accelerate the de-leveraging process and ensure an optimal business mix, Takeda will consider selected disposals of non-core assets.", "object": {"text": "selected disposals of non-core assets", "keywords": [{"text": "non-core assets"}, {"text": "disposals"}]}, "action": {"verb": {"text": "consider", "tense": "future"}, "text": "will consider", "normalized": "will consider"}}, {"subject": {"text": "An enlarged and well-positioned combined portfolio", "keywords": [{"text": "well-positioned combined portfolio"}]}, "sentence": " An enlarged and well-positioned combined portfolio will strengthen the combined group's ability to invest in the business and deliver returns to Takeda shareholders.", "object": {"text": "the combined group's ability to invest in the business and deliver returns to Takeda shareholders", "keywords": [{"text": "Takeda shareholders"}, {"text": "returns"}, {"text": "ability"}, {"text": "group"}]}, "action": {"verb": {"text": "strengthen", "tense": "future"}, "text": "will strengthen", "normalized": "will strengthen"}}, {"subject": {"text": "the combined group", "keywords": [{"text": "group"}]}, "sentence": " An enlarged and well-positioned combined portfolio will strengthen the combined group's ability to invest in the business and deliver returns to Takeda shareholders.", "object": {"text": "returns to Takeda shareholders", "keywords": [{"text": "Takeda shareholders"}, {"text": "returns"}]}, "action": {"verb": {"text": "deliver", "tense": "present"}, "text": "deliver", "normalized": "deliver"}}], "concepts": [{"text": "Stock market", "relevance": 0.986764, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "U.S. Securities and Exchange Commission", "relevance": 0.92822, "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}, {"text": "Stock exchange", "relevance": 0.832787, "dbpedia_resource": "http://dbpedia.org/resource/Stock_exchange"}, {"text": "Stock", "relevance": 0.832258, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.71022, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.648455, "label": "/finance/financial news"}, {"score": 0.42406, "label": "/finance/investing"}, {"score": 0.42406, "label": "/finance/investing/beginning investing"}], "relations": [{"type": "locatedAt", "sentence": "Reaffirms Strategic and Financial Rationale for the Acquisition NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Osaka, Japan, November 12 , 2018 --- Further to the announcement on May 8, 2018, by Takeda Pharmaceutical Company Limited ('Takeda' or the 'Company') regarding the proposed acquisition (the 'Acquisition') of Shire plc ('Shire'), Takeda announces the publication of a circular (the 'Circular') containing a notice of its decision to hold an Extraordinary General Meeting of Shareholders (the 'EGM') to vote on the necessary matters relating to the Acquisition.", "score": 0.968652, "arguments": [{"text": "Osaka", "location": [261, 266], "entities": [{"type": "GeopoliticalEntity", "text": "Osaka"}]}, {"text": "Japan", "location": [268, 273], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "'The acquisition of Shire will accelerate our strategic transformation to create a stronger, more global and more competitive company with the financial strength to continue investing in delivering highly innovative medicines and transformative care to patients around the world,' said Christophe Weber, President and Chief Executive Officer of Takeda.", "score": 0.788024, "arguments": [{"text": "Christophe Weber", "location": [1340, 1356], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "said", "location": [1335, 1339], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "managerOf", "sentence": "'The acquisition of Shire will accelerate our strategic transformation to create a stronger, more global and more competitive company with the financial strength to continue investing in delivering highly innovative medicines and transformative care to patients around the world,' said Christophe Weber, President and Chief Executive Officer of Takeda.", "score": 0.526085, "arguments": [{"text": "Chief Executive Officer", "location": [1372, 1395], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "Takeda", "location": [1399, 1405], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company\nTakeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "'With the date of our Extraordinary General Meeting of Shareholders now set, we are looking forward to continuing our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction.", "score": 0.498619, "arguments": [{"text": "our", "location": [1521, 1524], "entities": [{"type": "Person", "text": "our"}]}, {"text": "shareholders", "location": [1539, 1551], "entities": [{"type": "Person", "text": "shareholders"}]}]}, {"type": "participantIn", "sentence": "' Further to the announcement on October 26, 2018, Takeda and Shire have held discussions with the European Commission ('EC') in relation to the future potential overlap in the area of inflammatory bowel disease between Takeda's marketed product Entyvio (vedolizumab) and Shire's pipeline compound SHP647, which is currently in Phase III clinical trials.", "score": 0.723806, "arguments": [{"text": "Shire", "location": [1692, 1697], "entities": [{"type": "Organization", "text": "Shire plc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "discussions", "location": [1708, 1719], "entities": [{"type": "EventMeeting", "text": "discussions"}]}]}, {"type": "participantIn", "sentence": "' Further to the announcement on October 26, 2018, Takeda and Shire have held discussions with the European Commission ('EC') in relation to the future potential overlap in the area of inflammatory bowel disease between Takeda's marketed product Entyvio (vedolizumab) and Shire's pipeline compound SHP647, which is currently in Phase III clinical trials.", "score": 0.573165, "arguments": [{"text": "European Commission", "location": [1729, 1748], "entities": [{"type": "Organization", "text": "European Commission", "disambiguation": {"subtype": ["Multigov"]}}]}, {"text": "discussions", "location": [1708, 1719], "entities": [{"type": "EventMeeting", "text": "discussions"}]}]}, {"type": "clientOf", "sentence": "Compelling Strategic and Financial Rationale for the Acquisition Takeda also reaffirms the compelling strategic and financial rationale for the Acquisition: The Acquisition will create a global, values-based, R&D-driven biopharmaceutical company incorporated and headquartered in Japan, with an attractive geographic footprint and leading positions in Japan and the United States, respectively the third and first largest pharmaceutical markets globally.", "score": 0.267113, "arguments": [{"text": "biopharmaceutical company", "location": [2977, 3002], "entities": [{"type": "Organization", "text": "ARIAD Pharmaceuticals"}]}, {"text": "Acquisition", "location": [2918, 2929], "entities": [{"type": "Organization", "text": "Acquisition\nTakeda", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Following completion of the Acquisition, Takeda will continue to focus on the acceleration of its oncology business, following its recent acquisition of ARIAD Pharmaceuticals.", "score": 0.721281, "arguments": [{"text": "its", "location": [3556, 3559], "entities": [{"type": "Organization", "text": "Council Regulation"}]}, {"text": "acquisition", "location": [3567, 3578], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "partOf", "sentence": "Following completion of the Acquisition, Takeda will continue to focus on the acceleration of its oncology business, following its recent acquisition of ARIAD Pharmaceuticals.", "score": 0.540132, "arguments": [{"text": "its", "location": [3556, 3559], "entities": [{"type": "Organization", "text": "Council Regulation"}]}, {"text": "ARIAD Pharmaceuticals", "location": [3582, 3603], "entities": [{"type": "Organization", "text": "ARIAD Pharmaceuticals"}]}]}, {"type": "affectedBy", "sentence": "Following completion of the Acquisition, Takeda will continue to focus on the acceleration of its oncology business, following its recent acquisition of ARIAD Pharmaceuticals.", "score": 0.669241, "arguments": [{"text": "ARIAD Pharmaceuticals", "location": [3582, 3603], "entities": [{"type": "Organization", "text": "ARIAD Pharmaceuticals"}]}, {"text": "acquisition", "location": [3567, 3578], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "locatedAt", "sentence": "As a result of greater scale and efficiencies in commercial activities, the Acquisition will enable the combined group to further fuel its R&D investment, better positioning Takeda to deliver highly-innovative medicines and transformative care to patients around the world.", "score": 0.698691, "arguments": [{"text": "patients", "location": [4112, 4120], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "world", "location": [4132, 4137], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "agentOf", "sentence": "Reaffirms Strategic and Financial Rationale for the Acquisition NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Osaka, Japan, November 12 , 2018 --- Further to the announcement on May 8, 2018, by Takeda Pharmaceutical Company Limited ('Takeda' or the 'Company') regarding the proposed acquisition (the 'Acquisition') of Shire plc ('Shire'), Takeda announces the publication of a circular (the 'Circular') containing a notice of its decision to hold an Extraordinary General Meeting of Shareholders (the 'EGM') to vote on the necessary matters relating to the Acquisition.", "score": 0.561221, "arguments": [{"text": "Takeda Pharmaceutical Company Limited", "location": [345, 382], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company\nTakeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announces", "location": [497, 506], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Reaffirms Strategic and Financial Rationale for the Acquisition NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Osaka, Japan, November 12 , 2018 --- Further to the announcement on May 8, 2018, by Takeda Pharmaceutical Company Limited ('Takeda' or the 'Company') regarding the proposed acquisition (the 'Acquisition') of Shire plc ('Shire'), Takeda announces the publication of a circular (the 'Circular') containing a notice of its decision to hold an Extraordinary General Meeting of Shareholders (the 'EGM') to vote on the necessary matters relating to the Acquisition.", "score": 0.986418, "arguments": [{"text": "Takeda", "location": [490, 496], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company\nTakeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announces", "location": [497, 506], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "As a result of those discussions, Takeda has offered commitments to divest SHP647 and certain associated rights, with a view to the EC granting a Phase I conditional clearance for the Acquisition and not initiating proceedings under Article 6(1)(c) of Council Regulation (EC) 139/2004.", "score": 0.885153, "arguments": [{"text": "Takeda", "location": [2019, 2025], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company\nTakeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "offered", "location": [2030, 2037], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Related reports can be found in the Rule 2.7 Announcement made by Takeda on May 8, 2018, as well as information regarding the method of calculation of the synergies and the costs to achieve such synergies.", "score": 0.692237, "arguments": [{"text": "Takeda", "location": [6668, 6674], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company\nTakeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Announcement", "location": [6647, 6659], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "employedBy", "sentence": "The Acquisition is expected to result in attractive returns for Takeda shareholders, with the return on invested capital (ROIC) expected to exceed Takeda's cost of capital within the first full fiscal year following completion.", "score": 0.660917, "arguments": [{"text": "shareholders", "location": [4973, 4985], "entities": [{"type": "Person", "text": "shareholders"}]}, {"text": "Takeda", "location": [4966, 4972], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company\nTakeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "An enlarged and well-positioned combined portfolio will strengthen the combined group's ability to invest in the business and deliver returns to Takeda shareholders.", "score": 0.635393, "arguments": [{"text": "shareholders", "location": [5805, 5817], "entities": [{"type": "Person", "text": "shareholders"}]}, {"text": "Takeda", "location": [5798, 5804], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company\nTakeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Takeda's dividend policy has remained consistent over the past 9 years, with an annual dividend of JPY 180 per share having been paid to Takeda shareholders.", "score": 0.689245, "arguments": [{"text": "shareholders", "location": [5963, 5975], "entities": [{"type": "Person", "text": "shareholders"}]}, {"text": "Takeda", "location": [5956, 5962], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company\nTakeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "The Acquisition is expected to result in Takeda being the only pharmaceutical company listed on both the Tokyo Stock Exchange in Japan, where it will continue to have its primary listing, and the New York Stock Exchange in the U.S., enabling it to access two of the world's largest capital markets.", "score": 0.456249, "arguments": [{"text": "pharmaceutical company", "location": [6200, 6222], "entities": [{"type": "Organization", "text": "EGM"}]}, {"text": "Tokyo", "location": [6242, 6247], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo"}]}]}, {"type": "locatedAt", "sentence": "The Acquisition is expected to result in Takeda being the only pharmaceutical company listed on both the Tokyo Stock Exchange in Japan, where it will continue to have its primary listing, and the New York Stock Exchange in the U.S., enabling it to access two of the world's largest capital markets.", "score": 0.389947, "arguments": [{"text": "capital", "location": [6419, 6426], "entities": [{"type": "GeopoliticalEntity", "text": "Osaka"}]}, {"text": "world", "location": [6403, 6408], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "residesIn", "sentence": "[1] This statement includes a quantified financial benefits statement which has been reported on under Rule 28.1 of the City Code on Takeovers and Mergers in the UK.", "score": 0.612006, "arguments": [{"text": "Rule", "location": [6539, 6543], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "City Code", "location": [6556, 6565], "entities": [{"type": "GeopoliticalEntity", "text": "City Code"}]}]}, {"type": "agentOf", "sentence": "Related reports can be found in the Rule 2.7 Announcement made by Takeda on May 8, 2018, as well as information regarding the method of calculation of the synergies and the costs to achieve such synergies.", "score": 0.916694, "arguments": [{"text": "Rule", "location": [6638, 6642], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Announcement", "location": [6647, 6659], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "participantIn", "sentence": "Shire Scheme Document and Shareholder Meetings Takeda also notes that Shire has today published its scheme document (the 'Scheme Document') in relation to the Acquisition and plans to hold its shareholder meetings in connection with the Acquisition on December 5, 2018, following Takeda's EGM.", "score": 0.572815, "arguments": [{"text": "Shareholder", "location": [6834, 6845], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "Meetings", "location": [6846, 6854], "entities": [{"type": "EventMeeting", "text": "meetings"}]}]}, {"type": "participantIn", "sentence": "Shire Scheme Document and Shareholder Meetings Takeda also notes that Shire has today published its scheme document (the 'Scheme Document') in relation to the Acquisition and plans to hold its shareholder meetings in connection with the Acquisition on December 5, 2018, following Takeda's EGM.", "score": 0.730043, "arguments": [{"text": "Takeda", "location": [6855, 6861], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "Meetings", "location": [6846, 6854], "entities": [{"type": "EventMeeting", "text": "meetings"}]}]}, {"type": "partOf", "sentence": "Shire Scheme Document and Shareholder Meetings Takeda also notes that Shire has today published its scheme document (the 'Scheme Document') in relation to the Acquisition and plans to hold its shareholder meetings in connection with the Acquisition on December 5, 2018, following Takeda's EGM.", "score": 0.403453, "arguments": [{"text": "notes", "location": [6867, 6872], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}, {"text": "Meetings", "location": [6846, 6854], "entities": [{"type": "EventMeeting", "text": "meetings"}]}]}, {"type": "agentOf", "sentence": "Shire Scheme Document and Shareholder Meetings Takeda also notes that Shire has today published its scheme document (the 'Scheme Document') in relation to the Acquisition and plans to hold its shareholder meetings in connection with the Acquisition on December 5, 2018, following Takeda's EGM.", "score": 0.981864, "arguments": [{"text": "Takeda", "location": [6855, 6861], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "notes", "location": [6867, 6872], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "affectedBy", "sentence": "Shire Scheme Document and Shareholder Meetings Takeda also notes that Shire has today published its scheme document (the 'Scheme Document') in relation to the Acquisition and plans to hold its shareholder meetings in connection with the Acquisition on December 5, 2018, following Takeda's EGM.", "score": 0.498799, "arguments": [{"text": "Shire", "location": [6878, 6883], "entities": [{"type": "Organization", "text": "Shire plc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "notes", "location": [6867, 6872], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Shire Scheme Document and Shareholder Meetings Takeda also notes that Shire has today published its scheme document (the 'Scheme Document') in relation to the Acquisition and plans to hold its shareholder meetings in connection with the Acquisition on December 5, 2018, following Takeda's EGM.", "score": 0.596997, "arguments": [{"text": "shareholder", "location": [7001, 7012], "entities": [{"type": "Organization", "text": "shareholder approvals"}]}, {"text": "meetings", "location": [7013, 7021], "entities": [{"type": "EventMeeting", "text": "meetings"}]}]}, {"type": "agentOf", "sentence": "Reaffirms Strategic and Financial Rationale for the Acquisition NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Osaka, Japan, November 12 , 2018 --- Further to the announcement on May 8, 2018, by Takeda Pharmaceutical Company Limited ('Takeda' or the 'Company') regarding the proposed acquisition (the 'Acquisition') of Shire plc ('Shire'), Takeda announces the publication of a circular (the 'Circular') containing a notice of its decision to hold an Extraordinary General Meeting of Shareholders (the 'EGM') to vote on the necessary matters relating to the Acquisition.", "score": 0.48199, "arguments": [{"text": "Shire plc", "location": [469, 478], "entities": [{"type": "Organization", "text": "Shire plc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Acquisition", "location": [452, 463], "entities": [{"type": "EventLegal", "text": "Acquisition"}]}]}, {"type": "participantIn", "sentence": "Shire Scheme Document and Shareholder Meetings Takeda also notes that Shire has today published its scheme document (the 'Scheme Document') in relation to the Acquisition and plans to hold its shareholder meetings in connection with the Acquisition on December 5, 2018, following Takeda's EGM.", "score": 0.672221, "arguments": [{"text": "Acquisition", "location": [7045, 7056], "entities": [{"type": "Organization", "text": "Acquisition\nTakeda", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "meetings", "location": [7013, 7021], "entities": [{"type": "EventMeeting", "text": "meetings"}]}]}, {"type": "partOf", "sentence": "Shire Scheme Document and Shareholder Meetings Takeda also notes that Shire has today published its scheme document (the 'Scheme Document') in relation to the Acquisition and plans to hold its shareholder meetings in connection with the Acquisition on December 5, 2018, following Takeda's EGM.", "score": 0.820815, "arguments": [{"text": "EGM", "location": [7097, 7100], "entities": [{"type": "Organization", "text": "EGM"}]}, {"text": "Takeda", "location": [7088, 7094], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company\nTakeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Notice of the Resolution of the Date and Agenda of the Extraordinary General Meeting of Shareholders Takeda (Investor Relations) Takashi Okubo takeda.ir.contact@takeda.com +81 3 3278 2306 Takeda (Media - inside Japan) Kazumi Kobayashi Kazumi.Kobayashi@takeda.com +81 3 3278 2095 Takeda (Media - outside Japan) Tsuyoshi Tada Tsuyoshi.Tada@takeda.com +1 617 551 2933 Elissa Johnsen Elissa.Johnsen@takeda.com +1 312 285 3203 Finsbury (communications support to Takeda) (U.K.) Rollo Head / James Murgatroyd / Anjali Unnikrishnan +44 207 251 3801 (U.S.) Kal Goldberg / Chris Ryall +1 646 805 2000 About Takeda Pharmaceutical Company Takeda Pharmaceutical Company Limited (TSE: 4502) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines.", "score": 0.526651, "arguments": [{"text": "Takeda", "location": [7471, 7477], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "Media -", "location": [7479, 7486], "entities": [{"type": "Organization", "text": "Media -"}]}]}, {"type": "employedBy", "sentence": "Notice of the Resolution of the Date and Agenda of the Extraordinary General Meeting of Shareholders Takeda (Investor Relations) Takashi Okubo takeda.ir.contact@takeda.com +81 3 3278 2306 Takeda (Media - inside Japan) Kazumi Kobayashi Kazumi.Kobayashi@takeda.com +81 3 3278 2095 Takeda (Media - outside Japan) Tsuyoshi Tada Tsuyoshi.Tada@takeda.com +1 617 551 2933 Elissa Johnsen Elissa.Johnsen@takeda.com +1 312 285 3203 Finsbury (communications support to Takeda) (U.K.) Rollo Head / James Murgatroyd / Anjali Unnikrishnan +44 207 251 3801 (U.S.) Kal Goldberg / Chris Ryall +1 646 805 2000 About Takeda Pharmaceutical Company Takeda Pharmaceutical Company Limited (TSE: 4502) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines.", "score": 0.403113, "arguments": [{"text": "Takeda", "location": [7562, 7568], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "Media", "location": [7570, 7575], "entities": [{"type": "Organization", "text": "Media -"}]}]}, {"type": "residesIn", "sentence": "Notice of the Resolution of the Date and Agenda of the Extraordinary General Meeting of Shareholders Takeda (Investor Relations) Takashi Okubo takeda.ir.contact@takeda.com +81 3 3278 2306 Takeda (Media - inside Japan) Kazumi Kobayashi Kazumi.Kobayashi@takeda.com +81 3 3278 2095 Takeda (Media - outside Japan) Tsuyoshi Tada Tsuyoshi.Tada@takeda.com +1 617 551 2933 Elissa Johnsen Elissa.Johnsen@takeda.com +1 312 285 3203 Finsbury (communications support to Takeda) (U.K.) Rollo Head / James Murgatroyd / Anjali Unnikrishnan +44 207 251 3801 (U.S.) Kal Goldberg / Chris Ryall +1 646 805 2000 About Takeda Pharmaceutical Company Takeda Pharmaceutical Company Limited (TSE: 4502) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines.", "score": 0.598553, "arguments": [{"text": "Elissa Johnsen\nElissa.Johnsen@takeda.com", "location": [7648, 7688], "entities": [{"type": "Person", "text": "Elissa Johnsen\nElissa.Johnsen@takeda.com"}]}, {"text": "Finsbury", "location": [7705, 7713], "entities": [{"type": "GeopoliticalEntity", "text": "Finsbury"}]}]}, {"type": "colleague", "sentence": "Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda's partners in health care in more than 70 countries.", "score": 0.265518, "arguments": [{"text": "Takeda", "location": [8541, 8547], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "employees", "location": [8548, 8557], "entities": [{"type": "Person", "text": "employees"}]}]}, {"type": "managerOf", "sentence": "Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda's partners in health care in more than 70 countries.", "score": 0.547182, "arguments": [{"text": "Takeda", "location": [8628, 8634], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "partners", "location": [8637, 8645], "entities": [{"type": "Organization", "text": "partners"}]}]}, {"type": "locatedAt", "sentence": "Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda's partners in health care in more than 70 countries.", "score": 0.439521, "arguments": [{"text": "partners", "location": [8637, 8645], "entities": [{"type": "Organization", "text": "partners"}]}, {"text": "countries", "location": [8677, 8686], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "partOf", "sentence": "It is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the Acquisition or otherwise nor will there be any sale, issuance, exchange or transfer of securities of Shire or Takeda pursuant to the Acquisition or otherwise in any jurisdiction in contravention of applicable law.", "score": 0.340592, "arguments": [{"text": "Takeda", "location": [9245, 9251], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company\nTakeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Shire", "location": [9236, 9241], "entities": [{"type": "Organization", "text": "Shire plc", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct and you are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this Announcement.", "score": 0.880516, "arguments": [{"text": "you", "location": [11793, 11796], "entities": [{"type": "Person", "text": "you"}]}, {"text": "cautioned", "location": [11811, 11820], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "timeOf", "sentence": "Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct and you are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this Announcement.", "score": 0.545758, "arguments": [{"text": "date", "location": [11912, 11916], "entities": [{"type": "Date", "text": "date"}]}, {"text": "Announcement", "location": [11925, 11937], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "partOf", "sentence": "Reaffirms Strategic and Financial Rationale for the Acquisition NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Osaka, Japan, November 12 , 2018 --- Further to the announcement on May 8, 2018, by Takeda Pharmaceutical Company Limited ('Takeda' or the 'Company') regarding the proposed acquisition (the 'Acquisition') of Shire plc ('Shire'), Takeda announces the publication of a circular (the 'Circular') containing a notice of its decision to hold an Extraordinary General Meeting of Shareholders (the 'EGM') to vote on the necessary matters relating to the Acquisition.", "score": 0.48045, "arguments": [{"text": "Extraordinary General Meeting of Shareholders", "location": [601, 646], "entities": [{"type": "Organization", "text": "Extraordinary General Meeting of Shareholders\nTakeda"}]}, {"text": "its", "location": [577, 580], "entities": [{"type": "Organization", "text": "EGM"}]}]}, {"type": "agentOf", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in 'ITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.Shire.com and www.sec.gov), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.959491, "arguments": [{"text": "Shire", "location": [12011, 12016], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Report", "location": [12038, 12044], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "timeOf", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in 'ITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.Shire.com and www.sec.gov), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.865986, "arguments": [{"text": "10-K", "location": [12053, 12057], "entities": [{"type": "Date", "text": "10-K"}]}, {"text": "Report", "location": [12038, 12044], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in 'ITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.Shire.com and www.sec.gov), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.984957, "arguments": [{"text": "Shire", "location": [12065, 12070], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Reports", "location": [12094, 12101], "entities": [{"type": "EventCommunication", "text": "Reports"}]}]}, {"type": "hasAttribute", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in 'ITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.Shire.com and www.sec.gov), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.548308, "arguments": [{"text": "Securities and Exchange Commission", "location": [12243, 12277], "entities": [{"type": "Organization", "text": "Securities and Exchange Commission", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "www.Shire.com", "location": [12300, 12313], "entities": [{"type": "Web", "text": "www.Shire.com"}]}]}, {"type": "agentOf", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in 'ITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.Shire.com and www.sec.gov), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.413159, "arguments": [{"text": "they", "location": [12401, 12405], "entities": [{"type": "Person", "text": "their"}]}, {"text": "Announcement", "location": [12425, 12437], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "These risk factors expressly qualify all forward-looking statements contained in this Announcement and should also be considered by the reader.", "score": 0.492954, "arguments": [{"text": "reader", "location": [12575, 12581], "entities": [{"type": "Person", "text": "reader"}]}, {"text": "Announcement", "location": [12525, 12537], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "partOfMany", "sentence": "All forward-looking statements attributable to Takeda or Shire or any person acting on either company's behalf are expressly qualified in their entirety by this cautionary statement.", "score": 0.865201, "arguments": [{"text": "Takeda", "location": [12630, 12636], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "their", "location": [12721, 12726], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "All forward-looking statements attributable to Takeda or Shire or any person acting on either company's behalf are expressly qualified in their entirety by this cautionary statement.", "score": 0.958817, "arguments": [{"text": "Shire", "location": [12640, 12645], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "their", "location": [12721, 12726], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "All forward-looking statements attributable to Takeda or Shire or any person acting on either company's behalf are expressly qualified in their entirety by this cautionary statement.", "score": 0.803988, "arguments": [{"text": "person", "location": [12653, 12659], "entities": [{"type": "Person", "text": "person"}]}, {"text": "their", "location": [12721, 12726], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "agentOf", "sentence": "Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.", "score": 0.834273, "arguments": [{"text": "Readers", "location": [12766, 12773], "entities": [{"type": "Person", "text": "Readers"}]}, {"text": "cautioned", "location": [12778, 12787], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "locatedAt", "sentence": "The EGM is to be convened at 10:00 a.m. on December 5, 2018 at INTEX Osaka, Hall 6B Zone.", "score": 0.560681, "arguments": [{"text": "Hall 6B Zone", "location": [797, 809], "entities": [{"type": "Person", "text": "Hall 6B Zone"}]}, {"text": "INTEX Osaka", "location": [784, 795], "entities": [{"type": "Facility", "text": "INTEX Osaka"}]}]}, {"type": "employedBy", "sentence": "Publication on Website In accordance with Rule 26.1 of the Code, a copy of this Announcement will be made available (subject to certain restrictions relating to persons resident in restricted jurisdictions) on Takeda's website at www.takeda.com/investors/offer-for-shire by no later than 12 noon (London time) on November 13, 2018.", "score": 0.795636, "arguments": [{"text": "Rule", "location": [14119, 14123], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [14136, 14140], "entities": [{"type": "Organization", "text": "Code\nUnder Rule"}]}]}, {"type": "employedBy", "sentence": "Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror.", "score": 0.456059, "arguments": [{"text": "Rule", "location": [15901, 15905], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [15920, 15924], "entities": [{"type": "Organization", "text": "Code\nUnder Rule"}]}]}, {"type": "agentOf", "sentence": "Publication on Website In accordance with Rule 26.1 of the Code, a copy of this Announcement will be made available (subject to certain restrictions relating to persons resident in restricted jurisdictions) on Takeda's website at www.takeda.com/investors/offer-for-shire by no later than 12 noon (London time) on November 13, 2018.", "score": 0.537476, "arguments": [{"text": "Code", "location": [14136, 14140], "entities": [{"type": "Organization", "text": "Code\nUnder Rule"}]}, {"text": "Announcement", "location": [14157, 14169], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "hasAttribute", "sentence": "If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.", "score": 0.595313, "arguments": [{"text": "Rule", "location": [17014, 17018], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "8.3", "location": [17019, 17022], "entities": [{"type": "Money", "text": "8.3", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "participantIn", "sentence": "Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).", "score": 0.508911, "arguments": [{"text": "persons", "location": [17205, 17212], "entities": [{"type": "Person", "text": "persons"}]}, {"text": "concert", "location": [17223, 17230], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "locatedAt", "sentence": "You should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.", "score": 0.445235, "arguments": [{"text": "Panel", "location": [17684, 17689], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "Market Surveillance Unit", "location": [17692, 17716], "entities": [{"type": "Facility", "text": "Market Surveillance Unit"}]}]}, {"type": "agentOf", "sentence": "Attachments Original document Permalink Disclaimer Takeda Pharmaceutical Co. Ltd. published this content on 12 November 2018 and is solely responsible for the information contained herein.", "score": 0.982494, "arguments": [{"text": "Takeda Pharmaceutical Co. Ltd.", "location": [17910, 17940], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "published", "location": [17941, 17950], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "timeOf", "sentence": "Attachments Original document Permalink Disclaimer Takeda Pharmaceutical Co. Ltd. published this content on 12 November 2018 and is solely responsible for the information contained herein.", "score": 0.632716, "arguments": [{"text": "November 2018", "location": [17970, 17983], "entities": [{"type": "Date", "text": "November 2018"}]}, {"text": "published", "location": [17941, 17950], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "affectedBy", "sentence": "'The acquisition of Shire will accelerate our strategic transformation to create a stronger, more global and more competitive company with the financial strength to continue investing in delivering highly innovative medicines and transformative care to patients around the world,' said Christophe Weber, President and Chief Executive Officer of Takeda.", "score": 0.742062, "arguments": [{"text": "Shire", "location": [1074, 1079], "entities": [{"type": "Organization", "text": "Shire plc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [1059, 1070], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "'The acquisition of Shire will accelerate our strategic transformation to create a stronger, more global and more competitive company with the financial strength to continue investing in delivering highly innovative medicines and transformative care to patients around the world,' said Christophe Weber, President and Chief Executive Officer of Takeda.", "score": 0.433222, "arguments": [{"text": "company", "location": [1180, 1187], "entities": [{"type": "Organization", "text": "EGM"}]}, {"text": "acquisition", "location": [1059, 1070], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "partOf", "sentence": "'The acquisition of Shire will accelerate our strategic transformation to create a stronger, more global and more competitive company with the financial strength to continue investing in delivering highly innovative medicines and transformative care to patients around the world,' said Christophe Weber, President and Chief Executive Officer of Takeda.", "score": 0.286584, "arguments": [{"text": "company", "location": [1180, 1187], "entities": [{"type": "Organization", "text": "EGM"}]}, {"text": "Shire", "location": [1074, 1079], "entities": [{"type": "Organization", "text": "Shire plc", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "'The acquisition of Shire will accelerate our strategic transformation to create a stronger, more global and more competitive company with the financial strength to continue investing in delivering highly innovative medicines and transformative care to patients around the world,' said Christophe Weber, President and Chief Executive Officer of Takeda.", "score": 0.580861, "arguments": [{"text": "patients", "location": [1307, 1315], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "world", "location": [1327, 1332], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}], "keywords": [{"text": "Takeda", "sentiment": {"score": 0.193975, "label": "positive"}, "relevance": 0.954189}, {"text": "securities exchange offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.782971}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.778606}, {"text": "Takeda shareholders", "sentiment": {"score": 0.812251, "label": "positive"}, "relevance": 0.732983}, {"text": "better positioning Takeda", "sentiment": {"score": 0.606234, "label": "positive"}, "relevance": 0.703722}, {"text": "forward-looking statements", "sentiment": {"score": -0.283325, "label": "negative"}, "relevance": 0.694189}, {"text": "Takeda share", "sentiment": {"score": 0.5557, "label": "positive"}, "relevance": 0.694135}, {"text": "Takeda Pharmaceutical Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.68446}, {"text": "acquisition", "sentiment": {"score": 0.301693, "label": "positive"}, "relevance": 0.683384}, {"text": "Opening Position Disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.680414}, {"text": "Takeda employees", "sentiment": {"score": 0.688532, "label": "positive"}, "relevance": 0.668559}, {"text": "possible combination", "sentiment": {"score": 0.39568, "label": "positive"}, "relevance": 0.666182}, {"text": "relevant securities", "sentiment": {"score": 0.560374, "label": "positive"}, "relevance": 0.658472}, {"text": "Extraordinary General Meeting", "sentiment": {"score": 0.731088, "label": "positive"}, "relevance": 0.658444}, {"text": "offeree company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.657495}, {"text": "announcement", "sentiment": {"score": -0.131222, "label": "negative"}, "relevance": 0.635816}, {"text": "Pharmaceutical Company Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.617321}, {"text": "Shire", "sentiment": {"score": 0.40575, "label": "positive"}, "relevance": 0.614108}, {"text": "Dealing Disclosure", "sentiment": {"score": -0.404786, "label": "negative"}, "relevance": 0.605117}, {"text": "London time", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.593552}, {"text": "financial benefits", "sentiment": {"score": 0.808208, "label": "positive"}, "relevance": 0.589702}, {"text": "financial rationale", "sentiment": {"score": 0.630727, "label": "positive"}, "relevance": 0.585169}, {"text": "Shire Scheme Document", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.573847}, {"text": "relevant securities Opening", "sentiment": {"score": 0.560374, "label": "positive"}, "relevance": 0.572048}, {"text": "quickly following completion", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.568396}, {"text": "R&D-driven biopharmaceutical company", "sentiment": {"score": 0.201345, "label": "positive"}, "relevance": 0.56776}, {"text": "development-driven pharmaceutical company", "sentiment": {"score": 0.642238, "label": "positive"}, "relevance": 0.566363}, {"text": "recent acquisition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.564613}, {"text": "offer period", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.563788}, {"text": "risk factors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.562224}, {"text": "York Stock Exchange", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.561851}, {"text": "future potential overlap", "sentiment": {"score": -0.273174, "label": "negative"}, "relevance": 0.561624}, {"text": "transformative care", "sentiment": {"score": 0.632882, "label": "positive"}, "relevance": 0.561305}, {"text": "Tokyo Stock Exchange", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.560315}, {"text": "Hall 6B Zone", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.559487}, {"text": "compelling financial benefits", "sentiment": {"score": 0.74773, "label": "positive"}, "relevance": 0.559475}, {"text": "pre-tax cost synergies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.55946}, {"text": "financial benefits statement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.559005}, {"text": "additional revenue synergies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.557931}, {"text": "largest pharmaceutical markets", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.557301}, {"text": "future business combinations", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.5563}, {"text": "inflammatory bowel disease", "sentiment": {"score": -0.273174, "label": "negative"}, "relevance": 0.556173}, {"text": "certain associated rights", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.556088}, {"text": "Exchange Commission filings", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.556057}, {"text": "well-established dividend policy", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.555968}, {"text": "optimal business mix", "sentiment": {"score": 0.658982, "label": "positive"}, "relevance": 0.555864}, {"text": "Shire plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.555414}]}, "extracted_metadata": {"sha1": "4e3f1fdc2fe0ceb801db4308f493fdab021e738d", "filename": "1542008318849.zip-40fa0887e7cea13040f42b5c678883e4.xml", "file_type": "json"}, "external_links": ["http://www.publicnow.com/view/A41AF6B39425F55DAAD1C3B64C9F5DFF836E48AE", "https://www.takeda.com/siteassets/system/newsroom/2018/takeda-announces-publication-of-circular-and-notice-of-extraordinary-general-meeting-of-shareholders-in-relation-to-the-proposed-acquisition-of-shire/e-press-release-egm-for-tse.pdf", "https://www.takeda.com/newsroom/newsreleases/2018/takeda-announces-publication-of-circular-and-notice-of-extraordinary-general-meeting-of-shareholders-in-relation-to-the-proposed-acquisition-of-shire/", "https://www.takeda.com/investors/offer-for-shire/", "https://www.takeda.com/newsroom/"], "title": "Takeda Pharmaceutical : Announces Publication of Circular and Notice of Extraordinary General Meeting of Shareholders in relation to the Proposed Acquisition of Shire | MarketScreener", "forum_title": "Stock market news - Company News  - MarketScreener.com"}, {"id": "hnQ2YpCzp-qGZ3JI3ugTDDSfYvScrGi8AhEweCx-BJpkvq7dxxappNdUKKjRGu0T", "result_metadata": {"score": 31.796339}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.516374, "label": "/business and industrial/business operations/human resources/compensation and benefits"}, {"score": 0.495289, "label": "/business and industrial/company/merger and acquisition"}, {"score": 0.488333, "label": "/business and industrial/paper industry"}], "relations": [], "keywords": [{"text": "Shire plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.99725}, {"text": "Scheme Document", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.831362}, {"text": "Publication", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.308755}]}, "crawl_date": "2018-11-12T07:30:48Z", "url": "https://www.finanznachrichten.de/nachrichten-2018-11/45248696-shire-plc-publication-of-scheme-document-399.htm", "host": "finanznachrichten.de", "text": "JPMorgan Securities Japan Co., Ltd., together with its affiliate J.P.", "main_image_url": "https://fns1.de/g/fb.png", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-12T07:05:00Z", "enriched_text": {"entities": [{"count": 22, "sentiment": {"score": 0.355062, "label": "positive"}, "text": "Shire Shareholders", "relevance": 0.806495, "type": "Company"}, {"count": 19, "sentiment": {"score": 0.332177, "label": "positive"}, "text": "Shire", "relevance": 0.714415, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 19, "sentiment": {"score": 0.291205, "label": "positive"}, "text": "Takeda", "relevance": 0.543287, "type": "Person"}, {"count": 11, "sentiment": {"score": -0.130861, "label": "negative"}, "text": "Shire", "relevance": 0.493317, "type": "Person"}, {"count": 14, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.485901, "type": "Company"}, {"count": 12, "sentiment": {"score": -0.26658, "label": "negative"}, "text": "Shire General Meeting", "relevance": 0.475868, "type": "Organization"}, {"count": 24, "sentiment": {"score": 0.315605, "label": "positive"}, "text": "Scheme", "relevance": 0.466644, "type": "Organization"}, {"count": 9, "sentiment": {"score": -0.665719, "label": "negative"}, "text": "Shire Shares", "relevance": 0.463486, "type": "Company"}, {"count": 7, "sentiment": {"score": 0.277075, "label": "positive"}, "text": "Shire ADS Holders", "relevance": 0.439851, "type": "Company"}, {"count": 7, "sentiment": {"score": 0.238077, "label": "positive"}, "text": "Shire", "relevance": 0.434231, "type": "Company"}, {"count": 8, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire Depositary", "relevance": 0.413652, "type": "Organization"}, {"count": 9, "sentiment": {"score": 0.337874, "label": "positive"}, "text": "Shire ADSs", "relevance": 0.384205, "type": "Organization"}, {"count": 6, "sentiment": {"score": -0.537141, "label": "negative"}, "text": "New Takeda Securities", "relevance": 0.373961, "type": "Company"}, {"count": 32, "sentiment": {"score": -0.336105, "label": "negative"}, "text": "US", "relevance": 0.355375, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire PLC", "relevance": 0.351373, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.343503, "type": "Organization"}, {"count": 21, "sentiment": {"score": 0.851582, "label": "positive"}, "text": "United Kingdom", "relevance": 0.342601, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"count": 12, "sentiment": {"score": -0.288879, "label": "negative"}, "text": "New Takeda ADSs", "relevance": 0.300457, "type": "Company"}, {"count": 3, "sentiment": {"score": 0.296017, "label": "positive"}, "text": "New Takeda Shares", "relevance": 0.281012, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.27515, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0.745078, "label": "positive"}, "text": "Shire Shareholder", "relevance": 0.273482, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire ADSs", "relevance": 0.269213, "type": "Company"}, {"count": 11, "sentiment": {"score": 0, "label": "neutral"}, "text": "London", "relevance": 0.267898, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire Shareholder", "relevance": 0.262276, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire Depositary", "relevance": 0.256412, "type": "JobTitle"}, {"count": 7, "sentiment": {"score": 0.487038, "label": "positive"}, "text": "Court", "relevance": 0.255325, "type": "Organization", "disambiguation": {"subtype": ["Sport"], "name": "Volleyball", "dbpedia_resource": "http://dbpedia.org/resource/Volleyball"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Extraordinary General", "relevance": 0.245872, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Depositary", "relevance": 0.216543, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Extraordinary General Meeting.", "relevance": 0.209301, "type": "Organization"}, {"count": 10, "sentiment": {"score": 0, "label": "neutral"}, "text": "Prudential Regulation Authority", "relevance": 0.201804, "type": "Organization"}, {"count": 7, "sentiment": {"score": 0, "label": "neutral"}, "text": "Financial Conduct Authority", "relevance": 0.200652, "type": "Organization", "disambiguation": {"subtype": [], "name": "Financial Conduct Authority", "dbpedia_resource": "http://dbpedia.org/resource/Financial_Conduct_Authority"}}, {"count": 4, "sentiment": {"score": 0.277075, "label": "positive"}, "text": "PRINCIPAL", "relevance": 0.200169, "type": "JobTitle"}, {"count": 8, "sentiment": {"score": 0.851582, "label": "positive"}, "text": "Jersey", "relevance": 0.197169, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "London Stock Exchange", "relevance": 0.195528, "type": "Company", "disambiguation": {"subtype": ["Location", "Facility", "TouristAttraction"], "name": "London Stock Exchange", "dbpedia_resource": "http://dbpedia.org/resource/London_Stock_Exchange"}}, {"count": 6, "sentiment": {"score": 0, "label": "neutral"}, "text": "New York", "relevance": 0.182517, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "New York, Lincolnshire", "dbpedia_resource": "http://dbpedia.org/resource/New_York,_Lincolnshire"}}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "SEC", "relevance": 0.179834, "type": "Organization"}, {"count": 6, "sentiment": {"score": 0.107162, "label": "positive"}, "text": "Dealing Disclosures", "relevance": 0.175903, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Securities and Exchange Commission", "relevance": 0.170217, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "U.S. Securities and Exchange Commission", "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}}, {"count": 3, "sentiment": {"score": 0.442981, "label": "positive"}, "text": "European Commission", "relevance": 0.168117, "type": "Organization"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "solicitation", "relevance": 0.167854, "type": "Crime"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Equiniti", "relevance": 0.163988, "type": "Person"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chairman", "relevance": 0.163905, "type": "JobTitle"}, {"count": 3, "sentiment": {"score": -0.242287, "label": "negative"}, "text": "Regulatory Information Service", "relevance": 0.162357, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "International plc", "relevance": 0.162103, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "JPMorgan Securities Japan Co.", "relevance": 0.161951, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "J.P. Morgan Securities plc", "relevance": 0.159124, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dublin", "relevance": 0.155979, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "City"], "name": "Dublin", "dbpedia_resource": "http://dbpedia.org/resource/Dublin"}}, {"count": 5, "sentiment": {"score": -0.559235, "label": "negative"}, "text": "Goldman Sachs International", "relevance": 0.155848, "type": "Company", "disambiguation": {"subtype": ["CompanyShareholder"], "name": "Goldman Sachs", "dbpedia_resource": "http://dbpedia.org/resource/Goldman_Sachs"}}, {"count": 2, "sentiment": {"score": -0.319121, "label": "negative"}, "text": "England", "relevance": 0.153573, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "Country"], "name": "England", "dbpedia_resource": "http://dbpedia.org/resource/England"}}], "sentiment": {"document": {"score": 0.487836, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Shire plc (\" Shire \") and Takeda Pharmaceutical Company Limited (\" Takeda \")", "keywords": [{"text": "Takeda Pharmaceutical Company"}, {"text": "Shire plc"}, {"text": "Company Limited"}], "entities": [{"type": "Company", "text": "Shire PLC", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Takeda"}]}, "sentence": "TAKEDA PHARMACEUTICAL COMPANY LIMITED Publication of Scheme Document On May 8, 2018, Shire plc (\" Shire \") and Takeda Pharmaceutical Company Limited (\" Takeda \") announced that they had reached agreement on the terms of a recommended cash and share offer to be made by Takeda for the entire issued and to be issued share capital of Shire (the \" Acquisition \").", "object": {"text": "that they had reached agreement on the terms of a recommended cash and share offer to be made by Takeda for the entire issued and to be issued share capital of Shire (the \" Acquisition \")", "keywords": [{"text": "share offer"}, {"text": "share capital"}, {"text": "Takeda"}, {"text": "agreement"}], "entities": [{"type": "Company", "text": "Takeda"}, {"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "a recommended cash and share", "keywords": [{"text": "cash"}, {"text": "share"}]}, "sentence": "TAKEDA PHARMACEUTICAL COMPANY LIMITED Publication of Scheme Document On May 8, 2018, Shire plc (\" Shire \") and Takeda Pharmaceutical Company Limited (\" Takeda \") announced that they had reached agreement on the terms of a recommended cash and share offer to be made by Takeda for the entire issued and to be issued share capital of Shire (the \" Acquisition \").", "object": {"text": "made by Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "by Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": "TAKEDA PHARMACEUTICAL COMPANY LIMITED Publication of Scheme Document On May 8, 2018, Shire plc (\" Shire \") and Takeda Pharmaceutical Company Limited (\" Takeda \") announced that they had reached agreement on the terms of a recommended cash and share offer to be made by Takeda for the entire issued and to be issued share capital of Shire (the \" Acquisition \").", "object": {"text": "a recommended cash and share offer", "keywords": [{"text": "cash"}, {"text": "share offer"}]}, "action": {"verb": {"text": "make", "tense": "past"}, "text": "to be made", "normalized": "to be make"}}, {"subject": {"text": "by means of a scheme of arrangement under Article 125 of the Companies (Jersey) Law 1991 (as amended) (the \" Scheme \")", "keywords": [{"text": "scheme"}, {"text": "arrangement"}, {"text": "means"}, {"text": "Article"}], "entities": [{"type": "Organization", "text": "Scheme"}, {"type": "Organization", "text": "Scheme"}]}, "sentence": " The Acquisition will be effected by means of a scheme of arrangement under Article 125 of the Companies (Jersey) Law 1991 (as amended) (the \" Scheme \").", "object": {"text": "The Acquisition", "keywords": [{"text": "Acquisition"}]}, "action": {"verb": {"text": "effect", "tense": "future"}, "text": "will be effected", "normalized": "will be effect"}}, {"subject": {"text": "the notes accompanying them", "keywords": [{"text": "notes"}], "entities": [{"type": "Company", "text": "Shire Shareholders"}]}, "sentence": " Together with the Scheme Document, Forms of Proxy for the Court Meeting and the Shire General Meeting and Forms of Election and the notes accompanying them have also been published on the Shire website at www.shire.com.", "object": {"text": "published on the Shire website", "keywords": [{"text": "Shire website"}], "entities": [{"type": "Organization", "text": "Shire"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "Forms of Proxy for the Court Meeting and the Shire General Meeting and Forms of Election and the notes accompanying them", "keywords": [{"text": "Shire General Meeting"}, {"text": "Court Meeting"}, {"text": "Proxy"}, {"text": "Election"}], "entities": [{"type": "Organization", "text": "Shire General Meeting"}, {"type": "Company", "text": "Shire Shareholders"}]}, "sentence": " Together with the Scheme Document, Forms of Proxy for the Court Meeting and the Shire General Meeting and Forms of Election and the notes accompanying them have also been published on the Shire website at www.shire.com.", "action": {"verb": {"text": "publish", "tense": "past"}, "text": "have also been published", "normalized": "have also be publish"}}, {"subject": {"text": "Copies of these documents", "keywords": [{"text": "Copies"}, {"text": "documents"}]}, "sentence": " Copies of these documents are also being sent to Shire Shareholders today.", "object": {"text": "to Shire Shareholders", "keywords": [{"text": "Shire Shareholders"}], "entities": [{"type": "Company", "text": "Shire Shareholders"}]}, "action": {"verb": {"text": "send", "tense": "past"}, "text": "are also being sent", "normalized": "be also be send"}}, {"subject": {"text": "by the Shire Depositary", "keywords": [{"text": "Shire Depositary"}], "entities": [{"type": "Organization", "text": "Shire Depositary"}]}, "sentence": " A Notice of Court Meeting and Extraordinary General Meeting, together with an ADS Voting Card, is also being sent to Shire ADS Holders today by the Shire Depositary.", "object": {"text": "A Notice of Court Meeting and Extraordinary General Meeting", "keywords": [{"text": "Extraordinary General Meeting"}, {"text": "Notice"}, {"text": "Court Meeting"}]}, "action": {"verb": {"text": "send", "tense": "past"}, "text": "is also being sent", "normalized": "be also be send"}}, {"subject": {"text": "Forms of Proxy and Forms of Election", "keywords": [{"text": "Proxy"}, {"text": "Election"}, {"text": "Forms"}]}, "sentence": " The Scheme Document, Forms of Proxy and Forms of Election will be available shortly on the National Storage Mechanism at www.morningstar.co.uk/uk/nsm.", "object": {"text": "available shortly on the National Storage Mechanism", "keywords": [{"text": "National Storage Mechanism"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "will be", "normalized": "will be"}}, {"subject": {"text": "The Scheme Document", "keywords": [{"text": "Scheme Document"}]}, "sentence": " The Scheme Document has also been furnished to the SEC on Form 6-K and is available on the SEC's website at www.sec.gov.", "object": {"text": "furnished to the SEC on Form 6-K", "keywords": [{"text": "SEC"}, {"text": "Form"}], "entities": [{"type": "Organization", "text": "SEC"}, {"type": "Quantity", "text": "6-K"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "The Scheme Document", "keywords": [{"text": "Scheme Document"}]}, "sentence": " The Scheme Document has also been furnished to the SEC on Form 6-K and is available on the SEC's website at www.sec.gov.", "object": {"text": "to the SEC", "keywords": [{"text": "SEC"}], "entities": [{"type": "Organization", "text": "SEC"}]}, "action": {"verb": {"text": "furnish", "tense": "past"}, "text": "has also been furnished", "normalized": "have also be furnish"}}, {"subject": {"text": "The Scheme Document", "keywords": [{"text": "Scheme Document"}]}, "sentence": " The Scheme Document has also been furnished to the SEC on Form 6-K and is available on the SEC's website at www.sec.gov.", "object": {"text": "available on the SEC's website at www.sec.gov", "keywords": [{"text": "SEC"}, {"text": "website"}, {"text": "www.sec.gov"}], "entities": [{"type": "Organization", "text": "SEC"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Shire", "keywords": [{"text": "Shire"}], "entities": [{"type": "Person", "text": "Shire"}]}, "sentence": " Shire also notes Takeda's circular to shareholders published today, which relates to the convocation of the Takeda Extraordinary General Meeting scheduled to be held at 10.00 a.m. (Tokyo time) (1.00 a.m. (London time)) on December 5, 2018.", "object": {"text": "Takeda's circular to shareholders published today, which relates to the convocation of the Takeda Extraordinary General Meeting scheduled to be held at 10.00 a.m. (Tokyo time) (1.00 a.m. (London time)) on December 5, 2018", "keywords": [{"text": "Takeda Extraordinary General"}, {"text": "Tokyo time"}, {"text": "London time"}, {"text": "convocation"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Company", "text": "Shire Shareholders"}, {"type": "Organization", "text": "Takeda Extraordinary General"}, {"type": "Location", "text": "Tokyo", "disambiguation": {"subtype": ["City"]}}, {"type": "Location", "text": "London", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "note", "tense": "present"}, "text": "notes", "normalized": "note"}}, {"subject": {"text": "shareholders", "keywords": [{"text": "shareholders"}], "entities": [{"type": "Company", "text": "Shire Shareholders"}]}, "sentence": " Shire also notes Takeda's circular to shareholders published today, which relates to the convocation of the Takeda Extraordinary General Meeting scheduled to be held at 10.00 a.m. (Tokyo time) (1.00 a.m. (London time)) on December 5, 2018.", "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "the Takeda Extraordinary General Meeting", "keywords": [{"text": "Takeda Extraordinary General"}], "entities": [{"type": "Organization", "text": "Takeda Extraordinary General"}]}, "sentence": " Shire also notes Takeda's circular to shareholders published today, which relates to the convocation of the Takeda Extraordinary General Meeting scheduled to be held at 10.00 a.m. (Tokyo time) (1.00 a.m. (London time)) on December 5, 2018.", "object": {"text": "held"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "the Takeda Extraordinary General Meeting", "keywords": [{"text": "Takeda Extraordinary General"}], "entities": [{"type": "Organization", "text": "Takeda Extraordinary General"}]}, "sentence": " Shire also notes Takeda's circular to shareholders published today, which relates to the convocation of the Takeda Extraordinary General Meeting scheduled to be held at 10.00 a.m. (Tokyo time) (1.00 a.m. (London time)) on December 5, 2018.", "action": {"verb": {"text": "hold", "tense": "past"}, "text": "scheduled to be held", "normalized": "schedule to be hold"}}, {"subject": {"text": "This"}, "sentence": " This is available on Takeda's website at www.takeda.com/investors/offer-for-shire.", "object": {"text": "available on Takeda's website", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "terms", "keywords": [{"text": "terms"}]}, "sentence": " Unless otherwise defined, all capitalised terms in this announcement (the \" Announcement \") shall have the meaning given to them in the Scheme Document.", "action": {"verb": {"text": "capitalise", "tense": "past"}, "text": "capitalised", "normalized": "capitalise"}}, {"subject": {"text": "all capitalised terms in this announcement (the \" Announcement \")", "keywords": [{"text": "announcement"}, {"text": "terms"}]}, "sentence": " Unless otherwise defined, all capitalised terms in this announcement (the \" Announcement \") shall have the meaning given to them in the Scheme Document.", "object": {"text": "the meaning given to them in the Scheme Document", "keywords": [{"text": "Scheme Document"}, {"text": "meaning"}], "entities": [{"type": "Company", "text": "Shire Shareholders"}]}, "action": {"verb": {"text": "have", "tense": "future"}, "text": "shall have", "normalized": "shall have"}}, {"subject": {"text": "Notices of the Court Meeting and Shire General Meeting", "keywords": [{"text": "Shire General Meeting"}, {"text": "Notices"}, {"text": "Court Meeting"}], "entities": [{"type": "Organization", "text": "Shire General Meeting"}]}, "sentence": " Notices of the Court Meeting and Shire General Meeting As described in the Scheme Document, to become effective, the Scheme requires, among other things, the approval of Shire Shareholders at the Court Meeting, the passing of the Special Resolution at the Shire General Meeting and the subsequent sanction of the Court.", "object": {"text": "effective"}, "action": {"verb": {"text": "become", "tense": "future"}, "text": "to become", "normalized": "to become"}}, {"subject": {"text": "the Conditions and certain further terms", "keywords": [{"text": "certain further terms"}, {"text": "Conditions"}]}, "sentence": " The Acquisition is also subject to the satisfaction or waiver of the Conditions and certain further terms that are set out in the Scheme Document.", "object": {"text": "in the Scheme Document", "keywords": [{"text": "Scheme Document"}]}, "action": {"verb": {"text": "set", "tense": "past"}, "text": "are set", "normalized": "be set"}}, {"subject": {"text": "Notices of the Court Meeting and the Shire General Meeting", "keywords": [{"text": "Shire General Meeting"}, {"text": "Notices"}, {"text": "Court Meeting"}], "entities": [{"type": "Organization", "text": "Shire General Meeting"}]}, "sentence": " Notices of the Court Meeting and the Shire General Meeting, which are scheduled to be held at Block 3, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland on December 5, 2018, are set out in the Scheme Document.", "object": {"text": "scheduled to be held at Block 3", "keywords": [{"text": "Block"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "the Shire General Meeting", "keywords": [{"text": "Shire General Meeting"}], "entities": [{"type": "Organization", "text": "Shire General Meeting"}]}, "sentence": " Notices of the Court Meeting and the Shire General Meeting, which are scheduled to be held at Block 3, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland on December 5, 2018, are set out in the Scheme Document.", "object": {"text": "to be held at Block 3, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland", "keywords": [{"text": "Baggot Street Lower"}, {"text": "Miesian Plaza"}, {"text": "Block"}, {"text": "Dublin"}], "entities": [{"type": "Facility", "text": "Miesian Plaza"}, {"type": "Location", "text": "Dublin", "disambiguation": {"subtype": ["AdministrativeDivision", "CityTown", "City"], "name": "Dublin", "dbpedia_resource": "http://dbpedia.org/resource/Dublin"}}, {"type": "Location", "text": "Ireland", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "schedule", "tense": "past"}, "text": "scheduled", "normalized": "schedule"}}, {"subject": {"text": "Notices of the Court Meeting and the Shire General Meeting", "keywords": [{"text": "Shire General Meeting"}, {"text": "Notices"}, {"text": "Court Meeting"}], "entities": [{"type": "Organization", "text": "Shire General Meeting"}]}, "sentence": " Notices of the Court Meeting and the Shire General Meeting, which are scheduled to be held at Block 3, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland on December 5, 2018, are set out in the Scheme Document.", "object": {"text": "held at Block 3", "keywords": [{"text": "Block"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Notices of the Court Meeting and the Shire General Meeting", "keywords": [{"text": "Shire General Meeting"}, {"text": "Notices"}, {"text": "Court Meeting"}], "entities": [{"type": "Organization", "text": "Shire General Meeting"}]}, "sentence": " Notices of the Court Meeting and the Shire General Meeting, which are scheduled to be held at Block 3, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland on December 5, 2018, are set out in the Scheme Document.", "action": {"verb": {"text": "hold", "tense": "past"}, "text": "are scheduled to be held", "normalized": "be schedule to be hold"}}, {"subject": {"text": "Notices of the Court Meeting and the Shire General Meeting, which are scheduled to be held at Block 3, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland on December 5, 2018,", "keywords": [{"text": "Baggot Street Lower"}, {"text": "Shire General Meeting"}, {"text": "Miesian Plaza"}, {"text": "Court Meeting"}], "entities": [{"type": "Organization", "text": "Shire General Meeting"}, {"type": "Facility", "text": "Miesian Plaza"}, {"type": "Location", "text": "Dublin", "disambiguation": {"subtype": ["AdministrativeDivision", "CityTown", "City"], "name": "Dublin", "dbpedia_resource": "http://dbpedia.org/resource/Dublin"}}, {"type": "Location", "text": "Ireland", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Notices of the Court Meeting and the Shire General Meeting, which are scheduled to be held at Block 3, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland on December 5, 2018, are set out in the Scheme Document.", "object": {"text": "in the Scheme Document", "keywords": [{"text": "Scheme Document"}]}, "action": {"verb": {"text": "set", "tense": "past"}, "text": "are set", "normalized": "be set"}}, {"subject": {"text": "The Court Meeting", "keywords": [{"text": "Court Meeting"}]}, "sentence": " The Court Meeting is scheduled to commence at 11.15 a.m. and the Shire General Meeting at 11.30 a.m. (or as soon thereafter as the Court Meeting has concluded or been adjourned).", "object": {"text": "scheduled to commence", "keywords": [{"text": "commence"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Court Meeting", "keywords": [{"text": "Court Meeting"}]}, "sentence": " The Court Meeting is scheduled to commence at 11.15 a.m. and the Shire General Meeting at 11.30 a.m. (or as soon thereafter as the Court Meeting has concluded or been adjourned).", "object": {"text": "to commence at 11.15 a.m. and the Shire General Meeting", "keywords": [{"text": "Shire General Meeting"}], "entities": [{"type": "Organization", "text": "Shire General Meeting"}]}, "action": {"verb": {"text": "schedule", "tense": "past"}, "text": "scheduled", "normalized": "schedule"}}, {"subject": {"text": "the Court Meeting", "keywords": [{"text": "Court Meeting"}]}, "sentence": " The Court Meeting is scheduled to commence at 11.15 a.m. and the Shire General Meeting at 11.30 a.m. (or as soon thereafter as the Court Meeting has concluded or been adjourned).", "object": {"text": "concluded or been adjourned"}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "the Court Meeting", "keywords": [{"text": "Court Meeting"}]}, "sentence": " The Court Meeting is scheduled to commence at 11.15 a.m. and the Shire General Meeting at 11.30 a.m. (or as soon thereafter as the Court Meeting has concluded or been adjourned).", "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "It"}, "sentence": " It is important that, for the Court Meeting in particular, as many votes as possible are cast so that the Court may be satisfied that there is a fair and reasonable representation of Shire Shareholder opinion.", "object": {"text": "important that"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the Court", "keywords": [{"text": "Court"}], "entities": [{"type": "Organization", "text": "Court", "disambiguation": {"subtype": ["Sport"], "name": "Volleyball", "dbpedia_resource": "http://dbpedia.org/resource/Volleyball"}}]}, "sentence": " It is important that, for the Court Meeting in particular, as many votes as possible are cast so that the Court may be satisfied that there is a fair and reasonable representation of Shire Shareholder opinion.", "object": {"text": "satisfied that there"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Shire Shareholders and Shire ADS Holders", "keywords": [{"text": "Shire ADS Holders"}, {"text": "Shire Shareholders"}], "entities": [{"type": "Company", "text": "Shire Shareholders"}, {"type": "Company", "text": "Shire ADS Holders"}]}, "sentence": " Shire Shareholders and Shire ADS Holders are therefore strongly urged to complete, sign and return the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible.", "object": {"text": "the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible", "keywords": [{"text": "ADS Voting Card"}, {"text": "Shire General Meeting"}, {"text": "electronic means"}, {"text": "Court Meeting"}], "entities": [{"type": "Organization", "text": "Shire General Meeting"}]}, "action": {"verb": {"text": "complete", "tense": "future"}, "text": "urged to complete", "normalized": "urge to complete"}}, {"subject": {"text": "Shire Shareholders and Shire ADS Holders", "keywords": [{"text": "Shire ADS Holders"}, {"text": "Shire Shareholders"}], "entities": [{"type": "Company", "text": "Shire Shareholders"}, {"type": "Company", "text": "Shire ADS Holders"}]}, "sentence": " Shire Shareholders and Shire ADS Holders are therefore strongly urged to complete, sign and return the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible.", "object": {"text": "the Forms of Proxy", "keywords": [{"text": "Proxy"}, {"text": "Forms"}]}, "action": {"verb": {"text": "sign", "tense": "present"}, "text": "sign and return", "normalized": "sign and return"}}, {"subject": {"text": "Shire Shareholders and Shire ADS Holders", "keywords": [{"text": "Shire ADS Holders"}, {"text": "Shire Shareholders"}], "entities": [{"type": "Company", "text": "Shire Shareholders"}, {"type": "Company", "text": "Shire ADS Holders"}]}, "sentence": " Shire Shareholders and Shire ADS Holders are therefore strongly urged to complete, sign and return the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible.", "object": {"text": "the Forms of Proxy", "keywords": [{"text": "Proxy"}, {"text": "Forms"}]}, "action": {"verb": {"text": "return", "tense": "present"}, "text": "sign and return", "normalized": "sign and return"}}, {"subject": {"text": "The Scheme Document", "keywords": [{"text": "Scheme Document"}]}, "sentence": " Timetable The Scheme Document contains an expected timetable of principal events relating to the Scheme, which is also attached as an Appendix to this Announcement.", "object": {"text": "an expected timetable of principal events relating to the Scheme, which is also attached as an Appendix to this Announcement", "keywords": [{"text": "expected timetable"}, {"text": "principal events"}, {"text": "Appendix"}, {"text": "Scheme"}], "entities": [{"type": "JobTitle", "text": "PRINCIPAL"}, {"type": "Organization", "text": "Scheme"}]}, "action": {"verb": {"text": "contain", "tense": "present"}, "text": "contains", "normalized": "contain"}}, {"subject": {"text": "the satisfaction or waiver of the other Conditions", "keywords": [{"text": "waiver"}, {"text": "satisfaction"}, {"text": "Conditions"}]}, "sentence": " Subject to approval at the relevant meetings, the satisfaction or waiver of the other Conditions set out in the Scheme Document and the sanction of the Court, the Scheme is expected to become effective on or around January 8, 2019.", "object": {"text": "in the Scheme Document", "keywords": [{"text": "Scheme Document"}]}, "action": {"verb": {"text": "set", "tense": "past"}, "text": "set", "normalized": "set"}}, {"subject": {"text": "the Scheme", "keywords": [{"text": "Scheme"}], "entities": [{"type": "Organization", "text": "Scheme"}]}, "sentence": " Subject to approval at the relevant meetings, the satisfaction or waiver of the other Conditions set out in the Scheme Document and the sanction of the Court, the Scheme is expected to become effective on or around January 8, 2019.", "action": {"verb": {"text": "expect", "tense": "past"}, "text": "is expected to become", "normalized": "be expect to become"}}, {"subject": {"text": "the Scheme", "keywords": [{"text": "Scheme"}], "entities": [{"type": "Organization", "text": "Scheme"}]}, "sentence": " Subject to approval at the relevant meetings, the satisfaction or waiver of the other Conditions set out in the Scheme Document and the sanction of the Court, the Scheme is expected to become effective on or around January 8, 2019.", "object": {"text": "effective"}, "action": {"verb": {"text": "become", "tense": "future"}, "text": "is expected to become", "normalized": "be expect to become"}}, {"subject": {"text": "it"}, "sentence": " If it becomes necessary to change any of the dates and/or times in the expected timetable, including as a result of the timing of receipt of approval from the European Commission to proceed to completion of the Acquisition, it is intended that the Effective Date will be as soon as practicable after January 8, 2019.", "object": {"text": "necessary to change any of the dates and/or times in the expected timetable", "keywords": [{"text": "timetable"}, {"text": "dates"}, {"text": "times"}]}, "action": {"verb": {"text": "become", "tense": "present"}, "text": "becomes", "normalized": "become"}}, {"subject": {"text": "it"}, "sentence": " If it becomes necessary to change any of the dates and/or times in the expected timetable, including as a result of the timing of receipt of approval from the European Commission to proceed to completion of the Acquisition, it is intended that the Effective Date will be as soon as practicable after January 8, 2019.", "object": {"text": "intended that the Effective Date will be as soon as practicable", "keywords": [{"text": "Effective Date"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "that the Effective Date will be as soon as practicable after January 8, 2019", "keywords": [{"text": "Effective Date"}, {"text": "practicable"}]}, "sentence": " If it becomes necessary to change any of the dates and/or times in the expected timetable, including as a result of the timing of receipt of approval from the European Commission to proceed to completion of the Acquisition, it is intended that the Effective Date will be as soon as practicable after January 8, 2019.", "object": {"text": "it"}, "action": {"verb": {"text": "intend", "tense": "past"}, "text": "is intended", "normalized": "be intend"}}, {"subject": {"text": "the Scheme", "keywords": [{"text": "Scheme"}], "entities": [{"type": "Organization", "text": "Scheme"}]}, "sentence": " If the Scheme is approved as outlined above, it is expected that trading of Shire Shares on the London Stock Exchange's main market for listed securities will be suspended from 4.30 p.m. on January 4, 2019.", "object": {"text": "approved as outlined above"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the Scheme", "keywords": [{"text": "Scheme"}], "entities": [{"type": "Organization", "text": "Scheme"}]}, "sentence": " If the Scheme is approved as outlined above, it is expected that trading of Shire Shares on the London Stock Exchange's main market for listed securities will be suspended from 4.30 p.m. on January 4, 2019.", "object": {"text": "as outlined above"}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "is approved", "normalized": "be approve"}}, {"subject": {"text": "the Scheme", "keywords": [{"text": "Scheme"}], "entities": [{"type": "Organization", "text": "Scheme"}]}, "sentence": " If the Scheme is approved as outlined above, it is expected that trading of Shire Shares on the London Stock Exchange's main market for listed securities will be suspended from 4.30 p.m. on January 4, 2019.", "action": {"verb": {"text": "outline", "tense": "past"}, "text": "outlined", "normalized": "outline"}}, {"subject": {"text": "trading of Shire Shares on the London Stock Exchange's main market for listed securities", "keywords": [{"text": "London Stock Exchange"}, {"text": "Shire Shares"}, {"text": "listed securities"}, {"text": "main market"}], "entities": [{"type": "Company", "text": "Shire Shares"}, {"type": "Company", "text": "London Stock Exchange", "disambiguation": {"subtype": ["Organization", "Location", "Facility", "TouristAttraction"], "name": "London Stock Exchange", "dbpedia_resource": "http://dbpedia.org/resource/London_Stock_Exchange"}}]}, "sentence": " If the Scheme is approved as outlined above, it is expected that trading of Shire Shares on the London Stock Exchange's main market for listed securities will be suspended from 4.30 p.m. on January 4, 2019.", "action": {"verb": {"text": "suspend", "tense": "future"}, "text": "will be suspended", "normalized": "will be suspend"}}, {"subject": {"text": "It"}, "sentence": " It is intended that, following the Scheme becoming Effective, the London Stock Exchange and the FCA will be requested respectively to cancel trading in Shire Shares on the London Stock Exchange's main market for listed securities and to remove the listing of the Shire Shares from the Official List, in each case on or shortly after the Effective Date.", "object": {"text": "intended that"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "that"}, "sentence": " It is intended that, following the Scheme becoming Effective, the London Stock Exchange and the FCA will be requested respectively to cancel trading in Shire Shares on the London Stock Exchange's main market for listed securities and to remove the listing of the Shire Shares from the Official List, in each case on or shortly after the Effective Date.", "object": {"text": "It"}, "action": {"verb": {"text": "intend", "tense": "past"}, "text": "is intended", "normalized": "be intend"}}, {"subject": {"text": "the Scheme", "keywords": [{"text": "Scheme"}], "entities": [{"type": "Organization", "text": "Scheme"}]}, "sentence": " It is intended that, following the Scheme becoming Effective, the London Stock Exchange and the FCA will be requested respectively to cancel trading in Shire Shares on the London Stock Exchange's main market for listed securities and to remove the listing of the Shire Shares from the Official List, in each case on or shortly after the Effective Date.", "object": {"text": "Effective"}, "action": {"verb": {"text": "become", "tense": "present"}, "text": "becoming", "normalized": "become"}}, {"subject": {"text": "the FCA", "keywords": [{"text": "FCA"}], "entities": [{"type": "Organization", "text": "FCA", "disambiguation": {"subtype": ["Industry"], "name": "Airline", "dbpedia_resource": "http://dbpedia.org/resource/Airline"}}]}, "sentence": " It is intended that, following the Scheme becoming Effective, the London Stock Exchange and the FCA will be requested respectively to cancel trading in Shire Shares on the London Stock Exchange's main market for listed securities and to remove the listing of the Shire Shares from the Official List, in each case on or shortly after the Effective Date.", "object": {"text": "requested respectively"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}], "concepts": [{"text": "U.S. Securities and Exchange Commission", "relevance": 0.954479, "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}, {"text": "Stock market", "relevance": 0.798778, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "Stock", "relevance": 0.717668, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Stock exchange", "relevance": 0.704923, "dbpedia_resource": "http://dbpedia.org/resource/Stock_exchange"}, {"text": "Financial adviser", "relevance": 0.636573, "dbpedia_resource": "http://dbpedia.org/resource/Financial_adviser"}, {"text": "Securities Exchange Act of 1934", "relevance": 0.551609, "dbpedia_resource": "http://dbpedia.org/resource/Securities_Exchange_Act_of_1934"}, {"text": "London Stock Exchange", "relevance": 0.544315, "dbpedia_resource": "http://dbpedia.org/resource/London_Stock_Exchange"}, {"text": "New York Stock Exchange", "relevance": 0.528782, "dbpedia_resource": "http://dbpedia.org/resource/New_York_Stock_Exchange"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.483604, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Securities Act of 1933", "relevance": 0.4626, "dbpedia_resource": "http://dbpedia.org/resource/Securities_Act_of_1933"}, {"text": "Independent Financial Adviser", "relevance": 0.440197, "dbpedia_resource": "http://dbpedia.org/resource/Independent_Financial_Adviser"}, {"text": "Form 10-K", "relevance": 0.438214, "dbpedia_resource": "http://dbpedia.org/resource/Form_10-K"}], "categories": [{"score": 0.645202, "label": "/finance/financial news"}, {"score": 0.443323, "label": "/law, govt and politics"}, {"score": 0.408461, "label": "/real estate/buying and selling homes"}], "relations": [{"type": "partOfMany", "sentence": "TAKEDA PHARMACEUTICAL COMPANY LIMITED Publication of Scheme Document On May 8, 2018, Shire plc (\" Shire \") and Takeda Pharmaceutical Company Limited (\" Takeda \") announced that they had reached agreement on the terms of a recommended cash and share offer to be made by Takeda for the entire issued and to be issued share capital of Shire (the \" Acquisition \").", "score": 0.743728, "arguments": [{"text": "Shire plc", "location": [85, 94], "entities": [{"type": "Person", "text": "Shire plc"}]}, {"text": "they", "location": [177, 181], "entities": [{"type": "Person", "text": "they"}]}]}, {"type": "participantIn", "sentence": "A Notice of Court Meeting and Extraordinary General Meeting, together with an ADS Voting Card, is also being sent to Shire ADS Holders today by the Shire Depositary.", "score": 0.507852, "arguments": [{"text": "Court", "location": [1376, 1381], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [1382, 1389], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "partOfMany", "sentence": "Shire Shareholders who are in any doubt regarding such matters should consult an appropriate independent financial adviser in their relevant jurisdiction without delay.", "score": 0.510056, "arguments": [{"text": "Shareholders", "location": [19594, 19606], "entities": [{"type": "Person", "text": "Shareholders"}]}, {"text": "who", "location": [19607, 19610], "entities": [{"type": "Person", "text": "who"}]}]}, {"type": "colleague", "sentence": "Further details in relation to Shire Shareholders who are resident in, ordinarily resident in, or citizens of, jurisdictions outside the United Kingdom and Jersey will be contained in the Scheme Document.", "score": 0.340474, "arguments": [{"text": "Shire", "location": [20332, 20337], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Shareholders", "location": [20338, 20350], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "partOfMany", "sentence": "Further details in relation to Shire Shareholders who are resident in, ordinarily resident in, or citizens of, jurisdictions outside the United Kingdom and Jersey will be contained in the Scheme Document.", "score": 0.479561, "arguments": [{"text": "Shareholders", "location": [20338, 20350], "entities": [{"type": "Person", "text": "Shareholders"}]}, {"text": "who", "location": [20351, 20354], "entities": [{"type": "Person", "text": "who"}]}]}, {"type": "partOfMany", "sentence": "Further details in relation to Shire Shareholders who are resident in, ordinarily resident in, or citizens of, jurisdictions outside the United Kingdom and Jersey will be contained in the Scheme Document.", "score": 0.615283, "arguments": [{"text": "resident", "location": [20359, 20367], "entities": [{"type": "Person", "text": "resident"}]}, {"text": "who", "location": [20351, 20354], "entities": [{"type": "Person", "text": "who"}]}]}, {"type": "partOfMany", "sentence": "Further details in relation to Shire Shareholders who are resident in, ordinarily resident in, or citizens of, jurisdictions outside the United Kingdom and Jersey will be contained in the Scheme Document.", "score": 0.721339, "arguments": [{"text": "resident", "location": [20383, 20391], "entities": [{"type": "Person", "text": "resident"}]}, {"text": "who", "location": [20351, 20354], "entities": [{"type": "Person", "text": "who"}]}]}, {"type": "employedBy", "sentence": "Additional information for US investors Notice to US investors in Shire: the Acquisition relates to the shares of a Jersey company and is being made by means of a scheme of arrangement provided for under the Jersey Companies Law.", "score": 0.972641, "arguments": [{"text": "investors", "location": [20536, 20545], "entities": [{"type": "Person", "text": "investors"}]}, {"text": "US", "location": [20533, 20535], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "employedBy", "sentence": "Additional information for US investors Notice to US investors in Shire: the Acquisition relates to the shares of a Jersey company and is being made by means of a scheme of arrangement provided for under the Jersey Companies Law.", "score": 0.966762, "arguments": [{"text": "investors", "location": [20559, 20568], "entities": [{"type": "Person", "text": "investors"}]}, {"text": "US", "location": [20556, 20558], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "employedBy", "sentence": "Additional information for US investors Notice to US investors in Shire: the Acquisition relates to the shares of a Jersey company and is being made by means of a scheme of arrangement provided for under the Jersey Companies Law.", "score": 0.376571, "arguments": [{"text": "Shire", "location": [20572, 20577], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Acquisition", "location": [20583, 20594], "entities": [{"type": "Organization", "text": "Acquisition"}]}]}, {"type": "basedIn", "sentence": "Additional information for US investors Notice to US investors in Shire: the Acquisition relates to the shares of a Jersey company and is being made by means of a scheme of arrangement provided for under the Jersey Companies Law.", "score": 0.951866, "arguments": [{"text": "company", "location": [20629, 20636], "entities": [{"type": "Organization", "text": "company"}]}, {"text": "Jersey", "location": [20622, 20628], "entities": [{"type": "GeopoliticalEntity", "text": "Jersey"}]}]}, {"type": "partOf", "sentence": "A transaction effected by means of a scheme of arrangement is not subject to the tender offer rules or the proxy solicitation rules under the US Exchange Act, and it is expected that any New Takeda Securities to be issued pursuant to the Scheme to Shire Shareholders would be issued in reliance upon the exemption from the registration requirements under the US Securities Act provided by Section 3(a)(10) thereof.", "score": 0.988303, "arguments": [{"text": "Exchange Act", "location": [20881, 20893], "entities": [{"type": "Organization", "text": "Exchange Act"}]}, {"text": "US", "location": [20878, 20880], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "participantIn", "sentence": "A Notice of Court Meeting and Extraordinary General Meeting, together with an ADS Voting Card, is also being sent to Shire ADS Holders today by the Shire Depositary.", "score": 0.55396, "arguments": [{"text": "ADS Voting Card", "location": [1442, 1457], "entities": [{"type": "Person", "text": "ADS Voting Card"}]}, {"text": "Meeting", "location": [1382, 1389], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "employedBy", "sentence": "Under applicable US securities laws, persons (whether or not US persons) who are or will be \"affiliates\" (within the meaning of Rule 144 of the US Securities Act) of Takeda prior to, or after, the Effective Date will be subject to certain transfer restrictions relating to the New Takeda Securities received in connection with the Acquisition.", "score": 0.931891, "arguments": [{"text": "persons", "location": [21215, 21222], "entities": [{"type": "Person", "text": "persons"}]}, {"text": "US", "location": [21212, 21214], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "partOf", "sentence": "Under applicable US securities laws, persons (whether or not US persons) who are or will be \"affiliates\" (within the meaning of Rule 144 of the US Securities Act) of Takeda prior to, or after, the Effective Date will be subject to certain transfer restrictions relating to the New Takeda Securities received in connection with the Acquisition.", "score": 0.555179, "arguments": [{"text": "Rule 144", "location": [21279, 21287], "entities": [{"type": "Organization", "text": "Rule 144"}]}, {"text": "US Securities Act", "location": [21295, 21312], "entities": [{"type": "Organization", "text": "US Securities Act"}]}]}, {"type": "partOf", "sentence": "Accordingly, the Acquisition is subject to the disclosure requirements and practices applicable in the United Kingdom and Jersey to schemes of arrangement which differ from the disclosure requirements of United States tender offer and proxy solicitation rules and the US Securities Act.", "score": 0.949573, "arguments": [{"text": "tender", "location": [21713, 21719], "entities": [{"type": "Organization", "text": "tender"}]}, {"text": "United States", "location": [21699, 21712], "entities": [{"type": "GeopoliticalEntity", "text": "United States"}]}]}, {"type": "educatedAt", "sentence": "If, in the future, Takeda exercises the right to implement the Acquisition by way of a Takeover Offer and determines to extend the offer into the United States, the Acquisition will be made in compliance with applicable United States laws and regulations, including any applicable exemptions under the US Exchange Act.", "score": 0.430499, "arguments": [{"text": "Takeda", "location": [21801, 21807], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "Takeover Offer", "location": [21869, 21883], "entities": [{"type": "Organization", "text": "Takeover Offer"}]}]}, {"type": "agentOf", "sentence": "If, in the future, Takeda exercises the right to implement the Acquisition by way of a Takeover Offer and determines to extend the offer into the United States, the Acquisition will be made in compliance with applicable United States laws and regulations, including any applicable exemptions under the US Exchange Act.", "score": 0.606714, "arguments": [{"text": "Takeda", "location": [21801, 21807], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "determines", "location": [21888, 21898], "entities": [{"type": "EventCommunication", "text": "determines"}]}]}, {"type": "agentOf", "sentence": "Financial information included in this Announcement and the Scheme Document has been or will have been prepared in accordance with accounting standards applicable in the United Kingdom and Jersey that may not be comparable to financial information of US companies or companies whose financial statements are prepared in accordance with US GAAP.", "score": 0.784337, "arguments": [{"text": "Financial information", "location": [22101, 22122], "entities": [{"type": "Organization", "text": "Financial information"}]}, {"text": "Announcement", "location": [22140, 22152], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Financial information included in this Announcement and the Scheme Document has been or will have been prepared in accordance with accounting standards applicable in the United Kingdom and Jersey that may not be comparable to financial information of US companies or companies whose financial statements are prepared in accordance with US GAAP.", "score": 0.578556, "arguments": [{"text": "Scheme Document", "location": [22161, 22176], "entities": [{"type": "Organization", "text": "Scheme Document"}]}, {"text": "Announcement", "location": [22140, 22152], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "partOfMany", "sentence": "Financial information included in this Announcement and the Scheme Document has been or will have been prepared in accordance with accounting standards applicable in the United Kingdom and Jersey that may not be comparable to financial information of US companies or companies whose financial statements are prepared in accordance with US GAAP.", "score": 0.334276, "arguments": [{"text": "Jersey", "location": [22290, 22296], "entities": [{"type": "Organization", "text": "Jersey"}]}, {"text": "companies", "location": [22368, 22377], "entities": [{"type": "Organization", "text": "companies"}]}]}, {"type": "basedIn", "sentence": "Financial information included in this Announcement and the Scheme Document has been or will have been prepared in accordance with accounting standards applicable in the United Kingdom and Jersey that may not be comparable to financial information of US companies or companies whose financial statements are prepared in accordance with US GAAP.", "score": 0.959976, "arguments": [{"text": "companies", "location": [22355, 22364], "entities": [{"type": "Organization", "text": "companies"}]}, {"text": "US", "location": [22352, 22354], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "employedBy", "sentence": "Financial information included in this Announcement and the Scheme Document has been or will have been prepared in accordance with accounting standards applicable in the United Kingdom and Jersey that may not be comparable to financial information of US companies or companies whose financial statements are prepared in accordance with US GAAP.", "score": 0.555306, "arguments": [{"text": "whose", "location": [22378, 22383], "entities": [{"type": "Person", "text": "whose"}]}, {"text": "companies", "location": [22368, 22377], "entities": [{"type": "Organization", "text": "companies"}]}]}, {"type": "hasAttribute", "sentence": "The Scheme Document, Forms of Proxy and Forms of Election will be available shortly on the National Storage Mechanism at www.morningstar.co.uk/uk/nsm. The Scheme Document has also been furnished to the SEC on Form 6-K and is available on the SEC's website at www.sec.gov.", "score": 0.508651, "arguments": [{"text": "SEC", "location": [1772, 1775], "entities": [{"type": "Organization", "text": "SEC"}]}, {"text": "www.sec.gov", "location": [1789, 1800], "entities": [{"type": "Web", "text": "www.sec.gov"}]}]}, {"type": "employedBy", "sentence": "The receipt of consideration by a US holder for the transfer of its Shire Shares pursuant to the Scheme will be a taxable transaction for United States federal income tax purposes.", "score": 0.687229, "arguments": [{"text": "Shire", "location": [22514, 22519], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "its", "location": [22510, 22513], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "agentOf", "sentence": "Each Shire Shareholder is urged to consult his independent professional adviser immediately regarding the tax consequences of the Acquisition applicable to him, including under applicable United States state and local, as well as foreign and other, tax laws.", "score": 0.609404, "arguments": [{"text": "Shire", "location": [22632, 22637], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "urged", "location": [22653, 22658], "entities": [{"type": "EventCommunication", "text": "urged"}]}]}, {"type": "partOf", "sentence": "Each Shire Shareholder is urged to consult his independent professional adviser immediately regarding the tax consequences of the Acquisition applicable to him, including under applicable United States state and local, as well as foreign and other, tax laws.", "score": 0.562084, "arguments": [{"text": "United States", "location": [22815, 22828], "entities": [{"type": "GeopoliticalEntity", "text": "United States"}]}, {"text": "state", "location": [22829, 22834], "entities": [{"type": "GeopoliticalEntity", "text": "state"}]}]}, {"type": "employedBy", "sentence": "It may be difficult for US holders of Shire Shares to enforce their rights and any claim arising out of the US federal laws, since Takeda and Shire are located primarily in a non-US jurisdiction, and some or all of their officers and directors may be residents of a non-US jurisdiction.", "score": 0.924679, "arguments": [{"text": "holders", "location": [22913, 22920], "entities": [{"type": "Person", "text": "holders"}]}, {"text": "US", "location": [22910, 22912], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "partOfMany", "sentence": "It may be difficult for US holders of Shire Shares to enforce their rights and any claim arising out of the US federal laws, since Takeda and Shire are located primarily in a non-US jurisdiction, and some or all of their officers and directors may be residents of a non-US jurisdiction.", "score": 0.618096, "arguments": [{"text": "holders", "location": [22913, 22920], "entities": [{"type": "Person", "text": "holders"}]}, {"text": "their", "location": [22948, 22953], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "It may be difficult for US holders of Shire Shares to enforce their rights and any claim arising out of the US federal laws, since Takeda and Shire are located primarily in a non-US jurisdiction, and some or all of their officers and directors may be residents of a non-US jurisdiction.", "score": 0.789837, "arguments": [{"text": "Shire", "location": [22924, 22929], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "their", "location": [22948, 22953], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "It may be difficult for US holders of Shire Shares to enforce their rights and any claim arising out of the US federal laws, since Takeda and Shire are located primarily in a non-US jurisdiction, and some or all of their officers and directors may be residents of a non-US jurisdiction.", "score": 0.49106, "arguments": [{"text": "Takeda", "location": [23017, 23023], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "their", "location": [23101, 23106], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "It may be difficult for US holders of Shire Shares to enforce their rights and any claim arising out of the US federal laws, since Takeda and Shire are located primarily in a non-US jurisdiction, and some or all of their officers and directors may be residents of a non-US jurisdiction.", "score": 0.681985, "arguments": [{"text": "Shire", "location": [23028, 23033], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "some", "location": [23086, 23090], "entities": [{"type": "Cardinal", "text": "some"}]}]}, {"type": "partOfMany", "sentence": "It may be difficult for US holders of Shire Shares to enforce their rights and any claim arising out of the US federal laws, since Takeda and Shire are located primarily in a non-US jurisdiction, and some or all of their officers and directors may be residents of a non-US jurisdiction.", "score": 0.890011, "arguments": [{"text": "Shire", "location": [23028, 23033], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "their", "location": [23101, 23106], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "It may be difficult for US holders of Shire Shares to enforce their rights and any claim arising out of the US federal laws, since Takeda and Shire are located primarily in a non-US jurisdiction, and some or all of their officers and directors may be residents of a non-US jurisdiction.", "score": 0.759844, "arguments": [{"text": "some", "location": [23086, 23090], "entities": [{"type": "Cardinal", "text": "some"}]}, {"text": "directors", "location": [23120, 23129], "entities": [{"type": "Person", "text": "directors"}]}]}, {"type": "partOfMany", "sentence": "Shire also notes Takeda's circular to shareholders published today, which relates to the convocation of the Takeda Extraordinary General Meeting scheduled to be held at 10.00 a.m. (Tokyo time) (1.00 a.m. (London time)) on December 5, 2018.", "score": 0.627063, "arguments": [{"text": "Shire", "location": [1802, 1807], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "shareholders", "location": [1840, 1852], "entities": [{"type": "Person", "text": "shareholders"}]}]}, {"type": "employedBy", "sentence": "US holders of Shire Shares may not be able to sue a non-US company or its officers or directors in a non-US court for violations of the US securities laws.", "score": 0.930895, "arguments": [{"text": "holders", "location": [23176, 23183], "entities": [{"type": "Person", "text": "holders"}]}, {"text": "US", "location": [23173, 23175], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "employedBy", "sentence": "US holders of Shire Shares may not be able to sue a non-US company or its officers or directors in a non-US court for violations of the US securities laws.", "score": 0.495501, "arguments": [{"text": "officers", "location": [23247, 23255], "entities": [{"type": "Person", "text": "officers"}]}, {"text": "its", "location": [23243, 23246], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "employedBy", "sentence": "US holders of Shire Shares may not be able to sue a non-US company or its officers or directors in a non-US court for violations of the US securities laws.", "score": 0.531448, "arguments": [{"text": "directors", "location": [23259, 23268], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "its", "location": [23243, 23246], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "employedBy", "sentence": "US holders of Shire Shares may not be able to sue a non-US company or its officers or directors in a non-US court for violations of the US securities laws.", "score": 0.607332, "arguments": [{"text": "directors", "location": [23259, 23268], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "court", "location": [23281, 23286], "entities": [{"type": "Organization", "text": "court"}]}]}, {"type": "partOf", "sentence": "Further, it may be difficult to compel a non-US company and its affiliates to subject themselves to the jurisdiction and judgment of a US court.", "score": 0.86995, "arguments": [{"text": "affiliates", "location": [23393, 23403], "entities": [{"type": "Organization", "text": "affiliates"}]}, {"text": "its", "location": [23389, 23392], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "partOf", "sentence": "Further, it may be difficult to compel a non-US company and its affiliates to subject themselves to the jurisdiction and judgment of a US court.", "score": 0.963294, "arguments": [{"text": "court", "location": [23467, 23472], "entities": [{"type": "Organization", "text": "court"}]}, {"text": "US", "location": [23464, 23466], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "partOf", "sentence": "New Takeda Securities issued pursuant to the Scheme will not be registered under any US state securities laws and may only be issued to persons resident in a state pursuant to an exemption from the registration requirements of the securities laws of such state.", "score": 0.762332, "arguments": [{"text": "state", "location": [23562, 23567], "entities": [{"type": "GeopoliticalEntity", "text": "state"}]}, {"text": "US", "location": [23559, 23561], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "agentOf", "sentence": "For the purpose of qualifying for the exemption provided by Section 3(a)(10) of the US Securities Act, Shire will advise the Court that its sanctioning of the Scheme will be relied on by Takeda as an approval of the Scheme following a hearing on its fairness to Shire Shareholders, at which Court hearing all Shire Shareholders are entitled to attend in person or through counsel to support or oppose the sanctioning of the Scheme and with respect to which notification will be given to all such holders.", "score": 0.942436, "arguments": [{"text": "Shire", "location": [23839, 23844], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "advise", "location": [23850, 23856], "entities": [{"type": "EventCommunication", "text": "advise"}]}]}, {"type": "affectedBy", "sentence": "For the purpose of qualifying for the exemption provided by Section 3(a)(10) of the US Securities Act, Shire will advise the Court that its sanctioning of the Scheme will be relied on by Takeda as an approval of the Scheme following a hearing on its fairness to Shire Shareholders, at which Court hearing all Shire Shareholders are entitled to attend in person or through counsel to support or oppose the sanctioning of the Scheme and with respect to which notification will be given to all such holders.", "score": 0.963339, "arguments": [{"text": "Court", "location": [23861, 23866], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "advise", "location": [23850, 23856], "entities": [{"type": "EventCommunication", "text": "advise"}]}]}, {"type": "affectedBy", "sentence": "For the purpose of qualifying for the exemption provided by Section 3(a)(10) of the US Securities Act, Shire will advise the Court that its sanctioning of the Scheme will be relied on by Takeda as an approval of the Scheme following a hearing on its fairness to Shire Shareholders, at which Court hearing all Shire Shareholders are entitled to attend in person or through counsel to support or oppose the sanctioning of the Scheme and with respect to which notification will be given to all such holders.", "score": 0.337223, "arguments": [{"text": "Scheme", "location": [23952, 23958], "entities": [{"type": "Organization", "text": "Scheme"}]}, {"text": "hearing", "location": [23971, 23978], "entities": [{"type": "EventLegal", "text": "hearing"}]}]}, {"type": "participantIn", "sentence": "Shire also notes Takeda's circular to shareholders published today, which relates to the convocation of the Takeda Extraordinary General Meeting scheduled to be held at 10.00 a.m. (Tokyo time) (1.00 a.m. (London time)) on December 5, 2018.", "score": 0.504194, "arguments": [{"text": "Takeda Extraordinary General", "location": [1910, 1938], "entities": [{"type": "Organization", "text": "Takeda Extraordinary General"}]}, {"text": "Meeting", "location": [1939, 1946], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "agentOf", "sentence": "For the purpose of qualifying for the exemption provided by Section 3(a)(10) of the US Securities Act, Shire will advise the Court that its sanctioning of the Scheme will be relied on by Takeda as an approval of the Scheme following a hearing on its fairness to Shire Shareholders, at which Court hearing all Shire Shareholders are entitled to attend in person or through counsel to support or oppose the sanctioning of the Scheme and with respect to which notification will be given to all such holders.", "score": 0.861982, "arguments": [{"text": "Court", "location": [24027, 24032], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "hearing", "location": [24033, 24040], "entities": [{"type": "EventLegal", "text": "hearing"}]}]}, {"type": "affectedBy", "sentence": "For the purpose of qualifying for the exemption provided by Section 3(a)(10) of the US Securities Act, Shire will advise the Court that its sanctioning of the Scheme will be relied on by Takeda as an approval of the Scheme following a hearing on its fairness to Shire Shareholders, at which Court hearing all Shire Shareholders are entitled to attend in person or through counsel to support or oppose the sanctioning of the Scheme and with respect to which notification will be given to all such holders.", "score": 0.660267, "arguments": [{"text": "Shareholders", "location": [24051, 24063], "entities": [{"type": "Person", "text": "Shareholders"}]}, {"text": "hearing", "location": [24033, 24040], "entities": [{"type": "EventLegal", "text": "hearing"}]}]}, {"type": "agentOf", "sentence": "Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct and you are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this Announcement.", "score": 0.912144, "arguments": [{"text": "you", "location": [26696, 26699], "entities": [{"type": "Person", "text": "you"}]}, {"text": "cautioned", "location": [26714, 26723], "entities": [{"type": "EventCommunication", "text": "cautioned"}]}]}, {"type": "agentOf", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in 'ITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.shire.com and www.sec.gov), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.992023, "arguments": [{"text": "Shire", "location": [26914, 26919], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Report", "location": [26941, 26947], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "timeOf", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in 'ITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.shire.com and www.sec.gov), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.888434, "arguments": [{"text": "10-K", "location": [26956, 26960], "entities": [{"type": "Date", "text": "10-K"}]}, {"text": "Report", "location": [26941, 26947], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "agentOf", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in 'ITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.shire.com and www.sec.gov), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.984957, "arguments": [{"text": "Shire", "location": [26968, 26973], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Reports", "location": [26997, 27004], "entities": [{"type": "EventCommunication", "text": "Reports"}]}]}, {"type": "hasAttribute", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in 'ITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.shire.com and www.sec.gov), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.548308, "arguments": [{"text": "Securities and Exchange Commission", "location": [27146, 27180], "entities": [{"type": "Organization", "text": "Securities and Exchange Commission"}]}, {"text": "www.shire.com", "location": [27203, 27216], "entities": [{"type": "Web", "text": "www.shire.com"}]}]}, {"type": "agentOf", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in 'ITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.shire.com and www.sec.gov), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.530254, "arguments": [{"text": "they", "location": [27304, 27308], "entities": [{"type": "Person", "text": "they"}]}, {"text": "Announcement", "location": [27328, 27340], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "These risk factors expressly qualify all forward-looking statements contained in this Announcement and should also be considered by the reader.", "score": 0.492954, "arguments": [{"text": "reader", "location": [27478, 27484], "entities": [{"type": "Person", "text": "reader"}]}, {"text": "Announcement", "location": [27428, 27440], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "partOfMany", "sentence": "All forward-looking statements attributable to Takeda or Shire or any person acting on either company's behalf are expressly qualified in their entirety by this cautionary statement.", "score": 0.865201, "arguments": [{"text": "Takeda", "location": [27533, 27539], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "their", "location": [27624, 27629], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "locatedAt", "sentence": "Shire also notes Takeda's circular to shareholders published today, which relates to the convocation of the Takeda Extraordinary General Meeting scheduled to be held at 10.00 a.m. (Tokyo time) (1.00 a.m. (London time)) on December 5, 2018.", "score": 0.626335, "arguments": [{"text": "Meeting", "location": [1939, 1946], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}, {"text": "Tokyo", "location": [1983, 1988], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo"}]}]}, {"type": "partOfMany", "sentence": "All forward-looking statements attributable to Takeda or Shire or any person acting on either company's behalf are expressly qualified in their entirety by this cautionary statement.", "score": 0.958817, "arguments": [{"text": "Shire", "location": [27543, 27548], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "their", "location": [27624, 27629], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "All forward-looking statements attributable to Takeda or Shire or any person acting on either company's behalf are expressly qualified in their entirety by this cautionary statement.", "score": 0.803988, "arguments": [{"text": "person", "location": [27556, 27562], "entities": [{"type": "Person", "text": "person"}]}, {"text": "their", "location": [27624, 27629], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "agentOf", "sentence": "Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.", "score": 0.834273, "arguments": [{"text": "Readers", "location": [27669, 27676], "entities": [{"type": "Person", "text": "Readers"}]}, {"text": "cautioned", "location": [27681, 27690], "entities": [{"type": "EventCommunication", "text": "cautioned"}]}]}, {"type": "partOfMany", "sentence": "Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.", "score": 0.678392, "arguments": [{"text": "persons", "location": [29757, 29764], "entities": [{"type": "Person", "text": "persons"}]}, {"text": "who", "location": [29765, 29768], "entities": [{"type": "Person", "text": "who"}]}]}, {"type": "hasAttribute", "sentence": "If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.", "score": 0.824036, "arguments": [{"text": "Rule", "location": [31098, 31102], "entities": [{"type": "Organization", "text": "Rule"}]}, {"text": "8.3", "location": [31103, 31106], "entities": [{"type": "Money", "text": "8.3"}]}]}, {"type": "participantIn", "sentence": "Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).", "score": 0.534952, "arguments": [{"text": "persons", "location": [31289, 31296], "entities": [{"type": "Person", "text": "persons"}]}, {"text": "concert", "location": [31307, 31314], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Panel's website at http://www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the Offer Period commenced and when any offeror was first identified.", "score": 0.457967, "arguments": [{"text": "whose", "location": [31421, 31426], "entities": [{"type": "Person", "text": "whose"}]}, {"text": "companies", "location": [31397, 31406], "entities": [{"type": "Organization", "text": "companies"}]}]}, {"type": "timeOf", "sentence": "Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Panel's website at http://www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the Offer Period commenced and when any offeror was first identified.", "score": 0.556374, "arguments": [{"text": "http://www.thetakeoverpanel.org.uk", "location": [31576, 31610], "entities": [{"type": "Time", "text": "http://www.thetakeoverpanel.org.uk"}]}, {"text": "commenced", "location": [31699, 31708], "entities": [{"type": "EventCommunication", "text": "commenced"}]}]}, {"type": "agentOf", "sentence": "Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Panel's website at http://www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the Offer Period commenced and when any offeror was first identified.", "score": 0.991137, "arguments": [{"text": "Offer Period", "location": [31686, 31698], "entities": [{"type": "Organization", "text": "Offer Period"}]}, {"text": "commenced", "location": [31699, 31708], "entities": [{"type": "EventCommunication", "text": "commenced"}]}]}, {"type": "partOf", "sentence": "If you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure, you should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129.", "score": 0.886304, "arguments": [{"text": "Market Surveillance Unit", "location": [31902, 31926], "entities": [{"type": "Organization", "text": "Market Surveillance Unit"}]}, {"text": "Panel", "location": [31894, 31899], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "participantIn", "sentence": "Notices of the Court Meeting and Shire General Meeting As described in the Scheme Document, to become effective, the Scheme requires, among other things, the approval of Shire Shareholders at the Court Meeting, the passing of the Special Resolution at the Shire General Meeting and the subsequent sanction of the Court.", "score": 0.473197, "arguments": [{"text": "Court", "location": [2293, 2298], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [2299, 2306], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "colleague", "sentence": "Electronic Communications Please be aware that addresses, electronic addresses and certain other information provided by Shire Shareholders, persons with information rights and other relevant persons in connection with the receipt of communications from Shire may be provided to Takeda during the Offer Period as required under Section 4 of Appendix 4 of the Takeover Code to comply with Rule 2.11 of the Takeover Code.", "score": 0.229669, "arguments": [{"text": "Shire", "location": [32072, 32077], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Shareholders", "location": [32078, 32090], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "employedBy", "sentence": "Electronic Communications Please be aware that addresses, electronic addresses and certain other information provided by Shire Shareholders, persons with information rights and other relevant persons in connection with the receipt of communications from Shire may be provided to Takeda during the Offer Period as required under Section 4 of Appendix 4 of the Takeover Code to comply with Rule 2.11 of the Takeover Code.", "score": 0.540989, "arguments": [{"text": "Takeda", "location": [32230, 32236], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "Offer Period", "location": [32248, 32260], "entities": [{"type": "Organization", "text": "Offer Period"}]}]}, {"type": "partOf", "sentence": "Electronic Communications Please be aware that addresses, electronic addresses and certain other information provided by Shire Shareholders, persons with information rights and other relevant persons in connection with the receipt of communications from Shire may be provided to Takeda during the Offer Period as required under Section 4 of Appendix 4 of the Takeover Code to comply with Rule 2.11 of the Takeover Code.", "score": 0.523397, "arguments": [{"text": "Section 4", "location": [32279, 32288], "entities": [{"type": "Organization", "text": "Section 4"}]}, {"text": "Appendix 4", "location": [32292, 32302], "entities": [{"type": "Organization", "text": "Appendix 4"}]}]}, {"type": "partOf", "sentence": "Electronic Communications Please be aware that addresses, electronic addresses and certain other information provided by Shire Shareholders, persons with information rights and other relevant persons in connection with the receipt of communications from Shire may be provided to Takeda during the Offer Period as required under Section 4 of Appendix 4 of the Takeover Code to comply with Rule 2.11 of the Takeover Code.", "score": 0.545241, "arguments": [{"text": "Rule", "location": [32339, 32343], "entities": [{"type": "Organization", "text": "Rule"}]}, {"text": "Takeover Code", "location": [32356, 32369], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "ownerOf", "sentence": "Publication on Website and Availability of Hard Copies A copy of this Announcement and the documents required to be published by Rule 26 of the Takeover Code will be made available (subject to certain restrictions relating to persons resident in Restricted Jurisdictions) on Takeda 's and Shire's websites at www.takeda.com/investors/offer-for-shire and www.shire.com respectively by no later than 12 noon (London time) on November 13, 2018 , the Business Day following this Announcement .", "score": 0.542279, "arguments": [{"text": "Shire", "location": [32660, 32665], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "websites", "location": [32668, 32676], "entities": [{"type": "Facility", "text": "websites"}]}]}, {"type": "timeOf", "sentence": "Publication on Website and Availability of Hard Copies A copy of this Announcement and the documents required to be published by Rule 26 of the Takeover Code will be made available (subject to certain restrictions relating to persons resident in Restricted Jurisdictions) on Takeda 's and Shire's websites at www.takeda.com/investors/offer-for-shire and www.shire.com respectively by no later than 12 noon (London time) on November 13, 2018 , the Business Day following this Announcement .", "score": 0.642039, "arguments": [{"text": "November 13, 2018", "location": [32794, 32811], "entities": [{"type": "Date", "text": "November 13, 2018"}]}, {"text": "Announcement", "location": [32846, 32858], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Publication on Website and Availability of Hard Copies A copy of this Announcement and the documents required to be published by Rule 26 of the Takeover Code will be made available (subject to certain restrictions relating to persons resident in Restricted Jurisdictions) on Takeda 's and Shire's websites at www.takeda.com/investors/offer-for-shire and www.shire.com respectively by no later than 12 noon (London time) on November 13, 2018 , the Business Day following this Announcement .", "score": 0.592584, "arguments": [{"text": "Business Day", "location": [32818, 32830], "entities": [{"type": "Organization", "text": "Business Day"}]}, {"text": "Announcement", "location": [32846, 32858], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Shire Shareholders may request a hard copy of this Announcement by: (i) contacting Souheil Salah during business hours on +44 (0) 203 5490660 (lines are open from 9am to 5pm (London time), Monday to Friday (excluding public holidays in England and Wales), or (ii) by submitting a request by post to Souheil Salah, One Kingdom Street, 9th Floor, Paddington, London W2 6BD, UK.", "score": 0.626175, "arguments": [{"text": "Souheil Salah", "location": [33072, 33085], "entities": [{"type": "Person", "text": "Souheil Salah"}]}, {"text": "Announcement", "location": [33040, 33052], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "locatedAt", "sentence": "Shire Shareholders may request a hard copy of this Announcement by: (i) contacting Souheil Salah during business hours on +44 (0) 203 5490660 (lines are open from 9am to 5pm (London time), Monday to Friday (excluding public holidays in England and Wales), or (ii) by submitting a request by post to Souheil Salah, One Kingdom Street, 9th Floor, Paddington, London W2 6BD, UK.", "score": 0.504854, "arguments": [{"text": "9th Floor", "location": [33323, 33332], "entities": [{"type": "Organization", "text": "9th Floor"}]}, {"text": "Paddington", "location": [33334, 33344], "entities": [{"type": "GeopoliticalEntity", "text": "Paddington"}]}]}, {"type": "locatedAt", "sentence": "Shire Shareholders may request a hard copy of this Announcement by: (i) contacting Souheil Salah during business hours on +44 (0) 203 5490660 (lines are open from 9am to 5pm (London time), Monday to Friday (excluding public holidays in England and Wales), or (ii) by submitting a request by post to Souheil Salah, One Kingdom Street, 9th Floor, Paddington, London W2 6BD, UK.", "score": 0.657564, "arguments": [{"text": "Paddington", "location": [33334, 33344], "entities": [{"type": "GeopoliticalEntity", "text": "Paddington"}]}, {"text": "London", "location": [33346, 33352], "entities": [{"type": "GeopoliticalEntity", "text": "London"}]}]}, {"type": "agentOf", "sentence": "Notices of the Court Meeting and Shire General Meeting As described in the Scheme Document, to become effective, the Scheme requires, among other things, the approval of Shire Shareholders at the Court Meeting, the passing of the Special Resolution at the Shire General Meeting and the subsequent sanction of the Court.", "score": 0.563012, "arguments": [{"text": "Scheme Document", "location": [2353, 2368], "entities": [{"type": "Organization", "text": "Scheme Document"}]}, {"text": "described", "location": [2336, 2345], "entities": [{"type": "EventCommunication", "text": "described"}]}]}, {"type": "employedBy", "sentence": "Shire Shareholders may request a hard copy of this Announcement by: (i) contacting Souheil Salah during business hours on +44 (0) 203 5490660 (lines are open from 9am to 5pm (London time), Monday to Friday (excluding public holidays in England and Wales), or (ii) by submitting a request by post to Souheil Salah, One Kingdom Street, 9th Floor, Paddington, London W2 6BD, UK.", "score": 0.892815, "arguments": [{"text": "W2 6BD", "location": [33353, 33359], "entities": [{"type": "Person", "text": "W2 6BD"}]}, {"text": "UK", "location": [33361, 33363], "entities": [{"type": "GeopoliticalEntity", "text": "UK"}]}]}, {"type": "agentOf", "sentence": "If you have received this Announcement in electronic form, copies of this Announcement and any document or information incorporated by reference into this document will not be provided unless such a request is made.", "score": 0.909348, "arguments": [{"text": "you", "location": [33368, 33371], "entities": [{"type": "Person", "text": "you"}]}, {"text": "Announcement", "location": [33391, 33403], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "colleague", "sentence": "Shire Shareholders may also request that all future documents, announcements and information to be sent to them in relation to the Acquisition should be in hard copy form.", "score": 0.270028, "arguments": [{"text": "Shire", "location": [33581, 33586], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Shareholders", "location": [33587, 33599], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "agentOf", "sentence": "Shire Shareholders may also request that all future documents, announcements and information to be sent to them in relation to the Acquisition should be in hard copy form.", "score": 0.692299, "arguments": [{"text": "Shire", "location": [33581, 33586], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "request", "location": [33609, 33616], "entities": [{"type": "EventCommunication", "text": "request"}]}]}, {"type": "agentOf", "sentence": "If you are in any doubt about the contents of this Announcement or the action you should take, you are recommended to seek your own independent financial advice immediately from your stockbroker, bank manager, solicitor, accountant or independent financial adviser duly authorised under Financial Services (Jersey) Law 1998 (as amended) if you are resident in Jersey, the Financial Services and Markets Act 2000 (as amended) if you are resident in the United Kingdom, or, if not, from another appropriately authorised independent financial adviser.", "score": 0.584221, "arguments": [{"text": "you", "location": [33831, 33834], "entities": [{"type": "Person", "text": "you"}]}, {"text": "Announcement", "location": [33804, 33816], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "If you are in any doubt about the contents of this Announcement or the action you should take, you are recommended to seek your own independent financial advice immediately from your stockbroker, bank manager, solicitor, accountant or independent financial adviser duly authorised under Financial Services (Jersey) Law 1998 (as amended) if you are resident in Jersey, the Financial Services and Markets Act 2000 (as amended) if you are resident in the United Kingdom, or, if not, from another appropriately authorised independent financial adviser.", "score": 0.934639, "arguments": [{"text": "you", "location": [33848, 33851], "entities": [{"type": "Person", "text": "you"}]}, {"text": "recommended", "location": [33856, 33867], "entities": [{"type": "EventCommunication", "text": "recommended"}]}]}, {"type": "clientOf", "sentence": "If you are in any doubt about the contents of this Announcement or the action you should take, you are recommended to seek your own independent financial advice immediately from your stockbroker, bank manager, solicitor, accountant or independent financial adviser duly authorised under Financial Services (Jersey) Law 1998 (as amended) if you are resident in Jersey, the Financial Services and Markets Act 2000 (as amended) if you are resident in the United Kingdom, or, if not, from another appropriately authorised independent financial adviser.", "score": 0.323759, "arguments": [{"text": "your", "location": [33931, 33935], "entities": [{"type": "Person", "text": "your"}]}, {"text": "stockbroker", "location": [33936, 33947], "entities": [{"type": "Person", "text": "stockbroker"}]}]}, {"type": "managerOf", "sentence": "If you are in any doubt about the contents of this Announcement or the action you should take, you are recommended to seek your own independent financial advice immediately from your stockbroker, bank manager, solicitor, accountant or independent financial adviser duly authorised under Financial Services (Jersey) Law 1998 (as amended) if you are resident in Jersey, the Financial Services and Markets Act 2000 (as amended) if you are resident in the United Kingdom, or, if not, from another appropriately authorised independent financial adviser.", "score": 0.651856, "arguments": [{"text": "manager", "location": [33954, 33961], "entities": [{"type": "Person", "text": "manager"}]}, {"text": "bank", "location": [33949, 33953], "entities": [{"type": "Organization", "text": "bank"}]}]}, {"type": "locatedAt", "sentence": "If you are in any doubt about the contents of this Announcement or the action you should take, you are recommended to seek your own independent financial advice immediately from your stockbroker, bank manager, solicitor, accountant or independent financial adviser duly authorised under Financial Services (Jersey) Law 1998 (as amended) if you are resident in Jersey, the Financial Services and Markets Act 2000 (as amended) if you are resident in the United Kingdom, or, if not, from another appropriately authorised independent financial adviser.", "score": 0.373705, "arguments": [{"text": "Financial Services", "location": [34040, 34058], "entities": [{"type": "Organization", "text": "Financial Services"}]}, {"text": "Jersey", "location": [34060, 34066], "entities": [{"type": "GeopoliticalEntity", "text": "Jersey"}]}]}, {"type": "affectedBy", "sentence": "Rounding Certain figures included in this Announcement have been subjected to rounding adjustments.", "score": 0.509696, "arguments": [{"text": "figures", "location": [34319, 34326], "entities": [{"type": "Person", "text": "figures"}]}, {"text": "Announcement", "location": [34344, 34356], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "participantIn", "sentence": "Notices of the Court Meeting and Shire General Meeting As described in the Scheme Document, to become effective, the Scheme requires, among other things, the approval of Shire Shareholders at the Court Meeting, the passing of the Special Resolution at the Shire General Meeting and the subsequent sanction of the Court.", "score": 0.588946, "arguments": [{"text": "Shire", "location": [2448, 2453], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Meeting", "location": [2480, 2487], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "partOfMany", "sentence": "Accordingly, figures shown for the same category presented in different tables may vary slightly and figures shown as totals in certain tables may not be an arithmetic aggregation of the figures that precede them.", "score": 0.501776, "arguments": [{"text": "figures", "location": [34589, 34596], "entities": [{"type": "Person", "text": "figures"}]}, {"text": "them", "location": [34610, 34614], "entities": [{"type": "Person", "text": "them"}]}]}, {"type": "partOfMany", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: Court Meeting (BLUE form) 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form) 11.30 a.m. on December 3, 2018 (3", "score": 0.85893, "arguments": [{"text": "Shire ADS Holders", "location": [35070, 35087], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "Shareholders", "location": [35053, 35065], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "employedBy", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: Court Meeting (BLUE form) 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form) 11.30 a.m. on December 3, 2018 (3", "score": 0.491518, "arguments": [{"text": "Shire", "location": [35152, 35157], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "which", "location": [35146, 35151], "entities": [{"type": "Organization", "text": "which"}]}]}, {"type": "participantIn", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: Court Meeting (BLUE form) 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form) 11.30 a.m. on December 3, 2018 (3", "score": 0.419875, "arguments": [{"text": "Shire", "location": [35152, 35157], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Event", "location": [35195, 35200], "entities": [{"type": "EventPerformance", "text": "Event"}]}]}, {"type": "agentOf", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: Court Meeting (BLUE form) 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form) 11.30 a.m. on December 3, 2018 (3", "score": 0.669523, "arguments": [{"text": "Form", "location": [35185, 35189], "entities": [{"type": "Organization", "text": "Form"}]}, {"text": "Event", "location": [35195, 35200], "entities": [{"type": "EventPerformance", "text": "Event"}]}]}, {"type": "timeOf", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: Court Meeting (BLUE form) 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form) 11.30 a.m. on December 3, 2018 (3", "score": 0.912562, "arguments": [{"text": "8-K.", "location": [35190, 35194], "entities": [{"type": "Date", "text": "8-K."}]}, {"text": "Event", "location": [35195, 35200], "entities": [{"type": "EventPerformance", "text": "Event"}]}]}, {"type": "agentOf", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: Court Meeting (BLUE form) 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form) 11.30 a.m. on December 3, 2018 (3", "score": 0.335571, "arguments": [{"text": "ADS Voting Record Time", "location": [35201, 35223], "entities": [{"type": "Organization", "text": "ADS Voting Record Time"}]}, {"text": "Event", "location": [35195, 35200], "entities": [{"type": "EventPerformance", "text": "Event"}]}]}, {"type": "participantIn", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: Court Meeting (BLUE form) 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form) 11.30 a.m. on December 3, 2018 (3", "score": 0.473102, "arguments": [{"text": "Court", "location": [35375, 35380], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [35381, 35388], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "partOf", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: Court Meeting (BLUE form) 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form) 11.30 a.m. on December 3, 2018 (3", "score": 0.327407, "arguments": [{"text": "Meeting", "location": [35381, 35388], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}, {"text": "Meeting", "location": [35411, 35418], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "participantIn", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: Court Meeting (BLUE form) 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form) 11.30 a.m. on December 3, 2018 (3", "score": 0.732556, "arguments": [{"text": "Shire General", "location": [35397, 35410], "entities": [{"type": "Person", "text": "Shire General"}]}, {"text": "Meeting", "location": [35411, 35418], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "agentOf", "sentence": "Notices of the Court Meeting and Shire General Meeting As described in the Scheme Document, to become effective, the Scheme requires, among other things, the approval of Shire Shareholders at the Court Meeting, the passing of the Special Resolution at the Shire General Meeting and the subsequent sanction of the Court.", "score": 0.418295, "arguments": [{"text": "Court", "location": [2474, 2479], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [2480, 2487], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "timeOf", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: Court Meeting (BLUE form) 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form) 11.30 a.m. on December 3, 2018 (3", "score": 0.816891, "arguments": [{"text": "a.m.", "location": [35425, 35429], "entities": [{"type": "Time", "text": "a.m."}]}, {"text": "Meeting", "location": [35411, 35418], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "participantIn", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: Court Meeting (BLUE form) 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form) 11.30 a.m. on December 3, 2018 (3", "score": 0.469762, "arguments": [{"text": "Court", "location": [35518, 35523], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [35524, 35531], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "timeOf", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: Court Meeting (BLUE form) 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form) 11.30 a.m. on December 3, 2018 (3", "score": 0.896306, "arguments": [{"text": "a.m.", "location": [35550, 35554], "entities": [{"type": "Time", "text": "a.m."}]}, {"text": "Meeting", "location": [35524, 35531], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "participantIn", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: Court Meeting (BLUE form) 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form) 11.30 a.m. on December 3, 2018 (3", "score": 0.857986, "arguments": [{"text": "Shire General", "location": [35579, 35592], "entities": [{"type": "Person", "text": "Shire General"}]}, {"text": "Meeting", "location": [35593, 35600], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "timeOf", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: Court Meeting (BLUE form) 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form) 11.30 a.m. on December 3, 2018 (3", "score": 0.750195, "arguments": [{"text": "11.30 a.m.", "location": [35615, 35625], "entities": [{"type": "Time", "text": "11.30 a.m."}]}, {"text": "Meeting", "location": [35593, 35600], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "timeOf", "sentence": ") Voting Record Time 6.30 p.m. on December 3, 2018 (4) Takeda Extraordinary General Meeting 10.00 a.m. (Tokyo time) on December 5, 2018 Court Meeting 11.15 a.m. on December 5, 2018 (5) Shire General Meeting 11.30 a.m. on December 5, 2018 (5)(6) The following dates are indicative only and subject to change; please see note (7) below: Last time for Shire ADS Holders to present their Shire ADSs for cancellation and take delivery of Shire Shares to become Shire Shareholders before the Scheme Record Time 5.00 p.m. (New York time) on December 26, 2018 Latest time for receipt of Forms of Election 6.00 p.m. on January 2, 2019 Court Sanction Hearing 10.00 a.m. on January 3,", "score": 0.494984, "arguments": [{"text": "December 3, 2018", "location": [35682, 35698], "entities": [{"type": "Date", "text": "December 3, 2018"}]}, {"text": "Meeting", "location": [35732, 35739], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "participantIn", "sentence": ") Voting Record Time 6.30 p.m. on December 3, 2018 (4) Takeda Extraordinary General Meeting 10.00 a.m. (Tokyo time) on December 5, 2018 Court Meeting 11.15 a.m. on December 5, 2018 (5) Shire General Meeting 11.30 a.m. on December 5, 2018 (5)(6) The following dates are indicative only and subject to change; please see note (7) below: Last time for Shire ADS Holders to present their Shire ADSs for cancellation and take delivery of Shire Shares to become Shire Shareholders before the Scheme Record Time 5.00 p.m. (New York time) on December 26, 2018 Latest time for receipt of Forms of Election 6.00 p.m. on January 2, 2019 Court Sanction Hearing 10.00 a.m. on January 3,", "score": 0.852472, "arguments": [{"text": "Takeda Extraordinary General", "location": [35703, 35731], "entities": [{"type": "Person", "text": "Takeda Extraordinary General"}]}, {"text": "Meeting", "location": [35732, 35739], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "timeOf", "sentence": ") Voting Record Time 6.30 p.m. on December 3, 2018 (4) Takeda Extraordinary General Meeting 10.00 a.m. (Tokyo time) on December 5, 2018 Court Meeting 11.15 a.m. on December 5, 2018 (5) Shire General Meeting 11.30 a.m. on December 5, 2018 (5)(6) The following dates are indicative only and subject to change; please see note (7) below: Last time for Shire ADS Holders to present their Shire ADSs for cancellation and take delivery of Shire Shares to become Shire Shareholders before the Scheme Record Time 5.00 p.m. (New York time) on December 26, 2018 Latest time for receipt of Forms of Election 6.00 p.m. on January 2, 2019 Court Sanction Hearing 10.00 a.m. on January 3,", "score": 0.811119, "arguments": [{"text": "a.m.", "location": [35746, 35750], "entities": [{"type": "Time", "text": "a.m."}]}, {"text": "Meeting", "location": [35732, 35739], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "agentOf", "sentence": ") Voting Record Time 6.30 p.m. on December 3, 2018 (4) Takeda Extraordinary General Meeting 10.00 a.m. (Tokyo time) on December 5, 2018 Court Meeting 11.15 a.m. on December 5, 2018 (5) Shire General Meeting 11.30 a.m. on December 5, 2018 (5)(6) The following dates are indicative only and subject to change; please see note (7) below: Last time for Shire ADS Holders to present their Shire ADSs for cancellation and take delivery of Shire Shares to become Shire Shareholders before the Scheme Record Time 5.00 p.m. (New York time) on December 26, 2018 Latest time for receipt of Forms of Election 6.00 p.m. on January 2, 2019 Court Sanction Hearing 10.00 a.m. on January 3,", "score": 0.514639, "arguments": [{"text": "Court", "location": [35784, 35789], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [35790, 35797], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "timeOf", "sentence": ") Voting Record Time 6.30 p.m. on December 3, 2018 (4) Takeda Extraordinary General Meeting 10.00 a.m. (Tokyo time) on December 5, 2018 Court Meeting 11.15 a.m. on December 5, 2018 (5) Shire General Meeting 11.30 a.m. on December 5, 2018 (5)(6) The following dates are indicative only and subject to change; please see note (7) below: Last time for Shire ADS Holders to present their Shire ADSs for cancellation and take delivery of Shire Shares to become Shire Shareholders before the Scheme Record Time 5.00 p.m. (New York time) on December 26, 2018 Latest time for receipt of Forms of Election 6.00 p.m. on January 2, 2019 Court Sanction Hearing 10.00 a.m. on January 3,", "score": 0.88629, "arguments": [{"text": "a.m.", "location": [35804, 35808], "entities": [{"type": "Time", "text": "a.m."}]}, {"text": "Meeting", "location": [35790, 35797], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "partOfMany", "sentence": "TAKEDA PHARMACEUTICAL COMPANY LIMITED Publication of Scheme Document On May 8, 2018, Shire plc (\" Shire \") and Takeda Pharmaceutical Company Limited (\" Takeda \") announced that they had reached agreement on the terms of a recommended cash and share offer to be made by Takeda for the entire issued and to be issued share capital of Shire (the \" Acquisition \").", "score": 0.912501, "arguments": [{"text": "Shire", "location": [98, 103], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "they", "location": [177, 181], "entities": [{"type": "Person", "text": "they"}]}]}, {"type": "participantIn", "sentence": "Notices of the Court Meeting and Shire General Meeting As described in the Scheme Document, to become effective, the Scheme requires, among other things, the approval of Shire Shareholders at the Court Meeting, the passing of the Special Resolution at the Shire General Meeting and the subsequent sanction of the Court.", "score": 0.880371, "arguments": [{"text": "Shire General", "location": [2534, 2547], "entities": [{"type": "Person", "text": "Shire General"}]}, {"text": "Meeting", "location": [2548, 2555], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "participantIn", "sentence": ") Voting Record Time 6.30 p.m. on December 3, 2018 (4) Takeda Extraordinary General Meeting 10.00 a.m. (Tokyo time) on December 5, 2018 Court Meeting 11.15 a.m. on December 5, 2018 (5) Shire General Meeting 11.30 a.m. on December 5, 2018 (5)(6) The following dates are indicative only and subject to change; please see note (7) below: Last time for Shire ADS Holders to present their Shire ADSs for cancellation and take delivery of Shire Shares to become Shire Shareholders before the Scheme Record Time 5.00 p.m. (New York time) on December 26, 2018 Latest time for receipt of Forms of Election 6.00 p.m. on January 2, 2019 Court Sanction Hearing 10.00 a.m. on January 3,", "score": 0.902597, "arguments": [{"text": "Shire General", "location": [35833, 35846], "entities": [{"type": "Person", "text": "Shire General"}]}, {"text": "Meeting", "location": [35847, 35854], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "timeOf", "sentence": ") Voting Record Time 6.30 p.m. on December 3, 2018 (4) Takeda Extraordinary General Meeting 10.00 a.m. (Tokyo time) on December 5, 2018 Court Meeting 11.15 a.m. on December 5, 2018 (5) Shire General Meeting 11.30 a.m. on December 5, 2018 (5)(6) The following dates are indicative only and subject to change; please see note (7) below: Last time for Shire ADS Holders to present their Shire ADSs for cancellation and take delivery of Shire Shares to become Shire Shareholders before the Scheme Record Time 5.00 p.m. (New York time) on December 26, 2018 Latest time for receipt of Forms of Election 6.00 p.m. on January 2, 2019 Court Sanction Hearing 10.00 a.m. on January 3,", "score": 0.935827, "arguments": [{"text": "11.30 a.m.", "location": [35855, 35865], "entities": [{"type": "Time", "text": "11.30 a.m."}]}, {"text": "Meeting", "location": [35847, 35854], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "timeOf", "sentence": ") Voting Record Time 6.30 p.m. on December 3, 2018 (4) Takeda Extraordinary General Meeting 10.00 a.m. (Tokyo time) on December 5, 2018 Court Meeting 11.15 a.m. on December 5, 2018 (5) Shire General Meeting 11.30 a.m. on December 5, 2018 (5)(6) The following dates are indicative only and subject to change; please see note (7) below: Last time for Shire ADS Holders to present their Shire ADSs for cancellation and take delivery of Shire Shares to become Shire Shareholders before the Scheme Record Time 5.00 p.m. (New York time) on December 26, 2018 Latest time for receipt of Forms of Election 6.00 p.m. on January 2, 2019 Court Sanction Hearing 10.00 a.m. on January 3,", "score": 0.588562, "arguments": [{"text": "December 5, 2018", "location": [35869, 35885], "entities": [{"type": "Date", "text": "December 5, 2018"}]}, {"text": "Meeting", "location": [35847, 35854], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "partOfMany", "sentence": ") Voting Record Time 6.30 p.m. on December 3, 2018 (4) Takeda Extraordinary General Meeting 10.00 a.m. (Tokyo time) on December 5, 2018 Court Meeting 11.15 a.m. on December 5, 2018 (5) Shire General Meeting 11.30 a.m. on December 5, 2018 (5)(6) The following dates are indicative only and subject to change; please see note (7) below: Last time for Shire ADS Holders to present their Shire ADSs for cancellation and take delivery of Shire Shares to become Shire Shareholders before the Scheme Record Time 5.00 p.m. (New York time) on December 26, 2018 Latest time for receipt of Forms of Election 6.00 p.m. on January 2, 2019 Court Sanction Hearing 10.00 a.m. on January 3,", "score": 0.576983, "arguments": [{"text": "Shire ADS Holders", "location": [35997, 36014], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "their", "location": [36026, 36031], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "employedBy", "sentence": "2019 Last time for dealings in Shire Shares on the London Stock Exchange 4.30 p.m. on January 4, 2019 Latest time for receipt of TTE Instructions and disablement of Shire Shares in CREST 6.00 p.m. on January 4, 2019 Scheme Record Time 6.00 p.m. on January 4, 2019 Last time for dealings in Shire ADSs on NASDAQ close of business (New York time) on January 4, 2019 Suspension of dealings in Shire Shares on the London Stock Exchange before open of business on January 7, 2019 Halt of dealings in Shire ADSs on NASDAQ before open of business (New York time) on January 7, 2019 Commencement of \"when issued\" dealings in the New Takeda ADSs on the New York Stock Exchange 9.30 a.m. (New York time) on January 7,", "score": 0.536036, "arguments": [{"text": "Shire", "location": [36353, 36358], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "London Stock Exchange", "location": [36373, 36394], "entities": [{"type": "Organization", "text": "London Stock Exchange"}]}]}, {"type": "employedBy", "sentence": "2019 Last time for dealings in Shire Shares on the London Stock Exchange 4.30 p.m. on January 4, 2019 Latest time for receipt of TTE Instructions and disablement of Shire Shares in CREST 6.00 p.m. on January 4, 2019 Scheme Record Time 6.00 p.m. on January 4, 2019 Last time for dealings in Shire ADSs on NASDAQ close of business (New York time) on January 4, 2019 Suspension of dealings in Shire Shares on the London Stock Exchange before open of business on January 7, 2019 Halt of dealings in Shire ADSs on NASDAQ before open of business (New York time) on January 7, 2019 Commencement of \"when issued\" dealings in the New Takeda ADSs on the New York Stock Exchange 9.30 a.m. (New York time) on January 7,", "score": 0.588385, "arguments": [{"text": "Shire", "location": [36712, 36717], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "London Stock Exchange", "location": [36732, 36753], "entities": [{"type": "Organization", "text": "London Stock Exchange"}]}]}, {"type": "populationOf", "sentence": "2019 Last time for dealings in Shire Shares on the London Stock Exchange 4.30 p.m. on January 4, 2019 Latest time for receipt of TTE Instructions and disablement of Shire Shares in CREST 6.00 p.m. on January 4, 2019 Scheme Record Time 6.00 p.m. on January 4, 2019 Last time for dealings in Shire ADSs on NASDAQ close of business (New York time) on January 4, 2019 Suspension of dealings in Shire Shares on the London Stock Exchange before open of business on January 7, 2019 Halt of dealings in Shire ADSs on NASDAQ before open of business (New York time) on January 7, 2019 Commencement of \"when issued\" dealings in the New Takeda ADSs on the New York Stock Exchange 9.30 a.m. (New York time) on January 7,", "score": 0.592142, "arguments": [{"text": "6.00", "location": [36509, 36513], "entities": [{"type": "Cardinal", "text": "6.00"}]}, {"text": "CREST", "location": [36503, 36508], "entities": [{"type": "GeopoliticalEntity", "text": "CREST"}]}]}, {"type": "timeOf", "sentence": "2019 Effective Date of the Scheme January 8, 2019 Effective date of the issue of the New Takeda Shares January 8, 2019 Cancellation of listing of Shire Shares on the premium listing segment of the Official List and the main market of the London Stock Exchange 8.00 a.m. on January 9, 2019 Delisting of Shire ADSs by 9.30 a.m. (New York time) on January 9, 2019 Settlement Account credited with New Takeda Shares by 00.01 a.m. (9.01 a.m. (Tokyo time)) on January 10, 2019 New Takeda Shares transferred from the Settlement Account to JASDEC Accounts of former Shire Shareholders from January 10, 2019, but in any event not later than 14 calendar days after the Effective Date (8) Listing of, and commencement of dealings in,", "score": 0.764769, "arguments": [{"text": "January 9, 2019", "location": [37375, 37390], "entities": [{"type": "Date", "text": "January 9, 2019"}]}, {"text": "Settlement", "location": [37391, 37401], "entities": [{"type": "EventLegal", "text": "Settlement"}]}]}, {"type": "affectedBy", "sentence": "2019 Effective Date of the Scheme January 8, 2019 Effective date of the issue of the New Takeda Shares January 8, 2019 Cancellation of listing of Shire Shares on the premium listing segment of the Official List and the main market of the London Stock Exchange 8.00 a.m. on January 9, 2019 Delisting of Shire ADSs by 9.30 a.m. (New York time) on January 9, 2019 Settlement Account credited with New Takeda Shares by 00.01 a.m. (9.01 a.m. (Tokyo time)) on January 10, 2019 New Takeda Shares transferred from the Settlement Account to JASDEC Accounts of former Shire Shareholders from January 10, 2019, but in any event not later than 14 calendar days after the Effective Date (8) Listing of, and commencement of dealings in,", "score": 0.833849, "arguments": [{"text": "Account", "location": [37402, 37409], "entities": [{"type": "Person", "text": "Account"}]}, {"text": "Settlement", "location": [37391, 37401], "entities": [{"type": "EventLegal", "text": "Settlement"}]}]}, {"type": "agentOf", "sentence": "2019 Effective Date of the Scheme January 8, 2019 Effective date of the issue of the New Takeda Shares January 8, 2019 Cancellation of listing of Shire Shares on the premium listing segment of the Official List and the main market of the London Stock Exchange 8.00 a.m. on January 9, 2019 Delisting of Shire ADSs by 9.30 a.m. (New York time) on January 9, 2019 Settlement Account credited with New Takeda Shares by 00.01 a.m. (9.01 a.m. (Tokyo time)) on January 10, 2019 New Takeda Shares transferred from the Settlement Account to JASDEC Accounts of former Shire Shareholders from January 10, 2019, but in any event not later than 14 calendar days after the Effective Date (8) Listing of, and commencement of dealings in,", "score": 0.502895, "arguments": [{"text": "New Takeda", "location": [37501, 37511], "entities": [{"type": "Organization", "text": "New Takeda"}]}, {"text": "Settlement", "location": [37540, 37550], "entities": [{"type": "EventLegal", "text": "Settlement"}]}]}, {"type": "agentOf", "sentence": "the New Takeda Shares on the Tokyo Stock Exchange and the Local Japanese Stock Exchanges January 10, 2019 New Takeda Shares transferred from the Settlement Account to the Takeda Depositary's JASDEC Account January 10, 2019 New Takeda ADSs and CDIs representing New Takeda ADSs delivered to former Shire Shareholders from January 10, 2019, but in any event not later than 14 calendar days after the Effective Date (9) New Takeda ADSs delivered to former Shire ADS Holders from January 10, 2019 (10) Listing of, and commencement of regular-way dealings in, New Takeda ADSs on the New York Stock Exchange by 9.30 a.m. (New York time) on January 11, 2019 (11)", "score": 0.450269, "arguments": [{"text": "New Takeda", "location": [37859, 37869], "entities": [{"type": "Organization", "text": "New Takeda"}]}, {"text": "Settlement", "location": [37898, 37908], "entities": [{"type": "EventLegal", "text": "Settlement"}]}]}, {"type": "participantIn", "sentence": "Notices of the Court Meeting and the Shire General Meeting, which are scheduled to be held at Block 3, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland on December 5, 2018, are set out in the Scheme Document.", "score": 0.514803, "arguments": [{"text": "Court", "location": [2760, 2765], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [2766, 2773], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "partOf", "sentence": "the New Takeda Shares on the Tokyo Stock Exchange and the Local Japanese Stock Exchanges January 10, 2019 New Takeda Shares transferred from the Settlement Account to the Takeda Depositary's JASDEC Account January 10, 2019 New Takeda ADSs and CDIs representing New Takeda ADSs delivered to former Shire Shareholders from January 10, 2019, but in any event not later than 14 calendar days after the Effective Date (9) New Takeda ADSs delivered to former Shire ADS Holders from January 10, 2019 (10) Listing of, and commencement of regular-way dealings in, New Takeda ADSs on the New York Stock Exchange by 9.30 a.m. (New York time) on January 11, 2019 (11)", "score": 0.78208, "arguments": [{"text": "JASDEC Account", "location": [37944, 37958], "entities": [{"type": "Organization", "text": "JASDEC Account"}]}, {"text": "Takeda Depositary", "location": [37924, 37941], "entities": [{"type": "Organization", "text": "Takeda Depositary"}]}]}, {"type": "employedBy", "sentence": "the New Takeda Shares on the Tokyo Stock Exchange and the Local Japanese Stock Exchanges January 10, 2019 New Takeda Shares transferred from the Settlement Account to the Takeda Depositary's JASDEC Account January 10, 2019 New Takeda ADSs and CDIs representing New Takeda ADSs delivered to former Shire Shareholders from January 10, 2019, but in any event not later than 14 calendar days after the Effective Date (9) New Takeda ADSs delivered to former Shire ADS Holders from January 10, 2019 (10) Listing of, and commencement of regular-way dealings in, New Takeda ADSs on the New York Stock Exchange by 9.30 a.m. (New York time) on January 11, 2019 (11)", "score": 0.472961, "arguments": [{"text": "Shire", "location": [38050, 38055], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "New Takeda ADSs", "location": [38014, 38029], "entities": [{"type": "Organization", "text": "New Takeda ADSs"}]}]}, {"type": "employedBy", "sentence": "the New Takeda Shares on the Tokyo Stock Exchange and the Local Japanese Stock Exchanges January 10, 2019 New Takeda Shares transferred from the Settlement Account to the Takeda Depositary's JASDEC Account January 10, 2019 New Takeda ADSs and CDIs representing New Takeda ADSs delivered to former Shire Shareholders from January 10, 2019, but in any event not later than 14 calendar days after the Effective Date (9) New Takeda ADSs delivered to former Shire ADS Holders from January 10, 2019 (10) Listing of, and commencement of regular-way dealings in, New Takeda ADSs on the New York Stock Exchange by 9.30 a.m. (New York time) on January 11, 2019 (11)", "score": 0.255215, "arguments": [{"text": "Shareholders", "location": [38056, 38068], "entities": [{"type": "Person", "text": "Shareholders"}]}, {"text": "New Takeda ADSs", "location": [38014, 38029], "entities": [{"type": "Organization", "text": "New Takeda ADSs"}]}]}, {"type": "partOf", "sentence": "the New Takeda Shares on the Tokyo Stock Exchange and the Local Japanese Stock Exchanges January 10, 2019 New Takeda Shares transferred from the Settlement Account to the Takeda Depositary's JASDEC Account January 10, 2019 New Takeda ADSs and CDIs representing New Takeda ADSs delivered to former Shire Shareholders from January 10, 2019, but in any event not later than 14 calendar days after the Effective Date (9) New Takeda ADSs delivered to former Shire ADS Holders from January 10, 2019 (10) Listing of, and commencement of regular-way dealings in, New Takeda ADSs on the New York Stock Exchange by 9.30 a.m. (New York time) on January 11, 2019 (11)", "score": 0.496915, "arguments": [{"text": "New Takeda ADSs", "location": [38170, 38185], "entities": [{"type": "Organization", "text": "New Takeda ADSs"}]}, {"text": "Effective Date", "location": [38151, 38165], "entities": [{"type": "Organization", "text": "Effective Date"}]}]}, {"type": "bornOn", "sentence": "the New Takeda Shares on the Tokyo Stock Exchange and the Local Japanese Stock Exchanges January 10, 2019 New Takeda Shares transferred from the Settlement Account to the Takeda Depositary's JASDEC Account January 10, 2019 New Takeda ADSs and CDIs representing New Takeda ADSs delivered to former Shire Shareholders from January 10, 2019, but in any event not later than 14 calendar days after the Effective Date (9) New Takeda ADSs delivered to former Shire ADS Holders from January 10, 2019 (10) Listing of, and commencement of regular-way dealings in, New Takeda ADSs on the New York Stock Exchange by 9.30 a.m. (New York time) on January 11, 2019 (11)", "score": 0.331888, "arguments": [{"text": "Shire ADS Holders", "location": [38206, 38223], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "January 10, 2019", "location": [38229, 38245], "entities": [{"type": "Date", "text": "January 10, 2019"}]}]}, {"type": "partOf", "sentence": "the New Takeda Shares on the Tokyo Stock Exchange and the Local Japanese Stock Exchanges January 10, 2019 New Takeda Shares transferred from the Settlement Account to the Takeda Depositary's JASDEC Account January 10, 2019 New Takeda ADSs and CDIs representing New Takeda ADSs delivered to former Shire Shareholders from January 10, 2019, but in any event not later than 14 calendar days after the Effective Date (9) New Takeda ADSs delivered to former Shire ADS Holders from January 10, 2019 (10) Listing of, and commencement of regular-way dealings in, New Takeda ADSs on the New York Stock Exchange by 9.30 a.m. (New York time) on January 11, 2019 (11)", "score": 0.626596, "arguments": [{"text": "New Takeda ADSs", "location": [38308, 38323], "entities": [{"type": "Organization", "text": "New Takeda ADSs"}]}, {"text": "New York Stock Exchange", "location": [38331, 38354], "entities": [{"type": "Organization", "text": "New York Stock Exchange"}]}]}, {"type": "colleague", "sentence": "CREST accounts of former Shire Shareholders credited with cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date (12) Processing of electronic BACs transfers to former Shire Shareholders in respect of cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date Despatch of cheques to former Shire Shareholders for the cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date Despatch of cheques to former Shire Shareholders in relation to the New Takeda Shares sold under the Dealing Facility within 14 calendar days of the Effective Date Payment of the cash due to former Shire ADS Holders by the Shire Depositary following receipt of funds by the Shire Depositary (13)", "score": 0.361297, "arguments": [{"text": "Shire", "location": [38434, 38439], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Shareholders", "location": [38440, 38452], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "colleague", "sentence": "CREST accounts of former Shire Shareholders credited with cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date (12) Processing of electronic BACs transfers to former Shire Shareholders in respect of cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date Despatch of cheques to former Shire Shareholders for the cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date Despatch of cheques to former Shire Shareholders in relation to the New Takeda Shares sold under the Dealing Facility within 14 calendar days of the Effective Date Payment of the cash due to former Shire ADS Holders by the Shire Depositary following receipt of funds by the Shire Depositary (13)", "score": 0.391602, "arguments": [{"text": "Shire", "location": [38637, 38642], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Shareholders", "location": [38643, 38655], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "colleague", "sentence": "CREST accounts of former Shire Shareholders credited with cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date (12) Processing of electronic BACs transfers to former Shire Shareholders in respect of cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date Despatch of cheques to former Shire Shareholders for the cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date Despatch of cheques to former Shire Shareholders in relation to the New Takeda Shares sold under the Dealing Facility within 14 calendar days of the Effective Date Payment of the cash due to former Shire ADS Holders by the Shire Depositary following receipt of funds by the Shire Depositary (13)", "score": 0.375934, "arguments": [{"text": "Shire", "location": [38815, 38820], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Shareholders", "location": [38821, 38833], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "colleague", "sentence": "CREST accounts of former Shire Shareholders credited with cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date (12) Processing of electronic BACs transfers to former Shire Shareholders in respect of cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date Despatch of cheques to former Shire Shareholders for the cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date Despatch of cheques to former Shire Shareholders in relation to the New Takeda Shares sold under the Dealing Facility within 14 calendar days of the Effective Date Payment of the cash due to former Shire ADS Holders by the Shire Depositary following receipt of funds by the Shire Depositary (13)", "score": 0.389903, "arguments": [{"text": "Shire", "location": [38987, 38992], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Shareholders", "location": [38993, 39005], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "locatedAt", "sentence": "Notices of the Court Meeting and the Shire General Meeting, which are scheduled to be held at Block 3, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland on December 5, 2018, are set out in the Scheme Document.", "score": 0.496747, "arguments": [{"text": "Miesian Plaza", "location": [2848, 2861], "entities": [{"type": "Person", "text": "Miesian Plaza"}]}, {"text": "Baggot Street Lower", "location": [2869, 2888], "entities": [{"type": "Facility", "text": "Baggot Street Lower"}]}]}, {"type": "locatedAt", "sentence": "CREST accounts of former Shire Shareholders credited with cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date (12) Processing of electronic BACs transfers to former Shire Shareholders in respect of cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date Despatch of cheques to former Shire Shareholders for the cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date Despatch of cheques to former Shire Shareholders in relation to the New Takeda Shares sold under the Dealing Facility within 14 calendar days of the Effective Date Payment of the cash due to former Shire ADS Holders by the Shire Depositary following receipt of funds by the Shire Depositary (13)", "score": 0.527613, "arguments": [{"text": "Shareholders", "location": [38993, 39005], "entities": [{"type": "Person", "text": "Shareholders"}]}, {"text": "Facility", "location": [39066, 39074], "entities": [{"type": "Facility", "text": "Facility"}]}]}, {"type": "partOf", "sentence": "Latest date by which Scheme may become Effective May 8, 2019 (14) (1 ) In order to validly instruct the Shire Depositary as to voting at the Shire Meetings, the ADS Voting Card must be received by the Shire Depositary by 10.00 a.m. (New York time) on November 29, 2018 for each Shire Meeting or, if either Shire Meeting is adjourned, such later date as may be notified by the Shire Depositary, having consulted with Shire.", "score": 0.410084, "arguments": [{"text": "Scheme", "location": [39274, 39280], "entities": [{"type": "Organization", "text": "Scheme"}]}, {"text": "Latest", "location": [39253, 39259], "entities": [{"type": "Organization", "text": "Latest"}]}]}, {"type": "employedBy", "sentence": "Latest date by which Scheme may become Effective May 8, 2019 (14) (1 ) In order to validly instruct the Shire Depositary as to voting at the Shire Meetings, the ADS Voting Card must be received by the Shire Depositary by 10.00 a.m. (New York time) on November 29, 2018 for each Shire Meeting or, if either Shire Meeting is adjourned, such later date as may be notified by the Shire Depositary, having consulted with Shire.", "score": 0.736686, "arguments": [{"text": "Card", "location": [39425, 39429], "entities": [{"type": "Person", "text": "Card"}]}, {"text": "ADS Voting", "location": [39414, 39424], "entities": [{"type": "Organization", "text": "ADS Voting"}]}]}, {"type": "agentOf", "sentence": "Latest date by which Scheme may become Effective May 8, 2019 (14) (1 ) In order to validly instruct the Shire Depositary as to voting at the Shire Meetings, the ADS Voting Card must be received by the Shire Depositary by 10.00 a.m. (New York time) on November 29, 2018 for each Shire Meeting or, if either Shire Meeting is adjourned, such later date as may be notified by the Shire Depositary, having consulted with Shire.", "score": 0.456764, "arguments": [{"text": "Shire Meeting", "location": [39559, 39572], "entities": [{"type": "Person", "text": "Shire Meeting"}]}, {"text": "notified", "location": [39613, 39621], "entities": [{"type": "EventCommunication", "text": "notified"}]}]}, {"type": "agentOf", "sentence": "Latest date by which Scheme may become Effective May 8, 2019 (14) (1 ) In order to validly instruct the Shire Depositary as to voting at the Shire Meetings, the ADS Voting Card must be received by the Shire Depositary by 10.00 a.m. (New York time) on November 29, 2018 for each Shire Meeting or, if either Shire Meeting is adjourned, such later date as may be notified by the Shire Depositary, having consulted with Shire.", "score": 0.693898, "arguments": [{"text": "Shire Depositary", "location": [39629, 39645], "entities": [{"type": "Person", "text": "Shire Depositary"}]}, {"text": "notified", "location": [39613, 39621], "entities": [{"type": "EventCommunication", "text": "notified"}]}]}, {"type": "employedBy", "sentence": "(2 ) The BLUE Form of Proxy for the Court Meeting, if not received by Equiniti by the time stated above, may be handed to a representative of Equiniti, on behalf of the Chairman of the Court Meeting, or to the Chairman of the Court Meeting, before the start of the Court Meeting.", "score": 0.509834, "arguments": [{"text": "Chairman", "location": [39918, 39926], "entities": [{"type": "Person", "text": "Chairman"}]}, {"text": "Court Meeting", "location": [39934, 39947], "entities": [{"type": "Organization", "text": "Court Meeting"}]}]}, {"type": "employedBy", "sentence": "(2 ) The BLUE Form of Proxy for the Court Meeting, if not received by Equiniti by the time stated above, may be handed to a representative of Equiniti, on behalf of the Chairman of the Court Meeting, or to the Chairman of the Court Meeting, before the start of the Court Meeting.", "score": 0.560474, "arguments": [{"text": "Chairman", "location": [39959, 39967], "entities": [{"type": "Person", "text": "Chairman"}]}, {"text": "Court Meeting", "location": [39975, 39988], "entities": [{"type": "Organization", "text": "Court Meeting"}]}]}, {"type": "timeOf", "sentence": "(3 ) In order to be valid, the YELLOW Form of Proxy must be received by Equiniti not later than 11.30 a.m. on December 3, 2018 (or, if the Shire General Meeting is adjourned, not later than 48 hours before the time appointed for the adjourned Shire General Meeting).", "score": 0.438162, "arguments": [{"text": "48 hours", "location": [40219, 40227], "entities": [{"type": "Duration", "text": "48 hours"}]}, {"text": "appointed", "location": [40244, 40253], "entities": [{"type": "EventPersonnel", "text": "appointed"}]}]}, {"type": "agentOf", "sentence": "(3 ) In order to be valid, the YELLOW Form of Proxy must be received by Equiniti not later than 11.30 a.m. on December 3, 2018 (or, if the Shire General Meeting is adjourned, not later than 48 hours before the time appointed for the adjourned Shire General Meeting).", "score": 0.759745, "arguments": [{"text": "Shire General Meeting", "location": [40272, 40293], "entities": [{"type": "Person", "text": "Shire General Meeting"}]}, {"text": "appointed", "location": [40244, 40253], "entities": [{"type": "EventPersonnel", "text": "appointed"}]}]}, {"type": "participantIn", "sentence": "(4 ) If either the Court Meeting or the Shire General Meeting is adjourned, the Voting Record Time for the relevant adjourned Shire Meeting will be 6.30 p.m. on the date falling two calendar days before the date appointed for such adjourned Shire Meeting and the ADS Voting Record Time for the relevant adjourned Shire Meeting will be such later date as may be notified by the Shire Depositary, having consulted with Shire.", "score": 0.514803, "arguments": [{"text": "Court", "location": [40315, 40320], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [40321, 40328], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "agentOf", "sentence": "The Court Meeting is scheduled to commence at 11.15 a.m. and the Shire General Meeting at 11.30 a.m. (or as soon thereafter as the Court Meeting has concluded or been adjourned).", "score": 0.5622, "arguments": [{"text": "Court", "location": [2969, 2974], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [2975, 2982], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "agentOf", "sentence": "(4 ) If either the Court Meeting or the Shire General Meeting is adjourned, the Voting Record Time for the relevant adjourned Shire Meeting will be 6.30 p.m. on the date falling two calendar days before the date appointed for such adjourned Shire Meeting and the ADS Voting Record Time for the relevant adjourned Shire Meeting will be such later date as may be notified by the Shire Depositary, having consulted with Shire.", "score": 0.361618, "arguments": [{"text": "Shire Meeting", "location": [40537, 40550], "entities": [{"type": "Person", "text": "Shire Meeting"}]}, {"text": "appointed", "location": [40508, 40517], "entities": [{"type": "EventPersonnel", "text": "appointed"}]}]}, {"type": "agentOf", "sentence": "(4 ) If either the Court Meeting or the Shire General Meeting is adjourned, the Voting Record Time for the relevant adjourned Shire Meeting will be 6.30 p.m. on the date falling two calendar days before the date appointed for such adjourned Shire Meeting and the ADS Voting Record Time for the relevant adjourned Shire Meeting will be such later date as may be notified by the Shire Depositary, having consulted with Shire.", "score": 0.711808, "arguments": [{"text": "Shire Depositary", "location": [40673, 40689], "entities": [{"type": "Person", "text": "Shire Depositary"}]}, {"text": "notified", "location": [40657, 40665], "entities": [{"type": "EventCommunication", "text": "notified"}]}]}, {"type": "participantIn", "sentence": "(5 ) In the event that the Takeda Extraordinary General Meeting is postponed or adjourned, the Court Meeting and Shire General Meeting will be adjourned so that they will take place on the same date as the Takeda Extraordinary General Meeting.", "score": 0.907499, "arguments": [{"text": "Takeda Extraordinary General", "location": [40747, 40775], "entities": [{"type": "Person", "text": "Takeda Extraordinary General"}]}, {"text": "Meeting", "location": [40776, 40783], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "participantIn", "sentence": "(5 ) In the event that the Takeda Extraordinary General Meeting is postponed or adjourned, the Court Meeting and Shire General Meeting will be adjourned so that they will take place on the same date as the Takeda Extraordinary General Meeting.", "score": 0.914196, "arguments": [{"text": "Takeda Extraordinary General", "location": [40926, 40954], "entities": [{"type": "Person", "text": "Takeda Extraordinary General"}]}, {"text": "Meeting", "location": [40955, 40962], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "agentOf", "sentence": "(6 ) To commence at 11.30 a.m. (London time) or as soon thereafter as the Court Meeting shall have concluded or been adjourned.", "score": 0.441202, "arguments": [{"text": "Court", "location": [41038, 41043], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [41044, 41051], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "colleague", "sentence": "These dates will depend, among other things, on the dates upon which: (i) the Conditions are satisfied or (where applicable) waived; (ii) the European Commission gives its approval to proceed to completion of the Acquisition (see paragraph 7 of Part I (Letter from the Chairman of Shire PLC) of the Scheme Document for further details); (iii) the Court sanctions the Scheme; and (iv) the Court Order is delivered to the Registrar of Companies.", "score": 0.398897, "arguments": [{"text": "Chairman", "location": [41485, 41493], "entities": [{"type": "Person", "text": "Chairman"}]}, {"text": "Shire PLC", "location": [41497, 41506], "entities": [{"type": "Person", "text": "Shire PLC"}]}]}, {"type": "employedBy", "sentence": "These dates will depend, among other things, on the dates upon which: (i) the Conditions are satisfied or (where applicable) waived; (ii) the European Commission gives its approval to proceed to completion of the Acquisition (see paragraph 7 of Part I (Letter from the Chairman of Shire PLC) of the Scheme Document for further details); (iii) the Court sanctions the Scheme; and (iv) the Court Order is delivered to the Registrar of Companies.", "score": 0.701011, "arguments": [{"text": "Shire PLC", "location": [41497, 41506], "entities": [{"type": "Person", "text": "Shire PLC"}]}, {"text": "Scheme Document", "location": [41515, 41530], "entities": [{"type": "Organization", "text": "Scheme Document"}]}]}, {"type": "partOf", "sentence": "These dates will depend, among other things, on the dates upon which: (i) the Conditions are satisfied or (where applicable) waived; (ii) the European Commission gives its approval to proceed to completion of the Acquisition (see paragraph 7 of Part I (Letter from the Chairman of Shire PLC) of the Scheme Document for further details); (iii) the Court sanctions the Scheme; and (iv) the Court Order is delivered to the Registrar of Companies.", "score": 0.404673, "arguments": [{"text": "Court Order", "location": [41604, 41615], "entities": [{"type": "Organization", "text": "Court Order"}]}, {"text": "Registrar of Companies", "location": [41636, 41658], "entities": [{"type": "Organization", "text": "Registrar of Companies"}]}]}, {"type": "agentOf", "sentence": "Shire will give adequate notice of any changes by issuing an announcement through a Regulatory Information Service and will furnish such announcement to the SEC on Form 8-K. (8 ) In order to avoid a delay in the completion of any such transfer, Shire Shareholders who make a valid JASDEC Election to deliver their New Takeda Shares into an account with an AMI should contact their AMI to confirm any necessary steps in order for the AMI to record the delivery of the New Takeda Shares from the Settlement Account.", "score": 0.764401, "arguments": [{"text": "Shire", "location": [41977, 41982], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "issuing", "location": [42027, 42034], "entities": [{"type": "EventCommunication", "text": "issuing"}]}]}, {"type": "partOfMany", "sentence": "Shire will give adequate notice of any changes by issuing an announcement through a Regulatory Information Service and will furnish such announcement to the SEC on Form 8-K. (8 ) In order to avoid a delay in the completion of any such transfer, Shire Shareholders who make a valid JASDEC Election to deliver their New Takeda Shares into an account with an AMI should contact their AMI to confirm any necessary steps in order for the AMI to record the delivery of the New Takeda Shares from the Settlement Account.", "score": 0.656713, "arguments": [{"text": "Shareholders", "location": [42228, 42240], "entities": [{"type": "Person", "text": "Shareholders"}]}, {"text": "who", "location": [42241, 42244], "entities": [{"type": "Person", "text": "who"}]}]}, {"type": "timeOf", "sentence": "The Court Meeting is scheduled to commence at 11.15 a.m. and the Shire General Meeting at 11.30 a.m. (or as soon thereafter as the Court Meeting has concluded or been adjourned).", "score": 0.512617, "arguments": [{"text": "a.m.", "location": [3017, 3021], "entities": [{"type": "Time", "text": "a.m."}]}, {"text": "Meeting", "location": [2975, 2982], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "partOfMany", "sentence": "In order to avoid a delay in receiving their New Takeda ADSs, Shire Shareholders who make a valid ADS Election to deliver their New Takeda ADSs to their broker or other securities intermediary in DTC should contact their broker or other securities intermediary to request that it, or the DTC participant through which it clears, inputs valid instructions to receive delivery of the New Takeda ADSs free of payment from the Takeda Depositary's DTC participant account (account number 2504). (10 ) New Takeda ADSs will be delivered to the Shire Depositary from January 10, 2019 (and in any event not later than 14 calendar days after the Effective Date).", "score": 0.650752, "arguments": [{"text": "Takeda ADSs", "location": [42665, 42676], "entities": [{"type": "Person", "text": "Takeda ADSs"}]}, {"text": "their", "location": [42655, 42660], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "In order to avoid a delay in receiving their New Takeda ADSs, Shire Shareholders who make a valid ADS Election to deliver their New Takeda ADSs to their broker or other securities intermediary in DTC should contact their broker or other securities intermediary to request that it, or the DTC participant through which it clears, inputs valid instructions to receive delivery of the New Takeda ADSs free of payment from the Takeda Depositary's DTC participant account (account number 2504). (10 ) New Takeda ADSs will be delivered to the Shire Depositary from January 10, 2019 (and in any event not later than 14 calendar days after the Effective Date).", "score": 0.476973, "arguments": [{"text": "Shareholders", "location": [42684, 42696], "entities": [{"type": "Person", "text": "Shareholders"}]}, {"text": "who", "location": [42697, 42700], "entities": [{"type": "Person", "text": "who"}]}]}, {"type": "partOfMany", "sentence": "In order to avoid a delay in receiving their New Takeda ADSs, Shire Shareholders who make a valid ADS Election to deliver their New Takeda ADSs to their broker or other securities intermediary in DTC should contact their broker or other securities intermediary to request that it, or the DTC participant through which it clears, inputs valid instructions to receive delivery of the New Takeda ADSs free of payment from the Takeda Depositary's DTC participant account (account number 2504). (10 ) New Takeda ADSs will be delivered to the Shire Depositary from January 10, 2019 (and in any event not later than 14 calendar days after the Effective Date).", "score": 0.515523, "arguments": [{"text": "Takeda ADSs", "location": [42748, 42759], "entities": [{"type": "Person", "text": "Takeda ADSs"}]}, {"text": "their", "location": [42738, 42743], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "In order to avoid a delay in receiving their New Takeda ADSs, Shire Shareholders who make a valid ADS Election to deliver their New Takeda ADSs to their broker or other securities intermediary in DTC should contact their broker or other securities intermediary to request that it, or the DTC participant through which it clears, inputs valid instructions to receive delivery of the New Takeda ADSs free of payment from the Takeda Depositary's DTC participant account (account number 2504). (10 ) New Takeda ADSs will be delivered to the Shire Depositary from January 10, 2019 (and in any event not later than 14 calendar days after the Effective Date).", "score": 0.557882, "arguments": [{"text": "Takeda ADSs", "location": [42748, 42759], "entities": [{"type": "Person", "text": "Takeda ADSs"}]}, {"text": "their", "location": [42763, 42768], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "employedBy", "sentence": "In order to avoid a delay in receiving their New Takeda ADSs, Shire Shareholders who make a valid ADS Election to deliver their New Takeda ADSs to their broker or other securities intermediary in DTC should contact their broker or other securities intermediary to request that it, or the DTC participant through which it clears, inputs valid instructions to receive delivery of the New Takeda ADSs free of payment from the Takeda Depositary's DTC participant account (account number 2504). (10 ) New Takeda ADSs will be delivered to the Shire Depositary from January 10, 2019 (and in any event not later than 14 calendar days after the Effective Date).", "score": 0.526534, "arguments": [{"text": "Shire Depositary", "location": [43153, 43169], "entities": [{"type": "Person", "text": "Shire Depositary"}]}, {"text": "New Takeda ADSs", "location": [43112, 43127], "entities": [{"type": "Organization", "text": "New Takeda ADSs"}]}]}, {"type": "employedBy", "sentence": "It is expected that Shire ADS Holders holding through participants in DTC will receive delivery shortly after the receipt by the Shire Depositary of the New Takeda ADSs and that registered Shire ADS Holders holding uncertificated Shire ADSs (that is, Shire ADSs held outside of DTC for which no certificates have been issued) will be issued New Takeda ADSs in uncertificated form beginning approximately one week thereafter (and will receive a statement by post reflecting the issuance of New Takeda ADSs in their name).", "score": 0.570346, "arguments": [{"text": "Shire Depositary", "location": [43549, 43565], "entities": [{"type": "Person", "text": "Shire Depositary"}]}, {"text": "New Takeda ADSs", "location": [43573, 43588], "entities": [{"type": "Organization", "text": "New Takeda ADSs"}]}]}, {"type": "partOfMany", "sentence": "The date on which New Takeda ADSs will be delivered to Shire ADS Holders will depend on the way in which such Shire ADS Holders held their Shire ADSs.", "score": 0.555817, "arguments": [{"text": "Shire ADS Holders", "location": [43379, 43396], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "their", "location": [43402, 43407], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "The date on which New Takeda ADSs will be delivered to Shire ADS Holders will depend on the way in which such Shire ADS Holders held their Shire ADSs.", "score": 0.707123, "arguments": [{"text": "Shire ADSs", "location": [43408, 43418], "entities": [{"type": "Person", "text": "Shire ADSs"}]}, {"text": "their", "location": [43402, 43407], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "residesIn", "sentence": "It is expected that Shire ADS Holders holding through participants in DTC will receive delivery shortly after the receipt by the Shire Depositary of the New Takeda ADSs and that registered Shire ADS Holders holding uncertificated Shire ADSs (that is, Shire ADSs held outside of DTC for which no certificates have been issued) will be issued New Takeda ADSs in uncertificated form beginning approximately one week thereafter (and will receive a statement by post reflecting the issuance of New Takeda ADSs in their name).", "score": 0.510484, "arguments": [{"text": "Shire ADS Holders", "location": [43440, 43457], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "DTC", "location": [43490, 43493], "entities": [{"type": "GeopoliticalEntity", "text": "DTC"}]}]}, {"type": "locatedAt", "sentence": "It is expected that Shire ADS Holders holding through participants in DTC will receive delivery shortly after the receipt by the Shire Depositary of the New Takeda ADSs and that registered Shire ADS Holders holding uncertificated Shire ADSs (that is, Shire ADSs held outside of DTC for which no certificates have been issued) will be issued New Takeda ADSs in uncertificated form beginning approximately one week thereafter (and will receive a statement by post reflecting the issuance of New Takeda ADSs in their name).", "score": 0.468603, "arguments": [{"text": "participants", "location": [43474, 43486], "entities": [{"type": "Person", "text": "participants"}]}, {"text": "DTC", "location": [43490, 43493], "entities": [{"type": "GeopoliticalEntity", "text": "DTC"}]}]}, {"type": "partOf", "sentence": "It is expected that Shire ADS Holders holding through participants in DTC will receive delivery shortly after the receipt by the Shire Depositary of the New Takeda ADSs and that registered Shire ADS Holders holding uncertificated Shire ADSs (that is, Shire ADSs held outside of DTC for which no certificates have been issued) will be issued New Takeda ADSs in uncertificated form beginning approximately one week thereafter (and will receive a statement by post reflecting the issuance of New Takeda ADSs in their name).", "score": 0.622565, "arguments": [{"text": "which", "location": [43706, 43711], "entities": [{"type": "Organization", "text": "which"}]}, {"text": "DTC for", "location": [43698, 43705], "entities": [{"type": "Organization", "text": "DTC for"}]}]}, {"type": "partOf", "sentence": "The Court Meeting is scheduled to commence at 11.15 a.m. and the Shire General Meeting at 11.30 a.m. (or as soon thereafter as the Court Meeting has concluded or been adjourned).", "score": 0.34681, "arguments": [{"text": "Meeting", "location": [2975, 2982], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}, {"text": "Meeting", "location": [3044, 3051], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "memberOf", "sentence": "Registered Shire ADS Holders holding certificates for their Shire ADSs will only receive delivery of their New Takeda ADSs after they return their signed letter of transmittal and Shire ADS certificate to the Shire Depositary.", "score": 0.332671, "arguments": [{"text": "certificates", "location": [43978, 43990], "entities": [{"type": "Person", "text": "certificates"}]}, {"text": "Registered Shire ADS Holders", "location": [43941, 43969], "entities": [{"type": "Organization", "text": "Registered Shire ADS Holders"}]}]}, {"type": "partOfMany", "sentence": "(12 ) Shire Shareholders who hold Shire Shares in uncertificated form and receive the cash portion of the Consideration in US Dollars must ensure that an active US Dollar Cash Memorandum Account is in place in CREST by no later than the Scheme Record Time.", "score": 0.484278, "arguments": [{"text": "who", "location": [44625, 44628], "entities": [{"type": "Person", "text": "who"}]}, {"text": "Shareholders", "location": [44612, 44624], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "locatedAt", "sentence": "(12 ) Shire Shareholders who hold Shire Shares in uncertificated form and receive the cash portion of the Consideration in US Dollars must ensure that an active US Dollar Cash Memorandum Account is in place in CREST by no later than the Scheme Record Time.", "score": 0.708833, "arguments": [{"text": "Dollars", "location": [44726, 44733], "entities": [{"type": "Facility", "text": "Dollars"}]}, {"text": "US", "location": [44723, 44725], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "residesIn", "sentence": "(12 ) Shire Shareholders who hold Shire Shares in uncertificated form and receive the cash portion of the Consideration in US Dollars must ensure that an active US Dollar Cash Memorandum Account is in place in CREST by no later than the Scheme Record Time.", "score": 0.329653, "arguments": [{"text": "Dollar Cash Memorandum Account", "location": [44764, 44794], "entities": [{"type": "Person", "text": "Dollar Cash Memorandum Account"}]}, {"text": "US", "location": [44761, 44763], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "locatedAt", "sentence": "(12 ) Shire Shareholders who hold Shire Shares in uncertificated form and receive the cash portion of the Consideration in US Dollars must ensure that an active US Dollar Cash Memorandum Account is in place in CREST by no later than the Scheme Record Time.", "score": 0.678042, "arguments": [{"text": "Dollar Cash Memorandum Account", "location": [44764, 44794], "entities": [{"type": "Person", "text": "Dollar Cash Memorandum Account"}]}, {"text": "CREST", "location": [44810, 44815], "entities": [{"type": "GeopoliticalEntity", "text": "CREST"}]}]}, {"type": "managerOf", "sentence": "In the absence of a US Dollar Cash Memorandum Account, the payment of the cash portion of the Consideration will not settle, resulting in a delay and the settlement of the cash portion of the Consideration outside of CREST.", "score": 0.444366, "arguments": [{"text": "Dollar Cash Memorandum Account", "location": [44880, 44910], "entities": [{"type": "Person", "text": "Dollar Cash Memorandum Account"}]}, {"text": "US", "location": [44877, 44879], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "affectedBy", "sentence": "In the absence of a US Dollar Cash Memorandum Account, the payment of the cash portion of the Consideration will not settle, resulting in a delay and the settlement of the cash portion of the Consideration outside of CREST.", "score": 0.522945, "arguments": [{"text": "Dollar Cash Memorandum Account", "location": [44880, 44910], "entities": [{"type": "Person", "text": "Dollar Cash Memorandum Account"}]}, {"text": "settlement", "location": [45011, 45021], "entities": [{"type": "EventLegal", "text": "settlement"}]}]}, {"type": "participantIn", "sentence": "(13 ) In the case of Shire ADS Holders who hold Shire ADSs in certificated form, subject to presentation by such holders of their signed letters of transmittal and Shire ADS certificates to the Shire Depositary.", "score": 0.428942, "arguments": [{"text": "Shire ADS Holders", "location": [45102, 45119], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "case", "location": [45094, 45098], "entities": [{"type": "EventLegal", "text": "case"}]}]}, {"type": "partOfMany", "sentence": "(13 ) In the case of Shire ADS Holders who hold Shire ADSs in certificated form, subject to presentation by such holders of their signed letters of transmittal and Shire ADS certificates to the Shire Depositary.", "score": 0.537496, "arguments": [{"text": "Shire ADS Holders", "location": [45102, 45119], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "their", "location": [45205, 45210], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "(13 ) In the case of Shire ADS Holders who hold Shire ADSs in certificated form, subject to presentation by such holders of their signed letters of transmittal and Shire ADS certificates to the Shire Depositary.", "score": 0.82862, "arguments": [{"text": "Shire ADSs", "location": [45129, 45139], "entities": [{"type": "Person", "text": "Shire ADSs"}]}, {"text": "their", "location": [45205, 45210], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "participantIn", "sentence": "The Court Meeting is scheduled to commence at 11.15 a.m. and the Shire General Meeting at 11.30 a.m. (or as soon thereafter as the Court Meeting has concluded or been adjourned).", "score": 0.89355, "arguments": [{"text": "Shire General", "location": [3030, 3043], "entities": [{"type": "Person", "text": "Shire General"}]}, {"text": "Meeting", "location": [3044, 3051], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "partOfMany", "sentence": "(13 ) In the case of Shire ADS Holders who hold Shire ADSs in certificated form, subject to presentation by such holders of their signed letters of transmittal and Shire ADS certificates to the Shire Depositary.", "score": 0.827826, "arguments": [{"text": "holders", "location": [45194, 45201], "entities": [{"type": "Person", "text": "holders"}]}, {"text": "their", "location": [45205, 45210], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "(13 ) In the case of Shire ADS Holders who hold Shire ADSs in certificated form, subject to presentation by such holders of their signed letters of transmittal and Shire ADS certificates to the Shire Depositary.", "score": 0.750277, "arguments": [{"text": "their", "location": [45205, 45210], "entities": [{"type": "Person", "text": "their"}]}, {"text": "certificates", "location": [45255, 45267], "entities": [{"type": "Person", "text": "certificates"}]}]}, {"type": "colleague", "sentence": "(13 ) In the case of Shire ADS Holders who hold Shire ADSs in certificated form, subject to presentation by such holders of their signed letters of transmittal and Shire ADS certificates to the Shire Depositary.", "score": 0.253411, "arguments": [{"text": "Shire ADS", "location": [45245, 45254], "entities": [{"type": "Person", "text": "Shire ADS"}]}, {"text": "certificates", "location": [45255, 45267], "entities": [{"type": "Person", "text": "certificates"}]}]}, {"type": "timeOf", "sentence": "The Court Meeting is scheduled to commence at 11.15 a.m. and the Shire General Meeting at 11.30 a.m. (or as soon thereafter as the Court Meeting has concluded or been adjourned).", "score": 0.751479, "arguments": [{"text": "11.30 a.m.", "location": [3055, 3065], "entities": [{"type": "Time", "text": "11.30 a.m."}]}, {"text": "Meeting", "location": [3044, 3051], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "participantIn", "sentence": "The Court Meeting is scheduled to commence at 11.15 a.m. and the Shire General Meeting at 11.30 a.m. (or as soon thereafter as the Court Meeting has concluded or been adjourned).", "score": 0.463751, "arguments": [{"text": "Court", "location": [3096, 3101], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [3102, 3109], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "participantIn", "sentence": "It is important that, for the Court Meeting in particular, as many votes as possible are cast so that the Court may be satisfied that there is a fair and reasonable representation of Shire Shareholder opinion.", "score": 0.448505, "arguments": [{"text": "Court", "location": [3174, 3179], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [3180, 3187], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "partOf", "sentence": "The Acquisition will be effected by means of a scheme of arrangement under Article 125 of the Companies (Jersey) Law 1991 (as amended) (the \" Scheme \").", "score": 0.407208, "arguments": [{"text": "Companies", "location": [455, 464], "entities": [{"type": "Organization", "text": "Companies"}]}, {"text": "Jersey", "location": [466, 472], "entities": [{"type": "Organization", "text": "Jersey"}]}]}, {"type": "partOfMany", "sentence": "Shire Shareholders and Shire ADS Holders are therefore strongly urged to complete, sign and return the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible.", "score": 0.550635, "arguments": [{"text": "Shire", "location": [3354, 3359], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "their", "location": [3575, 3580], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "Shire Shareholders and Shire ADS Holders are therefore strongly urged to complete, sign and return the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible.", "score": 0.72046, "arguments": [{"text": "Shire ADS Holders", "location": [3377, 3394], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "Shareholders", "location": [3360, 3372], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "partOfMany", "sentence": "Shire Shareholders and Shire ADS Holders are therefore strongly urged to complete, sign and return the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible.", "score": 0.553355, "arguments": [{"text": "Shareholders", "location": [3360, 3372], "entities": [{"type": "Person", "text": "Shareholders"}]}, {"text": "their", "location": [3575, 3580], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "agentOf", "sentence": "Shire Shareholders and Shire ADS Holders are therefore strongly urged to complete, sign and return the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible.", "score": 0.692017, "arguments": [{"text": "Shire ADS Holders", "location": [3377, 3394], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "urged", "location": [3418, 3423], "entities": [{"type": "EventCommunication", "text": "urged"}]}]}, {"type": "partOfMany", "sentence": "Shire Shareholders and Shire ADS Holders are therefore strongly urged to complete, sign and return the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible.", "score": 0.789426, "arguments": [{"text": "Shire ADS Holders", "location": [3377, 3394], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "their", "location": [3575, 3580], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "Shire Shareholders and Shire ADS Holders are therefore strongly urged to complete, sign and return the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible.", "score": 0.746897, "arguments": [{"text": "Voting Card", "location": [3585, 3596], "entities": [{"type": "Person", "text": "Voting Card"}]}, {"text": "their", "location": [3575, 3580], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "participantIn", "sentence": "Shire Shareholders and Shire ADS Holders are therefore strongly urged to complete, sign and return the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible.", "score": 0.50097, "arguments": [{"text": "Court", "location": [3611, 3616], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [3617, 3624], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "productOf", "sentence": "Timetable The Scheme Document contains an expected timetable of principal events relating to the Scheme, which is also attached as an Appendix to this Announcement.", "score": 0.550334, "arguments": [{"text": "Appendix", "location": [3811, 3819], "entities": [{"type": "Product", "text": "Appendix"}]}, {"text": "which", "location": [3782, 3787], "entities": [{"type": "Organization", "text": "which"}]}]}, {"type": "agentOf", "sentence": "It is intended that, following the Scheme becoming Effective, the London Stock Exchange and the FCA will be requested respectively to cancel trading in Shire Shares on the London Stock Exchange's main market for listed securities and to remove the listing of the Shire Shares from the Official List, in each case on or shortly after the Effective Date.", "score": 0.932621, "arguments": [{"text": "FCA", "location": [4694, 4697], "entities": [{"type": "Organization", "text": "FCA"}]}, {"text": "requested", "location": [4706, 4715], "entities": [{"type": "EventCommunication", "text": "requested"}]}]}, {"type": "employedBy", "sentence": "It is intended that, following the Scheme becoming Effective, the London Stock Exchange and the FCA will be requested respectively to cancel trading in Shire Shares on the London Stock Exchange's main market for listed securities and to remove the listing of the Shire Shares from the Official List, in each case on or shortly after the Effective Date.", "score": 0.656879, "arguments": [{"text": "Shire", "location": [4861, 4866], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Official List", "location": [4883, 4896], "entities": [{"type": "Organization", "text": "Official List"}]}]}, {"type": "agentOf", "sentence": "Shire is pleased to announce that the scheme document which sets out, among other things, a letter from the Chairman of Shire, the full terms and conditions of the Scheme, an explanatory statement, notices of the Court Meeting and the Shire General Meeting, an expected timetable of principal events and details of the action to be taken by Shire Shareholders and Shire ADS Holders, is being sent, or made available, to Shire Shareholders and Shire ADS Holders today and has been published on the Shire website at www.shire.com (the \" Scheme Document \").", "score": 0.90618, "arguments": [{"text": "Shire", "location": [514, 519], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "announce", "location": [534, 542], "entities": [{"type": "EventCommunication", "text": "announce"}]}]}, {"type": "agentOf", "sentence": "If any of the key dates set out in the timetable change, Shire will give notice of this change by issuing an announcement through a Regulatory Information Service.", "score": 0.847208, "arguments": [{"text": "Shire", "location": [5096, 5101], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "issuing", "location": [5137, 5144], "entities": [{"type": "EventCommunication", "text": "issuing"}]}]}, {"type": "partOfMany", "sentence": "Information for Shire Shareholders and Shire ADS Holders If you have any questions in relation to this Announcement, the Scheme Document, the Court Meeting or the Shire General Meeting, or are in any doubt as to how to complete the Forms of Proxy or lodge a Form of Election, please call Equiniti between 8.30 a.m. and 5.30 p.m. (London time) Monday to Friday (except public holidays in England and Wales) on 0330 123 5506 (if calling from within the UK) or +44 (0)121 415 0856 (if calling from outside the UK).", "score": 0.642989, "arguments": [{"text": "Shire ADS Holders", "location": [5320, 5337], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "Shareholders", "location": [5303, 5315], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "agentOf", "sentence": "Information for Shire Shareholders and Shire ADS Holders If you have any questions in relation to this Announcement, the Scheme Document, the Court Meeting or the Shire General Meeting, or are in any doubt as to how to complete the Forms of Proxy or lodge a Form of Election, please call Equiniti between 8.30 a.m. and 5.30 p.m. (London time) Monday to Friday (except public holidays in England and Wales) on 0330 123 5506 (if calling from within the UK) or +44 (0)121 415 0856 (if calling from outside the UK).", "score": 0.763903, "arguments": [{"text": "you", "location": [5341, 5344], "entities": [{"type": "Person", "text": "you"}]}, {"text": "Announcement", "location": [5384, 5396], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "affectedBy", "sentence": "Information for Shire Shareholders and Shire ADS Holders If you have any questions in relation to this Announcement, the Scheme Document, the Court Meeting or the Shire General Meeting, or are in any doubt as to how to complete the Forms of Proxy or lodge a Form of Election, please call Equiniti between 8.30 a.m. and 5.30 p.m. (London time) Monday to Friday (except public holidays in England and Wales) on 0330 123 5506 (if calling from within the UK) or +44 (0)121 415 0856 (if calling from outside the UK).", "score": 0.459791, "arguments": [{"text": "Scheme Document", "location": [5402, 5417], "entities": [{"type": "Organization", "text": "Scheme Document"}]}, {"text": "Announcement", "location": [5384, 5396], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "participantIn", "sentence": "Information for Shire Shareholders and Shire ADS Holders If you have any questions in relation to this Announcement, the Scheme Document, the Court Meeting or the Shire General Meeting, or are in any doubt as to how to complete the Forms of Proxy or lodge a Form of Election, please call Equiniti between 8.30 a.m. and 5.30 p.m. (London time) Monday to Friday (except public holidays in England and Wales) on 0330 123 5506 (if calling from within the UK) or +44 (0)121 415 0856 (if calling from outside the UK).", "score": 0.451052, "arguments": [{"text": "Court", "location": [5423, 5428], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [5429, 5436], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "timeOf", "sentence": "Information for Shire Shareholders and Shire ADS Holders If you have any questions in relation to this Announcement, the Scheme Document, the Court Meeting or the Shire General Meeting, or are in any doubt as to how to complete the Forms of Proxy or lodge a Form of Election, please call Equiniti between 8.30 a.m. and 5.30 p.m. (London time) Monday to Friday (except public holidays in England and Wales) on 0330 123 5506 (if calling from within the UK) or +44 (0)121 415 0856 (if calling from outside the UK).", "score": 0.542799, "arguments": [{"text": "0330 123 5506", "location": [5690, 5703], "entities": [{"type": "Date", "text": "0330 123 5506"}]}, {"text": "calling", "location": [5708, 5715], "entities": [{"type": "EventCommunication", "text": "calling"}]}]}, {"type": "employedBy", "sentence": "Enquiries: +41 41 288 41 29 Scott Burrows (Investor Relations) +41 41 288 41 95 Sun Kim (Investor Relations) (joint financial adviser to Shire) (US) Chris Hite (joint financial adviser to Shire) Anthony Gutman Morgan Stanley & Co. International plc (joint financial adviser to Shire) Clint Gartin +44 (0) 203 727 1000 Takeda Elissa Johnsen (Media - outside of Japan) elissa.johnsen@takeda.com Kazumi Kobayashi (Media - within Japan) Kazumi.kobayashi@takeda.com Tsuyoshi Tada (Media - within Japan) tsuyoshi.tada@takeda.com (joint financial adviser to Takeda) (US) Will Hiltz (joint financial adviser to Takeda) Michele Colocci (joint financial adviser to Takeda) Akira Kiyota (UK) James Murgatroyd / Rollo Head / Anjali Unnikrishnan +44 207 251 3801 (US) Kal Goldberg / Chris Ryall +", "score": 0.521513, "arguments": [{"text": "Scott Burrows", "location": [6650, 6663], "entities": [{"type": "Person", "text": "Scott Burrows"}]}, {"text": "Investor Relations", "location": [6665, 6683], "entities": [{"type": "Organization", "text": "Investor Relations"}]}]}, {"type": "employedBy", "sentence": "Enquiries: +41 41 288 41 29 Scott Burrows (Investor Relations) +41 41 288 41 95 Sun Kim (Investor Relations) (joint financial adviser to Shire) (US) Chris Hite (joint financial adviser to Shire) Anthony Gutman Morgan Stanley & Co. International plc (joint financial adviser to Shire) Clint Gartin +44 (0) 203 727 1000 Takeda Elissa Johnsen (Media - outside of Japan) elissa.johnsen@takeda.com Kazumi Kobayashi (Media - within Japan) Kazumi.kobayashi@takeda.com Tsuyoshi Tada (Media - within Japan) tsuyoshi.tada@takeda.com (joint financial adviser to Takeda) (US) Will Hiltz (joint financial adviser to Takeda) Michele Colocci (joint financial adviser to Takeda) Akira Kiyota (UK) James Murgatroyd / Rollo Head / Anjali Unnikrishnan +44 207 251 3801 (US) Kal Goldberg / Chris Ryall +", "score": 0.539315, "arguments": [{"text": "Kim", "location": [6706, 6709], "entities": [{"type": "Person", "text": "Kim"}]}, {"text": "Investor Relations", "location": [6711, 6729], "entities": [{"type": "Organization", "text": "Investor Relations"}]}]}, {"type": "employedBy", "sentence": "Enquiries: +41 41 288 41 29 Scott Burrows (Investor Relations) +41 41 288 41 95 Sun Kim (Investor Relations) (joint financial adviser to Shire) (US) Chris Hite (joint financial adviser to Shire) Anthony Gutman Morgan Stanley & Co. International plc (joint financial adviser to Shire) Clint Gartin +44 (0) 203 727 1000 Takeda Elissa Johnsen (Media - outside of Japan) elissa.johnsen@takeda.com Kazumi Kobayashi (Media - within Japan) Kazumi.kobayashi@takeda.com Tsuyoshi Tada (Media - within Japan) tsuyoshi.tada@takeda.com (joint financial adviser to Takeda) (US) Will Hiltz (joint financial adviser to Takeda) Michele Colocci (joint financial adviser to Takeda) Akira Kiyota (UK) James Murgatroyd / Rollo Head / Anjali Unnikrishnan +44 207 251 3801 (US) Kal Goldberg / Chris Ryall +", "score": 0.596008, "arguments": [{"text": "Anthony Gutman", "location": [6817, 6831], "entities": [{"type": "Person", "text": "Anthony Gutman"}]}, {"text": "Morgan Stanley & Co. International plc", "location": [6832, 6870], "entities": [{"type": "Organization", "text": "Morgan Stanley & Co. International plc"}]}]}, {"type": "employedBy", "sentence": "Enquiries: +41 41 288 41 29 Scott Burrows (Investor Relations) +41 41 288 41 95 Sun Kim (Investor Relations) (joint financial adviser to Shire) (US) Chris Hite (joint financial adviser to Shire) Anthony Gutman Morgan Stanley & Co. International plc (joint financial adviser to Shire) Clint Gartin +44 (0) 203 727 1000 Takeda Elissa Johnsen (Media - outside of Japan) elissa.johnsen@takeda.com Kazumi Kobayashi (Media - within Japan) Kazumi.kobayashi@takeda.com Tsuyoshi Tada (Media - within Japan) tsuyoshi.tada@takeda.com (joint financial adviser to Takeda) (US) Will Hiltz (joint financial adviser to Takeda) Michele Colocci (joint financial adviser to Takeda) Akira Kiyota (UK) James Murgatroyd / Rollo Head / Anjali Unnikrishnan +44 207 251 3801 (US) Kal Goldberg / Chris Ryall +", "score": 0.499718, "arguments": [{"text": "Takeda Elissa Johnsen", "location": [6940, 6961], "entities": [{"type": "Person", "text": "Takeda Elissa Johnsen"}]}, {"text": "Media", "location": [6963, 6968], "entities": [{"type": "Organization", "text": "Media"}]}]}, {"type": "colleague", "sentence": "Shire is pleased to announce that the scheme document which sets out, among other things, a letter from the Chairman of Shire, the full terms and conditions of the Scheme, an explanatory statement, notices of the Court Meeting and the Shire General Meeting, an expected timetable of principal events and details of the action to be taken by Shire Shareholders and Shire ADS Holders, is being sent, or made available, to Shire Shareholders and Shire ADS Holders today and has been published on the Shire website at www.shire.com (the \" Scheme Document \").", "score": 0.340234, "arguments": [{"text": "Chairman", "location": [622, 630], "entities": [{"type": "Person", "text": "Chairman"}]}, {"text": "Shire", "location": [634, 639], "entities": [{"type": "Person", "text": "Shire"}]}]}, {"type": "employedBy", "sentence": "Enquiries: +41 41 288 41 29 Scott Burrows (Investor Relations) +41 41 288 41 95 Sun Kim (Investor Relations) (joint financial adviser to Shire) (US) Chris Hite (joint financial adviser to Shire) Anthony Gutman Morgan Stanley & Co. International plc (joint financial adviser to Shire) Clint Gartin +44 (0) 203 727 1000 Takeda Elissa Johnsen (Media - outside of Japan) elissa.johnsen@takeda.com Kazumi Kobayashi (Media - within Japan) Kazumi.kobayashi@takeda.com Tsuyoshi Tada (Media - within Japan) tsuyoshi.tada@takeda.com (joint financial adviser to Takeda) (US) Will Hiltz (joint financial adviser to Takeda) Michele Colocci (joint financial adviser to Takeda) Akira Kiyota (UK) James Murgatroyd / Rollo Head / Anjali Unnikrishnan +44 207 251 3801 (US) Kal Goldberg / Chris Ryall +", "score": 0.419966, "arguments": [{"text": "elissa.johnsen@takeda.com Kazumi Kobayashi", "location": [6989, 7031], "entities": [{"type": "Person", "text": "elissa.johnsen@takeda.com Kazumi Kobayashi"}]}, {"text": "Media - within Japan", "location": [7033, 7053], "entities": [{"type": "Organization", "text": "Media - within Japan"}]}]}, {"type": "employedBy", "sentence": "Enquiries: +41 41 288 41 29 Scott Burrows (Investor Relations) +41 41 288 41 95 Sun Kim (Investor Relations) (joint financial adviser to Shire) (US) Chris Hite (joint financial adviser to Shire) Anthony Gutman Morgan Stanley & Co. International plc (joint financial adviser to Shire) Clint Gartin +44 (0) 203 727 1000 Takeda Elissa Johnsen (Media - outside of Japan) elissa.johnsen@takeda.com Kazumi Kobayashi (Media - within Japan) Kazumi.kobayashi@takeda.com Tsuyoshi Tada (Media - within Japan) tsuyoshi.tada@takeda.com (joint financial adviser to Takeda) (US) Will Hiltz (joint financial adviser to Takeda) Michele Colocci (joint financial adviser to Takeda) Akira Kiyota (UK) James Murgatroyd / Rollo Head / Anjali Unnikrishnan +44 207 251 3801 (US) Kal Goldberg / Chris Ryall +", "score": 0.445336, "arguments": [{"text": "Kazumi.kobayashi@takeda.com Tsuyoshi Tada", "location": [7055, 7096], "entities": [{"type": "Person", "text": "Kazumi.kobayashi@takeda.com Tsuyoshi Tada"}]}, {"text": "Media - within Japan) tsuyoshi.tada@takeda.com", "location": [7098, 7144], "entities": [{"type": "Organization", "text": "Media - within Japan) tsuyoshi.tada@takeda.com"}]}]}, {"type": "employedBy", "sentence": "Enquiries: +41 41 288 41 29 Scott Burrows (Investor Relations) +41 41 288 41 95 Sun Kim (Investor Relations) (joint financial adviser to Shire) (US) Chris Hite (joint financial adviser to Shire) Anthony Gutman Morgan Stanley & Co. International plc (joint financial adviser to Shire) Clint Gartin +44 (0) 203 727 1000 Takeda Elissa Johnsen (Media - outside of Japan) elissa.johnsen@takeda.com Kazumi Kobayashi (Media - within Japan) Kazumi.kobayashi@takeda.com Tsuyoshi Tada (Media - within Japan) tsuyoshi.tada@takeda.com (joint financial adviser to Takeda) (US) Will Hiltz (joint financial adviser to Takeda) Michele Colocci (joint financial adviser to Takeda) Akira Kiyota (UK) James Murgatroyd / Rollo Head / Anjali Unnikrishnan +44 207 251 3801 (US) Kal Goldberg / Chris Ryall +", "score": 0.602443, "arguments": [{"text": "Takeda", "location": [7277, 7283], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "UK", "location": [7299, 7301], "entities": [{"type": "GeopoliticalEntity", "text": "UK"}]}]}, {"type": "employedBy", "sentence": "Enquiries: +41 41 288 41 29 Scott Burrows (Investor Relations) +41 41 288 41 95 Sun Kim (Investor Relations) (joint financial adviser to Shire) (US) Chris Hite (joint financial adviser to Shire) Anthony Gutman Morgan Stanley & Co. International plc (joint financial adviser to Shire) Clint Gartin +44 (0) 203 727 1000 Takeda Elissa Johnsen (Media - outside of Japan) elissa.johnsen@takeda.com Kazumi Kobayashi (Media - within Japan) Kazumi.kobayashi@takeda.com Tsuyoshi Tada (Media - within Japan) tsuyoshi.tada@takeda.com (joint financial adviser to Takeda) (US) Will Hiltz (joint financial adviser to Takeda) Michele Colocci (joint financial adviser to Takeda) Akira Kiyota (UK) James Murgatroyd / Rollo Head / Anjali Unnikrishnan +44 207 251 3801 (US) Kal Goldberg / Chris Ryall +", "score": 0.950292, "arguments": [{"text": "Akira Kiyota", "location": [7285, 7297], "entities": [{"type": "Person", "text": "Akira Kiyota"}]}, {"text": "UK", "location": [7299, 7301], "entities": [{"type": "GeopoliticalEntity", "text": "UK"}]}]}, {"type": "basedIn", "sentence": "Important Notices About Financial Advisers Evercore Partners International LLP (\" Evercore \"), which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and this Announcement and will not regard any other person as its client in relation to the Acquisition or this Announcement and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of Evercore, or for providing advice in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.433455, "arguments": [{"text": "Financial Conduct Authority", "location": [7799, 7826], "entities": [{"type": "Organization", "text": "Financial Conduct Authority"}]}, {"text": "United Kingdom", "location": [7777, 7791], "entities": [{"type": "GeopoliticalEntity", "text": "United Kingdom"}]}]}, {"type": "agentOf", "sentence": "Important Notices About Financial Advisers Evercore Partners International LLP (\" Evercore \"), which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and this Announcement and will not regard any other person as its client in relation to the Acquisition or this Announcement and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of Evercore, or for providing advice in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.415028, "arguments": [{"text": "anyone", "location": [8089, 8095], "entities": [{"type": "Person", "text": "anyone"}]}, {"text": "Announcement", "location": [8044, 8056], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "employedBy", "sentence": "Important Notices About Financial Advisers Evercore Partners International LLP (\" Evercore \"), which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and this Announcement and will not regard any other person as its client in relation to the Acquisition or this Announcement and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of Evercore, or for providing advice in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.358, "arguments": [{"text": "clients", "location": [8156, 8163], "entities": [{"type": "Person", "text": "clients"}]}, {"text": "Evercore", "location": [8167, 8175], "entities": [{"type": "Organization", "text": "Evercore"}]}]}, {"type": "partOf", "sentence": "Neither Evercore nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Evercore in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.788414, "arguments": [{"text": "subsidiaries", "location": [8321, 8333], "entities": [{"type": "Organization", "text": "subsidiaries"}]}, {"text": "its", "location": [8317, 8320], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "partOfMany", "sentence": "JPMorgan Securities Japan Co., Ltd., together with its affiliate J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove and which is authorised in the United Kingdom by the Prudential Regulation Authority and regulated in the United Kingdom by the Prudential Regulation Authority and the Financial Conduct Authority) (\" J.P. Morgan \"), is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and will not regard any other person as its client in relation to the Acquisition and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of J.P. Morgan, or for providing advice in connection with the Acquisition or any matter referred to herein.", "score": 0.392509, "arguments": [{"text": "JPMorgan Securities Japan Co., Ltd.", "location": [8644, 8679], "entities": [{"type": "Organization", "text": "JPMorgan Securities Japan Co., Ltd."}]}, {"text": "which", "location": [8737, 8742], "entities": [{"type": "Organization", "text": "which"}]}]}, {"type": "partOf", "sentence": "JPMorgan Securities Japan Co., Ltd., together with its affiliate J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove and which is authorised in the United Kingdom by the Prudential Regulation Authority and regulated in the United Kingdom by the Prudential Regulation Authority and the Financial Conduct Authority) (\" J.P. Morgan \"), is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and will not regard any other person as its client in relation to the Acquisition and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of J.P. Morgan, or for providing advice in connection with the Acquisition or any matter referred to herein.", "score": 0.87008, "arguments": [{"text": "affiliate", "location": [8699, 8708], "entities": [{"type": "Organization", "text": "affiliate"}]}, {"text": "its", "location": [8695, 8698], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "employedBy", "sentence": "Shire is pleased to announce that the scheme document which sets out, among other things, a letter from the Chairman of Shire, the full terms and conditions of the Scheme, an explanatory statement, notices of the Court Meeting and the Shire General Meeting, an expected timetable of principal events and details of the action to be taken by Shire Shareholders and Shire ADS Holders, is being sent, or made available, to Shire Shareholders and Shire ADS Holders today and has been published on the Shire website at www.shire.com (the \" Scheme Document \").", "score": 0.22409, "arguments": [{"text": "Shire", "location": [634, 639], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Scheme", "location": [678, 684], "entities": [{"type": "Organization", "text": "Scheme"}]}]}, {"type": "partOfMany", "sentence": "JPMorgan Securities Japan Co., Ltd., together with its affiliate J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove and which is authorised in the United Kingdom by the Prudential Regulation Authority and regulated in the United Kingdom by the Prudential Regulation Authority and the Financial Conduct Authority) (\" J.P. Morgan \"), is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and will not regard any other person as its client in relation to the Acquisition and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of J.P. Morgan, or for providing advice in connection with the Acquisition or any matter referred to herein.", "score": 0.667888, "arguments": [{"text": "J.P. Morgan Securities plc", "location": [8709, 8735], "entities": [{"type": "Organization", "text": "J.P. Morgan Securities plc"}]}, {"text": "affiliate", "location": [8699, 8708], "entities": [{"type": "Organization", "text": "affiliate"}]}]}, {"type": "partOfMany", "sentence": "JPMorgan Securities Japan Co., Ltd., together with its affiliate J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove and which is authorised in the United Kingdom by the Prudential Regulation Authority and regulated in the United Kingdom by the Prudential Regulation Authority and the Financial Conduct Authority) (\" J.P. Morgan \"), is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and will not regard any other person as its client in relation to the Acquisition and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of J.P. Morgan, or for providing advice in connection with the Acquisition or any matter referred to herein.", "score": 0.495335, "arguments": [{"text": "J.P. Morgan Securities plc", "location": [8709, 8735], "entities": [{"type": "Organization", "text": "J.P. Morgan Securities plc"}]}, {"text": "which", "location": [8737, 8742], "entities": [{"type": "Organization", "text": "which"}]}]}, {"type": "partOfMany", "sentence": "JPMorgan Securities Japan Co., Ltd., together with its affiliate J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove and which is authorised in the United Kingdom by the Prudential Regulation Authority and regulated in the United Kingdom by the Prudential Regulation Authority and the Financial Conduct Authority) (\" J.P. Morgan \"), is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and will not regard any other person as its client in relation to the Acquisition and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of J.P. Morgan, or for providing advice in connection with the Acquisition or any matter referred to herein.", "score": 0.528604, "arguments": [{"text": "J.P. Morgan Securities plc", "location": [8709, 8735], "entities": [{"type": "Organization", "text": "J.P. Morgan Securities plc"}]}, {"text": "its", "location": [8752, 8755], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "partOfMany", "sentence": "JPMorgan Securities Japan Co., Ltd., together with its affiliate J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove and which is authorised in the United Kingdom by the Prudential Regulation Authority and regulated in the United Kingdom by the Prudential Regulation Authority and the Financial Conduct Authority) (\" J.P. Morgan \"), is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and will not regard any other person as its client in relation to the Acquisition and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of J.P. Morgan, or for providing advice in connection with the Acquisition or any matter referred to herein.", "score": 0.530369, "arguments": [{"text": "J.P. Morgan Securities plc", "location": [8709, 8735], "entities": [{"type": "Organization", "text": "J.P. Morgan Securities plc"}]}, {"text": "which", "location": [8815, 8820], "entities": [{"type": "Organization", "text": "which"}]}]}, {"type": "basedIn", "sentence": "JPMorgan Securities Japan Co., Ltd., together with its affiliate J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove and which is authorised in the United Kingdom by the Prudential Regulation Authority and regulated in the United Kingdom by the Prudential Regulation Authority and the Financial Conduct Authority) (\" J.P. Morgan \"), is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and will not regard any other person as its client in relation to the Acquisition and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of J.P. Morgan, or for providing advice in connection with the Acquisition or any matter referred to herein.", "score": 0.656251, "arguments": [{"text": "Prudential Regulation Authority", "location": [8864, 8895], "entities": [{"type": "Organization", "text": "Prudential Regulation Authority"}]}, {"text": "United Kingdom", "location": [8842, 8856], "entities": [{"type": "GeopoliticalEntity", "text": "United Kingdom"}]}]}, {"type": "basedIn", "sentence": "JPMorgan Securities Japan Co., Ltd., together with its affiliate J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove and which is authorised in the United Kingdom by the Prudential Regulation Authority and regulated in the United Kingdom by the Prudential Regulation Authority and the Financial Conduct Authority) (\" J.P. Morgan \"), is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and will not regard any other person as its client in relation to the Acquisition and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of J.P. Morgan, or for providing advice in connection with the Acquisition or any matter referred to herein.", "score": 0.510276, "arguments": [{"text": "Prudential Regulation Authority", "location": [8939, 8970], "entities": [{"type": "Organization", "text": "Prudential Regulation Authority"}]}, {"text": "United Kingdom", "location": [8917, 8931], "entities": [{"type": "GeopoliticalEntity", "text": "United Kingdom"}]}]}, {"type": "employedBy", "sentence": "JPMorgan Securities Japan Co., Ltd., together with its affiliate J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove and which is authorised in the United Kingdom by the Prudential Regulation Authority and regulated in the United Kingdom by the Prudential Regulation Authority and the Financial Conduct Authority) (\" J.P. Morgan \"), is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and will not regard any other person as its client in relation to the Acquisition and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of J.P. Morgan, or for providing advice in connection with the Acquisition or any matter referred to herein.", "score": 0.352634, "arguments": [{"text": "clients", "location": [9312, 9319], "entities": [{"type": "Person", "text": "clients"}]}, {"text": "J.P. Morgan", "location": [9323, 9334], "entities": [{"type": "Organization", "text": "J.P. Morgan"}]}]}, {"type": "partOf", "sentence": "Nomura International plc (\" Nomura \"), which is authorised by the Prudential Regulation Authority and regulated by the Prudential Regulation Authority and the Financial Conduct Authority in the United Kingdom, is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and this Announcement and Nomura, its affiliates and its respective officers, employees, agents, representatives and/or associates will not regard any other person as their client, nor will they be responsible to anyone other than Takeda for providing the protections afforded to clients of Nomura or for giving advice in relation to the Acquisition, this Announcement or any matter or referred to herein.", "score": 0.425449, "arguments": [{"text": "Nomura International plc", "location": [9429, 9453], "entities": [{"type": "Organization", "text": "Nomura International plc"}]}, {"text": "Nomura", "location": [9457, 9463], "entities": [{"type": "Organization", "text": "Nomura"}]}]}, {"type": "locatedAt", "sentence": "Nomura International plc (\" Nomura \"), which is authorised by the Prudential Regulation Authority and regulated by the Prudential Regulation Authority and the Financial Conduct Authority in the United Kingdom, is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and this Announcement and Nomura, its affiliates and its respective officers, employees, agents, representatives and/or associates will not regard any other person as their client, nor will they be responsible to anyone other than Takeda for providing the protections afforded to clients of Nomura or for giving advice in relation to the Acquisition, this Announcement or any matter or referred to herein.", "score": 0.728307, "arguments": [{"text": "Financial Conduct Authority", "location": [9588, 9615], "entities": [{"type": "Organization", "text": "Financial Conduct Authority"}]}, {"text": "United Kingdom", "location": [9623, 9637], "entities": [{"type": "GeopoliticalEntity", "text": "United Kingdom"}]}]}, {"type": "agentOf", "sentence": "Nomura International plc (\" Nomura \"), which is authorised by the Prudential Regulation Authority and regulated by the Prudential Regulation Authority and the Financial Conduct Authority in the United Kingdom, is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and this Announcement and Nomura, its affiliates and its respective officers, employees, agents, representatives and/or associates will not regard any other person as their client, nor will they be responsible to anyone other than Takeda for providing the protections afforded to clients of Nomura or for giving advice in relation to the Acquisition, this Announcement or any matter or referred to herein.", "score": 0.549516, "arguments": [{"text": "Acquisition", "location": [9731, 9742], "entities": [{"type": "Organization", "text": "Acquisition"}]}, {"text": "Announcement", "location": [9752, 9764], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "partOf", "sentence": "Nomura International plc (\" Nomura \"), which is authorised by the Prudential Regulation Authority and regulated by the Prudential Regulation Authority and the Financial Conduct Authority in the United Kingdom, is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and this Announcement and Nomura, its affiliates and its respective officers, employees, agents, representatives and/or associates will not regard any other person as their client, nor will they be responsible to anyone other than Takeda for providing the protections afforded to clients of Nomura or for giving advice in relation to the Acquisition, this Announcement or any matter or referred to herein.", "score": 0.785092, "arguments": [{"text": "affiliates", "location": [9781, 9791], "entities": [{"type": "Organization", "text": "affiliates"}]}, {"text": "its", "location": [9777, 9780], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "participantIn", "sentence": "Shire is pleased to announce that the scheme document which sets out, among other things, a letter from the Chairman of Shire, the full terms and conditions of the Scheme, an explanatory statement, notices of the Court Meeting and the Shire General Meeting, an expected timetable of principal events and details of the action to be taken by Shire Shareholders and Shire ADS Holders, is being sent, or made available, to Shire Shareholders and Shire ADS Holders today and has been published on the Shire website at www.shire.com (the \" Scheme Document \").", "score": 0.51267, "arguments": [{"text": "Court", "location": [727, 732], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [733, 740], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "employedBy", "sentence": "Nomura International plc (\" Nomura \"), which is authorised by the Prudential Regulation Authority and regulated by the Prudential Regulation Authority and the Financial Conduct Authority in the United Kingdom, is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and this Announcement and Nomura, its affiliates and its respective officers, employees, agents, representatives and/or associates will not regard any other person as their client, nor will they be responsible to anyone other than Takeda for providing the protections afforded to clients of Nomura or for giving advice in relation to the Acquisition, this Announcement or any matter or referred to herein.", "score": 0.586859, "arguments": [{"text": "officers", "location": [9811, 9819], "entities": [{"type": "Person", "text": "officers"}]}, {"text": "its", "location": [9796, 9799], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "partOfMany", "sentence": "Nomura International plc (\" Nomura \"), which is authorised by the Prudential Regulation Authority and regulated by the Prudential Regulation Authority and the Financial Conduct Authority in the United Kingdom, is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and this Announcement and Nomura, its affiliates and its respective officers, employees, agents, representatives and/or associates will not regard any other person as their client, nor will they be responsible to anyone other than Takeda for providing the protections afforded to clients of Nomura or for giving advice in relation to the Acquisition, this Announcement or any matter or referred to herein.", "score": 0.688311, "arguments": [{"text": "associates", "location": [9863, 9873], "entities": [{"type": "Person", "text": "associates"}]}, {"text": "their", "location": [9910, 9915], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOf", "sentence": "Neither Nomura nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Nomura in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.788414, "arguments": [{"text": "subsidiaries", "location": [10179, 10191], "entities": [{"type": "Organization", "text": "subsidiaries"}]}, {"text": "its", "location": [10175, 10178], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "locatedAt", "sentence": "Citigroup Global Markets Limited (\" Citi \"), which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting exclusively as financial adviser to Shire and no one else in connection with the Acquisition, this Announcement and the matters described herein, and shall not be responsible to anyone other than Shire for providing the protections afforded to clients of Citi, or for providing advice in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.735763, "arguments": [{"text": "Prudential Regulation Authority", "location": [10661, 10692], "entities": [{"type": "Organization", "text": "Prudential Regulation Authority"}]}, {"text": "United Kingdom", "location": [10700, 10714], "entities": [{"type": "GeopoliticalEntity", "text": "United Kingdom"}]}]}, {"type": "locatedAt", "sentence": "Goldman Sachs International (\" Goldman Sachs \"), which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting exclusively as financial adviser to Shire and no one else in connection with the Acquisition, this Announcement and the matters described herein, and shall not be responsible to anyone other than Shire for providing the protections afforded to clients of Goldman Sachs or for providing advice in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.736631, "arguments": [{"text": "Prudential Regulation Authority", "location": [11611, 11642], "entities": [{"type": "Organization", "text": "Prudential Regulation Authority"}]}, {"text": "United Kingdom", "location": [11650, 11664], "entities": [{"type": "GeopoliticalEntity", "text": "United Kingdom"}]}]}, {"type": "locatedAt", "sentence": "Neither Goldman Sachs nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Goldman Sachs in connection with the Acquisition, this Announcement or any matter referred to herein Morgan Stanley & Co. International plc (\" Morgan Stanley \"), which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting exclusively as financial adviser to Shire and no one else in connection with the Acquisition, this Announcement and the matters described herein,", "score": 0.77181, "arguments": [{"text": "Prudential Regulation Authority", "location": [12598, 12629], "entities": [{"type": "Organization", "text": "Prudential Regulation Authority"}]}, {"text": "United Kingdom", "location": [12637, 12651], "entities": [{"type": "GeopoliticalEntity", "text": "United Kingdom"}]}]}, {"type": "partOf", "sentence": "Neither Citi nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Citi in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.788414, "arguments": [{"text": "subsidiaries", "location": [11127, 11139], "entities": [{"type": "Organization", "text": "subsidiaries"}]}, {"text": "its", "location": [11123, 11126], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "employedBy", "sentence": "Goldman Sachs International (\" Goldman Sachs \"), which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting exclusively as financial adviser to Shire and no one else in connection with the Acquisition, this Announcement and the matters described herein, and shall not be responsible to anyone other than Shire for providing the protections afforded to clients of Goldman Sachs or for providing advice in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.371283, "arguments": [{"text": "clients", "location": [11920, 11927], "entities": [{"type": "Person", "text": "clients"}]}, {"text": "Goldman Sachs", "location": [11931, 11944], "entities": [{"type": "Organization", "text": "Goldman Sachs"}]}]}, {"type": "partOf", "sentence": "Neither Goldman Sachs nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Goldman Sachs in connection with the Acquisition, this Announcement or any matter referred to herein Morgan Stanley & Co. International plc (\" Morgan Stanley \"), which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting exclusively as financial adviser to Shire and no one else in connection with the Acquisition, this Announcement and the matters described herein,", "score": 0.788414, "arguments": [{"text": "subsidiaries", "location": [12094, 12106], "entities": [{"type": "Organization", "text": "subsidiaries"}]}, {"text": "its", "location": [12090, 12093], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "employedBy", "sentence": "and shall not be responsible to anyone other than Shire for providing the protections afforded to clients of Morgan Stanley or for providing advice in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.376581, "arguments": [{"text": "clients", "location": [12907, 12914], "entities": [{"type": "Person", "text": "clients"}]}, {"text": "Morgan Stanley", "location": [12918, 12932], "entities": [{"type": "Organization", "text": "Morgan Stanley"}]}]}, {"type": "partOf", "sentence": "Neither Morgan Stanley nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Morgan Stanley in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.788414, "arguments": [{"text": "subsidiaries", "location": [13083, 13095], "entities": [{"type": "Organization", "text": "subsidiaries"}]}, {"text": "its", "location": [13079, 13082], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "colleague", "sentence": "Shire Shareholders are advised to read the Scheme Document (including the related Forms of Proxy and forms of election) carefully once these become available because they will contain important information in relation to the Acquisition, the New Takeda Shares and the Combined Group.", "score": 0.226994, "arguments": [{"text": "Shire", "location": [14740, 14745], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Shareholders", "location": [14746, 14758], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "participantIn", "sentence": "Together with the Scheme Document, Forms of Proxy for the Court Meeting and the Shire General Meeting and Forms of Election and the notes accompanying them have also been published on the Shire website at www.shire.com.", "score": 0.514803, "arguments": [{"text": "Court", "location": [1127, 1132], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [1133, 1140], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "agentOf", "sentence": "Shire Shareholders are advised to read the Scheme Document (including the related Forms of Proxy and forms of election) carefully once these become available because they will contain important information in relation to the Acquisition, the New Takeda Shares and the Combined Group.", "score": 0.617654, "arguments": [{"text": "Shire", "location": [14740, 14745], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "advised", "location": [14763, 14770], "entities": [{"type": "EventCommunication", "text": "advised"}]}]}, {"type": "agentOf", "sentence": "Shire Shareholders are advised to read the Scheme Document (including the related Forms of Proxy and forms of election) carefully once these become available because they will contain important information in relation to the Acquisition, the New Takeda Shares and the Combined Group.", "score": 0.521425, "arguments": [{"text": "Shareholders", "location": [14746, 14758], "entities": [{"type": "Person", "text": "Shareholders"}]}, {"text": "advised", "location": [14763, 14770], "entities": [{"type": "EventCommunication", "text": "advised"}]}]}, {"type": "affectedBy", "sentence": "Shire Shareholders are advised to read the Scheme Document (including the related Forms of Proxy and forms of election) carefully once these become available because they will contain important information in relation to the Acquisition, the New Takeda Shares and the Combined Group.", "score": 0.698459, "arguments": [{"text": "Scheme Document", "location": [14783, 14798], "entities": [{"type": "Organization", "text": "Scheme Document"}]}, {"text": "advised", "location": [14763, 14770], "entities": [{"type": "EventCommunication", "text": "advised"}]}]}, {"type": "agentOf", "sentence": "The New Takeda Securities are not being offered to the public by means of this Announcement.", "score": 0.641941, "arguments": [{"text": "public", "location": [15079, 15085], "entities": [{"type": "Person", "text": "public"}]}, {"text": "Announcement", "location": [15103, 15115], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Takeda reserves the right to elect (with the consent of the Panel and subject to the terms of the Co-operation Agreement) to implement the acquisition of the Shire Shares by way of a Takeover Offer as an alternative to the Scheme.", "score": 0.374582, "arguments": [{"text": "Panel", "location": [15263, 15268], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "acquisition", "location": [15342, 15353], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "clientOf", "sentence": "Restricted Jurisdictions The release, publication or distribution of this Announcement in jurisdictions other than the United Kingdom and Jersey may be restricted by law and therefore any persons into whose possession this Announcement comes who are subject to the laws of any jurisdiction other than the United Kingdom and Jersey should inform themselves about, and observe, any applicable requirements.", "score": 0.241675, "arguments": [{"text": "persons", "location": [16024, 16031], "entities": [{"type": "Person", "text": "persons"}]}, {"text": "Jersey", "location": [15974, 15980], "entities": [{"type": "Organization", "text": "Jersey"}]}]}, {"type": "agentOf", "sentence": "Restricted Jurisdictions The release, publication or distribution of this Announcement in jurisdictions other than the United Kingdom and Jersey may be restricted by law and therefore any persons into whose possession this Announcement comes who are subject to the laws of any jurisdiction other than the United Kingdom and Jersey should inform themselves about, and observe, any applicable requirements.", "score": 0.723281, "arguments": [{"text": "whose", "location": [16037, 16042], "entities": [{"type": "Person", "text": "whose"}]}, {"text": "Announcement", "location": [16059, 16071], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Restricted Jurisdictions The release, publication or distribution of this Announcement in jurisdictions other than the United Kingdom and Jersey may be restricted by law and therefore any persons into whose possession this Announcement comes who are subject to the laws of any jurisdiction other than the United Kingdom and Jersey should inform themselves about, and observe, any applicable requirements.", "score": 0.764785, "arguments": [{"text": "Jersey", "location": [16160, 16166], "entities": [{"type": "Organization", "text": "Jersey"}]}, {"text": "inform", "location": [16174, 16180], "entities": [{"type": "EventCommunication", "text": "inform"}]}]}, {"type": "affectedBy", "sentence": "Restricted Jurisdictions The release, publication or distribution of this Announcement in jurisdictions other than the United Kingdom and Jersey may be restricted by law and therefore any persons into whose possession this Announcement comes who are subject to the laws of any jurisdiction other than the United Kingdom and Jersey should inform themselves about, and observe, any applicable requirements.", "score": 0.824719, "arguments": [{"text": "themselves", "location": [16181, 16191], "entities": [{"type": "Person", "text": "themselves"}]}, {"text": "inform", "location": [16174, 16180], "entities": [{"type": "EventCommunication", "text": "inform"}]}]}, {"type": "partOfMany", "sentence": "In particular, the ability of persons who are not resident in the United Kingdom or Jersey to vote their Shire Shares with respect to the Scheme at the Court Meeting, to execute and deliver forms of proxy appointing another to vote at the Court Meeting on their behalf or to hold or vote Takeda Shares may be affected by the laws of the relevant jurisdiction in which they are located.", "score": 0.556775, "arguments": [{"text": "persons", "location": [16271, 16278], "entities": [{"type": "Person", "text": "persons"}]}, {"text": "who", "location": [16279, 16282], "entities": [{"type": "Person", "text": "who"}]}]}, {"type": "colleague", "sentence": "Copies of these documents are also being sent to Shire Shareholders today.", "score": 0.273729, "arguments": [{"text": "Shire", "location": [1338, 1343], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Shareholders", "location": [1344, 1356], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "agentOf", "sentence": "In particular, the ability of persons who are not resident in the United Kingdom or Jersey to vote their Shire Shares with respect to the Scheme at the Court Meeting, to execute and deliver forms of proxy appointing another to vote at the Court Meeting on their behalf or to hold or vote Takeda Shares may be affected by the laws of the relevant jurisdiction in which they are located.", "score": 0.443929, "arguments": [{"text": "Court", "location": [16393, 16398], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [16399, 16406], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "partOf", "sentence": "In particular, the ability of persons who are not resident in the United Kingdom or Jersey to vote their Shire Shares with respect to the Scheme at the Court Meeting, to execute and deliver forms of proxy appointing another to vote at the Court Meeting on their behalf or to hold or vote Takeda Shares may be affected by the laws of the relevant jurisdiction in which they are located.", "score": 0.501381, "arguments": [{"text": "Meeting", "location": [16399, 16406], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}, {"text": "Meeting", "location": [16486, 16493], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "agentOf", "sentence": "In particular, the ability of persons who are not resident in the United Kingdom or Jersey to vote their Shire Shares with respect to the Scheme at the Court Meeting, to execute and deliver forms of proxy appointing another to vote at the Court Meeting on their behalf or to hold or vote Takeda Shares may be affected by the laws of the relevant jurisdiction in which they are located.", "score": 0.515965, "arguments": [{"text": "Court", "location": [16480, 16485], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [16486, 16493], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "affectedBy", "sentence": "Accordingly, copies of this Announcement and any formal documentation relating to the Acquisition are not being, and must not be, directly or indirectly, mailed, transmitted or otherwise forwarded, distributed or sent in, into or from a Restricted Jurisdiction, where to do so would violate the laws in that jurisdiction, and persons receiving this Announcement and all documents relating to the Acquisition (including custodians, nominees and trustees) must not mail or otherwise distribute or send them in, into or from Restricted Jurisdictions, where to do so would violate the laws in that jurisdiction.", "score": 0.484298, "arguments": [{"text": "persons", "location": [18212, 18219], "entities": [{"type": "Person", "text": "persons"}]}, {"text": "Announcement", "location": [18235, 18247], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "colleague", "sentence": "The availability of the New Takeda Securities under the Acquisition to Shire Shareholders who are not resident in the United Kingdom or Jersey, or the ability of those persons to continue to hold such securities, may be affected by the laws or regulatory requirements of the relevant jurisdiction in which they are resident.", "score": 0.340474, "arguments": [{"text": "Shire", "location": [19166, 19171], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Shareholders", "location": [19172, 19184], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "partOfMany", "sentence": "The availability of the New Takeda Securities under the Acquisition to Shire Shareholders who are not resident in the United Kingdom or Jersey, or the ability of those persons to continue to hold such securities, may be affected by the laws or regulatory requirements of the relevant jurisdiction in which they are resident.", "score": 0.531789, "arguments": [{"text": "Shareholders", "location": [19172, 19184], "entities": [{"type": "Person", "text": "Shareholders"}]}, {"text": "who", "location": [19185, 19188], "entities": [{"type": "Person", "text": "who"}]}]}, {"type": "locatedAt", "sentence": "The availability of the New Takeda Securities under the Acquisition to Shire Shareholders who are not resident in the United Kingdom or Jersey, or the ability of those persons to continue to hold such securities, may be affected by the laws or regulatory requirements of the relevant jurisdiction in which they are resident.", "score": 0.408097, "arguments": [{"text": "who", "location": [19185, 19188], "entities": [{"type": "Person", "text": "who"}]}, {"text": "United Kingdom", "location": [19213, 19227], "entities": [{"type": "GeopoliticalEntity", "text": "United Kingdom"}]}]}, {"type": "agentOf", "sentence": "Persons into whose possession this Announcement comes who are not resident in the United Kingdom should inform themselves of, and observe, any applicable requirements.", "score": 0.850205, "arguments": [{"text": "whose", "location": [19433, 19438], "entities": [{"type": "Person", "text": "whose"}]}, {"text": "Announcement", "location": [19455, 19467], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "locatedAt", "sentence": "Persons into whose possession this Announcement comes who are not resident in the United Kingdom should inform themselves of, and observe, any applicable requirements.", "score": 0.509874, "arguments": [{"text": "who", "location": [19474, 19477], "entities": [{"type": "Person", "text": "who"}]}, {"text": "United Kingdom", "location": [19502, 19516], "entities": [{"type": "GeopoliticalEntity", "text": "United Kingdom"}]}]}, {"type": "affectedBy", "sentence": "Persons into whose possession this Announcement comes who are not resident in the United Kingdom should inform themselves of, and observe, any applicable requirements.", "score": 0.825248, "arguments": [{"text": "themselves", "location": [19531, 19541], "entities": [{"type": "Person", "text": "themselves"}]}, {"text": "inform", "location": [19524, 19530], "entities": [{"type": "EventCommunication", "text": "inform"}]}]}], "keywords": [{"text": "shire", "sentiment": {"score": 0.0578591, "label": "positive"}, "relevance": 0.959091}, {"text": "Shire Shareholders", "sentiment": {"score": 0.286585, "label": "positive"}, "relevance": 0.773835}, {"text": "Shire ADS Holders", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.671792}, {"text": "takeda", "sentiment": {"score": -0.167013, "label": "negative"}, "relevance": 0.592117}, {"text": "Shire General Meeting", "sentiment": {"score": -0.26658, "label": "negative"}, "relevance": 0.590201}, {"text": "New Takeda", "sentiment": {"score": -0.537141, "label": "negative"}, "relevance": 0.582136}, {"text": "scheme document", "sentiment": {"score": 0.627751, "label": "positive"}, "relevance": 0.490084}, {"text": "New Takeda ADSs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.48488}, {"text": "Court Meeting", "sentiment": {"score": 0.0221322, "label": "positive"}, "relevance": 0.438978}, {"text": "announcement", "sentiment": {"score": 0.140202, "label": "positive"}, "relevance": 0.43783}, {"text": "United Kingdom", "sentiment": {"score": 0.851582, "label": "positive"}, "relevance": 0.421839}, {"text": "Shire Shares", "sentiment": {"score": -0.665719, "label": "negative"}, "relevance": 0.408454}, {"text": "acquisition", "sentiment": {"score": 0.0897102, "label": "positive"}, "relevance": 0.386038}, {"text": "Prudential Regulation Authority", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.376479}, {"text": "Shire Depositary", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.375134}, {"text": "New Takeda Shares", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.371285}, {"text": "New Takeda Securities", "sentiment": {"score": -0.537141, "label": "negative"}, "relevance": 0.362647}, {"text": "financial adviser", "sentiment": {"score": 0.117462, "label": "positive"}, "relevance": 0.360214}, {"text": "New York time", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.358509}, {"text": "securities exchange offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.322266}, {"text": "London Stock Exchange", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.310496}, {"text": "Financial Conduct Authority", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.298515}, {"text": "Shire ADSs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.294769}, {"text": "Takeda Extraordinary General", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.292765}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.265806}, {"text": "Effective Date", "sentiment": {"score": 0.310133, "label": "positive"}, "relevance": 0.264725}, {"text": "relevant adjourned Shire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.264332}, {"text": "Shire website", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.262786}, {"text": "shire plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.262117}, {"text": "Shire Shareholder", "sentiment": {"score": 0.745078, "label": "positive"}, "relevance": 0.261957}, {"text": "joint financial adviser", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.261842}, {"text": "London time", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.261119}, {"text": "uncertificated Shire ADSs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.260854}, {"text": "Shire Shareholder opinion", "sentiment": {"score": 0.745078, "label": "positive"}, "relevance": 0.25886}, {"text": "takeda pharmaceutical company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.254535}, {"text": "Shire Meeting", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.254259}, {"text": "Shire ADS certificate", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.24606}, {"text": "Shire ADS certificates", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.244293}, {"text": "Opening Position Disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.238401}, {"text": "securities laws", "sentiment": {"score": -0.640674, "label": "negative"}, "relevance": 0.238352}, {"text": "forward-looking statements", "sentiment": {"score": -0.283325, "label": "negative"}, "relevance": 0.23544}, {"text": "Extraordinary General Meeting", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.233363}, {"text": "Shire Depositary.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.232832}, {"text": "offeree company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.230536}, {"text": "Shire Meetings", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.226892}, {"text": "SHIRE LEI", "sentiment": {"score": 0.398037, "label": "positive"}, "relevance": 0.222588}, {"text": "relevant securities", "sentiment": {"score": 0.619135, "label": "positive"}, "relevance": 0.22039}, {"text": "Takeover Offer", "sentiment": {"score": 0.426556, "label": "positive"}, "relevance": 0.218769}]}, "extracted_metadata": {"sha1": "9b9bd0c82553fcb80a7ade47602c8f5b4bdad60e", "filename": "1542007848498.zip-933aef350035d0166f27997b2f6bac26.xml", "file_type": "json"}, "title": "Shire plc: Publication of Scheme Document", "forum_title": "FinanzNachrichten.de: News"}, {"id": "1AHKlg8cpD2jxctl6_DhLZGZCTZbMnUZQFxpSB0AmDmXc_NIV8y3hBS5hCgwxXsz", "result_metadata": {"score": 31.725101}, "author": "Mrudula.k", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pantoprazole", "relevance": 0.33, "type": "Drug"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Stock market", "relevance": 0.919435, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "Pantoprazole", "relevance": 0.852144, "dbpedia_resource": "http://dbpedia.org/resource/Pantoprazole"}], "categories": [{"score": 0.504572, "label": "/business and industrial/paper industry"}, {"score": 0.497714, "label": "/finance/investing"}, {"score": 0.497714, "label": "/finance/investing/beginning investing"}], "relations": [], "keywords": [{"text": "Annual Growth Rate", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.961082}, {"text": "Pantoprazole Sodium", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.790855}, {"text": "Future Prospects", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.700555}, {"text": "Industry Share", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.570098}, {"text": "Market Growth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.534178}, {"text": "Cas", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.471317}]}, "crawl_date": "2018-11-12T00:22:16Z", "url": "https://www.military-technologies.net/2018/11/11/pantoprazole-sodium-cas-138786-67-1-market-growth-by-industry-share-annual-growth-rate-and-future-prospects-2023/", "host": "military-technologies.net", "text": ",Pfizer ,Takeda GmbH ,Teva Pharmaceutical ,Liaoning Nirvana Pharmaceutical ,Hubei Weisen Pharmaceutical ,Dr.", "country": "PL", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-11T20:55:00Z", "enriched_text": {"entities": [{"count": 19, "sentiment": {"score": -0.301655, "label": "negative"}, "text": "Pantoprazole", "relevance": 0.793464, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Industrial Chain Analysis", "relevance": 0.225624, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Key Manufactures", "relevance": 0.212097, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mreeo Pharmaceutical", "relevance": 0.202633, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.197857, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Hubei Weisen Pharmaceutical", "relevance": 0.197845, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teva Pharmaceutical", "relevance": 0.193574, "type": "Company", "disambiguation": {"subtype": [], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"count": 1, "sentiment": {"score": 0.325171, "label": "positive"}, "text": "South America", "relevance": 0.19064, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "South America", "dbpedia_resource": "http://dbpedia.org/resource/South_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shandong Renhetang Pharmaceutical", "relevance": 0.184583, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.18378, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.182139, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0.268531, "label": "positive"}, "text": "Liaoning Nirvana Pharmaceutical", "relevance": 0.180357, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Reddys Laboratories", "relevance": 0.179782, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.350129, "label": "positive"}, "text": "China", "relevance": 0.174991, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Luye Pharma Group", "relevance": 0.171273, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.166669, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "India", "relevance": 0.165698, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Lee Pharma Ltd.", "relevance": 0.157488, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer", "relevance": 0.15193, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.150458, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda GmbH", "relevance": 0.139865, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "5 years", "relevance": 0.139865, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$ 2960", "relevance": 0.139865, "type": "Quantity"}], "sentiment": {"document": {"score": 0.606782, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "this report", "keywords": [{"text": "report"}]}, "sentence": " Based on the industrial chain, this report primarily elaborates the definition, types, applications and major players of Pantoprazole Sodium (Cas 138786-67-1) market in details.", "object": {"text": "on the industrial chain", "keywords": [{"text": "industrial chain"}]}, "action": {"verb": {"text": "Based", "tense": "past"}, "text": "Based", "normalized": "Based"}}, {"subject": {"text": "this report", "keywords": [{"text": "report"}]}, "sentence": " Based on the industrial chain, this report primarily elaborates the definition, types, applications and major players of Pantoprazole Sodium (Cas 138786-67-1) market in details.", "object": {"text": "the definition, types, applications and major players of Pantoprazole Sodium (Cas 138786-67-1) market in details", "keywords": [{"text": "Pantoprazole Sodium"}, {"text": "major players"}, {"text": "Cas"}, {"text": "definition"}], "entities": [{"type": "Drug", "text": "Pantoprazole"}]}, "action": {"verb": {"text": "elaborate", "tense": "present"}, "text": "elaborates", "normalized": "elaborate"}}, {"subject": {"text": "Profound analysis", "keywords": [{"text": "Profound analysis"}]}, "sentence": " Profound analysis regarding Pantoprazole Sodium (Cas 138786-67-1) market status (2013-2018), enterprise competition outline, benefits and drawbacks of enterprise product, trade development trends (2018-2023), regional industrial layout characteristics and economics policies, industrial policy has additionally been enclosed.", "object": {"text": "Pantoprazole Sodium (Cas 138786-67-1) market status", "keywords": [{"text": "Pantoprazole Sodium"}, {"text": "Cas"}, {"text": "market status"}], "entities": [{"type": "Drug", "text": "Pantoprazole"}]}, "action": {"verb": {"text": "regard", "tense": "present"}, "text": "regarding", "normalized": "regard"}}, {"subject": {"text": "industrial policy", "keywords": [{"text": "industrial policy"}]}, "sentence": " Profound analysis regarding Pantoprazole Sodium (Cas 138786-67-1) market status (2013-2018), enterprise competition outline, benefits and drawbacks of enterprise product, trade development trends (2018-2023), regional industrial layout characteristics and economics policies, industrial policy has additionally been enclosed.", "object": {"text": "enclosed"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "From raw materials to downstream buyers of this industry", "keywords": [{"text": "downstream buyers"}, {"text": "raw materials"}, {"text": "industry"}]}, "sentence": " From raw materials to downstream buyers of this industry are analysed scientifically, the feature of product circulation and sales channel are given as well.", "object": {"text": "analysed scientifically"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "this Pantoprazole Sodium (Cas 138786-67-1) report", "keywords": [{"text": "Pantoprazole Sodium"}, {"text": "Cas"}, {"text": "report"}], "entities": [{"type": "Drug", "text": "Pantoprazole"}]}, "sentence": " In a word, this Pantoprazole Sodium (Cas 138786-67-1) report can assist you to determine a panorama of commercial development and characteristics of the Pantoprazole Sodium (Cas 138786-67-1) market.", "object": {"text": "you"}, "action": {"verb": {"text": "assist", "tense": "future"}, "text": "can assist", "normalized": "can assist"}}, {"subject": {"text": "you"}, "sentence": " In a word, this Pantoprazole Sodium (Cas 138786-67-1) report can assist you to determine a panorama of commercial development and characteristics of the Pantoprazole Sodium (Cas 138786-67-1) market.", "object": {"text": "a panorama of commercial development and characteristics of the Pantoprazole Sodium (Cas 138786-67-1) market", "keywords": [{"text": "Pantoprazole Sodium"}, {"text": "commercial development"}, {"text": "panorama"}, {"text": "Cas"}], "entities": [{"type": "Drug", "text": "Pantoprazole"}]}, "action": {"verb": {"text": "determine", "tense": "future"}, "text": "to determine", "normalized": "to determine"}}, {"subject": {"text": "The Pantoprazole Sodium (Cas 138786-67-1) market revenue", "keywords": [{"text": "Pantoprazole Sodium"}, {"text": "market revenue"}, {"text": "Cas"}], "entities": [{"type": "Drug", "text": "Pantoprazole"}]}, "sentence": " The Pantoprazole Sodium (Cas 138786-67-1) market revenue was xx.xx Million USD in 2013, grew to xx.xx Million USD in 2017, and will reach xx.xx Million USD in 2023, with a CAGR of x.x% during 2018-2023.", "object": {"text": "xx.xx Million USD", "keywords": [{"text": "USD"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Million USD", "keywords": [{"text": "USD"}]}, "sentence": " The Pantoprazole Sodium (Cas 138786-67-1) market revenue was xx.xx Million USD in 2013, grew to xx.xx Million USD in 2017, and will reach xx.xx Million USD in 2023, with a CAGR of x.x% during 2018-2023.", "action": {"verb": {"text": "xx.xx", "tense": "future"}, "text": "grew to xx.xx", "normalized": "grow to xx.xx"}}, {"subject": {"text": "xx.xx Million USD", "keywords": [{"text": "USD"}]}, "sentence": " The Pantoprazole Sodium (Cas 138786-67-1) market revenue was xx.xx Million USD in 2013, grew to xx.xx Million USD in 2017, and will reach xx.xx Million USD in 2023, with a CAGR of x.x% during 2018-2023.", "action": {"verb": {"text": "reach", "tense": "future"}, "text": "will reach", "normalized": "will reach"}}, {"subject": {"text": "Most important Regions", "keywords": [{"text": "Regions"}]}, "sentence": " Most important Regions play dynamic role in Pantoprazole Sodium (Cas 138786-67-1) market are: North America, Europe, China, Japan, Middle East & Africa, India, South America, Others", "object": {"text": "dynamic role", "keywords": [{"text": "dynamic role"}]}, "action": {"verb": {"text": "play", "tense": "present"}, "text": "play", "normalized": "play"}}, {"subject": {"text": "Research report", "keywords": [{"text": "Research report"}]}, "sentence": " Research report contains data about following major players in Pantoprazole Sodium (Cas 138786-67-1) market : Mreeo Pharmaceutical ,Lee Pharma Ltd. ,Pfizer ,Takeda GmbH ,Teva Pharmaceutical ,Liaoning Nirvana Pharmaceutical ,Hubei Weisen Pharmaceutical ,Dr.", "object": {"text": "data about following major players in Pantoprazole Sodium (Cas 138786-67-1) market : Mreeo Pharmaceutical ,Lee Pharma Ltd. ,Pfizer ,Takeda GmbH ,Teva Pharmaceutical ,Liaoning Nirvana Pharmaceutical ,Hubei Weisen Pharmaceutical ,Dr", "keywords": [{"text": "Hubei Weisen Pharmaceutical"}, {"text": "Liaoning Nirvana Pharmaceutical"}, {"text": "Lee Pharma Ltd."}, {"text": "Takeda GmbH"}], "entities": [{"type": "Drug", "text": "Pantoprazole"}, {"type": "Company", "text": "Mreeo Pharmaceutical"}, {"type": "Company", "text": "Lee Pharma Ltd."}, {"type": "Company", "text": "Pfizer", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "Takeda GmbH"}, {"type": "Company", "text": "Teva Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"type": "Company", "text": "Liaoning Nirvana Pharmaceutical"}, {"type": "Company", "text": "Hubei Weisen Pharmaceutical"}]}, "action": {"verb": {"text": "contain", "tense": "present"}, "text": "contains", "normalized": "contain"}}, {"subject": {"text": "data", "keywords": [{"text": "data"}]}, "sentence": " Research report contains data about following major players in Pantoprazole Sodium (Cas 138786-67-1) market : Mreeo Pharmaceutical ,Lee Pharma Ltd. ,Pfizer ,Takeda GmbH ,Teva Pharmaceutical ,Liaoning Nirvana Pharmaceutical ,Hubei Weisen Pharmaceutical ,Dr.", "object": {"text": "major players in Pantoprazole Sodium (Cas 138786-67-1) market : Mreeo Pharmaceutical ,Lee Pharma Ltd. ,Pfizer ,Takeda GmbH ,Teva Pharmaceutical ,Liaoning Nirvana Pharmaceutical ,Hubei Weisen Pharmaceutical ,Dr", "keywords": [{"text": "Hubei Weisen Pharmaceutical"}, {"text": "Liaoning Nirvana Pharmaceutical"}, {"text": "Lee Pharma Ltd."}, {"text": "Takeda GmbH"}], "entities": [{"type": "Drug", "text": "Pantoprazole"}, {"type": "Company", "text": "Mreeo Pharmaceutical"}, {"type": "Company", "text": "Lee Pharma Ltd."}, {"type": "Company", "text": "Pfizer", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "Takeda GmbH"}, {"type": "Company", "text": "Teva Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"type": "Company", "text": "Liaoning Nirvana Pharmaceutical"}, {"type": "Company", "text": "Hubei Weisen Pharmaceutical"}]}, "action": {"verb": {"text": "follow", "tense": "present"}, "text": "following", "normalized": "follow"}}, {"subject": {"text": "Pantoprazole Sodium (Cas 138786-67-1) Market report", "keywords": [{"text": "Pantoprazole Sodium"}, {"text": "Cas"}, {"text": "Market report"}], "entities": [{"type": "Drug", "text": "Pantoprazole"}]}, "sentence": " Pantoprazole Sodium (Cas 138786-67-1) Market report offers insights of industrial Chain, Major Player\u2019s Market Share and Upstream raw materials suppliers concerned in Pantoprazole Sodium (Cas 138786-67-1) Market based on Industrial Chain Analysis, Production process Analysis, Labour cost, raw material value price Structure of Pantoprazole Sodium (Cas 138786-67-1), supply of Raw Materials for Major manufacturers present in Pantoprazole Sodium (Cas 138786-67-1) trade until 2017 and Downstream patrons.", "object": {"text": "insights of industrial Chain, Major Player\u2019s Market Share and Upstream raw materials suppliers concerned in Pantoprazole Sodium (Cas 138786-67-1) Market based on Industrial Chain Analysis, Production process Analysis, Labour cost, raw material value price Structure of Pantoprazole Sodium (Cas 138786-67-1), supply of Raw Materials for Major manufacturers present in Pantoprazole Sodium (Cas 138786-67-1) trade until 2017 and Downstream patrons", "keywords": [{"text": "Pantoprazole Sodium"}, {"text": "Upstream raw materials"}, {"text": "material value price"}, {"text": "Production process Analysis"}], "entities": [{"type": "Drug", "text": "Pantoprazole"}, {"type": "Company", "text": "Industrial Chain Analysis"}, {"type": "Drug", "text": "Pantoprazole"}, {"type": "Drug", "text": "Pantoprazole"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "in Pantoprazole Sodium (Cas 138786-67-1) Market based on Industrial Chain Analysis", "keywords": [{"text": "Industrial Chain Analysis"}, {"text": "Pantoprazole Sodium"}, {"text": "Cas"}, {"text": "Market"}], "entities": [{"type": "Drug", "text": "Pantoprazole"}, {"type": "Company", "text": "Industrial Chain Analysis"}]}, "sentence": " Pantoprazole Sodium (Cas 138786-67-1) Market report offers insights of industrial Chain, Major Player\u2019s Market Share and Upstream raw materials suppliers concerned in Pantoprazole Sodium (Cas 138786-67-1) Market based on Industrial Chain Analysis, Production process Analysis, Labour cost, raw material value price Structure of Pantoprazole Sodium (Cas 138786-67-1), supply of Raw Materials for Major manufacturers present in Pantoprazole Sodium (Cas 138786-67-1) trade until 2017 and Downstream patrons.", "object": {"text": "raw materials suppliers", "keywords": [{"text": "raw materials suppliers"}]}, "action": {"verb": {"text": "concern", "tense": "past"}, "text": "concerned", "normalized": "concern"}}, {"subject": {"text": "supply of Raw Materials for Major manufacturers", "keywords": [{"text": "Raw Materials"}, {"text": "Major manufacturers"}, {"text": "supply"}]}, "sentence": " Pantoprazole Sodium (Cas 138786-67-1) Market report offers insights of industrial Chain, Major Player\u2019s Market Share and Upstream raw materials suppliers concerned in Pantoprazole Sodium (Cas 138786-67-1) Market based on Industrial Chain Analysis, Production process Analysis, Labour cost, raw material value price Structure of Pantoprazole Sodium (Cas 138786-67-1), supply of Raw Materials for Major manufacturers present in Pantoprazole Sodium (Cas 138786-67-1) trade until 2017 and Downstream patrons.", "action": {"verb": {"text": "present", "tense": "present"}, "text": "present", "normalized": "present"}}, {"subject": {"text": "This report", "keywords": [{"text": "report"}]}, "sentence": " This report offers Pantoprazole Sodium (Cas 138786-67-1) market research and Forecast considering Pantoprazole Sodium (Cas 138786-67-1) market price and Volume by type, applications and Regions for next 5 years.", "object": {"text": "Pantoprazole Sodium (Cas 138786-67-1) market research", "keywords": [{"text": "Pantoprazole Sodium"}, {"text": "Cas"}, {"text": "market research"}], "entities": [{"type": "Drug", "text": "Pantoprazole"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "The Pantoprazole Sodium (Cas 138786-67-1) market report", "keywords": [{"text": "Pantoprazole Sodium"}, {"text": "Cas"}, {"text": "market report"}], "entities": [{"type": "Drug", "text": "Pantoprazole"}]}, "sentence": " The Pantoprazole Sodium (Cas 138786-67-1) market report additionally provides New Project feasibility Analysis, trade Barriers, New Entrants SWOT Analysis and Suggestions on New Project Investment in Pantoprazole Sodium (Cas 138786-67-1) Market.", "object": {"text": "New Project", "keywords": [{"text": "New Project"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}], "concepts": [{"text": "Marketing", "relevance": 0.989416, "dbpedia_resource": "http://dbpedia.org/resource/Marketing"}, {"text": "Material", "relevance": 0.701323, "dbpedia_resource": "http://dbpedia.org/resource/Material"}, {"text": "Strategic management", "relevance": 0.661158, "dbpedia_resource": "http://dbpedia.org/resource/Strategic_management"}, {"text": "Market research", "relevance": 0.614094, "dbpedia_resource": "http://dbpedia.org/resource/Market_research"}, {"text": "Raw material", "relevance": 0.587363, "dbpedia_resource": "http://dbpedia.org/resource/Raw_material"}, {"text": "Trade", "relevance": 0.563725, "dbpedia_resource": "http://dbpedia.org/resource/Trade"}, {"text": "Materials", "relevance": 0.562967, "dbpedia_resource": "http://dbpedia.org/resource/Materials"}, {"text": "Pantoprazole", "relevance": 0.483748, "dbpedia_resource": "http://dbpedia.org/resource/Pantoprazole"}, {"text": "United States dollar", "relevance": 0.482542, "dbpedia_resource": "http://dbpedia.org/resource/United_States_dollar"}, {"text": "SWOT analysis", "relevance": 0.48143, "dbpedia_resource": "http://dbpedia.org/resource/SWOT_analysis"}, {"text": "Pharmacology", "relevance": 0.472664, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}], "categories": [{"score": 0.593786, "label": "/business and industrial/business operations/management/business process"}, {"score": 0.466738, "label": "/finance/financial news"}, {"score": 0.438711, "label": "/technology and computing/enterprise technology"}], "relations": [{"type": "locatedAt", "sentence": "- by Mrudula.k The Pantoprazole Sodium (Cas 138786-67-1) Market divided based on Key Manufactures, product types, major applications, and important regions.", "score": 0.474726, "arguments": [{"text": "Mrudula.k\nThe Pantoprazole Sodium", "location": [5, 38], "entities": [{"type": "Organization", "text": "Mrudula.k\nThe Pantoprazole Sodium"}]}, {"text": "Market", "location": [57, 63], "entities": [{"type": "Facility", "text": "Market Report"}]}]}, {"type": "locatedAt", "sentence": "- by Mrudula.k The Pantoprazole Sodium (Cas 138786-67-1) Market divided based on Key Manufactures, product types, major applications, and important regions.", "score": 0.415061, "arguments": [{"text": "Cas", "location": [40, 43], "entities": [{"type": "Organization", "text": "Mrudula.k\nThe Pantoprazole Sodium"}]}, {"text": "Market", "location": [57, 63], "entities": [{"type": "Facility", "text": "Market Report"}]}]}, {"type": "locatedAt", "sentence": "Get Sample of Pantoprazole Sodium (Cas 138786-67-1) Market Report at: https://www.industryresearch.co/enquiry/request-sample/12202883 Most important Regions play dynamic role in Pantoprazole Sodium (Cas 138786-67-1) market are: North America, Europe, China, Japan, Middle East & Africa, India, South America, Others Research report contains data about following major players in Pantoprazole Sodium (Cas 138786-67-1) market : Mreeo Pharmaceutical ,Lee Pharma Ltd. ,Pfizer ,Takeda GmbH ,Teva Pharmaceutical ,Liaoning Nirvana Pharmaceutical ,Hubei Weisen Pharmaceutical ,Dr. Reddys Laboratories ,Shandong Renhetang Pharmaceutical ,Luye Pharma Group .", "score": 0.485352, "arguments": [{"text": "Pantoprazole Sodium", "location": [1235, 1254], "entities": [{"type": "Organization", "text": "Mrudula.k\nThe Pantoprazole Sodium"}]}, {"text": "Market Report", "location": [1273, 1286], "entities": [{"type": "Facility", "text": "Market Report"}]}]}, {"type": "locatedAt", "sentence": "Get Sample of Pantoprazole Sodium (Cas 138786-67-1) Market Report at: https://www.industryresearch.co/enquiry/request-sample/12202883 Most important Regions play dynamic role in Pantoprazole Sodium (Cas 138786-67-1) market are: North America, Europe, China, Japan, Middle East & Africa, India, South America, Others Research report contains data about following major players in Pantoprazole Sodium (Cas 138786-67-1) market : Mreeo Pharmaceutical ,Lee Pharma Ltd. ,Pfizer ,Takeda GmbH ,Teva Pharmaceutical ,Liaoning Nirvana Pharmaceutical ,Hubei Weisen Pharmaceutical ,Dr. Reddys Laboratories ,Shandong Renhetang Pharmaceutical ,Luye Pharma Group .", "score": 0.605828, "arguments": [{"text": "Cas", "location": [1256, 1259], "entities": [{"type": "Organization", "text": "Mrudula.k\nThe Pantoprazole Sodium"}]}, {"text": "Market Report", "location": [1273, 1286], "entities": [{"type": "Facility", "text": "Market Report"}]}]}, {"type": "locatedAt", "sentence": "- by Mrudula.k The Pantoprazole Sodium (Cas 138786-67-1) Market divided based on Key Manufactures, product types, major applications, and important regions.", "score": 0.556561, "arguments": [{"text": "Market", "location": [57, 63], "entities": [{"type": "Facility", "text": "Market Report"}]}, {"text": "regions", "location": [148, 155], "entities": [{"type": "Location", "text": "regions"}]}]}, {"type": "locatedAt", "sentence": "Get Sample of Pantoprazole Sodium (Cas 138786-67-1) Market Report at: https://www.industryresearch.co/enquiry/request-sample/12202883 Most important Regions play dynamic role in Pantoprazole Sodium (Cas 138786-67-1) market are: North America, Europe, China, Japan, Middle East & Africa, India, South America, Others Research report contains data about following major players in Pantoprazole Sodium (Cas 138786-67-1) market : Mreeo Pharmaceutical ,Lee Pharma Ltd. ,Pfizer ,Takeda GmbH ,Teva Pharmaceutical ,Liaoning Nirvana Pharmaceutical ,Hubei Weisen Pharmaceutical ,Dr. Reddys Laboratories ,Shandong Renhetang Pharmaceutical ,Luye Pharma Group .", "score": 0.829186, "arguments": [{"text": "Market Report", "location": [1273, 1286], "entities": [{"type": "Facility", "text": "Market Report"}]}, {"text": "Regions", "location": [1370, 1377], "entities": [{"type": "Location", "text": "regions"}]}]}, {"type": "locatedAt", "sentence": "Get Sample of Pantoprazole Sodium (Cas 138786-67-1) Market Report at: https://www.industryresearch.co/enquiry/request-sample/12202883 Most important Regions play dynamic role in Pantoprazole Sodium (Cas 138786-67-1) market are: North America, Europe, China, Japan, Middle East & Africa, India, South America, Others Research report contains data about following major players in Pantoprazole Sodium (Cas 138786-67-1) market : Mreeo Pharmaceutical ,Lee Pharma Ltd. ,Pfizer ,Takeda GmbH ,Teva Pharmaceutical ,Liaoning Nirvana Pharmaceutical ,Hubei Weisen Pharmaceutical ,Dr. Reddys Laboratories ,Shandong Renhetang Pharmaceutical ,Luye Pharma Group .", "score": 0.502591, "arguments": [{"text": "Japan", "location": [1479, 1484], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "Middle East", "location": [1486, 1497], "entities": [{"type": "GeopoliticalEntity", "text": "Middle East"}]}]}, {"type": "residesIn", "sentence": "dynamics123 Ask for pre-order Enquiry of Pantoprazole Sodium (Cas 138786-67-1) in Full Report at: https://www.industryresearch.co/enquiry/pre-order-enquiry/12202883 Pantoprazole Sodium (Cas 138786-67-1) Market report offers insights of industrial Chain, Major Player's Market Share and Upstream raw materials suppliers concerned in Pantoprazole Sodium (Cas 138786-67-1) Market based on Industrial Chain Analysis, Production process Analysis, Labour cost, raw material value price Structure of Pantoprazole Sodium (Cas 138786-67-1), supply of Raw Materials for Major manufacturers present in Pantoprazole Sodium (Cas 138786-67-1) trade until 2017 and Downstream patrons.", "score": 0.23545, "arguments": [{"text": "Player", "location": [2130, 2136], "entities": [{"type": "Person", "text": "Player"}]}, {"text": "Market", "location": [2139, 2145], "entities": [{"type": "Facility", "text": "Market Report"}]}]}, {"type": "partOfMany", "sentence": "dynamics123 Ask for pre-order Enquiry of Pantoprazole Sodium (Cas 138786-67-1) in Full Report at: https://www.industryresearch.co/enquiry/pre-order-enquiry/12202883 Pantoprazole Sodium (Cas 138786-67-1) Market report offers insights of industrial Chain, Major Player's Market Share and Upstream raw materials suppliers concerned in Pantoprazole Sodium (Cas 138786-67-1) Market based on Industrial Chain Analysis, Production process Analysis, Labour cost, raw material value price Structure of Pantoprazole Sodium (Cas 138786-67-1), supply of Raw Materials for Major manufacturers present in Pantoprazole Sodium (Cas 138786-67-1) trade until 2017 and Downstream patrons.", "score": 0.320947, "arguments": [{"text": "Pantoprazole Sodium", "location": [2461, 2480], "entities": [{"type": "Organization", "text": "Mrudula.k\nThe Pantoprazole Sodium"}]}, {"text": "manufacturers", "location": [2436, 2449], "entities": [{"type": "Organization", "text": "manufacturers", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "This report offers Pantoprazole Sodium (Cas 138786-67-1) market research and Forecast considering Pantoprazole Sodium (Cas 138786-67-1) market price and Volume by type, applications and Regions for next 5 years.", "score": 0.397399, "arguments": [{"text": "Volume", "location": [2693, 2699], "entities": [{"type": "Person", "text": "Volume"}]}, {"text": "Regions", "location": [2726, 2733], "entities": [{"type": "Location", "text": "regions"}]}]}, {"type": "ownerOf", "sentence": "The Pantoprazole Sodium (Cas 138786-67-1) market report additionally provides New Project feasibility Analysis, trade Barriers, New Entrants SWOT Analysis and Suggestions on New Project Investment in Pantoprazole Sodium (Cas 138786-67-1) Market.", "score": 0.519074, "arguments": [{"text": "Cas", "location": [2973, 2976], "entities": [{"type": "Organization", "text": "Mrudula.k\nThe Pantoprazole Sodium"}]}, {"text": "Market", "location": [2990, 2996], "entities": [{"type": "Facility", "text": "Market Report"}]}]}, {"type": "agentOf", "sentence": "Report Price: $ 2960 (Single-User License) To Purchase Complete Pantoprazole Sodium (Cas 138786-67-1) Market Report, Click Here: https://www.industryresearch.co/purchase/12202883 Post Views: 48 Post navigation", "score": 0.548286, "arguments": [{"text": "License", "location": [3032, 3039], "entities": [{"type": "Person", "text": "License"}]}, {"text": "Report", "location": [3107, 3113], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "timeOf", "sentence": "Report Price: $ 2960 (Single-User License) To Purchase Complete Pantoprazole Sodium (Cas 138786-67-1) Market Report, Click Here: https://www.industryresearch.co/purchase/12202883 Post Views: 48 Post navigation", "score": 0.743967, "arguments": [{"text": "138786-67-1", "location": [3087, 3098], "entities": [{"type": "Date", "text": "138786-67-1"}]}, {"text": "Report", "location": [3107, 3113], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}], "keywords": [{"text": "Pantoprazole Sodium", "sentiment": {"score": -0.301655, "label": "negative"}, "relevance": 0.900142}, {"text": "Cas", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.646156}, {"text": "Complete Pantoprazole Sodium", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509844}, {"text": "market report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.427465}, {"text": "industrial chain", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.413289}, {"text": "raw materials", "sentiment": {"score": -0.290745, "label": "negative"}, "relevance": 0.412852}, {"text": "Hubei Weisen Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.389275}, {"text": "major players", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.387805}, {"text": "regional industrial layout", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.387534}, {"text": "Liaoning Nirvana Pharmaceutical", "sentiment": {"score": 0.268531, "label": "positive"}, "relevance": 0.385331}, {"text": "trade development trends", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.384799}, {"text": "enterprise competition outline", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.384028}, {"text": "Industrial Chain Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.383503}, {"text": "Lee Pharma Ltd.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.383326}, {"text": "Luye Pharma Group", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.382229}, {"text": "Entrants SWOT Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.381401}, {"text": "Upstream raw materials", "sentiment": {"score": -0.290745, "label": "negative"}, "relevance": 0.379437}, {"text": "Production process Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.379252}, {"text": "raw material value", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.377775}, {"text": "Project feasibility Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.375623}, {"text": "New Project Investment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.373639}, {"text": "market status", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.366518}, {"text": "market revenue", "sentiment": {"score": -0.27656, "label": "negative"}, "relevance": 0.362563}, {"text": "Player\u2019s Market", "sentiment": {"score": -0.290745, "label": "negative"}, "relevance": 0.358573}, {"text": "market price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.357715}, {"text": "Million USD", "sentiment": {"score": -0.27656, "label": "negative"}, "relevance": 0.35752}, {"text": "market research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.356984}, {"text": "major applications", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.355901}, {"text": "Research report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.35393}, {"text": "Report Price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.35227}, {"text": "product types", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.351664}, {"text": "Profound analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.351578}, {"text": "important regions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.351483}, {"text": "Key Manufactures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.350852}, {"text": "industrial policy", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.350627}, {"text": "Teva Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.349779}, {"text": "downstream buyers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.349016}, {"text": "enterprise product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.347804}, {"text": "economics policies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.346849}, {"text": "Mreeo Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.346821}, {"text": "product circulation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.346714}, {"text": "sales channel", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.346257}, {"text": "commercial development", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.345565}, {"text": "Downstream patrons", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.345276}, {"text": "Takeda GmbH", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.345276}, {"text": "pre-order Enquiry", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.344401}, {"text": "Major manufacturers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.344358}, {"text": "dynamic role", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.34409}, {"text": "Shandong Renhetang", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.343889}, {"text": "Middle East", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.343858}]}, "extracted_metadata": {"sha1": "591f5954fc7561496c87539d62e83fa704e5e3a7", "filename": "1541982136955.zip-78cb114065904a523e26204f8a2c2800.xml", "file_type": "json"}, "external_links": ["https://www.industryresearch.co/12202883", "https://www.industryresearch.co/purchase/12202883", "https://www.industryresearch.co/enquiry/request-sample/12202883", "https://www.industryresearch.co/enquiry/pre-order-enquiry/12202883"], "title": "Pantoprazole Sodium (Cas 138786-67-1) Market Growth by Industry Share, Annual Growth Rate and Future Prospects 2023", "forum_title": "MilTech"}, {"id": "AV_8rSoHAgwN6F0q9ERcUFBC7evAgiLhIbEXWH8C-c_ALBmjuyLun1Duqce0orie", "result_metadata": {"score": 31.292288}, "author": "pr-inside.com", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.57195, "label": "/business and industrial/paper industry"}, {"score": 0.483633, "label": "/law, govt and politics/government/government contracting and procurement"}, {"score": 0.444154, "label": "/technology and computing/computer certification"}], "relations": [], "keywords": [{"text": "Scheme Document", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.910699}, {"text": "Publication", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.555014}]}, "crawl_date": "2018-11-12T12:41:12Z", "url": "http://www.pr-inside.com/publication-of-scheme-document-r4709759.htm", "host": "pr-inside.com", "text": "JPMorgan Securities Japan Co., Ltd., together with its affiliate J.P.", "main_image_url": "http://www.pr-inside.com/images/logos/pr-inside/logo_pr-inside_fb.png", "country": "AT", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-12T08:01:00+01:00", "enriched_text": {"entities": [{"count": 23, "sentiment": {"score": 0.34824, "label": "positive"}, "text": "Shire", "relevance": 0.836315, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 29, "sentiment": {"score": 0.357517, "label": "positive"}, "text": "Shire Shareholders", "relevance": 0.820599, "type": "Company"}, {"count": 17, "sentiment": {"score": -0.0723308, "label": "negative"}, "text": "Takeda", "relevance": 0.605806, "type": "Company"}, {"count": 14, "sentiment": {"score": -0.665719, "label": "negative"}, "text": "Shire Shares", "relevance": 0.551737, "type": "Company"}, {"count": 16, "sentiment": {"score": 0.303648, "label": "positive"}, "text": "Takeda", "relevance": 0.546722, "type": "Person"}, {"count": 12, "sentiment": {"score": -0.26658, "label": "negative"}, "text": "Shire General Meeting", "relevance": 0.534492, "type": "Organization"}, {"count": 8, "sentiment": {"score": 0.238306, "label": "positive"}, "text": "Shire", "relevance": 0.498333, "type": "Company"}, {"count": 9, "sentiment": {"score": 0.277075, "label": "positive"}, "text": "Shire ADS Holders", "relevance": 0.49803, "type": "Company"}, {"count": 13, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire Depositary", "relevance": 0.497404, "type": "Organization"}, {"count": 33, "sentiment": {"score": -0.336105, "label": "negative"}, "text": "US", "relevance": 0.468237, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 7, "sentiment": {"score": -0.200388, "label": "negative"}, "text": "Shire", "relevance": 0.462255, "type": "Person"}, {"count": 13, "sentiment": {"score": -0.358208, "label": "negative"}, "text": "Shire ADSs", "relevance": 0.440672, "type": "Company"}, {"count": 28, "sentiment": {"score": 0.310528, "label": "positive"}, "text": "Scheme", "relevance": 0.432337, "type": "Organization"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire PLC", "relevance": 0.42689, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 23, "sentiment": {"score": 0.851582, "label": "positive"}, "text": "United Kingdom", "relevance": 0.425463, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.380095, "type": "Organization"}, {"count": 17, "sentiment": {"score": -0.288879, "label": "negative"}, "text": "New Takeda ADSs", "relevance": 0.362097, "type": "Company"}, {"count": 6, "sentiment": {"score": -0.537141, "label": "negative"}, "text": "New Takeda Securities", "relevance": 0.360206, "type": "Company"}, {"count": 6, "sentiment": {"score": 0.296017, "label": "positive"}, "text": "New Takeda Shares", "relevance": 0.333205, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.317588, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0.745078, "label": "positive"}, "text": "Shire Shareholder", "relevance": 0.308466, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire Shareholder", "relevance": 0.292973, "type": "Organization"}, {"count": 7, "sentiment": {"score": 0.487038, "label": "positive"}, "text": "Court", "relevance": 0.291532, "type": "Organization", "disambiguation": {"subtype": ["Sport"], "name": "Volleyball", "dbpedia_resource": "http://dbpedia.org/resource/Volleyball"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire Depositary", "relevance": 0.287862, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Extraordinary General", "relevance": 0.278937, "type": "Organization"}, {"count": 12, "sentiment": {"score": 0, "label": "neutral"}, "text": "London", "relevance": 0.278821, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 5, "sentiment": {"score": 0, "label": "neutral"}, "text": "London Stock Exchange", "relevance": 0.253573, "type": "Company", "disambiguation": {"subtype": ["Location", "Facility", "TouristAttraction"], "name": "London Stock Exchange", "dbpedia_resource": "http://dbpedia.org/resource/London_Stock_Exchange"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Depositary", "relevance": 0.250461, "type": "Organization"}, {"count": 15, "sentiment": {"score": 0, "label": "neutral"}, "text": "New York", "relevance": 0.243866, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "New York, Lincolnshire", "dbpedia_resource": "http://dbpedia.org/resource/New_York,_Lincolnshire"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Extraordinary General Meeting.", "relevance": 0.234444, "type": "Organization"}, {"count": 4, "sentiment": {"score": 0.277075, "label": "positive"}, "text": "principal", "relevance": 0.228847, "type": "JobTitle"}, {"count": 8, "sentiment": {"score": 0.851582, "label": "positive"}, "text": "Jersey", "relevance": 0.226383, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 7, "sentiment": {"score": 0, "label": "neutral"}, "text": "Financial Conduct Authority", "relevance": 0.222946, "type": "Organization", "disambiguation": {"subtype": [], "name": "Financial Conduct Authority", "dbpedia_resource": "http://dbpedia.org/resource/Financial_Conduct_Authority"}}, {"count": 6, "sentiment": {"score": -0.559235, "label": "negative"}, "text": "Goldman Sachs International", "relevance": 0.214507, "type": "Company", "disambiguation": {"subtype": ["CompanyShareholder"], "name": "Goldman Sachs", "dbpedia_resource": "http://dbpedia.org/resource/Goldman_Sachs"}}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "SEC", "relevance": 0.204877, "type": "Organization"}, {"count": 5, "sentiment": {"score": -0.20128, "label": "negative"}, "text": "Nomura", "relevance": 0.200684, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.577097, "label": "positive"}, "text": "Morgan Stanley & Co", "relevance": 0.200424, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.200221, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Investor Relations", "relevance": 0.195503, "type": "JobTitle"}, {"count": 3, "sentiment": {"score": 0.472432, "label": "positive"}, "text": "Tokyo", "relevance": 0.192226, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 3, "sentiment": {"score": 0.442981, "label": "positive"}, "text": "European Commission", "relevance": 0.191454, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Securities and Exchange Commission", "relevance": 0.19122, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "U.S. Securities and Exchange Commission", "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}}, {"count": 10, "sentiment": {"score": 0, "label": "neutral"}, "text": "Prudential Regulation Authority", "relevance": 0.190279, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "J.P. Morgan Cazenove", "relevance": 0.189394, "type": "Person"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "solicitation", "relevance": 0.188876, "type": "Crime"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "International plc", "relevance": 0.188858, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Equiniti", "relevance": 0.186773, "type": "Person"}, {"count": 2, "sentiment": {"score": -0.546808, "label": "negative"}, "text": "Citigroup Global Markets Limited", "relevance": 0.186605, "type": "Company"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chairman", "relevance": 0.186094, "type": "JobTitle"}], "sentiment": {"document": {"score": 0.391138, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Shire plc (\u201c Shire \u201d) and Takeda Pharmaceutical Company Limited (\u201c Takeda \u201d)", "keywords": [{"text": "Takeda Pharmaceutical Company"}, {"text": "Shire plc"}, {"text": "Company Limited"}], "entities": [{"type": "Company", "text": "Shire PLC", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Takeda"}]}, "sentence": " On May 8, 2018, Shire plc (\u201c Shire \u201d) and Takeda Pharmaceutical Company Limited (\u201c Takeda \u201d) announced that they had reached agreement on the terms of a recommended cash and share offer to be made by Takeda for the entire issued and to be issued share capital of Shire (the \u201c Acquisition \u201d).", "object": {"text": "that they had reached agreement on the terms of a recommended cash and share offer to be made by Takeda for the entire issued and to be issued share capital of Shire (the \u201c Acquisition \u201d)", "keywords": [{"text": "share offer"}, {"text": "share capital"}, {"text": "Takeda"}, {"text": "agreement"}], "entities": [{"type": "Company", "text": "Takeda"}, {"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "a recommended cash and share", "keywords": [{"text": "cash"}, {"text": "share"}]}, "sentence": " On May 8, 2018, Shire plc (\u201c Shire \u201d) and Takeda Pharmaceutical Company Limited (\u201c Takeda \u201d) announced that they had reached agreement on the terms of a recommended cash and share offer to be made by Takeda for the entire issued and to be issued share capital of Shire (the \u201c Acquisition \u201d).", "object": {"text": "made by Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "by Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " On May 8, 2018, Shire plc (\u201c Shire \u201d) and Takeda Pharmaceutical Company Limited (\u201c Takeda \u201d) announced that they had reached agreement on the terms of a recommended cash and share offer to be made by Takeda for the entire issued and to be issued share capital of Shire (the \u201c Acquisition \u201d).", "object": {"text": "a recommended cash and share offer", "keywords": [{"text": "cash"}, {"text": "share offer"}]}, "action": {"verb": {"text": "make", "tense": "past"}, "text": "to be made", "normalized": "to be make"}}, {"subject": {"text": "by means of a scheme of arrangement under Article 125 of the Companies (Jersey) Law 1991 (as amended) (the \u201c Scheme \u201d)", "keywords": [{"text": "scheme"}, {"text": "arrangement"}, {"text": "means"}, {"text": "Article"}], "entities": [{"type": "Organization", "text": "Scheme"}, {"type": "Organization", "text": "Scheme"}]}, "sentence": " The Acquisition will be effected by means of a scheme of arrangement under Article 125 of the Companies (Jersey) Law 1991 (as amended) (the \u201c Scheme \u201d).", "object": {"text": "The Acquisition", "keywords": [{"text": "Acquisition"}]}, "action": {"verb": {"text": "effect", "tense": "future"}, "text": "will be effected", "normalized": "will be effect"}}, {"subject": {"text": "the notes accompanying them", "keywords": [{"text": "notes"}]}, "sentence": " Together with the Scheme Document, Forms of Proxy for the Court Meeting and the Shire General Meeting and Forms of Election and the notes accompanying them have also been published on the Shire website at www.shire.com.", "object": {"text": "published on the Shire website", "keywords": [{"text": "Shire website"}], "entities": [{"type": "Organization", "text": "Shire"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "Forms of Proxy for the Court Meeting and the Shire General Meeting and Forms of Election and the notes accompanying them", "keywords": [{"text": "Shire General Meeting"}, {"text": "Court Meeting"}, {"text": "Proxy"}, {"text": "Election"}], "entities": [{"type": "Organization", "text": "Shire General Meeting"}]}, "sentence": " Together with the Scheme Document, Forms of Proxy for the Court Meeting and the Shire General Meeting and Forms of Election and the notes accompanying them have also been published on the Shire website at www.shire.com.", "action": {"verb": {"text": "publish", "tense": "past"}, "text": "have also been published", "normalized": "have also be publish"}}, {"subject": {"text": "Copies of these documents", "keywords": [{"text": "Copies"}, {"text": "documents"}]}, "sentence": " Copies of these documents are also being sent to Shire Shareholders today.", "object": {"text": "to Shire Shareholders", "keywords": [{"text": "Shire Shareholders"}], "entities": [{"type": "Company", "text": "Shire Shareholders"}]}, "action": {"verb": {"text": "send", "tense": "past"}, "text": "are also being sent", "normalized": "be also be send"}}, {"subject": {"text": "by the Shire Depositary", "keywords": [{"text": "Shire Depositary"}], "entities": [{"type": "Organization", "text": "Shire Depositary"}]}, "sentence": " A Notice of Court Meeting and Extraordinary General Meeting, together with an ADS Voting Card, is also being sent to Shire ADS Holders today by the Shire Depositary.", "object": {"text": "A Notice of Court Meeting and Extraordinary General Meeting", "keywords": [{"text": "Extraordinary General Meeting"}, {"text": "Notice"}, {"text": "Court Meeting"}]}, "action": {"verb": {"text": "send", "tense": "past"}, "text": "is also being sent", "normalized": "be also be send"}}, {"subject": {"text": "Forms of Proxy and Forms of Election", "keywords": [{"text": "Proxy"}, {"text": "Election"}, {"text": "Forms"}]}, "sentence": " The Scheme Document, Forms of Proxy and Forms of Election will be available shortly on the National Storage Mechanism at www.morningstar.co.uk/uk/nsm .", "object": {"text": "available shortly on the National Storage Mechanism", "keywords": [{"text": "National Storage Mechanism"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "will be", "normalized": "will be"}}, {"subject": {"text": "The Scheme Document", "keywords": [{"text": "Scheme Document"}]}, "sentence": " The Scheme Document has also been furnished to the SEC on Form 6-K and is available on the SEC\u2019s website at www.sec.gov.", "object": {"text": "furnished to the SEC on Form 6-K", "keywords": [{"text": "SEC"}, {"text": "Form"}], "entities": [{"type": "Organization", "text": "SEC"}, {"type": "Quantity", "text": "6-K"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "The Scheme Document", "keywords": [{"text": "Scheme Document"}]}, "sentence": " The Scheme Document has also been furnished to the SEC on Form 6-K and is available on the SEC\u2019s website at www.sec.gov.", "object": {"text": "to the SEC", "keywords": [{"text": "SEC"}], "entities": [{"type": "Organization", "text": "SEC"}]}, "action": {"verb": {"text": "furnish", "tense": "past"}, "text": "has also been furnished", "normalized": "have also be furnish"}}, {"subject": {"text": "The Scheme Document", "keywords": [{"text": "Scheme Document"}]}, "sentence": " The Scheme Document has also been furnished to the SEC on Form 6-K and is available on the SEC\u2019s website at www.sec.gov.", "object": {"text": "available on the SEC\u2019s website", "keywords": [{"text": "SEC\u2019s website"}], "entities": [{"type": "Organization", "text": "SEC"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Shire", "keywords": [{"text": "Shire"}], "entities": [{"type": "Person", "text": "Shire"}]}, "sentence": " Shire also notes Takeda\u2019s circular to shareholders published today, which relates to the convocation of the Takeda Extraordinary General Meeting scheduled to be held at 10.00 a.m. (Tokyo time) (1.00 a.m. (London time)) on December 5, 2018.", "object": {"text": "Takeda\u2019s circular to shareholders published today, which relates to the convocation of the Takeda Extraordinary General Meeting scheduled to be held at 10.00 a.m. (Tokyo time) (1.00 a.m. (London time)) on December 5, 2018", "keywords": [{"text": "Takeda Extraordinary General"}, {"text": "Tokyo time"}, {"text": "London time"}, {"text": "convocation"}], "entities": [{"type": "Organization", "text": "Takeda Extraordinary General"}, {"type": "Location", "text": "Tokyo", "disambiguation": {"subtype": ["City"]}}, {"type": "Location", "text": "London", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "note", "tense": "present"}, "text": "notes", "normalized": "note"}}, {"subject": {"text": "shareholders", "keywords": [{"text": "shareholders"}]}, "sentence": " Shire also notes Takeda\u2019s circular to shareholders published today, which relates to the convocation of the Takeda Extraordinary General Meeting scheduled to be held at 10.00 a.m. (Tokyo time) (1.00 a.m. (London time)) on December 5, 2018.", "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "the Takeda Extraordinary General Meeting", "keywords": [{"text": "Takeda Extraordinary General"}], "entities": [{"type": "Organization", "text": "Takeda Extraordinary General"}]}, "sentence": " Shire also notes Takeda\u2019s circular to shareholders published today, which relates to the convocation of the Takeda Extraordinary General Meeting scheduled to be held at 10.00 a.m. (Tokyo time) (1.00 a.m. (London time)) on December 5, 2018.", "object": {"text": "held"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "the Takeda Extraordinary General Meeting", "keywords": [{"text": "Takeda Extraordinary General"}], "entities": [{"type": "Organization", "text": "Takeda Extraordinary General"}]}, "sentence": " Shire also notes Takeda\u2019s circular to shareholders published today, which relates to the convocation of the Takeda Extraordinary General Meeting scheduled to be held at 10.00 a.m. (Tokyo time) (1.00 a.m. (London time)) on December 5, 2018.", "action": {"verb": {"text": "hold", "tense": "past"}, "text": "scheduled to be held", "normalized": "schedule to be hold"}}, {"subject": {"text": "This"}, "sentence": " This is available on Takeda\u2019s website at www.takeda.com/investors/offer-for-shire.", "object": {"text": "available on Takeda\u2019s website", "keywords": [{"text": "Takeda"}, {"text": "website"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "terms", "keywords": [{"text": "terms"}]}, "sentence": " Unless otherwise defined, all capitalised terms in this announcement (the \u201c Announcement \u201d) shall have the meaning given to them in the Scheme Document.", "action": {"verb": {"text": "capitalise", "tense": "past"}, "text": "capitalised", "normalized": "capitalise"}}, {"subject": {"text": "all capitalised terms in this announcement (the \u201c Announcement \u201d)", "keywords": [{"text": "announcement"}, {"text": "terms"}]}, "sentence": " Unless otherwise defined, all capitalised terms in this announcement (the \u201c Announcement \u201d) shall have the meaning given to them in the Scheme Document.", "object": {"text": "the meaning given to them in the Scheme Document", "keywords": [{"text": "Scheme Document"}, {"text": "meaning"}]}, "action": {"verb": {"text": "have", "tense": "future"}, "text": "shall have", "normalized": "shall have"}}, {"subject": {"text": "the Conditions and certain further terms", "keywords": [{"text": "certain further terms"}, {"text": "Conditions"}]}, "sentence": " The Acquisition is also subject to the satisfaction or waiver of the Conditions and certain further terms that are set out in the Scheme Document.", "object": {"text": "in the Scheme Document", "keywords": [{"text": "Scheme Document"}]}, "action": {"verb": {"text": "set", "tense": "past"}, "text": "are set", "normalized": "be set"}}, {"subject": {"text": "Notices of the Court Meeting and the Shire General Meeting", "keywords": [{"text": "Shire General Meeting"}, {"text": "Notices"}, {"text": "Court Meeting"}], "entities": [{"type": "Organization", "text": "Shire General Meeting"}]}, "sentence": " Notices of the Court Meeting and the Shire General Meeting, which are scheduled to be held at Block 3, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland on December 5, 2018, are set out in the Scheme Document.", "object": {"text": "scheduled to be held at Block 3", "keywords": [{"text": "Block"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "the Shire General Meeting", "keywords": [{"text": "Shire General Meeting"}], "entities": [{"type": "Organization", "text": "Shire General Meeting"}]}, "sentence": " Notices of the Court Meeting and the Shire General Meeting, which are scheduled to be held at Block 3, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland on December 5, 2018, are set out in the Scheme Document.", "object": {"text": "to be held at Block 3, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland", "keywords": [{"text": "Baggot Street Lower"}, {"text": "Miesian Plaza"}, {"text": "Block"}, {"text": "Dublin"}], "entities": [{"type": "Facility", "text": "Miesian Plaza"}, {"type": "Location", "text": "Dublin", "disambiguation": {"subtype": ["AdministrativeDivision", "CityTown", "City"], "name": "Dublin", "dbpedia_resource": "http://dbpedia.org/resource/Dublin"}}, {"type": "Location", "text": "Ireland", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "schedule", "tense": "past"}, "text": "scheduled", "normalized": "schedule"}}, {"subject": {"text": "Notices of the Court Meeting and the Shire General Meeting", "keywords": [{"text": "Shire General Meeting"}, {"text": "Notices"}, {"text": "Court Meeting"}], "entities": [{"type": "Organization", "text": "Shire General Meeting"}]}, "sentence": " Notices of the Court Meeting and the Shire General Meeting, which are scheduled to be held at Block 3, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland on December 5, 2018, are set out in the Scheme Document.", "object": {"text": "held at Block 3", "keywords": [{"text": "Block"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Notices of the Court Meeting and the Shire General Meeting", "keywords": [{"text": "Shire General Meeting"}, {"text": "Notices"}, {"text": "Court Meeting"}], "entities": [{"type": "Organization", "text": "Shire General Meeting"}]}, "sentence": " Notices of the Court Meeting and the Shire General Meeting, which are scheduled to be held at Block 3, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland on December 5, 2018, are set out in the Scheme Document.", "action": {"verb": {"text": "hold", "tense": "past"}, "text": "are scheduled to be held", "normalized": "be schedule to be hold"}}, {"subject": {"text": "Notices of the Court Meeting and the Shire General Meeting, which are scheduled to be held at Block 3, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland on December 5, 2018,", "keywords": [{"text": "Baggot Street Lower"}, {"text": "Shire General Meeting"}, {"text": "Miesian Plaza"}, {"text": "Court Meeting"}], "entities": [{"type": "Organization", "text": "Shire General Meeting"}, {"type": "Facility", "text": "Miesian Plaza"}, {"type": "Location", "text": "Dublin", "disambiguation": {"subtype": ["AdministrativeDivision", "CityTown", "City"], "name": "Dublin", "dbpedia_resource": "http://dbpedia.org/resource/Dublin"}}, {"type": "Location", "text": "Ireland", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Notices of the Court Meeting and the Shire General Meeting, which are scheduled to be held at Block 3, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland on December 5, 2018, are set out in the Scheme Document.", "object": {"text": "in the Scheme Document", "keywords": [{"text": "Scheme Document"}]}, "action": {"verb": {"text": "set", "tense": "past"}, "text": "are set", "normalized": "be set"}}, {"subject": {"text": "The Court Meeting", "keywords": [{"text": "Court Meeting"}]}, "sentence": " The Court Meeting is scheduled to commence at 11.15 a.m. and the Shire General Meeting at 11.30 a.m. (or as soon thereafter as the Court Meeting has concluded or been adjourned).", "object": {"text": "scheduled to commence", "keywords": [{"text": "commence"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Court Meeting", "keywords": [{"text": "Court Meeting"}]}, "sentence": " The Court Meeting is scheduled to commence at 11.15 a.m. and the Shire General Meeting at 11.30 a.m. (or as soon thereafter as the Court Meeting has concluded or been adjourned).", "object": {"text": "to commence at 11.15 a.m. and the Shire General Meeting", "keywords": [{"text": "Shire General Meeting"}], "entities": [{"type": "Organization", "text": "Shire General Meeting"}]}, "action": {"verb": {"text": "schedule", "tense": "past"}, "text": "scheduled", "normalized": "schedule"}}, {"subject": {"text": "the Court Meeting", "keywords": [{"text": "Court Meeting"}]}, "sentence": " The Court Meeting is scheduled to commence at 11.15 a.m. and the Shire General Meeting at 11.30 a.m. (or as soon thereafter as the Court Meeting has concluded or been adjourned).", "object": {"text": "concluded or been adjourned"}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "the Court Meeting", "keywords": [{"text": "Court Meeting"}]}, "sentence": " The Court Meeting is scheduled to commence at 11.15 a.m. and the Shire General Meeting at 11.30 a.m. (or as soon thereafter as the Court Meeting has concluded or been adjourned).", "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "It"}, "sentence": " It is important that, for the Court Meeting in particular, as many votes as possible are cast so that the Court may be satisfied that there is a fair and reasonable representation of Shire Shareholder opinion.", "object": {"text": "important that"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the Court", "keywords": [{"text": "Court"}], "entities": [{"type": "Organization", "text": "Court", "disambiguation": {"subtype": ["Sport"], "name": "Volleyball", "dbpedia_resource": "http://dbpedia.org/resource/Volleyball"}}]}, "sentence": " It is important that, for the Court Meeting in particular, as many votes as possible are cast so that the Court may be satisfied that there is a fair and reasonable representation of Shire Shareholder opinion.", "object": {"text": "satisfied that there"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Shire Shareholders and Shire ADS Holders", "keywords": [{"text": "Shire ADS Holders"}, {"text": "Shire Shareholders"}], "entities": [{"type": "Company", "text": "Shire Shareholders"}, {"type": "Company", "text": "Shire ADS Holders"}]}, "sentence": " Shire Shareholders and Shire ADS Holders are therefore strongly urged to complete, sign and return the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible.", "object": {"text": "the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible", "keywords": [{"text": "ADS Voting Card"}, {"text": "Shire General Meeting"}, {"text": "electronic means"}, {"text": "Court Meeting"}], "entities": [{"type": "Organization", "text": "Shire General Meeting"}]}, "action": {"verb": {"text": "complete", "tense": "future"}, "text": "urged to complete", "normalized": "urge to complete"}}, {"subject": {"text": "Shire Shareholders and Shire ADS Holders", "keywords": [{"text": "Shire ADS Holders"}, {"text": "Shire Shareholders"}], "entities": [{"type": "Company", "text": "Shire Shareholders"}, {"type": "Company", "text": "Shire ADS Holders"}]}, "sentence": " Shire Shareholders and Shire ADS Holders are therefore strongly urged to complete, sign and return the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible.", "object": {"text": "the Forms of Proxy", "keywords": [{"text": "Proxy"}, {"text": "Forms"}]}, "action": {"verb": {"text": "sign", "tense": "present"}, "text": "sign and return", "normalized": "sign and return"}}, {"subject": {"text": "Shire Shareholders and Shire ADS Holders", "keywords": [{"text": "Shire ADS Holders"}, {"text": "Shire Shareholders"}], "entities": [{"type": "Company", "text": "Shire Shareholders"}, {"type": "Company", "text": "Shire ADS Holders"}]}, "sentence": " Shire Shareholders and Shire ADS Holders are therefore strongly urged to complete, sign and return the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible.", "object": {"text": "the Forms of Proxy", "keywords": [{"text": "Proxy"}, {"text": "Forms"}]}, "action": {"verb": {"text": "return", "tense": "present"}, "text": "sign and return", "normalized": "sign and return"}}, {"subject": {"text": "The Scheme Document", "keywords": [{"text": "Scheme Document"}]}, "sentence": " The Scheme Document contains an expected timetable of principal events relating to the Scheme, which is also attached as an Appendix to this Announcement.", "object": {"text": "an expected timetable of principal events relating to the Scheme, which is also attached as an Appendix to this Announcement", "keywords": [{"text": "expected timetable"}, {"text": "principal events"}, {"text": "Appendix"}, {"text": "Scheme"}], "entities": [{"type": "JobTitle", "text": "principal"}, {"type": "Organization", "text": "Scheme"}]}, "action": {"verb": {"text": "contain", "tense": "present"}, "text": "contains", "normalized": "contain"}}, {"subject": {"text": "the satisfaction or waiver of the other Conditions", "keywords": [{"text": "waiver"}, {"text": "satisfaction"}, {"text": "Conditions"}]}, "sentence": " Subject to approval at the relevant meetings, the satisfaction or waiver of the other Conditions set out in the Scheme Document and the sanction of the Court, the Scheme is expected to become effective on or around January 8, 2019.", "object": {"text": "in the Scheme Document", "keywords": [{"text": "Scheme Document"}]}, "action": {"verb": {"text": "set", "tense": "past"}, "text": "set", "normalized": "set"}}, {"subject": {"text": "the Scheme", "keywords": [{"text": "Scheme"}], "entities": [{"type": "Organization", "text": "Scheme"}]}, "sentence": " Subject to approval at the relevant meetings, the satisfaction or waiver of the other Conditions set out in the Scheme Document and the sanction of the Court, the Scheme is expected to become effective on or around January 8, 2019.", "action": {"verb": {"text": "expect", "tense": "past"}, "text": "is expected to become", "normalized": "be expect to become"}}, {"subject": {"text": "the Scheme", "keywords": [{"text": "Scheme"}], "entities": [{"type": "Organization", "text": "Scheme"}]}, "sentence": " Subject to approval at the relevant meetings, the satisfaction or waiver of the other Conditions set out in the Scheme Document and the sanction of the Court, the Scheme is expected to become effective on or around January 8, 2019.", "object": {"text": "effective"}, "action": {"verb": {"text": "become", "tense": "future"}, "text": "is expected to become", "normalized": "be expect to become"}}, {"subject": {"text": "it"}, "sentence": " If it becomes necessary to change any of the dates and/or times in the expected timetable, including as a result of the timing of receipt of approval from the European Commission to proceed to completion of the Acquisition, it is intended that the Effective Date will be as soon as practicable after January 8, 2019.", "object": {"text": "necessary to change any of the dates and/or times in the expected timetable", "keywords": [{"text": "timetable"}, {"text": "dates"}, {"text": "times"}]}, "action": {"verb": {"text": "become", "tense": "present"}, "text": "becomes", "normalized": "become"}}, {"subject": {"text": "it"}, "sentence": " If it becomes necessary to change any of the dates and/or times in the expected timetable, including as a result of the timing of receipt of approval from the European Commission to proceed to completion of the Acquisition, it is intended that the Effective Date will be as soon as practicable after January 8, 2019.", "object": {"text": "intended that the Effective Date will be as soon as practicable", "keywords": [{"text": "Effective Date"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "that the Effective Date will be as soon as practicable after January 8, 2019", "keywords": [{"text": "Effective Date"}, {"text": "practicable"}]}, "sentence": " If it becomes necessary to change any of the dates and/or times in the expected timetable, including as a result of the timing of receipt of approval from the European Commission to proceed to completion of the Acquisition, it is intended that the Effective Date will be as soon as practicable after January 8, 2019.", "object": {"text": "it"}, "action": {"verb": {"text": "intend", "tense": "past"}, "text": "is intended", "normalized": "be intend"}}, {"subject": {"text": "the Scheme", "keywords": [{"text": "Scheme"}], "entities": [{"type": "Organization", "text": "Scheme"}]}, "sentence": " If the Scheme is approved as outlined above, it is expected that trading of Shire Shares on the London Stock Exchange's main market for listed securities will be suspended from 4.30 p.m. on January 4, 2019.", "object": {"text": "approved as outlined above"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the Scheme", "keywords": [{"text": "Scheme"}], "entities": [{"type": "Organization", "text": "Scheme"}]}, "sentence": " If the Scheme is approved as outlined above, it is expected that trading of Shire Shares on the London Stock Exchange's main market for listed securities will be suspended from 4.30 p.m. on January 4, 2019.", "object": {"text": "as outlined above"}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "is approved", "normalized": "be approve"}}, {"subject": {"text": "the Scheme", "keywords": [{"text": "Scheme"}], "entities": [{"type": "Organization", "text": "Scheme"}]}, "sentence": " If the Scheme is approved as outlined above, it is expected that trading of Shire Shares on the London Stock Exchange's main market for listed securities will be suspended from 4.30 p.m. on January 4, 2019.", "action": {"verb": {"text": "outline", "tense": "past"}, "text": "outlined", "normalized": "outline"}}, {"subject": {"text": "trading of Shire Shares on the London Stock Exchange's main market for listed securities", "keywords": [{"text": "London Stock Exchange"}, {"text": "Shire Shares"}, {"text": "listed securities"}, {"text": "main market"}], "entities": [{"type": "Company", "text": "Shire Shares"}, {"type": "Company", "text": "London Stock Exchange", "disambiguation": {"subtype": ["Organization", "Location", "Facility", "TouristAttraction"], "name": "London Stock Exchange", "dbpedia_resource": "http://dbpedia.org/resource/London_Stock_Exchange"}}]}, "sentence": " If the Scheme is approved as outlined above, it is expected that trading of Shire Shares on the London Stock Exchange's main market for listed securities will be suspended from 4.30 p.m. on January 4, 2019.", "action": {"verb": {"text": "suspend", "tense": "future"}, "text": "will be suspended", "normalized": "will be suspend"}}, {"subject": {"text": "It"}, "sentence": " It is intended that, following the Scheme becoming Effective, the London Stock Exchange and the FCA will be requested respectively to cancel trading in Shire Shares on the London Stock Exchange's main market for listed securities and to remove the listing of the Shire Shares from the Official List, in each case on or shortly after the Effective Date.", "object": {"text": "intended that"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "that"}, "sentence": " It is intended that, following the Scheme becoming Effective, the London Stock Exchange and the FCA will be requested respectively to cancel trading in Shire Shares on the London Stock Exchange's main market for listed securities and to remove the listing of the Shire Shares from the Official List, in each case on or shortly after the Effective Date.", "object": {"text": "It"}, "action": {"verb": {"text": "intend", "tense": "past"}, "text": "is intended", "normalized": "be intend"}}, {"subject": {"text": "the Scheme", "keywords": [{"text": "Scheme"}], "entities": [{"type": "Organization", "text": "Scheme"}]}, "sentence": " It is intended that, following the Scheme becoming Effective, the London Stock Exchange and the FCA will be requested respectively to cancel trading in Shire Shares on the London Stock Exchange's main market for listed securities and to remove the listing of the Shire Shares from the Official List, in each case on or shortly after the Effective Date.", "object": {"text": "Effective"}, "action": {"verb": {"text": "become", "tense": "present"}, "text": "becoming", "normalized": "become"}}, {"subject": {"text": "the FCA", "keywords": [{"text": "FCA"}], "entities": [{"type": "Organization", "text": "FCA", "disambiguation": {"subtype": ["Industry"], "name": "Airline", "dbpedia_resource": "http://dbpedia.org/resource/Airline"}}]}, "sentence": " It is intended that, following the Scheme becoming Effective, the London Stock Exchange and the FCA will be requested respectively to cancel trading in Shire Shares on the London Stock Exchange's main market for listed securities and to remove the listing of the Shire Shares from the Official List, in each case on or shortly after the Effective Date.", "object": {"text": "requested respectively"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "the FCA", "keywords": [{"text": "FCA"}], "entities": [{"type": "Organization", "text": "FCA", "disambiguation": {"subtype": ["Industry"], "name": "Airline", "dbpedia_resource": "http://dbpedia.org/resource/Airline"}}]}, "sentence": " It is intended that, following the Scheme becoming Effective, the London Stock Exchange and the FCA will be requested respectively to cancel trading in Shire Shares on the London Stock Exchange's main market for listed securities and to remove the listing of the Shire Shares from the Official List, in each case on or shortly after the Effective Date.", "action": {"verb": {"text": "request", "tense": "future"}, "text": "will be requested", "normalized": "will be request"}}], "concepts": [{"text": "U.S. Securities and Exchange Commission", "relevance": 0.979815, "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}, {"text": "Stock market", "relevance": 0.811213, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "Stock", "relevance": 0.725208, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Stock exchange", "relevance": 0.718416, "dbpedia_resource": "http://dbpedia.org/resource/Stock_exchange"}, {"text": "Financial adviser", "relevance": 0.649292, "dbpedia_resource": "http://dbpedia.org/resource/Financial_adviser"}, {"text": "Securities Exchange Act of 1934", "relevance": 0.557005, "dbpedia_resource": "http://dbpedia.org/resource/Securities_Exchange_Act_of_1934"}, {"text": "London Stock Exchange", "relevance": 0.550181, "dbpedia_resource": "http://dbpedia.org/resource/London_Stock_Exchange"}, {"text": "New York Stock Exchange", "relevance": 0.533365, "dbpedia_resource": "http://dbpedia.org/resource/New_York_Stock_Exchange"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.506632, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Securities Act of 1933", "relevance": 0.476887, "dbpedia_resource": "http://dbpedia.org/resource/Securities_Act_of_1933"}, {"text": "Independent Financial Adviser", "relevance": 0.446587, "dbpedia_resource": "http://dbpedia.org/resource/Independent_Financial_Adviser"}, {"text": "Form 10-K", "relevance": 0.444486, "dbpedia_resource": "http://dbpedia.org/resource/Form_10-K"}], "categories": [{"score": 0.649104, "label": "/finance/financial news"}, {"score": 0.439552, "label": "/law, govt and politics"}, {"score": 0.408029, "label": "/real estate/buying and selling homes"}], "relations": [{"type": "partOfMany", "sentence": "12 08:01:01 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE NOVEMBER 12, 2018 RECOMMENDED OFFER for SHIRE PLC by TAKEDA PHARMACEUTICAL COMPANY LIMITED Publication of Scheme Document On May 8, 2018, Shire plc (\" Shire \") and Takeda Pharmaceutical Company Limited (\" Takeda \") announced that they had reached agreement on the terms of a recommended cash and share offer to be made by Takeda for the entire issued and to be issued share capital of Shire (the \" Acquisition \").", "score": 0.862751, "arguments": [{"text": "Shire plc", "location": [383, 392], "entities": [{"type": "Person", "text": "Shire plc"}]}, {"text": "they", "location": [475, 479], "entities": [{"type": "Person", "text": "they"}]}]}, {"type": "participantIn", "sentence": "A Notice of Court Meeting and Extraordinary General Meeting, together with an ADS Voting Card, is also being sent to Shire ADS Holders today by the Shire Depositary.", "score": 0.507852, "arguments": [{"text": "Court", "location": [1674, 1679], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [1680, 1687], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "colleague", "sentence": "The availability of the New Takeda Securities under the Acquisition to Shire Shareholders who are not resident in the United Kingdom or Jersey, or the ability of those persons to continue to hold such securities, may be affected by the laws or regulatory requirements of the relevant jurisdiction in which they are resident.", "score": 0.340474, "arguments": [{"text": "Shire", "location": [20407, 20412], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Shareholders", "location": [20413, 20425], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "partOfMany", "sentence": "The availability of the New Takeda Securities under the Acquisition to Shire Shareholders who are not resident in the United Kingdom or Jersey, or the ability of those persons to continue to hold such securities, may be affected by the laws or regulatory requirements of the relevant jurisdiction in which they are resident.", "score": 0.531789, "arguments": [{"text": "Shareholders", "location": [20413, 20425], "entities": [{"type": "Person", "text": "Shareholders"}]}, {"text": "who", "location": [20426, 20429], "entities": [{"type": "Person", "text": "who"}]}]}, {"type": "locatedAt", "sentence": "The availability of the New Takeda Securities under the Acquisition to Shire Shareholders who are not resident in the United Kingdom or Jersey, or the ability of those persons to continue to hold such securities, may be affected by the laws or regulatory requirements of the relevant jurisdiction in which they are resident.", "score": 0.408097, "arguments": [{"text": "who", "location": [20426, 20429], "entities": [{"type": "Person", "text": "who"}]}, {"text": "United Kingdom", "location": [20454, 20468], "entities": [{"type": "GeopoliticalEntity", "text": "United Kingdom"}]}]}, {"type": "agentOf", "sentence": "Persons into whose possession this Announcement comes who are not resident in the United Kingdom should inform themselves of, and observe, any applicable requirements.", "score": 0.850205, "arguments": [{"text": "whose", "location": [20674, 20679], "entities": [{"type": "Person", "text": "whose"}]}, {"text": "Announcement", "location": [20696, 20708], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "locatedAt", "sentence": "Persons into whose possession this Announcement comes who are not resident in the United Kingdom should inform themselves of, and observe, any applicable requirements.", "score": 0.509874, "arguments": [{"text": "who", "location": [20715, 20718], "entities": [{"type": "Person", "text": "who"}]}, {"text": "United Kingdom", "location": [20743, 20757], "entities": [{"type": "GeopoliticalEntity", "text": "United Kingdom"}]}]}, {"type": "affectedBy", "sentence": "Persons into whose possession this Announcement comes who are not resident in the United Kingdom should inform themselves of, and observe, any applicable requirements.", "score": 0.825248, "arguments": [{"text": "themselves", "location": [20772, 20782], "entities": [{"type": "Person", "text": "themselves"}]}, {"text": "inform", "location": [20765, 20771], "entities": [{"type": "EventCommunication", "text": "inform"}]}]}, {"type": "partOfMany", "sentence": "Shire Shareholders who are in any doubt regarding such matters should consult an appropriate independent financial adviser in their relevant jurisdiction without delay.", "score": 0.510056, "arguments": [{"text": "Shareholders", "location": [20835, 20847], "entities": [{"type": "Person", "text": "Shareholders"}]}, {"text": "who", "location": [20848, 20851], "entities": [{"type": "Person", "text": "who"}]}]}, {"type": "colleague", "sentence": "Further details in relation to Shire Shareholders who are resident in, ordinarily resident in, or citizens of, jurisdictions outside the United Kingdom and Jersey will be contained in the Scheme Document.", "score": 0.340474, "arguments": [{"text": "Shire", "location": [21573, 21578], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Shareholders", "location": [21579, 21591], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "partOfMany", "sentence": "Further details in relation to Shire Shareholders who are resident in, ordinarily resident in, or citizens of, jurisdictions outside the United Kingdom and Jersey will be contained in the Scheme Document.", "score": 0.479561, "arguments": [{"text": "Shareholders", "location": [21579, 21591], "entities": [{"type": "Person", "text": "Shareholders"}]}, {"text": "who", "location": [21592, 21595], "entities": [{"type": "Person", "text": "who"}]}]}, {"type": "partOfMany", "sentence": "Further details in relation to Shire Shareholders who are resident in, ordinarily resident in, or citizens of, jurisdictions outside the United Kingdom and Jersey will be contained in the Scheme Document.", "score": 0.615283, "arguments": [{"text": "resident", "location": [21600, 21608], "entities": [{"type": "Person", "text": "resident"}]}, {"text": "who", "location": [21592, 21595], "entities": [{"type": "Person", "text": "who"}]}]}, {"type": "participantIn", "sentence": "A Notice of Court Meeting and Extraordinary General Meeting, together with an ADS Voting Card, is also being sent to Shire ADS Holders today by the Shire Depositary.", "score": 0.55396, "arguments": [{"text": "ADS Voting Card", "location": [1740, 1755], "entities": [{"type": "Person", "text": "ADS Voting Card"}]}, {"text": "Meeting", "location": [1680, 1687], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "partOfMany", "sentence": "Further details in relation to Shire Shareholders who are resident in, ordinarily resident in, or citizens of, jurisdictions outside the United Kingdom and Jersey will be contained in the Scheme Document.", "score": 0.721339, "arguments": [{"text": "resident", "location": [21624, 21632], "entities": [{"type": "Person", "text": "resident"}]}, {"text": "who", "location": [21592, 21595], "entities": [{"type": "Person", "text": "who"}]}]}, {"type": "employedBy", "sentence": "Additional information for US investors Notice to US investors in Shire: the Acquisition relates to the shares of a Jersey company and is being made by means of a scheme of arrangement provided for under the Jersey Companies Law.", "score": 0.972641, "arguments": [{"text": "investors", "location": [21777, 21786], "entities": [{"type": "Person", "text": "investors"}]}, {"text": "US", "location": [21774, 21776], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "employedBy", "sentence": "Additional information for US investors Notice to US investors in Shire: the Acquisition relates to the shares of a Jersey company and is being made by means of a scheme of arrangement provided for under the Jersey Companies Law.", "score": 0.966762, "arguments": [{"text": "investors", "location": [21800, 21809], "entities": [{"type": "Person", "text": "investors"}]}, {"text": "US", "location": [21797, 21799], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "employedBy", "sentence": "Additional information for US investors Notice to US investors in Shire: the Acquisition relates to the shares of a Jersey company and is being made by means of a scheme of arrangement provided for under the Jersey Companies Law.", "score": 0.376571, "arguments": [{"text": "Shire", "location": [21813, 21818], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Acquisition", "location": [21824, 21835], "entities": [{"type": "Organization", "text": "Acquisition"}]}]}, {"type": "basedIn", "sentence": "Additional information for US investors Notice to US investors in Shire: the Acquisition relates to the shares of a Jersey company and is being made by means of a scheme of arrangement provided for under the Jersey Companies Law.", "score": 0.951866, "arguments": [{"text": "company", "location": [21870, 21877], "entities": [{"type": "Organization", "text": "company"}]}, {"text": "Jersey", "location": [21863, 21869], "entities": [{"type": "GeopoliticalEntity", "text": "Jersey"}]}]}, {"type": "partOf", "sentence": "A transaction effected by means of a scheme of arrangement is not subject to the tender offer rules or the proxy solicitation rules under the US Exchange Act, and it is expected that any New Takeda Securities to be issued pursuant to the Scheme to Shire Shareholders would be issued in reliance upon the exemption from the registration requirements under the US Securities Act provided by Section 3(a)(10) thereof.", "score": 0.988303, "arguments": [{"text": "Exchange Act", "location": [22122, 22134], "entities": [{"type": "Organization", "text": "Exchange Act"}]}, {"text": "US", "location": [22119, 22121], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "employedBy", "sentence": "Under applicable US securities laws, persons (whether or not US persons) who are or will be \"affiliates\" (within the meaning of Rule 144 of the US Securities Act) of Takeda prior to, or after, the Effective Date will be subject to certain transfer restrictions relating to the New Takeda Securities received in connection with the Acquisition.", "score": 0.931891, "arguments": [{"text": "persons", "location": [22456, 22463], "entities": [{"type": "Person", "text": "persons"}]}, {"text": "US", "location": [22453, 22455], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "partOf", "sentence": "Under applicable US securities laws, persons (whether or not US persons) who are or will be \"affiliates\" (within the meaning of Rule 144 of the US Securities Act) of Takeda prior to, or after, the Effective Date will be subject to certain transfer restrictions relating to the New Takeda Securities received in connection with the Acquisition.", "score": 0.555179, "arguments": [{"text": "Rule 144", "location": [22520, 22528], "entities": [{"type": "Organization", "text": "Rule 144"}]}, {"text": "US Securities Act", "location": [22536, 22553], "entities": [{"type": "Organization", "text": "US Securities Act"}]}]}, {"type": "partOf", "sentence": "Accordingly, the Acquisition is subject to the disclosure requirements and practices applicable in the United Kingdom and Jersey to schemes of arrangement which differ from the disclosure requirements of United States tender offer and proxy solicitation rules and the US Securities Act.", "score": 0.949573, "arguments": [{"text": "tender", "location": [22954, 22960], "entities": [{"type": "Organization", "text": "tender"}]}, {"text": "United States", "location": [22940, 22953], "entities": [{"type": "GeopoliticalEntity", "text": "United States"}]}]}, {"type": "educatedAt", "sentence": "If, in the future, Takeda exercises the right to implement the Acquisition by way of a Takeover Offer and determines to extend the offer into the United States, the Acquisition will be made in compliance with applicable United States laws and regulations, including any applicable exemptions under the US Exchange Act.", "score": 0.430499, "arguments": [{"text": "Takeda", "location": [23042, 23048], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "Takeover Offer", "location": [23110, 23124], "entities": [{"type": "Organization", "text": "Takeover Offer"}]}]}, {"type": "hasAttribute", "sentence": "The Scheme Document, Forms of Proxy and Forms of Election will be available shortly on the National Storage Mechanism at www.morningstar.co.uk/uk/nsm .", "score": 0.715971, "arguments": [{"text": "National Storage Mechanism", "location": [1919, 1945], "entities": [{"type": "Organization", "text": "National Storage Mechanism"}]}, {"text": "www.morningstar.co.uk/uk/nsm", "location": [1949, 1977], "entities": [{"type": "Web", "text": "www.morningstar.co.uk/uk/nsm"}]}]}, {"type": "agentOf", "sentence": "If, in the future, Takeda exercises the right to implement the Acquisition by way of a Takeover Offer and determines to extend the offer into the United States, the Acquisition will be made in compliance with applicable United States laws and regulations, including any applicable exemptions under the US Exchange Act.", "score": 0.606714, "arguments": [{"text": "Takeda", "location": [23042, 23048], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "determines", "location": [23129, 23139], "entities": [{"type": "EventCommunication", "text": "determines"}]}]}, {"type": "agentOf", "sentence": "Financial information included in this Announcement and the Scheme Document has been or will have been prepared in accordance with accounting standards applicable in the United Kingdom and Jersey that may not be comparable to financial information of US companies or companies whose financial statements are prepared in accordance with US GAAP.", "score": 0.784337, "arguments": [{"text": "Financial information", "location": [23342, 23363], "entities": [{"type": "Organization", "text": "Financial information"}]}, {"text": "Announcement", "location": [23381, 23393], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Financial information included in this Announcement and the Scheme Document has been or will have been prepared in accordance with accounting standards applicable in the United Kingdom and Jersey that may not be comparable to financial information of US companies or companies whose financial statements are prepared in accordance with US GAAP.", "score": 0.578556, "arguments": [{"text": "Scheme Document", "location": [23402, 23417], "entities": [{"type": "Organization", "text": "Scheme Document"}]}, {"text": "Announcement", "location": [23381, 23393], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "partOfMany", "sentence": "Financial information included in this Announcement and the Scheme Document has been or will have been prepared in accordance with accounting standards applicable in the United Kingdom and Jersey that may not be comparable to financial information of US companies or companies whose financial statements are prepared in accordance with US GAAP.", "score": 0.334276, "arguments": [{"text": "Jersey", "location": [23531, 23537], "entities": [{"type": "Organization", "text": "Jersey"}]}, {"text": "companies", "location": [23609, 23618], "entities": [{"type": "Organization", "text": "companies"}]}]}, {"type": "basedIn", "sentence": "Financial information included in this Announcement and the Scheme Document has been or will have been prepared in accordance with accounting standards applicable in the United Kingdom and Jersey that may not be comparable to financial information of US companies or companies whose financial statements are prepared in accordance with US GAAP.", "score": 0.959976, "arguments": [{"text": "companies", "location": [23596, 23605], "entities": [{"type": "Organization", "text": "companies"}]}, {"text": "US", "location": [23593, 23595], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "employedBy", "sentence": "Financial information included in this Announcement and the Scheme Document has been or will have been prepared in accordance with accounting standards applicable in the United Kingdom and Jersey that may not be comparable to financial information of US companies or companies whose financial statements are prepared in accordance with US GAAP.", "score": 0.555306, "arguments": [{"text": "whose", "location": [23619, 23624], "entities": [{"type": "Person", "text": "whose"}]}, {"text": "companies", "location": [23609, 23618], "entities": [{"type": "Organization", "text": "companies"}]}]}, {"type": "employedBy", "sentence": "The receipt of consideration by a US holder for the transfer of its Shire Shares pursuant to the Scheme will be a taxable transaction for United States federal income tax purposes.", "score": 0.687229, "arguments": [{"text": "Shire", "location": [23755, 23760], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "its", "location": [23751, 23754], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "agentOf", "sentence": "Each Shire Shareholder is urged to consult his independent professional adviser immediately regarding the tax consequences of the Acquisition applicable to him, including under applicable United States state and local, as well as foreign and other, tax laws.", "score": 0.609404, "arguments": [{"text": "Shire", "location": [23873, 23878], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "urged", "location": [23894, 23899], "entities": [{"type": "EventCommunication", "text": "urged"}]}]}, {"type": "partOf", "sentence": "Each Shire Shareholder is urged to consult his independent professional adviser immediately regarding the tax consequences of the Acquisition applicable to him, including under applicable United States state and local, as well as foreign and other, tax laws.", "score": 0.562084, "arguments": [{"text": "United States", "location": [24056, 24069], "entities": [{"type": "GeopoliticalEntity", "text": "United States"}]}, {"text": "state", "location": [24070, 24075], "entities": [{"type": "GeopoliticalEntity", "text": "state"}]}]}, {"type": "employedBy", "sentence": "It may be difficult for US holders of Shire Shares to enforce their rights and any claim arising out of the US federal laws, since Takeda and Shire are located primarily in a non-US jurisdiction, and some or all of their officers and directors may be residents of a non-US jurisdiction.", "score": 0.924679, "arguments": [{"text": "holders", "location": [24154, 24161], "entities": [{"type": "Person", "text": "holders"}]}, {"text": "US", "location": [24151, 24153], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "hasAttribute", "sentence": "The Scheme Document has also been furnished to the SEC on Form 6-K and is available on the SEC's website at www.sec.gov.", "score": 0.508651, "arguments": [{"text": "SEC", "location": [2071, 2074], "entities": [{"type": "Organization", "text": "SEC"}]}, {"text": "www.sec.gov", "location": [2088, 2099], "entities": [{"type": "Web", "text": "www.sec.gov"}]}]}, {"type": "partOfMany", "sentence": "It may be difficult for US holders of Shire Shares to enforce their rights and any claim arising out of the US federal laws, since Takeda and Shire are located primarily in a non-US jurisdiction, and some or all of their officers and directors may be residents of a non-US jurisdiction.", "score": 0.618096, "arguments": [{"text": "holders", "location": [24154, 24161], "entities": [{"type": "Person", "text": "holders"}]}, {"text": "their", "location": [24189, 24194], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "It may be difficult for US holders of Shire Shares to enforce their rights and any claim arising out of the US federal laws, since Takeda and Shire are located primarily in a non-US jurisdiction, and some or all of their officers and directors may be residents of a non-US jurisdiction.", "score": 0.789837, "arguments": [{"text": "Shire", "location": [24165, 24170], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "their", "location": [24189, 24194], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "It may be difficult for US holders of Shire Shares to enforce their rights and any claim arising out of the US federal laws, since Takeda and Shire are located primarily in a non-US jurisdiction, and some or all of their officers and directors may be residents of a non-US jurisdiction.", "score": 0.49106, "arguments": [{"text": "Takeda", "location": [24258, 24264], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "their", "location": [24342, 24347], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "It may be difficult for US holders of Shire Shares to enforce their rights and any claim arising out of the US federal laws, since Takeda and Shire are located primarily in a non-US jurisdiction, and some or all of their officers and directors may be residents of a non-US jurisdiction.", "score": 0.681985, "arguments": [{"text": "Shire", "location": [24269, 24274], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "some", "location": [24327, 24331], "entities": [{"type": "Cardinal", "text": "some"}]}]}, {"type": "partOfMany", "sentence": "It may be difficult for US holders of Shire Shares to enforce their rights and any claim arising out of the US federal laws, since Takeda and Shire are located primarily in a non-US jurisdiction, and some or all of their officers and directors may be residents of a non-US jurisdiction.", "score": 0.890011, "arguments": [{"text": "Shire", "location": [24269, 24274], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "their", "location": [24342, 24347], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "It may be difficult for US holders of Shire Shares to enforce their rights and any claim arising out of the US federal laws, since Takeda and Shire are located primarily in a non-US jurisdiction, and some or all of their officers and directors may be residents of a non-US jurisdiction.", "score": 0.759844, "arguments": [{"text": "some", "location": [24327, 24331], "entities": [{"type": "Cardinal", "text": "some"}]}, {"text": "directors", "location": [24361, 24370], "entities": [{"type": "Person", "text": "directors"}]}]}, {"type": "employedBy", "sentence": "US holders of Shire Shares may not be able to sue a non-US company or its officers or directors in a non-US court for violations of the US securities laws.", "score": 0.930895, "arguments": [{"text": "holders", "location": [24417, 24424], "entities": [{"type": "Person", "text": "holders"}]}, {"text": "US", "location": [24414, 24416], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "employedBy", "sentence": "US holders of Shire Shares may not be able to sue a non-US company or its officers or directors in a non-US court for violations of the US securities laws.", "score": 0.495501, "arguments": [{"text": "officers", "location": [24488, 24496], "entities": [{"type": "Person", "text": "officers"}]}, {"text": "its", "location": [24484, 24487], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "employedBy", "sentence": "US holders of Shire Shares may not be able to sue a non-US company or its officers or directors in a non-US court for violations of the US securities laws.", "score": 0.531448, "arguments": [{"text": "directors", "location": [24500, 24509], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "its", "location": [24484, 24487], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "employedBy", "sentence": "US holders of Shire Shares may not be able to sue a non-US company or its officers or directors in a non-US court for violations of the US securities laws.", "score": 0.607332, "arguments": [{"text": "directors", "location": [24500, 24509], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "court", "location": [24522, 24527], "entities": [{"type": "Organization", "text": "court"}]}]}, {"type": "partOfMany", "sentence": "Shire also notes Takeda's circular to shareholders published today, which relates to the convocation of the Takeda Extraordinary General Meeting scheduled to be held at 10.00 a.m. (Tokyo time) (1.00 a.m. (London time)) on December 5, 2018.", "score": 0.627063, "arguments": [{"text": "Shire", "location": [2101, 2106], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "shareholders", "location": [2139, 2151], "entities": [{"type": "Person", "text": "shareholders"}]}]}, {"type": "partOf", "sentence": "Further, it may be difficult to compel a non-US company and its affiliates to subject themselves to the jurisdiction and judgment of a US court.", "score": 0.86995, "arguments": [{"text": "affiliates", "location": [24634, 24644], "entities": [{"type": "Organization", "text": "affiliates"}]}, {"text": "its", "location": [24630, 24633], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "partOf", "sentence": "Further, it may be difficult to compel a non-US company and its affiliates to subject themselves to the jurisdiction and judgment of a US court.", "score": 0.963294, "arguments": [{"text": "court", "location": [24708, 24713], "entities": [{"type": "Organization", "text": "court"}]}, {"text": "US", "location": [24705, 24707], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "partOf", "sentence": "New Takeda Securities issued pursuant to the Scheme will not be registered under any US state securities laws and may only be issued to persons resident in a state pursuant to an exemption from the registration requirements of the securities laws of such state.", "score": 0.762332, "arguments": [{"text": "state", "location": [24803, 24808], "entities": [{"type": "GeopoliticalEntity", "text": "state"}]}, {"text": "US", "location": [24800, 24802], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "agentOf", "sentence": "For the purpose of qualifying for the exemption provided by Section 3(a)(10) of the US Securities Act, Shire will advise the Court that its sanctioning of the Scheme will be relied on by Takeda as an approval of the Scheme following a hearing on its fairness to Shire Shareholders, at which Court hearing all Shire Shareholders are entitled to attend in person or through counsel to support or oppose the sanctioning of the Scheme and with respect to which notification will be given to all such holders.", "score": 0.942436, "arguments": [{"text": "Shire", "location": [25080, 25085], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "advise", "location": [25091, 25097], "entities": [{"type": "EventCommunication", "text": "advise"}]}]}, {"type": "affectedBy", "sentence": "For the purpose of qualifying for the exemption provided by Section 3(a)(10) of the US Securities Act, Shire will advise the Court that its sanctioning of the Scheme will be relied on by Takeda as an approval of the Scheme following a hearing on its fairness to Shire Shareholders, at which Court hearing all Shire Shareholders are entitled to attend in person or through counsel to support or oppose the sanctioning of the Scheme and with respect to which notification will be given to all such holders.", "score": 0.963339, "arguments": [{"text": "Court", "location": [25102, 25107], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "advise", "location": [25091, 25097], "entities": [{"type": "EventCommunication", "text": "advise"}]}]}, {"type": "affectedBy", "sentence": "For the purpose of qualifying for the exemption provided by Section 3(a)(10) of the US Securities Act, Shire will advise the Court that its sanctioning of the Scheme will be relied on by Takeda as an approval of the Scheme following a hearing on its fairness to Shire Shareholders, at which Court hearing all Shire Shareholders are entitled to attend in person or through counsel to support or oppose the sanctioning of the Scheme and with respect to which notification will be given to all such holders.", "score": 0.337223, "arguments": [{"text": "Scheme", "location": [25193, 25199], "entities": [{"type": "Organization", "text": "Scheme"}]}, {"text": "hearing", "location": [25212, 25219], "entities": [{"type": "EventLegal", "text": "hearing"}]}]}, {"type": "agentOf", "sentence": "For the purpose of qualifying for the exemption provided by Section 3(a)(10) of the US Securities Act, Shire will advise the Court that its sanctioning of the Scheme will be relied on by Takeda as an approval of the Scheme following a hearing on its fairness to Shire Shareholders, at which Court hearing all Shire Shareholders are entitled to attend in person or through counsel to support or oppose the sanctioning of the Scheme and with respect to which notification will be given to all such holders.", "score": 0.861982, "arguments": [{"text": "Court", "location": [25268, 25273], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "hearing", "location": [25274, 25281], "entities": [{"type": "EventLegal", "text": "hearing"}]}]}, {"type": "affectedBy", "sentence": "For the purpose of qualifying for the exemption provided by Section 3(a)(10) of the US Securities Act, Shire will advise the Court that its sanctioning of the Scheme will be relied on by Takeda as an approval of the Scheme following a hearing on its fairness to Shire Shareholders, at which Court hearing all Shire Shareholders are entitled to attend in person or through counsel to support or oppose the sanctioning of the Scheme and with respect to which notification will be given to all such holders.", "score": 0.660267, "arguments": [{"text": "Shareholders", "location": [25292, 25304], "entities": [{"type": "Person", "text": "Shareholders"}]}, {"text": "hearing", "location": [25274, 25281], "entities": [{"type": "EventLegal", "text": "hearing"}]}]}, {"type": "agentOf", "sentence": "Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct and you are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this Announcement.", "score": 0.912144, "arguments": [{"text": "you", "location": [27937, 27940], "entities": [{"type": "Person", "text": "you"}]}, {"text": "cautioned", "location": [27955, 27964], "entities": [{"type": "EventCommunication", "text": "cautioned"}]}]}, {"type": "agentOf", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in \u02bbITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.shire.com and www.sec.gov), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.992023, "arguments": [{"text": "Shire", "location": [28155, 28160], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Report", "location": [28182, 28188], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "participantIn", "sentence": "Shire also notes Takeda's circular to shareholders published today, which relates to the convocation of the Takeda Extraordinary General Meeting scheduled to be held at 10.00 a.m. (Tokyo time) (1.00 a.m. (London time)) on December 5, 2018.", "score": 0.504194, "arguments": [{"text": "Takeda Extraordinary General", "location": [2209, 2237], "entities": [{"type": "Organization", "text": "Takeda Extraordinary General"}]}, {"text": "Meeting", "location": [2238, 2245], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "timeOf", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in \u02bbITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.shire.com and www.sec.gov), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.888434, "arguments": [{"text": "10-K", "location": [28197, 28201], "entities": [{"type": "Date", "text": "10-K"}]}, {"text": "Report", "location": [28182, 28188], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "agentOf", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in \u02bbITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.shire.com and www.sec.gov), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.984957, "arguments": [{"text": "Shire", "location": [28209, 28214], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Reports", "location": [28238, 28245], "entities": [{"type": "EventCommunication", "text": "Reports"}]}]}, {"type": "hasAttribute", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in \u02bbITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.shire.com and www.sec.gov), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.548308, "arguments": [{"text": "Securities and Exchange Commission", "location": [28387, 28421], "entities": [{"type": "Organization", "text": "Securities and Exchange Commission"}]}, {"text": "www.shire.com", "location": [28444, 28457], "entities": [{"type": "Web", "text": "www.shire.com"}]}]}, {"type": "agentOf", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in \u02bbITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.shire.com and www.sec.gov), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.530254, "arguments": [{"text": "they", "location": [28545, 28549], "entities": [{"type": "Person", "text": "they"}]}, {"text": "Announcement", "location": [28569, 28581], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "These risk factors expressly qualify all forward-looking statements contained in this Announcement and should also be considered by the reader.", "score": 0.492954, "arguments": [{"text": "reader", "location": [28719, 28725], "entities": [{"type": "Person", "text": "reader"}]}, {"text": "Announcement", "location": [28669, 28681], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "partOfMany", "sentence": "All forward-looking statements attributable to Takeda or Shire or any person acting on either company's behalf are expressly qualified in their entirety by this cautionary statement.", "score": 0.865201, "arguments": [{"text": "Takeda", "location": [28774, 28780], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "their", "location": [28865, 28870], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "All forward-looking statements attributable to Takeda or Shire or any person acting on either company's behalf are expressly qualified in their entirety by this cautionary statement.", "score": 0.958817, "arguments": [{"text": "Shire", "location": [28784, 28789], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "their", "location": [28865, 28870], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "All forward-looking statements attributable to Takeda or Shire or any person acting on either company's behalf are expressly qualified in their entirety by this cautionary statement.", "score": 0.803988, "arguments": [{"text": "person", "location": [28797, 28803], "entities": [{"type": "Person", "text": "person"}]}, {"text": "their", "location": [28865, 28870], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "agentOf", "sentence": "Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.", "score": 0.834273, "arguments": [{"text": "Readers", "location": [28910, 28917], "entities": [{"type": "Person", "text": "Readers"}]}, {"text": "cautioned", "location": [28922, 28931], "entities": [{"type": "EventCommunication", "text": "cautioned"}]}]}, {"type": "partOfMany", "sentence": "Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.", "score": 0.678392, "arguments": [{"text": "persons", "location": [30998, 31005], "entities": [{"type": "Person", "text": "persons"}]}, {"text": "who", "location": [31006, 31009], "entities": [{"type": "Person", "text": "who"}]}]}, {"type": "locatedAt", "sentence": "Shire also notes Takeda's circular to shareholders published today, which relates to the convocation of the Takeda Extraordinary General Meeting scheduled to be held at 10.00 a.m. (Tokyo time) (1.00 a.m. (London time)) on December 5, 2018.", "score": 0.626335, "arguments": [{"text": "Meeting", "location": [2238, 2245], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}, {"text": "Tokyo", "location": [2282, 2287], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo"}]}]}, {"type": "hasAttribute", "sentence": "If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.", "score": 0.824036, "arguments": [{"text": "Rule", "location": [32339, 32343], "entities": [{"type": "Organization", "text": "Rule"}]}, {"text": "8.3", "location": [32344, 32347], "entities": [{"type": "Money", "text": "8.3"}]}]}, {"type": "participantIn", "sentence": "Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).", "score": 0.534952, "arguments": [{"text": "persons", "location": [32530, 32537], "entities": [{"type": "Person", "text": "persons"}]}, {"text": "concert", "location": [32548, 32555], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Panel's website at http://www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the Offer Period commenced and when any offeror was first identified.", "score": 0.457967, "arguments": [{"text": "whose", "location": [32662, 32667], "entities": [{"type": "Person", "text": "whose"}]}, {"text": "companies", "location": [32638, 32647], "entities": [{"type": "Organization", "text": "companies"}]}]}, {"type": "timeOf", "sentence": "Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Panel's website at http://www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the Offer Period commenced and when any offeror was first identified.", "score": 0.556374, "arguments": [{"text": "http://www.thetakeoverpanel.org.uk", "location": [32817, 32851], "entities": [{"type": "Time", "text": "http://www.thetakeoverpanel.org.uk"}]}, {"text": "commenced", "location": [32940, 32949], "entities": [{"type": "EventCommunication", "text": "commenced"}]}]}, {"type": "agentOf", "sentence": "Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Panel's website at http://www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the Offer Period commenced and when any offeror was first identified.", "score": 0.991137, "arguments": [{"text": "Offer Period", "location": [32927, 32939], "entities": [{"type": "Organization", "text": "Offer Period"}]}, {"text": "commenced", "location": [32940, 32949], "entities": [{"type": "EventCommunication", "text": "commenced"}]}]}, {"type": "partOf", "sentence": "If you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure, you should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129.", "score": 0.733376, "arguments": [{"text": "Market Surveillance Unit on +44", "location": [33143, 33174], "entities": [{"type": "Organization", "text": "Market Surveillance Unit on +44"}]}, {"text": "Panel", "location": [33135, 33140], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "colleague", "sentence": "Electronic Communications Please be aware that addresses, electronic addresses and certain other information provided by Shire Shareholders, persons with information rights and other relevant persons in connection with the receipt of communications from Shire may be provided to Takeda during the Offer Period as required under Section 4 of Appendix 4 of the Takeover Code to comply with Rule 2.11 of the Takeover Code.", "score": 0.229669, "arguments": [{"text": "Shire", "location": [33313, 33318], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Shareholders", "location": [33319, 33331], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "employedBy", "sentence": "Electronic Communications Please be aware that addresses, electronic addresses and certain other information provided by Shire Shareholders, persons with information rights and other relevant persons in connection with the receipt of communications from Shire may be provided to Takeda during the Offer Period as required under Section 4 of Appendix 4 of the Takeover Code to comply with Rule 2.11 of the Takeover Code.", "score": 0.540989, "arguments": [{"text": "Takeda", "location": [33471, 33477], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "Offer Period", "location": [33489, 33501], "entities": [{"type": "Organization", "text": "Offer Period"}]}]}, {"type": "partOf", "sentence": "Electronic Communications Please be aware that addresses, electronic addresses and certain other information provided by Shire Shareholders, persons with information rights and other relevant persons in connection with the receipt of communications from Shire may be provided to Takeda during the Offer Period as required under Section 4 of Appendix 4 of the Takeover Code to comply with Rule 2.11 of the Takeover Code.", "score": 0.523397, "arguments": [{"text": "Section 4", "location": [33520, 33529], "entities": [{"type": "Organization", "text": "Section 4"}]}, {"text": "Appendix 4", "location": [33533, 33543], "entities": [{"type": "Organization", "text": "Appendix 4"}]}]}, {"type": "partOf", "sentence": "Electronic Communications Please be aware that addresses, electronic addresses and certain other information provided by Shire Shareholders, persons with information rights and other relevant persons in connection with the receipt of communications from Shire may be provided to Takeda during the Offer Period as required under Section 4 of Appendix 4 of the Takeover Code to comply with Rule 2.11 of the Takeover Code.", "score": 0.545241, "arguments": [{"text": "Rule", "location": [33580, 33584], "entities": [{"type": "Organization", "text": "Rule"}]}, {"text": "Takeover Code", "location": [33597, 33610], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "participantIn", "sentence": "Notices of the Court Meeting and Shire General Meeting As described in the Scheme Document, to become effective, the Scheme requires, among other things, the approval of Shire Shareholders at the Court Meeting, the passing of the Special Resolution at the Shire General Meeting and the subsequent sanction of the Court.", "score": 0.473197, "arguments": [{"text": "Court", "location": [2592, 2597], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [2598, 2605], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "ownerOf", "sentence": "Publication on Website and Availability of Hard Copies A copy of this Announcement and the documents required to be published by Rule 26 of the Takeover Code will be made available (subject to certain restrictions relating to persons resident in Restricted Jurisdictions) on Takeda 's and Shire's websites at www.takeda.com/investors/offer-for-shire and www.shire.com respectively by no later than 12 noon (London time) on November 13, 2018 , the Business Day following this Announcement .", "score": 0.542279, "arguments": [{"text": "Shire", "location": [33901, 33906], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "websites", "location": [33909, 33917], "entities": [{"type": "Facility", "text": "websites"}]}]}, {"type": "timeOf", "sentence": "Publication on Website and Availability of Hard Copies A copy of this Announcement and the documents required to be published by Rule 26 of the Takeover Code will be made available (subject to certain restrictions relating to persons resident in Restricted Jurisdictions) on Takeda 's and Shire's websites at www.takeda.com/investors/offer-for-shire and www.shire.com respectively by no later than 12 noon (London time) on November 13, 2018 , the Business Day following this Announcement .", "score": 0.642039, "arguments": [{"text": "November 13, 2018", "location": [34035, 34052], "entities": [{"type": "Date", "text": "November 13, 2018"}]}, {"text": "Announcement", "location": [34087, 34099], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Publication on Website and Availability of Hard Copies A copy of this Announcement and the documents required to be published by Rule 26 of the Takeover Code will be made available (subject to certain restrictions relating to persons resident in Restricted Jurisdictions) on Takeda 's and Shire's websites at www.takeda.com/investors/offer-for-shire and www.shire.com respectively by no later than 12 noon (London time) on November 13, 2018 , the Business Day following this Announcement .", "score": 0.592584, "arguments": [{"text": "Business Day", "location": [34059, 34071], "entities": [{"type": "Organization", "text": "Business Day"}]}, {"text": "Announcement", "location": [34087, 34099], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Shire Shareholders may request a hard copy of this Announcement by: (i) contacting Souheil Salah during business hours on +44 (0) 203 5490660 (lines are open from 9am to 5pm (London time), Monday to Friday (excluding public holidays in England and Wales), or (ii) by submitting a request by post to Souheil Salah, One Kingdom Street, 9th Floor, Paddington, London W2 6BD, UK.", "score": 0.626175, "arguments": [{"text": "Souheil Salah", "location": [34313, 34326], "entities": [{"type": "Person", "text": "Souheil Salah"}]}, {"text": "Announcement", "location": [34281, 34293], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "locatedAt", "sentence": "Shire Shareholders may request a hard copy of this Announcement by: (i) contacting Souheil Salah during business hours on +44 (0) 203 5490660 (lines are open from 9am to 5pm (London time), Monday to Friday (excluding public holidays in England and Wales), or (ii) by submitting a request by post to Souheil Salah, One Kingdom Street, 9th Floor, Paddington, London W2 6BD, UK.", "score": 0.504854, "arguments": [{"text": "9th Floor", "location": [34564, 34573], "entities": [{"type": "Organization", "text": "9th Floor"}]}, {"text": "Paddington", "location": [34575, 34585], "entities": [{"type": "GeopoliticalEntity", "text": "Paddington"}]}]}, {"type": "locatedAt", "sentence": "Shire Shareholders may request a hard copy of this Announcement by: (i) contacting Souheil Salah during business hours on +44 (0) 203 5490660 (lines are open from 9am to 5pm (London time), Monday to Friday (excluding public holidays in England and Wales), or (ii) by submitting a request by post to Souheil Salah, One Kingdom Street, 9th Floor, Paddington, London W2 6BD, UK.", "score": 0.657564, "arguments": [{"text": "Paddington", "location": [34575, 34585], "entities": [{"type": "GeopoliticalEntity", "text": "Paddington"}]}, {"text": "London", "location": [34587, 34593], "entities": [{"type": "GeopoliticalEntity", "text": "London"}]}]}, {"type": "employedBy", "sentence": "Shire Shareholders may request a hard copy of this Announcement by: (i) contacting Souheil Salah during business hours on +44 (0) 203 5490660 (lines are open from 9am to 5pm (London time), Monday to Friday (excluding public holidays in England and Wales), or (ii) by submitting a request by post to Souheil Salah, One Kingdom Street, 9th Floor, Paddington, London W2 6BD, UK.", "score": 0.892815, "arguments": [{"text": "W2 6BD", "location": [34594, 34600], "entities": [{"type": "Person", "text": "W2 6BD"}]}, {"text": "UK", "location": [34602, 34604], "entities": [{"type": "GeopoliticalEntity", "text": "UK"}]}]}, {"type": "agentOf", "sentence": "If you have received this Announcement in electronic form, copies of this Announcement and any document or information incorporated by reference into this document will not be provided unless such a request is made.", "score": 0.909348, "arguments": [{"text": "you", "location": [34609, 34612], "entities": [{"type": "Person", "text": "you"}]}, {"text": "Announcement", "location": [34632, 34644], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "colleague", "sentence": "Shire Shareholders may also request that all future documents, announcements and information to be sent to them in relation to the Acquisition should be in hard copy form.", "score": 0.270028, "arguments": [{"text": "Shire", "location": [34822, 34827], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Shareholders", "location": [34828, 34840], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "agentOf", "sentence": "Shire Shareholders may also request that all future documents, announcements and information to be sent to them in relation to the Acquisition should be in hard copy form.", "score": 0.692299, "arguments": [{"text": "Shire", "location": [34822, 34827], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "request", "location": [34850, 34857], "entities": [{"type": "EventCommunication", "text": "request"}]}]}, {"type": "agentOf", "sentence": "Notices of the Court Meeting and Shire General Meeting As described in the Scheme Document, to become effective, the Scheme requires, among other things, the approval of Shire Shareholders at the Court Meeting, the passing of the Special Resolution at the Shire General Meeting and the subsequent sanction of the Court.", "score": 0.563012, "arguments": [{"text": "Scheme Document", "location": [2652, 2667], "entities": [{"type": "Organization", "text": "Scheme Document"}]}, {"text": "described", "location": [2635, 2644], "entities": [{"type": "EventCommunication", "text": "described"}]}]}, {"type": "agentOf", "sentence": "If you are in any doubt about the contents of this Announcement or the action you should take, you are recommended to seek your own independent financial advice immediately from your stockbroker, bank manager, solicitor, accountant or independent financial adviser duly authorised under Financial Services (Jersey) Law 1998 (as amended) if you are resident in Jersey, the Financial Services and Markets Act 2000 (as amended) if you are resident in the United Kingdom, or, if not, from another appropriately authorised independent financial adviser.", "score": 0.584221, "arguments": [{"text": "you", "location": [35072, 35075], "entities": [{"type": "Person", "text": "you"}]}, {"text": "Announcement", "location": [35045, 35057], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "If you are in any doubt about the contents of this Announcement or the action you should take, you are recommended to seek your own independent financial advice immediately from your stockbroker, bank manager, solicitor, accountant or independent financial adviser duly authorised under Financial Services (Jersey) Law 1998 (as amended) if you are resident in Jersey, the Financial Services and Markets Act 2000 (as amended) if you are resident in the United Kingdom, or, if not, from another appropriately authorised independent financial adviser.", "score": 0.934639, "arguments": [{"text": "you", "location": [35089, 35092], "entities": [{"type": "Person", "text": "you"}]}, {"text": "recommended", "location": [35097, 35108], "entities": [{"type": "EventCommunication", "text": "recommended"}]}]}, {"type": "clientOf", "sentence": "If you are in any doubt about the contents of this Announcement or the action you should take, you are recommended to seek your own independent financial advice immediately from your stockbroker, bank manager, solicitor, accountant or independent financial adviser duly authorised under Financial Services (Jersey) Law 1998 (as amended) if you are resident in Jersey, the Financial Services and Markets Act 2000 (as amended) if you are resident in the United Kingdom, or, if not, from another appropriately authorised independent financial adviser.", "score": 0.323759, "arguments": [{"text": "your", "location": [35172, 35176], "entities": [{"type": "Person", "text": "your"}]}, {"text": "stockbroker", "location": [35177, 35188], "entities": [{"type": "Person", "text": "stockbroker"}]}]}, {"type": "managerOf", "sentence": "If you are in any doubt about the contents of this Announcement or the action you should take, you are recommended to seek your own independent financial advice immediately from your stockbroker, bank manager, solicitor, accountant or independent financial adviser duly authorised under Financial Services (Jersey) Law 1998 (as amended) if you are resident in Jersey, the Financial Services and Markets Act 2000 (as amended) if you are resident in the United Kingdom, or, if not, from another appropriately authorised independent financial adviser.", "score": 0.651856, "arguments": [{"text": "manager", "location": [35195, 35202], "entities": [{"type": "Person", "text": "manager"}]}, {"text": "bank", "location": [35190, 35194], "entities": [{"type": "Organization", "text": "bank"}]}]}, {"type": "locatedAt", "sentence": "If you are in any doubt about the contents of this Announcement or the action you should take, you are recommended to seek your own independent financial advice immediately from your stockbroker, bank manager, solicitor, accountant or independent financial adviser duly authorised under Financial Services (Jersey) Law 1998 (as amended) if you are resident in Jersey, the Financial Services and Markets Act 2000 (as amended) if you are resident in the United Kingdom, or, if not, from another appropriately authorised independent financial adviser.", "score": 0.373705, "arguments": [{"text": "Financial Services", "location": [35281, 35299], "entities": [{"type": "Organization", "text": "Financial Services"}]}, {"text": "Jersey", "location": [35301, 35307], "entities": [{"type": "GeopoliticalEntity", "text": "Jersey"}]}]}, {"type": "affectedBy", "sentence": "Rounding Certain figures included in this Announcement have been subjected to rounding adjustments.", "score": 0.509696, "arguments": [{"text": "figures", "location": [35560, 35567], "entities": [{"type": "Person", "text": "figures"}]}, {"text": "Announcement", "location": [35585, 35597], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "partOfMany", "sentence": "Accordingly, figures shown for the same category presented in different tables may vary slightly and figures shown as totals in certain tables may not be an arithmetic aggregation of the figures that precede them.", "score": 0.501776, "arguments": [{"text": "figures", "location": [35830, 35837], "entities": [{"type": "Person", "text": "figures"}]}, {"text": "them", "location": [35851, 35855], "entities": [{"type": "Person", "text": "them"}]}]}, {"type": "partOfMany", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event Time and/or date ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: Court Meeting (BLUE form) 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form)", "score": 0.85893, "arguments": [{"text": "Shire ADS Holders", "location": [36311, 36328], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "Shareholders", "location": [36294, 36306], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "employedBy", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event Time and/or date ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: Court Meeting (BLUE form) 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form)", "score": 0.491518, "arguments": [{"text": "Shire", "location": [36393, 36398], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "which", "location": [36387, 36392], "entities": [{"type": "Organization", "text": "which"}]}]}, {"type": "agentOf", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event Time and/or date ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: Court Meeting (BLUE form) 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form)", "score": 0.448308, "arguments": [{"text": "Court", "location": [36633, 36638], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [36639, 36646], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "participantIn", "sentence": "Notices of the Court Meeting and Shire General Meeting As described in the Scheme Document, to become effective, the Scheme requires, among other things, the approval of Shire Shareholders at the Court Meeting, the passing of the Special Resolution at the Shire General Meeting and the subsequent sanction of the Court.", "score": 0.588946, "arguments": [{"text": "Shire", "location": [2747, 2752], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Meeting", "location": [2779, 2786], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "partOf", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event Time and/or date ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: Court Meeting (BLUE form) 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form)", "score": 0.398444, "arguments": [{"text": "Meeting", "location": [36639, 36646], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}, {"text": "Meeting", "location": [36669, 36676], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "participantIn", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event Time and/or date ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: Court Meeting (BLUE form) 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form)", "score": 0.794421, "arguments": [{"text": "Shire General", "location": [36655, 36668], "entities": [{"type": "Person", "text": "Shire General"}]}, {"text": "Meeting", "location": [36669, 36676], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "timeOf", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event Time and/or date ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: Court Meeting (BLUE form) 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form)", "score": 0.849077, "arguments": [{"text": "a.m.", "location": [36683, 36687], "entities": [{"type": "Time", "text": "a.m."}]}, {"text": "Meeting", "location": [36669, 36676], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "participantIn", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event Time and/or date ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: Court Meeting (BLUE form) 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form)", "score": 0.469762, "arguments": [{"text": "Court", "location": [36776, 36781], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [36782, 36789], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "timeOf", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event Time and/or date ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: Court Meeting (BLUE form) 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form)", "score": 0.896306, "arguments": [{"text": "a.m.", "location": [36808, 36812], "entities": [{"type": "Time", "text": "a.m."}]}, {"text": "Meeting", "location": [36782, 36789], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "participantIn", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event Time and/or date ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: Court Meeting (BLUE form) 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form)", "score": 0.863899, "arguments": [{"text": "Shire General", "location": [36837, 36850], "entities": [{"type": "Person", "text": "Shire General"}]}, {"text": "Meeting", "location": [36851, 36858], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "timeOf", "sentence": "11.30 a.m. on December 3, 2018 (3) Voting Record Time 6.30 p.m. on December 3, 2018 (4) Takeda Extraordinary General Meeting 10.00 a.m. (Tokyo time) on December 5, 2018 Court Meeting 11.15 a.m. on December 5, 2018 (5) Shire General Meeting 11.30 a.m. on December 5, 2018 (5)(6) The following dates are indicative only and subject to change; please see note (7) below: Last time for Shire ADS Holders to present their Shire ADSs for cancellation and take delivery of Shire Shares to become Shire Shareholders before the Scheme Record Time 5.00 p.m. (New York time) on December 26, 2018 Latest time for receipt of Forms of Election 6.00 p.m. on January 2, 2019 Court Sanction Hearing 10.00 a.m. on January 3,", "score": 0.494984, "arguments": [{"text": "December 3, 2018", "location": [36940, 36956], "entities": [{"type": "Date", "text": "December 3, 2018"}]}, {"text": "Meeting", "location": [36990, 36997], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "participantIn", "sentence": "11.30 a.m. on December 3, 2018 (3) Voting Record Time 6.30 p.m. on December 3, 2018 (4) Takeda Extraordinary General Meeting 10.00 a.m. (Tokyo time) on December 5, 2018 Court Meeting 11.15 a.m. on December 5, 2018 (5) Shire General Meeting 11.30 a.m. on December 5, 2018 (5)(6) The following dates are indicative only and subject to change; please see note (7) below: Last time for Shire ADS Holders to present their Shire ADSs for cancellation and take delivery of Shire Shares to become Shire Shareholders before the Scheme Record Time 5.00 p.m. (New York time) on December 26, 2018 Latest time for receipt of Forms of Election 6.00 p.m. on January 2, 2019 Court Sanction Hearing 10.00 a.m. on January 3,", "score": 0.852472, "arguments": [{"text": "Takeda Extraordinary General", "location": [36961, 36989], "entities": [{"type": "Person", "text": "Takeda Extraordinary General"}]}, {"text": "Meeting", "location": [36990, 36997], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "timeOf", "sentence": "11.30 a.m. on December 3, 2018 (3) Voting Record Time 6.30 p.m. on December 3, 2018 (4) Takeda Extraordinary General Meeting 10.00 a.m. (Tokyo time) on December 5, 2018 Court Meeting 11.15 a.m. on December 5, 2018 (5) Shire General Meeting 11.30 a.m. on December 5, 2018 (5)(6) The following dates are indicative only and subject to change; please see note (7) below: Last time for Shire ADS Holders to present their Shire ADSs for cancellation and take delivery of Shire Shares to become Shire Shareholders before the Scheme Record Time 5.00 p.m. (New York time) on December 26, 2018 Latest time for receipt of Forms of Election 6.00 p.m. on January 2, 2019 Court Sanction Hearing 10.00 a.m. on January 3,", "score": 0.750291, "arguments": [{"text": "a.m.", "location": [37004, 37008], "entities": [{"type": "Time", "text": "a.m."}]}, {"text": "Meeting", "location": [36990, 36997], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "agentOf", "sentence": "11.30 a.m. on December 3, 2018 (3) Voting Record Time 6.30 p.m. on December 3, 2018 (4) Takeda Extraordinary General Meeting 10.00 a.m. (Tokyo time) on December 5, 2018 Court Meeting 11.15 a.m. on December 5, 2018 (5) Shire General Meeting 11.30 a.m. on December 5, 2018 (5)(6) The following dates are indicative only and subject to change; please see note (7) below: Last time for Shire ADS Holders to present their Shire ADSs for cancellation and take delivery of Shire Shares to become Shire Shareholders before the Scheme Record Time 5.00 p.m. (New York time) on December 26, 2018 Latest time for receipt of Forms of Election 6.00 p.m. on January 2, 2019 Court Sanction Hearing 10.00 a.m. on January 3,", "score": 0.514639, "arguments": [{"text": "Court", "location": [37042, 37047], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [37048, 37055], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "partOfMany", "sentence": "12 08:01:01 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE NOVEMBER 12, 2018 RECOMMENDED OFFER for SHIRE PLC by TAKEDA PHARMACEUTICAL COMPANY LIMITED Publication of Scheme Document On May 8, 2018, Shire plc (\" Shire \") and Takeda Pharmaceutical Company Limited (\" Takeda \") announced that they had reached agreement on the terms of a recommended cash and share offer to be made by Takeda for the entire issued and to be issued share capital of Shire (the \" Acquisition \").", "score": 0.960081, "arguments": [{"text": "Shire", "location": [396, 401], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "they", "location": [475, 479], "entities": [{"type": "Person", "text": "they"}]}]}, {"type": "agentOf", "sentence": "Notices of the Court Meeting and Shire General Meeting As described in the Scheme Document, to become effective, the Scheme requires, among other things, the approval of Shire Shareholders at the Court Meeting, the passing of the Special Resolution at the Shire General Meeting and the subsequent sanction of the Court.", "score": 0.418295, "arguments": [{"text": "Court", "location": [2773, 2778], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [2779, 2786], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "timeOf", "sentence": "11.30 a.m. on December 3, 2018 (3) Voting Record Time 6.30 p.m. on December 3, 2018 (4) Takeda Extraordinary General Meeting 10.00 a.m. (Tokyo time) on December 5, 2018 Court Meeting 11.15 a.m. on December 5, 2018 (5) Shire General Meeting 11.30 a.m. on December 5, 2018 (5)(6) The following dates are indicative only and subject to change; please see note (7) below: Last time for Shire ADS Holders to present their Shire ADSs for cancellation and take delivery of Shire Shares to become Shire Shareholders before the Scheme Record Time 5.00 p.m. (New York time) on December 26, 2018 Latest time for receipt of Forms of Election 6.00 p.m. on January 2, 2019 Court Sanction Hearing 10.00 a.m. on January 3,", "score": 0.88629, "arguments": [{"text": "a.m.", "location": [37062, 37066], "entities": [{"type": "Time", "text": "a.m."}]}, {"text": "Meeting", "location": [37048, 37055], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "timeOf", "sentence": "11.30 a.m. on December 3, 2018 (3) Voting Record Time 6.30 p.m. on December 3, 2018 (4) Takeda Extraordinary General Meeting 10.00 a.m. (Tokyo time) on December 5, 2018 Court Meeting 11.15 a.m. on December 5, 2018 (5) Shire General Meeting 11.30 a.m. on December 5, 2018 (5)(6) The following dates are indicative only and subject to change; please see note (7) below: Last time for Shire ADS Holders to present their Shire ADSs for cancellation and take delivery of Shire Shares to become Shire Shareholders before the Scheme Record Time 5.00 p.m. (New York time) on December 26, 2018 Latest time for receipt of Forms of Election 6.00 p.m. on January 2, 2019 Court Sanction Hearing 10.00 a.m. on January 3,", "score": 0.494514, "arguments": [{"text": "December 5, 2018", "location": [37070, 37086], "entities": [{"type": "Date", "text": "December 5, 2018"}]}, {"text": "Meeting", "location": [37048, 37055], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "participantIn", "sentence": "11.30 a.m. on December 3, 2018 (3) Voting Record Time 6.30 p.m. on December 3, 2018 (4) Takeda Extraordinary General Meeting 10.00 a.m. (Tokyo time) on December 5, 2018 Court Meeting 11.15 a.m. on December 5, 2018 (5) Shire General Meeting 11.30 a.m. on December 5, 2018 (5)(6) The following dates are indicative only and subject to change; please see note (7) below: Last time for Shire ADS Holders to present their Shire ADSs for cancellation and take delivery of Shire Shares to become Shire Shareholders before the Scheme Record Time 5.00 p.m. (New York time) on December 26, 2018 Latest time for receipt of Forms of Election 6.00 p.m. on January 2, 2019 Court Sanction Hearing 10.00 a.m. on January 3,", "score": 0.891152, "arguments": [{"text": "Shire General", "location": [37091, 37104], "entities": [{"type": "Person", "text": "Shire General"}]}, {"text": "Meeting", "location": [37105, 37112], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "timeOf", "sentence": "11.30 a.m. on December 3, 2018 (3) Voting Record Time 6.30 p.m. on December 3, 2018 (4) Takeda Extraordinary General Meeting 10.00 a.m. (Tokyo time) on December 5, 2018 Court Meeting 11.15 a.m. on December 5, 2018 (5) Shire General Meeting 11.30 a.m. on December 5, 2018 (5)(6) The following dates are indicative only and subject to change; please see note (7) below: Last time for Shire ADS Holders to present their Shire ADSs for cancellation and take delivery of Shire Shares to become Shire Shareholders before the Scheme Record Time 5.00 p.m. (New York time) on December 26, 2018 Latest time for receipt of Forms of Election 6.00 p.m. on January 2, 2019 Court Sanction Hearing 10.00 a.m. on January 3,", "score": 0.933301, "arguments": [{"text": "11.30 a.m.", "location": [37113, 37123], "entities": [{"type": "Time", "text": "11.30 a.m."}]}, {"text": "Meeting", "location": [37105, 37112], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "timeOf", "sentence": "11.30 a.m. on December 3, 2018 (3) Voting Record Time 6.30 p.m. on December 3, 2018 (4) Takeda Extraordinary General Meeting 10.00 a.m. (Tokyo time) on December 5, 2018 Court Meeting 11.15 a.m. on December 5, 2018 (5) Shire General Meeting 11.30 a.m. on December 5, 2018 (5)(6) The following dates are indicative only and subject to change; please see note (7) below: Last time for Shire ADS Holders to present their Shire ADSs for cancellation and take delivery of Shire Shares to become Shire Shareholders before the Scheme Record Time 5.00 p.m. (New York time) on December 26, 2018 Latest time for receipt of Forms of Election 6.00 p.m. on January 2, 2019 Court Sanction Hearing 10.00 a.m. on January 3,", "score": 0.653878, "arguments": [{"text": "December 5, 2018", "location": [37127, 37143], "entities": [{"type": "Date", "text": "December 5, 2018"}]}, {"text": "Meeting", "location": [37105, 37112], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "partOfMany", "sentence": "11.30 a.m. on December 3, 2018 (3) Voting Record Time 6.30 p.m. on December 3, 2018 (4) Takeda Extraordinary General Meeting 10.00 a.m. (Tokyo time) on December 5, 2018 Court Meeting 11.15 a.m. on December 5, 2018 (5) Shire General Meeting 11.30 a.m. on December 5, 2018 (5)(6) The following dates are indicative only and subject to change; please see note (7) below: Last time for Shire ADS Holders to present their Shire ADSs for cancellation and take delivery of Shire Shares to become Shire Shareholders before the Scheme Record Time 5.00 p.m. (New York time) on December 26, 2018 Latest time for receipt of Forms of Election 6.00 p.m. on January 2, 2019 Court Sanction Hearing 10.00 a.m. on January 3,", "score": 0.576983, "arguments": [{"text": "Shire ADS Holders", "location": [37255, 37272], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "their", "location": [37284, 37289], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "employedBy", "sentence": "2019 Last time for dealings in Shire Shares on the London Stock Exchange 4.30 p.m. on January 4, 2019 Latest time for receipt of TTE Instructions and disablement of Shire Shares in CREST 6.00 p.m. on January 4, 2019 Scheme Record Time 6.00 p.m. on January 4, 2019 Last time for dealings in Shire ADSs on NASDAQ close of business (New York time) on January 4, 2019 Suspension of dealings in Shire Shares on the London Stock Exchange before open of business on January 7, 2019 Halt of dealings in Shire ADSs on NASDAQ before open of business (New York time) on January 7, 2019 Commencement of \"when issued\" dealings in the New Takeda ADSs on the New York Stock Exchange 9.30 a.m. (New York time) on January 7,", "score": 0.536036, "arguments": [{"text": "Shire", "location": [37611, 37616], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "London Stock Exchange", "location": [37631, 37652], "entities": [{"type": "Organization", "text": "London Stock Exchange"}]}]}, {"type": "employedBy", "sentence": "2019 Last time for dealings in Shire Shares on the London Stock Exchange 4.30 p.m. on January 4, 2019 Latest time for receipt of TTE Instructions and disablement of Shire Shares in CREST 6.00 p.m. on January 4, 2019 Scheme Record Time 6.00 p.m. on January 4, 2019 Last time for dealings in Shire ADSs on NASDAQ close of business (New York time) on January 4, 2019 Suspension of dealings in Shire Shares on the London Stock Exchange before open of business on January 7, 2019 Halt of dealings in Shire ADSs on NASDAQ before open of business (New York time) on January 7, 2019 Commencement of \"when issued\" dealings in the New Takeda ADSs on the New York Stock Exchange 9.30 a.m. (New York time) on January 7,", "score": 0.588385, "arguments": [{"text": "Shire", "location": [37970, 37975], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "London Stock Exchange", "location": [37990, 38011], "entities": [{"type": "Organization", "text": "London Stock Exchange"}]}]}, {"type": "populationOf", "sentence": "2019 Last time for dealings in Shire Shares on the London Stock Exchange 4.30 p.m. on January 4, 2019 Latest time for receipt of TTE Instructions and disablement of Shire Shares in CREST 6.00 p.m. on January 4, 2019 Scheme Record Time 6.00 p.m. on January 4, 2019 Last time for dealings in Shire ADSs on NASDAQ close of business (New York time) on January 4, 2019 Suspension of dealings in Shire Shares on the London Stock Exchange before open of business on January 7, 2019 Halt of dealings in Shire ADSs on NASDAQ before open of business (New York time) on January 7, 2019 Commencement of \"when issued\" dealings in the New Takeda ADSs on the New York Stock Exchange 9.30 a.m. (New York time) on January 7,", "score": 0.592142, "arguments": [{"text": "6.00", "location": [37767, 37771], "entities": [{"type": "Cardinal", "text": "6.00"}]}, {"text": "CREST", "location": [37761, 37766], "entities": [{"type": "GeopoliticalEntity", "text": "CREST"}]}]}, {"type": "timeOf", "sentence": "2019 Effective Date of the Scheme January 8, 2019 Effective date of the issue of the New Takeda Shares January 8, 2019 Cancellation of listing of Shire Shares on the premium listing segment of the Official List and the main market of the London Stock Exchange 8.00 a.m. on January 9, 2019 Delisting of Shire ADSs by 9.30 a.m. (New York time) on January 9, 2019 Settlement Account credited with New Takeda Shares by 00.01 a.m. (9.01 a.m. (Tokyo time)) on January 10, 2019 New Takeda Shares transferred from the Settlement Account to JASDEC Accounts of former Shire Shareholders from January 10, 2019, but in any event not later than 14 calendar days after the Effective Date (8) Listing of, and commencement of dealings in,", "score": 0.764769, "arguments": [{"text": "January 9, 2019", "location": [38633, 38648], "entities": [{"type": "Date", "text": "January 9, 2019"}]}, {"text": "Settlement", "location": [38649, 38659], "entities": [{"type": "EventLegal", "text": "Settlement"}]}]}, {"type": "affectedBy", "sentence": "2019 Effective Date of the Scheme January 8, 2019 Effective date of the issue of the New Takeda Shares January 8, 2019 Cancellation of listing of Shire Shares on the premium listing segment of the Official List and the main market of the London Stock Exchange 8.00 a.m. on January 9, 2019 Delisting of Shire ADSs by 9.30 a.m. (New York time) on January 9, 2019 Settlement Account credited with New Takeda Shares by 00.01 a.m. (9.01 a.m. (Tokyo time)) on January 10, 2019 New Takeda Shares transferred from the Settlement Account to JASDEC Accounts of former Shire Shareholders from January 10, 2019, but in any event not later than 14 calendar days after the Effective Date (8) Listing of, and commencement of dealings in,", "score": 0.833849, "arguments": [{"text": "Account", "location": [38660, 38667], "entities": [{"type": "Person", "text": "Account"}]}, {"text": "Settlement", "location": [38649, 38659], "entities": [{"type": "EventLegal", "text": "Settlement"}]}]}, {"type": "participantIn", "sentence": "Notices of the Court Meeting and Shire General Meeting As described in the Scheme Document, to become effective, the Scheme requires, among other things, the approval of Shire Shareholders at the Court Meeting, the passing of the Special Resolution at the Shire General Meeting and the subsequent sanction of the Court.", "score": 0.880371, "arguments": [{"text": "Shire General", "location": [2833, 2846], "entities": [{"type": "Person", "text": "Shire General"}]}, {"text": "Meeting", "location": [2847, 2854], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "agentOf", "sentence": "2019 Effective Date of the Scheme January 8, 2019 Effective date of the issue of the New Takeda Shares January 8, 2019 Cancellation of listing of Shire Shares on the premium listing segment of the Official List and the main market of the London Stock Exchange 8.00 a.m. on January 9, 2019 Delisting of Shire ADSs by 9.30 a.m. (New York time) on January 9, 2019 Settlement Account credited with New Takeda Shares by 00.01 a.m. (9.01 a.m. (Tokyo time)) on January 10, 2019 New Takeda Shares transferred from the Settlement Account to JASDEC Accounts of former Shire Shareholders from January 10, 2019, but in any event not later than 14 calendar days after the Effective Date (8) Listing of, and commencement of dealings in,", "score": 0.502895, "arguments": [{"text": "New Takeda", "location": [38759, 38769], "entities": [{"type": "Organization", "text": "New Takeda"}]}, {"text": "Settlement", "location": [38798, 38808], "entities": [{"type": "EventLegal", "text": "Settlement"}]}]}, {"type": "agentOf", "sentence": "the New Takeda Shares on the Tokyo Stock Exchange and the Local Japanese Stock Exchanges January 10, 2019 New Takeda Shares transferred from the Settlement Account to the Takeda Depositary's JASDEC Account January 10, 2019 New Takeda ADSs and CDIs representing New Takeda ADSs delivered to former Shire Shareholders from January 10, 2019, but in any event not later than 14 calendar days after the Effective Date (9) New Takeda ADSs delivered to former Shire ADS Holders from January 10, 2019 (10) Listing of, and commencement of regular-way dealings in, New Takeda ADSs on the New York Stock Exchange by 9.30 a.m. (New York time) on January 11, 2019 (11)", "score": 0.450269, "arguments": [{"text": "New Takeda", "location": [39117, 39127], "entities": [{"type": "Organization", "text": "New Takeda"}]}, {"text": "Settlement", "location": [39156, 39166], "entities": [{"type": "EventLegal", "text": "Settlement"}]}]}, {"type": "partOf", "sentence": "the New Takeda Shares on the Tokyo Stock Exchange and the Local Japanese Stock Exchanges January 10, 2019 New Takeda Shares transferred from the Settlement Account to the Takeda Depositary's JASDEC Account January 10, 2019 New Takeda ADSs and CDIs representing New Takeda ADSs delivered to former Shire Shareholders from January 10, 2019, but in any event not later than 14 calendar days after the Effective Date (9) New Takeda ADSs delivered to former Shire ADS Holders from January 10, 2019 (10) Listing of, and commencement of regular-way dealings in, New Takeda ADSs on the New York Stock Exchange by 9.30 a.m. (New York time) on January 11, 2019 (11)", "score": 0.78208, "arguments": [{"text": "JASDEC Account", "location": [39202, 39216], "entities": [{"type": "Organization", "text": "JASDEC Account"}]}, {"text": "Takeda Depositary", "location": [39182, 39199], "entities": [{"type": "Organization", "text": "Takeda Depositary"}]}]}, {"type": "employedBy", "sentence": "the New Takeda Shares on the Tokyo Stock Exchange and the Local Japanese Stock Exchanges January 10, 2019 New Takeda Shares transferred from the Settlement Account to the Takeda Depositary's JASDEC Account January 10, 2019 New Takeda ADSs and CDIs representing New Takeda ADSs delivered to former Shire Shareholders from January 10, 2019, but in any event not later than 14 calendar days after the Effective Date (9) New Takeda ADSs delivered to former Shire ADS Holders from January 10, 2019 (10) Listing of, and commencement of regular-way dealings in, New Takeda ADSs on the New York Stock Exchange by 9.30 a.m. (New York time) on January 11, 2019 (11)", "score": 0.472961, "arguments": [{"text": "Shire", "location": [39308, 39313], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "New Takeda ADSs", "location": [39272, 39287], "entities": [{"type": "Organization", "text": "New Takeda ADSs"}]}]}, {"type": "employedBy", "sentence": "the New Takeda Shares on the Tokyo Stock Exchange and the Local Japanese Stock Exchanges January 10, 2019 New Takeda Shares transferred from the Settlement Account to the Takeda Depositary's JASDEC Account January 10, 2019 New Takeda ADSs and CDIs representing New Takeda ADSs delivered to former Shire Shareholders from January 10, 2019, but in any event not later than 14 calendar days after the Effective Date (9) New Takeda ADSs delivered to former Shire ADS Holders from January 10, 2019 (10) Listing of, and commencement of regular-way dealings in, New Takeda ADSs on the New York Stock Exchange by 9.30 a.m. (New York time) on January 11, 2019 (11)", "score": 0.255215, "arguments": [{"text": "Shareholders", "location": [39314, 39326], "entities": [{"type": "Person", "text": "Shareholders"}]}, {"text": "New Takeda ADSs", "location": [39272, 39287], "entities": [{"type": "Organization", "text": "New Takeda ADSs"}]}]}, {"type": "partOf", "sentence": "the New Takeda Shares on the Tokyo Stock Exchange and the Local Japanese Stock Exchanges January 10, 2019 New Takeda Shares transferred from the Settlement Account to the Takeda Depositary's JASDEC Account January 10, 2019 New Takeda ADSs and CDIs representing New Takeda ADSs delivered to former Shire Shareholders from January 10, 2019, but in any event not later than 14 calendar days after the Effective Date (9) New Takeda ADSs delivered to former Shire ADS Holders from January 10, 2019 (10) Listing of, and commencement of regular-way dealings in, New Takeda ADSs on the New York Stock Exchange by 9.30 a.m. (New York time) on January 11, 2019 (11)", "score": 0.496915, "arguments": [{"text": "New Takeda ADSs", "location": [39428, 39443], "entities": [{"type": "Organization", "text": "New Takeda ADSs"}]}, {"text": "Effective Date", "location": [39409, 39423], "entities": [{"type": "Organization", "text": "Effective Date"}]}]}, {"type": "bornOn", "sentence": "the New Takeda Shares on the Tokyo Stock Exchange and the Local Japanese Stock Exchanges January 10, 2019 New Takeda Shares transferred from the Settlement Account to the Takeda Depositary's JASDEC Account January 10, 2019 New Takeda ADSs and CDIs representing New Takeda ADSs delivered to former Shire Shareholders from January 10, 2019, but in any event not later than 14 calendar days after the Effective Date (9) New Takeda ADSs delivered to former Shire ADS Holders from January 10, 2019 (10) Listing of, and commencement of regular-way dealings in, New Takeda ADSs on the New York Stock Exchange by 9.30 a.m. (New York time) on January 11, 2019 (11)", "score": 0.331888, "arguments": [{"text": "Shire ADS Holders", "location": [39464, 39481], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "January 10, 2019", "location": [39487, 39503], "entities": [{"type": "Date", "text": "January 10, 2019"}]}]}, {"type": "partOf", "sentence": "the New Takeda Shares on the Tokyo Stock Exchange and the Local Japanese Stock Exchanges January 10, 2019 New Takeda Shares transferred from the Settlement Account to the Takeda Depositary's JASDEC Account January 10, 2019 New Takeda ADSs and CDIs representing New Takeda ADSs delivered to former Shire Shareholders from January 10, 2019, but in any event not later than 14 calendar days after the Effective Date (9) New Takeda ADSs delivered to former Shire ADS Holders from January 10, 2019 (10) Listing of, and commencement of regular-way dealings in, New Takeda ADSs on the New York Stock Exchange by 9.30 a.m. (New York time) on January 11, 2019 (11)", "score": 0.626596, "arguments": [{"text": "New Takeda ADSs", "location": [39566, 39581], "entities": [{"type": "Organization", "text": "New Takeda ADSs"}]}, {"text": "New York Stock Exchange", "location": [39589, 39612], "entities": [{"type": "Organization", "text": "New York Stock Exchange"}]}]}, {"type": "colleague", "sentence": "CREST accounts of former Shire Shareholders credited with cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date (12) Processing of electronic BACs transfers to former Shire Shareholders in respect of cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date Despatch of cheques to former Shire Shareholders for the cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date Despatch of cheques to former Shire Shareholders in relation to the New Takeda Shares sold under the Dealing Facility within 14 calendar days of the Effective Date Payment of the cash due to former Shire ADS Holders by the Shire Depositary following receipt of funds by the Shire Depositary (13)", "score": 0.361297, "arguments": [{"text": "Shire", "location": [39692, 39697], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Shareholders", "location": [39698, 39710], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "colleague", "sentence": "CREST accounts of former Shire Shareholders credited with cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date (12) Processing of electronic BACs transfers to former Shire Shareholders in respect of cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date Despatch of cheques to former Shire Shareholders for the cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date Despatch of cheques to former Shire Shareholders in relation to the New Takeda Shares sold under the Dealing Facility within 14 calendar days of the Effective Date Payment of the cash due to former Shire ADS Holders by the Shire Depositary following receipt of funds by the Shire Depositary (13)", "score": 0.391602, "arguments": [{"text": "Shire", "location": [39895, 39900], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Shareholders", "location": [39901, 39913], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "participantIn", "sentence": "Notices of the Court Meeting and the Shire General Meeting, which are scheduled to be held at Block 3, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland on December 5, 2018, are set out in the Scheme Document.", "score": 0.514803, "arguments": [{"text": "Court", "location": [3059, 3064], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [3065, 3072], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "colleague", "sentence": "CREST accounts of former Shire Shareholders credited with cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date (12) Processing of electronic BACs transfers to former Shire Shareholders in respect of cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date Despatch of cheques to former Shire Shareholders for the cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date Despatch of cheques to former Shire Shareholders in relation to the New Takeda Shares sold under the Dealing Facility within 14 calendar days of the Effective Date Payment of the cash due to former Shire ADS Holders by the Shire Depositary following receipt of funds by the Shire Depositary (13)", "score": 0.375934, "arguments": [{"text": "Shire", "location": [40073, 40078], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Shareholders", "location": [40079, 40091], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "colleague", "sentence": "CREST accounts of former Shire Shareholders credited with cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date (12) Processing of electronic BACs transfers to former Shire Shareholders in respect of cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date Despatch of cheques to former Shire Shareholders for the cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date Despatch of cheques to former Shire Shareholders in relation to the New Takeda Shares sold under the Dealing Facility within 14 calendar days of the Effective Date Payment of the cash due to former Shire ADS Holders by the Shire Depositary following receipt of funds by the Shire Depositary (13)", "score": 0.389903, "arguments": [{"text": "Shire", "location": [40245, 40250], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Shareholders", "location": [40251, 40263], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "locatedAt", "sentence": "CREST accounts of former Shire Shareholders credited with cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date (12) Processing of electronic BACs transfers to former Shire Shareholders in respect of cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date Despatch of cheques to former Shire Shareholders for the cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date Despatch of cheques to former Shire Shareholders in relation to the New Takeda Shares sold under the Dealing Facility within 14 calendar days of the Effective Date Payment of the cash due to former Shire ADS Holders by the Shire Depositary following receipt of funds by the Shire Depositary (13)", "score": 0.527613, "arguments": [{"text": "Shareholders", "location": [40251, 40263], "entities": [{"type": "Person", "text": "Shareholders"}]}, {"text": "Facility", "location": [40324, 40332], "entities": [{"type": "Facility", "text": "Facility"}]}]}, {"type": "partOf", "sentence": "Latest date by which Scheme may become Effective May 8, 2019 (14) Notes: (1 ) In order to validly instruct the Shire Depositary as to voting at the Shire Meetings, the ADS Voting Card must be received by the Shire Depositary by 10.00 a.m. (New York time) on November 29, 2018 for each Shire Meeting or, if either Shire Meeting is adjourned, such later date as may be notified by the Shire Depositary, having consulted with Shire.", "score": 0.410084, "arguments": [{"text": "Scheme", "location": [40532, 40538], "entities": [{"type": "Organization", "text": "Scheme"}]}, {"text": "Latest", "location": [40511, 40517], "entities": [{"type": "Organization", "text": "Latest"}]}]}, {"type": "employedBy", "sentence": "Latest date by which Scheme may become Effective May 8, 2019 (14) Notes: (1 ) In order to validly instruct the Shire Depositary as to voting at the Shire Meetings, the ADS Voting Card must be received by the Shire Depositary by 10.00 a.m. (New York time) on November 29, 2018 for each Shire Meeting or, if either Shire Meeting is adjourned, such later date as may be notified by the Shire Depositary, having consulted with Shire.", "score": 0.736686, "arguments": [{"text": "Card", "location": [40690, 40694], "entities": [{"type": "Person", "text": "Card"}]}, {"text": "ADS Voting", "location": [40679, 40689], "entities": [{"type": "Organization", "text": "ADS Voting"}]}]}, {"type": "agentOf", "sentence": "Latest date by which Scheme may become Effective May 8, 2019 (14) Notes: (1 ) In order to validly instruct the Shire Depositary as to voting at the Shire Meetings, the ADS Voting Card must be received by the Shire Depositary by 10.00 a.m. (New York time) on November 29, 2018 for each Shire Meeting or, if either Shire Meeting is adjourned, such later date as may be notified by the Shire Depositary, having consulted with Shire.", "score": 0.781267, "arguments": [{"text": "Shire Meeting", "location": [40824, 40837], "entities": [{"type": "Person", "text": "Shire Meeting"}]}, {"text": "notified", "location": [40878, 40886], "entities": [{"type": "EventCommunication", "text": "notified"}]}]}, {"type": "agentOf", "sentence": "Latest date by which Scheme may become Effective May 8, 2019 (14) Notes: (1 ) In order to validly instruct the Shire Depositary as to voting at the Shire Meetings, the ADS Voting Card must be received by the Shire Depositary by 10.00 a.m. (New York time) on November 29, 2018 for each Shire Meeting or, if either Shire Meeting is adjourned, such later date as may be notified by the Shire Depositary, having consulted with Shire.", "score": 0.721094, "arguments": [{"text": "Shire Depositary", "location": [40894, 40910], "entities": [{"type": "Person", "text": "Shire Depositary"}]}, {"text": "notified", "location": [40878, 40886], "entities": [{"type": "EventCommunication", "text": "notified"}]}]}, {"type": "employedBy", "sentence": "(2 ) The BLUE Form of Proxy for the Court Meeting, if not received by Equiniti by the time stated above, may be handed to a representative of Equiniti, on behalf of the Chairman of the Court Meeting, or to the Chairman of the Court Meeting, before the start of the Court Meeting.", "score": 0.509834, "arguments": [{"text": "Chairman", "location": [41183, 41191], "entities": [{"type": "Person", "text": "Chairman"}]}, {"text": "Court Meeting", "location": [41199, 41212], "entities": [{"type": "Organization", "text": "Court Meeting"}]}]}, {"type": "employedBy", "sentence": "(2 ) The BLUE Form of Proxy for the Court Meeting, if not received by Equiniti by the time stated above, may be handed to a representative of Equiniti, on behalf of the Chairman of the Court Meeting, or to the Chairman of the Court Meeting, before the start of the Court Meeting.", "score": 0.560474, "arguments": [{"text": "Chairman", "location": [41224, 41232], "entities": [{"type": "Person", "text": "Chairman"}]}, {"text": "Court Meeting", "location": [41240, 41253], "entities": [{"type": "Organization", "text": "Court Meeting"}]}]}, {"type": "timeOf", "sentence": "(3 ) In order to be valid, the YELLOW Form of Proxy must be received by Equiniti not later than 11.30 a.m. on December 3, 2018 (or, if the Shire General Meeting is adjourned, not later than 48 hours before the time appointed for the adjourned Shire General Meeting).", "score": 0.438162, "arguments": [{"text": "48 hours", "location": [41484, 41492], "entities": [{"type": "Duration", "text": "48 hours"}]}, {"text": "appointed", "location": [41509, 41518], "entities": [{"type": "EventPersonnel", "text": "appointed"}]}]}, {"type": "locatedAt", "sentence": "Notices of the Court Meeting and the Shire General Meeting, which are scheduled to be held at Block 3, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland on December 5, 2018, are set out in the Scheme Document.", "score": 0.496747, "arguments": [{"text": "Miesian Plaza", "location": [3147, 3160], "entities": [{"type": "Person", "text": "Miesian Plaza"}]}, {"text": "Baggot Street Lower", "location": [3168, 3187], "entities": [{"type": "Facility", "text": "Baggot Street Lower"}]}]}, {"type": "agentOf", "sentence": "(3 ) In order to be valid, the YELLOW Form of Proxy must be received by Equiniti not later than 11.30 a.m. on December 3, 2018 (or, if the Shire General Meeting is adjourned, not later than 48 hours before the time appointed for the adjourned Shire General Meeting).", "score": 0.759745, "arguments": [{"text": "Shire General Meeting", "location": [41537, 41558], "entities": [{"type": "Person", "text": "Shire General Meeting"}]}, {"text": "appointed", "location": [41509, 41518], "entities": [{"type": "EventPersonnel", "text": "appointed"}]}]}, {"type": "participantIn", "sentence": "(4 ) If either the Court Meeting or the Shire General Meeting is adjourned, the Voting Record Time for the relevant adjourned Shire Meeting will be 6.30 p.m. on the date falling two calendar days before the date appointed for such adjourned Shire Meeting and the ADS Voting Record Time for the relevant adjourned Shire Meeting will be such later date as may be notified by the Shire Depositary, having consulted with Shire.", "score": 0.514803, "arguments": [{"text": "Court", "location": [41580, 41585], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [41586, 41593], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "agentOf", "sentence": "(4 ) If either the Court Meeting or the Shire General Meeting is adjourned, the Voting Record Time for the relevant adjourned Shire Meeting will be 6.30 p.m. on the date falling two calendar days before the date appointed for such adjourned Shire Meeting and the ADS Voting Record Time for the relevant adjourned Shire Meeting will be such later date as may be notified by the Shire Depositary, having consulted with Shire.", "score": 0.361618, "arguments": [{"text": "Shire Meeting", "location": [41802, 41815], "entities": [{"type": "Person", "text": "Shire Meeting"}]}, {"text": "appointed", "location": [41773, 41782], "entities": [{"type": "EventPersonnel", "text": "appointed"}]}]}, {"type": "agentOf", "sentence": "(4 ) If either the Court Meeting or the Shire General Meeting is adjourned, the Voting Record Time for the relevant adjourned Shire Meeting will be 6.30 p.m. on the date falling two calendar days before the date appointed for such adjourned Shire Meeting and the ADS Voting Record Time for the relevant adjourned Shire Meeting will be such later date as may be notified by the Shire Depositary, having consulted with Shire.", "score": 0.711808, "arguments": [{"text": "Shire Depositary", "location": [41938, 41954], "entities": [{"type": "Person", "text": "Shire Depositary"}]}, {"text": "notified", "location": [41922, 41930], "entities": [{"type": "EventCommunication", "text": "notified"}]}]}, {"type": "participantIn", "sentence": "(5 ) In the event that the Takeda Extraordinary General Meeting is postponed or adjourned, the Court Meeting and Shire General Meeting will be adjourned so that they will take place on the same date as the Takeda Extraordinary General Meeting.", "score": 0.907499, "arguments": [{"text": "Takeda Extraordinary General", "location": [42012, 42040], "entities": [{"type": "Person", "text": "Takeda Extraordinary General"}]}, {"text": "Meeting", "location": [42041, 42048], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "participantIn", "sentence": "(5 ) In the event that the Takeda Extraordinary General Meeting is postponed or adjourned, the Court Meeting and Shire General Meeting will be adjourned so that they will take place on the same date as the Takeda Extraordinary General Meeting.", "score": 0.914196, "arguments": [{"text": "Takeda Extraordinary General", "location": [42191, 42219], "entities": [{"type": "Person", "text": "Takeda Extraordinary General"}]}, {"text": "Meeting", "location": [42220, 42227], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "agentOf", "sentence": "(6 ) To commence at 11.30 a.m. (London time) or as soon thereafter as the Court Meeting shall have concluded or been adjourned.", "score": 0.441202, "arguments": [{"text": "Court", "location": [42303, 42308], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [42309, 42316], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "colleague", "sentence": "These dates will depend, among other things, on the dates upon which: (i) the Conditions are satisfied or (where applicable) waived; (ii) the European Commission gives its approval to proceed to completion of the Acquisition (see paragraph 7 of Part I (Letter from the Chairman of Shire PLC) of the Scheme Document for further details); (iii) the Court sanctions the Scheme; and (iv) the Court Order is delivered to the Registrar of Companies.", "score": 0.398897, "arguments": [{"text": "Chairman", "location": [42750, 42758], "entities": [{"type": "Person", "text": "Chairman"}]}, {"text": "Shire PLC", "location": [42762, 42771], "entities": [{"type": "Person", "text": "Shire PLC"}]}]}, {"type": "employedBy", "sentence": "These dates will depend, among other things, on the dates upon which: (i) the Conditions are satisfied or (where applicable) waived; (ii) the European Commission gives its approval to proceed to completion of the Acquisition (see paragraph 7 of Part I (Letter from the Chairman of Shire PLC) of the Scheme Document for further details); (iii) the Court sanctions the Scheme; and (iv) the Court Order is delivered to the Registrar of Companies.", "score": 0.701011, "arguments": [{"text": "Shire PLC", "location": [42762, 42771], "entities": [{"type": "Person", "text": "Shire PLC"}]}, {"text": "Scheme Document", "location": [42780, 42795], "entities": [{"type": "Organization", "text": "Scheme Document"}]}]}, {"type": "partOf", "sentence": "These dates will depend, among other things, on the dates upon which: (i) the Conditions are satisfied or (where applicable) waived; (ii) the European Commission gives its approval to proceed to completion of the Acquisition (see paragraph 7 of Part I (Letter from the Chairman of Shire PLC) of the Scheme Document for further details); (iii) the Court sanctions the Scheme; and (iv) the Court Order is delivered to the Registrar of Companies.", "score": 0.404673, "arguments": [{"text": "Court Order", "location": [42869, 42880], "entities": [{"type": "Organization", "text": "Court Order"}]}, {"text": "Registrar of Companies", "location": [42901, 42923], "entities": [{"type": "Organization", "text": "Registrar of Companies"}]}]}, {"type": "agentOf", "sentence": "The Court Meeting is scheduled to commence at 11.15 a.m. and the Shire General Meeting at 11.30 a.m. (or as soon thereafter as the Court Meeting has concluded or been adjourned).", "score": 0.5622, "arguments": [{"text": "Court", "location": [3268, 3273], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [3274, 3281], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "agentOf", "sentence": "Shire will give adequate notice of any changes by issuing an announcement through a Regulatory Information Service and will furnish such announcement to the SEC on Form 8-K. (8 ) In order to avoid a delay in the completion of any such transfer, Shire Shareholders who make a valid JASDEC Election to deliver their New Takeda Shares into an account with an AMI should contact their AMI to confirm any necessary steps in order for the AMI to record the delivery of the New Takeda Shares from the Settlement Account.", "score": 0.764401, "arguments": [{"text": "Shire", "location": [43242, 43247], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "issuing", "location": [43292, 43299], "entities": [{"type": "EventCommunication", "text": "issuing"}]}]}, {"type": "partOfMany", "sentence": "Shire will give adequate notice of any changes by issuing an announcement through a Regulatory Information Service and will furnish such announcement to the SEC on Form 8-K. (8 ) In order to avoid a delay in the completion of any such transfer, Shire Shareholders who make a valid JASDEC Election to deliver their New Takeda Shares into an account with an AMI should contact their AMI to confirm any necessary steps in order for the AMI to record the delivery of the New Takeda Shares from the Settlement Account.", "score": 0.656713, "arguments": [{"text": "Shareholders", "location": [43493, 43505], "entities": [{"type": "Person", "text": "Shareholders"}]}, {"text": "who", "location": [43506, 43509], "entities": [{"type": "Person", "text": "who"}]}]}, {"type": "partOfMany", "sentence": "In order to avoid a delay in receiving their New Takeda ADSs, Shire Shareholders who make a valid ADS Election to deliver their New Takeda ADSs to their broker or other securities intermediary in DTC should contact their broker or other securities intermediary to request that it, or the DTC participant through which it clears, inputs valid instructions to receive delivery of the New Takeda ADSs free of payment from the Takeda Depositary's DTC participant account (account number 2504). (10 ) New Takeda ADSs will be delivered to the Shire Depositary from January 10, 2019 (and in any event not later than 14 calendar days after the Effective Date).", "score": 0.650752, "arguments": [{"text": "Takeda ADSs", "location": [43930, 43941], "entities": [{"type": "Person", "text": "Takeda ADSs"}]}, {"text": "their", "location": [43920, 43925], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "In order to avoid a delay in receiving their New Takeda ADSs, Shire Shareholders who make a valid ADS Election to deliver their New Takeda ADSs to their broker or other securities intermediary in DTC should contact their broker or other securities intermediary to request that it, or the DTC participant through which it clears, inputs valid instructions to receive delivery of the New Takeda ADSs free of payment from the Takeda Depositary's DTC participant account (account number 2504). (10 ) New Takeda ADSs will be delivered to the Shire Depositary from January 10, 2019 (and in any event not later than 14 calendar days after the Effective Date).", "score": 0.476973, "arguments": [{"text": "Shareholders", "location": [43949, 43961], "entities": [{"type": "Person", "text": "Shareholders"}]}, {"text": "who", "location": [43962, 43965], "entities": [{"type": "Person", "text": "who"}]}]}, {"type": "partOfMany", "sentence": "In order to avoid a delay in receiving their New Takeda ADSs, Shire Shareholders who make a valid ADS Election to deliver their New Takeda ADSs to their broker or other securities intermediary in DTC should contact their broker or other securities intermediary to request that it, or the DTC participant through which it clears, inputs valid instructions to receive delivery of the New Takeda ADSs free of payment from the Takeda Depositary's DTC participant account (account number 2504). (10 ) New Takeda ADSs will be delivered to the Shire Depositary from January 10, 2019 (and in any event not later than 14 calendar days after the Effective Date).", "score": 0.515523, "arguments": [{"text": "Takeda ADSs", "location": [44013, 44024], "entities": [{"type": "Person", "text": "Takeda ADSs"}]}, {"text": "their", "location": [44003, 44008], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "In order to avoid a delay in receiving their New Takeda ADSs, Shire Shareholders who make a valid ADS Election to deliver their New Takeda ADSs to their broker or other securities intermediary in DTC should contact their broker or other securities intermediary to request that it, or the DTC participant through which it clears, inputs valid instructions to receive delivery of the New Takeda ADSs free of payment from the Takeda Depositary's DTC participant account (account number 2504). (10 ) New Takeda ADSs will be delivered to the Shire Depositary from January 10, 2019 (and in any event not later than 14 calendar days after the Effective Date).", "score": 0.557882, "arguments": [{"text": "Takeda ADSs", "location": [44013, 44024], "entities": [{"type": "Person", "text": "Takeda ADSs"}]}, {"text": "their", "location": [44028, 44033], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "employedBy", "sentence": "In order to avoid a delay in receiving their New Takeda ADSs, Shire Shareholders who make a valid ADS Election to deliver their New Takeda ADSs to their broker or other securities intermediary in DTC should contact their broker or other securities intermediary to request that it, or the DTC participant through which it clears, inputs valid instructions to receive delivery of the New Takeda ADSs free of payment from the Takeda Depositary's DTC participant account (account number 2504). (10 ) New Takeda ADSs will be delivered to the Shire Depositary from January 10, 2019 (and in any event not later than 14 calendar days after the Effective Date).", "score": 0.526534, "arguments": [{"text": "Shire Depositary", "location": [44418, 44434], "entities": [{"type": "Person", "text": "Shire Depositary"}]}, {"text": "New Takeda ADSs", "location": [44377, 44392], "entities": [{"type": "Organization", "text": "New Takeda ADSs"}]}]}, {"type": "employedBy", "sentence": "It is expected that Shire ADS Holders holding through participants in DTC will receive delivery shortly after the receipt by the Shire Depositary of the New Takeda ADSs and that registered Shire ADS Holders holding uncertificated Shire ADSs (that is, Shire ADSs held outside of DTC for which no certificates have been issued) will be issued New Takeda ADSs in uncertificated form beginning approximately one week thereafter (and will receive a statement by post reflecting the issuance of New Takeda ADSs in their name).", "score": 0.570346, "arguments": [{"text": "Shire Depositary", "location": [44814, 44830], "entities": [{"type": "Person", "text": "Shire Depositary"}]}, {"text": "New Takeda ADSs", "location": [44838, 44853], "entities": [{"type": "Organization", "text": "New Takeda ADSs"}]}]}, {"type": "partOfMany", "sentence": "The date on which New Takeda ADSs will be delivered to Shire ADS Holders will depend on the way in which such Shire ADS Holders held their Shire ADSs.", "score": 0.555817, "arguments": [{"text": "Shire ADS Holders", "location": [44644, 44661], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "their", "location": [44667, 44672], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "The date on which New Takeda ADSs will be delivered to Shire ADS Holders will depend on the way in which such Shire ADS Holders held their Shire ADSs.", "score": 0.707123, "arguments": [{"text": "Shire ADSs", "location": [44673, 44683], "entities": [{"type": "Person", "text": "Shire ADSs"}]}, {"text": "their", "location": [44667, 44672], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "residesIn", "sentence": "It is expected that Shire ADS Holders holding through participants in DTC will receive delivery shortly after the receipt by the Shire Depositary of the New Takeda ADSs and that registered Shire ADS Holders holding uncertificated Shire ADSs (that is, Shire ADSs held outside of DTC for which no certificates have been issued) will be issued New Takeda ADSs in uncertificated form beginning approximately one week thereafter (and will receive a statement by post reflecting the issuance of New Takeda ADSs in their name).", "score": 0.510484, "arguments": [{"text": "Shire ADS Holders", "location": [44705, 44722], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "DTC", "location": [44755, 44758], "entities": [{"type": "GeopoliticalEntity", "text": "DTC"}]}]}, {"type": "timeOf", "sentence": "The Court Meeting is scheduled to commence at 11.15 a.m. and the Shire General Meeting at 11.30 a.m. (or as soon thereafter as the Court Meeting has concluded or been adjourned).", "score": 0.512617, "arguments": [{"text": "a.m.", "location": [3316, 3320], "entities": [{"type": "Time", "text": "a.m."}]}, {"text": "Meeting", "location": [3274, 3281], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "locatedAt", "sentence": "It is expected that Shire ADS Holders holding through participants in DTC will receive delivery shortly after the receipt by the Shire Depositary of the New Takeda ADSs and that registered Shire ADS Holders holding uncertificated Shire ADSs (that is, Shire ADSs held outside of DTC for which no certificates have been issued) will be issued New Takeda ADSs in uncertificated form beginning approximately one week thereafter (and will receive a statement by post reflecting the issuance of New Takeda ADSs in their name).", "score": 0.468603, "arguments": [{"text": "participants", "location": [44739, 44751], "entities": [{"type": "Person", "text": "participants"}]}, {"text": "DTC", "location": [44755, 44758], "entities": [{"type": "GeopoliticalEntity", "text": "DTC"}]}]}, {"type": "partOf", "sentence": "It is expected that Shire ADS Holders holding through participants in DTC will receive delivery shortly after the receipt by the Shire Depositary of the New Takeda ADSs and that registered Shire ADS Holders holding uncertificated Shire ADSs (that is, Shire ADSs held outside of DTC for which no certificates have been issued) will be issued New Takeda ADSs in uncertificated form beginning approximately one week thereafter (and will receive a statement by post reflecting the issuance of New Takeda ADSs in their name).", "score": 0.622565, "arguments": [{"text": "which", "location": [44971, 44976], "entities": [{"type": "Organization", "text": "which"}]}, {"text": "DTC for", "location": [44963, 44970], "entities": [{"type": "Organization", "text": "DTC for"}]}]}, {"type": "memberOf", "sentence": "Registered Shire ADS Holders holding certificates for their Shire ADSs will only receive delivery of their New Takeda ADSs after they return their signed letter of transmittal and Shire ADS certificate to the Shire Depositary.", "score": 0.332671, "arguments": [{"text": "certificates", "location": [45243, 45255], "entities": [{"type": "Person", "text": "certificates"}]}, {"text": "Registered Shire ADS Holders", "location": [45206, 45234], "entities": [{"type": "Organization", "text": "Registered Shire ADS Holders"}]}]}, {"type": "partOfMany", "sentence": "(12 ) Shire Shareholders who hold Shire Shares in uncertificated form and receive the cash portion of the Consideration in US Dollars must ensure that an active US Dollar Cash Memorandum Account is in place in CREST by no later than the Scheme Record Time.", "score": 0.484278, "arguments": [{"text": "who", "location": [45890, 45893], "entities": [{"type": "Person", "text": "who"}]}, {"text": "Shareholders", "location": [45877, 45889], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "locatedAt", "sentence": "(12 ) Shire Shareholders who hold Shire Shares in uncertificated form and receive the cash portion of the Consideration in US Dollars must ensure that an active US Dollar Cash Memorandum Account is in place in CREST by no later than the Scheme Record Time.", "score": 0.708833, "arguments": [{"text": "Dollars", "location": [45991, 45998], "entities": [{"type": "Facility", "text": "Dollars"}]}, {"text": "US", "location": [45988, 45990], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "residesIn", "sentence": "(12 ) Shire Shareholders who hold Shire Shares in uncertificated form and receive the cash portion of the Consideration in US Dollars must ensure that an active US Dollar Cash Memorandum Account is in place in CREST by no later than the Scheme Record Time.", "score": 0.329653, "arguments": [{"text": "Dollar Cash Memorandum Account", "location": [46029, 46059], "entities": [{"type": "Person", "text": "Dollar Cash Memorandum Account"}]}, {"text": "US", "location": [46026, 46028], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "locatedAt", "sentence": "(12 ) Shire Shareholders who hold Shire Shares in uncertificated form and receive the cash portion of the Consideration in US Dollars must ensure that an active US Dollar Cash Memorandum Account is in place in CREST by no later than the Scheme Record Time.", "score": 0.678042, "arguments": [{"text": "Dollar Cash Memorandum Account", "location": [46029, 46059], "entities": [{"type": "Person", "text": "Dollar Cash Memorandum Account"}]}, {"text": "CREST", "location": [46075, 46080], "entities": [{"type": "GeopoliticalEntity", "text": "CREST"}]}]}, {"type": "managerOf", "sentence": "In the absence of a US Dollar Cash Memorandum Account, the payment of the cash portion of the Consideration will not settle, resulting in a delay and the settlement of the cash portion of the Consideration outside of CREST.", "score": 0.444366, "arguments": [{"text": "Dollar Cash Memorandum Account", "location": [46145, 46175], "entities": [{"type": "Person", "text": "Dollar Cash Memorandum Account"}]}, {"text": "US", "location": [46142, 46144], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "affectedBy", "sentence": "In the absence of a US Dollar Cash Memorandum Account, the payment of the cash portion of the Consideration will not settle, resulting in a delay and the settlement of the cash portion of the Consideration outside of CREST.", "score": 0.522945, "arguments": [{"text": "Dollar Cash Memorandum Account", "location": [46145, 46175], "entities": [{"type": "Person", "text": "Dollar Cash Memorandum Account"}]}, {"text": "settlement", "location": [46276, 46286], "entities": [{"type": "EventLegal", "text": "settlement"}]}]}, {"type": "participantIn", "sentence": "(13 ) In the case of Shire ADS Holders who hold Shire ADSs in certificated form, subject to presentation by such holders of their signed letters of transmittal and Shire ADS certificates to the Shire Depositary.", "score": 0.428942, "arguments": [{"text": "Shire ADS Holders", "location": [46367, 46384], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "case", "location": [46359, 46363], "entities": [{"type": "EventLegal", "text": "case"}]}]}, {"type": "partOf", "sentence": "The Court Meeting is scheduled to commence at 11.15 a.m. and the Shire General Meeting at 11.30 a.m. (or as soon thereafter as the Court Meeting has concluded or been adjourned).", "score": 0.34681, "arguments": [{"text": "Meeting", "location": [3274, 3281], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}, {"text": "Meeting", "location": [3343, 3350], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "partOfMany", "sentence": "(13 ) In the case of Shire ADS Holders who hold Shire ADSs in certificated form, subject to presentation by such holders of their signed letters of transmittal and Shire ADS certificates to the Shire Depositary.", "score": 0.537496, "arguments": [{"text": "Shire ADS Holders", "location": [46367, 46384], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "their", "location": [46470, 46475], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "(13 ) In the case of Shire ADS Holders who hold Shire ADSs in certificated form, subject to presentation by such holders of their signed letters of transmittal and Shire ADS certificates to the Shire Depositary.", "score": 0.82862, "arguments": [{"text": "Shire ADSs", "location": [46394, 46404], "entities": [{"type": "Person", "text": "Shire ADSs"}]}, {"text": "their", "location": [46470, 46475], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "(13 ) In the case of Shire ADS Holders who hold Shire ADSs in certificated form, subject to presentation by such holders of their signed letters of transmittal and Shire ADS certificates to the Shire Depositary.", "score": 0.827826, "arguments": [{"text": "holders", "location": [46459, 46466], "entities": [{"type": "Person", "text": "holders"}]}, {"text": "their", "location": [46470, 46475], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "(13 ) In the case of Shire ADS Holders who hold Shire ADSs in certificated form, subject to presentation by such holders of their signed letters of transmittal and Shire ADS certificates to the Shire Depositary.", "score": 0.750277, "arguments": [{"text": "their", "location": [46470, 46475], "entities": [{"type": "Person", "text": "their"}]}, {"text": "certificates", "location": [46520, 46532], "entities": [{"type": "Person", "text": "certificates"}]}]}, {"type": "colleague", "sentence": "(13 ) In the case of Shire ADS Holders who hold Shire ADSs in certificated form, subject to presentation by such holders of their signed letters of transmittal and Shire ADS certificates to the Shire Depositary.", "score": 0.253411, "arguments": [{"text": "Shire ADS", "location": [46510, 46519], "entities": [{"type": "Person", "text": "Shire ADS"}]}, {"text": "certificates", "location": [46520, 46532], "entities": [{"type": "Person", "text": "certificates"}]}]}, {"type": "participantIn", "sentence": "The Court Meeting is scheduled to commence at 11.15 a.m. and the Shire General Meeting at 11.30 a.m. (or as soon thereafter as the Court Meeting has concluded or been adjourned).", "score": 0.89355, "arguments": [{"text": "Shire General", "location": [3329, 3342], "entities": [{"type": "Person", "text": "Shire General"}]}, {"text": "Meeting", "location": [3343, 3350], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "timeOf", "sentence": "The Court Meeting is scheduled to commence at 11.15 a.m. and the Shire General Meeting at 11.30 a.m. (or as soon thereafter as the Court Meeting has concluded or been adjourned).", "score": 0.751479, "arguments": [{"text": "11.30 a.m.", "location": [3354, 3364], "entities": [{"type": "Time", "text": "11.30 a.m."}]}, {"text": "Meeting", "location": [3343, 3350], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "participantIn", "sentence": "The Court Meeting is scheduled to commence at 11.15 a.m. and the Shire General Meeting at 11.30 a.m. (or as soon thereafter as the Court Meeting has concluded or been adjourned).", "score": 0.463751, "arguments": [{"text": "Court", "location": [3395, 3400], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [3401, 3408], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "partOf", "sentence": "The Acquisition will be effected by means of a scheme of arrangement under Article 125 of the Companies (Jersey) Law 1991 (as amended) (the \" Scheme \").", "score": 0.407208, "arguments": [{"text": "Companies", "location": [753, 762], "entities": [{"type": "Organization", "text": "Companies"}]}, {"text": "Jersey", "location": [764, 770], "entities": [{"type": "Organization", "text": "Jersey"}]}]}, {"type": "participantIn", "sentence": "It is important that, for the Court Meeting in particular, as many votes as possible are cast so that the Court may be satisfied that there is a fair and reasonable representation of Shire Shareholder opinion.", "score": 0.448505, "arguments": [{"text": "Court", "location": [3473, 3478], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [3479, 3486], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "partOfMany", "sentence": "Shire Shareholders and Shire ADS Holders are therefore strongly urged to complete, sign and return the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible.", "score": 0.550635, "arguments": [{"text": "Shire", "location": [3653, 3658], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "their", "location": [3874, 3879], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "Shire Shareholders and Shire ADS Holders are therefore strongly urged to complete, sign and return the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible.", "score": 0.72046, "arguments": [{"text": "Shire ADS Holders", "location": [3676, 3693], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "Shareholders", "location": [3659, 3671], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "partOfMany", "sentence": "Shire Shareholders and Shire ADS Holders are therefore strongly urged to complete, sign and return the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible.", "score": 0.553355, "arguments": [{"text": "Shareholders", "location": [3659, 3671], "entities": [{"type": "Person", "text": "Shareholders"}]}, {"text": "their", "location": [3874, 3879], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "agentOf", "sentence": "Shire Shareholders and Shire ADS Holders are therefore strongly urged to complete, sign and return the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible.", "score": 0.692017, "arguments": [{"text": "Shire ADS Holders", "location": [3676, 3693], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "urged", "location": [3717, 3722], "entities": [{"type": "EventCommunication", "text": "urged"}]}]}, {"type": "partOfMany", "sentence": "Shire Shareholders and Shire ADS Holders are therefore strongly urged to complete, sign and return the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible.", "score": 0.789426, "arguments": [{"text": "Shire ADS Holders", "location": [3676, 3693], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "their", "location": [3874, 3879], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "Shire Shareholders and Shire ADS Holders are therefore strongly urged to complete, sign and return the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible.", "score": 0.746897, "arguments": [{"text": "Voting Card", "location": [3884, 3895], "entities": [{"type": "Person", "text": "Voting Card"}]}, {"text": "their", "location": [3874, 3879], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "participantIn", "sentence": "Shire Shareholders and Shire ADS Holders are therefore strongly urged to complete, sign and return the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible.", "score": 0.50097, "arguments": [{"text": "Court", "location": [3910, 3915], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [3916, 3923], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "productOf", "sentence": "Timetable The Scheme Document contains an expected timetable of principal events relating to the Scheme, which is also attached as an Appendix to this Announcement.", "score": 0.550334, "arguments": [{"text": "Appendix", "location": [4110, 4118], "entities": [{"type": "Product", "text": "Appendix"}]}, {"text": "which", "location": [4081, 4086], "entities": [{"type": "Organization", "text": "which"}]}]}, {"type": "agentOf", "sentence": "It is intended that, following the Scheme becoming Effective, the London Stock Exchange and the FCA will be requested respectively to cancel trading in Shire Shares on the London Stock Exchange's main market for listed securities and to remove the listing of the Shire Shares from the Official List, in each case on or shortly after the Effective Date.", "score": 0.932621, "arguments": [{"text": "FCA", "location": [4993, 4996], "entities": [{"type": "Organization", "text": "FCA"}]}, {"text": "requested", "location": [5005, 5014], "entities": [{"type": "EventCommunication", "text": "requested"}]}]}, {"type": "agentOf", "sentence": "Shire is pleased to announce that the scheme document which sets out, among other things, a letter from the Chairman of Shire, the full terms and conditions of the Scheme, an explanatory statement, notices of the Court Meeting and the Shire General Meeting, an expected timetable of principal events and details of the action to be taken by Shire Shareholders and Shire ADS Holders, is being sent, or made available, to Shire Shareholders and Shire ADS Holders today and has been published on the Shire website at www.shire.com (the \" Scheme Document \").", "score": 0.90618, "arguments": [{"text": "Shire", "location": [812, 817], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "announce", "location": [832, 840], "entities": [{"type": "EventCommunication", "text": "announce"}]}]}, {"type": "employedBy", "sentence": "It is intended that, following the Scheme becoming Effective, the London Stock Exchange and the FCA will be requested respectively to cancel trading in Shire Shares on the London Stock Exchange's main market for listed securities and to remove the listing of the Shire Shares from the Official List, in each case on or shortly after the Effective Date.", "score": 0.656879, "arguments": [{"text": "Shire", "location": [5160, 5165], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Official List", "location": [5182, 5195], "entities": [{"type": "Organization", "text": "Official List"}]}]}, {"type": "agentOf", "sentence": "If any of the key dates set out in the timetable change, Shire will give notice of this change by issuing an announcement through a Regulatory Information Service.", "score": 0.847208, "arguments": [{"text": "Shire", "location": [5395, 5400], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "issuing", "location": [5436, 5443], "entities": [{"type": "EventCommunication", "text": "issuing"}]}]}, {"type": "partOfMany", "sentence": "Information for Shire Shareholders and Shire ADS Holders If you have any questions in relation to this Announcement, the Scheme Document, the Court Meeting or the Shire General Meeting, or are in any doubt as to how to complete the Forms of Proxy or lodge a Form of Election, please call Equiniti between 8.30 a.m. and 5.30 p.m. (London time) Monday to Friday (except public holidays in England and Wales) on 0330 123 5506 (if calling from within the UK) or +44 (0)121 415 0856 (if calling from outside the UK).", "score": 0.642989, "arguments": [{"text": "Shire ADS Holders", "location": [5619, 5636], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "Shareholders", "location": [5602, 5614], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "agentOf", "sentence": "Information for Shire Shareholders and Shire ADS Holders If you have any questions in relation to this Announcement, the Scheme Document, the Court Meeting or the Shire General Meeting, or are in any doubt as to how to complete the Forms of Proxy or lodge a Form of Election, please call Equiniti between 8.30 a.m. and 5.30 p.m. (London time) Monday to Friday (except public holidays in England and Wales) on 0330 123 5506 (if calling from within the UK) or +44 (0)121 415 0856 (if calling from outside the UK).", "score": 0.763903, "arguments": [{"text": "you", "location": [5640, 5643], "entities": [{"type": "Person", "text": "you"}]}, {"text": "Announcement", "location": [5683, 5695], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "affectedBy", "sentence": "Information for Shire Shareholders and Shire ADS Holders If you have any questions in relation to this Announcement, the Scheme Document, the Court Meeting or the Shire General Meeting, or are in any doubt as to how to complete the Forms of Proxy or lodge a Form of Election, please call Equiniti between 8.30 a.m. and 5.30 p.m. (London time) Monday to Friday (except public holidays in England and Wales) on 0330 123 5506 (if calling from within the UK) or +44 (0)121 415 0856 (if calling from outside the UK).", "score": 0.459791, "arguments": [{"text": "Scheme Document", "location": [5701, 5716], "entities": [{"type": "Organization", "text": "Scheme Document"}]}, {"text": "Announcement", "location": [5683, 5695], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "participantIn", "sentence": "Information for Shire Shareholders and Shire ADS Holders If you have any questions in relation to this Announcement, the Scheme Document, the Court Meeting or the Shire General Meeting, or are in any doubt as to how to complete the Forms of Proxy or lodge a Form of Election, please call Equiniti between 8.30 a.m. and 5.30 p.m. (London time) Monday to Friday (except public holidays in England and Wales) on 0330 123 5506 (if calling from within the UK) or +44 (0)121 415 0856 (if calling from outside the UK).", "score": 0.451052, "arguments": [{"text": "Court", "location": [5722, 5727], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [5728, 5735], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "timeOf", "sentence": "Information for Shire Shareholders and Shire ADS Holders If you have any questions in relation to this Announcement, the Scheme Document, the Court Meeting or the Shire General Meeting, or are in any doubt as to how to complete the Forms of Proxy or lodge a Form of Election, please call Equiniti between 8.30 a.m. and 5.30 p.m. (London time) Monday to Friday (except public holidays in England and Wales) on 0330 123 5506 (if calling from within the UK) or +44 (0)121 415 0856 (if calling from outside the UK).", "score": 0.542799, "arguments": [{"text": "0330 123 5506", "location": [5989, 6002], "entities": [{"type": "Date", "text": "0330 123 5506"}]}, {"text": "calling", "location": [6007, 6014], "entities": [{"type": "EventCommunication", "text": "calling"}]}]}, {"type": "employedBy", "sentence": "Enquiries: Shire Christoph Brackmann (Investor Relations) christoph.brackmann@shire.com +41 41 288 41 29 Scott Burrows (Investor Relations) scott.burrows@shire.com +41 41 288 41 95 Sun Kim (Investor Relations) sun.kim@shire.com +1 617 588 8175 Katie Joyce (Media) kjoyce@shire.com +1 781 482 2779 Citigroup Global Markets Limited (joint financial adviser to Shire) (US) Chris Hite +1 212 816 6000 Cary Kochman (UK) Jan Skarbek Andrew Seaton (Corporate Broking) +44 207 986 4000 Goldman Sachs International (joint financial adviser to Shire) Anthony Gutman Robert King Nick Harper +44 207 774 1000 Morgan Stanley & Co. International plc (joint financial adviser to Shire) Clint Gartin Philippe Gallone David Kitterick Peter Moorhouse (Corporate Broking) +44 207 425 8000 FTI Consulting (communications support to Shire)", "score": 0.47966, "arguments": [{"text": "Shire\nChristoph Brackmann", "location": [6932, 6957], "entities": [{"type": "Person", "text": "Shire\nChristoph Brackmann"}]}, {"text": "Investor Relations", "location": [6959, 6977], "entities": [{"type": "Organization", "text": "Investor Relations"}]}]}, {"type": "employedBy", "sentence": "Enquiries: Shire Christoph Brackmann (Investor Relations) christoph.brackmann@shire.com +41 41 288 41 29 Scott Burrows (Investor Relations) scott.burrows@shire.com +41 41 288 41 95 Sun Kim (Investor Relations) sun.kim@shire.com +1 617 588 8175 Katie Joyce (Media) kjoyce@shire.com +1 781 482 2779 Citigroup Global Markets Limited (joint financial adviser to Shire) (US) Chris Hite +1 212 816 6000 Cary Kochman (UK) Jan Skarbek Andrew Seaton (Corporate Broking) +44 207 986 4000 Goldman Sachs International (joint financial adviser to Shire) Anthony Gutman Robert King Nick Harper +44 207 774 1000 Morgan Stanley & Co. International plc (joint financial adviser to Shire) Clint Gartin Philippe Gallone David Kitterick Peter Moorhouse (Corporate Broking) +44 207 425 8000 FTI Consulting (communications support to Shire)", "score": 0.365892, "arguments": [{"text": "financial adviser", "location": [7258, 7275], "entities": [{"type": "Person", "text": "financial adviser"}]}, {"text": "Citigroup Global Markets Limited", "location": [7218, 7250], "entities": [{"type": "Organization", "text": "Citigroup Global Markets Limited"}]}]}, {"type": "locatedAt", "sentence": "Enquiries: Shire Christoph Brackmann (Investor Relations) christoph.brackmann@shire.com +41 41 288 41 29 Scott Burrows (Investor Relations) scott.burrows@shire.com +41 41 288 41 95 Sun Kim (Investor Relations) sun.kim@shire.com +1 617 588 8175 Katie Joyce (Media) kjoyce@shire.com +1 781 482 2779 Citigroup Global Markets Limited (joint financial adviser to Shire) (US) Chris Hite +1 212 816 6000 Cary Kochman (UK) Jan Skarbek Andrew Seaton (Corporate Broking) +44 207 986 4000 Goldman Sachs International (joint financial adviser to Shire) Anthony Gutman Robert King Nick Harper +44 207 774 1000 Morgan Stanley & Co. International plc (joint financial adviser to Shire) Clint Gartin Philippe Gallone David Kitterick Peter Moorhouse (Corporate Broking) +44 207 425 8000 FTI Consulting (communications support to Shire)", "score": 0.454136, "arguments": [{"text": "Shire", "location": [7279, 7284], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "US", "location": [7287, 7289], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "colleague", "sentence": "Shire is pleased to announce that the scheme document which sets out, among other things, a letter from the Chairman of Shire, the full terms and conditions of the Scheme, an explanatory statement, notices of the Court Meeting and the Shire General Meeting, an expected timetable of principal events and details of the action to be taken by Shire Shareholders and Shire ADS Holders, is being sent, or made available, to Shire Shareholders and Shire ADS Holders today and has been published on the Shire website at www.shire.com (the \" Scheme Document \").", "score": 0.340234, "arguments": [{"text": "Chairman", "location": [920, 928], "entities": [{"type": "Person", "text": "Chairman"}]}, {"text": "Shire", "location": [932, 937], "entities": [{"type": "Person", "text": "Shire"}]}]}, {"type": "employedBy", "sentence": "Enquiries: Shire Christoph Brackmann (Investor Relations) christoph.brackmann@shire.com +41 41 288 41 29 Scott Burrows (Investor Relations) scott.burrows@shire.com +41 41 288 41 95 Sun Kim (Investor Relations) sun.kim@shire.com +1 617 588 8175 Katie Joyce (Media) kjoyce@shire.com +1 781 482 2779 Citigroup Global Markets Limited (joint financial adviser to Shire) (US) Chris Hite +1 212 816 6000 Cary Kochman (UK) Jan Skarbek Andrew Seaton (Corporate Broking) +44 207 986 4000 Goldman Sachs International (joint financial adviser to Shire) Anthony Gutman Robert King Nick Harper +44 207 774 1000 Morgan Stanley & Co. International plc (joint financial adviser to Shire) Clint Gartin Philippe Gallone David Kitterick Peter Moorhouse (Corporate Broking) +44 207 425 8000 FTI Consulting (communications support to Shire)", "score": 0.765115, "arguments": [{"text": "Cary Kochman", "location": [7318, 7330], "entities": [{"type": "Person", "text": "Cary Kochman"}]}, {"text": "UK", "location": [7332, 7334], "entities": [{"type": "GeopoliticalEntity", "text": "UK"}]}]}, {"type": "employedBy", "sentence": "Enquiries: Shire Christoph Brackmann (Investor Relations) christoph.brackmann@shire.com +41 41 288 41 29 Scott Burrows (Investor Relations) scott.burrows@shire.com +41 41 288 41 95 Sun Kim (Investor Relations) sun.kim@shire.com +1 617 588 8175 Katie Joyce (Media) kjoyce@shire.com +1 781 482 2779 Citigroup Global Markets Limited (joint financial adviser to Shire) (US) Chris Hite +1 212 816 6000 Cary Kochman (UK) Jan Skarbek Andrew Seaton (Corporate Broking) +44 207 986 4000 Goldman Sachs International (joint financial adviser to Shire) Anthony Gutman Robert King Nick Harper +44 207 774 1000 Morgan Stanley & Co. International plc (joint financial adviser to Shire) Clint Gartin Philippe Gallone David Kitterick Peter Moorhouse (Corporate Broking) +44 207 425 8000 FTI Consulting (communications support to Shire)", "score": 0.536509, "arguments": [{"text": "Jan Skarbek\nAndrew Seaton", "location": [7336, 7361], "entities": [{"type": "Person", "text": "Jan Skarbek\nAndrew Seaton"}]}, {"text": "Corporate Broking", "location": [7363, 7380], "entities": [{"type": "Organization", "text": "Corporate Broking"}]}]}, {"type": "residesIn", "sentence": "Ben Atwell Brett Pollard +44 (0) 203 727 1000 Takeda Elissa Johnsen (Media - outside of Japan) elissa.johnsen@takeda.com +1 224 554 3185 Kazumi Kobayashi (Media - within Japan) Kazumi.kobayashi@takeda.com +81 3 3278 2095 Tsuyoshi Tada (Media - within Japan) tsuyoshi.tada@takeda.com +81 3 3278 2417 Takashi Okubo (Investor Relations) takeda.ir.contact@takeda.com +81 3 3278 2306 Evercore (joint financial adviser to Takeda) (US) Will Hiltz John Honts +1 212 857 3100 (UK) Julian Oakley +44 207 653 6000 J.P. Morgan Cazenove (joint financial adviser to Takeda) Michele Colocci Dwayne Lysaght James Mitford James Robinson +44 207 742 4000 Nomura (joint financial adviser to Takeda) Akira Kiyota Paolo Cicchine Andrew McNaught Oliver Tucker +44 207 102 1000 Finsbury (communications support to Takeda) (UK) James Murgatroyd /", "score": 0.433389, "arguments": [{"text": "Takeda\nElissa Johnsen", "location": [7786, 7807], "entities": [{"type": "Person", "text": "Takeda\nElissa Johnsen"}]}, {"text": "Japan", "location": [7828, 7833], "entities": [{"type": "GeopoliticalEntity", "text": "Japan"}]}]}, {"type": "locatedAt", "sentence": "Ben Atwell Brett Pollard +44 (0) 203 727 1000 Takeda Elissa Johnsen (Media - outside of Japan) elissa.johnsen@takeda.com +1 224 554 3185 Kazumi Kobayashi (Media - within Japan) Kazumi.kobayashi@takeda.com +81 3 3278 2095 Tsuyoshi Tada (Media - within Japan) tsuyoshi.tada@takeda.com +81 3 3278 2417 Takashi Okubo (Investor Relations) takeda.ir.contact@takeda.com +81 3 3278 2306 Evercore (joint financial adviser to Takeda) (US) Will Hiltz John Honts +1 212 857 3100 (UK) Julian Oakley +44 207 653 6000 J.P. Morgan Cazenove (joint financial adviser to Takeda) Michele Colocci Dwayne Lysaght James Mitford James Robinson +44 207 742 4000 Nomura (joint financial adviser to Takeda) Akira Kiyota Paolo Cicchine Andrew McNaught Oliver Tucker +44 207 102 1000 Finsbury (communications support to Takeda) (UK) James Murgatroyd /", "score": 0.368867, "arguments": [{"text": "Media", "location": [7809, 7814], "entities": [{"type": "Organization", "text": "Media"}]}, {"text": "Japan", "location": [7828, 7833], "entities": [{"type": "GeopoliticalEntity", "text": "Japan"}]}]}, {"type": "populationOf", "sentence": "Ben Atwell Brett Pollard +44 (0) 203 727 1000 Takeda Elissa Johnsen (Media - outside of Japan) elissa.johnsen@takeda.com +1 224 554 3185 Kazumi Kobayashi (Media - within Japan) Kazumi.kobayashi@takeda.com +81 3 3278 2095 Tsuyoshi Tada (Media - within Japan) tsuyoshi.tada@takeda.com +81 3 3278 2417 Takashi Okubo (Investor Relations) takeda.ir.contact@takeda.com +81 3 3278 2306 Evercore (joint financial adviser to Takeda) (US) Will Hiltz John Honts +1 212 857 3100 (UK) Julian Oakley +44 207 653 6000 J.P. Morgan Cazenove (joint financial adviser to Takeda) Michele Colocci Dwayne Lysaght James Mitford James Robinson +44 207 742 4000 Nomura (joint financial adviser to Takeda) Akira Kiyota Paolo Cicchine Andrew McNaught Oliver Tucker +44 207 102 1000 Finsbury (communications support to Takeda) (UK) James Murgatroyd /", "score": 0.396135, "arguments": [{"text": "1 224 554", "location": [7862, 7871], "entities": [{"type": "Cardinal", "text": "1 224 554"}]}, {"text": "Japan", "location": [7828, 7833], "entities": [{"type": "GeopoliticalEntity", "text": "Japan"}]}]}, {"type": "employedBy", "sentence": "Ben Atwell Brett Pollard +44 (0) 203 727 1000 Takeda Elissa Johnsen (Media - outside of Japan) elissa.johnsen@takeda.com +1 224 554 3185 Kazumi Kobayashi (Media - within Japan) Kazumi.kobayashi@takeda.com +81 3 3278 2095 Tsuyoshi Tada (Media - within Japan) tsuyoshi.tada@takeda.com +81 3 3278 2417 Takashi Okubo (Investor Relations) takeda.ir.contact@takeda.com +81 3 3278 2306 Evercore (joint financial adviser to Takeda) (US) Will Hiltz John Honts +1 212 857 3100 (UK) Julian Oakley +44 207 653 6000 J.P. Morgan Cazenove (joint financial adviser to Takeda) Michele Colocci Dwayne Lysaght James Mitford James Robinson +44 207 742 4000 Nomura (joint financial adviser to Takeda) Akira Kiyota Paolo Cicchine Andrew McNaught Oliver Tucker +44 207 102 1000 Finsbury (communications support to Takeda) (UK) James Murgatroyd /", "score": 0.481618, "arguments": [{"text": "Takashi Okubo", "location": [8039, 8052], "entities": [{"type": "Person", "text": "Takashi Okubo"}]}, {"text": "Investor Relations", "location": [8054, 8072], "entities": [{"type": "Organization", "text": "Investor Relations"}]}]}, {"type": "employedBy", "sentence": "Ben Atwell Brett Pollard +44 (0) 203 727 1000 Takeda Elissa Johnsen (Media - outside of Japan) elissa.johnsen@takeda.com +1 224 554 3185 Kazumi Kobayashi (Media - within Japan) Kazumi.kobayashi@takeda.com +81 3 3278 2095 Tsuyoshi Tada (Media - within Japan) tsuyoshi.tada@takeda.com +81 3 3278 2417 Takashi Okubo (Investor Relations) takeda.ir.contact@takeda.com +81 3 3278 2306 Evercore (joint financial adviser to Takeda) (US) Will Hiltz John Honts +1 212 857 3100 (UK) Julian Oakley +44 207 653 6000 J.P. Morgan Cazenove (joint financial adviser to Takeda) Michele Colocci Dwayne Lysaght James Mitford James Robinson +44 207 742 4000 Nomura (joint financial adviser to Takeda) Akira Kiyota Paolo Cicchine Andrew McNaught Oliver Tucker +44 207 102 1000 Finsbury (communications support to Takeda) (UK) James Murgatroyd /", "score": 0.563114, "arguments": [{"text": "takeda.ir.contact@takeda.com\n+81 3", "location": [8074, 8108], "entities": [{"type": "Person", "text": "takeda.ir.contact@takeda.com\n+81 3"}]}, {"text": "Investor Relations", "location": [8054, 8072], "entities": [{"type": "Organization", "text": "Investor Relations"}]}]}, {"type": "locatedAt", "sentence": "Ben Atwell Brett Pollard +44 (0) 203 727 1000 Takeda Elissa Johnsen (Media - outside of Japan) elissa.johnsen@takeda.com +1 224 554 3185 Kazumi Kobayashi (Media - within Japan) Kazumi.kobayashi@takeda.com +81 3 3278 2095 Tsuyoshi Tada (Media - within Japan) tsuyoshi.tada@takeda.com +81 3 3278 2417 Takashi Okubo (Investor Relations) takeda.ir.contact@takeda.com +81 3 3278 2306 Evercore (joint financial adviser to Takeda) (US) Will Hiltz John Honts +1 212 857 3100 (UK) Julian Oakley +44 207 653 6000 J.P. Morgan Cazenove (joint financial adviser to Takeda) Michele Colocci Dwayne Lysaght James Mitford James Robinson +44 207 742 4000 Nomura (joint financial adviser to Takeda) Akira Kiyota Paolo Cicchine Andrew McNaught Oliver Tucker +44 207 102 1000 Finsbury (communications support to Takeda) (UK) James Murgatroyd /", "score": 0.362466, "arguments": [{"text": "Takeda", "location": [8156, 8162], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "US", "location": [8165, 8167], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "residesIn", "sentence": "Ben Atwell Brett Pollard +44 (0) 203 727 1000 Takeda Elissa Johnsen (Media - outside of Japan) elissa.johnsen@takeda.com +1 224 554 3185 Kazumi Kobayashi (Media - within Japan) Kazumi.kobayashi@takeda.com +81 3 3278 2095 Tsuyoshi Tada (Media - within Japan) tsuyoshi.tada@takeda.com +81 3 3278 2417 Takashi Okubo (Investor Relations) takeda.ir.contact@takeda.com +81 3 3278 2306 Evercore (joint financial adviser to Takeda) (US) Will Hiltz John Honts +1 212 857 3100 (UK) Julian Oakley +44 207 653 6000 J.P. Morgan Cazenove (joint financial adviser to Takeda) Michele Colocci Dwayne Lysaght James Mitford James Robinson +44 207 742 4000 Nomura (joint financial adviser to Takeda) Akira Kiyota Paolo Cicchine Andrew McNaught Oliver Tucker +44 207 102 1000 Finsbury (communications support to Takeda) (UK) James Murgatroyd /", "score": 0.663508, "arguments": [{"text": "Takeda", "location": [8412, 8418], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "Finsbury", "location": [8495, 8503], "entities": [{"type": "GeopoliticalEntity", "text": "Finsbury"}]}]}, {"type": "residesIn", "sentence": "Ben Atwell Brett Pollard +44 (0) 203 727 1000 Takeda Elissa Johnsen (Media - outside of Japan) elissa.johnsen@takeda.com +1 224 554 3185 Kazumi Kobayashi (Media - within Japan) Kazumi.kobayashi@takeda.com +81 3 3278 2095 Tsuyoshi Tada (Media - within Japan) tsuyoshi.tada@takeda.com +81 3 3278 2417 Takashi Okubo (Investor Relations) takeda.ir.contact@takeda.com +81 3 3278 2306 Evercore (joint financial adviser to Takeda) (US) Will Hiltz John Honts +1 212 857 3100 (UK) Julian Oakley +44 207 653 6000 J.P. Morgan Cazenove (joint financial adviser to Takeda) Michele Colocci Dwayne Lysaght James Mitford James Robinson +44 207 742 4000 Nomura (joint financial adviser to Takeda) Akira Kiyota Paolo Cicchine Andrew McNaught Oliver Tucker +44 207 102 1000 Finsbury (communications support to Takeda) (UK) James Murgatroyd /", "score": 0.785872, "arguments": [{"text": "Akira Kiyota\nPaolo Cicchine\nAndrew McNaught\nOliver Tucker\n+44", "location": [8420, 8481], "entities": [{"type": "Person", "text": "Akira Kiyota\nPaolo Cicchine\nAndrew McNaught\nOliver Tucker\n+44"}]}, {"text": "Finsbury", "location": [8495, 8503], "entities": [{"type": "GeopoliticalEntity", "text": "Finsbury"}]}]}, {"type": "employedBy", "sentence": "Shire is pleased to announce that the scheme document which sets out, among other things, a letter from the Chairman of Shire, the full terms and conditions of the Scheme, an explanatory statement, notices of the Court Meeting and the Shire General Meeting, an expected timetable of principal events and details of the action to be taken by Shire Shareholders and Shire ADS Holders, is being sent, or made available, to Shire Shareholders and Shire ADS Holders today and has been published on the Shire website at www.shire.com (the \" Scheme Document \").", "score": 0.22409, "arguments": [{"text": "Shire", "location": [932, 937], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Scheme", "location": [976, 982], "entities": [{"type": "Organization", "text": "Scheme"}]}]}, {"type": "employedBy", "sentence": "Ben Atwell Brett Pollard +44 (0) 203 727 1000 Takeda Elissa Johnsen (Media - outside of Japan) elissa.johnsen@takeda.com +1 224 554 3185 Kazumi Kobayashi (Media - within Japan) Kazumi.kobayashi@takeda.com +81 3 3278 2095 Tsuyoshi Tada (Media - within Japan) tsuyoshi.tada@takeda.com +81 3 3278 2417 Takashi Okubo (Investor Relations) takeda.ir.contact@takeda.com +81 3 3278 2306 Evercore (joint financial adviser to Takeda) (US) Will Hiltz John Honts +1 212 857 3100 (UK) Julian Oakley +44 207 653 6000 J.P. Morgan Cazenove (joint financial adviser to Takeda) Michele Colocci Dwayne Lysaght James Mitford James Robinson +44 207 742 4000 Nomura (joint financial adviser to Takeda) Akira Kiyota Paolo Cicchine Andrew McNaught Oliver Tucker +44 207 102 1000 Finsbury (communications support to Takeda) (UK) James Murgatroyd /", "score": 0.799752, "arguments": [{"text": "Takeda", "location": [8531, 8537], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "UK", "location": [8540, 8542], "entities": [{"type": "GeopoliticalEntity", "text": "UK"}]}]}, {"type": "basedIn", "sentence": "Important Notices About Financial Advisers Evercore Partners International LLP (\" Evercore \"), which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and this Announcement and will not regard any other person as its client in relation to the Acquisition or this Announcement and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of Evercore, or for providing advice in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.433455, "arguments": [{"text": "Financial Conduct Authority", "location": [9040, 9067], "entities": [{"type": "Organization", "text": "Financial Conduct Authority"}]}, {"text": "United Kingdom", "location": [9018, 9032], "entities": [{"type": "GeopoliticalEntity", "text": "United Kingdom"}]}]}, {"type": "agentOf", "sentence": "Important Notices About Financial Advisers Evercore Partners International LLP (\" Evercore \"), which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and this Announcement and will not regard any other person as its client in relation to the Acquisition or this Announcement and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of Evercore, or for providing advice in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.415028, "arguments": [{"text": "anyone", "location": [9330, 9336], "entities": [{"type": "Person", "text": "anyone"}]}, {"text": "Announcement", "location": [9285, 9297], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "employedBy", "sentence": "Important Notices About Financial Advisers Evercore Partners International LLP (\" Evercore \"), which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and this Announcement and will not regard any other person as its client in relation to the Acquisition or this Announcement and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of Evercore, or for providing advice in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.358, "arguments": [{"text": "clients", "location": [9397, 9404], "entities": [{"type": "Person", "text": "clients"}]}, {"text": "Evercore", "location": [9408, 9416], "entities": [{"type": "Organization", "text": "Evercore"}]}]}, {"type": "partOf", "sentence": "Neither Evercore nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Evercore in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.788414, "arguments": [{"text": "subsidiaries", "location": [9562, 9574], "entities": [{"type": "Organization", "text": "subsidiaries"}]}, {"text": "its", "location": [9558, 9561], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "partOfMany", "sentence": "JPMorgan Securities Japan Co., Ltd., together with its affiliate J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove and which is authorised in the United Kingdom by the Prudential Regulation Authority and regulated in the United Kingdom by the Prudential Regulation Authority and the Financial Conduct Authority) (\" J.P. Morgan \"), is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and will not regard any other person as its client in relation to the Acquisition and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of J.P. Morgan, or for providing advice in connection with the Acquisition or any matter referred to herein.", "score": 0.392509, "arguments": [{"text": "JPMorgan Securities Japan Co., Ltd.", "location": [9885, 9920], "entities": [{"type": "Organization", "text": "JPMorgan Securities Japan Co., Ltd."}]}, {"text": "which", "location": [9978, 9983], "entities": [{"type": "Organization", "text": "which"}]}]}, {"type": "partOf", "sentence": "JPMorgan Securities Japan Co., Ltd., together with its affiliate J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove and which is authorised in the United Kingdom by the Prudential Regulation Authority and regulated in the United Kingdom by the Prudential Regulation Authority and the Financial Conduct Authority) (\" J.P. Morgan \"), is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and will not regard any other person as its client in relation to the Acquisition and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of J.P. Morgan, or for providing advice in connection with the Acquisition or any matter referred to herein.", "score": 0.87008, "arguments": [{"text": "affiliate", "location": [9940, 9949], "entities": [{"type": "Organization", "text": "affiliate"}]}, {"text": "its", "location": [9936, 9939], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "partOfMany", "sentence": "JPMorgan Securities Japan Co., Ltd., together with its affiliate J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove and which is authorised in the United Kingdom by the Prudential Regulation Authority and regulated in the United Kingdom by the Prudential Regulation Authority and the Financial Conduct Authority) (\" J.P. Morgan \"), is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and will not regard any other person as its client in relation to the Acquisition and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of J.P. Morgan, or for providing advice in connection with the Acquisition or any matter referred to herein.", "score": 0.667888, "arguments": [{"text": "J.P. Morgan Securities plc", "location": [9950, 9976], "entities": [{"type": "Organization", "text": "J.P. Morgan Securities plc"}]}, {"text": "affiliate", "location": [9940, 9949], "entities": [{"type": "Organization", "text": "affiliate"}]}]}, {"type": "partOfMany", "sentence": "JPMorgan Securities Japan Co., Ltd., together with its affiliate J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove and which is authorised in the United Kingdom by the Prudential Regulation Authority and regulated in the United Kingdom by the Prudential Regulation Authority and the Financial Conduct Authority) (\" J.P. Morgan \"), is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and will not regard any other person as its client in relation to the Acquisition and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of J.P. Morgan, or for providing advice in connection with the Acquisition or any matter referred to herein.", "score": 0.495335, "arguments": [{"text": "J.P. Morgan Securities plc", "location": [9950, 9976], "entities": [{"type": "Organization", "text": "J.P. Morgan Securities plc"}]}, {"text": "which", "location": [9978, 9983], "entities": [{"type": "Organization", "text": "which"}]}]}, {"type": "partOfMany", "sentence": "JPMorgan Securities Japan Co., Ltd., together with its affiliate J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove and which is authorised in the United Kingdom by the Prudential Regulation Authority and regulated in the United Kingdom by the Prudential Regulation Authority and the Financial Conduct Authority) (\" J.P. Morgan \"), is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and will not regard any other person as its client in relation to the Acquisition and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of J.P. Morgan, or for providing advice in connection with the Acquisition or any matter referred to herein.", "score": 0.528604, "arguments": [{"text": "J.P. Morgan Securities plc", "location": [9950, 9976], "entities": [{"type": "Organization", "text": "J.P. Morgan Securities plc"}]}, {"text": "its", "location": [9993, 9996], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "participantIn", "sentence": "Shire is pleased to announce that the scheme document which sets out, among other things, a letter from the Chairman of Shire, the full terms and conditions of the Scheme, an explanatory statement, notices of the Court Meeting and the Shire General Meeting, an expected timetable of principal events and details of the action to be taken by Shire Shareholders and Shire ADS Holders, is being sent, or made available, to Shire Shareholders and Shire ADS Holders today and has been published on the Shire website at www.shire.com (the \" Scheme Document \").", "score": 0.51267, "arguments": [{"text": "Court", "location": [1025, 1030], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [1031, 1038], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "partOfMany", "sentence": "JPMorgan Securities Japan Co., Ltd., together with its affiliate J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove and which is authorised in the United Kingdom by the Prudential Regulation Authority and regulated in the United Kingdom by the Prudential Regulation Authority and the Financial Conduct Authority) (\" J.P. Morgan \"), is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and will not regard any other person as its client in relation to the Acquisition and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of J.P. Morgan, or for providing advice in connection with the Acquisition or any matter referred to herein.", "score": 0.530369, "arguments": [{"text": "J.P. Morgan Securities plc", "location": [9950, 9976], "entities": [{"type": "Organization", "text": "J.P. Morgan Securities plc"}]}, {"text": "which", "location": [10056, 10061], "entities": [{"type": "Organization", "text": "which"}]}]}, {"type": "basedIn", "sentence": "JPMorgan Securities Japan Co., Ltd., together with its affiliate J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove and which is authorised in the United Kingdom by the Prudential Regulation Authority and regulated in the United Kingdom by the Prudential Regulation Authority and the Financial Conduct Authority) (\" J.P. Morgan \"), is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and will not regard any other person as its client in relation to the Acquisition and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of J.P. Morgan, or for providing advice in connection with the Acquisition or any matter referred to herein.", "score": 0.656251, "arguments": [{"text": "Prudential Regulation Authority", "location": [10105, 10136], "entities": [{"type": "Organization", "text": "Prudential Regulation Authority"}]}, {"text": "United Kingdom", "location": [10083, 10097], "entities": [{"type": "GeopoliticalEntity", "text": "United Kingdom"}]}]}, {"type": "basedIn", "sentence": "JPMorgan Securities Japan Co., Ltd., together with its affiliate J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove and which is authorised in the United Kingdom by the Prudential Regulation Authority and regulated in the United Kingdom by the Prudential Regulation Authority and the Financial Conduct Authority) (\" J.P. Morgan \"), is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and will not regard any other person as its client in relation to the Acquisition and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of J.P. Morgan, or for providing advice in connection with the Acquisition or any matter referred to herein.", "score": 0.510276, "arguments": [{"text": "Prudential Regulation Authority", "location": [10180, 10211], "entities": [{"type": "Organization", "text": "Prudential Regulation Authority"}]}, {"text": "United Kingdom", "location": [10158, 10172], "entities": [{"type": "GeopoliticalEntity", "text": "United Kingdom"}]}]}, {"type": "employedBy", "sentence": "JPMorgan Securities Japan Co., Ltd., together with its affiliate J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove and which is authorised in the United Kingdom by the Prudential Regulation Authority and regulated in the United Kingdom by the Prudential Regulation Authority and the Financial Conduct Authority) (\" J.P. Morgan \"), is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and will not regard any other person as its client in relation to the Acquisition and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of J.P. Morgan, or for providing advice in connection with the Acquisition or any matter referred to herein.", "score": 0.352634, "arguments": [{"text": "clients", "location": [10553, 10560], "entities": [{"type": "Person", "text": "clients"}]}, {"text": "J.P. Morgan", "location": [10564, 10575], "entities": [{"type": "Organization", "text": "J.P. Morgan"}]}]}, {"type": "locatedAt", "sentence": "Nomura International plc (\" Nomura \"), which is authorised by the Prudential Regulation Authority and regulated by the Prudential Regulation Authority and the Financial Conduct Authority in the United Kingdom, is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and this Announcement and Nomura, its affiliates and its respective officers, employees, agents, representatives and/or associates will not regard any other person as their client, nor will they be responsible to anyone other than Takeda for providing the protections afforded to clients of Nomura or for giving advice in relation to the Acquisition, this Announcement or any matter or referred to herein.", "score": 0.688333, "arguments": [{"text": "Financial Conduct Authority", "location": [10829, 10856], "entities": [{"type": "Organization", "text": "Financial Conduct Authority"}]}, {"text": "United Kingdom", "location": [10864, 10878], "entities": [{"type": "GeopoliticalEntity", "text": "United Kingdom"}]}]}, {"type": "agentOf", "sentence": "Nomura International plc (\" Nomura \"), which is authorised by the Prudential Regulation Authority and regulated by the Prudential Regulation Authority and the Financial Conduct Authority in the United Kingdom, is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and this Announcement and Nomura, its affiliates and its respective officers, employees, agents, representatives and/or associates will not regard any other person as their client, nor will they be responsible to anyone other than Takeda for providing the protections afforded to clients of Nomura or for giving advice in relation to the Acquisition, this Announcement or any matter or referred to herein.", "score": 0.534536, "arguments": [{"text": "Acquisition", "location": [10972, 10983], "entities": [{"type": "Organization", "text": "Acquisition"}]}, {"text": "Announcement", "location": [10993, 11005], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "partOf", "sentence": "Nomura International plc (\" Nomura \"), which is authorised by the Prudential Regulation Authority and regulated by the Prudential Regulation Authority and the Financial Conduct Authority in the United Kingdom, is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and this Announcement and Nomura, its affiliates and its respective officers, employees, agents, representatives and/or associates will not regard any other person as their client, nor will they be responsible to anyone other than Takeda for providing the protections afforded to clients of Nomura or for giving advice in relation to the Acquisition, this Announcement or any matter or referred to herein.", "score": 0.790887, "arguments": [{"text": "affiliates", "location": [11022, 11032], "entities": [{"type": "Organization", "text": "affiliates"}]}, {"text": "its", "location": [11018, 11021], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "employedBy", "sentence": "Nomura International plc (\" Nomura \"), which is authorised by the Prudential Regulation Authority and regulated by the Prudential Regulation Authority and the Financial Conduct Authority in the United Kingdom, is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and this Announcement and Nomura, its affiliates and its respective officers, employees, agents, representatives and/or associates will not regard any other person as their client, nor will they be responsible to anyone other than Takeda for providing the protections afforded to clients of Nomura or for giving advice in relation to the Acquisition, this Announcement or any matter or referred to herein.", "score": 0.586859, "arguments": [{"text": "officers", "location": [11052, 11060], "entities": [{"type": "Person", "text": "officers"}]}, {"text": "its", "location": [11037, 11040], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "partOfMany", "sentence": "Nomura International plc (\" Nomura \"), which is authorised by the Prudential Regulation Authority and regulated by the Prudential Regulation Authority and the Financial Conduct Authority in the United Kingdom, is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and this Announcement and Nomura, its affiliates and its respective officers, employees, agents, representatives and/or associates will not regard any other person as their client, nor will they be responsible to anyone other than Takeda for providing the protections afforded to clients of Nomura or for giving advice in relation to the Acquisition, this Announcement or any matter or referred to herein.", "score": 0.688311, "arguments": [{"text": "associates", "location": [11104, 11114], "entities": [{"type": "Person", "text": "associates"}]}, {"text": "their", "location": [11151, 11156], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOf", "sentence": "Neither Nomura nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Nomura in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.788414, "arguments": [{"text": "subsidiaries", "location": [11420, 11432], "entities": [{"type": "Organization", "text": "subsidiaries"}]}, {"text": "its", "location": [11416, 11419], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "locatedAt", "sentence": "Citigroup Global Markets Limited (\" Citi \"), which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting exclusively as financial adviser to Shire and no one else in connection with the Acquisition, this Announcement and the matters described herein, and shall not be responsible to anyone other than Shire for providing the protections afforded to clients of Citi, or for providing advice in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.735763, "arguments": [{"text": "Prudential Regulation Authority", "location": [11902, 11933], "entities": [{"type": "Organization", "text": "Prudential Regulation Authority"}]}, {"text": "United Kingdom", "location": [11941, 11955], "entities": [{"type": "GeopoliticalEntity", "text": "United Kingdom"}]}]}, {"type": "locatedAt", "sentence": "Goldman Sachs International (\" Goldman Sachs \"), which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting exclusively as financial adviser to Shire and no one else in connection with the Acquisition, this Announcement and the matters described herein, and shall not be responsible to anyone other than Shire for providing the protections afforded to clients of Goldman Sachs or for providing advice in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.736631, "arguments": [{"text": "Prudential Regulation Authority", "location": [12852, 12883], "entities": [{"type": "Organization", "text": "Prudential Regulation Authority"}]}, {"text": "United Kingdom", "location": [12891, 12905], "entities": [{"type": "GeopoliticalEntity", "text": "United Kingdom"}]}]}, {"type": "locatedAt", "sentence": "Neither Goldman Sachs nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Goldman Sachs in connection with the Acquisition, this Announcement or any matter referred to herein Morgan Stanley & Co. International plc (\" Morgan Stanley \"), which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting exclusively as financial adviser to Shire and no one else in connection with the Acquisition, this Announcement and the matters described herein,", "score": 0.77181, "arguments": [{"text": "Prudential Regulation Authority", "location": [13839, 13870], "entities": [{"type": "Organization", "text": "Prudential Regulation Authority"}]}, {"text": "United Kingdom", "location": [13878, 13892], "entities": [{"type": "GeopoliticalEntity", "text": "United Kingdom"}]}]}, {"type": "participantIn", "sentence": "Together with the Scheme Document, Forms of Proxy for the Court Meeting and the Shire General Meeting and Forms of Election and the notes accompanying them have also been published on the Shire website at www.shire.com.", "score": 0.514803, "arguments": [{"text": "Court", "location": [1425, 1430], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [1431, 1438], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "partOf", "sentence": "Neither Citi nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Citi in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.788414, "arguments": [{"text": "subsidiaries", "location": [12368, 12380], "entities": [{"type": "Organization", "text": "subsidiaries"}]}, {"text": "its", "location": [12364, 12367], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "employedBy", "sentence": "Goldman Sachs International (\" Goldman Sachs \"), which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting exclusively as financial adviser to Shire and no one else in connection with the Acquisition, this Announcement and the matters described herein, and shall not be responsible to anyone other than Shire for providing the protections afforded to clients of Goldman Sachs or for providing advice in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.371283, "arguments": [{"text": "clients", "location": [13161, 13168], "entities": [{"type": "Person", "text": "clients"}]}, {"text": "Goldman Sachs", "location": [13172, 13185], "entities": [{"type": "Organization", "text": "Goldman Sachs"}]}]}, {"type": "partOf", "sentence": "Neither Goldman Sachs nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Goldman Sachs in connection with the Acquisition, this Announcement or any matter referred to herein Morgan Stanley & Co. International plc (\" Morgan Stanley \"), which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting exclusively as financial adviser to Shire and no one else in connection with the Acquisition, this Announcement and the matters described herein,", "score": 0.788414, "arguments": [{"text": "subsidiaries", "location": [13335, 13347], "entities": [{"type": "Organization", "text": "subsidiaries"}]}, {"text": "its", "location": [13331, 13334], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "employedBy", "sentence": "and shall not be responsible to anyone other than Shire for providing the protections afforded to clients of Morgan Stanley or for providing advice in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.376581, "arguments": [{"text": "clients", "location": [14148, 14155], "entities": [{"type": "Person", "text": "clients"}]}, {"text": "Morgan Stanley", "location": [14159, 14173], "entities": [{"type": "Organization", "text": "Morgan Stanley"}]}]}, {"type": "partOf", "sentence": "Neither Morgan Stanley nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Morgan Stanley in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.788414, "arguments": [{"text": "subsidiaries", "location": [14324, 14336], "entities": [{"type": "Organization", "text": "subsidiaries"}]}, {"text": "its", "location": [14320, 14323], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "colleague", "sentence": "Shire Shareholders are advised to read the Scheme Document (including the related Forms of Proxy and forms of election) carefully once these become available because they will contain important information in relation to the Acquisition, the New Takeda Shares and the Combined Group.", "score": 0.226994, "arguments": [{"text": "Shire", "location": [15981, 15986], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Shareholders", "location": [15987, 15999], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "agentOf", "sentence": "Shire Shareholders are advised to read the Scheme Document (including the related Forms of Proxy and forms of election) carefully once these become available because they will contain important information in relation to the Acquisition, the New Takeda Shares and the Combined Group.", "score": 0.617654, "arguments": [{"text": "Shire", "location": [15981, 15986], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "advised", "location": [16004, 16011], "entities": [{"type": "EventCommunication", "text": "advised"}]}]}, {"type": "agentOf", "sentence": "Shire Shareholders are advised to read the Scheme Document (including the related Forms of Proxy and forms of election) carefully once these become available because they will contain important information in relation to the Acquisition, the New Takeda Shares and the Combined Group.", "score": 0.521425, "arguments": [{"text": "Shareholders", "location": [15987, 15999], "entities": [{"type": "Person", "text": "Shareholders"}]}, {"text": "advised", "location": [16004, 16011], "entities": [{"type": "EventCommunication", "text": "advised"}]}]}, {"type": "affectedBy", "sentence": "Shire Shareholders are advised to read the Scheme Document (including the related Forms of Proxy and forms of election) carefully once these become available because they will contain important information in relation to the Acquisition, the New Takeda Shares and the Combined Group.", "score": 0.698459, "arguments": [{"text": "Scheme Document", "location": [16024, 16039], "entities": [{"type": "Organization", "text": "Scheme Document"}]}, {"text": "advised", "location": [16004, 16011], "entities": [{"type": "EventCommunication", "text": "advised"}]}]}, {"type": "agentOf", "sentence": "The New Takeda Securities are not being offered to the public by means of this Announcement.", "score": 0.641941, "arguments": [{"text": "public", "location": [16320, 16326], "entities": [{"type": "Person", "text": "public"}]}, {"text": "Announcement", "location": [16344, 16356], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "colleague", "sentence": "Copies of these documents are also being sent to Shire Shareholders today.", "score": 0.273729, "arguments": [{"text": "Shire", "location": [1636, 1641], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Shareholders", "location": [1642, 1654], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "agentOf", "sentence": "Takeda reserves the right to elect (with the consent of the Panel and subject to the terms of the Co-operation Agreement) to implement the acquisition of the Shire Shares by way of a Takeover Offer as an alternative to the Scheme.", "score": 0.374582, "arguments": [{"text": "Panel", "location": [16504, 16509], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "acquisition", "location": [16583, 16594], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "clientOf", "sentence": "Restricted Jurisdictions The release, publication or distribution of this Announcement in jurisdictions other than the United Kingdom and Jersey may be restricted by law and therefore any persons into whose possession this Announcement comes who are subject to the laws of any jurisdiction other than the United Kingdom and Jersey should inform themselves about, and observe, any applicable requirements.", "score": 0.241675, "arguments": [{"text": "persons", "location": [17265, 17272], "entities": [{"type": "Person", "text": "persons"}]}, {"text": "Jersey", "location": [17215, 17221], "entities": [{"type": "Organization", "text": "Jersey"}]}]}, {"type": "agentOf", "sentence": "Restricted Jurisdictions The release, publication or distribution of this Announcement in jurisdictions other than the United Kingdom and Jersey may be restricted by law and therefore any persons into whose possession this Announcement comes who are subject to the laws of any jurisdiction other than the United Kingdom and Jersey should inform themselves about, and observe, any applicable requirements.", "score": 0.723281, "arguments": [{"text": "whose", "location": [17278, 17283], "entities": [{"type": "Person", "text": "whose"}]}, {"text": "Announcement", "location": [17300, 17312], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Restricted Jurisdictions The release, publication or distribution of this Announcement in jurisdictions other than the United Kingdom and Jersey may be restricted by law and therefore any persons into whose possession this Announcement comes who are subject to the laws of any jurisdiction other than the United Kingdom and Jersey should inform themselves about, and observe, any applicable requirements.", "score": 0.764785, "arguments": [{"text": "Jersey", "location": [17401, 17407], "entities": [{"type": "Organization", "text": "Jersey"}]}, {"text": "inform", "location": [17415, 17421], "entities": [{"type": "EventCommunication", "text": "inform"}]}]}, {"type": "affectedBy", "sentence": "Restricted Jurisdictions The release, publication or distribution of this Announcement in jurisdictions other than the United Kingdom and Jersey may be restricted by law and therefore any persons into whose possession this Announcement comes who are subject to the laws of any jurisdiction other than the United Kingdom and Jersey should inform themselves about, and observe, any applicable requirements.", "score": 0.824719, "arguments": [{"text": "themselves", "location": [17422, 17432], "entities": [{"type": "Person", "text": "themselves"}]}, {"text": "inform", "location": [17415, 17421], "entities": [{"type": "EventCommunication", "text": "inform"}]}]}, {"type": "partOfMany", "sentence": "In particular, the ability of persons who are not resident in the United Kingdom or Jersey to vote their Shire Shares with respect to the Scheme at the Court Meeting, to execute and deliver forms of proxy appointing another to vote at the Court Meeting on their behalf or to hold or vote Takeda Shares may be affected by the laws of the relevant jurisdiction in which they are located.", "score": 0.556775, "arguments": [{"text": "persons", "location": [17512, 17519], "entities": [{"type": "Person", "text": "persons"}]}, {"text": "who", "location": [17520, 17523], "entities": [{"type": "Person", "text": "who"}]}]}, {"type": "agentOf", "sentence": "In particular, the ability of persons who are not resident in the United Kingdom or Jersey to vote their Shire Shares with respect to the Scheme at the Court Meeting, to execute and deliver forms of proxy appointing another to vote at the Court Meeting on their behalf or to hold or vote Takeda Shares may be affected by the laws of the relevant jurisdiction in which they are located.", "score": 0.443929, "arguments": [{"text": "Court", "location": [17634, 17639], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [17640, 17647], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "partOf", "sentence": "In particular, the ability of persons who are not resident in the United Kingdom or Jersey to vote their Shire Shares with respect to the Scheme at the Court Meeting, to execute and deliver forms of proxy appointing another to vote at the Court Meeting on their behalf or to hold or vote Takeda Shares may be affected by the laws of the relevant jurisdiction in which they are located.", "score": 0.501381, "arguments": [{"text": "Meeting", "location": [17640, 17647], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}, {"text": "Meeting", "location": [17727, 17734], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "agentOf", "sentence": "In particular, the ability of persons who are not resident in the United Kingdom or Jersey to vote their Shire Shares with respect to the Scheme at the Court Meeting, to execute and deliver forms of proxy appointing another to vote at the Court Meeting on their behalf or to hold or vote Takeda Shares may be affected by the laws of the relevant jurisdiction in which they are located.", "score": 0.515965, "arguments": [{"text": "Court", "location": [17721, 17726], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [17727, 17734], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "affectedBy", "sentence": "Accordingly, copies of this Announcement and any formal documentation relating to the Acquisition are not being, and must not be, directly or indirectly, mailed, transmitted or otherwise forwarded, distributed or sent in, into or from a Restricted Jurisdiction, where to do so would violate the laws in that jurisdiction, and persons receiving this Announcement and all documents relating to the Acquisition (including custodians, nominees and trustees) must not mail or otherwise distribute or send them in, into or from Restricted Jurisdictions, where to do so would violate the laws in that jurisdiction.", "score": 0.484298, "arguments": [{"text": "persons", "location": [19453, 19460], "entities": [{"type": "Person", "text": "persons"}]}, {"text": "Announcement", "location": [19476, 19488], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}], "keywords": [{"text": "shire", "sentiment": {"score": 0.079862, "label": "positive"}, "relevance": 0.989533}, {"text": "Shire Shareholders", "sentiment": {"score": 0.286585, "label": "positive"}, "relevance": 0.871214}, {"text": "Shire ADS Holders", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.811887}, {"text": "Shire General Meeting", "sentiment": {"score": -0.26658, "label": "negative"}, "relevance": 0.779141}, {"text": "Takeda", "sentiment": {"score": -0.129749, "label": "negative"}, "relevance": 0.746041}, {"text": "New Takeda", "sentiment": {"score": -0.537141, "label": "negative"}, "relevance": 0.729452}, {"text": "New Takeda ADSs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.675051}, {"text": "scheme document", "sentiment": {"score": 0.627751, "label": "positive"}, "relevance": 0.651062}, {"text": "Court Meeting", "sentiment": {"score": 0.0221321, "label": "positive"}, "relevance": 0.631033}, {"text": "United Kingdom", "sentiment": {"score": 0.851582, "label": "positive"}, "relevance": 0.607954}, {"text": "Shire Shares", "sentiment": {"score": -0.665719, "label": "negative"}, "relevance": 0.598562}, {"text": "financial adviser", "sentiment": {"score": 0.117462, "label": "positive"}, "relevance": 0.596304}, {"text": "announcement", "sentiment": {"score": 0.154824, "label": "positive"}, "relevance": 0.569827}, {"text": "Shire Depositary", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.568501}, {"text": "New Takeda Shares", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.565534}, {"text": "New York time", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.554043}, {"text": "Prudential Regulation Authority", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.536086}, {"text": "New Takeda Securities", "sentiment": {"score": -0.537141, "label": "negative"}, "relevance": 0.527523}, {"text": "acquisition", "sentiment": {"score": 0.0897102, "label": "positive"}, "relevance": 0.524466}, {"text": "London Stock Exchange", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.504582}, {"text": "joint financial adviser", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.498981}, {"text": "securities exchange offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.493178}, {"text": "Shire ADSs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.488898}, {"text": "Financial Conduct Authority", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.488403}, {"text": "Takeda Extraordinary General", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.486632}, {"text": "Effective Date", "sentiment": {"score": 0.310133, "label": "positive"}, "relevance": 0.459827}, {"text": "relevant adjourned Shire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.459351}, {"text": "Shire website", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.457925}, {"text": "shire plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.457032}, {"text": "Shire Shareholder", "sentiment": {"score": 0.745078, "label": "positive"}, "relevance": 0.456587}, {"text": "uncertificated Shire ADSs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.455816}, {"text": "Shire Shareholder opinion", "sentiment": {"score": 0.745078, "label": "positive"}, "relevance": 0.454707}, {"text": "Shire Meeting", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.449568}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.447011}, {"text": "London time", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.444594}, {"text": "Shire ADS certificate", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.441966}, {"text": "Shire ADS certificates", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.440299}, {"text": "forward-looking statements", "sentiment": {"score": -0.283325, "label": "negative"}, "relevance": 0.430585}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.429693}, {"text": "Extraordinary General Meeting", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.429589}, {"text": "SHIRE LEI", "sentiment": {"score": 0.398037, "label": "positive"}, "relevance": 0.429215}, {"text": "Shire Depositary.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.429201}, {"text": "Shire Meetings", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.422921}, {"text": "Opening Position Disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.420253}, {"text": "Shire\u2019s websites", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.419919}, {"text": "securities laws", "sentiment": {"score": -0.640674, "label": "negative"}, "relevance": 0.41989}, {"text": "offeree company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.41375}, {"text": "possible combination", "sentiment": {"score": 0.39568, "label": "positive"}, "relevance": 0.413124}, {"text": "ADS Voting Card", "sentiment": {"score": 0.358438, "label": "positive"}, "relevance": 0.410775}, {"text": "relevant securities", "sentiment": {"score": 0.606322, "label": "positive"}, "relevance": 0.404228}]}, "extracted_metadata": {"sha1": "448a68a77791413097b09c43d9cfd3b20c4a8fba", "filename": "1542026472660.zip-467eb1eac1ff941ee022e7d8b5a0621a.xml", "file_type": "json"}, "external_links": ["https://www.globenewswire.com/Tracker?data=QkY0KWPknd4wvMioN3vKnsaqbE-Z11Gp1lT-cQvhQnlWcM_-GH5Wo6kH3fN7Z3_XcY48VuPQh8G6kXfR4HLWeZ-VJCeSPGnmUSXxBRz7YZP2s90QE93JGEb6rO4l64OA", "https://www.globenewswire.com/newsroom/ti?nf=MTAwMDEzNjAyNCM0MDAyMzU0ODAjMjAwMzQwNg=="], "title": "Publication of Scheme Document 12", "forum_title": "PR-Inside.com"}, {"id": "CVWFKQF-VdjY9GiquyH51-pDYXo5w75I9MOC6tnP_2RbEneFjG6ffHV8rC-Qheso", "result_metadata": {"score": 31.224949}, "author": "Mrudula.k", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pantoprazole", "relevance": 0.33, "type": "Drug"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Stock market", "relevance": 0.919435, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "Pantoprazole", "relevance": 0.852144, "dbpedia_resource": "http://dbpedia.org/resource/Pantoprazole"}], "categories": [{"score": 0.504572, "label": "/business and industrial/paper industry"}, {"score": 0.497714, "label": "/finance/investing"}, {"score": 0.497714, "label": "/finance/investing/beginning investing"}], "relations": [], "keywords": [{"text": "Annual Growth Rate", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.961082}, {"text": "Pantoprazole Sodium", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.790855}, {"text": "Future Prospects", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.700555}, {"text": "Industry Share", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.570098}, {"text": "Market Growth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.534178}, {"text": "Cas", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.471317}]}, "crawl_date": "2018-11-12T00:22:16Z", "url": "https://www.military-technologies.net/2018/11/11/pantoprazole-sodium-cas-138786-67-1-market-growth-by-industry-share-annual-growth-rate-and-future-prospects-2023-2/", "host": "military-technologies.net", "text": ",Pfizer ,Takeda GmbH ,Teva Pharmaceutical ,Liaoning Nirvana Pharmaceutical ,Hubei Weisen Pharmaceutical ,Dr.", "country": "PL", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-11T20:55:00Z", "enriched_text": {"entities": [{"count": 19, "sentiment": {"score": -0.301655, "label": "negative"}, "text": "Pantoprazole", "relevance": 0.793464, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Industrial Chain Analysis", "relevance": 0.225624, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Key Manufactures", "relevance": 0.212097, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mreeo Pharmaceutical", "relevance": 0.202633, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.197857, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Hubei Weisen Pharmaceutical", "relevance": 0.197845, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teva Pharmaceutical", "relevance": 0.193574, "type": "Company", "disambiguation": {"subtype": [], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"count": 1, "sentiment": {"score": 0.325171, "label": "positive"}, "text": "South America", "relevance": 0.19064, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "South America", "dbpedia_resource": "http://dbpedia.org/resource/South_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shandong Renhetang Pharmaceutical", "relevance": 0.184583, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.18378, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.182139, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0.268531, "label": "positive"}, "text": "Liaoning Nirvana Pharmaceutical", "relevance": 0.180357, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Reddys Laboratories", "relevance": 0.179782, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.350129, "label": "positive"}, "text": "China", "relevance": 0.174991, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Luye Pharma Group", "relevance": 0.171273, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.166669, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "India", "relevance": 0.165698, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Lee Pharma Ltd.", "relevance": 0.157488, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer", "relevance": 0.15193, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.150458, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda GmbH", "relevance": 0.139865, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "5 years", "relevance": 0.139865, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$ 2960", "relevance": 0.139865, "type": "Quantity"}], "sentiment": {"document": {"score": 0.606782, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "this report", "keywords": [{"text": "report"}]}, "sentence": " Based on the industrial chain, this report primarily elaborates the definition, types, applications and major players of Pantoprazole Sodium (Cas 138786-67-1) market in details.", "object": {"text": "on the industrial chain", "keywords": [{"text": "industrial chain"}]}, "action": {"verb": {"text": "Based", "tense": "past"}, "text": "Based", "normalized": "Based"}}, {"subject": {"text": "this report", "keywords": [{"text": "report"}]}, "sentence": " Based on the industrial chain, this report primarily elaborates the definition, types, applications and major players of Pantoprazole Sodium (Cas 138786-67-1) market in details.", "object": {"text": "the definition, types, applications and major players of Pantoprazole Sodium (Cas 138786-67-1) market in details", "keywords": [{"text": "Pantoprazole Sodium"}, {"text": "major players"}, {"text": "Cas"}, {"text": "definition"}], "entities": [{"type": "Drug", "text": "Pantoprazole"}]}, "action": {"verb": {"text": "elaborate", "tense": "present"}, "text": "elaborates", "normalized": "elaborate"}}, {"subject": {"text": "Profound analysis", "keywords": [{"text": "Profound analysis"}]}, "sentence": " Profound analysis regarding Pantoprazole Sodium (Cas 138786-67-1) market status (2013-2018), enterprise competition outline, benefits and drawbacks of enterprise product, trade development trends (2018-2023), regional industrial layout characteristics and economics policies, industrial policy has additionally been enclosed.", "object": {"text": "Pantoprazole Sodium (Cas 138786-67-1) market status", "keywords": [{"text": "Pantoprazole Sodium"}, {"text": "Cas"}, {"text": "market status"}], "entities": [{"type": "Drug", "text": "Pantoprazole"}]}, "action": {"verb": {"text": "regard", "tense": "present"}, "text": "regarding", "normalized": "regard"}}, {"subject": {"text": "industrial policy", "keywords": [{"text": "industrial policy"}]}, "sentence": " Profound analysis regarding Pantoprazole Sodium (Cas 138786-67-1) market status (2013-2018), enterprise competition outline, benefits and drawbacks of enterprise product, trade development trends (2018-2023), regional industrial layout characteristics and economics policies, industrial policy has additionally been enclosed.", "object": {"text": "enclosed"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "From raw materials to downstream buyers of this industry", "keywords": [{"text": "downstream buyers"}, {"text": "raw materials"}, {"text": "industry"}]}, "sentence": " From raw materials to downstream buyers of this industry are analysed scientifically, the feature of product circulation and sales channel are given as well.", "object": {"text": "analysed scientifically"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "this Pantoprazole Sodium (Cas 138786-67-1) report", "keywords": [{"text": "Pantoprazole Sodium"}, {"text": "Cas"}, {"text": "report"}], "entities": [{"type": "Drug", "text": "Pantoprazole"}]}, "sentence": " In a word, this Pantoprazole Sodium (Cas 138786-67-1) report can assist you to determine a panorama of commercial development and characteristics of the Pantoprazole Sodium (Cas 138786-67-1) market.", "object": {"text": "you"}, "action": {"verb": {"text": "assist", "tense": "future"}, "text": "can assist", "normalized": "can assist"}}, {"subject": {"text": "you"}, "sentence": " In a word, this Pantoprazole Sodium (Cas 138786-67-1) report can assist you to determine a panorama of commercial development and characteristics of the Pantoprazole Sodium (Cas 138786-67-1) market.", "object": {"text": "a panorama of commercial development and characteristics of the Pantoprazole Sodium (Cas 138786-67-1) market", "keywords": [{"text": "Pantoprazole Sodium"}, {"text": "commercial development"}, {"text": "panorama"}, {"text": "Cas"}], "entities": [{"type": "Drug", "text": "Pantoprazole"}]}, "action": {"verb": {"text": "determine", "tense": "future"}, "text": "to determine", "normalized": "to determine"}}, {"subject": {"text": "The Pantoprazole Sodium (Cas 138786-67-1) market revenue", "keywords": [{"text": "Pantoprazole Sodium"}, {"text": "market revenue"}, {"text": "Cas"}], "entities": [{"type": "Drug", "text": "Pantoprazole"}]}, "sentence": " The Pantoprazole Sodium (Cas 138786-67-1) market revenue was xx.xx Million USD in 2013, grew to xx.xx Million USD in 2017, and will reach xx.xx Million USD in 2023, with a CAGR of x.x% during 2018-2023.", "object": {"text": "xx.xx Million USD", "keywords": [{"text": "USD"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Million USD", "keywords": [{"text": "USD"}]}, "sentence": " The Pantoprazole Sodium (Cas 138786-67-1) market revenue was xx.xx Million USD in 2013, grew to xx.xx Million USD in 2017, and will reach xx.xx Million USD in 2023, with a CAGR of x.x% during 2018-2023.", "action": {"verb": {"text": "xx.xx", "tense": "future"}, "text": "grew to xx.xx", "normalized": "grow to xx.xx"}}, {"subject": {"text": "xx.xx Million USD", "keywords": [{"text": "USD"}]}, "sentence": " The Pantoprazole Sodium (Cas 138786-67-1) market revenue was xx.xx Million USD in 2013, grew to xx.xx Million USD in 2017, and will reach xx.xx Million USD in 2023, with a CAGR of x.x% during 2018-2023.", "action": {"verb": {"text": "reach", "tense": "future"}, "text": "will reach", "normalized": "will reach"}}, {"subject": {"text": "Most important Regions", "keywords": [{"text": "Regions"}]}, "sentence": " Most important Regions play dynamic role in Pantoprazole Sodium (Cas 138786-67-1) market are: North America, Europe, China, Japan, Middle East & Africa, India, South America, Others", "object": {"text": "dynamic role", "keywords": [{"text": "dynamic role"}]}, "action": {"verb": {"text": "play", "tense": "present"}, "text": "play", "normalized": "play"}}, {"subject": {"text": "Research report", "keywords": [{"text": "Research report"}]}, "sentence": " Research report contains data about following major players in Pantoprazole Sodium (Cas 138786-67-1) market : Mreeo Pharmaceutical ,Lee Pharma Ltd. ,Pfizer ,Takeda GmbH ,Teva Pharmaceutical ,Liaoning Nirvana Pharmaceutical ,Hubei Weisen Pharmaceutical ,Dr.", "object": {"text": "data about following major players in Pantoprazole Sodium (Cas 138786-67-1) market : Mreeo Pharmaceutical ,Lee Pharma Ltd. ,Pfizer ,Takeda GmbH ,Teva Pharmaceutical ,Liaoning Nirvana Pharmaceutical ,Hubei Weisen Pharmaceutical ,Dr", "keywords": [{"text": "Hubei Weisen Pharmaceutical"}, {"text": "Liaoning Nirvana Pharmaceutical"}, {"text": "Lee Pharma Ltd."}, {"text": "Takeda GmbH"}], "entities": [{"type": "Drug", "text": "Pantoprazole"}, {"type": "Company", "text": "Mreeo Pharmaceutical"}, {"type": "Company", "text": "Lee Pharma Ltd."}, {"type": "Company", "text": "Pfizer", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "Takeda GmbH"}, {"type": "Company", "text": "Teva Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"type": "Company", "text": "Liaoning Nirvana Pharmaceutical"}, {"type": "Company", "text": "Hubei Weisen Pharmaceutical"}]}, "action": {"verb": {"text": "contain", "tense": "present"}, "text": "contains", "normalized": "contain"}}, {"subject": {"text": "data", "keywords": [{"text": "data"}]}, "sentence": " Research report contains data about following major players in Pantoprazole Sodium (Cas 138786-67-1) market : Mreeo Pharmaceutical ,Lee Pharma Ltd. ,Pfizer ,Takeda GmbH ,Teva Pharmaceutical ,Liaoning Nirvana Pharmaceutical ,Hubei Weisen Pharmaceutical ,Dr.", "object": {"text": "major players in Pantoprazole Sodium (Cas 138786-67-1) market : Mreeo Pharmaceutical ,Lee Pharma Ltd. ,Pfizer ,Takeda GmbH ,Teva Pharmaceutical ,Liaoning Nirvana Pharmaceutical ,Hubei Weisen Pharmaceutical ,Dr", "keywords": [{"text": "Hubei Weisen Pharmaceutical"}, {"text": "Liaoning Nirvana Pharmaceutical"}, {"text": "Lee Pharma Ltd."}, {"text": "Takeda GmbH"}], "entities": [{"type": "Drug", "text": "Pantoprazole"}, {"type": "Company", "text": "Mreeo Pharmaceutical"}, {"type": "Company", "text": "Lee Pharma Ltd."}, {"type": "Company", "text": "Pfizer", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "Takeda GmbH"}, {"type": "Company", "text": "Teva Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"type": "Company", "text": "Liaoning Nirvana Pharmaceutical"}, {"type": "Company", "text": "Hubei Weisen Pharmaceutical"}]}, "action": {"verb": {"text": "follow", "tense": "present"}, "text": "following", "normalized": "follow"}}, {"subject": {"text": "Pantoprazole Sodium (Cas 138786-67-1) Market report", "keywords": [{"text": "Pantoprazole Sodium"}, {"text": "Cas"}, {"text": "Market report"}], "entities": [{"type": "Drug", "text": "Pantoprazole"}]}, "sentence": " Pantoprazole Sodium (Cas 138786-67-1) Market report offers insights of industrial Chain, Major Player\u2019s Market Share and Upstream raw materials suppliers concerned in Pantoprazole Sodium (Cas 138786-67-1) Market based on Industrial Chain Analysis, Production process Analysis, Labour cost, raw material value price Structure of Pantoprazole Sodium (Cas 138786-67-1), supply of Raw Materials for Major manufacturers present in Pantoprazole Sodium (Cas 138786-67-1) trade until 2017 and Downstream patrons.", "object": {"text": "insights of industrial Chain, Major Player\u2019s Market Share and Upstream raw materials suppliers concerned in Pantoprazole Sodium (Cas 138786-67-1) Market based on Industrial Chain Analysis, Production process Analysis, Labour cost, raw material value price Structure of Pantoprazole Sodium (Cas 138786-67-1), supply of Raw Materials for Major manufacturers present in Pantoprazole Sodium (Cas 138786-67-1) trade until 2017 and Downstream patrons", "keywords": [{"text": "Pantoprazole Sodium"}, {"text": "Upstream raw materials"}, {"text": "material value price"}, {"text": "Production process Analysis"}], "entities": [{"type": "Drug", "text": "Pantoprazole"}, {"type": "Company", "text": "Industrial Chain Analysis"}, {"type": "Drug", "text": "Pantoprazole"}, {"type": "Drug", "text": "Pantoprazole"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "in Pantoprazole Sodium (Cas 138786-67-1) Market based on Industrial Chain Analysis", "keywords": [{"text": "Industrial Chain Analysis"}, {"text": "Pantoprazole Sodium"}, {"text": "Cas"}, {"text": "Market"}], "entities": [{"type": "Drug", "text": "Pantoprazole"}, {"type": "Company", "text": "Industrial Chain Analysis"}]}, "sentence": " Pantoprazole Sodium (Cas 138786-67-1) Market report offers insights of industrial Chain, Major Player\u2019s Market Share and Upstream raw materials suppliers concerned in Pantoprazole Sodium (Cas 138786-67-1) Market based on Industrial Chain Analysis, Production process Analysis, Labour cost, raw material value price Structure of Pantoprazole Sodium (Cas 138786-67-1), supply of Raw Materials for Major manufacturers present in Pantoprazole Sodium (Cas 138786-67-1) trade until 2017 and Downstream patrons.", "object": {"text": "raw materials suppliers", "keywords": [{"text": "raw materials suppliers"}]}, "action": {"verb": {"text": "concern", "tense": "past"}, "text": "concerned", "normalized": "concern"}}, {"subject": {"text": "supply of Raw Materials for Major manufacturers", "keywords": [{"text": "Raw Materials"}, {"text": "Major manufacturers"}, {"text": "supply"}]}, "sentence": " Pantoprazole Sodium (Cas 138786-67-1) Market report offers insights of industrial Chain, Major Player\u2019s Market Share and Upstream raw materials suppliers concerned in Pantoprazole Sodium (Cas 138786-67-1) Market based on Industrial Chain Analysis, Production process Analysis, Labour cost, raw material value price Structure of Pantoprazole Sodium (Cas 138786-67-1), supply of Raw Materials for Major manufacturers present in Pantoprazole Sodium (Cas 138786-67-1) trade until 2017 and Downstream patrons.", "action": {"verb": {"text": "present", "tense": "present"}, "text": "present", "normalized": "present"}}, {"subject": {"text": "This report", "keywords": [{"text": "report"}]}, "sentence": " This report offers Pantoprazole Sodium (Cas 138786-67-1) market research and Forecast considering Pantoprazole Sodium (Cas 138786-67-1) market price and Volume by type, applications and Regions for next 5 years.", "object": {"text": "Pantoprazole Sodium (Cas 138786-67-1) market research", "keywords": [{"text": "Pantoprazole Sodium"}, {"text": "Cas"}, {"text": "market research"}], "entities": [{"type": "Drug", "text": "Pantoprazole"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "The Pantoprazole Sodium (Cas 138786-67-1) market report", "keywords": [{"text": "Pantoprazole Sodium"}, {"text": "Cas"}, {"text": "market report"}], "entities": [{"type": "Drug", "text": "Pantoprazole"}]}, "sentence": " The Pantoprazole Sodium (Cas 138786-67-1) market report additionally provides New Project feasibility Analysis, trade Barriers, New Entrants SWOT Analysis and Suggestions on New Project Investment in Pantoprazole Sodium (Cas 138786-67-1) Market.", "object": {"text": "New Project", "keywords": [{"text": "New Project"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}], "concepts": [{"text": "Marketing", "relevance": 0.989416, "dbpedia_resource": "http://dbpedia.org/resource/Marketing"}, {"text": "Material", "relevance": 0.701323, "dbpedia_resource": "http://dbpedia.org/resource/Material"}, {"text": "Strategic management", "relevance": 0.661158, "dbpedia_resource": "http://dbpedia.org/resource/Strategic_management"}, {"text": "Market research", "relevance": 0.614094, "dbpedia_resource": "http://dbpedia.org/resource/Market_research"}, {"text": "Raw material", "relevance": 0.587363, "dbpedia_resource": "http://dbpedia.org/resource/Raw_material"}, {"text": "Trade", "relevance": 0.563725, "dbpedia_resource": "http://dbpedia.org/resource/Trade"}, {"text": "Materials", "relevance": 0.562967, "dbpedia_resource": "http://dbpedia.org/resource/Materials"}, {"text": "Pantoprazole", "relevance": 0.483748, "dbpedia_resource": "http://dbpedia.org/resource/Pantoprazole"}, {"text": "United States dollar", "relevance": 0.482542, "dbpedia_resource": "http://dbpedia.org/resource/United_States_dollar"}, {"text": "SWOT analysis", "relevance": 0.48143, "dbpedia_resource": "http://dbpedia.org/resource/SWOT_analysis"}, {"text": "Pharmacology", "relevance": 0.472664, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}], "categories": [{"score": 0.593786, "label": "/business and industrial/business operations/management/business process"}, {"score": 0.466738, "label": "/finance/financial news"}, {"score": 0.438711, "label": "/technology and computing/enterprise technology"}], "relations": [{"type": "locatedAt", "sentence": "- by Mrudula.k The Pantoprazole Sodium (Cas 138786-67-1) Market divided based on Key Manufactures, product types, major applications, and important regions.", "score": 0.474726, "arguments": [{"text": "Mrudula.k\nThe Pantoprazole Sodium", "location": [5, 38], "entities": [{"type": "Organization", "text": "Mrudula.k\nThe Pantoprazole Sodium"}]}, {"text": "Market", "location": [57, 63], "entities": [{"type": "Facility", "text": "Market Report"}]}]}, {"type": "locatedAt", "sentence": "- by Mrudula.k The Pantoprazole Sodium (Cas 138786-67-1) Market divided based on Key Manufactures, product types, major applications, and important regions.", "score": 0.415061, "arguments": [{"text": "Cas", "location": [40, 43], "entities": [{"type": "Organization", "text": "Mrudula.k\nThe Pantoprazole Sodium"}]}, {"text": "Market", "location": [57, 63], "entities": [{"type": "Facility", "text": "Market Report"}]}]}, {"type": "locatedAt", "sentence": "Get Sample of Pantoprazole Sodium (Cas 138786-67-1) Market Report at: https://www.industryresearch.co/enquiry/request-sample/12202883 Most important Regions play dynamic role in Pantoprazole Sodium (Cas 138786-67-1) market are: North America, Europe, China, Japan, Middle East & Africa, India, South America, Others Research report contains data about following major players in Pantoprazole Sodium (Cas 138786-67-1) market : Mreeo Pharmaceutical ,Lee Pharma Ltd. ,Pfizer ,Takeda GmbH ,Teva Pharmaceutical ,Liaoning Nirvana Pharmaceutical ,Hubei Weisen Pharmaceutical ,Dr. Reddys Laboratories ,Shandong Renhetang Pharmaceutical ,Luye Pharma Group .", "score": 0.485352, "arguments": [{"text": "Pantoprazole Sodium", "location": [1235, 1254], "entities": [{"type": "Organization", "text": "Mrudula.k\nThe Pantoprazole Sodium"}]}, {"text": "Market Report", "location": [1273, 1286], "entities": [{"type": "Facility", "text": "Market Report"}]}]}, {"type": "locatedAt", "sentence": "Get Sample of Pantoprazole Sodium (Cas 138786-67-1) Market Report at: https://www.industryresearch.co/enquiry/request-sample/12202883 Most important Regions play dynamic role in Pantoprazole Sodium (Cas 138786-67-1) market are: North America, Europe, China, Japan, Middle East & Africa, India, South America, Others Research report contains data about following major players in Pantoprazole Sodium (Cas 138786-67-1) market : Mreeo Pharmaceutical ,Lee Pharma Ltd. ,Pfizer ,Takeda GmbH ,Teva Pharmaceutical ,Liaoning Nirvana Pharmaceutical ,Hubei Weisen Pharmaceutical ,Dr. Reddys Laboratories ,Shandong Renhetang Pharmaceutical ,Luye Pharma Group .", "score": 0.605828, "arguments": [{"text": "Cas", "location": [1256, 1259], "entities": [{"type": "Organization", "text": "Mrudula.k\nThe Pantoprazole Sodium"}]}, {"text": "Market Report", "location": [1273, 1286], "entities": [{"type": "Facility", "text": "Market Report"}]}]}, {"type": "locatedAt", "sentence": "- by Mrudula.k The Pantoprazole Sodium (Cas 138786-67-1) Market divided based on Key Manufactures, product types, major applications, and important regions.", "score": 0.556561, "arguments": [{"text": "Market", "location": [57, 63], "entities": [{"type": "Facility", "text": "Market Report"}]}, {"text": "regions", "location": [148, 155], "entities": [{"type": "Location", "text": "regions"}]}]}, {"type": "locatedAt", "sentence": "Get Sample of Pantoprazole Sodium (Cas 138786-67-1) Market Report at: https://www.industryresearch.co/enquiry/request-sample/12202883 Most important Regions play dynamic role in Pantoprazole Sodium (Cas 138786-67-1) market are: North America, Europe, China, Japan, Middle East & Africa, India, South America, Others Research report contains data about following major players in Pantoprazole Sodium (Cas 138786-67-1) market : Mreeo Pharmaceutical ,Lee Pharma Ltd. ,Pfizer ,Takeda GmbH ,Teva Pharmaceutical ,Liaoning Nirvana Pharmaceutical ,Hubei Weisen Pharmaceutical ,Dr. Reddys Laboratories ,Shandong Renhetang Pharmaceutical ,Luye Pharma Group .", "score": 0.829186, "arguments": [{"text": "Market Report", "location": [1273, 1286], "entities": [{"type": "Facility", "text": "Market Report"}]}, {"text": "Regions", "location": [1370, 1377], "entities": [{"type": "Location", "text": "regions"}]}]}, {"type": "locatedAt", "sentence": "Get Sample of Pantoprazole Sodium (Cas 138786-67-1) Market Report at: https://www.industryresearch.co/enquiry/request-sample/12202883 Most important Regions play dynamic role in Pantoprazole Sodium (Cas 138786-67-1) market are: North America, Europe, China, Japan, Middle East & Africa, India, South America, Others Research report contains data about following major players in Pantoprazole Sodium (Cas 138786-67-1) market : Mreeo Pharmaceutical ,Lee Pharma Ltd. ,Pfizer ,Takeda GmbH ,Teva Pharmaceutical ,Liaoning Nirvana Pharmaceutical ,Hubei Weisen Pharmaceutical ,Dr. Reddys Laboratories ,Shandong Renhetang Pharmaceutical ,Luye Pharma Group .", "score": 0.502591, "arguments": [{"text": "Japan", "location": [1479, 1484], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "Middle East", "location": [1486, 1497], "entities": [{"type": "GeopoliticalEntity", "text": "Middle East"}]}]}, {"type": "residesIn", "sentence": "dynamics123 Ask for pre-order Enquiry of Pantoprazole Sodium (Cas 138786-67-1) in Full Report at: https://www.industryresearch.co/enquiry/pre-order-enquiry/12202883 Pantoprazole Sodium (Cas 138786-67-1) Market report offers insights of industrial Chain, Major Player's Market Share and Upstream raw materials suppliers concerned in Pantoprazole Sodium (Cas 138786-67-1) Market based on Industrial Chain Analysis, Production process Analysis, Labour cost, raw material value price Structure of Pantoprazole Sodium (Cas 138786-67-1), supply of Raw Materials for Major manufacturers present in Pantoprazole Sodium (Cas 138786-67-1) trade until 2017 and Downstream patrons.", "score": 0.23545, "arguments": [{"text": "Player", "location": [2130, 2136], "entities": [{"type": "Person", "text": "Player"}]}, {"text": "Market", "location": [2139, 2145], "entities": [{"type": "Facility", "text": "Market Report"}]}]}, {"type": "partOfMany", "sentence": "dynamics123 Ask for pre-order Enquiry of Pantoprazole Sodium (Cas 138786-67-1) in Full Report at: https://www.industryresearch.co/enquiry/pre-order-enquiry/12202883 Pantoprazole Sodium (Cas 138786-67-1) Market report offers insights of industrial Chain, Major Player's Market Share and Upstream raw materials suppliers concerned in Pantoprazole Sodium (Cas 138786-67-1) Market based on Industrial Chain Analysis, Production process Analysis, Labour cost, raw material value price Structure of Pantoprazole Sodium (Cas 138786-67-1), supply of Raw Materials for Major manufacturers present in Pantoprazole Sodium (Cas 138786-67-1) trade until 2017 and Downstream patrons.", "score": 0.320947, "arguments": [{"text": "Pantoprazole Sodium", "location": [2461, 2480], "entities": [{"type": "Organization", "text": "Mrudula.k\nThe Pantoprazole Sodium"}]}, {"text": "manufacturers", "location": [2436, 2449], "entities": [{"type": "Organization", "text": "manufacturers", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "This report offers Pantoprazole Sodium (Cas 138786-67-1) market research and Forecast considering Pantoprazole Sodium (Cas 138786-67-1) market price and Volume by type, applications and Regions for next 5 years.", "score": 0.397399, "arguments": [{"text": "Volume", "location": [2693, 2699], "entities": [{"type": "Person", "text": "Volume"}]}, {"text": "Regions", "location": [2726, 2733], "entities": [{"type": "Location", "text": "regions"}]}]}, {"type": "ownerOf", "sentence": "The Pantoprazole Sodium (Cas 138786-67-1) market report additionally provides New Project feasibility Analysis, trade Barriers, New Entrants SWOT Analysis and Suggestions on New Project Investment in Pantoprazole Sodium (Cas 138786-67-1) Market.", "score": 0.519074, "arguments": [{"text": "Cas", "location": [2973, 2976], "entities": [{"type": "Organization", "text": "Mrudula.k\nThe Pantoprazole Sodium"}]}, {"text": "Market", "location": [2990, 2996], "entities": [{"type": "Facility", "text": "Market Report"}]}]}, {"type": "agentOf", "sentence": "Report Price: $ 2960 (Single-User License) To Purchase Complete Pantoprazole Sodium (Cas 138786-67-1) Market Report, Click Here: https://www.industryresearch.co/purchase/12202883 Post Views: 55 Post navigation", "score": 0.548286, "arguments": [{"text": "License", "location": [3032, 3039], "entities": [{"type": "Person", "text": "License"}]}, {"text": "Report", "location": [3107, 3113], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "timeOf", "sentence": "Report Price: $ 2960 (Single-User License) To Purchase Complete Pantoprazole Sodium (Cas 138786-67-1) Market Report, Click Here: https://www.industryresearch.co/purchase/12202883 Post Views: 55 Post navigation", "score": 0.743967, "arguments": [{"text": "138786-67-1", "location": [3087, 3098], "entities": [{"type": "Date", "text": "138786-67-1"}]}, {"text": "Report", "location": [3107, 3113], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}], "keywords": [{"text": "Pantoprazole Sodium", "sentiment": {"score": -0.301655, "label": "negative"}, "relevance": 0.900142}, {"text": "Cas", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.646156}, {"text": "Complete Pantoprazole Sodium", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509844}, {"text": "market report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.427465}, {"text": "industrial chain", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.413289}, {"text": "raw materials", "sentiment": {"score": -0.290745, "label": "negative"}, "relevance": 0.412852}, {"text": "Hubei Weisen Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.389275}, {"text": "major players", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.387805}, {"text": "regional industrial layout", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.387534}, {"text": "Liaoning Nirvana Pharmaceutical", "sentiment": {"score": 0.268531, "label": "positive"}, "relevance": 0.385331}, {"text": "trade development trends", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.384799}, {"text": "enterprise competition outline", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.384028}, {"text": "Industrial Chain Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.383503}, {"text": "Lee Pharma Ltd.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.383326}, {"text": "Luye Pharma Group", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.382229}, {"text": "Entrants SWOT Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.381401}, {"text": "Upstream raw materials", "sentiment": {"score": -0.290745, "label": "negative"}, "relevance": 0.379437}, {"text": "Production process Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.379252}, {"text": "raw material value", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.377775}, {"text": "Project feasibility Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.375623}, {"text": "New Project Investment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.373639}, {"text": "market status", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.366518}, {"text": "market revenue", "sentiment": {"score": -0.27656, "label": "negative"}, "relevance": 0.362563}, {"text": "Player\u2019s Market", "sentiment": {"score": -0.290745, "label": "negative"}, "relevance": 0.358573}, {"text": "market price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.357715}, {"text": "Million USD", "sentiment": {"score": -0.27656, "label": "negative"}, "relevance": 0.35752}, {"text": "market research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.356984}, {"text": "major applications", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.355901}, {"text": "Research report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.35393}, {"text": "Report Price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.35227}, {"text": "product types", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.351664}, {"text": "Profound analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.351578}, {"text": "important regions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.351483}, {"text": "Key Manufactures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.350852}, {"text": "industrial policy", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.350627}, {"text": "Teva Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.349779}, {"text": "downstream buyers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.349016}, {"text": "enterprise product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.347804}, {"text": "economics policies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.346849}, {"text": "Mreeo Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.346821}, {"text": "product circulation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.346714}, {"text": "sales channel", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.346257}, {"text": "commercial development", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.345565}, {"text": "Downstream patrons", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.345276}, {"text": "Takeda GmbH", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.345276}, {"text": "pre-order Enquiry", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.344401}, {"text": "Major manufacturers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.344358}, {"text": "dynamic role", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.34409}, {"text": "Shandong Renhetang", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.343889}, {"text": "Middle East", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.343858}]}, "extracted_metadata": {"sha1": "84f0f4fccfbb80df83b8e0a08c464bbd11172dfb", "filename": "1541982136955.zip-f4cf91725604018494852cbcaecfd1d1.xml", "file_type": "json"}, "external_links": ["https://www.industryresearch.co/12202883", "https://www.industryresearch.co/purchase/12202883", "https://www.industryresearch.co/enquiry/request-sample/12202883", "https://www.industryresearch.co/enquiry/pre-order-enquiry/12202883"], "title": "Pantoprazole Sodium (Cas 138786-67-1) Market Growth by Industry Share, Annual Growth Rate and Future Prospects 2023", "forum_title": "MilTech"}, {"id": "PYJDNQe33Txic5SYPhaXsA0fOOri3tQL26hEd0bxAEgI5uqKHsWNTCd3RLqrrIFZ", "result_metadata": {"score": 31.217566}, "author": "Staff Writer", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.57195, "label": "/business and industrial/paper industry"}, {"score": 0.483633, "label": "/law, govt and politics/government/government contracting and procurement"}, {"score": 0.444154, "label": "/technology and computing/computer certification"}], "relations": [], "keywords": [{"text": "Scheme Document", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.938059}, {"text": "Publication", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.483211}]}, "crawl_date": "2018-11-12T08:30:03Z", "url": "http://thenewsreports.com/publication-of-scheme-document/60842/staff", "host": "thenewsreports.com", "text": "JPMorgan Securities Japan Co., Ltd., together with its affiliate J.P.", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-12T07:00:00Z", "enriched_text": {"entities": [{"count": 22, "sentiment": {"score": 0.355062, "label": "positive"}, "text": "Shire Shareholders", "relevance": 0.851579, "type": "Company"}, {"count": 20, "sentiment": {"score": 0.321772, "label": "positive"}, "text": "Shire", "relevance": 0.824338, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 16, "sentiment": {"score": -0.200446, "label": "negative"}, "text": "Takeda", "relevance": 0.556623, "type": "Company"}, {"count": 12, "sentiment": {"score": -0.26658, "label": "negative"}, "text": "Shire General Meeting", "relevance": 0.542541, "type": "Organization"}, {"count": 8, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire Depositary", "relevance": 0.531068, "type": "Organization"}, {"count": 9, "sentiment": {"score": -0.665719, "label": "negative"}, "text": "Shire Shares", "relevance": 0.526304, "type": "Company"}, {"count": 7, "sentiment": {"score": 0.277075, "label": "positive"}, "text": "Shire ADS Holders", "relevance": 0.500898, "type": "Company"}, {"count": 15, "sentiment": {"score": 0.30361, "label": "positive"}, "text": "Takeda", "relevance": 0.496003, "type": "Person"}, {"count": 24, "sentiment": {"score": 0.315605, "label": "positive"}, "text": "Scheme", "relevance": 0.493453, "type": "Organization"}, {"count": 7, "sentiment": {"score": -0.200388, "label": "negative"}, "text": "Shire", "relevance": 0.469225, "type": "Person"}, {"count": 8, "sentiment": {"score": 0.238077, "label": "positive"}, "text": "Shire", "relevance": 0.447087, "type": "Company"}, {"count": 33, "sentiment": {"score": -0.336105, "label": "negative"}, "text": "US", "relevance": 0.438253, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 9, "sentiment": {"score": 0.337874, "label": "positive"}, "text": "Shire ADSs", "relevance": 0.436952, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire PLC", "relevance": 0.400762, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 21, "sentiment": {"score": 0.851582, "label": "positive"}, "text": "United Kingdom", "relevance": 0.388609, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"count": 6, "sentiment": {"score": -0.537141, "label": "negative"}, "text": "New Takeda Securities", "relevance": 0.366343, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.343237, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0.745078, "label": "positive"}, "text": "Shire Shareholder", "relevance": 0.341411, "type": "Company"}, {"count": 12, "sentiment": {"score": -0.288879, "label": "negative"}, "text": "New Takeda ADSs", "relevance": 0.339206, "type": "Company"}, {"count": 3, "sentiment": {"score": 0.296017, "label": "positive"}, "text": "New Takeda Shares", "relevance": 0.317856, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.312033, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire ADSs", "relevance": 0.307413, "type": "Company"}, {"count": 11, "sentiment": {"score": 0, "label": "neutral"}, "text": "London", "relevance": 0.305288, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire Shareholder", "relevance": 0.297529, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire Depositary", "relevance": 0.292808, "type": "JobTitle"}, {"count": 7, "sentiment": {"score": 0.487038, "label": "positive"}, "text": "Court", "relevance": 0.292049, "type": "Organization", "disambiguation": {"subtype": ["Sport"], "name": "Volleyball", "dbpedia_resource": "http://dbpedia.org/resource/Volleyball"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Extraordinary General", "relevance": 0.281701, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Depositary", "relevance": 0.245928, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Extraordinary General Meeting.", "relevance": 0.237482, "type": "Organization"}, {"count": 4, "sentiment": {"score": 0.277075, "label": "positive"}, "text": "PRINCIPAL", "relevance": 0.228433, "type": "JobTitle"}, {"count": 7, "sentiment": {"score": 0, "label": "neutral"}, "text": "Financial Conduct Authority", "relevance": 0.226581, "type": "Organization", "disambiguation": {"subtype": [], "name": "Financial Conduct Authority", "dbpedia_resource": "http://dbpedia.org/resource/Financial_Conduct_Authority"}}, {"count": 8, "sentiment": {"score": 0.851582, "label": "positive"}, "text": "Jersey", "relevance": 0.223606, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "London Stock Exchange", "relevance": 0.222864, "type": "Company", "disambiguation": {"subtype": ["Location", "Facility", "TouristAttraction"], "name": "London Stock Exchange", "dbpedia_resource": "http://dbpedia.org/resource/London_Stock_Exchange"}}, {"count": 6, "sentiment": {"score": 0, "label": "neutral"}, "text": "New York", "relevance": 0.208081, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "New York, Lincolnshire", "dbpedia_resource": "http://dbpedia.org/resource/New_York,_Lincolnshire"}}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "SEC", "relevance": 0.205191, "type": "Organization"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.201382, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 6, "sentiment": {"score": 0.0994646, "label": "positive"}, "text": "Dealing Disclosures", "relevance": 0.199992, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Evercore", "relevance": 0.196732, "type": "Company", "disambiguation": {"subtype": [], "name": "Evercore Partners", "dbpedia_resource": "http://dbpedia.org/resource/Evercore_Partners"}}, {"count": 10, "sentiment": {"score": 0, "label": "neutral"}, "text": "Prudential Regulation Authority", "relevance": 0.193745, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Securities and Exchange Commission", "relevance": 0.193504, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "U.S. Securities and Exchange Commission", "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}}, {"count": 3, "sentiment": {"score": 0.442981, "label": "positive"}, "text": "European Commission", "relevance": 0.19199, "type": "Organization"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "solicitation", "relevance": 0.19019, "type": "Crime"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "International plc", "relevance": 0.189348, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Equiniti", "relevance": 0.18732, "type": "Person"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chairman", "relevance": 0.186929, "type": "JobTitle"}, {"count": 3, "sentiment": {"score": -0.242287, "label": "negative"}, "text": "Regulatory Information Service", "relevance": 0.185406, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "JPMorgan Securities Japan Co.", "relevance": 0.182851, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "J.P. Morgan Securities plc", "relevance": 0.179541, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dublin", "relevance": 0.178418, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "City"], "name": "Dublin", "dbpedia_resource": "http://dbpedia.org/resource/Dublin"}}], "sentiment": {"document": {"score": 0.473361, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Shire plc (\u201c Shire \u201d) and Takeda Pharmaceutical Company Limited (\u201c Takeda \u201d)", "keywords": [{"text": "Takeda Pharmaceutical Company"}, {"text": "Shire plc"}, {"text": "Company Limited"}], "entities": [{"type": "Company", "text": "Shire PLC", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Takeda"}]}, "sentence": "TAKEDA PHARMACEUTICAL COMPANY LIMITED Publication of Scheme Document On May 8, 2018, Shire plc (\u201c Shire \u201d) and Takeda Pharmaceutical Company Limited (\u201c Takeda \u201d) announced that they had reached agreement on the terms of a recommended cash and share offer to be made by Takeda for the entire issued and to be issued share capital of Shire (the \u201c Acquisition \u201d).", "object": {"text": "that they had reached agreement on the terms of a recommended cash and share offer to be made by Takeda for the entire issued and to be issued share capital of Shire (the \u201c Acquisition \u201d)", "keywords": [{"text": "share offer"}, {"text": "share capital"}, {"text": "Takeda"}, {"text": "agreement"}], "entities": [{"type": "Company", "text": "Takeda"}, {"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "a recommended cash and share", "keywords": [{"text": "cash"}, {"text": "share"}]}, "sentence": "TAKEDA PHARMACEUTICAL COMPANY LIMITED Publication of Scheme Document On May 8, 2018, Shire plc (\u201c Shire \u201d) and Takeda Pharmaceutical Company Limited (\u201c Takeda \u201d) announced that they had reached agreement on the terms of a recommended cash and share offer to be made by Takeda for the entire issued and to be issued share capital of Shire (the \u201c Acquisition \u201d).", "object": {"text": "made by Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "by Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": "TAKEDA PHARMACEUTICAL COMPANY LIMITED Publication of Scheme Document On May 8, 2018, Shire plc (\u201c Shire \u201d) and Takeda Pharmaceutical Company Limited (\u201c Takeda \u201d) announced that they had reached agreement on the terms of a recommended cash and share offer to be made by Takeda for the entire issued and to be issued share capital of Shire (the \u201c Acquisition \u201d).", "object": {"text": "a recommended cash and share offer", "keywords": [{"text": "cash"}, {"text": "share offer"}]}, "action": {"verb": {"text": "make", "tense": "past"}, "text": "to be made", "normalized": "to be make"}}, {"subject": {"text": "by means of a scheme of arrangement under Article 125 of the Companies (Jersey) Law 1991 (as amended) (the \u201c Scheme \u201d)", "keywords": [{"text": "scheme"}, {"text": "arrangement"}, {"text": "means"}, {"text": "Article"}], "entities": [{"type": "Organization", "text": "Scheme"}, {"type": "Organization", "text": "Scheme"}]}, "sentence": " The Acquisition will be effected by means of a scheme of arrangement under Article 125 of the Companies (Jersey) Law 1991 (as amended) (the \u201c Scheme \u201d).", "object": {"text": "The Acquisition", "keywords": [{"text": "Acquisition"}]}, "action": {"verb": {"text": "effect", "tense": "future"}, "text": "will be effected", "normalized": "will be effect"}}, {"subject": {"text": "the notes accompanying them", "keywords": [{"text": "notes"}]}, "sentence": " Together with the Scheme Document, Forms of Proxy for the Court Meeting and the Shire General Meeting and Forms of Election and the notes accompanying them have also been published on the Shire website at www.shire.com.", "object": {"text": "published on the Shire website", "keywords": [{"text": "Shire website"}], "entities": [{"type": "Organization", "text": "Shire"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "Forms of Proxy for the Court Meeting and the Shire General Meeting and Forms of Election and the notes accompanying them", "keywords": [{"text": "Shire General Meeting"}, {"text": "Court Meeting"}, {"text": "Proxy"}, {"text": "Election"}], "entities": [{"type": "Organization", "text": "Shire General Meeting"}]}, "sentence": " Together with the Scheme Document, Forms of Proxy for the Court Meeting and the Shire General Meeting and Forms of Election and the notes accompanying them have also been published on the Shire website at www.shire.com.", "action": {"verb": {"text": "publish", "tense": "past"}, "text": "have also been published", "normalized": "have also be publish"}}, {"subject": {"text": "Copies of these documents", "keywords": [{"text": "Copies"}, {"text": "documents"}]}, "sentence": " Copies of these documents are also being sent to Shire Shareholders today.", "object": {"text": "to Shire Shareholders", "keywords": [{"text": "Shire Shareholders"}], "entities": [{"type": "Company", "text": "Shire Shareholders"}]}, "action": {"verb": {"text": "send", "tense": "past"}, "text": "are also being sent", "normalized": "be also be send"}}, {"subject": {"text": "by the Shire Depositary", "keywords": [{"text": "Shire Depositary"}], "entities": [{"type": "Organization", "text": "Shire Depositary"}]}, "sentence": " A Notice of Court Meeting and Extraordinary General Meeting, together with an ADS Voting Card, is also being sent to Shire ADS Holders today by the Shire Depositary.", "object": {"text": "A Notice of Court Meeting and Extraordinary General Meeting", "keywords": [{"text": "Extraordinary General Meeting"}, {"text": "Notice"}, {"text": "Court Meeting"}]}, "action": {"verb": {"text": "send", "tense": "past"}, "text": "is also being sent", "normalized": "be also be send"}}, {"subject": {"text": "Forms of Proxy and Forms of Election", "keywords": [{"text": "Proxy"}, {"text": "Election"}, {"text": "Forms"}]}, "sentence": " The Scheme Document, Forms of Proxy and Forms of Election will be available shortly on the National Storage Mechanism at www.morningstar.co.uk/uk/nsm .", "object": {"text": "available shortly on the National Storage Mechanism", "keywords": [{"text": "National Storage Mechanism"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "will be", "normalized": "will be"}}, {"subject": {"text": "The Scheme Document", "keywords": [{"text": "Scheme Document"}]}, "sentence": " The Scheme Document has also been furnished to the SEC on Form 6-K and is available on the SEC\u2019s website at www.sec.gov.", "object": {"text": "furnished to the SEC on Form 6-K", "keywords": [{"text": "SEC"}, {"text": "Form"}], "entities": [{"type": "Organization", "text": "SEC"}, {"type": "Quantity", "text": "6-K"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "The Scheme Document", "keywords": [{"text": "Scheme Document"}]}, "sentence": " The Scheme Document has also been furnished to the SEC on Form 6-K and is available on the SEC\u2019s website at www.sec.gov.", "object": {"text": "to the SEC", "keywords": [{"text": "SEC"}], "entities": [{"type": "Organization", "text": "SEC"}]}, "action": {"verb": {"text": "furnish", "tense": "past"}, "text": "has also been furnished", "normalized": "have also be furnish"}}, {"subject": {"text": "The Scheme Document", "keywords": [{"text": "Scheme Document"}]}, "sentence": " The Scheme Document has also been furnished to the SEC on Form 6-K and is available on the SEC\u2019s website at www.sec.gov.", "object": {"text": "available on the SEC\u2019s website", "keywords": [{"text": "SEC\u2019s website"}], "entities": [{"type": "Organization", "text": "SEC"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Shire", "keywords": [{"text": "Shire"}], "entities": [{"type": "Person", "text": "Shire"}]}, "sentence": " Shire also notes Takeda\u2019s circular to shareholders published today, which relates to the convocation of the Takeda Extraordinary General Meeting scheduled to be held at 10.00 a.m. (Tokyo time) (1.00 a.m. (London time)) on December 5, 2018.", "object": {"text": "Takeda\u2019s circular to shareholders published today, which relates to the convocation of the Takeda Extraordinary General Meeting scheduled to be held at 10.00 a.m. (Tokyo time) (1.00 a.m. (London time)) on December 5, 2018", "keywords": [{"text": "Takeda Extraordinary General"}, {"text": "Tokyo time"}, {"text": "London time"}, {"text": "convocation"}], "entities": [{"type": "Organization", "text": "Takeda Extraordinary General"}, {"type": "Location", "text": "Tokyo", "disambiguation": {"subtype": ["City"]}}, {"type": "Location", "text": "London", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "note", "tense": "present"}, "text": "notes", "normalized": "note"}}, {"subject": {"text": "shareholders", "keywords": [{"text": "shareholders"}]}, "sentence": " Shire also notes Takeda\u2019s circular to shareholders published today, which relates to the convocation of the Takeda Extraordinary General Meeting scheduled to be held at 10.00 a.m. (Tokyo time) (1.00 a.m. (London time)) on December 5, 2018.", "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "the Takeda Extraordinary General Meeting", "keywords": [{"text": "Takeda Extraordinary General"}], "entities": [{"type": "Organization", "text": "Takeda Extraordinary General"}]}, "sentence": " Shire also notes Takeda\u2019s circular to shareholders published today, which relates to the convocation of the Takeda Extraordinary General Meeting scheduled to be held at 10.00 a.m. (Tokyo time) (1.00 a.m. (London time)) on December 5, 2018.", "object": {"text": "held"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "the Takeda Extraordinary General Meeting", "keywords": [{"text": "Takeda Extraordinary General"}], "entities": [{"type": "Organization", "text": "Takeda Extraordinary General"}]}, "sentence": " Shire also notes Takeda\u2019s circular to shareholders published today, which relates to the convocation of the Takeda Extraordinary General Meeting scheduled to be held at 10.00 a.m. (Tokyo time) (1.00 a.m. (London time)) on December 5, 2018.", "action": {"verb": {"text": "hold", "tense": "past"}, "text": "scheduled to be held", "normalized": "schedule to be hold"}}, {"subject": {"text": "This"}, "sentence": " This is available on Takeda\u2019s website at www.takeda.com/investors/offer-for-shire.", "object": {"text": "available on Takeda\u2019s website", "keywords": [{"text": "Takeda"}, {"text": "website"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "terms", "keywords": [{"text": "terms"}]}, "sentence": " Unless otherwise defined, all capitalised terms in this announcement (the \u201c Announcement \u201d) shall have the meaning given to them in the Scheme Document.", "action": {"verb": {"text": "capitalise", "tense": "past"}, "text": "capitalised", "normalized": "capitalise"}}, {"subject": {"text": "all capitalised terms in this announcement (the \u201c Announcement \u201d)", "keywords": [{"text": "announcement"}, {"text": "terms"}]}, "sentence": " Unless otherwise defined, all capitalised terms in this announcement (the \u201c Announcement \u201d) shall have the meaning given to them in the Scheme Document.", "object": {"text": "the meaning given to them in the Scheme Document", "keywords": [{"text": "Scheme Document"}, {"text": "meaning"}]}, "action": {"verb": {"text": "have", "tense": "future"}, "text": "shall have", "normalized": "shall have"}}, {"subject": {"text": "Notices of the Court Meeting and Shire General Meeting", "keywords": [{"text": "Shire General Meeting"}, {"text": "Notices"}, {"text": "Court Meeting"}], "entities": [{"type": "Organization", "text": "Shire General Meeting"}]}, "sentence": " Notices of the Court Meeting and Shire General Meeting As described in the Scheme Document, to become effective, the Scheme requires, among other things, the approval of Shire Shareholders at the Court Meeting, the passing of the Special Resolution at the Shire General Meeting and the subsequent sanction of the Court.", "object": {"text": "effective"}, "action": {"verb": {"text": "become", "tense": "future"}, "text": "to become", "normalized": "to become"}}, {"subject": {"text": "the Conditions and certain further terms", "keywords": [{"text": "certain further terms"}, {"text": "Conditions"}]}, "sentence": " The Acquisition is also subject to the satisfaction or waiver of the Conditions and certain further terms that are set out in the Scheme Document.", "object": {"text": "in the Scheme Document", "keywords": [{"text": "Scheme Document"}]}, "action": {"verb": {"text": "set", "tense": "past"}, "text": "are set", "normalized": "be set"}}, {"subject": {"text": "Notices of the Court Meeting and the Shire General Meeting", "keywords": [{"text": "Shire General Meeting"}, {"text": "Notices"}, {"text": "Court Meeting"}], "entities": [{"type": "Organization", "text": "Shire General Meeting"}]}, "sentence": " Notices of the Court Meeting and the Shire General Meeting, which are scheduled to be held at Block 3, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland on December 5, 2018, are set out in the Scheme Document.", "object": {"text": "scheduled to be held at Block 3", "keywords": [{"text": "Block"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "the Shire General Meeting", "keywords": [{"text": "Shire General Meeting"}], "entities": [{"type": "Organization", "text": "Shire General Meeting"}]}, "sentence": " Notices of the Court Meeting and the Shire General Meeting, which are scheduled to be held at Block 3, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland on December 5, 2018, are set out in the Scheme Document.", "object": {"text": "to be held at Block 3, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland", "keywords": [{"text": "Baggot Street Lower"}, {"text": "Miesian Plaza"}, {"text": "Block"}, {"text": "Dublin"}], "entities": [{"type": "Facility", "text": "Miesian Plaza"}, {"type": "Location", "text": "Dublin", "disambiguation": {"subtype": ["AdministrativeDivision", "CityTown", "City"], "name": "Dublin", "dbpedia_resource": "http://dbpedia.org/resource/Dublin"}}, {"type": "Location", "text": "Ireland", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "schedule", "tense": "past"}, "text": "scheduled", "normalized": "schedule"}}, {"subject": {"text": "Notices of the Court Meeting and the Shire General Meeting", "keywords": [{"text": "Shire General Meeting"}, {"text": "Notices"}, {"text": "Court Meeting"}], "entities": [{"type": "Organization", "text": "Shire General Meeting"}]}, "sentence": " Notices of the Court Meeting and the Shire General Meeting, which are scheduled to be held at Block 3, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland on December 5, 2018, are set out in the Scheme Document.", "object": {"text": "held at Block 3", "keywords": [{"text": "Block"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Notices of the Court Meeting and the Shire General Meeting", "keywords": [{"text": "Shire General Meeting"}, {"text": "Notices"}, {"text": "Court Meeting"}], "entities": [{"type": "Organization", "text": "Shire General Meeting"}]}, "sentence": " Notices of the Court Meeting and the Shire General Meeting, which are scheduled to be held at Block 3, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland on December 5, 2018, are set out in the Scheme Document.", "action": {"verb": {"text": "hold", "tense": "past"}, "text": "are scheduled to be held", "normalized": "be schedule to be hold"}}, {"subject": {"text": "Notices of the Court Meeting and the Shire General Meeting, which are scheduled to be held at Block 3, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland on December 5, 2018,", "keywords": [{"text": "Baggot Street Lower"}, {"text": "Shire General Meeting"}, {"text": "Miesian Plaza"}, {"text": "Court Meeting"}], "entities": [{"type": "Organization", "text": "Shire General Meeting"}, {"type": "Facility", "text": "Miesian Plaza"}, {"type": "Location", "text": "Dublin", "disambiguation": {"subtype": ["AdministrativeDivision", "CityTown", "City"], "name": "Dublin", "dbpedia_resource": "http://dbpedia.org/resource/Dublin"}}, {"type": "Location", "text": "Ireland", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Notices of the Court Meeting and the Shire General Meeting, which are scheduled to be held at Block 3, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland on December 5, 2018, are set out in the Scheme Document.", "object": {"text": "in the Scheme Document", "keywords": [{"text": "Scheme Document"}]}, "action": {"verb": {"text": "set", "tense": "past"}, "text": "are set", "normalized": "be set"}}, {"subject": {"text": "The Court Meeting", "keywords": [{"text": "Court Meeting"}]}, "sentence": " The Court Meeting is scheduled to commence at 11.15 a.m. and the Shire General Meeting at 11.30 a.m. (or as soon thereafter as the Court Meeting has concluded or been adjourned).", "object": {"text": "scheduled to commence", "keywords": [{"text": "commence"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Court Meeting", "keywords": [{"text": "Court Meeting"}]}, "sentence": " The Court Meeting is scheduled to commence at 11.15 a.m. and the Shire General Meeting at 11.30 a.m. (or as soon thereafter as the Court Meeting has concluded or been adjourned).", "object": {"text": "to commence at 11.15 a.m. and the Shire General Meeting", "keywords": [{"text": "Shire General Meeting"}], "entities": [{"type": "Organization", "text": "Shire General Meeting"}]}, "action": {"verb": {"text": "schedule", "tense": "past"}, "text": "scheduled", "normalized": "schedule"}}, {"subject": {"text": "the Court Meeting", "keywords": [{"text": "Court Meeting"}]}, "sentence": " The Court Meeting is scheduled to commence at 11.15 a.m. and the Shire General Meeting at 11.30 a.m. (or as soon thereafter as the Court Meeting has concluded or been adjourned).", "object": {"text": "concluded or been adjourned"}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "the Court Meeting", "keywords": [{"text": "Court Meeting"}]}, "sentence": " The Court Meeting is scheduled to commence at 11.15 a.m. and the Shire General Meeting at 11.30 a.m. (or as soon thereafter as the Court Meeting has concluded or been adjourned).", "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "It"}, "sentence": " It is important that, for the Court Meeting in particular, as many votes as possible are cast so that the Court may be satisfied that there is a fair and reasonable representation of Shire Shareholder opinion.", "object": {"text": "important that"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the Court", "keywords": [{"text": "Court"}], "entities": [{"type": "Organization", "text": "Court", "disambiguation": {"subtype": ["Sport"], "name": "Volleyball", "dbpedia_resource": "http://dbpedia.org/resource/Volleyball"}}]}, "sentence": " It is important that, for the Court Meeting in particular, as many votes as possible are cast so that the Court may be satisfied that there is a fair and reasonable representation of Shire Shareholder opinion.", "object": {"text": "satisfied that there"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Shire Shareholders and Shire ADS Holders", "keywords": [{"text": "Shire ADS Holders"}, {"text": "Shire Shareholders"}], "entities": [{"type": "Company", "text": "Shire Shareholders"}, {"type": "Company", "text": "Shire ADS Holders"}]}, "sentence": " Shire Shareholders and Shire ADS Holders are therefore strongly urged to complete, sign and return the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible.", "object": {"text": "the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible", "keywords": [{"text": "ADS Voting Card"}, {"text": "Shire General Meeting"}, {"text": "electronic means"}, {"text": "Court Meeting"}], "entities": [{"type": "Organization", "text": "Shire General Meeting"}]}, "action": {"verb": {"text": "complete", "tense": "future"}, "text": "urged to complete", "normalized": "urge to complete"}}, {"subject": {"text": "Shire Shareholders and Shire ADS Holders", "keywords": [{"text": "Shire ADS Holders"}, {"text": "Shire Shareholders"}], "entities": [{"type": "Company", "text": "Shire Shareholders"}, {"type": "Company", "text": "Shire ADS Holders"}]}, "sentence": " Shire Shareholders and Shire ADS Holders are therefore strongly urged to complete, sign and return the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible.", "object": {"text": "the Forms of Proxy", "keywords": [{"text": "Proxy"}, {"text": "Forms"}]}, "action": {"verb": {"text": "sign", "tense": "present"}, "text": "sign and return", "normalized": "sign and return"}}, {"subject": {"text": "Shire Shareholders and Shire ADS Holders", "keywords": [{"text": "Shire ADS Holders"}, {"text": "Shire Shareholders"}], "entities": [{"type": "Company", "text": "Shire Shareholders"}, {"type": "Company", "text": "Shire ADS Holders"}]}, "sentence": " Shire Shareholders and Shire ADS Holders are therefore strongly urged to complete, sign and return the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible.", "object": {"text": "the Forms of Proxy", "keywords": [{"text": "Proxy"}, {"text": "Forms"}]}, "action": {"verb": {"text": "return", "tense": "present"}, "text": "sign and return", "normalized": "sign and return"}}, {"subject": {"text": "The Scheme Document", "keywords": [{"text": "Scheme Document"}]}, "sentence": " Timetable The Scheme Document contains an expected timetable of principal events relating to the Scheme, which is also attached as an Appendix to this Announcement.", "object": {"text": "an expected timetable of principal events relating to the Scheme, which is also attached as an Appendix to this Announcement", "keywords": [{"text": "expected timetable"}, {"text": "principal events"}, {"text": "Appendix"}, {"text": "Scheme"}], "entities": [{"type": "JobTitle", "text": "PRINCIPAL"}, {"type": "Organization", "text": "Scheme"}]}, "action": {"verb": {"text": "contain", "tense": "present"}, "text": "contains", "normalized": "contain"}}, {"subject": {"text": "the satisfaction or waiver of the other Conditions", "keywords": [{"text": "waiver"}, {"text": "satisfaction"}, {"text": "Conditions"}]}, "sentence": " Subject to approval at the relevant meetings, the satisfaction or waiver of the other Conditions set out in the Scheme Document and the sanction of the Court, the Scheme is expected to become effective on or around January 8, 2019.", "object": {"text": "in the Scheme Document", "keywords": [{"text": "Scheme Document"}]}, "action": {"verb": {"text": "set", "tense": "past"}, "text": "set", "normalized": "set"}}, {"subject": {"text": "the Scheme", "keywords": [{"text": "Scheme"}], "entities": [{"type": "Organization", "text": "Scheme"}]}, "sentence": " Subject to approval at the relevant meetings, the satisfaction or waiver of the other Conditions set out in the Scheme Document and the sanction of the Court, the Scheme is expected to become effective on or around January 8, 2019.", "action": {"verb": {"text": "expect", "tense": "past"}, "text": "is expected to become", "normalized": "be expect to become"}}, {"subject": {"text": "the Scheme", "keywords": [{"text": "Scheme"}], "entities": [{"type": "Organization", "text": "Scheme"}]}, "sentence": " Subject to approval at the relevant meetings, the satisfaction or waiver of the other Conditions set out in the Scheme Document and the sanction of the Court, the Scheme is expected to become effective on or around January 8, 2019.", "object": {"text": "effective"}, "action": {"verb": {"text": "become", "tense": "future"}, "text": "is expected to become", "normalized": "be expect to become"}}, {"subject": {"text": "it"}, "sentence": " If it becomes necessary to change any of the dates and/or times in the expected timetable, including as a result of the timing of receipt of approval from the European Commission to proceed to completion of the Acquisition, it is intended that the Effective Date will be as soon as practicable after January 8, 2019.", "object": {"text": "necessary to change any of the dates and/or times in the expected timetable", "keywords": [{"text": "timetable"}, {"text": "dates"}, {"text": "times"}]}, "action": {"verb": {"text": "become", "tense": "present"}, "text": "becomes", "normalized": "become"}}, {"subject": {"text": "it"}, "sentence": " If it becomes necessary to change any of the dates and/or times in the expected timetable, including as a result of the timing of receipt of approval from the European Commission to proceed to completion of the Acquisition, it is intended that the Effective Date will be as soon as practicable after January 8, 2019.", "object": {"text": "intended that the Effective Date will be as soon as practicable", "keywords": [{"text": "Effective Date"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "that the Effective Date will be as soon as practicable after January 8, 2019", "keywords": [{"text": "Effective Date"}, {"text": "practicable"}]}, "sentence": " If it becomes necessary to change any of the dates and/or times in the expected timetable, including as a result of the timing of receipt of approval from the European Commission to proceed to completion of the Acquisition, it is intended that the Effective Date will be as soon as practicable after January 8, 2019.", "object": {"text": "it"}, "action": {"verb": {"text": "intend", "tense": "past"}, "text": "is intended", "normalized": "be intend"}}, {"subject": {"text": "the Scheme", "keywords": [{"text": "Scheme"}], "entities": [{"type": "Organization", "text": "Scheme"}]}, "sentence": " If the Scheme is approved as outlined above, it is expected that trading of Shire Shares on the London Stock Exchange\u2019s main market for listed securities will be suspended from 4.30 p.m. on January 4, 2019.", "object": {"text": "approved as outlined above"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the Scheme", "keywords": [{"text": "Scheme"}], "entities": [{"type": "Organization", "text": "Scheme"}]}, "sentence": " If the Scheme is approved as outlined above, it is expected that trading of Shire Shares on the London Stock Exchange\u2019s main market for listed securities will be suspended from 4.30 p.m. on January 4, 2019.", "object": {"text": "as outlined above"}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "is approved", "normalized": "be approve"}}, {"subject": {"text": "the Scheme", "keywords": [{"text": "Scheme"}], "entities": [{"type": "Organization", "text": "Scheme"}]}, "sentence": " If the Scheme is approved as outlined above, it is expected that trading of Shire Shares on the London Stock Exchange\u2019s main market for listed securities will be suspended from 4.30 p.m. on January 4, 2019.", "action": {"verb": {"text": "outline", "tense": "past"}, "text": "outlined", "normalized": "outline"}}, {"subject": {"text": "trading of Shire Shares on the London Stock Exchange\u2019s main market for listed securities", "keywords": [{"text": "London Stock Exchange"}, {"text": "Shire Shares"}, {"text": "listed securities"}, {"text": "main market"}], "entities": [{"type": "Company", "text": "Shire Shares"}, {"type": "Company", "text": "London Stock Exchange", "disambiguation": {"subtype": ["Organization", "Location", "Facility", "TouristAttraction"], "name": "London Stock Exchange", "dbpedia_resource": "http://dbpedia.org/resource/London_Stock_Exchange"}}]}, "sentence": " If the Scheme is approved as outlined above, it is expected that trading of Shire Shares on the London Stock Exchange\u2019s main market for listed securities will be suspended from 4.30 p.m. on January 4, 2019.", "action": {"verb": {"text": "suspend", "tense": "future"}, "text": "will be suspended", "normalized": "will be suspend"}}, {"subject": {"text": "It"}, "sentence": " It is intended that, following the Scheme becoming Effective, the London Stock Exchange and the FCA will be requested respectively to cancel trading in Shire Shares on the London Stock Exchange\u2019s main market for listed securities and to remove the listing of the Shire Shares from the Official List, in each case on or shortly after the Effective Date.", "object": {"text": "intended that"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "that"}, "sentence": " It is intended that, following the Scheme becoming Effective, the London Stock Exchange and the FCA will be requested respectively to cancel trading in Shire Shares on the London Stock Exchange\u2019s main market for listed securities and to remove the listing of the Shire Shares from the Official List, in each case on or shortly after the Effective Date.", "object": {"text": "It"}, "action": {"verb": {"text": "intend", "tense": "past"}, "text": "is intended", "normalized": "be intend"}}, {"subject": {"text": "the Scheme", "keywords": [{"text": "Scheme"}], "entities": [{"type": "Organization", "text": "Scheme"}]}, "sentence": " It is intended that, following the Scheme becoming Effective, the London Stock Exchange and the FCA will be requested respectively to cancel trading in Shire Shares on the London Stock Exchange\u2019s main market for listed securities and to remove the listing of the Shire Shares from the Official List, in each case on or shortly after the Effective Date.", "object": {"text": "Effective"}, "action": {"verb": {"text": "become", "tense": "present"}, "text": "becoming", "normalized": "become"}}, {"subject": {"text": "the FCA", "keywords": [{"text": "FCA"}], "entities": [{"type": "Organization", "text": "FCA", "disambiguation": {"subtype": ["Industry"], "name": "Airline", "dbpedia_resource": "http://dbpedia.org/resource/Airline"}}]}, "sentence": " It is intended that, following the Scheme becoming Effective, the London Stock Exchange and the FCA will be requested respectively to cancel trading in Shire Shares on the London Stock Exchange\u2019s main market for listed securities and to remove the listing of the Shire Shares from the Official List, in each case on or shortly after the Effective Date.", "object": {"text": "requested respectively"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}], "concepts": [{"text": "U.S. Securities and Exchange Commission", "relevance": 0.951262, "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}, {"text": "Stock market", "relevance": 0.797799, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "Stock", "relevance": 0.716874, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Stock exchange", "relevance": 0.704153, "dbpedia_resource": "http://dbpedia.org/resource/Stock_exchange"}, {"text": "Financial adviser", "relevance": 0.635904, "dbpedia_resource": "http://dbpedia.org/resource/Financial_adviser"}, {"text": "London Stock Exchange", "relevance": 0.54354, "dbpedia_resource": "http://dbpedia.org/resource/London_Stock_Exchange"}, {"text": "Securities Exchange Act of 1934", "relevance": 0.543376, "dbpedia_resource": "http://dbpedia.org/resource/Securities_Exchange_Act_of_1934"}, {"text": "New York Stock Exchange", "relevance": 0.528256, "dbpedia_resource": "http://dbpedia.org/resource/New_York_Stock_Exchange"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.483604, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Securities Act of 1933", "relevance": 0.462304, "dbpedia_resource": "http://dbpedia.org/resource/Securities_Act_of_1933"}, {"text": "Independent Financial Adviser", "relevance": 0.439638, "dbpedia_resource": "http://dbpedia.org/resource/Independent_Financial_Adviser"}, {"text": "Form 10-K", "relevance": 0.42826, "dbpedia_resource": "http://dbpedia.org/resource/Form_10-K"}], "categories": [{"score": 0.644605, "label": "/finance/financial news"}, {"score": 0.444325, "label": "/law, govt and politics"}, {"score": 0.408111, "label": "/real estate/buying and selling homes"}], "relations": [{"type": "partOfMany", "sentence": "TAKEDA PHARMACEUTICAL COMPANY LIMITED Publication of Scheme Document On May 8, 2018, Shire plc (\" Shire \") and Takeda Pharmaceutical Company Limited (\" Takeda \") announced that they had reached agreement on the terms of a recommended cash and share offer to be made by Takeda for the entire issued and to be issued share capital of Shire (the \" Acquisition \").", "score": 0.743728, "arguments": [{"text": "Shire plc", "location": [85, 94], "entities": [{"type": "Person", "text": "Shire plc"}]}, {"text": "they", "location": [177, 181], "entities": [{"type": "Person", "text": "they"}]}]}, {"type": "participantIn", "sentence": "A Notice of Court Meeting and Extraordinary General Meeting, together with an ADS Voting Card, is also being sent to Shire ADS Holders today by the Shire Depositary.", "score": 0.507852, "arguments": [{"text": "Court", "location": [1376, 1381], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [1382, 1389], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "locatedAt", "sentence": "Persons into whose possession this Announcement comes who are not resident in the United Kingdom should inform themselves of, and observe, any applicable requirements.", "score": 0.509874, "arguments": [{"text": "who", "location": [19468, 19471], "entities": [{"type": "Person", "text": "who"}]}, {"text": "United Kingdom", "location": [19496, 19510], "entities": [{"type": "GeopoliticalEntity", "text": "United Kingdom"}]}]}, {"type": "affectedBy", "sentence": "Persons into whose possession this Announcement comes who are not resident in the United Kingdom should inform themselves of, and observe, any applicable requirements.", "score": 0.825248, "arguments": [{"text": "themselves", "location": [19525, 19535], "entities": [{"type": "Person", "text": "themselves"}]}, {"text": "inform", "location": [19518, 19524], "entities": [{"type": "EventCommunication", "text": "inform"}]}]}, {"type": "partOfMany", "sentence": "Shire Shareholders who are in any doubt regarding such matters should consult an appropriate independent financial adviser in their relevant jurisdiction without delay.", "score": 0.510056, "arguments": [{"text": "Shareholders", "location": [19588, 19600], "entities": [{"type": "Person", "text": "Shareholders"}]}, {"text": "who", "location": [19601, 19604], "entities": [{"type": "Person", "text": "who"}]}]}, {"type": "colleague", "sentence": "Further details in relation to Shire Shareholders who are resident in, ordinarily resident in, or citizens of, jurisdictions outside the United Kingdom and Jersey will be contained in the Scheme Document.", "score": 0.340474, "arguments": [{"text": "Shire", "location": [20326, 20331], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Shareholders", "location": [20332, 20344], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "partOfMany", "sentence": "Further details in relation to Shire Shareholders who are resident in, ordinarily resident in, or citizens of, jurisdictions outside the United Kingdom and Jersey will be contained in the Scheme Document.", "score": 0.479561, "arguments": [{"text": "Shareholders", "location": [20332, 20344], "entities": [{"type": "Person", "text": "Shareholders"}]}, {"text": "who", "location": [20345, 20348], "entities": [{"type": "Person", "text": "who"}]}]}, {"type": "partOfMany", "sentence": "Further details in relation to Shire Shareholders who are resident in, ordinarily resident in, or citizens of, jurisdictions outside the United Kingdom and Jersey will be contained in the Scheme Document.", "score": 0.615283, "arguments": [{"text": "resident", "location": [20353, 20361], "entities": [{"type": "Person", "text": "resident"}]}, {"text": "who", "location": [20345, 20348], "entities": [{"type": "Person", "text": "who"}]}]}, {"type": "partOfMany", "sentence": "Further details in relation to Shire Shareholders who are resident in, ordinarily resident in, or citizens of, jurisdictions outside the United Kingdom and Jersey will be contained in the Scheme Document.", "score": 0.721339, "arguments": [{"text": "resident", "location": [20377, 20385], "entities": [{"type": "Person", "text": "resident"}]}, {"text": "who", "location": [20345, 20348], "entities": [{"type": "Person", "text": "who"}]}]}, {"type": "employedBy", "sentence": "Additional information for US investors Notice to US investors in Shire: the Acquisition relates to the shares of a Jersey company and is being made by means of a scheme of arrangement provided for under the Jersey Companies Law.", "score": 0.972641, "arguments": [{"text": "investors", "location": [20530, 20539], "entities": [{"type": "Person", "text": "investors"}]}, {"text": "US", "location": [20527, 20529], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "employedBy", "sentence": "Additional information for US investors Notice to US investors in Shire: the Acquisition relates to the shares of a Jersey company and is being made by means of a scheme of arrangement provided for under the Jersey Companies Law.", "score": 0.966762, "arguments": [{"text": "investors", "location": [20553, 20562], "entities": [{"type": "Person", "text": "investors"}]}, {"text": "US", "location": [20550, 20552], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "employedBy", "sentence": "Additional information for US investors Notice to US investors in Shire: the Acquisition relates to the shares of a Jersey company and is being made by means of a scheme of arrangement provided for under the Jersey Companies Law.", "score": 0.376571, "arguments": [{"text": "Shire", "location": [20566, 20571], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Acquisition", "location": [20577, 20588], "entities": [{"type": "Organization", "text": "Acquisition"}]}]}, {"type": "participantIn", "sentence": "A Notice of Court Meeting and Extraordinary General Meeting, together with an ADS Voting Card, is also being sent to Shire ADS Holders today by the Shire Depositary.", "score": 0.55396, "arguments": [{"text": "ADS Voting Card", "location": [1442, 1457], "entities": [{"type": "Person", "text": "ADS Voting Card"}]}, {"text": "Meeting", "location": [1382, 1389], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "basedIn", "sentence": "Additional information for US investors Notice to US investors in Shire: the Acquisition relates to the shares of a Jersey company and is being made by means of a scheme of arrangement provided for under the Jersey Companies Law.", "score": 0.951866, "arguments": [{"text": "company", "location": [20623, 20630], "entities": [{"type": "Organization", "text": "company"}]}, {"text": "Jersey", "location": [20616, 20622], "entities": [{"type": "GeopoliticalEntity", "text": "Jersey"}]}]}, {"type": "partOf", "sentence": "A transaction effected by means of a scheme of arrangement is not subject to the tender offer rules or the proxy solicitation rules under the US Exchange Act, and it is expected that any New Takeda Securities to be issued pursuant to the Scheme to Shire Shareholders would be issued in reliance upon the exemption from the registration requirements under the US Securities Act provided by Section 3(a)(10) thereof.", "score": 0.988303, "arguments": [{"text": "Exchange Act", "location": [20875, 20887], "entities": [{"type": "Organization", "text": "Exchange Act"}]}, {"text": "US", "location": [20872, 20874], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "employedBy", "sentence": "Under applicable US securities laws, persons (whether or not US persons) who are or will be \"affiliates\" (within the meaning of Rule 144 of the US Securities Act) of Takeda prior to, or after, the Effective Date will be subject to certain transfer restrictions relating to the New Takeda Securities received in connection with the Acquisition.", "score": 0.931891, "arguments": [{"text": "persons", "location": [21209, 21216], "entities": [{"type": "Person", "text": "persons"}]}, {"text": "US", "location": [21206, 21208], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "partOf", "sentence": "Under applicable US securities laws, persons (whether or not US persons) who are or will be \"affiliates\" (within the meaning of Rule 144 of the US Securities Act) of Takeda prior to, or after, the Effective Date will be subject to certain transfer restrictions relating to the New Takeda Securities received in connection with the Acquisition.", "score": 0.555179, "arguments": [{"text": "Rule 144", "location": [21273, 21281], "entities": [{"type": "Organization", "text": "Rule 144"}]}, {"text": "US Securities Act", "location": [21289, 21306], "entities": [{"type": "Organization", "text": "US Securities Act"}]}]}, {"type": "partOf", "sentence": "Accordingly, the Acquisition is subject to the disclosure requirements and practices applicable in the United Kingdom and Jersey to schemes of arrangement which differ from the disclosure requirements of United States tender offer and proxy solicitation rules and the US Securities Act.", "score": 0.949573, "arguments": [{"text": "tender", "location": [21707, 21713], "entities": [{"type": "Organization", "text": "tender"}]}, {"text": "United States", "location": [21693, 21706], "entities": [{"type": "GeopoliticalEntity", "text": "United States"}]}]}, {"type": "educatedAt", "sentence": "If, in the future, Takeda exercises the right to implement the Acquisition by way of a Takeover Offer and determines to extend the offer into the United States, the Acquisition will be made in compliance with applicable United States laws and regulations, including any applicable exemptions under the US Exchange Act.", "score": 0.430499, "arguments": [{"text": "Takeda", "location": [21795, 21801], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "Takeover Offer", "location": [21863, 21877], "entities": [{"type": "Organization", "text": "Takeover Offer"}]}]}, {"type": "agentOf", "sentence": "If, in the future, Takeda exercises the right to implement the Acquisition by way of a Takeover Offer and determines to extend the offer into the United States, the Acquisition will be made in compliance with applicable United States laws and regulations, including any applicable exemptions under the US Exchange Act.", "score": 0.606714, "arguments": [{"text": "Takeda", "location": [21795, 21801], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "determines", "location": [21882, 21892], "entities": [{"type": "EventCommunication", "text": "determines"}]}]}, {"type": "agentOf", "sentence": "Financial information included in this Announcement and the Scheme Document has been or will have been prepared in accordance with accounting standards applicable in the United Kingdom and Jersey that may not be comparable to financial information of US companies or companies whose financial statements are prepared in accordance with US GAAP.", "score": 0.784337, "arguments": [{"text": "Financial information", "location": [22095, 22116], "entities": [{"type": "Organization", "text": "Financial information"}]}, {"text": "Announcement", "location": [22134, 22146], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Financial information included in this Announcement and the Scheme Document has been or will have been prepared in accordance with accounting standards applicable in the United Kingdom and Jersey that may not be comparable to financial information of US companies or companies whose financial statements are prepared in accordance with US GAAP.", "score": 0.578556, "arguments": [{"text": "Scheme Document", "location": [22155, 22170], "entities": [{"type": "Organization", "text": "Scheme Document"}]}, {"text": "Announcement", "location": [22134, 22146], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "partOfMany", "sentence": "Financial information included in this Announcement and the Scheme Document has been or will have been prepared in accordance with accounting standards applicable in the United Kingdom and Jersey that may not be comparable to financial information of US companies or companies whose financial statements are prepared in accordance with US GAAP.", "score": 0.334276, "arguments": [{"text": "Jersey", "location": [22284, 22290], "entities": [{"type": "Organization", "text": "Jersey"}]}, {"text": "companies", "location": [22362, 22371], "entities": [{"type": "Organization", "text": "companies"}]}]}, {"type": "hasAttribute", "sentence": "The Scheme Document, Forms of Proxy and Forms of Election will be available shortly on the National Storage Mechanism at www.morningstar.co.uk/uk/nsm .", "score": 0.715971, "arguments": [{"text": "National Storage Mechanism", "location": [1621, 1647], "entities": [{"type": "Organization", "text": "National Storage Mechanism"}]}, {"text": "www.morningstar.co.uk/uk/nsm", "location": [1651, 1679], "entities": [{"type": "Web", "text": "www.morningstar.co.uk/uk/nsm"}]}]}, {"type": "basedIn", "sentence": "Financial information included in this Announcement and the Scheme Document has been or will have been prepared in accordance with accounting standards applicable in the United Kingdom and Jersey that may not be comparable to financial information of US companies or companies whose financial statements are prepared in accordance with US GAAP.", "score": 0.959976, "arguments": [{"text": "companies", "location": [22349, 22358], "entities": [{"type": "Organization", "text": "companies"}]}, {"text": "US", "location": [22346, 22348], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "employedBy", "sentence": "Financial information included in this Announcement and the Scheme Document has been or will have been prepared in accordance with accounting standards applicable in the United Kingdom and Jersey that may not be comparable to financial information of US companies or companies whose financial statements are prepared in accordance with US GAAP.", "score": 0.555306, "arguments": [{"text": "whose", "location": [22372, 22377], "entities": [{"type": "Person", "text": "whose"}]}, {"text": "companies", "location": [22362, 22371], "entities": [{"type": "Organization", "text": "companies"}]}]}, {"type": "employedBy", "sentence": "The receipt of consideration by a US holder for the transfer of its Shire Shares pursuant to the Scheme will be a taxable transaction for United States federal income tax purposes.", "score": 0.687229, "arguments": [{"text": "Shire", "location": [22508, 22513], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "its", "location": [22504, 22507], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "agentOf", "sentence": "Each Shire Shareholder is urged to consult his independent professional adviser immediately regarding the tax consequences of the Acquisition applicable to him, including under applicable United States state and local, as well as foreign and other, tax laws.", "score": 0.609404, "arguments": [{"text": "Shire", "location": [22626, 22631], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "urged", "location": [22647, 22652], "entities": [{"type": "EventCommunication", "text": "urged"}]}]}, {"type": "partOf", "sentence": "Each Shire Shareholder is urged to consult his independent professional adviser immediately regarding the tax consequences of the Acquisition applicable to him, including under applicable United States state and local, as well as foreign and other, tax laws.", "score": 0.562084, "arguments": [{"text": "United States", "location": [22809, 22822], "entities": [{"type": "GeopoliticalEntity", "text": "United States"}]}, {"text": "state", "location": [22823, 22828], "entities": [{"type": "GeopoliticalEntity", "text": "state"}]}]}, {"type": "employedBy", "sentence": "It may be difficult for US holders of Shire Shares to enforce their rights and any claim arising out of the US federal laws, since Takeda and Shire are located primarily in a non-US jurisdiction, and some or all of their officers and directors may be residents of a non-US jurisdiction.", "score": 0.924679, "arguments": [{"text": "holders", "location": [22907, 22914], "entities": [{"type": "Person", "text": "holders"}]}, {"text": "US", "location": [22904, 22906], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "partOfMany", "sentence": "It may be difficult for US holders of Shire Shares to enforce their rights and any claim arising out of the US federal laws, since Takeda and Shire are located primarily in a non-US jurisdiction, and some or all of their officers and directors may be residents of a non-US jurisdiction.", "score": 0.618096, "arguments": [{"text": "holders", "location": [22907, 22914], "entities": [{"type": "Person", "text": "holders"}]}, {"text": "their", "location": [22942, 22947], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "It may be difficult for US holders of Shire Shares to enforce their rights and any claim arising out of the US federal laws, since Takeda and Shire are located primarily in a non-US jurisdiction, and some or all of their officers and directors may be residents of a non-US jurisdiction.", "score": 0.789837, "arguments": [{"text": "Shire", "location": [22918, 22923], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "their", "location": [22942, 22947], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "It may be difficult for US holders of Shire Shares to enforce their rights and any claim arising out of the US federal laws, since Takeda and Shire are located primarily in a non-US jurisdiction, and some or all of their officers and directors may be residents of a non-US jurisdiction.", "score": 0.49106, "arguments": [{"text": "Takeda", "location": [23011, 23017], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "their", "location": [23095, 23100], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "It may be difficult for US holders of Shire Shares to enforce their rights and any claim arising out of the US federal laws, since Takeda and Shire are located primarily in a non-US jurisdiction, and some or all of their officers and directors may be residents of a non-US jurisdiction.", "score": 0.681985, "arguments": [{"text": "Shire", "location": [23022, 23027], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "some", "location": [23080, 23084], "entities": [{"type": "Cardinal", "text": "some"}]}]}, {"type": "hasAttribute", "sentence": "The Scheme Document has also been furnished to the SEC on Form 6-K and is available on the SEC's website at www.sec.gov.", "score": 0.508651, "arguments": [{"text": "SEC", "location": [1773, 1776], "entities": [{"type": "Organization", "text": "SEC"}]}, {"text": "www.sec.gov", "location": [1790, 1801], "entities": [{"type": "Web", "text": "www.sec.gov"}]}]}, {"type": "partOfMany", "sentence": "It may be difficult for US holders of Shire Shares to enforce their rights and any claim arising out of the US federal laws, since Takeda and Shire are located primarily in a non-US jurisdiction, and some or all of their officers and directors may be residents of a non-US jurisdiction.", "score": 0.890011, "arguments": [{"text": "Shire", "location": [23022, 23027], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "their", "location": [23095, 23100], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "It may be difficult for US holders of Shire Shares to enforce their rights and any claim arising out of the US federal laws, since Takeda and Shire are located primarily in a non-US jurisdiction, and some or all of their officers and directors may be residents of a non-US jurisdiction.", "score": 0.759844, "arguments": [{"text": "some", "location": [23080, 23084], "entities": [{"type": "Cardinal", "text": "some"}]}, {"text": "directors", "location": [23114, 23123], "entities": [{"type": "Person", "text": "directors"}]}]}, {"type": "employedBy", "sentence": "US holders of Shire Shares may not be able to sue a non-US company or its officers or directors in a non-US court for violations of the US securities laws.", "score": 0.930895, "arguments": [{"text": "holders", "location": [23170, 23177], "entities": [{"type": "Person", "text": "holders"}]}, {"text": "US", "location": [23167, 23169], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "employedBy", "sentence": "US holders of Shire Shares may not be able to sue a non-US company or its officers or directors in a non-US court for violations of the US securities laws.", "score": 0.495501, "arguments": [{"text": "officers", "location": [23241, 23249], "entities": [{"type": "Person", "text": "officers"}]}, {"text": "its", "location": [23237, 23240], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "employedBy", "sentence": "US holders of Shire Shares may not be able to sue a non-US company or its officers or directors in a non-US court for violations of the US securities laws.", "score": 0.531448, "arguments": [{"text": "directors", "location": [23253, 23262], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "its", "location": [23237, 23240], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "employedBy", "sentence": "US holders of Shire Shares may not be able to sue a non-US company or its officers or directors in a non-US court for violations of the US securities laws.", "score": 0.607332, "arguments": [{"text": "directors", "location": [23253, 23262], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "court", "location": [23275, 23280], "entities": [{"type": "Organization", "text": "court"}]}]}, {"type": "partOf", "sentence": "Further, it may be difficult to compel a non-US company and its affiliates to subject themselves to the jurisdiction and judgment of a US court.", "score": 0.86995, "arguments": [{"text": "affiliates", "location": [23387, 23397], "entities": [{"type": "Organization", "text": "affiliates"}]}, {"text": "its", "location": [23383, 23386], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "partOf", "sentence": "Further, it may be difficult to compel a non-US company and its affiliates to subject themselves to the jurisdiction and judgment of a US court.", "score": 0.963294, "arguments": [{"text": "court", "location": [23461, 23466], "entities": [{"type": "Organization", "text": "court"}]}, {"text": "US", "location": [23458, 23460], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "partOf", "sentence": "New Takeda Securities issued pursuant to the Scheme will not be registered under any US state securities laws and may only be issued to persons resident in a state pursuant to an exemption from the registration requirements of the securities laws of such state.", "score": 0.762332, "arguments": [{"text": "state", "location": [23556, 23561], "entities": [{"type": "GeopoliticalEntity", "text": "state"}]}, {"text": "US", "location": [23553, 23555], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "agentOf", "sentence": "For the purpose of qualifying for the exemption provided by Section 3(a)(10) of the US Securities Act, Shire will advise the Court that its sanctioning of the Scheme will be relied on by Takeda as an approval of the Scheme following a hearing on its fairness to Shire Shareholders, at which Court hearing all Shire Shareholders are entitled to attend in person or through counsel to support or oppose the sanctioning of the Scheme and with respect to which notification will be given to all such holders.", "score": 0.942436, "arguments": [{"text": "Shire", "location": [23833, 23838], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "advise", "location": [23844, 23850], "entities": [{"type": "EventCommunication", "text": "advise"}]}]}, {"type": "partOfMany", "sentence": "Shire also notes Takeda's circular to shareholders published today, which relates to the convocation of the Takeda Extraordinary General Meeting scheduled to be held at 10.00 a.m. (Tokyo time) (1.00 a.m. (London time)) on December 5, 2018.", "score": 0.627063, "arguments": [{"text": "Shire", "location": [1803, 1808], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "shareholders", "location": [1841, 1853], "entities": [{"type": "Person", "text": "shareholders"}]}]}, {"type": "affectedBy", "sentence": "For the purpose of qualifying for the exemption provided by Section 3(a)(10) of the US Securities Act, Shire will advise the Court that its sanctioning of the Scheme will be relied on by Takeda as an approval of the Scheme following a hearing on its fairness to Shire Shareholders, at which Court hearing all Shire Shareholders are entitled to attend in person or through counsel to support or oppose the sanctioning of the Scheme and with respect to which notification will be given to all such holders.", "score": 0.963339, "arguments": [{"text": "Court", "location": [23855, 23860], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "advise", "location": [23844, 23850], "entities": [{"type": "EventCommunication", "text": "advise"}]}]}, {"type": "affectedBy", "sentence": "For the purpose of qualifying for the exemption provided by Section 3(a)(10) of the US Securities Act, Shire will advise the Court that its sanctioning of the Scheme will be relied on by Takeda as an approval of the Scheme following a hearing on its fairness to Shire Shareholders, at which Court hearing all Shire Shareholders are entitled to attend in person or through counsel to support or oppose the sanctioning of the Scheme and with respect to which notification will be given to all such holders.", "score": 0.337223, "arguments": [{"text": "Scheme", "location": [23946, 23952], "entities": [{"type": "Organization", "text": "Scheme"}]}, {"text": "hearing", "location": [23965, 23972], "entities": [{"type": "EventLegal", "text": "hearing"}]}]}, {"type": "agentOf", "sentence": "For the purpose of qualifying for the exemption provided by Section 3(a)(10) of the US Securities Act, Shire will advise the Court that its sanctioning of the Scheme will be relied on by Takeda as an approval of the Scheme following a hearing on its fairness to Shire Shareholders, at which Court hearing all Shire Shareholders are entitled to attend in person or through counsel to support or oppose the sanctioning of the Scheme and with respect to which notification will be given to all such holders.", "score": 0.861982, "arguments": [{"text": "Court", "location": [24021, 24026], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "hearing", "location": [24027, 24034], "entities": [{"type": "EventLegal", "text": "hearing"}]}]}, {"type": "affectedBy", "sentence": "For the purpose of qualifying for the exemption provided by Section 3(a)(10) of the US Securities Act, Shire will advise the Court that its sanctioning of the Scheme will be relied on by Takeda as an approval of the Scheme following a hearing on its fairness to Shire Shareholders, at which Court hearing all Shire Shareholders are entitled to attend in person or through counsel to support or oppose the sanctioning of the Scheme and with respect to which notification will be given to all such holders.", "score": 0.660267, "arguments": [{"text": "Shareholders", "location": [24045, 24057], "entities": [{"type": "Person", "text": "Shareholders"}]}, {"text": "hearing", "location": [24027, 24034], "entities": [{"type": "EventLegal", "text": "hearing"}]}]}, {"type": "agentOf", "sentence": "Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct and you are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this Announcement.", "score": 0.912144, "arguments": [{"text": "you", "location": [26690, 26693], "entities": [{"type": "Person", "text": "you"}]}, {"text": "cautioned", "location": [26708, 26717], "entities": [{"type": "EventCommunication", "text": "cautioned"}]}]}, {"type": "agentOf", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in \u02bbITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.shire.com and www.sec.gov), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.992023, "arguments": [{"text": "Shire", "location": [26908, 26913], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Report", "location": [26935, 26941], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "timeOf", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in \u02bbITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.shire.com and www.sec.gov), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.888434, "arguments": [{"text": "10-K", "location": [26950, 26954], "entities": [{"type": "Date", "text": "10-K"}]}, {"text": "Report", "location": [26935, 26941], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "agentOf", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in \u02bbITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.shire.com and www.sec.gov), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.984957, "arguments": [{"text": "Shire", "location": [26962, 26967], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Reports", "location": [26991, 26998], "entities": [{"type": "EventCommunication", "text": "Reports"}]}]}, {"type": "hasAttribute", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in \u02bbITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.shire.com and www.sec.gov), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.548308, "arguments": [{"text": "Securities and Exchange Commission", "location": [27140, 27174], "entities": [{"type": "Organization", "text": "Securities and Exchange Commission"}]}, {"text": "www.shire.com", "location": [27197, 27210], "entities": [{"type": "Web", "text": "www.shire.com"}]}]}, {"type": "agentOf", "sentence": "Additional risk factors that may affect future results are contained in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in \u02bbITEM1A: Risk Factors', and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.shire.com and www.sec.gov), the contents of which are not incorporated by reference into, nor do they form part of, this Announcement.", "score": 0.530254, "arguments": [{"text": "they", "location": [27298, 27302], "entities": [{"type": "Person", "text": "they"}]}, {"text": "Announcement", "location": [27322, 27334], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "participantIn", "sentence": "Shire also notes Takeda's circular to shareholders published today, which relates to the convocation of the Takeda Extraordinary General Meeting scheduled to be held at 10.00 a.m. (Tokyo time) (1.00 a.m. (London time)) on December 5, 2018.", "score": 0.504194, "arguments": [{"text": "Takeda Extraordinary General", "location": [1911, 1939], "entities": [{"type": "Organization", "text": "Takeda Extraordinary General"}]}, {"text": "Meeting", "location": [1940, 1947], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "agentOf", "sentence": "These risk factors expressly qualify all forward-looking statements contained in this Announcement and should also be considered by the reader.", "score": 0.492954, "arguments": [{"text": "reader", "location": [27472, 27478], "entities": [{"type": "Person", "text": "reader"}]}, {"text": "Announcement", "location": [27422, 27434], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "partOfMany", "sentence": "All forward-looking statements attributable to Takeda or Shire or any person acting on either company's behalf are expressly qualified in their entirety by this cautionary statement.", "score": 0.865201, "arguments": [{"text": "Takeda", "location": [27527, 27533], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "their", "location": [27618, 27623], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "All forward-looking statements attributable to Takeda or Shire or any person acting on either company's behalf are expressly qualified in their entirety by this cautionary statement.", "score": 0.958817, "arguments": [{"text": "Shire", "location": [27537, 27542], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "their", "location": [27618, 27623], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "All forward-looking statements attributable to Takeda or Shire or any person acting on either company's behalf are expressly qualified in their entirety by this cautionary statement.", "score": 0.803988, "arguments": [{"text": "person", "location": [27550, 27556], "entities": [{"type": "Person", "text": "person"}]}, {"text": "their", "location": [27618, 27623], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "agentOf", "sentence": "Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.", "score": 0.834273, "arguments": [{"text": "Readers", "location": [27663, 27670], "entities": [{"type": "Person", "text": "Readers"}]}, {"text": "cautioned", "location": [27675, 27684], "entities": [{"type": "EventCommunication", "text": "cautioned"}]}]}, {"type": "partOfMany", "sentence": "Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.", "score": 0.678392, "arguments": [{"text": "persons", "location": [29751, 29758], "entities": [{"type": "Person", "text": "persons"}]}, {"text": "who", "location": [29759, 29762], "entities": [{"type": "Person", "text": "who"}]}]}, {"type": "hasAttribute", "sentence": "If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.", "score": 0.824036, "arguments": [{"text": "Rule", "location": [31092, 31096], "entities": [{"type": "Organization", "text": "Rule"}]}, {"text": "8.3", "location": [31097, 31100], "entities": [{"type": "Money", "text": "8.3"}]}]}, {"type": "participantIn", "sentence": "Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).", "score": 0.534952, "arguments": [{"text": "persons", "location": [31283, 31290], "entities": [{"type": "Person", "text": "persons"}]}, {"text": "concert", "location": [31301, 31308], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Panel's website at http://www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the Offer Period commenced and when any offeror was first identified.", "score": 0.457967, "arguments": [{"text": "whose", "location": [31415, 31420], "entities": [{"type": "Person", "text": "whose"}]}, {"text": "companies", "location": [31391, 31400], "entities": [{"type": "Organization", "text": "companies"}]}]}, {"type": "timeOf", "sentence": "Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Panel's website at http://www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the Offer Period commenced and when any offeror was first identified.", "score": 0.556374, "arguments": [{"text": "http://www.thetakeoverpanel.org.uk", "location": [31570, 31604], "entities": [{"type": "Time", "text": "http://www.thetakeoverpanel.org.uk"}]}, {"text": "commenced", "location": [31693, 31702], "entities": [{"type": "EventCommunication", "text": "commenced"}]}]}, {"type": "locatedAt", "sentence": "Shire also notes Takeda's circular to shareholders published today, which relates to the convocation of the Takeda Extraordinary General Meeting scheduled to be held at 10.00 a.m. (Tokyo time) (1.00 a.m. (London time)) on December 5, 2018.", "score": 0.626335, "arguments": [{"text": "Meeting", "location": [1940, 1947], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}, {"text": "Tokyo", "location": [1984, 1989], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo"}]}]}, {"type": "agentOf", "sentence": "Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Panel's website at http://www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the Offer Period commenced and when any offeror was first identified.", "score": 0.991137, "arguments": [{"text": "Offer Period", "location": [31680, 31692], "entities": [{"type": "Organization", "text": "Offer Period"}]}, {"text": "commenced", "location": [31693, 31702], "entities": [{"type": "EventCommunication", "text": "commenced"}]}]}, {"type": "partOf", "sentence": "If you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure, you should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129.", "score": 0.886304, "arguments": [{"text": "Market Surveillance Unit", "location": [31896, 31920], "entities": [{"type": "Organization", "text": "Market Surveillance Unit"}]}, {"text": "Panel", "location": [31888, 31893], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "colleague", "sentence": "Electronic Communications Please be aware that addresses, electronic addresses and certain other information provided by Shire Shareholders, persons with information rights and other relevant persons in connection with the receipt of communications from Shire may be provided to Takeda during the Offer Period as required under Section 4 of Appendix 4 of the Takeover Code to comply with Rule 2.11 of the Takeover Code.", "score": 0.229669, "arguments": [{"text": "Shire", "location": [32066, 32071], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Shareholders", "location": [32072, 32084], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "employedBy", "sentence": "Electronic Communications Please be aware that addresses, electronic addresses and certain other information provided by Shire Shareholders, persons with information rights and other relevant persons in connection with the receipt of communications from Shire may be provided to Takeda during the Offer Period as required under Section 4 of Appendix 4 of the Takeover Code to comply with Rule 2.11 of the Takeover Code.", "score": 0.540989, "arguments": [{"text": "Takeda", "location": [32224, 32230], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "Offer Period", "location": [32242, 32254], "entities": [{"type": "Organization", "text": "Offer Period"}]}]}, {"type": "partOf", "sentence": "Electronic Communications Please be aware that addresses, electronic addresses and certain other information provided by Shire Shareholders, persons with information rights and other relevant persons in connection with the receipt of communications from Shire may be provided to Takeda during the Offer Period as required under Section 4 of Appendix 4 of the Takeover Code to comply with Rule 2.11 of the Takeover Code.", "score": 0.523397, "arguments": [{"text": "Section 4", "location": [32273, 32282], "entities": [{"type": "Organization", "text": "Section 4"}]}, {"text": "Appendix 4", "location": [32286, 32296], "entities": [{"type": "Organization", "text": "Appendix 4"}]}]}, {"type": "partOf", "sentence": "Electronic Communications Please be aware that addresses, electronic addresses and certain other information provided by Shire Shareholders, persons with information rights and other relevant persons in connection with the receipt of communications from Shire may be provided to Takeda during the Offer Period as required under Section 4 of Appendix 4 of the Takeover Code to comply with Rule 2.11 of the Takeover Code.", "score": 0.545241, "arguments": [{"text": "Rule", "location": [32333, 32337], "entities": [{"type": "Organization", "text": "Rule"}]}, {"text": "Takeover Code", "location": [32350, 32363], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "ownerOf", "sentence": "Publication on Website and Availability of Hard Copies A copy of this Announcement and the documents required to be published by Rule 26 of the Takeover Code will be made available (subject to certain restrictions relating to persons resident in Restricted Jurisdictions) on Takeda 's and Shire's websites at www.takeda.com/investors/offer-for-shire and www.shire.com respectively by no later than 12 noon (London time) on November 13, 2018 , the Business Day following this Announcement .", "score": 0.542279, "arguments": [{"text": "Shire", "location": [32654, 32659], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "websites", "location": [32662, 32670], "entities": [{"type": "Facility", "text": "websites"}]}]}, {"type": "timeOf", "sentence": "Publication on Website and Availability of Hard Copies A copy of this Announcement and the documents required to be published by Rule 26 of the Takeover Code will be made available (subject to certain restrictions relating to persons resident in Restricted Jurisdictions) on Takeda 's and Shire's websites at www.takeda.com/investors/offer-for-shire and www.shire.com respectively by no later than 12 noon (London time) on November 13, 2018 , the Business Day following this Announcement .", "score": 0.642039, "arguments": [{"text": "November 13, 2018", "location": [32788, 32805], "entities": [{"type": "Date", "text": "November 13, 2018"}]}, {"text": "Announcement", "location": [32840, 32852], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Publication on Website and Availability of Hard Copies A copy of this Announcement and the documents required to be published by Rule 26 of the Takeover Code will be made available (subject to certain restrictions relating to persons resident in Restricted Jurisdictions) on Takeda 's and Shire's websites at www.takeda.com/investors/offer-for-shire and www.shire.com respectively by no later than 12 noon (London time) on November 13, 2018 , the Business Day following this Announcement .", "score": 0.592584, "arguments": [{"text": "Business Day", "location": [32812, 32824], "entities": [{"type": "Organization", "text": "Business Day"}]}, {"text": "Announcement", "location": [32840, 32852], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Shire Shareholders may request a hard copy of this Announcement by: (i) contacting Souheil Salah during business hours on +44 (0) 203 5490660 (lines are open from 9am to 5pm (London time), Monday to Friday (excluding public holidays in England and Wales), or (ii) by submitting a request by post to Souheil Salah, One Kingdom Street, 9th Floor, Paddington, London W2 6BD, UK.", "score": 0.626175, "arguments": [{"text": "Souheil Salah", "location": [33066, 33079], "entities": [{"type": "Person", "text": "Souheil Salah"}]}, {"text": "Announcement", "location": [33034, 33046], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "participantIn", "sentence": "Notices of the Court Meeting and Shire General Meeting As described in the Scheme Document, to become effective, the Scheme requires, among other things, the approval of Shire Shareholders at the Court Meeting, the passing of the Special Resolution at the Shire General Meeting and the subsequent sanction of the Court.", "score": 0.473197, "arguments": [{"text": "Court", "location": [2294, 2299], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [2300, 2307], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "locatedAt", "sentence": "Shire Shareholders may request a hard copy of this Announcement by: (i) contacting Souheil Salah during business hours on +44 (0) 203 5490660 (lines are open from 9am to 5pm (London time), Monday to Friday (excluding public holidays in England and Wales), or (ii) by submitting a request by post to Souheil Salah, One Kingdom Street, 9th Floor, Paddington, London W2 6BD, UK.", "score": 0.504854, "arguments": [{"text": "9th Floor", "location": [33317, 33326], "entities": [{"type": "Organization", "text": "9th Floor"}]}, {"text": "Paddington", "location": [33328, 33338], "entities": [{"type": "GeopoliticalEntity", "text": "Paddington"}]}]}, {"type": "locatedAt", "sentence": "Shire Shareholders may request a hard copy of this Announcement by: (i) contacting Souheil Salah during business hours on +44 (0) 203 5490660 (lines are open from 9am to 5pm (London time), Monday to Friday (excluding public holidays in England and Wales), or (ii) by submitting a request by post to Souheil Salah, One Kingdom Street, 9th Floor, Paddington, London W2 6BD, UK.", "score": 0.657564, "arguments": [{"text": "Paddington", "location": [33328, 33338], "entities": [{"type": "GeopoliticalEntity", "text": "Paddington"}]}, {"text": "London", "location": [33340, 33346], "entities": [{"type": "GeopoliticalEntity", "text": "London"}]}]}, {"type": "employedBy", "sentence": "Shire Shareholders may request a hard copy of this Announcement by: (i) contacting Souheil Salah during business hours on +44 (0) 203 5490660 (lines are open from 9am to 5pm (London time), Monday to Friday (excluding public holidays in England and Wales), or (ii) by submitting a request by post to Souheil Salah, One Kingdom Street, 9th Floor, Paddington, London W2 6BD, UK.", "score": 0.892815, "arguments": [{"text": "W2 6BD", "location": [33347, 33353], "entities": [{"type": "Person", "text": "W2 6BD"}]}, {"text": "UK", "location": [33355, 33357], "entities": [{"type": "GeopoliticalEntity", "text": "UK"}]}]}, {"type": "agentOf", "sentence": "If you have received this Announcement in electronic form, copies of this Announcement and any document or information incorporated by reference into this document will not be provided unless such a request is made.", "score": 0.909348, "arguments": [{"text": "you", "location": [33362, 33365], "entities": [{"type": "Person", "text": "you"}]}, {"text": "Announcement", "location": [33385, 33397], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "colleague", "sentence": "Shire Shareholders may also request that all future documents, announcements and information to be sent to them in relation to the Acquisition should be in hard copy form.", "score": 0.270028, "arguments": [{"text": "Shire", "location": [33575, 33580], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Shareholders", "location": [33581, 33593], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "agentOf", "sentence": "Shire Shareholders may also request that all future documents, announcements and information to be sent to them in relation to the Acquisition should be in hard copy form.", "score": 0.692299, "arguments": [{"text": "Shire", "location": [33575, 33580], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "request", "location": [33603, 33610], "entities": [{"type": "EventCommunication", "text": "request"}]}]}, {"type": "agentOf", "sentence": "If you are in any doubt about the contents of this Announcement or the action you should take, you are recommended to seek your own independent financial advice immediately from your stockbroker, bank manager, solicitor, accountant or independent financial adviser duly authorised under Financial Services (Jersey) Law 1998 (as amended) if you are resident in Jersey, the Financial Services and Markets Act 2000 (as amended) if you are resident in the United Kingdom, or, if not, from another appropriately authorised independent financial adviser.", "score": 0.584221, "arguments": [{"text": "you", "location": [33825, 33828], "entities": [{"type": "Person", "text": "you"}]}, {"text": "Announcement", "location": [33798, 33810], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "If you are in any doubt about the contents of this Announcement or the action you should take, you are recommended to seek your own independent financial advice immediately from your stockbroker, bank manager, solicitor, accountant or independent financial adviser duly authorised under Financial Services (Jersey) Law 1998 (as amended) if you are resident in Jersey, the Financial Services and Markets Act 2000 (as amended) if you are resident in the United Kingdom, or, if not, from another appropriately authorised independent financial adviser.", "score": 0.934639, "arguments": [{"text": "you", "location": [33842, 33845], "entities": [{"type": "Person", "text": "you"}]}, {"text": "recommended", "location": [33850, 33861], "entities": [{"type": "EventCommunication", "text": "recommended"}]}]}, {"type": "clientOf", "sentence": "If you are in any doubt about the contents of this Announcement or the action you should take, you are recommended to seek your own independent financial advice immediately from your stockbroker, bank manager, solicitor, accountant or independent financial adviser duly authorised under Financial Services (Jersey) Law 1998 (as amended) if you are resident in Jersey, the Financial Services and Markets Act 2000 (as amended) if you are resident in the United Kingdom, or, if not, from another appropriately authorised independent financial adviser.", "score": 0.323759, "arguments": [{"text": "your", "location": [33925, 33929], "entities": [{"type": "Person", "text": "your"}]}, {"text": "stockbroker", "location": [33930, 33941], "entities": [{"type": "Person", "text": "stockbroker"}]}]}, {"type": "managerOf", "sentence": "If you are in any doubt about the contents of this Announcement or the action you should take, you are recommended to seek your own independent financial advice immediately from your stockbroker, bank manager, solicitor, accountant or independent financial adviser duly authorised under Financial Services (Jersey) Law 1998 (as amended) if you are resident in Jersey, the Financial Services and Markets Act 2000 (as amended) if you are resident in the United Kingdom, or, if not, from another appropriately authorised independent financial adviser.", "score": 0.651856, "arguments": [{"text": "manager", "location": [33948, 33955], "entities": [{"type": "Person", "text": "manager"}]}, {"text": "bank", "location": [33943, 33947], "entities": [{"type": "Organization", "text": "bank"}]}]}, {"type": "agentOf", "sentence": "Notices of the Court Meeting and Shire General Meeting As described in the Scheme Document, to become effective, the Scheme requires, among other things, the approval of Shire Shareholders at the Court Meeting, the passing of the Special Resolution at the Shire General Meeting and the subsequent sanction of the Court.", "score": 0.563012, "arguments": [{"text": "Scheme Document", "location": [2354, 2369], "entities": [{"type": "Organization", "text": "Scheme Document"}]}, {"text": "described", "location": [2337, 2346], "entities": [{"type": "EventCommunication", "text": "described"}]}]}, {"type": "locatedAt", "sentence": "If you are in any doubt about the contents of this Announcement or the action you should take, you are recommended to seek your own independent financial advice immediately from your stockbroker, bank manager, solicitor, accountant or independent financial adviser duly authorised under Financial Services (Jersey) Law 1998 (as amended) if you are resident in Jersey, the Financial Services and Markets Act 2000 (as amended) if you are resident in the United Kingdom, or, if not, from another appropriately authorised independent financial adviser.", "score": 0.373705, "arguments": [{"text": "Financial Services", "location": [34034, 34052], "entities": [{"type": "Organization", "text": "Financial Services"}]}, {"text": "Jersey", "location": [34054, 34060], "entities": [{"type": "GeopoliticalEntity", "text": "Jersey"}]}]}, {"type": "affectedBy", "sentence": "Rounding Certain figures included in this Announcement have been subjected to rounding adjustments.", "score": 0.509696, "arguments": [{"text": "figures", "location": [34313, 34320], "entities": [{"type": "Person", "text": "figures"}]}, {"text": "Announcement", "location": [34338, 34350], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "partOfMany", "sentence": "Accordingly, figures shown for the same category presented in different tables may vary slightly and figures shown as totals in certain tables may not be an arithmetic aggregation of the figures that precede them.", "score": 0.501776, "arguments": [{"text": "figures", "location": [34583, 34590], "entities": [{"type": "Person", "text": "figures"}]}, {"text": "them", "location": [34604, 34608], "entities": [{"type": "Person", "text": "them"}]}]}, {"type": "partOfMany", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form) 11.30 a.m. on December 3, 2018 (3)", "score": 0.85893, "arguments": [{"text": "Shire ADS Holders", "location": [35064, 35081], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "Shareholders", "location": [35047, 35059], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "employedBy", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form) 11.30 a.m. on December 3, 2018 (3)", "score": 0.491518, "arguments": [{"text": "Shire", "location": [35146, 35151], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "which", "location": [35140, 35145], "entities": [{"type": "Organization", "text": "which"}]}]}, {"type": "participantIn", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form) 11.30 a.m. on December 3, 2018 (3)", "score": 0.419875, "arguments": [{"text": "Shire", "location": [35146, 35151], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Event", "location": [35189, 35194], "entities": [{"type": "EventPerformance", "text": "Event"}]}]}, {"type": "agentOf", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form) 11.30 a.m. on December 3, 2018 (3)", "score": 0.669523, "arguments": [{"text": "Form", "location": [35179, 35183], "entities": [{"type": "Organization", "text": "Form"}]}, {"text": "Event", "location": [35189, 35194], "entities": [{"type": "EventPerformance", "text": "Event"}]}]}, {"type": "timeOf", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form) 11.30 a.m. on December 3, 2018 (3)", "score": 0.912562, "arguments": [{"text": "8-K.", "location": [35184, 35188], "entities": [{"type": "Date", "text": "8-K."}]}, {"text": "Event", "location": [35189, 35194], "entities": [{"type": "EventPerformance", "text": "Event"}]}]}, {"type": "agentOf", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form) 11.30 a.m. on December 3, 2018 (3)", "score": 0.335571, "arguments": [{"text": "ADS Voting Record Time", "location": [35195, 35217], "entities": [{"type": "Organization", "text": "ADS Voting Record Time"}]}, {"text": "Event", "location": [35189, 35194], "entities": [{"type": "EventPerformance", "text": "Event"}]}]}, {"type": "participantIn", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form) 11.30 a.m. on December 3, 2018 (3)", "score": 0.473102, "arguments": [{"text": "Court", "location": [35369, 35374], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [35375, 35382], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "participantIn", "sentence": "Notices of the Court Meeting and Shire General Meeting As described in the Scheme Document, to become effective, the Scheme requires, among other things, the approval of Shire Shareholders at the Court Meeting, the passing of the Special Resolution at the Shire General Meeting and the subsequent sanction of the Court.", "score": 0.588946, "arguments": [{"text": "Shire", "location": [2449, 2454], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Meeting", "location": [2481, 2488], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "partOf", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form) 11.30 a.m. on December 3, 2018 (3)", "score": 0.327407, "arguments": [{"text": "Meeting", "location": [35375, 35382], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}, {"text": "Meeting", "location": [35405, 35412], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "participantIn", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form) 11.30 a.m. on December 3, 2018 (3)", "score": 0.732556, "arguments": [{"text": "Shire General", "location": [35391, 35404], "entities": [{"type": "Person", "text": "Shire General"}]}, {"text": "Meeting", "location": [35405, 35412], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "timeOf", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form) 11.30 a.m. on December 3, 2018 (3)", "score": 0.816891, "arguments": [{"text": "a.m.", "location": [35419, 35423], "entities": [{"type": "Time", "text": "a.m."}]}, {"text": "Meeting", "location": [35405, 35412], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "participantIn", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form) 11.30 a.m. on December 3, 2018 (3)", "score": 0.880446, "arguments": [{"text": "Shire General", "location": [35547, 35560], "entities": [{"type": "Person", "text": "Shire General"}]}, {"text": "Meeting", "location": [35561, 35568], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "timeOf", "sentence": "If any of the dates and/or times in this expected timetable change, the revised dates and/or times will be notified to Shire Shareholders and Shire ADS Holders by announcement through a Regulatory Information Service, which Shire will furnish to the SEC on Form 8-K. Event ADS Voting Record Time 5.00 p.m. (New York time) on November 7, 2018 Latest time for receipt of ADS Voting Cards (or valid telephone or internet voting instructions) for the Court Meeting and the Shire General Meeting 10.00 a.m. (New York time) on November 29, 2018 (1) Latest time for receipt of Forms of Proxy for: 11.15 a.m. on December 3, 2018 (2) Shire General Meeting (YELLOW form) 11.30 a.m. on December 3, 2018 (3)", "score": 0.771392, "arguments": [{"text": "11.30 a.m.", "location": [35583, 35593], "entities": [{"type": "Time", "text": "11.30 a.m."}]}, {"text": "Meeting", "location": [35561, 35568], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "timeOf", "sentence": "Voting Record Time 6.30 p.m. on December 3, 2018 (4) Takeda Extraordinary General Meeting 10.00 a.m. (Tokyo time) on December 5, 2018 Court Meeting 11.15 a.m. on December 5, 2018 (5) Shire General Meeting 11.30 a.m. on December 5, 2018 (5)(6) The following dates are indicative only and subject to change; please see note (7) below: Last time for Shire ADS Holders to present their Shire ADSs for cancellation and take delivery of Shire Shares to become Shire Shareholders before the Scheme Record Time 5.00 p.m. (New York time) on December 26, 2018 Latest time for receipt of Forms of Election 6.00 p.m. on January 2, 2019 Court Sanction Hearing 10.00 a.m. on January 3,", "score": 0.494984, "arguments": [{"text": "December 3, 2018", "location": [35650, 35666], "entities": [{"type": "Date", "text": "December 3, 2018"}]}, {"text": "Meeting", "location": [35700, 35707], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "participantIn", "sentence": "Voting Record Time 6.30 p.m. on December 3, 2018 (4) Takeda Extraordinary General Meeting 10.00 a.m. (Tokyo time) on December 5, 2018 Court Meeting 11.15 a.m. on December 5, 2018 (5) Shire General Meeting 11.30 a.m. on December 5, 2018 (5)(6) The following dates are indicative only and subject to change; please see note (7) below: Last time for Shire ADS Holders to present their Shire ADSs for cancellation and take delivery of Shire Shares to become Shire Shareholders before the Scheme Record Time 5.00 p.m. (New York time) on December 26, 2018 Latest time for receipt of Forms of Election 6.00 p.m. on January 2, 2019 Court Sanction Hearing 10.00 a.m. on January 3,", "score": 0.852472, "arguments": [{"text": "Takeda Extraordinary General", "location": [35671, 35699], "entities": [{"type": "Person", "text": "Takeda Extraordinary General"}]}, {"text": "Meeting", "location": [35700, 35707], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "timeOf", "sentence": "Voting Record Time 6.30 p.m. on December 3, 2018 (4) Takeda Extraordinary General Meeting 10.00 a.m. (Tokyo time) on December 5, 2018 Court Meeting 11.15 a.m. on December 5, 2018 (5) Shire General Meeting 11.30 a.m. on December 5, 2018 (5)(6) The following dates are indicative only and subject to change; please see note (7) below: Last time for Shire ADS Holders to present their Shire ADSs for cancellation and take delivery of Shire Shares to become Shire Shareholders before the Scheme Record Time 5.00 p.m. (New York time) on December 26, 2018 Latest time for receipt of Forms of Election 6.00 p.m. on January 2, 2019 Court Sanction Hearing 10.00 a.m. on January 3,", "score": 0.811119, "arguments": [{"text": "a.m.", "location": [35714, 35718], "entities": [{"type": "Time", "text": "a.m."}]}, {"text": "Meeting", "location": [35700, 35707], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "agentOf", "sentence": "Voting Record Time 6.30 p.m. on December 3, 2018 (4) Takeda Extraordinary General Meeting 10.00 a.m. (Tokyo time) on December 5, 2018 Court Meeting 11.15 a.m. on December 5, 2018 (5) Shire General Meeting 11.30 a.m. on December 5, 2018 (5)(6) The following dates are indicative only and subject to change; please see note (7) below: Last time for Shire ADS Holders to present their Shire ADSs for cancellation and take delivery of Shire Shares to become Shire Shareholders before the Scheme Record Time 5.00 p.m. (New York time) on December 26, 2018 Latest time for receipt of Forms of Election 6.00 p.m. on January 2, 2019 Court Sanction Hearing 10.00 a.m. on January 3,", "score": 0.514639, "arguments": [{"text": "Court", "location": [35752, 35757], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [35758, 35765], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "timeOf", "sentence": "Voting Record Time 6.30 p.m. on December 3, 2018 (4) Takeda Extraordinary General Meeting 10.00 a.m. (Tokyo time) on December 5, 2018 Court Meeting 11.15 a.m. on December 5, 2018 (5) Shire General Meeting 11.30 a.m. on December 5, 2018 (5)(6) The following dates are indicative only and subject to change; please see note (7) below: Last time for Shire ADS Holders to present their Shire ADSs for cancellation and take delivery of Shire Shares to become Shire Shareholders before the Scheme Record Time 5.00 p.m. (New York time) on December 26, 2018 Latest time for receipt of Forms of Election 6.00 p.m. on January 2, 2019 Court Sanction Hearing 10.00 a.m. on January 3,", "score": 0.88629, "arguments": [{"text": "a.m.", "location": [35772, 35776], "entities": [{"type": "Time", "text": "a.m."}]}, {"text": "Meeting", "location": [35758, 35765], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "partOfMany", "sentence": "TAKEDA PHARMACEUTICAL COMPANY LIMITED Publication of Scheme Document On May 8, 2018, Shire plc (\" Shire \") and Takeda Pharmaceutical Company Limited (\" Takeda \") announced that they had reached agreement on the terms of a recommended cash and share offer to be made by Takeda for the entire issued and to be issued share capital of Shire (the \" Acquisition \").", "score": 0.912501, "arguments": [{"text": "Shire", "location": [98, 103], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "they", "location": [177, 181], "entities": [{"type": "Person", "text": "they"}]}]}, {"type": "agentOf", "sentence": "Notices of the Court Meeting and Shire General Meeting As described in the Scheme Document, to become effective, the Scheme requires, among other things, the approval of Shire Shareholders at the Court Meeting, the passing of the Special Resolution at the Shire General Meeting and the subsequent sanction of the Court.", "score": 0.418295, "arguments": [{"text": "Court", "location": [2475, 2480], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [2481, 2488], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "participantIn", "sentence": "Voting Record Time 6.30 p.m. on December 3, 2018 (4) Takeda Extraordinary General Meeting 10.00 a.m. (Tokyo time) on December 5, 2018 Court Meeting 11.15 a.m. on December 5, 2018 (5) Shire General Meeting 11.30 a.m. on December 5, 2018 (5)(6) The following dates are indicative only and subject to change; please see note (7) below: Last time for Shire ADS Holders to present their Shire ADSs for cancellation and take delivery of Shire Shares to become Shire Shareholders before the Scheme Record Time 5.00 p.m. (New York time) on December 26, 2018 Latest time for receipt of Forms of Election 6.00 p.m. on January 2, 2019 Court Sanction Hearing 10.00 a.m. on January 3,", "score": 0.902597, "arguments": [{"text": "Shire General", "location": [35801, 35814], "entities": [{"type": "Person", "text": "Shire General"}]}, {"text": "Meeting", "location": [35815, 35822], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "timeOf", "sentence": "Voting Record Time 6.30 p.m. on December 3, 2018 (4) Takeda Extraordinary General Meeting 10.00 a.m. (Tokyo time) on December 5, 2018 Court Meeting 11.15 a.m. on December 5, 2018 (5) Shire General Meeting 11.30 a.m. on December 5, 2018 (5)(6) The following dates are indicative only and subject to change; please see note (7) below: Last time for Shire ADS Holders to present their Shire ADSs for cancellation and take delivery of Shire Shares to become Shire Shareholders before the Scheme Record Time 5.00 p.m. (New York time) on December 26, 2018 Latest time for receipt of Forms of Election 6.00 p.m. on January 2, 2019 Court Sanction Hearing 10.00 a.m. on January 3,", "score": 0.935827, "arguments": [{"text": "11.30 a.m.", "location": [35823, 35833], "entities": [{"type": "Time", "text": "11.30 a.m."}]}, {"text": "Meeting", "location": [35815, 35822], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "timeOf", "sentence": "Voting Record Time 6.30 p.m. on December 3, 2018 (4) Takeda Extraordinary General Meeting 10.00 a.m. (Tokyo time) on December 5, 2018 Court Meeting 11.15 a.m. on December 5, 2018 (5) Shire General Meeting 11.30 a.m. on December 5, 2018 (5)(6) The following dates are indicative only and subject to change; please see note (7) below: Last time for Shire ADS Holders to present their Shire ADSs for cancellation and take delivery of Shire Shares to become Shire Shareholders before the Scheme Record Time 5.00 p.m. (New York time) on December 26, 2018 Latest time for receipt of Forms of Election 6.00 p.m. on January 2, 2019 Court Sanction Hearing 10.00 a.m. on January 3,", "score": 0.588562, "arguments": [{"text": "December 5, 2018", "location": [35837, 35853], "entities": [{"type": "Date", "text": "December 5, 2018"}]}, {"text": "Meeting", "location": [35815, 35822], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "partOfMany", "sentence": "Voting Record Time 6.30 p.m. on December 3, 2018 (4) Takeda Extraordinary General Meeting 10.00 a.m. (Tokyo time) on December 5, 2018 Court Meeting 11.15 a.m. on December 5, 2018 (5) Shire General Meeting 11.30 a.m. on December 5, 2018 (5)(6) The following dates are indicative only and subject to change; please see note (7) below: Last time for Shire ADS Holders to present their Shire ADSs for cancellation and take delivery of Shire Shares to become Shire Shareholders before the Scheme Record Time 5.00 p.m. (New York time) on December 26, 2018 Latest time for receipt of Forms of Election 6.00 p.m. on January 2, 2019 Court Sanction Hearing 10.00 a.m. on January 3,", "score": 0.576983, "arguments": [{"text": "Shire ADS Holders", "location": [35965, 35982], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "their", "location": [35994, 35999], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "employedBy", "sentence": "2019 Last time for dealings in Shire Shares on the London Stock Exchange 4.30 p.m. on January 4, 2019 Latest time for receipt of TTE Instructions and disablement of Shire Shares in CREST 6.00 p.m. on January 4, 2019 Scheme Record Time 6.00 p.m. on January 4, 2019 Last time for dealings in Shire ADSs on NASDAQ close of business (New York time) on January 4, 2019 Suspension of dealings in Shire Shares on the London Stock Exchange before open of business on January 7, 2019 Halt of dealings in Shire ADSs on NASDAQ before open of business (New York time) on January 7, 2019 Commencement of \"when issued\" dealings in the New Takeda ADSs on the New York Stock Exchange 9.30 a.m. (New York time) on January 7,", "score": 0.536036, "arguments": [{"text": "Shire", "location": [36321, 36326], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "London Stock Exchange", "location": [36341, 36362], "entities": [{"type": "Organization", "text": "London Stock Exchange"}]}]}, {"type": "employedBy", "sentence": "2019 Last time for dealings in Shire Shares on the London Stock Exchange 4.30 p.m. on January 4, 2019 Latest time for receipt of TTE Instructions and disablement of Shire Shares in CREST 6.00 p.m. on January 4, 2019 Scheme Record Time 6.00 p.m. on January 4, 2019 Last time for dealings in Shire ADSs on NASDAQ close of business (New York time) on January 4, 2019 Suspension of dealings in Shire Shares on the London Stock Exchange before open of business on January 7, 2019 Halt of dealings in Shire ADSs on NASDAQ before open of business (New York time) on January 7, 2019 Commencement of \"when issued\" dealings in the New Takeda ADSs on the New York Stock Exchange 9.30 a.m. (New York time) on January 7,", "score": 0.588385, "arguments": [{"text": "Shire", "location": [36680, 36685], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "London Stock Exchange", "location": [36700, 36721], "entities": [{"type": "Organization", "text": "London Stock Exchange"}]}]}, {"type": "populationOf", "sentence": "2019 Last time for dealings in Shire Shares on the London Stock Exchange 4.30 p.m. on January 4, 2019 Latest time for receipt of TTE Instructions and disablement of Shire Shares in CREST 6.00 p.m. on January 4, 2019 Scheme Record Time 6.00 p.m. on January 4, 2019 Last time for dealings in Shire ADSs on NASDAQ close of business (New York time) on January 4, 2019 Suspension of dealings in Shire Shares on the London Stock Exchange before open of business on January 7, 2019 Halt of dealings in Shire ADSs on NASDAQ before open of business (New York time) on January 7, 2019 Commencement of \"when issued\" dealings in the New Takeda ADSs on the New York Stock Exchange 9.30 a.m. (New York time) on January 7,", "score": 0.592142, "arguments": [{"text": "6.00", "location": [36477, 36481], "entities": [{"type": "Cardinal", "text": "6.00"}]}, {"text": "CREST", "location": [36471, 36476], "entities": [{"type": "GeopoliticalEntity", "text": "CREST"}]}]}, {"type": "timeOf", "sentence": "2019 Effective Date of the Scheme January 8, 2019 Effective date of the issue of the New Takeda Shares January 8, 2019 Cancellation of listing of Shire Shares on the premium listing segment of the Official List and the main market of the London Stock Exchange 8.00 a.m. on January 9, 2019 Delisting of Shire ADSs by 9.30 a.m. (New York time) on January 9, 2019 Settlement Account credited with New Takeda Shares by 00.01 a.m. (9.01 a.m. (Tokyo time)) on January 10, 2019 New Takeda Shares transferred from the Settlement Account to JASDEC Accounts of former Shire Shareholders from January 10, 2019, but in any event not later than 14 calendar days after the Effective Date (8) Listing of, and commencement of dealings in,", "score": 0.764769, "arguments": [{"text": "January 9, 2019", "location": [37343, 37358], "entities": [{"type": "Date", "text": "January 9, 2019"}]}, {"text": "Settlement", "location": [37359, 37369], "entities": [{"type": "EventLegal", "text": "Settlement"}]}]}, {"type": "affectedBy", "sentence": "2019 Effective Date of the Scheme January 8, 2019 Effective date of the issue of the New Takeda Shares January 8, 2019 Cancellation of listing of Shire Shares on the premium listing segment of the Official List and the main market of the London Stock Exchange 8.00 a.m. on January 9, 2019 Delisting of Shire ADSs by 9.30 a.m. (New York time) on January 9, 2019 Settlement Account credited with New Takeda Shares by 00.01 a.m. (9.01 a.m. (Tokyo time)) on January 10, 2019 New Takeda Shares transferred from the Settlement Account to JASDEC Accounts of former Shire Shareholders from January 10, 2019, but in any event not later than 14 calendar days after the Effective Date (8) Listing of, and commencement of dealings in,", "score": 0.833849, "arguments": [{"text": "Account", "location": [37370, 37377], "entities": [{"type": "Person", "text": "Account"}]}, {"text": "Settlement", "location": [37359, 37369], "entities": [{"type": "EventLegal", "text": "Settlement"}]}]}, {"type": "agentOf", "sentence": "2019 Effective Date of the Scheme January 8, 2019 Effective date of the issue of the New Takeda Shares January 8, 2019 Cancellation of listing of Shire Shares on the premium listing segment of the Official List and the main market of the London Stock Exchange 8.00 a.m. on January 9, 2019 Delisting of Shire ADSs by 9.30 a.m. (New York time) on January 9, 2019 Settlement Account credited with New Takeda Shares by 00.01 a.m. (9.01 a.m. (Tokyo time)) on January 10, 2019 New Takeda Shares transferred from the Settlement Account to JASDEC Accounts of former Shire Shareholders from January 10, 2019, but in any event not later than 14 calendar days after the Effective Date (8) Listing of, and commencement of dealings in,", "score": 0.502895, "arguments": [{"text": "New Takeda", "location": [37469, 37479], "entities": [{"type": "Organization", "text": "New Takeda"}]}, {"text": "Settlement", "location": [37508, 37518], "entities": [{"type": "EventLegal", "text": "Settlement"}]}]}, {"type": "agentOf", "sentence": "the New Takeda Shares on the Tokyo Stock Exchange and the Local Japanese Stock Exchanges January 10, 2019 New Takeda Shares transferred from the Settlement Account to the Takeda Depositary's JASDEC Account January 10, 2019 New Takeda ADSs and CDIs representing New Takeda ADSs delivered to former Shire Shareholders from January 10, 2019, but in any event not later than 14 calendar days after the Effective Date (9) New Takeda ADSs delivered to former Shire ADS Holders from January 10, 2019 (10) Listing of, and commencement of regular-way dealings in, New Takeda ADSs on the New York Stock Exchange by 9.30 a.m. (New York time) on January 11, 2019 (11)", "score": 0.450269, "arguments": [{"text": "New Takeda", "location": [37827, 37837], "entities": [{"type": "Organization", "text": "New Takeda"}]}, {"text": "Settlement", "location": [37866, 37876], "entities": [{"type": "EventLegal", "text": "Settlement"}]}]}, {"type": "participantIn", "sentence": "Notices of the Court Meeting and Shire General Meeting As described in the Scheme Document, to become effective, the Scheme requires, among other things, the approval of Shire Shareholders at the Court Meeting, the passing of the Special Resolution at the Shire General Meeting and the subsequent sanction of the Court.", "score": 0.880371, "arguments": [{"text": "Shire General", "location": [2535, 2548], "entities": [{"type": "Person", "text": "Shire General"}]}, {"text": "Meeting", "location": [2549, 2556], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "partOf", "sentence": "the New Takeda Shares on the Tokyo Stock Exchange and the Local Japanese Stock Exchanges January 10, 2019 New Takeda Shares transferred from the Settlement Account to the Takeda Depositary's JASDEC Account January 10, 2019 New Takeda ADSs and CDIs representing New Takeda ADSs delivered to former Shire Shareholders from January 10, 2019, but in any event not later than 14 calendar days after the Effective Date (9) New Takeda ADSs delivered to former Shire ADS Holders from January 10, 2019 (10) Listing of, and commencement of regular-way dealings in, New Takeda ADSs on the New York Stock Exchange by 9.30 a.m. (New York time) on January 11, 2019 (11)", "score": 0.78208, "arguments": [{"text": "JASDEC Account", "location": [37912, 37926], "entities": [{"type": "Organization", "text": "JASDEC Account"}]}, {"text": "Takeda Depositary", "location": [37892, 37909], "entities": [{"type": "Organization", "text": "Takeda Depositary"}]}]}, {"type": "employedBy", "sentence": "the New Takeda Shares on the Tokyo Stock Exchange and the Local Japanese Stock Exchanges January 10, 2019 New Takeda Shares transferred from the Settlement Account to the Takeda Depositary's JASDEC Account January 10, 2019 New Takeda ADSs and CDIs representing New Takeda ADSs delivered to former Shire Shareholders from January 10, 2019, but in any event not later than 14 calendar days after the Effective Date (9) New Takeda ADSs delivered to former Shire ADS Holders from January 10, 2019 (10) Listing of, and commencement of regular-way dealings in, New Takeda ADSs on the New York Stock Exchange by 9.30 a.m. (New York time) on January 11, 2019 (11)", "score": 0.472961, "arguments": [{"text": "Shire", "location": [38018, 38023], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "New Takeda ADSs", "location": [37982, 37997], "entities": [{"type": "Organization", "text": "New Takeda ADSs"}]}]}, {"type": "employedBy", "sentence": "the New Takeda Shares on the Tokyo Stock Exchange and the Local Japanese Stock Exchanges January 10, 2019 New Takeda Shares transferred from the Settlement Account to the Takeda Depositary's JASDEC Account January 10, 2019 New Takeda ADSs and CDIs representing New Takeda ADSs delivered to former Shire Shareholders from January 10, 2019, but in any event not later than 14 calendar days after the Effective Date (9) New Takeda ADSs delivered to former Shire ADS Holders from January 10, 2019 (10) Listing of, and commencement of regular-way dealings in, New Takeda ADSs on the New York Stock Exchange by 9.30 a.m. (New York time) on January 11, 2019 (11)", "score": 0.255215, "arguments": [{"text": "Shareholders", "location": [38024, 38036], "entities": [{"type": "Person", "text": "Shareholders"}]}, {"text": "New Takeda ADSs", "location": [37982, 37997], "entities": [{"type": "Organization", "text": "New Takeda ADSs"}]}]}, {"type": "partOf", "sentence": "the New Takeda Shares on the Tokyo Stock Exchange and the Local Japanese Stock Exchanges January 10, 2019 New Takeda Shares transferred from the Settlement Account to the Takeda Depositary's JASDEC Account January 10, 2019 New Takeda ADSs and CDIs representing New Takeda ADSs delivered to former Shire Shareholders from January 10, 2019, but in any event not later than 14 calendar days after the Effective Date (9) New Takeda ADSs delivered to former Shire ADS Holders from January 10, 2019 (10) Listing of, and commencement of regular-way dealings in, New Takeda ADSs on the New York Stock Exchange by 9.30 a.m. (New York time) on January 11, 2019 (11)", "score": 0.496915, "arguments": [{"text": "New Takeda ADSs", "location": [38138, 38153], "entities": [{"type": "Organization", "text": "New Takeda ADSs"}]}, {"text": "Effective Date", "location": [38119, 38133], "entities": [{"type": "Organization", "text": "Effective Date"}]}]}, {"type": "bornOn", "sentence": "the New Takeda Shares on the Tokyo Stock Exchange and the Local Japanese Stock Exchanges January 10, 2019 New Takeda Shares transferred from the Settlement Account to the Takeda Depositary's JASDEC Account January 10, 2019 New Takeda ADSs and CDIs representing New Takeda ADSs delivered to former Shire Shareholders from January 10, 2019, but in any event not later than 14 calendar days after the Effective Date (9) New Takeda ADSs delivered to former Shire ADS Holders from January 10, 2019 (10) Listing of, and commencement of regular-way dealings in, New Takeda ADSs on the New York Stock Exchange by 9.30 a.m. (New York time) on January 11, 2019 (11)", "score": 0.331888, "arguments": [{"text": "Shire ADS Holders", "location": [38174, 38191], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "January 10, 2019", "location": [38197, 38213], "entities": [{"type": "Date", "text": "January 10, 2019"}]}]}, {"type": "partOf", "sentence": "the New Takeda Shares on the Tokyo Stock Exchange and the Local Japanese Stock Exchanges January 10, 2019 New Takeda Shares transferred from the Settlement Account to the Takeda Depositary's JASDEC Account January 10, 2019 New Takeda ADSs and CDIs representing New Takeda ADSs delivered to former Shire Shareholders from January 10, 2019, but in any event not later than 14 calendar days after the Effective Date (9) New Takeda ADSs delivered to former Shire ADS Holders from January 10, 2019 (10) Listing of, and commencement of regular-way dealings in, New Takeda ADSs on the New York Stock Exchange by 9.30 a.m. (New York time) on January 11, 2019 (11)", "score": 0.626596, "arguments": [{"text": "New Takeda ADSs", "location": [38276, 38291], "entities": [{"type": "Organization", "text": "New Takeda ADSs"}]}, {"text": "New York Stock Exchange", "location": [38299, 38322], "entities": [{"type": "Organization", "text": "New York Stock Exchange"}]}]}, {"type": "colleague", "sentence": "CREST accounts of former Shire Shareholders credited with cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date (12) Processing of electronic BACs transfers to former Shire Shareholders in respect of cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date Despatch of cheques to former Shire Shareholders for the cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date Despatch of cheques to former Shire Shareholders in relation to the New Takeda Shares sold under the Dealing Facility within 14 calendar days of the Effective Date Payment of the cash due to former Shire ADS Holders by the Shire Depositary following receipt of funds by the Shire Depositary (13)", "score": 0.361297, "arguments": [{"text": "Shire", "location": [38402, 38407], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Shareholders", "location": [38408, 38420], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "colleague", "sentence": "CREST accounts of former Shire Shareholders credited with cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date (12) Processing of electronic BACs transfers to former Shire Shareholders in respect of cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date Despatch of cheques to former Shire Shareholders for the cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date Despatch of cheques to former Shire Shareholders in relation to the New Takeda Shares sold under the Dealing Facility within 14 calendar days of the Effective Date Payment of the cash due to former Shire ADS Holders by the Shire Depositary following receipt of funds by the Shire Depositary (13)", "score": 0.391602, "arguments": [{"text": "Shire", "location": [38605, 38610], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Shareholders", "location": [38611, 38623], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "colleague", "sentence": "CREST accounts of former Shire Shareholders credited with cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date (12) Processing of electronic BACs transfers to former Shire Shareholders in respect of cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date Despatch of cheques to former Shire Shareholders for the cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date Despatch of cheques to former Shire Shareholders in relation to the New Takeda Shares sold under the Dealing Facility within 14 calendar days of the Effective Date Payment of the cash due to former Shire ADS Holders by the Shire Depositary following receipt of funds by the Shire Depositary (13)", "score": 0.375934, "arguments": [{"text": "Shire", "location": [38783, 38788], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Shareholders", "location": [38789, 38801], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "colleague", "sentence": "CREST accounts of former Shire Shareholders credited with cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date (12) Processing of electronic BACs transfers to former Shire Shareholders in respect of cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date Despatch of cheques to former Shire Shareholders for the cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date Despatch of cheques to former Shire Shareholders in relation to the New Takeda Shares sold under the Dealing Facility within 14 calendar days of the Effective Date Payment of the cash due to former Shire ADS Holders by the Shire Depositary following receipt of funds by the Shire Depositary (13)", "score": 0.389903, "arguments": [{"text": "Shire", "location": [38955, 38960], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Shareholders", "location": [38961, 38973], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "participantIn", "sentence": "Notices of the Court Meeting and the Shire General Meeting, which are scheduled to be held at Block 3, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland on December 5, 2018, are set out in the Scheme Document.", "score": 0.514803, "arguments": [{"text": "Court", "location": [2761, 2766], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [2767, 2774], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "locatedAt", "sentence": "CREST accounts of former Shire Shareholders credited with cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date (12) Processing of electronic BACs transfers to former Shire Shareholders in respect of cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date Despatch of cheques to former Shire Shareholders for the cash due under the Scheme and in relation to fractional entitlements within 14 calendar days of the Effective Date Despatch of cheques to former Shire Shareholders in relation to the New Takeda Shares sold under the Dealing Facility within 14 calendar days of the Effective Date Payment of the cash due to former Shire ADS Holders by the Shire Depositary following receipt of funds by the Shire Depositary (13)", "score": 0.527613, "arguments": [{"text": "Shareholders", "location": [38961, 38973], "entities": [{"type": "Person", "text": "Shareholders"}]}, {"text": "Facility", "location": [39034, 39042], "entities": [{"type": "Facility", "text": "Facility"}]}]}, {"type": "partOf", "sentence": "Latest date by which Scheme may become Effective May 8, 2019 (14) (1 ) In order to validly instruct the Shire Depositary as to voting at the Shire Meetings, the ADS Voting Card must be received by the Shire Depositary by 10.00 a.m. (New York time) on November 29, 2018 for each Shire Meeting or, if either Shire Meeting is adjourned, such later date as may be notified by the Shire Depositary, having consulted with Shire.", "score": 0.410084, "arguments": [{"text": "Scheme", "location": [39242, 39248], "entities": [{"type": "Organization", "text": "Scheme"}]}, {"text": "Latest", "location": [39221, 39227], "entities": [{"type": "Organization", "text": "Latest"}]}]}, {"type": "employedBy", "sentence": "Latest date by which Scheme may become Effective May 8, 2019 (14) (1 ) In order to validly instruct the Shire Depositary as to voting at the Shire Meetings, the ADS Voting Card must be received by the Shire Depositary by 10.00 a.m. (New York time) on November 29, 2018 for each Shire Meeting or, if either Shire Meeting is adjourned, such later date as may be notified by the Shire Depositary, having consulted with Shire.", "score": 0.736686, "arguments": [{"text": "Card", "location": [39393, 39397], "entities": [{"type": "Person", "text": "Card"}]}, {"text": "ADS Voting", "location": [39382, 39392], "entities": [{"type": "Organization", "text": "ADS Voting"}]}]}, {"type": "agentOf", "sentence": "Latest date by which Scheme may become Effective May 8, 2019 (14) (1 ) In order to validly instruct the Shire Depositary as to voting at the Shire Meetings, the ADS Voting Card must be received by the Shire Depositary by 10.00 a.m. (New York time) on November 29, 2018 for each Shire Meeting or, if either Shire Meeting is adjourned, such later date as may be notified by the Shire Depositary, having consulted with Shire.", "score": 0.456764, "arguments": [{"text": "Shire Meeting", "location": [39527, 39540], "entities": [{"type": "Person", "text": "Shire Meeting"}]}, {"text": "notified", "location": [39581, 39589], "entities": [{"type": "EventCommunication", "text": "notified"}]}]}, {"type": "agentOf", "sentence": "Latest date by which Scheme may become Effective May 8, 2019 (14) (1 ) In order to validly instruct the Shire Depositary as to voting at the Shire Meetings, the ADS Voting Card must be received by the Shire Depositary by 10.00 a.m. (New York time) on November 29, 2018 for each Shire Meeting or, if either Shire Meeting is adjourned, such later date as may be notified by the Shire Depositary, having consulted with Shire.", "score": 0.693898, "arguments": [{"text": "Shire Depositary", "location": [39597, 39613], "entities": [{"type": "Person", "text": "Shire Depositary"}]}, {"text": "notified", "location": [39581, 39589], "entities": [{"type": "EventCommunication", "text": "notified"}]}]}, {"type": "employedBy", "sentence": "(2 ) The BLUE Form of Proxy for the Court Meeting, if not received by Equiniti by the time stated above, may be handed to a representative of Equiniti, on behalf of the Chairman of the Court Meeting, or to the Chairman of the Court Meeting, before the start of the Court Meeting.", "score": 0.509834, "arguments": [{"text": "Chairman", "location": [39886, 39894], "entities": [{"type": "Person", "text": "Chairman"}]}, {"text": "Court Meeting", "location": [39902, 39915], "entities": [{"type": "Organization", "text": "Court Meeting"}]}]}, {"type": "employedBy", "sentence": "(2 ) The BLUE Form of Proxy for the Court Meeting, if not received by Equiniti by the time stated above, may be handed to a representative of Equiniti, on behalf of the Chairman of the Court Meeting, or to the Chairman of the Court Meeting, before the start of the Court Meeting.", "score": 0.560474, "arguments": [{"text": "Chairman", "location": [39927, 39935], "entities": [{"type": "Person", "text": "Chairman"}]}, {"text": "Court Meeting", "location": [39943, 39956], "entities": [{"type": "Organization", "text": "Court Meeting"}]}]}, {"type": "timeOf", "sentence": "(3 ) In order to be valid, the YELLOW Form of Proxy must be received by Equiniti not later than 11.30 a.m. on December 3, 2018 (or, if the Shire General Meeting is adjourned, not later than 48 hours before the time appointed for the adjourned Shire General Meeting).", "score": 0.438162, "arguments": [{"text": "48 hours", "location": [40187, 40195], "entities": [{"type": "Duration", "text": "48 hours"}]}, {"text": "appointed", "location": [40212, 40221], "entities": [{"type": "EventPersonnel", "text": "appointed"}]}]}, {"type": "agentOf", "sentence": "(3 ) In order to be valid, the YELLOW Form of Proxy must be received by Equiniti not later than 11.30 a.m. on December 3, 2018 (or, if the Shire General Meeting is adjourned, not later than 48 hours before the time appointed for the adjourned Shire General Meeting).", "score": 0.759745, "arguments": [{"text": "Shire General Meeting", "location": [40240, 40261], "entities": [{"type": "Person", "text": "Shire General Meeting"}]}, {"text": "appointed", "location": [40212, 40221], "entities": [{"type": "EventPersonnel", "text": "appointed"}]}]}, {"type": "participantIn", "sentence": "(4 ) If either the Court Meeting or the Shire General Meeting is adjourned, the Voting Record Time for the relevant adjourned Shire Meeting will be 6.30 p.m. on the date falling two calendar days before the date appointed for such adjourned Shire Meeting and the ADS Voting Record Time for the relevant adjourned Shire Meeting will be such later date as may be notified by the Shire Depositary, having consulted with Shire.", "score": 0.514803, "arguments": [{"text": "Court", "location": [40283, 40288], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [40289, 40296], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "locatedAt", "sentence": "Notices of the Court Meeting and the Shire General Meeting, which are scheduled to be held at Block 3, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland on December 5, 2018, are set out in the Scheme Document.", "score": 0.496747, "arguments": [{"text": "Miesian Plaza", "location": [2849, 2862], "entities": [{"type": "Person", "text": "Miesian Plaza"}]}, {"text": "Baggot Street Lower", "location": [2870, 2889], "entities": [{"type": "Facility", "text": "Baggot Street Lower"}]}]}, {"type": "agentOf", "sentence": "(4 ) If either the Court Meeting or the Shire General Meeting is adjourned, the Voting Record Time for the relevant adjourned Shire Meeting will be 6.30 p.m. on the date falling two calendar days before the date appointed for such adjourned Shire Meeting and the ADS Voting Record Time for the relevant adjourned Shire Meeting will be such later date as may be notified by the Shire Depositary, having consulted with Shire.", "score": 0.361618, "arguments": [{"text": "Shire Meeting", "location": [40505, 40518], "entities": [{"type": "Person", "text": "Shire Meeting"}]}, {"text": "appointed", "location": [40476, 40485], "entities": [{"type": "EventPersonnel", "text": "appointed"}]}]}, {"type": "agentOf", "sentence": "(4 ) If either the Court Meeting or the Shire General Meeting is adjourned, the Voting Record Time for the relevant adjourned Shire Meeting will be 6.30 p.m. on the date falling two calendar days before the date appointed for such adjourned Shire Meeting and the ADS Voting Record Time for the relevant adjourned Shire Meeting will be such later date as may be notified by the Shire Depositary, having consulted with Shire.", "score": 0.711808, "arguments": [{"text": "Shire Depositary", "location": [40641, 40657], "entities": [{"type": "Person", "text": "Shire Depositary"}]}, {"text": "notified", "location": [40625, 40633], "entities": [{"type": "EventCommunication", "text": "notified"}]}]}, {"type": "participantIn", "sentence": "(5 ) In the event that the Takeda Extraordinary General Meeting is postponed or adjourned, the Court Meeting and Shire General Meeting will be adjourned so that they will take place on the same date as the Takeda Extraordinary General Meeting.", "score": 0.907499, "arguments": [{"text": "Takeda Extraordinary General", "location": [40715, 40743], "entities": [{"type": "Person", "text": "Takeda Extraordinary General"}]}, {"text": "Meeting", "location": [40744, 40751], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "participantIn", "sentence": "(5 ) In the event that the Takeda Extraordinary General Meeting is postponed or adjourned, the Court Meeting and Shire General Meeting will be adjourned so that they will take place on the same date as the Takeda Extraordinary General Meeting.", "score": 0.914196, "arguments": [{"text": "Takeda Extraordinary General", "location": [40894, 40922], "entities": [{"type": "Person", "text": "Takeda Extraordinary General"}]}, {"text": "Meeting", "location": [40923, 40930], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "agentOf", "sentence": "(6 ) To commence at 11.30 a.m. (London time) or as soon thereafter as the Court Meeting shall have concluded or been adjourned.", "score": 0.441202, "arguments": [{"text": "Court", "location": [41006, 41011], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [41012, 41019], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "colleague", "sentence": "These dates will depend, among other things, on the dates upon which: (i) the Conditions are satisfied or (where applicable) waived; (ii) the European Commission gives its approval to proceed to completion of the Acquisition (see paragraph 7 of Part I (Letter from the Chairman of Shire PLC) of the Scheme Document for further details); (iii) the Court sanctions the Scheme; and (iv) the Court Order is delivered to the Registrar of Companies.", "score": 0.398897, "arguments": [{"text": "Chairman", "location": [41453, 41461], "entities": [{"type": "Person", "text": "Chairman"}]}, {"text": "Shire PLC", "location": [41465, 41474], "entities": [{"type": "Person", "text": "Shire PLC"}]}]}, {"type": "employedBy", "sentence": "These dates will depend, among other things, on the dates upon which: (i) the Conditions are satisfied or (where applicable) waived; (ii) the European Commission gives its approval to proceed to completion of the Acquisition (see paragraph 7 of Part I (Letter from the Chairman of Shire PLC) of the Scheme Document for further details); (iii) the Court sanctions the Scheme; and (iv) the Court Order is delivered to the Registrar of Companies.", "score": 0.701011, "arguments": [{"text": "Shire PLC", "location": [41465, 41474], "entities": [{"type": "Person", "text": "Shire PLC"}]}, {"text": "Scheme Document", "location": [41483, 41498], "entities": [{"type": "Organization", "text": "Scheme Document"}]}]}, {"type": "partOf", "sentence": "These dates will depend, among other things, on the dates upon which: (i) the Conditions are satisfied or (where applicable) waived; (ii) the European Commission gives its approval to proceed to completion of the Acquisition (see paragraph 7 of Part I (Letter from the Chairman of Shire PLC) of the Scheme Document for further details); (iii) the Court sanctions the Scheme; and (iv) the Court Order is delivered to the Registrar of Companies.", "score": 0.404673, "arguments": [{"text": "Court Order", "location": [41572, 41583], "entities": [{"type": "Organization", "text": "Court Order"}]}, {"text": "Registrar of Companies", "location": [41604, 41626], "entities": [{"type": "Organization", "text": "Registrar of Companies"}]}]}, {"type": "agentOf", "sentence": "Shire will give adequate notice of any changes by issuing an announcement through a Regulatory Information Service and will furnish such announcement to the SEC on Form 8-K. (8 ) In order to avoid a delay in the completion of any such transfer, Shire Shareholders who make a valid JASDEC Election to deliver their New Takeda Shares into an account with an AMI should contact their AMI to confirm any necessary steps in order for the AMI to record the delivery of the New Takeda Shares from the Settlement Account.", "score": 0.764401, "arguments": [{"text": "Shire", "location": [41945, 41950], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "issuing", "location": [41995, 42002], "entities": [{"type": "EventCommunication", "text": "issuing"}]}]}, {"type": "partOfMany", "sentence": "Shire will give adequate notice of any changes by issuing an announcement through a Regulatory Information Service and will furnish such announcement to the SEC on Form 8-K. (8 ) In order to avoid a delay in the completion of any such transfer, Shire Shareholders who make a valid JASDEC Election to deliver their New Takeda Shares into an account with an AMI should contact their AMI to confirm any necessary steps in order for the AMI to record the delivery of the New Takeda Shares from the Settlement Account.", "score": 0.656713, "arguments": [{"text": "Shareholders", "location": [42196, 42208], "entities": [{"type": "Person", "text": "Shareholders"}]}, {"text": "who", "location": [42209, 42212], "entities": [{"type": "Person", "text": "who"}]}]}, {"type": "agentOf", "sentence": "The Court Meeting is scheduled to commence at 11.15 a.m. and the Shire General Meeting at 11.30 a.m. (or as soon thereafter as the Court Meeting has concluded or been adjourned).", "score": 0.5622, "arguments": [{"text": "Court", "location": [2970, 2975], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [2976, 2983], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "partOfMany", "sentence": "In order to avoid a delay in receiving their New Takeda ADSs, Shire Shareholders who make a valid ADS Election to deliver their New Takeda ADSs to their broker or other securities intermediary in DTC should contact their broker or other securities intermediary to request that it, or the DTC participant through which it clears, inputs valid instructions to receive delivery of the New Takeda ADSs free of payment from the Takeda Depositary's DTC participant account (account number 2504). (10 ) New Takeda ADSs will be delivered to the Shire Depositary from January 10, 2019 (and in any event not later than 14 calendar days after the Effective Date).", "score": 0.650752, "arguments": [{"text": "Takeda ADSs", "location": [42633, 42644], "entities": [{"type": "Person", "text": "Takeda ADSs"}]}, {"text": "their", "location": [42623, 42628], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "In order to avoid a delay in receiving their New Takeda ADSs, Shire Shareholders who make a valid ADS Election to deliver their New Takeda ADSs to their broker or other securities intermediary in DTC should contact their broker or other securities intermediary to request that it, or the DTC participant through which it clears, inputs valid instructions to receive delivery of the New Takeda ADSs free of payment from the Takeda Depositary's DTC participant account (account number 2504). (10 ) New Takeda ADSs will be delivered to the Shire Depositary from January 10, 2019 (and in any event not later than 14 calendar days after the Effective Date).", "score": 0.476973, "arguments": [{"text": "Shareholders", "location": [42652, 42664], "entities": [{"type": "Person", "text": "Shareholders"}]}, {"text": "who", "location": [42665, 42668], "entities": [{"type": "Person", "text": "who"}]}]}, {"type": "partOfMany", "sentence": "In order to avoid a delay in receiving their New Takeda ADSs, Shire Shareholders who make a valid ADS Election to deliver their New Takeda ADSs to their broker or other securities intermediary in DTC should contact their broker or other securities intermediary to request that it, or the DTC participant through which it clears, inputs valid instructions to receive delivery of the New Takeda ADSs free of payment from the Takeda Depositary's DTC participant account (account number 2504). (10 ) New Takeda ADSs will be delivered to the Shire Depositary from January 10, 2019 (and in any event not later than 14 calendar days after the Effective Date).", "score": 0.515523, "arguments": [{"text": "Takeda ADSs", "location": [42716, 42727], "entities": [{"type": "Person", "text": "Takeda ADSs"}]}, {"text": "their", "location": [42706, 42711], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "In order to avoid a delay in receiving their New Takeda ADSs, Shire Shareholders who make a valid ADS Election to deliver their New Takeda ADSs to their broker or other securities intermediary in DTC should contact their broker or other securities intermediary to request that it, or the DTC participant through which it clears, inputs valid instructions to receive delivery of the New Takeda ADSs free of payment from the Takeda Depositary's DTC participant account (account number 2504). (10 ) New Takeda ADSs will be delivered to the Shire Depositary from January 10, 2019 (and in any event not later than 14 calendar days after the Effective Date).", "score": 0.557882, "arguments": [{"text": "Takeda ADSs", "location": [42716, 42727], "entities": [{"type": "Person", "text": "Takeda ADSs"}]}, {"text": "their", "location": [42731, 42736], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "employedBy", "sentence": "In order to avoid a delay in receiving their New Takeda ADSs, Shire Shareholders who make a valid ADS Election to deliver their New Takeda ADSs to their broker or other securities intermediary in DTC should contact their broker or other securities intermediary to request that it, or the DTC participant through which it clears, inputs valid instructions to receive delivery of the New Takeda ADSs free of payment from the Takeda Depositary's DTC participant account (account number 2504). (10 ) New Takeda ADSs will be delivered to the Shire Depositary from January 10, 2019 (and in any event not later than 14 calendar days after the Effective Date).", "score": 0.526534, "arguments": [{"text": "Shire Depositary", "location": [43121, 43137], "entities": [{"type": "Person", "text": "Shire Depositary"}]}, {"text": "New Takeda ADSs", "location": [43080, 43095], "entities": [{"type": "Organization", "text": "New Takeda ADSs"}]}]}, {"type": "employedBy", "sentence": "It is expected that Shire ADS Holders holding through participants in DTC will receive delivery shortly after the receipt by the Shire Depositary of the New Takeda ADSs and that registered Shire ADS Holders holding uncertificated Shire ADSs (that is, Shire ADSs held outside of DTC for which no certificates have been issued) will be issued New Takeda ADSs in uncertificated form beginning approximately one week thereafter (and will receive a statement by post reflecting the issuance of New Takeda ADSs in their name).", "score": 0.570346, "arguments": [{"text": "Shire Depositary", "location": [43517, 43533], "entities": [{"type": "Person", "text": "Shire Depositary"}]}, {"text": "New Takeda ADSs", "location": [43541, 43556], "entities": [{"type": "Organization", "text": "New Takeda ADSs"}]}]}, {"type": "partOfMany", "sentence": "The date on which New Takeda ADSs will be delivered to Shire ADS Holders will depend on the way in which such Shire ADS Holders held their Shire ADSs.", "score": 0.555817, "arguments": [{"text": "Shire ADS Holders", "location": [43347, 43364], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "their", "location": [43370, 43375], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "The date on which New Takeda ADSs will be delivered to Shire ADS Holders will depend on the way in which such Shire ADS Holders held their Shire ADSs.", "score": 0.707123, "arguments": [{"text": "Shire ADSs", "location": [43376, 43386], "entities": [{"type": "Person", "text": "Shire ADSs"}]}, {"text": "their", "location": [43370, 43375], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "residesIn", "sentence": "It is expected that Shire ADS Holders holding through participants in DTC will receive delivery shortly after the receipt by the Shire Depositary of the New Takeda ADSs and that registered Shire ADS Holders holding uncertificated Shire ADSs (that is, Shire ADSs held outside of DTC for which no certificates have been issued) will be issued New Takeda ADSs in uncertificated form beginning approximately one week thereafter (and will receive a statement by post reflecting the issuance of New Takeda ADSs in their name).", "score": 0.510484, "arguments": [{"text": "Shire ADS Holders", "location": [43408, 43425], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "DTC", "location": [43458, 43461], "entities": [{"type": "GeopoliticalEntity", "text": "DTC"}]}]}, {"type": "locatedAt", "sentence": "It is expected that Shire ADS Holders holding through participants in DTC will receive delivery shortly after the receipt by the Shire Depositary of the New Takeda ADSs and that registered Shire ADS Holders holding uncertificated Shire ADSs (that is, Shire ADSs held outside of DTC for which no certificates have been issued) will be issued New Takeda ADSs in uncertificated form beginning approximately one week thereafter (and will receive a statement by post reflecting the issuance of New Takeda ADSs in their name).", "score": 0.468603, "arguments": [{"text": "participants", "location": [43442, 43454], "entities": [{"type": "Person", "text": "participants"}]}, {"text": "DTC", "location": [43458, 43461], "entities": [{"type": "GeopoliticalEntity", "text": "DTC"}]}]}, {"type": "partOf", "sentence": "It is expected that Shire ADS Holders holding through participants in DTC will receive delivery shortly after the receipt by the Shire Depositary of the New Takeda ADSs and that registered Shire ADS Holders holding uncertificated Shire ADSs (that is, Shire ADSs held outside of DTC for which no certificates have been issued) will be issued New Takeda ADSs in uncertificated form beginning approximately one week thereafter (and will receive a statement by post reflecting the issuance of New Takeda ADSs in their name).", "score": 0.622565, "arguments": [{"text": "which", "location": [43674, 43679], "entities": [{"type": "Organization", "text": "which"}]}, {"text": "DTC for", "location": [43666, 43673], "entities": [{"type": "Organization", "text": "DTC for"}]}]}, {"type": "timeOf", "sentence": "The Court Meeting is scheduled to commence at 11.15 a.m. and the Shire General Meeting at 11.30 a.m. (or as soon thereafter as the Court Meeting has concluded or been adjourned).", "score": 0.512617, "arguments": [{"text": "a.m.", "location": [3018, 3022], "entities": [{"type": "Time", "text": "a.m."}]}, {"text": "Meeting", "location": [2976, 2983], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "memberOf", "sentence": "Registered Shire ADS Holders holding certificates for their Shire ADSs will only receive delivery of their New Takeda ADSs after they return their signed letter of transmittal and Shire ADS certificate to the Shire Depositary.", "score": 0.332671, "arguments": [{"text": "certificates", "location": [43946, 43958], "entities": [{"type": "Person", "text": "certificates"}]}, {"text": "Registered Shire ADS Holders", "location": [43909, 43937], "entities": [{"type": "Organization", "text": "Registered Shire ADS Holders"}]}]}, {"type": "partOfMany", "sentence": "(12 ) Shire Shareholders who hold Shire Shares in uncertificated form and receive the cash portion of the Consideration in US Dollars must ensure that an active US Dollar Cash Memorandum Account is in place in CREST by no later than the Scheme Record Time.", "score": 0.484278, "arguments": [{"text": "who", "location": [44593, 44596], "entities": [{"type": "Person", "text": "who"}]}, {"text": "Shareholders", "location": [44580, 44592], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "locatedAt", "sentence": "(12 ) Shire Shareholders who hold Shire Shares in uncertificated form and receive the cash portion of the Consideration in US Dollars must ensure that an active US Dollar Cash Memorandum Account is in place in CREST by no later than the Scheme Record Time.", "score": 0.708833, "arguments": [{"text": "Dollars", "location": [44694, 44701], "entities": [{"type": "Facility", "text": "Dollars"}]}, {"text": "US", "location": [44691, 44693], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "residesIn", "sentence": "(12 ) Shire Shareholders who hold Shire Shares in uncertificated form and receive the cash portion of the Consideration in US Dollars must ensure that an active US Dollar Cash Memorandum Account is in place in CREST by no later than the Scheme Record Time.", "score": 0.329653, "arguments": [{"text": "Dollar Cash Memorandum Account", "location": [44732, 44762], "entities": [{"type": "Person", "text": "Dollar Cash Memorandum Account"}]}, {"text": "US", "location": [44729, 44731], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "locatedAt", "sentence": "(12 ) Shire Shareholders who hold Shire Shares in uncertificated form and receive the cash portion of the Consideration in US Dollars must ensure that an active US Dollar Cash Memorandum Account is in place in CREST by no later than the Scheme Record Time.", "score": 0.678042, "arguments": [{"text": "Dollar Cash Memorandum Account", "location": [44732, 44762], "entities": [{"type": "Person", "text": "Dollar Cash Memorandum Account"}]}, {"text": "CREST", "location": [44778, 44783], "entities": [{"type": "GeopoliticalEntity", "text": "CREST"}]}]}, {"type": "managerOf", "sentence": "In the absence of a US Dollar Cash Memorandum Account, the payment of the cash portion of the Consideration will not settle, resulting in a delay and the settlement of the cash portion of the Consideration outside of CREST.", "score": 0.444366, "arguments": [{"text": "Dollar Cash Memorandum Account", "location": [44848, 44878], "entities": [{"type": "Person", "text": "Dollar Cash Memorandum Account"}]}, {"text": "US", "location": [44845, 44847], "entities": [{"type": "GeopoliticalEntity", "text": "US"}]}]}, {"type": "affectedBy", "sentence": "In the absence of a US Dollar Cash Memorandum Account, the payment of the cash portion of the Consideration will not settle, resulting in a delay and the settlement of the cash portion of the Consideration outside of CREST.", "score": 0.522945, "arguments": [{"text": "Dollar Cash Memorandum Account", "location": [44848, 44878], "entities": [{"type": "Person", "text": "Dollar Cash Memorandum Account"}]}, {"text": "settlement", "location": [44979, 44989], "entities": [{"type": "EventLegal", "text": "settlement"}]}]}, {"type": "participantIn", "sentence": "(13 ) In the case of Shire ADS Holders who hold Shire ADSs in certificated form, subject to presentation by such holders of their signed letters of transmittal and Shire ADS certificates to the Shire Depositary.", "score": 0.428942, "arguments": [{"text": "Shire ADS Holders", "location": [45070, 45087], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "case", "location": [45062, 45066], "entities": [{"type": "EventLegal", "text": "case"}]}]}, {"type": "partOfMany", "sentence": "(13 ) In the case of Shire ADS Holders who hold Shire ADSs in certificated form, subject to presentation by such holders of their signed letters of transmittal and Shire ADS certificates to the Shire Depositary.", "score": 0.537496, "arguments": [{"text": "Shire ADS Holders", "location": [45070, 45087], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "their", "location": [45173, 45178], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "(13 ) In the case of Shire ADS Holders who hold Shire ADSs in certificated form, subject to presentation by such holders of their signed letters of transmittal and Shire ADS certificates to the Shire Depositary.", "score": 0.82862, "arguments": [{"text": "Shire ADSs", "location": [45097, 45107], "entities": [{"type": "Person", "text": "Shire ADSs"}]}, {"text": "their", "location": [45173, 45178], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOf", "sentence": "The Court Meeting is scheduled to commence at 11.15 a.m. and the Shire General Meeting at 11.30 a.m. (or as soon thereafter as the Court Meeting has concluded or been adjourned).", "score": 0.34681, "arguments": [{"text": "Meeting", "location": [2976, 2983], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}, {"text": "Meeting", "location": [3045, 3052], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "partOfMany", "sentence": "(13 ) In the case of Shire ADS Holders who hold Shire ADSs in certificated form, subject to presentation by such holders of their signed letters of transmittal and Shire ADS certificates to the Shire Depositary.", "score": 0.827826, "arguments": [{"text": "holders", "location": [45162, 45169], "entities": [{"type": "Person", "text": "holders"}]}, {"text": "their", "location": [45173, 45178], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "(13 ) In the case of Shire ADS Holders who hold Shire ADSs in certificated form, subject to presentation by such holders of their signed letters of transmittal and Shire ADS certificates to the Shire Depositary.", "score": 0.750277, "arguments": [{"text": "their", "location": [45173, 45178], "entities": [{"type": "Person", "text": "their"}]}, {"text": "certificates", "location": [45223, 45235], "entities": [{"type": "Person", "text": "certificates"}]}]}, {"type": "colleague", "sentence": "(13 ) In the case of Shire ADS Holders who hold Shire ADSs in certificated form, subject to presentation by such holders of their signed letters of transmittal and Shire ADS certificates to the Shire Depositary.", "score": 0.253411, "arguments": [{"text": "Shire ADS", "location": [45213, 45222], "entities": [{"type": "Person", "text": "Shire ADS"}]}, {"text": "certificates", "location": [45223, 45235], "entities": [{"type": "Person", "text": "certificates"}]}]}, {"type": "participantIn", "sentence": "The Court Meeting is scheduled to commence at 11.15 a.m. and the Shire General Meeting at 11.30 a.m. (or as soon thereafter as the Court Meeting has concluded or been adjourned).", "score": 0.89355, "arguments": [{"text": "Shire General", "location": [3031, 3044], "entities": [{"type": "Person", "text": "Shire General"}]}, {"text": "Meeting", "location": [3045, 3052], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "timeOf", "sentence": "The Court Meeting is scheduled to commence at 11.15 a.m. and the Shire General Meeting at 11.30 a.m. (or as soon thereafter as the Court Meeting has concluded or been adjourned).", "score": 0.751479, "arguments": [{"text": "11.30 a.m.", "location": [3056, 3066], "entities": [{"type": "Time", "text": "11.30 a.m."}]}, {"text": "Meeting", "location": [3045, 3052], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "participantIn", "sentence": "The Court Meeting is scheduled to commence at 11.15 a.m. and the Shire General Meeting at 11.30 a.m. (or as soon thereafter as the Court Meeting has concluded or been adjourned).", "score": 0.463751, "arguments": [{"text": "Court", "location": [3097, 3102], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [3103, 3110], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "partOf", "sentence": "The Acquisition will be effected by means of a scheme of arrangement under Article 125 of the Companies (Jersey) Law 1991 (as amended) (the \" Scheme \").", "score": 0.407208, "arguments": [{"text": "Companies", "location": [455, 464], "entities": [{"type": "Organization", "text": "Companies"}]}, {"text": "Jersey", "location": [466, 472], "entities": [{"type": "Organization", "text": "Jersey"}]}]}, {"type": "participantIn", "sentence": "It is important that, for the Court Meeting in particular, as many votes as possible are cast so that the Court may be satisfied that there is a fair and reasonable representation of Shire Shareholder opinion.", "score": 0.448505, "arguments": [{"text": "Court", "location": [3175, 3180], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [3181, 3188], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "partOfMany", "sentence": "Shire Shareholders and Shire ADS Holders are therefore strongly urged to complete, sign and return the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible.", "score": 0.550635, "arguments": [{"text": "Shire", "location": [3355, 3360], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "their", "location": [3576, 3581], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "Shire Shareholders and Shire ADS Holders are therefore strongly urged to complete, sign and return the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible.", "score": 0.72046, "arguments": [{"text": "Shire ADS Holders", "location": [3378, 3395], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "Shareholders", "location": [3361, 3373], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "partOfMany", "sentence": "Shire Shareholders and Shire ADS Holders are therefore strongly urged to complete, sign and return the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible.", "score": 0.553355, "arguments": [{"text": "Shareholders", "location": [3361, 3373], "entities": [{"type": "Person", "text": "Shareholders"}]}, {"text": "their", "location": [3576, 3581], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "agentOf", "sentence": "Shire Shareholders and Shire ADS Holders are therefore strongly urged to complete, sign and return the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible.", "score": 0.692017, "arguments": [{"text": "Shire ADS Holders", "location": [3378, 3395], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "urged", "location": [3419, 3424], "entities": [{"type": "EventCommunication", "text": "urged"}]}]}, {"type": "partOfMany", "sentence": "Shire Shareholders and Shire ADS Holders are therefore strongly urged to complete, sign and return the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible.", "score": 0.789426, "arguments": [{"text": "Shire ADS Holders", "location": [3378, 3395], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "their", "location": [3576, 3581], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "Shire Shareholders and Shire ADS Holders are therefore strongly urged to complete, sign and return the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible.", "score": 0.746897, "arguments": [{"text": "Voting Card", "location": [3586, 3597], "entities": [{"type": "Person", "text": "Voting Card"}]}, {"text": "their", "location": [3576, 3581], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "participantIn", "sentence": "Shire Shareholders and Shire ADS Holders are therefore strongly urged to complete, sign and return the Forms of Proxy (once received) or submit their proxy by electronic means or, if applicable, complete, sign and return their ADS Voting Card, for both the Court Meeting and the Shire General Meeting, as soon as possible.", "score": 0.50097, "arguments": [{"text": "Court", "location": [3612, 3617], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [3618, 3625], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "productOf", "sentence": "Timetable The Scheme Document contains an expected timetable of principal events relating to the Scheme, which is also attached as an Appendix to this Announcement.", "score": 0.550334, "arguments": [{"text": "Appendix", "location": [3812, 3820], "entities": [{"type": "Product", "text": "Appendix"}]}, {"text": "which", "location": [3783, 3788], "entities": [{"type": "Organization", "text": "which"}]}]}, {"type": "agentOf", "sentence": "It is intended that, following the Scheme becoming Effective, the London Stock Exchange and the FCA will be requested respectively to cancel trading in Shire Shares on the London Stock Exchange's main market for listed securities and to remove the listing of the Shire Shares from the Official List, in each case on or shortly after the Effective Date.", "score": 0.932621, "arguments": [{"text": "FCA", "location": [4695, 4698], "entities": [{"type": "Organization", "text": "FCA"}]}, {"text": "requested", "location": [4707, 4716], "entities": [{"type": "EventCommunication", "text": "requested"}]}]}, {"type": "agentOf", "sentence": "Shire is pleased to announce that the scheme document which sets out, among other things, a letter from the Chairman of Shire, the full terms and conditions of the Scheme, an explanatory statement, notices of the Court Meeting and the Shire General Meeting, an expected timetable of principal events and details of the action to be taken by Shire Shareholders and Shire ADS Holders, is being sent, or made available, to Shire Shareholders and Shire ADS Holders today and has been published on the Shire website at www.shire.com (the \" Scheme Document \").", "score": 0.90618, "arguments": [{"text": "Shire", "location": [514, 519], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "announce", "location": [534, 542], "entities": [{"type": "EventCommunication", "text": "announce"}]}]}, {"type": "employedBy", "sentence": "It is intended that, following the Scheme becoming Effective, the London Stock Exchange and the FCA will be requested respectively to cancel trading in Shire Shares on the London Stock Exchange's main market for listed securities and to remove the listing of the Shire Shares from the Official List, in each case on or shortly after the Effective Date.", "score": 0.656879, "arguments": [{"text": "Shire", "location": [4862, 4867], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Official List", "location": [4884, 4897], "entities": [{"type": "Organization", "text": "Official List"}]}]}, {"type": "agentOf", "sentence": "If any of the key dates set out in the timetable change, Shire will give notice of this change by issuing an announcement through a Regulatory Information Service.", "score": 0.847208, "arguments": [{"text": "Shire", "location": [5097, 5102], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "issuing", "location": [5138, 5145], "entities": [{"type": "EventCommunication", "text": "issuing"}]}]}, {"type": "partOfMany", "sentence": "Information for Shire Shareholders and Shire ADS Holders If you have any questions in relation to this Announcement, the Scheme Document, the Court Meeting or the Shire General Meeting, or are in any doubt as to how to complete the Forms of Proxy or lodge a Form of Election, please call Equiniti between 8.30 a.m. and 5.30 p.m. (London time) Monday to Friday (except public holidays in England and Wales) on 0330 123 5506 (if calling from within the UK) or +44 (0)121 415 0856 (if calling from outside the UK).", "score": 0.642989, "arguments": [{"text": "Shire ADS Holders", "location": [5321, 5338], "entities": [{"type": "Person", "text": "Shire ADS Holders"}]}, {"text": "Shareholders", "location": [5304, 5316], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "agentOf", "sentence": "Information for Shire Shareholders and Shire ADS Holders If you have any questions in relation to this Announcement, the Scheme Document, the Court Meeting or the Shire General Meeting, or are in any doubt as to how to complete the Forms of Proxy or lodge a Form of Election, please call Equiniti between 8.30 a.m. and 5.30 p.m. (London time) Monday to Friday (except public holidays in England and Wales) on 0330 123 5506 (if calling from within the UK) or +44 (0)121 415 0856 (if calling from outside the UK).", "score": 0.763903, "arguments": [{"text": "you", "location": [5342, 5345], "entities": [{"type": "Person", "text": "you"}]}, {"text": "Announcement", "location": [5385, 5397], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "affectedBy", "sentence": "Information for Shire Shareholders and Shire ADS Holders If you have any questions in relation to this Announcement, the Scheme Document, the Court Meeting or the Shire General Meeting, or are in any doubt as to how to complete the Forms of Proxy or lodge a Form of Election, please call Equiniti between 8.30 a.m. and 5.30 p.m. (London time) Monday to Friday (except public holidays in England and Wales) on 0330 123 5506 (if calling from within the UK) or +44 (0)121 415 0856 (if calling from outside the UK).", "score": 0.459791, "arguments": [{"text": "Scheme Document", "location": [5403, 5418], "entities": [{"type": "Organization", "text": "Scheme Document"}]}, {"text": "Announcement", "location": [5385, 5397], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "participantIn", "sentence": "Information for Shire Shareholders and Shire ADS Holders If you have any questions in relation to this Announcement, the Scheme Document, the Court Meeting or the Shire General Meeting, or are in any doubt as to how to complete the Forms of Proxy or lodge a Form of Election, please call Equiniti between 8.30 a.m. and 5.30 p.m. (London time) Monday to Friday (except public holidays in England and Wales) on 0330 123 5506 (if calling from within the UK) or +44 (0)121 415 0856 (if calling from outside the UK).", "score": 0.451052, "arguments": [{"text": "Court", "location": [5424, 5429], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [5430, 5437], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "timeOf", "sentence": "Information for Shire Shareholders and Shire ADS Holders If you have any questions in relation to this Announcement, the Scheme Document, the Court Meeting or the Shire General Meeting, or are in any doubt as to how to complete the Forms of Proxy or lodge a Form of Election, please call Equiniti between 8.30 a.m. and 5.30 p.m. (London time) Monday to Friday (except public holidays in England and Wales) on 0330 123 5506 (if calling from within the UK) or +44 (0)121 415 0856 (if calling from outside the UK).", "score": 0.542799, "arguments": [{"text": "0330 123 5506", "location": [5691, 5704], "entities": [{"type": "Date", "text": "0330 123 5506"}]}, {"text": "calling", "location": [5709, 5716], "entities": [{"type": "EventCommunication", "text": "calling"}]}]}, {"type": "employedBy", "sentence": "Enquiries: +41 41 288 41 29 Scott Burrows (Investor Relations) +41 41 288 41 95 Sun Kim (Investor Relations) (joint financial adviser to Shire) (US) Chris Hite (joint financial adviser to Shire) Anthony Gutman Morgan Stanley & Co. International plc (joint financial adviser to Shire) Clint Gartin +44 (0) 203 727 1000 Elissa Johnsen (Media - outside of Japan) elissa.johnsen@takeda.com Kazumi Kobayashi (Media - within Japan) Kazumi.kobayashi@takeda.com Tsuyoshi Tada (Media - within Japan) tsuyoshi.tada@takeda.com (joint financial adviser to Takeda) (US) Will Hiltz (joint financial adviser to Takeda) Michele Colocci (joint financial adviser to Takeda) Akira Kiyota (UK) James Murgatroyd / Rollo Head / Anjali Unnikrishnan +44 207 251 3801 (US) Kal Goldberg / Chris Ryall +1", "score": 0.521513, "arguments": [{"text": "Scott Burrows", "location": [6651, 6664], "entities": [{"type": "Person", "text": "Scott Burrows"}]}, {"text": "Investor Relations", "location": [6666, 6684], "entities": [{"type": "Organization", "text": "Investor Relations"}]}]}, {"type": "employedBy", "sentence": "Enquiries: +41 41 288 41 29 Scott Burrows (Investor Relations) +41 41 288 41 95 Sun Kim (Investor Relations) (joint financial adviser to Shire) (US) Chris Hite (joint financial adviser to Shire) Anthony Gutman Morgan Stanley & Co. International plc (joint financial adviser to Shire) Clint Gartin +44 (0) 203 727 1000 Elissa Johnsen (Media - outside of Japan) elissa.johnsen@takeda.com Kazumi Kobayashi (Media - within Japan) Kazumi.kobayashi@takeda.com Tsuyoshi Tada (Media - within Japan) tsuyoshi.tada@takeda.com (joint financial adviser to Takeda) (US) Will Hiltz (joint financial adviser to Takeda) Michele Colocci (joint financial adviser to Takeda) Akira Kiyota (UK) James Murgatroyd / Rollo Head / Anjali Unnikrishnan +44 207 251 3801 (US) Kal Goldberg / Chris Ryall +1", "score": 0.539315, "arguments": [{"text": "Kim", "location": [6707, 6710], "entities": [{"type": "Person", "text": "Kim"}]}, {"text": "Investor Relations", "location": [6712, 6730], "entities": [{"type": "Organization", "text": "Investor Relations"}]}]}, {"type": "employedBy", "sentence": "Enquiries: +41 41 288 41 29 Scott Burrows (Investor Relations) +41 41 288 41 95 Sun Kim (Investor Relations) (joint financial adviser to Shire) (US) Chris Hite (joint financial adviser to Shire) Anthony Gutman Morgan Stanley & Co. International plc (joint financial adviser to Shire) Clint Gartin +44 (0) 203 727 1000 Elissa Johnsen (Media - outside of Japan) elissa.johnsen@takeda.com Kazumi Kobayashi (Media - within Japan) Kazumi.kobayashi@takeda.com Tsuyoshi Tada (Media - within Japan) tsuyoshi.tada@takeda.com (joint financial adviser to Takeda) (US) Will Hiltz (joint financial adviser to Takeda) Michele Colocci (joint financial adviser to Takeda) Akira Kiyota (UK) James Murgatroyd / Rollo Head / Anjali Unnikrishnan +44 207 251 3801 (US) Kal Goldberg / Chris Ryall +1", "score": 0.596008, "arguments": [{"text": "Anthony Gutman", "location": [6818, 6832], "entities": [{"type": "Person", "text": "Anthony Gutman"}]}, {"text": "Morgan Stanley & Co. International plc", "location": [6833, 6871], "entities": [{"type": "Organization", "text": "Morgan Stanley & Co. International plc"}]}]}, {"type": "colleague", "sentence": "Shire is pleased to announce that the scheme document which sets out, among other things, a letter from the Chairman of Shire, the full terms and conditions of the Scheme, an explanatory statement, notices of the Court Meeting and the Shire General Meeting, an expected timetable of principal events and details of the action to be taken by Shire Shareholders and Shire ADS Holders, is being sent, or made available, to Shire Shareholders and Shire ADS Holders today and has been published on the Shire website at www.shire.com (the \" Scheme Document \").", "score": 0.340234, "arguments": [{"text": "Chairman", "location": [622, 630], "entities": [{"type": "Person", "text": "Chairman"}]}, {"text": "Shire", "location": [634, 639], "entities": [{"type": "Person", "text": "Shire"}]}]}, {"type": "employedBy", "sentence": "Enquiries: +41 41 288 41 29 Scott Burrows (Investor Relations) +41 41 288 41 95 Sun Kim (Investor Relations) (joint financial adviser to Shire) (US) Chris Hite (joint financial adviser to Shire) Anthony Gutman Morgan Stanley & Co. International plc (joint financial adviser to Shire) Clint Gartin +44 (0) 203 727 1000 Elissa Johnsen (Media - outside of Japan) elissa.johnsen@takeda.com Kazumi Kobayashi (Media - within Japan) Kazumi.kobayashi@takeda.com Tsuyoshi Tada (Media - within Japan) tsuyoshi.tada@takeda.com (joint financial adviser to Takeda) (US) Will Hiltz (joint financial adviser to Takeda) Michele Colocci (joint financial adviser to Takeda) Akira Kiyota (UK) James Murgatroyd / Rollo Head / Anjali Unnikrishnan +44 207 251 3801 (US) Kal Goldberg / Chris Ryall +1", "score": 0.464419, "arguments": [{"text": "Shire", "location": [6900, 6905], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Media", "location": [6957, 6962], "entities": [{"type": "Organization", "text": "Media"}]}]}, {"type": "employedBy", "sentence": "Enquiries: +41 41 288 41 29 Scott Burrows (Investor Relations) +41 41 288 41 95 Sun Kim (Investor Relations) (joint financial adviser to Shire) (US) Chris Hite (joint financial adviser to Shire) Anthony Gutman Morgan Stanley & Co. International plc (joint financial adviser to Shire) Clint Gartin +44 (0) 203 727 1000 Elissa Johnsen (Media - outside of Japan) elissa.johnsen@takeda.com Kazumi Kobayashi (Media - within Japan) Kazumi.kobayashi@takeda.com Tsuyoshi Tada (Media - within Japan) tsuyoshi.tada@takeda.com (joint financial adviser to Takeda) (US) Will Hiltz (joint financial adviser to Takeda) Michele Colocci (joint financial adviser to Takeda) Akira Kiyota (UK) James Murgatroyd / Rollo Head / Anjali Unnikrishnan +44 207 251 3801 (US) Kal Goldberg / Chris Ryall +1", "score": 0.583261, "arguments": [{"text": "Elissa Johnsen", "location": [6941, 6955], "entities": [{"type": "Person", "text": "Elissa Johnsen"}]}, {"text": "Media", "location": [6957, 6962], "entities": [{"type": "Organization", "text": "Media"}]}]}, {"type": "employedBy", "sentence": "Enquiries: +41 41 288 41 29 Scott Burrows (Investor Relations) +41 41 288 41 95 Sun Kim (Investor Relations) (joint financial adviser to Shire) (US) Chris Hite (joint financial adviser to Shire) Anthony Gutman Morgan Stanley & Co. International plc (joint financial adviser to Shire) Clint Gartin +44 (0) 203 727 1000 Elissa Johnsen (Media - outside of Japan) elissa.johnsen@takeda.com Kazumi Kobayashi (Media - within Japan) Kazumi.kobayashi@takeda.com Tsuyoshi Tada (Media - within Japan) tsuyoshi.tada@takeda.com (joint financial adviser to Takeda) (US) Will Hiltz (joint financial adviser to Takeda) Michele Colocci (joint financial adviser to Takeda) Akira Kiyota (UK) James Murgatroyd / Rollo Head / Anjali Unnikrishnan +44 207 251 3801 (US) Kal Goldberg / Chris Ryall +1", "score": 0.419966, "arguments": [{"text": "elissa.johnsen@takeda.com\nKazumi Kobayashi", "location": [6983, 7025], "entities": [{"type": "Person", "text": "elissa.johnsen@takeda.com\nKazumi Kobayashi"}]}, {"text": "Media \u2013 within Japan", "location": [7027, 7047], "entities": [{"type": "Organization", "text": "Media \u2013 within Japan"}]}]}, {"type": "employedBy", "sentence": "Enquiries: +41 41 288 41 29 Scott Burrows (Investor Relations) +41 41 288 41 95 Sun Kim (Investor Relations) (joint financial adviser to Shire) (US) Chris Hite (joint financial adviser to Shire) Anthony Gutman Morgan Stanley & Co. International plc (joint financial adviser to Shire) Clint Gartin +44 (0) 203 727 1000 Elissa Johnsen (Media - outside of Japan) elissa.johnsen@takeda.com Kazumi Kobayashi (Media - within Japan) Kazumi.kobayashi@takeda.com Tsuyoshi Tada (Media - within Japan) tsuyoshi.tada@takeda.com (joint financial adviser to Takeda) (US) Will Hiltz (joint financial adviser to Takeda) Michele Colocci (joint financial adviser to Takeda) Akira Kiyota (UK) James Murgatroyd / Rollo Head / Anjali Unnikrishnan +44 207 251 3801 (US) Kal Goldberg / Chris Ryall +1", "score": 0.445336, "arguments": [{"text": "Kazumi.kobayashi@takeda.com\nTsuyoshi Tada", "location": [7049, 7090], "entities": [{"type": "Person", "text": "Kazumi.kobayashi@takeda.com\nTsuyoshi Tada"}]}, {"text": "Media \u2013 within Japan)\ntsuyoshi.tada@takeda.com", "location": [7092, 7138], "entities": [{"type": "Organization", "text": "Media \u2013 within Japan)\ntsuyoshi.tada@takeda.com"}]}]}, {"type": "employedBy", "sentence": "Enquiries: +41 41 288 41 29 Scott Burrows (Investor Relations) +41 41 288 41 95 Sun Kim (Investor Relations) (joint financial adviser to Shire) (US) Chris Hite (joint financial adviser to Shire) Anthony Gutman Morgan Stanley & Co. International plc (joint financial adviser to Shire) Clint Gartin +44 (0) 203 727 1000 Elissa Johnsen (Media - outside of Japan) elissa.johnsen@takeda.com Kazumi Kobayashi (Media - within Japan) Kazumi.kobayashi@takeda.com Tsuyoshi Tada (Media - within Japan) tsuyoshi.tada@takeda.com (joint financial adviser to Takeda) (US) Will Hiltz (joint financial adviser to Takeda) Michele Colocci (joint financial adviser to Takeda) Akira Kiyota (UK) James Murgatroyd / Rollo Head / Anjali Unnikrishnan +44 207 251 3801 (US) Kal Goldberg / Chris Ryall +1", "score": 0.602443, "arguments": [{"text": "Takeda", "location": [7271, 7277], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "UK", "location": [7293, 7295], "entities": [{"type": "GeopoliticalEntity", "text": "UK"}]}]}, {"type": "employedBy", "sentence": "Enquiries: +41 41 288 41 29 Scott Burrows (Investor Relations) +41 41 288 41 95 Sun Kim (Investor Relations) (joint financial adviser to Shire) (US) Chris Hite (joint financial adviser to Shire) Anthony Gutman Morgan Stanley & Co. International plc (joint financial adviser to Shire) Clint Gartin +44 (0) 203 727 1000 Elissa Johnsen (Media - outside of Japan) elissa.johnsen@takeda.com Kazumi Kobayashi (Media - within Japan) Kazumi.kobayashi@takeda.com Tsuyoshi Tada (Media - within Japan) tsuyoshi.tada@takeda.com (joint financial adviser to Takeda) (US) Will Hiltz (joint financial adviser to Takeda) Michele Colocci (joint financial adviser to Takeda) Akira Kiyota (UK) James Murgatroyd / Rollo Head / Anjali Unnikrishnan +44 207 251 3801 (US) Kal Goldberg / Chris Ryall +1", "score": 0.950292, "arguments": [{"text": "Akira Kiyota", "location": [7279, 7291], "entities": [{"type": "Person", "text": "Akira Kiyota"}]}, {"text": "UK", "location": [7293, 7295], "entities": [{"type": "GeopoliticalEntity", "text": "UK"}]}]}, {"type": "basedIn", "sentence": "Important Notices About Financial Advisers Evercore Partners International LLP (\" Evercore \"), which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and this Announcement and will not regard any other person as its client in relation to the Acquisition or this Announcement and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of Evercore, or for providing advice in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.433455, "arguments": [{"text": "Financial Conduct Authority", "location": [7793, 7820], "entities": [{"type": "Organization", "text": "Financial Conduct Authority"}]}, {"text": "United Kingdom", "location": [7771, 7785], "entities": [{"type": "GeopoliticalEntity", "text": "United Kingdom"}]}]}, {"type": "agentOf", "sentence": "Important Notices About Financial Advisers Evercore Partners International LLP (\" Evercore \"), which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and this Announcement and will not regard any other person as its client in relation to the Acquisition or this Announcement and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of Evercore, or for providing advice in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.415028, "arguments": [{"text": "anyone", "location": [8083, 8089], "entities": [{"type": "Person", "text": "anyone"}]}, {"text": "Announcement", "location": [8038, 8050], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "employedBy", "sentence": "Important Notices About Financial Advisers Evercore Partners International LLP (\" Evercore \"), which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and this Announcement and will not regard any other person as its client in relation to the Acquisition or this Announcement and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of Evercore, or for providing advice in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.358, "arguments": [{"text": "clients", "location": [8150, 8157], "entities": [{"type": "Person", "text": "clients"}]}, {"text": "Evercore", "location": [8161, 8169], "entities": [{"type": "Organization", "text": "Evercore"}]}]}, {"type": "partOf", "sentence": "Neither Evercore nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Evercore in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.788414, "arguments": [{"text": "subsidiaries", "location": [8315, 8327], "entities": [{"type": "Organization", "text": "subsidiaries"}]}, {"text": "its", "location": [8311, 8314], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "employedBy", "sentence": "Shire is pleased to announce that the scheme document which sets out, among other things, a letter from the Chairman of Shire, the full terms and conditions of the Scheme, an explanatory statement, notices of the Court Meeting and the Shire General Meeting, an expected timetable of principal events and details of the action to be taken by Shire Shareholders and Shire ADS Holders, is being sent, or made available, to Shire Shareholders and Shire ADS Holders today and has been published on the Shire website at www.shire.com (the \" Scheme Document \").", "score": 0.22409, "arguments": [{"text": "Shire", "location": [634, 639], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Scheme", "location": [678, 684], "entities": [{"type": "Organization", "text": "Scheme"}]}]}, {"type": "partOfMany", "sentence": "JPMorgan Securities Japan Co., Ltd., together with its affiliate J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove and which is authorised in the United Kingdom by the Prudential Regulation Authority and regulated in the United Kingdom by the Prudential Regulation Authority and the Financial Conduct Authority) (\" J.P. Morgan \"), is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and will not regard any other person as its client in relation to the Acquisition and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of J.P. Morgan, or for providing advice in connection with the Acquisition or any matter referred to herein.", "score": 0.392509, "arguments": [{"text": "JPMorgan Securities Japan Co., Ltd.", "location": [8638, 8673], "entities": [{"type": "Organization", "text": "JPMorgan Securities Japan Co., Ltd."}]}, {"text": "which", "location": [8731, 8736], "entities": [{"type": "Organization", "text": "which"}]}]}, {"type": "partOf", "sentence": "JPMorgan Securities Japan Co., Ltd., together with its affiliate J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove and which is authorised in the United Kingdom by the Prudential Regulation Authority and regulated in the United Kingdom by the Prudential Regulation Authority and the Financial Conduct Authority) (\" J.P. Morgan \"), is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and will not regard any other person as its client in relation to the Acquisition and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of J.P. Morgan, or for providing advice in connection with the Acquisition or any matter referred to herein.", "score": 0.87008, "arguments": [{"text": "affiliate", "location": [8693, 8702], "entities": [{"type": "Organization", "text": "affiliate"}]}, {"text": "its", "location": [8689, 8692], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "partOfMany", "sentence": "JPMorgan Securities Japan Co., Ltd., together with its affiliate J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove and which is authorised in the United Kingdom by the Prudential Regulation Authority and regulated in the United Kingdom by the Prudential Regulation Authority and the Financial Conduct Authority) (\" J.P. Morgan \"), is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and will not regard any other person as its client in relation to the Acquisition and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of J.P. Morgan, or for providing advice in connection with the Acquisition or any matter referred to herein.", "score": 0.667888, "arguments": [{"text": "J.P. Morgan Securities plc", "location": [8703, 8729], "entities": [{"type": "Organization", "text": "J.P. Morgan Securities plc"}]}, {"text": "affiliate", "location": [8693, 8702], "entities": [{"type": "Organization", "text": "affiliate"}]}]}, {"type": "partOfMany", "sentence": "JPMorgan Securities Japan Co., Ltd., together with its affiliate J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove and which is authorised in the United Kingdom by the Prudential Regulation Authority and regulated in the United Kingdom by the Prudential Regulation Authority and the Financial Conduct Authority) (\" J.P. Morgan \"), is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and will not regard any other person as its client in relation to the Acquisition and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of J.P. Morgan, or for providing advice in connection with the Acquisition or any matter referred to herein.", "score": 0.495335, "arguments": [{"text": "J.P. Morgan Securities plc", "location": [8703, 8729], "entities": [{"type": "Organization", "text": "J.P. Morgan Securities plc"}]}, {"text": "which", "location": [8731, 8736], "entities": [{"type": "Organization", "text": "which"}]}]}, {"type": "partOfMany", "sentence": "JPMorgan Securities Japan Co., Ltd., together with its affiliate J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove and which is authorised in the United Kingdom by the Prudential Regulation Authority and regulated in the United Kingdom by the Prudential Regulation Authority and the Financial Conduct Authority) (\" J.P. Morgan \"), is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and will not regard any other person as its client in relation to the Acquisition and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of J.P. Morgan, or for providing advice in connection with the Acquisition or any matter referred to herein.", "score": 0.528604, "arguments": [{"text": "J.P. Morgan Securities plc", "location": [8703, 8729], "entities": [{"type": "Organization", "text": "J.P. Morgan Securities plc"}]}, {"text": "its", "location": [8746, 8749], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "partOfMany", "sentence": "JPMorgan Securities Japan Co., Ltd., together with its affiliate J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove and which is authorised in the United Kingdom by the Prudential Regulation Authority and regulated in the United Kingdom by the Prudential Regulation Authority and the Financial Conduct Authority) (\" J.P. Morgan \"), is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and will not regard any other person as its client in relation to the Acquisition and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of J.P. Morgan, or for providing advice in connection with the Acquisition or any matter referred to herein.", "score": 0.530369, "arguments": [{"text": "J.P. Morgan Securities plc", "location": [8703, 8729], "entities": [{"type": "Organization", "text": "J.P. Morgan Securities plc"}]}, {"text": "which", "location": [8809, 8814], "entities": [{"type": "Organization", "text": "which"}]}]}, {"type": "basedIn", "sentence": "JPMorgan Securities Japan Co., Ltd., together with its affiliate J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove and which is authorised in the United Kingdom by the Prudential Regulation Authority and regulated in the United Kingdom by the Prudential Regulation Authority and the Financial Conduct Authority) (\" J.P. Morgan \"), is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and will not regard any other person as its client in relation to the Acquisition and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of J.P. Morgan, or for providing advice in connection with the Acquisition or any matter referred to herein.", "score": 0.656251, "arguments": [{"text": "Prudential Regulation Authority", "location": [8858, 8889], "entities": [{"type": "Organization", "text": "Prudential Regulation Authority"}]}, {"text": "United Kingdom", "location": [8836, 8850], "entities": [{"type": "GeopoliticalEntity", "text": "United Kingdom"}]}]}, {"type": "basedIn", "sentence": "JPMorgan Securities Japan Co., Ltd., together with its affiliate J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove and which is authorised in the United Kingdom by the Prudential Regulation Authority and regulated in the United Kingdom by the Prudential Regulation Authority and the Financial Conduct Authority) (\" J.P. Morgan \"), is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and will not regard any other person as its client in relation to the Acquisition and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of J.P. Morgan, or for providing advice in connection with the Acquisition or any matter referred to herein.", "score": 0.510276, "arguments": [{"text": "Prudential Regulation Authority", "location": [8933, 8964], "entities": [{"type": "Organization", "text": "Prudential Regulation Authority"}]}, {"text": "United Kingdom", "location": [8911, 8925], "entities": [{"type": "GeopoliticalEntity", "text": "United Kingdom"}]}]}, {"type": "employedBy", "sentence": "JPMorgan Securities Japan Co., Ltd., together with its affiliate J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove and which is authorised in the United Kingdom by the Prudential Regulation Authority and regulated in the United Kingdom by the Prudential Regulation Authority and the Financial Conduct Authority) (\" J.P. Morgan \"), is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and will not regard any other person as its client in relation to the Acquisition and shall not be responsible to anyone other than Takeda for providing the protections afforded to clients of J.P. Morgan, or for providing advice in connection with the Acquisition or any matter referred to herein.", "score": 0.352634, "arguments": [{"text": "clients", "location": [9306, 9313], "entities": [{"type": "Person", "text": "clients"}]}, {"text": "J.P. Morgan", "location": [9317, 9328], "entities": [{"type": "Organization", "text": "J.P. Morgan"}]}]}, {"type": "partOf", "sentence": "Nomura International plc (\" Nomura \"), which is authorised by the Prudential Regulation Authority and regulated by the Prudential Regulation Authority and the Financial Conduct Authority in the United Kingdom, is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and this Announcement and Nomura, its affiliates and its respective officers, employees, agents, representatives and/or associates will not regard any other person as their client, nor will they be responsible to anyone other than Takeda for providing the protections afforded to clients of Nomura or for giving advice in relation to the Acquisition, this Announcement or any matter or referred to herein.", "score": 0.425449, "arguments": [{"text": "Nomura International plc", "location": [9423, 9447], "entities": [{"type": "Organization", "text": "Nomura International plc"}]}, {"text": "Nomura", "location": [9451, 9457], "entities": [{"type": "Organization", "text": "Nomura"}]}]}, {"type": "locatedAt", "sentence": "Nomura International plc (\" Nomura \"), which is authorised by the Prudential Regulation Authority and regulated by the Prudential Regulation Authority and the Financial Conduct Authority in the United Kingdom, is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and this Announcement and Nomura, its affiliates and its respective officers, employees, agents, representatives and/or associates will not regard any other person as their client, nor will they be responsible to anyone other than Takeda for providing the protections afforded to clients of Nomura or for giving advice in relation to the Acquisition, this Announcement or any matter or referred to herein.", "score": 0.728307, "arguments": [{"text": "Financial Conduct Authority", "location": [9582, 9609], "entities": [{"type": "Organization", "text": "Financial Conduct Authority"}]}, {"text": "United Kingdom", "location": [9617, 9631], "entities": [{"type": "GeopoliticalEntity", "text": "United Kingdom"}]}]}, {"type": "participantIn", "sentence": "Shire is pleased to announce that the scheme document which sets out, among other things, a letter from the Chairman of Shire, the full terms and conditions of the Scheme, an explanatory statement, notices of the Court Meeting and the Shire General Meeting, an expected timetable of principal events and details of the action to be taken by Shire Shareholders and Shire ADS Holders, is being sent, or made available, to Shire Shareholders and Shire ADS Holders today and has been published on the Shire website at www.shire.com (the \" Scheme Document \").", "score": 0.51267, "arguments": [{"text": "Court", "location": [727, 732], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [733, 740], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "agentOf", "sentence": "Nomura International plc (\" Nomura \"), which is authorised by the Prudential Regulation Authority and regulated by the Prudential Regulation Authority and the Financial Conduct Authority in the United Kingdom, is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and this Announcement and Nomura, its affiliates and its respective officers, employees, agents, representatives and/or associates will not regard any other person as their client, nor will they be responsible to anyone other than Takeda for providing the protections afforded to clients of Nomura or for giving advice in relation to the Acquisition, this Announcement or any matter or referred to herein.", "score": 0.549516, "arguments": [{"text": "Acquisition", "location": [9725, 9736], "entities": [{"type": "Organization", "text": "Acquisition"}]}, {"text": "Announcement", "location": [9746, 9758], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "partOf", "sentence": "Nomura International plc (\" Nomura \"), which is authorised by the Prudential Regulation Authority and regulated by the Prudential Regulation Authority and the Financial Conduct Authority in the United Kingdom, is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and this Announcement and Nomura, its affiliates and its respective officers, employees, agents, representatives and/or associates will not regard any other person as their client, nor will they be responsible to anyone other than Takeda for providing the protections afforded to clients of Nomura or for giving advice in relation to the Acquisition, this Announcement or any matter or referred to herein.", "score": 0.785092, "arguments": [{"text": "affiliates", "location": [9775, 9785], "entities": [{"type": "Organization", "text": "affiliates"}]}, {"text": "its", "location": [9771, 9774], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "employedBy", "sentence": "Nomura International plc (\" Nomura \"), which is authorised by the Prudential Regulation Authority and regulated by the Prudential Regulation Authority and the Financial Conduct Authority in the United Kingdom, is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and this Announcement and Nomura, its affiliates and its respective officers, employees, agents, representatives and/or associates will not regard any other person as their client, nor will they be responsible to anyone other than Takeda for providing the protections afforded to clients of Nomura or for giving advice in relation to the Acquisition, this Announcement or any matter or referred to herein.", "score": 0.586859, "arguments": [{"text": "officers", "location": [9805, 9813], "entities": [{"type": "Person", "text": "officers"}]}, {"text": "its", "location": [9790, 9793], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "partOfMany", "sentence": "Nomura International plc (\" Nomura \"), which is authorised by the Prudential Regulation Authority and regulated by the Prudential Regulation Authority and the Financial Conduct Authority in the United Kingdom, is acting as financial adviser exclusively to Takeda and no one else in connection with the Acquisition and this Announcement and Nomura, its affiliates and its respective officers, employees, agents, representatives and/or associates will not regard any other person as their client, nor will they be responsible to anyone other than Takeda for providing the protections afforded to clients of Nomura or for giving advice in relation to the Acquisition, this Announcement or any matter or referred to herein.", "score": 0.688311, "arguments": [{"text": "associates", "location": [9857, 9867], "entities": [{"type": "Person", "text": "associates"}]}, {"text": "their", "location": [9904, 9909], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOf", "sentence": "Neither Nomura nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Nomura in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.788414, "arguments": [{"text": "subsidiaries", "location": [10173, 10185], "entities": [{"type": "Organization", "text": "subsidiaries"}]}, {"text": "its", "location": [10169, 10172], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "locatedAt", "sentence": "Citigroup Global Markets Limited (\" Citi \"), which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting exclusively as financial adviser to Shire and no one else in connection with the Acquisition, this Announcement and the matters described herein, and shall not be responsible to anyone other than Shire for providing the protections afforded to clients of Citi, or for providing advice in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.735763, "arguments": [{"text": "Prudential Regulation Authority", "location": [10655, 10686], "entities": [{"type": "Organization", "text": "Prudential Regulation Authority"}]}, {"text": "United Kingdom", "location": [10694, 10708], "entities": [{"type": "GeopoliticalEntity", "text": "United Kingdom"}]}]}, {"type": "locatedAt", "sentence": "Goldman Sachs International (\" Goldman Sachs \"), which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting exclusively as financial adviser to Shire and no one else in connection with the Acquisition, this Announcement and the matters described herein, and shall not be responsible to anyone other than Shire for providing the protections afforded to clients of Goldman Sachs or for providing advice in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.736631, "arguments": [{"text": "Prudential Regulation Authority", "location": [11605, 11636], "entities": [{"type": "Organization", "text": "Prudential Regulation Authority"}]}, {"text": "United Kingdom", "location": [11644, 11658], "entities": [{"type": "GeopoliticalEntity", "text": "United Kingdom"}]}]}, {"type": "locatedAt", "sentence": "Neither Goldman Sachs nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Goldman Sachs in connection with the Acquisition, this Announcement or any matter referred to herein Morgan Stanley & Co. International plc (\" Morgan Stanley \"), which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting exclusively as financial adviser to Shire and no one else in connection with the Acquisition, this Announcement and the matters described herein,", "score": 0.77181, "arguments": [{"text": "Prudential Regulation Authority", "location": [12592, 12623], "entities": [{"type": "Organization", "text": "Prudential Regulation Authority"}]}, {"text": "United Kingdom", "location": [12631, 12645], "entities": [{"type": "GeopoliticalEntity", "text": "United Kingdom"}]}]}, {"type": "partOf", "sentence": "Neither Citi nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Citi in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.788414, "arguments": [{"text": "subsidiaries", "location": [11121, 11133], "entities": [{"type": "Organization", "text": "subsidiaries"}]}, {"text": "its", "location": [11117, 11120], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "employedBy", "sentence": "Goldman Sachs International (\" Goldman Sachs \"), which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting exclusively as financial adviser to Shire and no one else in connection with the Acquisition, this Announcement and the matters described herein, and shall not be responsible to anyone other than Shire for providing the protections afforded to clients of Goldman Sachs or for providing advice in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.371283, "arguments": [{"text": "clients", "location": [11914, 11921], "entities": [{"type": "Person", "text": "clients"}]}, {"text": "Goldman Sachs", "location": [11925, 11938], "entities": [{"type": "Organization", "text": "Goldman Sachs"}]}]}, {"type": "partOf", "sentence": "Neither Goldman Sachs nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Goldman Sachs in connection with the Acquisition, this Announcement or any matter referred to herein Morgan Stanley & Co. International plc (\" Morgan Stanley \"), which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting exclusively as financial adviser to Shire and no one else in connection with the Acquisition, this Announcement and the matters described herein,", "score": 0.788414, "arguments": [{"text": "subsidiaries", "location": [12088, 12100], "entities": [{"type": "Organization", "text": "subsidiaries"}]}, {"text": "its", "location": [12084, 12087], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "employedBy", "sentence": "and shall not be responsible to anyone other than Shire for providing the protections afforded to clients of Morgan Stanley or for providing advice in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.376581, "arguments": [{"text": "clients", "location": [12901, 12908], "entities": [{"type": "Person", "text": "clients"}]}, {"text": "Morgan Stanley", "location": [12912, 12926], "entities": [{"type": "Organization", "text": "Morgan Stanley"}]}]}, {"type": "participantIn", "sentence": "Together with the Scheme Document, Forms of Proxy for the Court Meeting and the Shire General Meeting and Forms of Election and the notes accompanying them have also been published on the Shire website at www.shire.com.", "score": 0.514803, "arguments": [{"text": "Court", "location": [1127, 1132], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [1133, 1140], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "partOf", "sentence": "Neither Morgan Stanley nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Morgan Stanley in connection with the Acquisition, this Announcement or any matter referred to herein.", "score": 0.788414, "arguments": [{"text": "subsidiaries", "location": [13077, 13089], "entities": [{"type": "Organization", "text": "subsidiaries"}]}, {"text": "its", "location": [13073, 13076], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "colleague", "sentence": "Shire Shareholders are advised to read the Scheme Document (including the related Forms of Proxy and forms of election) carefully once these become available because they will contain important information in relation to the Acquisition, the New Takeda Shares and the Combined Group.", "score": 0.226994, "arguments": [{"text": "Shire", "location": [14734, 14739], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Shareholders", "location": [14740, 14752], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "agentOf", "sentence": "Shire Shareholders are advised to read the Scheme Document (including the related Forms of Proxy and forms of election) carefully once these become available because they will contain important information in relation to the Acquisition, the New Takeda Shares and the Combined Group.", "score": 0.617654, "arguments": [{"text": "Shire", "location": [14734, 14739], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "advised", "location": [14757, 14764], "entities": [{"type": "EventCommunication", "text": "advised"}]}]}, {"type": "agentOf", "sentence": "Shire Shareholders are advised to read the Scheme Document (including the related Forms of Proxy and forms of election) carefully once these become available because they will contain important information in relation to the Acquisition, the New Takeda Shares and the Combined Group.", "score": 0.521425, "arguments": [{"text": "Shareholders", "location": [14740, 14752], "entities": [{"type": "Person", "text": "Shareholders"}]}, {"text": "advised", "location": [14757, 14764], "entities": [{"type": "EventCommunication", "text": "advised"}]}]}, {"type": "affectedBy", "sentence": "Shire Shareholders are advised to read the Scheme Document (including the related Forms of Proxy and forms of election) carefully once these become available because they will contain important information in relation to the Acquisition, the New Takeda Shares and the Combined Group.", "score": 0.698459, "arguments": [{"text": "Scheme Document", "location": [14777, 14792], "entities": [{"type": "Organization", "text": "Scheme Document"}]}, {"text": "advised", "location": [14757, 14764], "entities": [{"type": "EventCommunication", "text": "advised"}]}]}, {"type": "agentOf", "sentence": "The New Takeda Securities are not being offered to the public by means of this Announcement.", "score": 0.641941, "arguments": [{"text": "public", "location": [15073, 15079], "entities": [{"type": "Person", "text": "public"}]}, {"text": "Announcement", "location": [15097, 15109], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Takeda reserves the right to elect (with the consent of the Panel and subject to the terms of the Co-operation Agreement) to implement the acquisition of the Shire Shares by way of a Takeover Offer as an alternative to the Scheme.", "score": 0.374582, "arguments": [{"text": "Panel", "location": [15257, 15262], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "acquisition", "location": [15336, 15347], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "clientOf", "sentence": "Restricted Jurisdictions The release, publication or distribution of this Announcement in jurisdictions other than the United Kingdom and Jersey may be restricted by law and therefore any persons into whose possession this Announcement comes who are subject to the laws of any jurisdiction other than the United Kingdom and Jersey should inform themselves about, and observe, any applicable requirements.", "score": 0.241675, "arguments": [{"text": "persons", "location": [16018, 16025], "entities": [{"type": "Person", "text": "persons"}]}, {"text": "Jersey", "location": [15968, 15974], "entities": [{"type": "Organization", "text": "Jersey"}]}]}, {"type": "agentOf", "sentence": "Restricted Jurisdictions The release, publication or distribution of this Announcement in jurisdictions other than the United Kingdom and Jersey may be restricted by law and therefore any persons into whose possession this Announcement comes who are subject to the laws of any jurisdiction other than the United Kingdom and Jersey should inform themselves about, and observe, any applicable requirements.", "score": 0.723281, "arguments": [{"text": "whose", "location": [16031, 16036], "entities": [{"type": "Person", "text": "whose"}]}, {"text": "Announcement", "location": [16053, 16065], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "agentOf", "sentence": "Restricted Jurisdictions The release, publication or distribution of this Announcement in jurisdictions other than the United Kingdom and Jersey may be restricted by law and therefore any persons into whose possession this Announcement comes who are subject to the laws of any jurisdiction other than the United Kingdom and Jersey should inform themselves about, and observe, any applicable requirements.", "score": 0.764785, "arguments": [{"text": "Jersey", "location": [16154, 16160], "entities": [{"type": "Organization", "text": "Jersey"}]}, {"text": "inform", "location": [16168, 16174], "entities": [{"type": "EventCommunication", "text": "inform"}]}]}, {"type": "colleague", "sentence": "Copies of these documents are also being sent to Shire Shareholders today.", "score": 0.273729, "arguments": [{"text": "Shire", "location": [1338, 1343], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Shareholders", "location": [1344, 1356], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "affectedBy", "sentence": "Restricted Jurisdictions The release, publication or distribution of this Announcement in jurisdictions other than the United Kingdom and Jersey may be restricted by law and therefore any persons into whose possession this Announcement comes who are subject to the laws of any jurisdiction other than the United Kingdom and Jersey should inform themselves about, and observe, any applicable requirements.", "score": 0.824719, "arguments": [{"text": "themselves", "location": [16175, 16185], "entities": [{"type": "Person", "text": "themselves"}]}, {"text": "inform", "location": [16168, 16174], "entities": [{"type": "EventCommunication", "text": "inform"}]}]}, {"type": "partOfMany", "sentence": "In particular, the ability of persons who are not resident in the United Kingdom or Jersey to vote their Shire Shares with respect to the Scheme at the Court Meeting, to execute and deliver forms of proxy appointing another to vote at the Court Meeting on their behalf or to hold or vote Takeda Shares may be affected by the laws of the relevant jurisdiction in which they are located.", "score": 0.556775, "arguments": [{"text": "persons", "location": [16265, 16272], "entities": [{"type": "Person", "text": "persons"}]}, {"text": "who", "location": [16273, 16276], "entities": [{"type": "Person", "text": "who"}]}]}, {"type": "agentOf", "sentence": "In particular, the ability of persons who are not resident in the United Kingdom or Jersey to vote their Shire Shares with respect to the Scheme at the Court Meeting, to execute and deliver forms of proxy appointing another to vote at the Court Meeting on their behalf or to hold or vote Takeda Shares may be affected by the laws of the relevant jurisdiction in which they are located.", "score": 0.443929, "arguments": [{"text": "Court", "location": [16387, 16392], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [16393, 16400], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "partOf", "sentence": "In particular, the ability of persons who are not resident in the United Kingdom or Jersey to vote their Shire Shares with respect to the Scheme at the Court Meeting, to execute and deliver forms of proxy appointing another to vote at the Court Meeting on their behalf or to hold or vote Takeda Shares may be affected by the laws of the relevant jurisdiction in which they are located.", "score": 0.501381, "arguments": [{"text": "Meeting", "location": [16393, 16400], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}, {"text": "Meeting", "location": [16480, 16487], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "agentOf", "sentence": "In particular, the ability of persons who are not resident in the United Kingdom or Jersey to vote their Shire Shares with respect to the Scheme at the Court Meeting, to execute and deliver forms of proxy appointing another to vote at the Court Meeting on their behalf or to hold or vote Takeda Shares may be affected by the laws of the relevant jurisdiction in which they are located.", "score": 0.515965, "arguments": [{"text": "Court", "location": [16474, 16479], "entities": [{"type": "Organization", "text": "Court"}]}, {"text": "Meeting", "location": [16480, 16487], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "affectedBy", "sentence": "Accordingly, copies of this Announcement and any formal documentation relating to the Acquisition are not being, and must not be, directly or indirectly, mailed, transmitted or otherwise forwarded, distributed or sent in, into or from a Restricted Jurisdiction, where to do so would violate the laws in that jurisdiction, and persons receiving this Announcement and all documents relating to the Acquisition (including custodians, nominees and trustees) must not mail or otherwise distribute or send them in, into or from Restricted Jurisdictions, where to do so would violate the laws in that jurisdiction.", "score": 0.484298, "arguments": [{"text": "persons", "location": [18206, 18213], "entities": [{"type": "Person", "text": "persons"}]}, {"text": "Announcement", "location": [18229, 18241], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}, {"type": "colleague", "sentence": "The availability of the New Takeda Securities under the Acquisition to Shire Shareholders who are not resident in the United Kingdom or Jersey, or the ability of those persons to continue to hold such securities, may be affected by the laws or regulatory requirements of the relevant jurisdiction in which they are resident.", "score": 0.340474, "arguments": [{"text": "Shire", "location": [19160, 19165], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Shareholders", "location": [19166, 19178], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "partOfMany", "sentence": "The availability of the New Takeda Securities under the Acquisition to Shire Shareholders who are not resident in the United Kingdom or Jersey, or the ability of those persons to continue to hold such securities, may be affected by the laws or regulatory requirements of the relevant jurisdiction in which they are resident.", "score": 0.531789, "arguments": [{"text": "Shareholders", "location": [19166, 19178], "entities": [{"type": "Person", "text": "Shareholders"}]}, {"text": "who", "location": [19179, 19182], "entities": [{"type": "Person", "text": "who"}]}]}, {"type": "locatedAt", "sentence": "The availability of the New Takeda Securities under the Acquisition to Shire Shareholders who are not resident in the United Kingdom or Jersey, or the ability of those persons to continue to hold such securities, may be affected by the laws or regulatory requirements of the relevant jurisdiction in which they are resident.", "score": 0.408097, "arguments": [{"text": "who", "location": [19179, 19182], "entities": [{"type": "Person", "text": "who"}]}, {"text": "United Kingdom", "location": [19207, 19221], "entities": [{"type": "GeopoliticalEntity", "text": "United Kingdom"}]}]}, {"type": "agentOf", "sentence": "Persons into whose possession this Announcement comes who are not resident in the United Kingdom should inform themselves of, and observe, any applicable requirements.", "score": 0.850205, "arguments": [{"text": "whose", "location": [19427, 19432], "entities": [{"type": "Person", "text": "whose"}]}, {"text": "Announcement", "location": [19449, 19461], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}], "keywords": [{"text": "shire", "sentiment": {"score": 0.0798045, "label": "positive"}, "relevance": 0.974239}, {"text": "Shire Shareholders", "sentiment": {"score": 0.286585, "label": "positive"}, "relevance": 0.836458}, {"text": "Shire ADS Holders", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.730293}, {"text": "Shire General Meeting", "sentiment": {"score": -0.26658, "label": "negative"}, "relevance": 0.697827}, {"text": "New Takeda", "sentiment": {"score": -0.537141, "label": "negative"}, "relevance": 0.685077}, {"text": "New Takeda ADSs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.587219}, {"text": "scheme document", "sentiment": {"score": 0.627751, "label": "positive"}, "relevance": 0.565354}, {"text": "United Kingdom", "sentiment": {"score": 0.851582, "label": "positive"}, "relevance": 0.547362}, {"text": "Court Meeting", "sentiment": {"score": 0.0221322, "label": "positive"}, "relevance": 0.533651}, {"text": "announcement", "sentiment": {"score": 0.140202, "label": "positive"}, "relevance": 0.521893}, {"text": "Shire Shares", "sentiment": {"score": -0.665719, "label": "negative"}, "relevance": 0.509323}, {"text": "Shire Depositary", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.501839}, {"text": "financial adviser", "sentiment": {"score": 0.117462, "label": "positive"}, "relevance": 0.488031}, {"text": "New Takeda Shares", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.471436}, {"text": "acquisition", "sentiment": {"score": 0.0897102, "label": "positive"}, "relevance": 0.470943}, {"text": "New York time", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.460935}, {"text": "Prudential Regulation Authority", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.44849}, {"text": "New Takeda Securities", "sentiment": {"score": -0.537141, "label": "negative"}, "relevance": 0.436647}, {"text": "securities exchange offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.423452}, {"text": "London Stock Exchange", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.412331}, {"text": "Financial Conduct Authority", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.398115}, {"text": "Shire ADSs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.395427}, {"text": "Takeda Extraordinary General", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.392348}, {"text": "joint financial adviser", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.388948}, {"text": "Shire Shareholder opinion", "sentiment": {"score": 0.745078, "label": "positive"}, "relevance": 0.367674}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.366625}, {"text": "Effective Date", "sentiment": {"score": 0.310133, "label": "positive"}, "relevance": 0.366369}, {"text": "relevant adjourned Shire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.364491}, {"text": "Shire website", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.362851}, {"text": "London time", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.362469}, {"text": "shire plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.362158}, {"text": "uncertificated Shire ADSs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.361021}, {"text": "Shire Meeting", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.35425}, {"text": "takeda pharmaceutical company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.35354}, {"text": "Shire ADS certificate", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.346275}, {"text": "Shire ADS certificates", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.344509}, {"text": "Opening Position Disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.339303}, {"text": "Extraordinary General Meeting", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.334195}, {"text": "Shire Depositary.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333062}, {"text": "offeree company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331496}, {"text": "SHIRE LEI", "sentiment": {"score": 0.398037, "label": "positive"}, "relevance": 0.328904}, {"text": "Shire Meetings", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.326817}, {"text": "securities laws", "sentiment": {"score": -0.640674, "label": "negative"}, "relevance": 0.325879}, {"text": "Shire\u2019s websites", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.323646}, {"text": "forward-looking statements", "sentiment": {"score": -0.283325, "label": "negative"}, "relevance": 0.322564}, {"text": "relevant securities", "sentiment": {"score": 0.606322, "label": "positive"}, "relevance": 0.321026}, {"text": "Takeover Offer", "sentiment": {"score": 0.426556, "label": "positive"}, "relevance": 0.318794}, {"text": "possible combination", "sentiment": {"score": 0.39568, "label": "positive"}, "relevance": 0.318044}, {"text": "ADS Voting Card", "sentiment": {"score": 0.358438, "label": "positive"}, "relevance": 0.317116}, {"text": "Takeda Depositary", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.305408}]}, "extracted_metadata": {"sha1": "46da9d1f37ab3f2b19a332b1f4e2a0e9df803708", "filename": "1542011403041.zip-f12e9a163c6ff894a517032661e97734.xml", "file_type": "json"}, "external_links": ["https://www.globenewswire.com/Tracker?data=QkY0KWPknd4wvMioN3vKnsaqbE-Z11Gp1lT-cQvhQnlWcM_-GH5Wo6kH3fN7Z3_XcY48VuPQh8G6kXfR4HLWeZ-VJCeSPGnmUSXxBRz7YZP2s90QE93JGEb6rO4l64OA"], "title": "Publication of Scheme Document", "forum_title": "The News Reports"}, {"id": "UggQZuI99IZsz1Hw7Mr-MZIVngVgvbJunNrIvqyk2urqUHvOIgyaBGbdKnoNAnwJ", "result_metadata": {"score": 30.944214}, "author": "Midwest Communications Inc.", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0.419369, "label": "positive"}, "text": "Takeda", "relevance": 0.33, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$62 billion", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": "Takeda sets vote date, aims to close $62 billion Shire deal Jan. 8 | News | 1330 & 101.5 WHBL", "object": {"text": "vote date", "keywords": [{"text": "vote date"}]}, "action": {"verb": {"text": "set", "tense": "present"}, "text": "sets", "normalized": "set"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": "Takeda sets vote date, aims to close $62 billion Shire deal Jan. 8 | News | 1330 & 101.5 WHBL", "object": {"text": "to close $62 billion Shire deal Jan. 8 | News | 1330 & 101.5 WHBL", "keywords": [{"text": "Shire deal"}, {"text": "Jan."}, {"text": "News"}, {"text": "101.5"}], "entities": [{"type": "Quantity", "text": "$62 billion"}]}, "action": {"verb": {"text": "aim", "tense": "present"}, "text": "aims", "normalized": "aim"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": "Takeda sets vote date, aims to close $62 billion Shire deal Jan. 8 | News | 1330 & 101.5 WHBL", "object": {"text": "$62 billion Shire deal", "keywords": [{"text": "Shire deal"}], "entities": [{"type": "Quantity", "text": "$62 billion"}]}, "action": {"verb": {"text": "close", "tense": "future"}, "text": "aims to close", "normalized": "aim to close"}}], "concepts": [], "categories": [{"score": 0.524595, "label": "/finance/financial news"}, {"score": 0.492256, "label": "/business and industrial/business news"}, {"score": 0.483135, "label": "/news/national news"}], "relations": [], "keywords": [{"text": "Shire deal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.980224}, {"text": "vote date", "sentiment": {"score": 0.419369, "label": "positive"}, "relevance": 0.897067}, {"text": "Takeda", "sentiment": {"score": 0.419369, "label": "positive"}, "relevance": 0.780365}, {"text": "Jan.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514867}, {"text": "News", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513118}, {"text": "101.5", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.510786}, {"text": "WHBL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.510203}]}, "crawl_date": "2018-11-12T12:27:11Z", "url": "https://whbl.com/news/articles/2018/nov/12/takeda-sets-vote-date-aims-to-close-62-billion-shire-deal-jan-8/", "host": "whbl.com", "text": "CST FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "main_image_url": "https://radiocms-images.us1.eldarioncloud.com/resize/1200/https://storage.googleapis.com/media.mwcradio.com/mimesis/2018-11/12/2018-11-12T090027Z_2_LYNXNPEEAB0FN-OUSBS_RTROPTP_3_BUSINESS-US-TAKEDA-PHARMA-SHIRE.JPG?upscale=False", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-12T00:00:00-06:00", "enriched_text": {"entities": [{"count": 9, "sentiment": {"score": -0.0473364, "label": "negative"}, "text": "Takeda", "relevance": 0.862686, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co", "relevance": 0.534577, "type": "Company"}, {"count": 7, "sentiment": {"score": -0.307208, "label": "negative"}, "text": "Shire", "relevance": 0.406117, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.41776, "label": "positive"}, "text": "London-listed Shire", "relevance": 0.287432, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ben Hirschler", "relevance": 0.249416, "type": "Person"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.244211, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 4, "sentiment": {"score": 0.371996, "label": "positive"}, "text": "Chief Executive Christophe Weber", "relevance": 0.228794, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Reuters", "relevance": 0.217439, "type": "Company", "disambiguation": {"subtype": [], "name": "Reuters", "dbpedia_resource": "http://dbpedia.org/resource/Reuters"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tokyo", "relevance": 0.175943, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "JapanesePrefecture", "OlympicHostCity", "PlaceWithNeighborhoods", "City"], "name": "Tokyo", "dbpedia_resource": "http://dbpedia.org/resource/Tokyo"}}, {"count": 1, "sentiment": {"score": -0.454906, "label": "negative"}, "text": "Roche", "relevance": 0.149967, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "EU", "relevance": 0.14877, "type": "Organization", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.145347, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0.223648, "label": "positive"}, "text": "CEO", "relevance": 0.143559, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "United States", "relevance": 0.139481, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0.402517, "label": "positive"}, "text": "Louise Heavens", "relevance": 0.136499, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.402517, "label": "positive"}, "text": "Jason Neely", "relevance": 0.129533, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "China", "relevance": 0.120146, "type": "Location", "disambiguation": {"subtype": ["GeographicFeature", "Island", "Country"], "name": "Taiwan", "dbpedia_resource": "http://dbpedia.org/resource/Taiwan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Brazil", "relevance": 0.116137, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "$62 billion", "relevance": 0.116137, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$30.9 billion", "relevance": 0.116137, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$32 billion", "relevance": 0.116137, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "3 percent", "relevance": 0.116137, "type": "Quantity"}], "sentiment": {"document": {"score": 0.296925, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": "Takeda sets vote date, aims to close $62 billion Shire deal Jan. 8 Monday, November 12, 2018 3 a.m.", "object": {"text": "vote date", "keywords": [{"text": "vote date"}]}, "action": {"verb": {"text": "set", "tense": "present"}, "text": "sets", "normalized": "set"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": "Takeda sets vote date, aims to close $62 billion Shire deal Jan. 8 Monday, November 12, 2018 3 a.m.", "object": {"text": "$62 billion Shire deal", "keywords": [{"text": "Shire deal"}], "entities": [{"type": "Quantity", "text": "$62 billion"}]}, "action": {"verb": {"text": "close", "tense": "future"}, "text": "aims to close", "normalized": "aim to close"}}, {"subject": {"text": "Takeda Pharmaceutical Co's logo", "keywords": [{"text": "Takeda Pharmaceutical"}, {"text": "logo"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co"}]}, "sentence": " CST FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "object": {"text": "seen at its new headquarters in Tokyo, Japan, July 2, 2018", "keywords": [{"text": "new headquarters"}, {"text": "Tokyo"}, {"text": "Japan"}], "entities": [{"type": "Location", "text": "Tokyo", "disambiguation": {"subtype": ["AdministrativeDivision", "JapanesePrefecture", "OlympicHostCity", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Tokyo", "dbpedia_resource": "http://dbpedia.org/resource/Tokyo"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Takeda Pharmaceutical Co's logo", "keywords": [{"text": "Takeda Pharmaceutical"}, {"text": "logo"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co"}]}, "sentence": " CST FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "action": {"verb": {"text": "see", "tense": "past"}, "text": "is seen", "normalized": "be see"}}, {"subject": {"text": "Japan's Takeda Pharmaceutical <4502.T>", "keywords": [{"text": "Takeda Pharmaceutical"}, {"text": "Japan"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Company", "text": "Takeda Pharmaceutical Co", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " LONDON (Reuters) - Japan's Takeda Pharmaceutical <4502.T> will hold an investor vote on its $62 billion acquisition of Shire next month and aims to close the deal on Jan. 8, signaling its confidence in securing the required support.", "object": {"text": "an investor vote", "keywords": [{"text": "investor vote"}]}, "action": {"verb": {"text": "hold", "tense": "future"}, "text": "will hold", "normalized": "will hold"}}, {"subject": {"text": "Shares in London-listed Shire", "keywords": [{"text": "London-listed Shire"}, {"text": "Shares"}], "entities": [{"type": "Location", "text": "London-listed Shire", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Shares in London-listed Shire rose 3 percent on the news, hitting their highest level since Takeda first disclosed its interest in buying the rare diseases specialist in March.", "object": {"text": "3 percent", "keywords": [{"text": "percent"}], "entities": [{"type": "Quantity", "text": "3 percent"}]}, "action": {"verb": {"text": "rise", "tense": "past"}, "text": "rose", "normalized": "rise"}}, {"subject": {"text": "Shares in London-listed Shire", "keywords": [{"text": "London-listed Shire"}, {"text": "Shares"}], "entities": [{"type": "Location", "text": "London-listed Shire", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Shares in London-listed Shire rose 3 percent on the news, hitting their highest level since Takeda first disclosed its interest in buying the rare diseases specialist in March.", "object": {"text": "their highest level", "keywords": [{"text": "highest level"}]}, "action": {"verb": {"text": "hit", "tense": "present"}, "text": "hitting", "normalized": "hit"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Shares in London-listed Shire rose 3 percent on the news, hitting their highest level since Takeda first disclosed its interest in buying the rare diseases specialist in March.", "object": {"text": "its interest"}, "action": {"verb": {"text": "disclose", "tense": "past"}, "text": "disclosed", "normalized": "disclose"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Shares in London-listed Shire rose 3 percent on the news, hitting their highest level since Takeda first disclosed its interest in buying the rare diseases specialist in March.", "object": {"text": "the rare diseases specialist", "keywords": [{"text": "rare diseases specialist"}]}, "action": {"verb": {"text": "buy", "tense": "present"}, "text": "buying", "normalized": "buy"}}, {"subject": {"text": "The deal", "keywords": [{"text": "deal"}], "entities": []}, "sentence": " The deal would be the biggest-ever overseas acquisition by a Japanese company - but it needs two-thirds support from shareholders, some of whom are worried about the enlarged company's resulting debt burden.", "object": {"text": "the biggest-ever overseas acquisition", "keywords": [{"text": "biggest-ever overseas acquisition"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "would be", "normalized": "would be"}}, {"subject": {"text": "it"}, "sentence": " The deal would be the biggest-ever overseas acquisition by a Japanese company - but it needs two-thirds support from shareholders, some of whom are worried about the enlarged company's resulting debt burden.", "object": {"text": "two-thirds support from shareholders, some of whom are worried about the enlarged company's resulting debt burden", "keywords": [{"text": "debt burden"}, {"text": "enlarged company"}, {"text": "two-thirds"}, {"text": "shareholders"}]}, "action": {"verb": {"text": "need", "tense": "present"}, "text": "needs", "normalized": "need"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda said on Monday it would hold an extraordinary general meeting (EGM) of shareholders to vote on the transaction on Dec. 5.", "object": {"text": "it would hold an extraordinary general meeting (EGM) of shareholders to vote on the transaction on Dec. 5", "keywords": [{"text": "extraordinary general meeting"}, {"text": "EGM"}, {"text": "shareholders"}, {"text": "transaction"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Previously, Takeda had said it hoped to hold the EGM early in 2019, leaving uncertain the level of backing for the deal, which has been opposed by some members of the founding Takeda family.", "object": {"text": "it hoped to hold the EGM early in 2019, leaving uncertain the level of backing for the deal, which has been opposed by some members of the founding Takeda family", "keywords": [{"text": "founding Takeda family"}, {"text": "EGM"}, {"text": "deal"}, {"text": "level"}], "entities": []}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "had said", "normalized": "have say"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Previously, Takeda had said it hoped to hold the EGM early in 2019, leaving uncertain the level of backing for the deal, which has been opposed by some members of the founding Takeda family.", "object": {"text": "the level of backing for the deal, which has been opposed by some members of the founding Takeda family", "keywords": [{"text": "founding Takeda family"}, {"text": "deal"}, {"text": "level"}, {"text": "members"}], "entities": []}, "action": {"verb": {"text": "leave", "tense": "present"}, "text": "leaving", "normalized": "leave"}}, {"subject": {"text": "by some members of the founding Takeda family", "keywords": [{"text": "founding Takeda family"}]}, "sentence": " Previously, Takeda had said it hoped to hold the EGM early in 2019, leaving uncertain the level of backing for the deal, which has been opposed by some members of the founding Takeda family.", "object": {"text": "the deal", "keywords": [{"text": "deal"}], "entities": []}, "action": {"verb": {"text": "oppose", "tense": "past"}, "text": "has been opposed", "normalized": "have be oppose"}}, {"subject": {"text": "the date of our extraordinary general meeting of shareholders", "keywords": [{"text": "extraordinary general meeting"}, {"text": "shareholders"}, {"text": "date"}]}, "sentence": " \"With the date of our extraordinary general meeting of shareholders now set, we are looking forward to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction,\" Chief Executive Christophe Weber said.", "action": {"verb": {"text": "set", "tense": "past"}, "text": "set", "normalized": "set"}}, {"subject": {"text": "we"}, "sentence": " \"With the date of our extraordinary general meeting of shareholders now set, we are looking forward to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction,\" Chief Executive Christophe Weber said.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "we"}, "sentence": " \"With the date of our extraordinary general meeting of shareholders now set, we are looking forward to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction,\" Chief Executive Christophe Weber said.", "object": {"text": "to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction", "keywords": [{"text": "financial benefits"}, {"text": "shareholders"}, {"text": "dialogue"}, {"text": "transaction"}]}, "action": {"verb": {"text": "look", "tense": "present"}, "text": "are looking", "normalized": "be look"}}, {"subject": {"text": "we"}, "sentence": " \"With the date of our extraordinary general meeting of shareholders now set, we are looking forward to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction,\" Chief Executive Christophe Weber said.", "object": {"text": "our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction", "keywords": [{"text": "financial benefits"}, {"text": "shareholders"}, {"text": "dialogue"}, {"text": "transaction"}]}, "action": {"verb": {"text": "continue", "tense": "future"}, "text": "to continue", "normalized": "to continue"}}, {"subject": {"text": "Chief Executive Christophe Weber", "keywords": [{"text": "Executive Christophe Weber"}], "entities": [{"type": "Person", "text": "Chief Executive Christophe Weber"}]}, "sentence": " \"With the date of our extraordinary general meeting of shareholders now set, we are looking forward to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction,\" Chief Executive Christophe Weber said.", "object": {"text": "With the date of our extraordinary general meeting of shareholders now set, we are looking forward to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction", "keywords": [{"text": "extraordinary general meeting"}, {"text": "financial benefits"}, {"text": "shareholders"}, {"text": "dialogue"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Weber -- a Frenchman and the first non-Japanese CEO of the company --", "keywords": [{"text": "non-Japanese CEO"}, {"text": "Frenchman"}, {"text": "Weber"}, {"text": "company"}], "entities": [{"type": "Person", "text": "Chief Executive Christophe Weber"}, {"type": "JobTitle", "text": "CEO"}]}, "sentence": " Weber -- a Frenchman and the first non-Japanese CEO of the company -- believes that buying Shire will accelerate Takeda's growth and increase its international reach, boosting earnings.", "object": {"text": "that buying Shire will accelerate Takeda's growth and increase its international reach, boosting earnings", "keywords": [{"text": "international reach"}, {"text": "Takeda"}, {"text": "earnings"}, {"text": "Shire"}], "entities": [{"type": "Company", "text": "Shire"}, {"type": "Location", "text": "Takeda", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "believe", "tense": "present"}, "text": "believes", "normalized": "believe"}}, {"subject": {"text": "that buying Shire", "keywords": [{"text": "Shire"}], "entities": [{"type": "Company", "text": "Shire"}]}, "sentence": " Weber -- a Frenchman and the first non-Japanese CEO of the company -- believes that buying Shire will accelerate Takeda's growth and increase its international reach, boosting earnings.", "object": {"text": "its international reach", "keywords": [{"text": "international reach"}]}, "action": {"verb": {"text": "increase", "tense": "present"}, "text": "increase", "normalized": "increase"}}, {"subject": {"text": "The transaction", "keywords": [{"text": "transaction"}]}, "sentence": " The transaction is still awaiting approval from European regulators, although two people familiar with the matter told Reuters last week that Takeda was set to win conditional EU antitrust approval.", "object": {"text": "still awaiting approval from European regulators", "keywords": [{"text": "European regulators"}, {"text": "approval"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The transaction", "keywords": [{"text": "transaction"}]}, "sentence": " The transaction is still awaiting approval from European regulators, although two people familiar with the matter told Reuters last week that Takeda was set to win conditional EU antitrust approval.", "object": {"text": "approval from European regulators", "keywords": [{"text": "European regulators"}, {"text": "approval"}]}, "action": {"verb": {"text": "await", "tense": "present"}, "text": "awaiting", "normalized": "await"}}, {"subject": {"text": "two people familiar with the matter", "keywords": [{"text": "matter"}, {"text": "people"}]}, "sentence": " The transaction is still awaiting approval from European regulators, although two people familiar with the matter told Reuters last week that Takeda was set to win conditional EU antitrust approval.", "object": {"text": "that Takeda was set to win conditional EU antitrust approval", "keywords": [{"text": "EU antitrust approval"}, {"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "action": {"verb": {"text": "tell", "tense": "past"}, "text": "told", "normalized": "tell"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " The transaction is still awaiting approval from European regulators, although two people familiar with the matter told Reuters last week that Takeda was set to win conditional EU antitrust approval.", "object": {"text": "to win conditional EU antitrust approval", "keywords": [{"text": "EU antitrust approval"}], "entities": [{"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "action": {"verb": {"text": "set", "tense": "past"}, "text": "set", "normalized": "set"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda has offered to divest Shire's experimental drug SHP647 to address concerns about overlap in inflammatory bowel disease treatments.", "object": {"text": "offered to divest Shire's experimental drug SHP647 to address concerns about overlap in inflammatory bowel disease treatments", "keywords": [{"text": "inflammatory bowel disease"}, {"text": "experimental drug SHP647"}, {"text": "overlap"}, {"text": "Shire"}], "entities": [{"type": "Organization", "text": "Shire"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda has offered to divest Shire's experimental drug SHP647 to address concerns about overlap in inflammatory bowel disease treatments.", "object": {"text": "Shire's experimental drug SHP647", "keywords": [{"text": "experimental drug"}, {"text": "Shire"}], "entities": [{"type": "Organization", "text": "Shire"}]}, "action": {"verb": {"text": "divest", "tense": "future"}, "text": "has offered to divest", "normalized": "have offer to divest"}}, {"subject": {"text": "The takeover", "keywords": [{"text": "takeover"}]}, "sentence": " The takeover has already secured clearance from regulators in the United States, Japan, China and Brazil.", "object": {"text": "already secured clearance from regulators in the United States, Japan, China and Brazil", "keywords": [{"text": "United States"}, {"text": "clearance"}, {"text": "regulators"}, {"text": "Brazil"}], "entities": [{"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["GeographicFeature", "Country", "Island", "Country"], "name": "Taiwan", "dbpedia_resource": "http://dbpedia.org/resource/Taiwan"}}, {"type": "Location", "text": "Brazil", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The takeover", "keywords": [{"text": "takeover"}]}, "sentence": " The takeover has already secured clearance from regulators in the United States, Japan, China and Brazil.", "object": {"text": "clearance", "keywords": [{"text": "clearance"}]}, "action": {"verb": {"text": "secure", "tense": "past"}, "text": "secured", "normalized": "secure"}}, {"subject": {"text": "Weber", "keywords": [{"text": "Weber"}], "entities": [{"type": "Person", "text": "Chief Executive Christophe Weber"}]}, "sentence": " Weber said last week he was confident of securing investor backing for the purchase of Shire, but until now it has not been clear when exactly Takeda would call its EGM.", "object": {"text": "he was confident of securing investor backing for the purchase of Shire, but until now it has not been clear when exactly Takeda would call its EGM", "keywords": [{"text": "exactly Takeda"}, {"text": "investor backing"}, {"text": "EGM"}, {"text": "Shire"}], "entities": [{"type": "Person", "text": "Chief Executive Christophe Weber"}, {"type": "Company", "text": "Shire"}, {"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Chief Executive Christophe Weber"}]}, "sentence": " Weber said last week he was confident of securing investor backing for the purchase of Shire, but until now it has not been clear when exactly Takeda would call its EGM.", "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Chief Executive Christophe Weber"}]}, "sentence": " Weber said last week he was confident of securing investor backing for the purchase of Shire, but until now it has not been clear when exactly Takeda would call its EGM.", "object": {"text": "investor backing", "keywords": [{"text": "investor backing"}]}, "action": {"verb": {"text": "secure", "tense": "future"}, "text": "securing", "normalized": "secure"}}, {"subject": {"text": "it"}, "sentence": " Weber said last week he was confident of securing investor backing for the purchase of Shire, but until now it has not been clear when exactly Takeda would call its EGM.", "object": {"text": "clear"}, "action": {"verb": {"text": "be", "tense": "past", "negated": true}, "text": "been", "normalized": "be"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda, which has a market value of around $32 billion, has secured a $30.9 billion bridge loan to help finance the Shire acquisition and some investors are concerned as to how well it will cope with debt repayments.", "object": {"text": "a market value of around $32 billion", "keywords": [{"text": "market value"}], "entities": [{"type": "Quantity", "text": "$32 billion"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Takeda, which has a market value of around $32 billion,", "keywords": [{"text": "Takeda"}, {"text": "market value"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Quantity", "text": "$32 billion"}]}, "sentence": " Takeda, which has a market value of around $32 billion, has secured a $30.9 billion bridge loan to help finance the Shire acquisition and some investors are concerned as to how well it will cope with debt repayments.", "object": {"text": "secured a $30.9 billion bridge loan", "keywords": [{"text": "bridge loan"}], "entities": [{"type": "Quantity", "text": "$30.9 billion"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Takeda, which has a market value of around $32 billion,", "keywords": [{"text": "Takeda"}, {"text": "market value"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Quantity", "text": "$32 billion"}]}, "sentence": " Takeda, which has a market value of around $32 billion, has secured a $30.9 billion bridge loan to help finance the Shire acquisition and some investors are concerned as to how well it will cope with debt repayments.", "object": {"text": "a $30.9 billion bridge loan", "keywords": [{"text": "bridge loan"}], "entities": [{"type": "Quantity", "text": "$30.9 billion"}]}, "action": {"verb": {"text": "secure", "tense": "past"}, "text": "has secured", "normalized": "have secure"}}, {"subject": {"text": "some investors", "keywords": [{"text": "investors"}]}, "sentence": " Takeda, which has a market value of around $32 billion, has secured a $30.9 billion bridge loan to help finance the Shire acquisition and some investors are concerned as to how well it will cope with debt repayments.", "object": {"text": "concerned as to how well it will cope with debt repayments", "keywords": [{"text": "debt repayments"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "some investors", "keywords": [{"text": "investors"}]}, "sentence": " Takeda, which has a market value of around $32 billion, has secured a $30.9 billion bridge loan to help finance the Shire acquisition and some investors are concerned as to how well it will cope with debt repayments.", "object": {"text": "as to how well it will cope with debt repayments", "keywords": [{"text": "debt repayments"}]}, "action": {"verb": {"text": "concern", "tense": "past"}, "text": "concerned", "normalized": "concern"}}, {"subject": {"text": "The Japanese company", "keywords": [{"text": "Japanese company"}]}, "sentence": " The Japanese company struck its agreement to take over Shire in May, in a deal that will propel it into the top 10 rankings of global drugmakers by sales.", "object": {"text": "its agreement to take over Shire in May", "keywords": [{"text": "agreement"}, {"text": "Shire"}], "entities": [{"type": "Organization", "text": "Shire"}]}, "action": {"verb": {"text": "strike", "tense": "past"}, "text": "struck", "normalized": "strike"}}, {"subject": {"text": "The Japanese company", "keywords": [{"text": "Japanese company"}]}, "sentence": " The Japanese company struck its agreement to take over Shire in May, in a deal that will propel it into the top 10 rankings of global drugmakers by sales.", "object": {"text": "its agreement", "keywords": [{"text": "agreement"}]}, "action": {"verb": {"text": "take", "tense": "future"}, "text": "to take", "normalized": "to take"}}, {"subject": {"text": "a deal", "keywords": [{"text": "deal"}], "entities": []}, "sentence": " The Japanese company struck its agreement to take over Shire in May, in a deal that will propel it into the top 10 rankings of global drugmakers by sales.", "object": {"text": "it"}, "action": {"verb": {"text": "propel", "tense": "future"}, "text": "will propel", "normalized": "will propel"}}, {"subject": {"text": "the enlarged group", "keywords": [{"text": "enlarged group"}]}, "sentence": " However, the enlarged group faces significant challenges, particularly in hemophilia, where a new drug from Roche and the prospect of new gene therapies now in development threaten a key part of Shire's existing business.", "object": {"text": "significant challenges", "keywords": [{"text": "significant challenges"}]}, "action": {"verb": {"text": "face", "tense": "present"}, "text": "faces", "normalized": "face"}}], "concepts": [{"text": "Inflammatory bowel disease", "relevance": 0.911765, "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}, {"text": "Ulcerative colitis", "relevance": 0.662317, "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}, {"text": "Inflammation", "relevance": 0.650485, "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}, {"text": "Japanese clans", "relevance": 0.646143, "dbpedia_resource": "http://dbpedia.org/resource/Japanese_clans"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.644805, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Takeda clan", "relevance": 0.627417, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_clan"}], "categories": [{"score": 0.601083, "label": "/finance/financial news"}, {"score": 0.502975, "label": "/business and industrial/company/merger and acquisition"}, {"score": 0.396067, "label": "/finance/investing"}], "relations": [{"type": "hasAttribute", "sentence": "Takeda sets vote date, aims to close $62 billion Shire deal Jan. 8 Monday, November 12, 2018 3 a.m. CST FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "score": 0.681311, "arguments": [{"text": "Takeda", "location": [0, 6], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}, {"text": "$62 billion", "location": [37, 48], "entities": [{"type": "Money", "text": "$62 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "partOfMany", "sentence": "Shares in London-listed Shire rose 3 percent on the news, hitting their highest level since Takeda first disclosed its interest in buying the rare diseases specialist in March.", "score": 0.650279, "arguments": [{"text": "Shire", "location": [519, 524], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "their", "location": [561, 566], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "Shares in London-listed Shire rose 3 percent on the news, hitting their highest level since Takeda first disclosed its interest in buying the rare diseases specialist in March.", "score": 0.497501, "arguments": [{"text": "Takeda", "location": [587, 593], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}, {"text": "their", "location": [561, 566], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "agentOf", "sentence": "Shares in London-listed Shire rose 3 percent on the news, hitting their highest level since Takeda first disclosed its interest in buying the rare diseases specialist in March.", "score": 0.973447, "arguments": [{"text": "Takeda", "location": [587, 593], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}, {"text": "disclosed", "location": [600, 609], "entities": [{"type": "EventCommunication", "text": "disclosed"}]}]}, {"type": "hasAttribute", "sentence": "Shares in London-listed Shire rose 3 percent on the news, hitting their highest level since Takeda first disclosed its interest in buying the rare diseases specialist in March.", "score": 0.889646, "arguments": [{"text": "specialist", "location": [651, 661], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}, {"text": "diseases", "location": [642, 650], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "affectedBy", "sentence": "The deal would be the biggest-ever overseas acquisition by a Japanese company - but it needs two-thirds support from shareholders, some of whom are worried about the enlarged company's resulting debt burden.", "score": 0.510604, "arguments": [{"text": "company", "location": [742, 749], "entities": [{"type": "Organization", "text": "company", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [716, 727], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "basedIn", "sentence": "The deal would be the biggest-ever overseas acquisition by a Japanese company - but it needs two-thirds support from shareholders, some of whom are worried about the enlarged company's resulting debt burden.", "score": 0.986137, "arguments": [{"text": "company", "location": [742, 749], "entities": [{"type": "Organization", "text": "company", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Japanese", "location": [733, 741], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "Takeda said on Monday it would hold an extraordinary general meeting (EGM) of shareholders to vote on the transaction on Dec. 5.", "score": 0.998022, "arguments": [{"text": "Takeda", "location": [880, 886], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}, {"text": "said", "location": [887, 891], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "Previously, Takeda had said it hoped to hold the EGM early in 2019, leaving uncertain the level of backing for the deal, which has been opposed by some members of the founding Takeda family.", "score": 0.976386, "arguments": [{"text": "Takeda", "location": [1021, 1027], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}, {"text": "said", "location": [1032, 1036], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "timeOf", "sentence": "Takeda said on Monday it would hold an extraordinary general meeting (EGM) of shareholders to vote on the transaction on Dec. 5.", "score": 0.957937, "arguments": [{"text": "Monday", "location": [895, 901], "entities": [{"type": "Date", "text": "Monday"}]}, {"text": "said", "location": [887, 891], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "participantIn", "sentence": "Takeda said on Monday it would hold an extraordinary general meeting (EGM) of shareholders to vote on the transaction on Dec. 5.", "score": 0.856573, "arguments": [{"text": "shareholders", "location": [958, 970], "entities": [{"type": "Person", "text": "shareholders"}]}, {"text": "meeting", "location": [941, 948], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "agentOf", "sentence": "Previously, Takeda had said it hoped to hold the EGM early in 2019, leaving uncertain the level of backing for the deal, which has been opposed by some members of the founding Takeda family.", "score": 0.479637, "arguments": [{"text": "members", "location": [1161, 1168], "entities": [{"type": "Person", "text": "members"}]}, {"text": "opposed", "location": [1145, 1152], "entities": [{"type": "EventCommunication", "text": "opposed"}]}]}, {"type": "ownerOf", "sentence": "Takeda sets vote date, aims to close $62 billion Shire deal Jan. 8 Monday, November 12, 2018 3 a.m. CST FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "score": 0.634058, "arguments": [{"text": "its", "location": [159, 162], "entities": [{"type": "Organization", "text": "its"}]}, {"text": "headquarters", "location": [167, 179], "entities": [{"type": "Facility", "text": "headquarters"}]}]}, {"type": "partOfMany", "sentence": "Previously, Takeda had said it hoped to hold the EGM early in 2019, leaving uncertain the level of backing for the deal, which has been opposed by some members of the founding Takeda family.", "score": 0.498158, "arguments": [{"text": "members", "location": [1161, 1168], "entities": [{"type": "Person", "text": "members"}]}, {"text": "Takeda family", "location": [1185, 1198], "entities": [{"type": "Person", "text": "Takeda family"}]}]}, {"type": "participantIn", "sentence": "\"With the date of our extraordinary general meeting of shareholders now set, we are looking forward to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction,\" Chief Executive Christophe Weber said.", "score": 0.548738, "arguments": [{"text": "our", "location": [1218, 1221], "entities": [{"type": "Organization", "text": "its"}]}, {"text": "meeting", "location": [1244, 1251], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "participantIn", "sentence": "\"With the date of our extraordinary general meeting of shareholders now set, we are looking forward to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction,\" Chief Executive Christophe Weber said.", "score": 0.917476, "arguments": [{"text": "shareholders", "location": [1255, 1267], "entities": [{"type": "Person", "text": "shareholders"}]}, {"text": "meeting", "location": [1244, 1251], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "agentOf", "sentence": "\"With the date of our extraordinary general meeting of shareholders now set, we are looking forward to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction,\" Chief Executive Christophe Weber said.", "score": 0.989981, "arguments": [{"text": "Christophe Weber", "location": [1439, 1455], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "said", "location": [1456, 1460], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "Weber said last week he was confident of securing investor backing for the purchase of Shire, but until now it has not been clear when exactly Takeda would call its EGM.", "score": 0.997505, "arguments": [{"text": "Weber", "location": [2091, 2096], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "said", "location": [2097, 2101], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "employedBy", "sentence": "Weber -- a Frenchman and the first non-Japanese CEO of the company -- believes that buying Shire will accelerate Takeda's growth and increase its international reach, boosting earnings.", "score": 0.505568, "arguments": [{"text": "CEO", "location": [1510, 1513], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "company", "location": [1521, 1528], "entities": [{"type": "Organization", "text": "company"}]}]}, {"type": "employedBy", "sentence": "The transaction is still awaiting approval from European regulators, although two people familiar with the matter told Reuters last week that Takeda was set to win conditional EU antitrust approval.", "score": 0.631878, "arguments": [{"text": "regulators", "location": [1705, 1715], "entities": [{"type": "Person", "text": "regulators"}]}, {"text": "European", "location": [1696, 1704], "entities": [{"type": "GeopoliticalEntity", "text": "European", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "agentOf", "sentence": "The transaction is still awaiting approval from European regulators, although two people familiar with the matter told Reuters last week that Takeda was set to win conditional EU antitrust approval.", "score": 0.846481, "arguments": [{"text": "people", "location": [1730, 1736], "entities": [{"type": "Person", "text": "people"}]}, {"text": "told", "location": [1762, 1766], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "affectedBy", "sentence": "The transaction is still awaiting approval from European regulators, although two people familiar with the matter told Reuters last week that Takeda was set to win conditional EU antitrust approval.", "score": 0.921743, "arguments": [{"text": "Reuters", "location": [1767, 1774], "entities": [{"type": "Organization", "text": "Reuters", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "told", "location": [1762, 1766], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "timeOf", "sentence": "The transaction is still awaiting approval from European regulators, although two people familiar with the matter told Reuters last week that Takeda was set to win conditional EU antitrust approval.", "score": 0.903787, "arguments": [{"text": "last week", "location": [1775, 1784], "entities": [{"type": "Date", "text": "last week"}]}, {"text": "told", "location": [1762, 1766], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "Takeda has offered to divest Shire's experimental drug SHP647 to address concerns about overlap in inflammatory bowel disease treatments.", "score": 0.980835, "arguments": [{"text": "Takeda", "location": [1847, 1853], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}, {"text": "offered", "location": [1858, 1865], "entities": [{"type": "EventCommunication", "text": "offered"}]}]}, {"type": "locatedAt", "sentence": "Takeda sets vote date, aims to close $62 billion Shire deal Jan. 8 Monday, November 12, 2018 3 a.m. CST FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "score": 0.957707, "arguments": [{"text": "headquarters", "location": [167, 179], "entities": [{"type": "Facility", "text": "headquarters"}]}, {"text": "Tokyo", "location": [183, 188], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo"}]}]}, {"type": "agentOf", "sentence": "Takeda has offered to divest Shire's experimental drug SHP647 to address concerns about overlap in inflammatory bowel disease treatments.", "score": 0.736775, "arguments": [{"text": "SHP647", "location": [1902, 1908], "entities": [{"type": "Person", "text": "SHP647"}]}, {"text": "address", "location": [1912, 1919], "entities": [{"type": "EventCommunication", "text": "address"}]}]}, {"type": "timeOf", "sentence": "Weber said last week he was confident of securing investor backing for the purchase of Shire, but until now it has not been clear when exactly Takeda would call its EGM.", "score": 0.95426, "arguments": [{"text": "last week", "location": [2102, 2111], "entities": [{"type": "Date", "text": "last week"}]}, {"text": "said", "location": [2097, 2101], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "partOf", "sentence": "Weber said last week he was confident of securing investor backing for the purchase of Shire, but until now it has not been clear when exactly Takeda would call its EGM.", "score": 0.887056, "arguments": [{"text": "EGM", "location": [2256, 2259], "entities": [{"type": "Organization", "text": "EGM"}]}, {"text": "its", "location": [2252, 2255], "entities": [{"type": "Organization", "text": "company"}]}]}, {"type": "hasAttribute", "sentence": "Takeda, which has a market value of around $32 billion, has secured a $30.9 billion bridge loan to help finance the Shire acquisition and some investors are concerned as to how well it will cope with debt repayments.", "score": 0.790851, "arguments": [{"text": "which", "location": [2269, 2274], "entities": [{"type": "Organization", "text": "EGM"}]}, {"text": "$32 billion", "location": [2304, 2315], "entities": [{"type": "Money", "text": "$32 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "Takeda, which has a market value of around $32 billion, has secured a $30.9 billion bridge loan to help finance the Shire acquisition and some investors are concerned as to how well it will cope with debt repayments.", "score": 0.54792, "arguments": [{"text": "which", "location": [2269, 2274], "entities": [{"type": "Organization", "text": "EGM"}]}, {"text": "$30.9 billion", "location": [2331, 2344], "entities": [{"type": "Money", "text": "$30.9 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "agentOf", "sentence": "Takeda, which has a market value of around $32 billion, has secured a $30.9 billion bridge loan to help finance the Shire acquisition and some investors are concerned as to how well it will cope with debt repayments.", "score": 0.478164, "arguments": [{"text": "Shire", "location": [2377, 2382], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "acquisition", "location": [2383, 2394], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "basedIn", "sentence": "The Japanese company struck its agreement to take over Shire in May, in a deal that will propel it into the top 10 rankings of global drugmakers by sales.", "score": 0.981252, "arguments": [{"text": "company", "location": [2491, 2498], "entities": [{"type": "Organization", "text": "company"}]}, {"text": "Japanese", "location": [2482, 2490], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "The Japanese company struck its agreement to take over Shire in May, in a deal that will propel it into the top 10 rankings of global drugmakers by sales.", "score": 0.409352, "arguments": [{"text": "drugmakers", "location": [2612, 2622], "entities": [{"type": "Person", "text": "drugmakers"}]}, {"text": "its", "location": [2506, 2509], "entities": [{"type": "Organization", "text": "company"}]}]}, {"type": "locatedAt", "sentence": "Takeda sets vote date, aims to close $62 billion Shire deal Jan. 8 Monday, November 12, 2018 3 a.m. CST FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "score": 0.947769, "arguments": [{"text": "Tokyo", "location": [183, 188], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo"}]}, {"text": "Japan", "location": [190, 195], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "residesIn", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo By Ben Hirschler LONDON (Reuters) - Japan's Takeda Pharmaceutical <4502.T> will hold an investor vote on its $62 billion acquisition of Shire next month and aims to close the deal on Jan. 8, signaling its confidence in securing the required support.", "score": 0.856351, "arguments": [{"text": "Ben Hirschler", "location": [248, 261], "entities": [{"type": "Person", "text": "Ben Hirschler"}]}, {"text": "LONDON", "location": [262, 268], "entities": [{"type": "GeopoliticalEntity", "text": "LONDON"}]}]}, {"type": "employedBy", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo By Ben Hirschler LONDON (Reuters) - Japan's Takeda Pharmaceutical <4502.T> will hold an investor vote on its $62 billion acquisition of Shire next month and aims to close the deal on Jan. 8, signaling its confidence in securing the required support.", "score": 0.564514, "arguments": [{"text": "Ben Hirschler", "location": [248, 261], "entities": [{"type": "Person", "text": "Ben Hirschler"}]}, {"text": "Reuters", "location": [270, 277], "entities": [{"type": "Organization", "text": "Reuters", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo By Ben Hirschler LONDON (Reuters) - Japan's Takeda Pharmaceutical <4502.T> will hold an investor vote on its $62 billion acquisition of Shire next month and aims to close the deal on Jan. 8, signaling its confidence in securing the required support.", "score": 0.533679, "arguments": [{"text": "its", "location": [350, 353], "entities": [{"type": "Organization", "text": "its"}]}, {"text": "$62 billion", "location": [354, 365], "entities": [{"type": "Money", "text": "$62 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "agentOf", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo By Ben Hirschler LONDON (Reuters) - Japan's Takeda Pharmaceutical <4502.T> will hold an investor vote on its $62 billion acquisition of Shire next month and aims to close the deal on Jan. 8, signaling its confidence in securing the required support.", "score": 0.678597, "arguments": [{"text": "its", "location": [350, 353], "entities": [{"type": "Organization", "text": "its"}]}, {"text": "acquisition", "location": [366, 377], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "timeOf", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo By Ben Hirschler LONDON (Reuters) - Japan's Takeda Pharmaceutical <4502.T> will hold an investor vote on its $62 billion acquisition of Shire next month and aims to close the deal on Jan. 8, signaling its confidence in securing the required support.", "score": 0.884759, "arguments": [{"text": "next month", "location": [387, 397], "entities": [{"type": "Date", "text": "next month"}]}, {"text": "acquisition", "location": [366, 377], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}], "keywords": [{"text": "Takeda", "sentiment": {"score": -0.0946727, "label": "negative"}, "relevance": 0.93906}, {"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.756048}, {"text": "founding Takeda family", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.667727}, {"text": "extraordinary general meeting", "sentiment": {"score": 0.738908, "label": "positive"}, "relevance": 0.628116}, {"text": "exactly Takeda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.491664}, {"text": "Shire", "sentiment": {"score": -0.118341, "label": "negative"}, "relevance": 0.395464}, {"text": "Shire deal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.394607}, {"text": "Ben Hirschler", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.391756}, {"text": "CST FILE PHOTO", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.362936}, {"text": "REUTERS/Kim Kyung-Hoon/File Photo", "sentiment": {"score": 0.439013, "label": "positive"}, "relevance": 0.338873}, {"text": "London-listed Shire", "sentiment": {"score": 0.41776, "label": "positive"}, "relevance": 0.336078}, {"text": "Executive Christophe Weber", "sentiment": {"score": 0.207328, "label": "positive"}, "relevance": 0.334062}, {"text": "rare diseases specialist", "sentiment": {"score": -0.294672, "label": "negative"}, "relevance": 0.327566}, {"text": "biggest-ever overseas acquisition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.321904}, {"text": "Japanese company", "sentiment": {"score": -0.484551, "label": "negative"}, "relevance": 0.315908}, {"text": "EU antitrust approval", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.306233}, {"text": "inflammatory bowel disease", "sentiment": {"score": -0.783712, "label": "negative"}, "relevance": 0.30279}, {"text": "experimental drug SHP647", "sentiment": {"score": -0.783712, "label": "negative"}, "relevance": 0.298637}, {"text": "Shire acquisition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.285343}, {"text": "new gene therapies", "sentiment": {"score": -0.454906, "label": "negative"}, "relevance": 0.28494}, {"text": "vote date", "sentiment": {"score": 0.3947, "label": "positive"}, "relevance": 0.212098}]}, "extracted_metadata": {"sha1": "69519f6afd82600a87b66b6335075eaa10fc2b98", "filename": "1542025631875.zip-af21d9dfabf57e7bf58c7c202af71635.xml", "file_type": "json"}, "title": "Takeda sets vote date, aims to close $62 billion Shire deal Jan. 8 | News | 1330 & 101.5 WHBL"}, {"id": "HZas98fFEKqYZ86zztWlJnBl9pEQW0POkyobfEKttCORb0zpi9r_7RCGlPAM3rMm", "result_metadata": {"score": 30.944214}, "author": "Midwest Communications Inc.", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0.519173, "label": "positive"}, "text": "Takeda", "relevance": 0.33, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$62 billion", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": "Takeda sets vote date, aims to close $62 billion Shire deal Jan. 8 | News | WIN 98.5", "object": {"text": "vote date", "keywords": [{"text": "vote date"}]}, "action": {"verb": {"text": "set", "tense": "present"}, "text": "sets", "normalized": "set"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": "Takeda sets vote date, aims to close $62 billion Shire deal Jan. 8 | News | WIN 98.5", "object": {"text": "to close $62 billion Shire deal Jan. 8 | News | WIN 98", "keywords": [{"text": "Shire deal"}, {"text": "Jan."}, {"text": "News"}, {"text": "WIN"}], "entities": [{"type": "Quantity", "text": "$62 billion"}]}, "action": {"verb": {"text": "aim", "tense": "present"}, "text": "aims", "normalized": "aim"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": "Takeda sets vote date, aims to close $62 billion Shire deal Jan. 8 | News | WIN 98.5", "object": {"text": "$62 billion Shire deal", "keywords": [{"text": "Shire deal"}], "entities": [{"type": "Quantity", "text": "$62 billion"}]}, "action": {"verb": {"text": "close", "tense": "future"}, "text": "aims to close", "normalized": "aim to close"}}], "concepts": [{"text": "1956 births", "relevance": 0.862794, "dbpedia_resource": "http://dbpedia.org/resource/1956_births"}], "categories": [{"score": 0.554721, "label": "/finance/financial news"}, {"score": 0.485054, "label": "/business and industrial/business news"}, {"score": 0.460094, "label": "/news/national news"}], "relations": [], "keywords": [{"text": "Shire deal", "sentiment": {"score": 0.506579, "label": "positive"}, "relevance": 0.953736}, {"text": "vote date", "sentiment": {"score": 0.519173, "label": "positive"}, "relevance": 0.860581}, {"text": "Takeda", "sentiment": {"score": 0.519173, "label": "positive"}, "relevance": 0.716219}, {"text": "Jan.", "sentiment": {"score": 0.506579, "label": "positive"}, "relevance": 0.42692}, {"text": "News", "sentiment": {"score": 0.506579, "label": "positive"}, "relevance": 0.424987}, {"text": "WIN", "sentiment": {"score": 0.506579, "label": "positive"}, "relevance": 0.423699}]}, "crawl_date": "2018-11-12T09:34:00Z", "url": "https://wincountry.com/news/articles/2018/nov/12/takeda-sets-vote-date-aims-to-close-62-billion-shire-deal-jan-8/", "host": "wincountry.com", "text": "EST FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "main_image_url": "https://radiocms-images.us1.eldarioncloud.com/resize/1200/https://storage.googleapis.com/media.mwcradio.com/mimesis/2018-11/12/2018-11-12T090027Z_2_LYNXNPEEAB0FN-OUSBS_RTROPTP_3_BUSINESS-US-TAKEDA-PHARMA-SHIRE.JPG?upscale=False", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-12T00:00:00-05:00", "enriched_text": {"entities": [{"count": 9, "sentiment": {"score": -0.0473364, "label": "negative"}, "text": "Takeda", "relevance": 0.862686, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co", "relevance": 0.534577, "type": "Company"}, {"count": 7, "sentiment": {"score": -0.307208, "label": "negative"}, "text": "Shire", "relevance": 0.406117, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.41776, "label": "positive"}, "text": "London-listed Shire", "relevance": 0.287432, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ben Hirschler", "relevance": 0.249416, "type": "Person"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.244211, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 4, "sentiment": {"score": 0.371996, "label": "positive"}, "text": "Chief Executive Christophe Weber", "relevance": 0.228794, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Reuters", "relevance": 0.217439, "type": "Company", "disambiguation": {"subtype": [], "name": "Reuters", "dbpedia_resource": "http://dbpedia.org/resource/Reuters"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tokyo", "relevance": 0.175943, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "JapanesePrefecture", "OlympicHostCity", "PlaceWithNeighborhoods", "City"], "name": "Tokyo", "dbpedia_resource": "http://dbpedia.org/resource/Tokyo"}}, {"count": 1, "sentiment": {"score": -0.454906, "label": "negative"}, "text": "Roche", "relevance": 0.149967, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "EU", "relevance": 0.14877, "type": "Organization", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.145347, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0.223648, "label": "positive"}, "text": "CEO", "relevance": 0.143559, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "United States", "relevance": 0.139481, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0.402517, "label": "positive"}, "text": "Louise Heavens", "relevance": 0.136499, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.402517, "label": "positive"}, "text": "Jason Neely", "relevance": 0.129533, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "China", "relevance": 0.120146, "type": "Location", "disambiguation": {"subtype": ["GeographicFeature", "Island", "Country"], "name": "Taiwan", "dbpedia_resource": "http://dbpedia.org/resource/Taiwan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Brazil", "relevance": 0.116137, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "$62 billion", "relevance": 0.116137, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$30.9 billion", "relevance": 0.116137, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$32 billion", "relevance": 0.116137, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "3 percent", "relevance": 0.116137, "type": "Quantity"}], "sentiment": {"document": {"score": 0.296925, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": "Takeda sets vote date, aims to close $62 billion Shire deal Jan. 8 Monday, November 12, 2018 4 a.m.", "object": {"text": "vote date", "keywords": [{"text": "vote date"}]}, "action": {"verb": {"text": "set", "tense": "present"}, "text": "sets", "normalized": "set"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": "Takeda sets vote date, aims to close $62 billion Shire deal Jan. 8 Monday, November 12, 2018 4 a.m.", "object": {"text": "$62 billion Shire deal", "keywords": [{"text": "Shire deal"}], "entities": [{"type": "Quantity", "text": "$62 billion"}]}, "action": {"verb": {"text": "close", "tense": "future"}, "text": "aims to close", "normalized": "aim to close"}}, {"subject": {"text": "Takeda Pharmaceutical Co's logo", "keywords": [{"text": "Takeda Pharmaceutical"}, {"text": "logo"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co"}]}, "sentence": " EST FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "object": {"text": "seen at its new headquarters in Tokyo, Japan, July 2, 2018", "keywords": [{"text": "new headquarters"}, {"text": "Tokyo"}, {"text": "Japan"}], "entities": [{"type": "Location", "text": "Tokyo", "disambiguation": {"subtype": ["AdministrativeDivision", "JapanesePrefecture", "OlympicHostCity", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Tokyo", "dbpedia_resource": "http://dbpedia.org/resource/Tokyo"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Takeda Pharmaceutical Co's logo", "keywords": [{"text": "Takeda Pharmaceutical"}, {"text": "logo"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co"}]}, "sentence": " EST FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "action": {"verb": {"text": "see", "tense": "past"}, "text": "is seen", "normalized": "be see"}}, {"subject": {"text": "Japan's Takeda Pharmaceutical <4502.T>", "keywords": [{"text": "Takeda Pharmaceutical"}, {"text": "Japan"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Company", "text": "Takeda Pharmaceutical Co", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " LONDON (Reuters) - Japan's Takeda Pharmaceutical <4502.T> will hold an investor vote on its $62 billion acquisition of Shire next month and aims to close the deal on Jan. 8, signaling its confidence in securing the required support.", "object": {"text": "an investor vote", "keywords": [{"text": "investor vote"}]}, "action": {"verb": {"text": "hold", "tense": "future"}, "text": "will hold", "normalized": "will hold"}}, {"subject": {"text": "Shares in London-listed Shire", "keywords": [{"text": "London-listed Shire"}, {"text": "Shares"}], "entities": [{"type": "Location", "text": "London-listed Shire", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Shares in London-listed Shire rose 3 percent on the news, hitting their highest level since Takeda first disclosed its interest in buying the rare diseases specialist in March.", "object": {"text": "3 percent", "keywords": [{"text": "percent"}], "entities": [{"type": "Quantity", "text": "3 percent"}]}, "action": {"verb": {"text": "rise", "tense": "past"}, "text": "rose", "normalized": "rise"}}, {"subject": {"text": "Shares in London-listed Shire", "keywords": [{"text": "London-listed Shire"}, {"text": "Shares"}], "entities": [{"type": "Location", "text": "London-listed Shire", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Shares in London-listed Shire rose 3 percent on the news, hitting their highest level since Takeda first disclosed its interest in buying the rare diseases specialist in March.", "object": {"text": "their highest level", "keywords": [{"text": "highest level"}]}, "action": {"verb": {"text": "hit", "tense": "present"}, "text": "hitting", "normalized": "hit"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Shares in London-listed Shire rose 3 percent on the news, hitting their highest level since Takeda first disclosed its interest in buying the rare diseases specialist in March.", "object": {"text": "its interest"}, "action": {"verb": {"text": "disclose", "tense": "past"}, "text": "disclosed", "normalized": "disclose"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Shares in London-listed Shire rose 3 percent on the news, hitting their highest level since Takeda first disclosed its interest in buying the rare diseases specialist in March.", "object": {"text": "the rare diseases specialist", "keywords": [{"text": "rare diseases specialist"}]}, "action": {"verb": {"text": "buy", "tense": "present"}, "text": "buying", "normalized": "buy"}}, {"subject": {"text": "The deal", "keywords": [{"text": "deal"}], "entities": []}, "sentence": " The deal would be the biggest-ever overseas acquisition by a Japanese company - but it needs two-thirds support from shareholders, some of whom are worried about the enlarged company's resulting debt burden.", "object": {"text": "the biggest-ever overseas acquisition", "keywords": [{"text": "biggest-ever overseas acquisition"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "would be", "normalized": "would be"}}, {"subject": {"text": "it"}, "sentence": " The deal would be the biggest-ever overseas acquisition by a Japanese company - but it needs two-thirds support from shareholders, some of whom are worried about the enlarged company's resulting debt burden.", "object": {"text": "two-thirds support from shareholders, some of whom are worried about the enlarged company's resulting debt burden", "keywords": [{"text": "debt burden"}, {"text": "enlarged company"}, {"text": "two-thirds"}, {"text": "shareholders"}]}, "action": {"verb": {"text": "need", "tense": "present"}, "text": "needs", "normalized": "need"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda said on Monday it would hold an extraordinary general meeting (EGM) of shareholders to vote on the transaction on Dec. 5.", "object": {"text": "it would hold an extraordinary general meeting (EGM) of shareholders to vote on the transaction on Dec. 5", "keywords": [{"text": "extraordinary general meeting"}, {"text": "EGM"}, {"text": "shareholders"}, {"text": "transaction"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Previously, Takeda had said it hoped to hold the EGM early in 2019, leaving uncertain the level of backing for the deal, which has been opposed by some members of the founding Takeda family.", "object": {"text": "it hoped to hold the EGM early in 2019, leaving uncertain the level of backing for the deal, which has been opposed by some members of the founding Takeda family", "keywords": [{"text": "founding Takeda family"}, {"text": "EGM"}, {"text": "deal"}, {"text": "level"}], "entities": []}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "had said", "normalized": "have say"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Previously, Takeda had said it hoped to hold the EGM early in 2019, leaving uncertain the level of backing for the deal, which has been opposed by some members of the founding Takeda family.", "object": {"text": "the level of backing for the deal, which has been opposed by some members of the founding Takeda family", "keywords": [{"text": "founding Takeda family"}, {"text": "deal"}, {"text": "level"}, {"text": "members"}], "entities": []}, "action": {"verb": {"text": "leave", "tense": "present"}, "text": "leaving", "normalized": "leave"}}, {"subject": {"text": "by some members of the founding Takeda family", "keywords": [{"text": "founding Takeda family"}]}, "sentence": " Previously, Takeda had said it hoped to hold the EGM early in 2019, leaving uncertain the level of backing for the deal, which has been opposed by some members of the founding Takeda family.", "object": {"text": "the deal", "keywords": [{"text": "deal"}], "entities": []}, "action": {"verb": {"text": "oppose", "tense": "past"}, "text": "has been opposed", "normalized": "have be oppose"}}, {"subject": {"text": "the date of our extraordinary general meeting of shareholders", "keywords": [{"text": "extraordinary general meeting"}, {"text": "shareholders"}, {"text": "date"}]}, "sentence": " \"With the date of our extraordinary general meeting of shareholders now set, we are looking forward to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction,\" Chief Executive Christophe Weber said.", "action": {"verb": {"text": "set", "tense": "past"}, "text": "set", "normalized": "set"}}, {"subject": {"text": "we"}, "sentence": " \"With the date of our extraordinary general meeting of shareholders now set, we are looking forward to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction,\" Chief Executive Christophe Weber said.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "we"}, "sentence": " \"With the date of our extraordinary general meeting of shareholders now set, we are looking forward to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction,\" Chief Executive Christophe Weber said.", "object": {"text": "to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction", "keywords": [{"text": "financial benefits"}, {"text": "shareholders"}, {"text": "dialogue"}, {"text": "transaction"}]}, "action": {"verb": {"text": "look", "tense": "present"}, "text": "are looking", "normalized": "be look"}}, {"subject": {"text": "we"}, "sentence": " \"With the date of our extraordinary general meeting of shareholders now set, we are looking forward to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction,\" Chief Executive Christophe Weber said.", "object": {"text": "our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction", "keywords": [{"text": "financial benefits"}, {"text": "shareholders"}, {"text": "dialogue"}, {"text": "transaction"}]}, "action": {"verb": {"text": "continue", "tense": "future"}, "text": "to continue", "normalized": "to continue"}}, {"subject": {"text": "Chief Executive Christophe Weber", "keywords": [{"text": "Executive Christophe Weber"}], "entities": [{"type": "Person", "text": "Chief Executive Christophe Weber"}]}, "sentence": " \"With the date of our extraordinary general meeting of shareholders now set, we are looking forward to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction,\" Chief Executive Christophe Weber said.", "object": {"text": "With the date of our extraordinary general meeting of shareholders now set, we are looking forward to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction", "keywords": [{"text": "extraordinary general meeting"}, {"text": "financial benefits"}, {"text": "shareholders"}, {"text": "dialogue"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Weber -- a Frenchman and the first non-Japanese CEO of the company --", "keywords": [{"text": "non-Japanese CEO"}, {"text": "Frenchman"}, {"text": "Weber"}, {"text": "company"}], "entities": [{"type": "Person", "text": "Chief Executive Christophe Weber"}, {"type": "JobTitle", "text": "CEO"}]}, "sentence": " Weber -- a Frenchman and the first non-Japanese CEO of the company -- believes that buying Shire will accelerate Takeda's growth and increase its international reach, boosting earnings.", "object": {"text": "that buying Shire will accelerate Takeda's growth and increase its international reach, boosting earnings", "keywords": [{"text": "international reach"}, {"text": "Takeda"}, {"text": "earnings"}, {"text": "Shire"}], "entities": [{"type": "Company", "text": "Shire"}, {"type": "Location", "text": "Takeda", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "believe", "tense": "present"}, "text": "believes", "normalized": "believe"}}, {"subject": {"text": "that buying Shire", "keywords": [{"text": "Shire"}], "entities": [{"type": "Company", "text": "Shire"}]}, "sentence": " Weber -- a Frenchman and the first non-Japanese CEO of the company -- believes that buying Shire will accelerate Takeda's growth and increase its international reach, boosting earnings.", "object": {"text": "its international reach", "keywords": [{"text": "international reach"}]}, "action": {"verb": {"text": "increase", "tense": "present"}, "text": "increase", "normalized": "increase"}}, {"subject": {"text": "The transaction", "keywords": [{"text": "transaction"}]}, "sentence": " The transaction is still awaiting approval from European regulators, although two people familiar with the matter told Reuters last week that Takeda was set to win conditional EU antitrust approval.", "object": {"text": "still awaiting approval from European regulators", "keywords": [{"text": "European regulators"}, {"text": "approval"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The transaction", "keywords": [{"text": "transaction"}]}, "sentence": " The transaction is still awaiting approval from European regulators, although two people familiar with the matter told Reuters last week that Takeda was set to win conditional EU antitrust approval.", "object": {"text": "approval from European regulators", "keywords": [{"text": "European regulators"}, {"text": "approval"}]}, "action": {"verb": {"text": "await", "tense": "present"}, "text": "awaiting", "normalized": "await"}}, {"subject": {"text": "two people familiar with the matter", "keywords": [{"text": "matter"}, {"text": "people"}]}, "sentence": " The transaction is still awaiting approval from European regulators, although two people familiar with the matter told Reuters last week that Takeda was set to win conditional EU antitrust approval.", "object": {"text": "that Takeda was set to win conditional EU antitrust approval", "keywords": [{"text": "EU antitrust approval"}, {"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "action": {"verb": {"text": "tell", "tense": "past"}, "text": "told", "normalized": "tell"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " The transaction is still awaiting approval from European regulators, although two people familiar with the matter told Reuters last week that Takeda was set to win conditional EU antitrust approval.", "object": {"text": "to win conditional EU antitrust approval", "keywords": [{"text": "EU antitrust approval"}], "entities": [{"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "action": {"verb": {"text": "set", "tense": "past"}, "text": "set", "normalized": "set"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda has offered to divest Shire's experimental drug SHP647 to address concerns about overlap in inflammatory bowel disease treatments.", "object": {"text": "offered to divest Shire's experimental drug SHP647 to address concerns about overlap in inflammatory bowel disease treatments", "keywords": [{"text": "inflammatory bowel disease"}, {"text": "experimental drug SHP647"}, {"text": "overlap"}, {"text": "Shire"}], "entities": [{"type": "Organization", "text": "Shire"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda has offered to divest Shire's experimental drug SHP647 to address concerns about overlap in inflammatory bowel disease treatments.", "object": {"text": "Shire's experimental drug SHP647", "keywords": [{"text": "experimental drug"}, {"text": "Shire"}], "entities": [{"type": "Organization", "text": "Shire"}]}, "action": {"verb": {"text": "divest", "tense": "future"}, "text": "has offered to divest", "normalized": "have offer to divest"}}, {"subject": {"text": "The takeover", "keywords": [{"text": "takeover"}]}, "sentence": " The takeover has already secured clearance from regulators in the United States, Japan, China and Brazil.", "object": {"text": "already secured clearance from regulators in the United States, Japan, China and Brazil", "keywords": [{"text": "United States"}, {"text": "clearance"}, {"text": "regulators"}, {"text": "Brazil"}], "entities": [{"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["GeographicFeature", "Country", "Island", "Country"], "name": "Taiwan", "dbpedia_resource": "http://dbpedia.org/resource/Taiwan"}}, {"type": "Location", "text": "Brazil", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The takeover", "keywords": [{"text": "takeover"}]}, "sentence": " The takeover has already secured clearance from regulators in the United States, Japan, China and Brazil.", "object": {"text": "clearance", "keywords": [{"text": "clearance"}]}, "action": {"verb": {"text": "secure", "tense": "past"}, "text": "secured", "normalized": "secure"}}, {"subject": {"text": "Weber", "keywords": [{"text": "Weber"}], "entities": [{"type": "Person", "text": "Chief Executive Christophe Weber"}]}, "sentence": " Weber said last week he was confident of securing investor backing for the purchase of Shire, but until now it has not been clear when exactly Takeda would call its EGM.", "object": {"text": "he was confident of securing investor backing for the purchase of Shire, but until now it has not been clear when exactly Takeda would call its EGM", "keywords": [{"text": "exactly Takeda"}, {"text": "investor backing"}, {"text": "EGM"}, {"text": "Shire"}], "entities": [{"type": "Person", "text": "Chief Executive Christophe Weber"}, {"type": "Company", "text": "Shire"}, {"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Chief Executive Christophe Weber"}]}, "sentence": " Weber said last week he was confident of securing investor backing for the purchase of Shire, but until now it has not been clear when exactly Takeda would call its EGM.", "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Chief Executive Christophe Weber"}]}, "sentence": " Weber said last week he was confident of securing investor backing for the purchase of Shire, but until now it has not been clear when exactly Takeda would call its EGM.", "object": {"text": "investor backing", "keywords": [{"text": "investor backing"}]}, "action": {"verb": {"text": "secure", "tense": "future"}, "text": "securing", "normalized": "secure"}}, {"subject": {"text": "it"}, "sentence": " Weber said last week he was confident of securing investor backing for the purchase of Shire, but until now it has not been clear when exactly Takeda would call its EGM.", "object": {"text": "clear"}, "action": {"verb": {"text": "be", "tense": "past", "negated": true}, "text": "been", "normalized": "be"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda, which has a market value of around $32 billion, has secured a $30.9 billion bridge loan to help finance the Shire acquisition and some investors are concerned as to how well it will cope with debt repayments.", "object": {"text": "a market value of around $32 billion", "keywords": [{"text": "market value"}], "entities": [{"type": "Quantity", "text": "$32 billion"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Takeda, which has a market value of around $32 billion,", "keywords": [{"text": "Takeda"}, {"text": "market value"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Quantity", "text": "$32 billion"}]}, "sentence": " Takeda, which has a market value of around $32 billion, has secured a $30.9 billion bridge loan to help finance the Shire acquisition and some investors are concerned as to how well it will cope with debt repayments.", "object": {"text": "secured a $30.9 billion bridge loan", "keywords": [{"text": "bridge loan"}], "entities": [{"type": "Quantity", "text": "$30.9 billion"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Takeda, which has a market value of around $32 billion,", "keywords": [{"text": "Takeda"}, {"text": "market value"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Quantity", "text": "$32 billion"}]}, "sentence": " Takeda, which has a market value of around $32 billion, has secured a $30.9 billion bridge loan to help finance the Shire acquisition and some investors are concerned as to how well it will cope with debt repayments.", "object": {"text": "a $30.9 billion bridge loan", "keywords": [{"text": "bridge loan"}], "entities": [{"type": "Quantity", "text": "$30.9 billion"}]}, "action": {"verb": {"text": "secure", "tense": "past"}, "text": "has secured", "normalized": "have secure"}}, {"subject": {"text": "some investors", "keywords": [{"text": "investors"}]}, "sentence": " Takeda, which has a market value of around $32 billion, has secured a $30.9 billion bridge loan to help finance the Shire acquisition and some investors are concerned as to how well it will cope with debt repayments.", "object": {"text": "concerned as to how well it will cope with debt repayments", "keywords": [{"text": "debt repayments"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "some investors", "keywords": [{"text": "investors"}]}, "sentence": " Takeda, which has a market value of around $32 billion, has secured a $30.9 billion bridge loan to help finance the Shire acquisition and some investors are concerned as to how well it will cope with debt repayments.", "object": {"text": "as to how well it will cope with debt repayments", "keywords": [{"text": "debt repayments"}]}, "action": {"verb": {"text": "concern", "tense": "past"}, "text": "concerned", "normalized": "concern"}}, {"subject": {"text": "The Japanese company", "keywords": [{"text": "Japanese company"}]}, "sentence": " The Japanese company struck its agreement to take over Shire in May, in a deal that will propel it into the top 10 rankings of global drugmakers by sales.", "object": {"text": "its agreement to take over Shire in May", "keywords": [{"text": "agreement"}, {"text": "Shire"}], "entities": [{"type": "Organization", "text": "Shire"}]}, "action": {"verb": {"text": "strike", "tense": "past"}, "text": "struck", "normalized": "strike"}}, {"subject": {"text": "The Japanese company", "keywords": [{"text": "Japanese company"}]}, "sentence": " The Japanese company struck its agreement to take over Shire in May, in a deal that will propel it into the top 10 rankings of global drugmakers by sales.", "object": {"text": "its agreement", "keywords": [{"text": "agreement"}]}, "action": {"verb": {"text": "take", "tense": "future"}, "text": "to take", "normalized": "to take"}}, {"subject": {"text": "a deal", "keywords": [{"text": "deal"}], "entities": []}, "sentence": " The Japanese company struck its agreement to take over Shire in May, in a deal that will propel it into the top 10 rankings of global drugmakers by sales.", "object": {"text": "it"}, "action": {"verb": {"text": "propel", "tense": "future"}, "text": "will propel", "normalized": "will propel"}}, {"subject": {"text": "the enlarged group", "keywords": [{"text": "enlarged group"}]}, "sentence": " However, the enlarged group faces significant challenges, particularly in hemophilia, where a new drug from Roche and the prospect of new gene therapies now in development threaten a key part of Shire's existing business.", "object": {"text": "significant challenges", "keywords": [{"text": "significant challenges"}]}, "action": {"verb": {"text": "face", "tense": "present"}, "text": "faces", "normalized": "face"}}], "concepts": [{"text": "Inflammatory bowel disease", "relevance": 0.911765, "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}, {"text": "Ulcerative colitis", "relevance": 0.662317, "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}, {"text": "Inflammation", "relevance": 0.650485, "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}, {"text": "Japanese clans", "relevance": 0.646143, "dbpedia_resource": "http://dbpedia.org/resource/Japanese_clans"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.644805, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Takeda clan", "relevance": 0.627417, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_clan"}], "categories": [{"score": 0.595403, "label": "/finance/financial news"}, {"score": 0.503379, "label": "/business and industrial/company/merger and acquisition"}, {"score": 0.401345, "label": "/finance/investing"}], "relations": [{"type": "hasAttribute", "sentence": "Takeda sets vote date, aims to close $62 billion Shire deal Jan. 8 Monday, November 12, 2018 4 a.m. EST FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "score": 0.681311, "arguments": [{"text": "Takeda", "location": [0, 6], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}, {"text": "$62 billion", "location": [37, 48], "entities": [{"type": "Money", "text": "$62 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "partOfMany", "sentence": "Shares in London-listed Shire rose 3 percent on the news, hitting their highest level since Takeda first disclosed its interest in buying the rare diseases specialist in March.", "score": 0.650279, "arguments": [{"text": "Shire", "location": [519, 524], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "their", "location": [561, 566], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "Shares in London-listed Shire rose 3 percent on the news, hitting their highest level since Takeda first disclosed its interest in buying the rare diseases specialist in March.", "score": 0.497501, "arguments": [{"text": "Takeda", "location": [587, 593], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}, {"text": "their", "location": [561, 566], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "agentOf", "sentence": "Shares in London-listed Shire rose 3 percent on the news, hitting their highest level since Takeda first disclosed its interest in buying the rare diseases specialist in March.", "score": 0.973447, "arguments": [{"text": "Takeda", "location": [587, 593], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}, {"text": "disclosed", "location": [600, 609], "entities": [{"type": "EventCommunication", "text": "disclosed"}]}]}, {"type": "hasAttribute", "sentence": "Shares in London-listed Shire rose 3 percent on the news, hitting their highest level since Takeda first disclosed its interest in buying the rare diseases specialist in March.", "score": 0.889646, "arguments": [{"text": "specialist", "location": [651, 661], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}, {"text": "diseases", "location": [642, 650], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "affectedBy", "sentence": "The deal would be the biggest-ever overseas acquisition by a Japanese company - but it needs two-thirds support from shareholders, some of whom are worried about the enlarged company's resulting debt burden.", "score": 0.510604, "arguments": [{"text": "company", "location": [742, 749], "entities": [{"type": "Organization", "text": "company", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [716, 727], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "basedIn", "sentence": "The deal would be the biggest-ever overseas acquisition by a Japanese company - but it needs two-thirds support from shareholders, some of whom are worried about the enlarged company's resulting debt burden.", "score": 0.986137, "arguments": [{"text": "company", "location": [742, 749], "entities": [{"type": "Organization", "text": "company", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Japanese", "location": [733, 741], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "Takeda said on Monday it would hold an extraordinary general meeting (EGM) of shareholders to vote on the transaction on Dec. 5.", "score": 0.998022, "arguments": [{"text": "Takeda", "location": [880, 886], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}, {"text": "said", "location": [887, 891], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "Previously, Takeda had said it hoped to hold the EGM early in 2019, leaving uncertain the level of backing for the deal, which has been opposed by some members of the founding Takeda family.", "score": 0.976386, "arguments": [{"text": "Takeda", "location": [1021, 1027], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}, {"text": "said", "location": [1032, 1036], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "timeOf", "sentence": "Takeda said on Monday it would hold an extraordinary general meeting (EGM) of shareholders to vote on the transaction on Dec. 5.", "score": 0.957937, "arguments": [{"text": "Monday", "location": [895, 901], "entities": [{"type": "Date", "text": "Monday"}]}, {"text": "said", "location": [887, 891], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "participantIn", "sentence": "Takeda said on Monday it would hold an extraordinary general meeting (EGM) of shareholders to vote on the transaction on Dec. 5.", "score": 0.856573, "arguments": [{"text": "shareholders", "location": [958, 970], "entities": [{"type": "Person", "text": "shareholders"}]}, {"text": "meeting", "location": [941, 948], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "agentOf", "sentence": "Previously, Takeda had said it hoped to hold the EGM early in 2019, leaving uncertain the level of backing for the deal, which has been opposed by some members of the founding Takeda family.", "score": 0.479637, "arguments": [{"text": "members", "location": [1161, 1168], "entities": [{"type": "Person", "text": "members"}]}, {"text": "opposed", "location": [1145, 1152], "entities": [{"type": "EventCommunication", "text": "opposed"}]}]}, {"type": "ownerOf", "sentence": "Takeda sets vote date, aims to close $62 billion Shire deal Jan. 8 Monday, November 12, 2018 4 a.m. EST FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "score": 0.634058, "arguments": [{"text": "its", "location": [159, 162], "entities": [{"type": "Organization", "text": "its"}]}, {"text": "headquarters", "location": [167, 179], "entities": [{"type": "Facility", "text": "headquarters"}]}]}, {"type": "partOfMany", "sentence": "Previously, Takeda had said it hoped to hold the EGM early in 2019, leaving uncertain the level of backing for the deal, which has been opposed by some members of the founding Takeda family.", "score": 0.498158, "arguments": [{"text": "members", "location": [1161, 1168], "entities": [{"type": "Person", "text": "members"}]}, {"text": "Takeda family", "location": [1185, 1198], "entities": [{"type": "Person", "text": "Takeda family"}]}]}, {"type": "participantIn", "sentence": "\"With the date of our extraordinary general meeting of shareholders now set, we are looking forward to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction,\" Chief Executive Christophe Weber said.", "score": 0.548738, "arguments": [{"text": "our", "location": [1218, 1221], "entities": [{"type": "Organization", "text": "its"}]}, {"text": "meeting", "location": [1244, 1251], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "participantIn", "sentence": "\"With the date of our extraordinary general meeting of shareholders now set, we are looking forward to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction,\" Chief Executive Christophe Weber said.", "score": 0.917476, "arguments": [{"text": "shareholders", "location": [1255, 1267], "entities": [{"type": "Person", "text": "shareholders"}]}, {"text": "meeting", "location": [1244, 1251], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "agentOf", "sentence": "\"With the date of our extraordinary general meeting of shareholders now set, we are looking forward to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction,\" Chief Executive Christophe Weber said.", "score": 0.989981, "arguments": [{"text": "Christophe Weber", "location": [1439, 1455], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "said", "location": [1456, 1460], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "Weber said last week he was confident of securing investor backing for the purchase of Shire, but until now it has not been clear when exactly Takeda would call its EGM.", "score": 0.997505, "arguments": [{"text": "Weber", "location": [2091, 2096], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "said", "location": [2097, 2101], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "employedBy", "sentence": "Weber -- a Frenchman and the first non-Japanese CEO of the company -- believes that buying Shire will accelerate Takeda's growth and increase its international reach, boosting earnings.", "score": 0.505568, "arguments": [{"text": "CEO", "location": [1510, 1513], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "company", "location": [1521, 1528], "entities": [{"type": "Organization", "text": "company"}]}]}, {"type": "employedBy", "sentence": "The transaction is still awaiting approval from European regulators, although two people familiar with the matter told Reuters last week that Takeda was set to win conditional EU antitrust approval.", "score": 0.631878, "arguments": [{"text": "regulators", "location": [1705, 1715], "entities": [{"type": "Person", "text": "regulators"}]}, {"text": "European", "location": [1696, 1704], "entities": [{"type": "GeopoliticalEntity", "text": "European", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "agentOf", "sentence": "The transaction is still awaiting approval from European regulators, although two people familiar with the matter told Reuters last week that Takeda was set to win conditional EU antitrust approval.", "score": 0.846481, "arguments": [{"text": "people", "location": [1730, 1736], "entities": [{"type": "Person", "text": "people"}]}, {"text": "told", "location": [1762, 1766], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "affectedBy", "sentence": "The transaction is still awaiting approval from European regulators, although two people familiar with the matter told Reuters last week that Takeda was set to win conditional EU antitrust approval.", "score": 0.921743, "arguments": [{"text": "Reuters", "location": [1767, 1774], "entities": [{"type": "Organization", "text": "Reuters", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "told", "location": [1762, 1766], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "timeOf", "sentence": "The transaction is still awaiting approval from European regulators, although two people familiar with the matter told Reuters last week that Takeda was set to win conditional EU antitrust approval.", "score": 0.903787, "arguments": [{"text": "last week", "location": [1775, 1784], "entities": [{"type": "Date", "text": "last week"}]}, {"text": "told", "location": [1762, 1766], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "Takeda has offered to divest Shire's experimental drug SHP647 to address concerns about overlap in inflammatory bowel disease treatments.", "score": 0.980835, "arguments": [{"text": "Takeda", "location": [1847, 1853], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co"}]}, {"text": "offered", "location": [1858, 1865], "entities": [{"type": "EventCommunication", "text": "offered"}]}]}, {"type": "locatedAt", "sentence": "Takeda sets vote date, aims to close $62 billion Shire deal Jan. 8 Monday, November 12, 2018 4 a.m. EST FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "score": 0.957707, "arguments": [{"text": "headquarters", "location": [167, 179], "entities": [{"type": "Facility", "text": "headquarters"}]}, {"text": "Tokyo", "location": [183, 188], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo"}]}]}, {"type": "agentOf", "sentence": "Takeda has offered to divest Shire's experimental drug SHP647 to address concerns about overlap in inflammatory bowel disease treatments.", "score": 0.736775, "arguments": [{"text": "SHP647", "location": [1902, 1908], "entities": [{"type": "Person", "text": "SHP647"}]}, {"text": "address", "location": [1912, 1919], "entities": [{"type": "EventCommunication", "text": "address"}]}]}, {"type": "timeOf", "sentence": "Weber said last week he was confident of securing investor backing for the purchase of Shire, but until now it has not been clear when exactly Takeda would call its EGM.", "score": 0.95426, "arguments": [{"text": "last week", "location": [2102, 2111], "entities": [{"type": "Date", "text": "last week"}]}, {"text": "said", "location": [2097, 2101], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "partOf", "sentence": "Weber said last week he was confident of securing investor backing for the purchase of Shire, but until now it has not been clear when exactly Takeda would call its EGM.", "score": 0.887056, "arguments": [{"text": "EGM", "location": [2256, 2259], "entities": [{"type": "Organization", "text": "EGM"}]}, {"text": "its", "location": [2252, 2255], "entities": [{"type": "Organization", "text": "company"}]}]}, {"type": "hasAttribute", "sentence": "Takeda, which has a market value of around $32 billion, has secured a $30.9 billion bridge loan to help finance the Shire acquisition and some investors are concerned as to how well it will cope with debt repayments.", "score": 0.790851, "arguments": [{"text": "which", "location": [2269, 2274], "entities": [{"type": "Organization", "text": "EGM"}]}, {"text": "$32 billion", "location": [2304, 2315], "entities": [{"type": "Money", "text": "$32 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "Takeda, which has a market value of around $32 billion, has secured a $30.9 billion bridge loan to help finance the Shire acquisition and some investors are concerned as to how well it will cope with debt repayments.", "score": 0.54792, "arguments": [{"text": "which", "location": [2269, 2274], "entities": [{"type": "Organization", "text": "EGM"}]}, {"text": "$30.9 billion", "location": [2331, 2344], "entities": [{"type": "Money", "text": "$30.9 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "agentOf", "sentence": "Takeda, which has a market value of around $32 billion, has secured a $30.9 billion bridge loan to help finance the Shire acquisition and some investors are concerned as to how well it will cope with debt repayments.", "score": 0.478164, "arguments": [{"text": "Shire", "location": [2377, 2382], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "acquisition", "location": [2383, 2394], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "basedIn", "sentence": "The Japanese company struck its agreement to take over Shire in May, in a deal that will propel it into the top 10 rankings of global drugmakers by sales.", "score": 0.981252, "arguments": [{"text": "company", "location": [2491, 2498], "entities": [{"type": "Organization", "text": "company"}]}, {"text": "Japanese", "location": [2482, 2490], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "The Japanese company struck its agreement to take over Shire in May, in a deal that will propel it into the top 10 rankings of global drugmakers by sales.", "score": 0.409352, "arguments": [{"text": "drugmakers", "location": [2612, 2622], "entities": [{"type": "Person", "text": "drugmakers"}]}, {"text": "its", "location": [2506, 2509], "entities": [{"type": "Organization", "text": "company"}]}]}, {"type": "locatedAt", "sentence": "Takeda sets vote date, aims to close $62 billion Shire deal Jan. 8 Monday, November 12, 2018 4 a.m. EST FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018.", "score": 0.947769, "arguments": [{"text": "Tokyo", "location": [183, 188], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo"}]}, {"text": "Japan", "location": [190, 195], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "residesIn", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo By Ben Hirschler LONDON (Reuters) - Japan's Takeda Pharmaceutical <4502.T> will hold an investor vote on its $62 billion acquisition of Shire next month and aims to close the deal on Jan. 8, signaling its confidence in securing the required support.", "score": 0.856351, "arguments": [{"text": "Ben Hirschler", "location": [248, 261], "entities": [{"type": "Person", "text": "Ben Hirschler"}]}, {"text": "LONDON", "location": [262, 268], "entities": [{"type": "GeopoliticalEntity", "text": "LONDON"}]}]}, {"type": "employedBy", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo By Ben Hirschler LONDON (Reuters) - Japan's Takeda Pharmaceutical <4502.T> will hold an investor vote on its $62 billion acquisition of Shire next month and aims to close the deal on Jan. 8, signaling its confidence in securing the required support.", "score": 0.564514, "arguments": [{"text": "Ben Hirschler", "location": [248, 261], "entities": [{"type": "Person", "text": "Ben Hirschler"}]}, {"text": "Reuters", "location": [270, 277], "entities": [{"type": "Organization", "text": "Reuters", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo By Ben Hirschler LONDON (Reuters) - Japan's Takeda Pharmaceutical <4502.T> will hold an investor vote on its $62 billion acquisition of Shire next month and aims to close the deal on Jan. 8, signaling its confidence in securing the required support.", "score": 0.533679, "arguments": [{"text": "its", "location": [350, 353], "entities": [{"type": "Organization", "text": "its"}]}, {"text": "$62 billion", "location": [354, 365], "entities": [{"type": "Money", "text": "$62 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "agentOf", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo By Ben Hirschler LONDON (Reuters) - Japan's Takeda Pharmaceutical <4502.T> will hold an investor vote on its $62 billion acquisition of Shire next month and aims to close the deal on Jan. 8, signaling its confidence in securing the required support.", "score": 0.678597, "arguments": [{"text": "its", "location": [350, 353], "entities": [{"type": "Organization", "text": "its"}]}, {"text": "acquisition", "location": [366, 377], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "timeOf", "sentence": "REUTERS/Kim Kyung-Hoon/File Photo By Ben Hirschler LONDON (Reuters) - Japan's Takeda Pharmaceutical <4502.T> will hold an investor vote on its $62 billion acquisition of Shire next month and aims to close the deal on Jan. 8, signaling its confidence in securing the required support.", "score": 0.884759, "arguments": [{"text": "next month", "location": [387, 397], "entities": [{"type": "Date", "text": "next month"}]}, {"text": "acquisition", "location": [366, 377], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}], "keywords": [{"text": "Takeda", "sentiment": {"score": -0.0946727, "label": "negative"}, "relevance": 0.93906}, {"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.756048}, {"text": "founding Takeda family", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.667727}, {"text": "extraordinary general meeting", "sentiment": {"score": 0.738908, "label": "positive"}, "relevance": 0.628116}, {"text": "exactly Takeda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.491664}, {"text": "Shire", "sentiment": {"score": -0.118341, "label": "negative"}, "relevance": 0.395464}, {"text": "Shire deal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.394607}, {"text": "Ben Hirschler", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.391756}, {"text": "EST FILE PHOTO", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.357878}, {"text": "REUTERS/Kim Kyung-Hoon/File Photo", "sentiment": {"score": 0.439013, "label": "positive"}, "relevance": 0.338873}, {"text": "London-listed Shire", "sentiment": {"score": 0.41776, "label": "positive"}, "relevance": 0.336078}, {"text": "Executive Christophe Weber", "sentiment": {"score": 0.207328, "label": "positive"}, "relevance": 0.334062}, {"text": "rare diseases specialist", "sentiment": {"score": -0.294672, "label": "negative"}, "relevance": 0.327566}, {"text": "biggest-ever overseas acquisition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.321904}, {"text": "Japanese company", "sentiment": {"score": -0.484551, "label": "negative"}, "relevance": 0.315908}, {"text": "EU antitrust approval", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.306233}, {"text": "inflammatory bowel disease", "sentiment": {"score": -0.783712, "label": "negative"}, "relevance": 0.30279}, {"text": "experimental drug SHP647", "sentiment": {"score": -0.783712, "label": "negative"}, "relevance": 0.298637}, {"text": "Shire acquisition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.285343}, {"text": "new gene therapies", "sentiment": {"score": -0.454906, "label": "negative"}, "relevance": 0.28494}, {"text": "vote date", "sentiment": {"score": 0.3947, "label": "positive"}, "relevance": 0.212098}]}, "extracted_metadata": {"sha1": "d6515562b99fd3c12dbaedc36dc124782a8561a0", "filename": "1542015240155.zip-b509ff253f06f38c33c8c4dacd6de66c.xml", "file_type": "json"}, "title": "Takeda sets vote date, aims to close $62 billion Shire deal Jan. 8 | News | WIN 98.5"}, {"id": "PmdeJ8UAh5f-KIfPZ64cXta9v6uAUgAcUPsyGGWfwXFgCZjsx5PiA2WzhrKEShJ5", "result_metadata": {"score": 30.93672}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0.328886, "label": "positive"}, "text": "Barclays", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.751332, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.960106}, {"text": "Barclays", "sentiment": {"score": 0.328886, "label": "positive"}, "relevance": 0.796292}]}, "crawl_date": "2018-11-12T13:43:54Z", "url": "http://www.4-traders.com/BARCLAYS-9583556/news/Barclays-Form-8-3-TAKEDA-PHARMACEUTICAL-CO-LTD-27591234/", "host": "4-traders.com", "text": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC. are being disclosed: Name of offeror/offeree in relation to whose TAKEDA PHARMACEUTICAL CO LTD relevant securities this from relates: 2.", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-12T00:00:00+01:00", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS PLC", "relevance": 0.747957, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC.", "relevance": 0.658731, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.614567, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.532455, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.516667, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Class of Product Nature", "relevance": 0.508034, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.469457, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.42552, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.41035, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,255,100 1.29%", "relevance": 0.41035, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,521,600 1.32%", "relevance": 0.41035, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,941,600 1.38%", "relevance": 0.41035, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,046,454 1.39%", "relevance": 0.41035, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,823,286 1.49%", "relevance": 0.41035, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12,220,869 1.54%", "relevance": 0.41035, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,391,340 4.20%", "relevance": 0.41035, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,417,569 4.21%", "relevance": 0.41035, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.41035, "type": "Quantity"}], "sentiment": {"document": {"score": 0.108646, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "33,391,340 4.20% 33,417,569 4.21% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "33,391,340 4.20"}, {"type": "Quantity", "text": "33,417,569 4.21"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,046,454 1.39% 12,220,869 1.54% (2) Cash-settled derivatives: 11,823,286 1.49% 10,255,100 1.29% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% TOTAL: 33,391,340 4.20% 33,417,569 4.21% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors' and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors' and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020 3134 7213 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " YES Date of disclosure: 12 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "disclosure requirements"}, {"text": "relation"}, {"text": "consultation"}, {"text": "Code"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "disclosure requirements"}, {"text": "relation"}, {"text": "consultation"}, {"text": "Code"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "Barclays plc", "keywords": [{"text": "Barclays plc"}], "entities": [{"type": "Company", "text": "BARCLAYS PLC", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}]}, "sentence": " Barclays plc published this content on 12 November 2018 and is solely responsible for the information contained herein.", "object": {"text": "this content", "keywords": [{"text": "content"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "by Public", "keywords": [{"text": "Public"}]}, "sentence": " Distributed by Public, unedited and unaltered, on 12 November 2018 13:33:04 UTC", "object": {"text": "04 UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "Distributed", "tense": "past"}, "text": "Distributed", "normalized": "Distributed"}}], "concepts": [{"text": "Option", "relevance": 0.960321, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.748766, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.688004, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.595485, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.591358, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option style", "relevance": 0.430048, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Derivative", "relevance": 0.397336, "dbpedia_resource": "http://dbpedia.org/resource/Derivative_(finance)"}, {"text": "Moneyness", "relevance": 0.376931, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Options", "relevance": 0.368198, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "United States dollar", "relevance": 0.360714, "dbpedia_resource": "http://dbpedia.org/resource/United_States_dollar"}, {"text": "Security", "relevance": 0.347384, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Barclays", "relevance": 0.338057, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "December", "relevance": 0.324504, "dbpedia_resource": "http://dbpedia.org/resource/December"}, {"text": "Bond", "relevance": 0.322397, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Contract", "relevance": 0.322087, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}], "categories": [{"score": 0.56755, "label": "/real estate/buying and selling homes"}, {"score": 0.478176, "label": "/finance/financial news"}, {"score": 0.454003, "label": "/finance/investing"}], "relations": [{"type": "hasAttribute", "sentence": "sale Number of Price per unit security securities ADR Purchase 18,626 19.7817 USD ADR Purchase 39,805 19.7456 USD ADR Purchase 50,320 19.7964 USD ADR Purchase 70,900 19.8773 USD ADR Sale 18,626 19.7816 USD ADR Sale 39,805 19.7456 USD ADR Sale 50,320 19.7964 USD ADR Sale 70,900 19.8773 USD Ordinary NPV Purchase 100 4,570.0000 JPY Ordinary NPV Purchase 100 4,542.0000 JPY Ordinary NPV Purchase 200 4,538.6500 JPY Ordinary NPV Purchase 300 4,529.3333 JPY Ordinary NPV Purchase 900 4,526.4444 JPY Ordinary NPV Purchase 1,700 4,509.0588 JPY Ordinary NPV Purchase 1,800 4,506.0000 JPY Ordinary NPV Purchase 1,900 4,508.9473 JPY Ordinary NPV Purchase 2,300 4,528.9347 JPY Ordinary NPV Purchase 2,400 4,529.2291 JPY Ordinary NPV Purchase 2,400 4,546.3750 JPY Ordinary NPV Purchase 2,900 4,534.4310 JPY Ordinary NPV Purchase 3,000 4,525.5333 JPY Ordinary NPV Purchase 3,100 4,526.8129 JPY Ordinary NPV Purchase 3,400 4,526.9147 JPY Ordinary NPV Purchase 5,200 4,527.9423 JPY Ordinary NPV Purchase 5,300 4,509.8301 JPY Ordinary", "score": 0.658918, "arguments": [{"text": "USD ADR Sale", "location": [2754, 2766], "entities": [{"type": "Organization", "text": "USD ADR Sale"}]}, {"text": "50,320 19.7964 USD", "location": [2767, 2785], "entities": [{"type": "Money", "text": "50,320 19.7964 USD", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "managerOf", "sentence": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC.", "score": 0.419441, "arguments": [{"text": "person", "location": [8919, 8925], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Barclays PLC", "location": [8951, 8963], "entities": [{"type": "Organization", "text": "BARCLAYS PLC\nAttachments\nOriginal", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "View source version on businesswire.com: https://www.businesswire.com/news/home/20181112005402/en/ BARCLAYS PLC Source: BARCLAYS PLC Attachments Original document Permalink Disclaimer Barclays plc published this content on 12 November 2018 and is solely responsible for the information contained herein.", "score": 0.990154, "arguments": [{"text": "Permalink Disclaimer\nBarclays plc", "location": [11360, 11393], "entities": [{"type": "Organization", "text": "BARCLAYS PLC\nAttachments\nOriginal", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "published", "location": [11394, 11403], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "timeOf", "sentence": "View source version on businesswire.com: https://www.businesswire.com/news/home/20181112005402/en/ BARCLAYS PLC Source: BARCLAYS PLC Attachments Original document Permalink Disclaimer Barclays plc published this content on 12 November 2018 and is solely responsible for the information contained herein.", "score": 0.642236, "arguments": [{"text": "November 2018", "location": [11423, 11436], "entities": [{"type": "Date", "text": "November 2018"}]}, {"text": "published", "location": [11394, 11403], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "hasAttribute", "sentence": "sale Number of Price per unit security securities ADR Purchase 18,626 19.7817 USD ADR Purchase 39,805 19.7456 USD ADR Purchase 50,320 19.7964 USD ADR Purchase 70,900 19.8773 USD ADR Sale 18,626 19.7816 USD ADR Sale 39,805 19.7456 USD ADR Sale 50,320 19.7964 USD ADR Sale 70,900 19.8773 USD Ordinary NPV Purchase 100 4,570.0000 JPY Ordinary NPV Purchase 100 4,542.0000 JPY Ordinary NPV Purchase 200 4,538.6500 JPY Ordinary NPV Purchase 300 4,529.3333 JPY Ordinary NPV Purchase 900 4,526.4444 JPY Ordinary NPV Purchase 1,700 4,509.0588 JPY Ordinary NPV Purchase 1,800 4,506.0000 JPY Ordinary NPV Purchase 1,900 4,508.9473 JPY Ordinary NPV Purchase 2,300 4,528.9347 JPY Ordinary NPV Purchase 2,400 4,529.2291 JPY Ordinary NPV Purchase 2,400 4,546.3750 JPY Ordinary NPV Purchase 2,900 4,534.4310 JPY Ordinary NPV Purchase 3,000 4,525.5333 JPY Ordinary NPV Purchase 3,100 4,526.8129 JPY Ordinary NPV Purchase 3,400 4,526.9147 JPY Ordinary NPV Purchase 5,200 4,527.9423 JPY Ordinary NPV Purchase 5,300 4,509.8301 JPY Ordinary", "score": 0.744559, "arguments": [{"text": "ADR Sale", "location": [2786, 2794], "entities": [{"type": "Organization", "text": "ADR Sale"}]}, {"text": "50,320 19.7964 USD", "location": [2767, 2785], "entities": [{"type": "Money", "text": "50,320 19.7964 USD", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "employedBy", "sentence": "JPY Ordinary NPV Sale 404,400 4,535.2940 JPY Ordinary NPV Sale 407,400 4,535.5365 JPY (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV SWAP Long 78 4,571.5428 JPY Ordinary NPV SWAP Long 382 4,558.3634 JPY Ordinary NPV SWAP Long 691 4,541.4471 JPY Ordinary NPV SWAP Long 717 4,538.6033 JPY Ordinary NPV SWAP Long 999 4,538.0397 JPY Ordinary NPV SWAP Long 1,059 4,549.4604 JPY Ordinary NPV SWAP Long 1,518 4,537.8333 JPY Ordinary NPV SWAP Long 3,148 4,537.7489 JPY Ordinary NPV SWAP Long 4,435 4,539.3993 JPY Ordinary NPV SWAP Long 4,884 4,533.8328 JPY Ordinary NPV SWAP Long 5,900 4,544.3740 JPY Ordinary NPV SWAP Long 7,689 4,546.0685 JPY Ordinary NPV CFD Long 12,500 4,497.0000 JPY Ordinary NPV SWAP Short 600 4,525.8333 JPY Ordinary NPV CFD Short 8,000 4,570.4570 JPY (c) Stock-", "score": 0.500498, "arguments": [{"text": "Cash", "location": [5638, 5642], "entities": [{"type": "Person", "text": "Cash"}]}, {"text": "Product Nature", "location": [5684, 5698], "entities": [{"type": "Organization", "text": "Product Nature", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "managerOf", "sentence": "JPY Ordinary NPV Sale 404,400 4,535.2940 JPY Ordinary NPV Sale 407,400 4,535.5365 JPY (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV SWAP Long 78 4,571.5428 JPY Ordinary NPV SWAP Long 382 4,558.3634 JPY Ordinary NPV SWAP Long 691 4,541.4471 JPY Ordinary NPV SWAP Long 717 4,538.6033 JPY Ordinary NPV SWAP Long 999 4,538.0397 JPY Ordinary NPV SWAP Long 1,059 4,549.4604 JPY Ordinary NPV SWAP Long 1,518 4,537.8333 JPY Ordinary NPV SWAP Long 3,148 4,537.7489 JPY Ordinary NPV SWAP Long 4,435 4,539.3993 JPY Ordinary NPV SWAP Long 4,884 4,533.8328 JPY Ordinary NPV SWAP Long 5,900 4,544.3740 JPY Ordinary NPV SWAP Long 7,689 4,546.0685 JPY Ordinary NPV CFD Long 12,500 4,497.0000 JPY Ordinary NPV SWAP Short 600 4,525.8333 JPY Ordinary NPV CFD Short 8,000 4,570.4570 JPY (c) Stock-", "score": 0.410487, "arguments": [{"text": "JPY Ordinary NPV", "location": [5865, 5881], "entities": [{"type": "Person", "text": "JPY Ordinary NPV Purchase"}]}, {"text": "SWAP Long 691", "location": [5882, 5895], "entities": [{"type": "Organization", "text": "SWAP Long 691"}]}]}, {"type": "agentOf", "sentence": "settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii) Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 4.", "score": 0.796028, "arguments": [{"text": "i", "location": [6497, 6498], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "Writing", "location": [6500, 6507], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [7471, 7477], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [7488, 7495], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 12 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [8397, 8403], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [8411, 8415], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the 'Code') 1.", "score": 0.846433, "arguments": [{"text": "Rule 8", "location": [8843, 8849], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [8857, 8870], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [8478, 8502], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [8470, 8475], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [10989, 11013], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [10981, 10986], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [8637, 8642], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [8656, 8683], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [11148, 11153], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [11167, 11194], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}], "keywords": [{"text": "JPY Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.930386}, {"text": "Ordinary NPV Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.634522}, {"text": "Ordinary NPV Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.497084}, {"text": "Ordinary NPV SWAP", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.373935}, {"text": "NPV SWAP Long", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.343586}, {"text": "Ordinary NPV Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.285579}, {"text": "TRANSFER Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.28301}, {"text": "USD Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.282123}, {"text": "Ordinary NPV CFD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.279544}, {"text": "securities Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.277764}, {"text": "relevant securities", "sentiment": {"score": 0.229926, "label": "positive"}, "relevance": 0.242653}, {"text": "NPV Call Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.235506}, {"text": "NPV Put Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.225548}, {"text": "NPV SWAP Short", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.222445}, {"text": "NPV CFD Long", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.221426}, {"text": "NPV CFD Short", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.220474}]}, "extracted_metadata": {"sha1": "d00d1973c4c9552b037cc7076385e34bbb6e0aa8", "filename": "1542030234670.zip-a6a988076c02612b034a29fd8ad8b0d9.xml", "file_type": "json"}, "external_links": ["http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.thetakeoverpanel.org.uk&esheet=51898054&newsitemid=20181112005402&lan=en-US&anchor=www.thetakeoverpanel.org.uk&index=1&md5=05db3d54c4b25d21c698bac5d3a8b677", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.thetakeoverpanel.org.uk&esheet=51898054&newsitemid=20181112005402&lan=en-US&anchor=www.thetakeoverpanel.org.uk&index=2&md5=6555ea23604de8a1a62f261f34b66924", "https://www.businesswire.com/news/home/20181112005402/en/", "http://otp.investis.com/clients/uk/barclays1/rns/regulatory-story.aspx?cid=68&newsid=1206795", "http://www.publicnow.com/view/2E49EA8F48D12F4AE4DF0A97838859B7197A27F6"], "title": "Barclays : Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD", "forum_title": "Markets : News, Companies, All News - Marketscreener.com"}]}